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Thesis Overview  
 
Chapter 0 Contains the thesis introduction thesis and concepts of NDIs, 
derivations and applications. It also summarizes the PNDIs that are 
derived in the subsequent chapters.  
 
Chapter 1  Introduces the concept of using Physiological Non-Dimensional 
Indexes (PNDI) for distinguishing or classifying patients who were 
diabetic from non-diabetic and those who are the risk of becoming 
diabetic. In the authors work, he has also demonstrated that those 
who were diabetic were actually at-risk and those who were normal 
were in fact at the rim of becoming diabetic. All the works were 
verified against with clinical data by parametric identification 
techniques.  
 
Chapter 2  Using the findings of the above chapter, the author conceptualized, 
and design and simulated a dynamic activity-based insulin infusion 
system. He has used the clinical data of diabetic patients in the 
above chapter for demonstrating the operations of the system. He 
has even demonstrated the stability of the system by having 
continual simulations till 4-hour. 
 
Chapter 3  In this chapter, the author has derived a series of system equations 
for identification of pulmonary diseases based in the inhale and 
exhale gas mixtures concentrations and volume space.  
 
Chapter 4  In this chapter, the author has derived a series of system equations 
for identification of diseased lungs based of the lungs’ pressure-
volume graphs. He has even demonstrated the techniques of 
obtaining the Cardiac Output (CO) non-invasively  
 
Chapter 5  The author has demonstrated how to obtain the relative urine 
outflow non-invasively for normal kidneys.  
 
Chapter 6  The author has described the significance and derivation 
background of PNDI.  
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Chapter 0 Introduction 
 
 
In physiological medicine, the use of Non-Dimensional Physiological Indices 
(NDPI)s or numbers can provide a generalized approach by which unification or 
integration of a number of isolated but related events into one non-dimensional 
physiological index (NDPI) can help to characterize an abnormal state associated with 
a particular physiological system. The evaluation of the distribution of the values of 
such NDPI(s), in a big patient-population, can then enable us to designate normal and 
disordered ranges of NDPI, with a critical value of NDPI separating these two ranges, 
illustrated in figure 1. Herein, we have formulated several such new NDPIs. 
 
The concept of Non-Dimensional Physiological Index is quite new, and has been 
adopted from Engineering, wherein non-dimensional numbers (made up of several 
parameters) are employed to characterize a regime or strata disturbance phenomena. 
For example, in a cardiovascular fluid-flow regime, the Reynold’s number. 
 
Re VDρµ=    (1) 
 
The Reynolds number for the flow of a fluid of density ρ and viscosity µ through a 
pipe of inside diameter D and V is the velocity. The Reynolds factor represents a 
complex dimensionless factor that characterized a complex property of a physical 
situation, i.e. its susceptibility to turbulence.  
 
Similarly, we can construct other such physiological numbers is employed to 
characterize the conditions when  Re exceeds 2000, at which laminar flow changes to 
turbulent flow, which can occur in the ascending aorta when either the aortic valve is 
stenotic (giving rise to mururs) or in the case of anaemia (decrease blood viscosity). 
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0.1 Use of NDPIs in Author’s Work 
The author’s work focuses on systematic application of dimensional analysis in 
human physiology, in which use is made of parameters of functional second order 
linear differential equations of physiological systems, to develop non-dimensional 
physiological indexes (NDPIs) to qualify  patient health and diseases status as well as 
patient improvement. NDPIs have been developed for several physiological 
phenomena and systems (Chapters 1, 3 through 5), and indicated as to how they can 
be employed diagnostically. In this chapter, we will describe the principles behind the 
NDPIs formulations. We have formulated NDPIs for: 
 
(i) Chapter 0, Introduction, contains the theoretical details how the NDIs in 
this thesis are formed. 
(ii) In Chapter 1, we have use Oral Glucose Tolerance Test, to classify the 
patients into non-diabetic, diabetic or at-risk. The NDPIs can also 
distinguish the patients who are at-risk from non-diabetic and diabetic. 
Then they can undergo pre-emptive medications. 
(iii) Chapter 3, Lung Ventilatory function, to enable us to diagnose lung 
diseases in terms of just one non-dimensional lung-ventilatory index (VTI) 
number, incorporating the lung parameters resistance (R) and compliance 
(C) as well as the lung breathing rate.  
(iv) Chapter 4, Lung Gases Metabolism, to enable us to determine the lung 
efficiency in oxygen consumption and carbon dioxide rates, by one NDPI 
incorporating oxygen diffusion coefficient
2OD and carbon dioxide 
diffusion coefficient 
2COD . 
(v) Chapter 5, Kidney Renal Dysfunctions, to enable us to quantify the 
severity of renal obstructions of both the patient’s kidneys by a NDPI. 
(vi)     Chapter 6, Non-dimensional Physiological Indices for Clinical Assessment, 
contains the summary of Author’s work. 
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0.2 Literature Review 
 
Dimensional Analysis is not just a systematic method for checking the consistency of 
equations and converting systems of units. In fact, it is a complex and interesting 
branch of algebraic theory, with a very broad range of applications [6, 8, 15]. 
 
One of the most important applications of dimensional analysis is Reynolds number 
(Re) as shown in (1). Reynolds number was discovered by Osborne Reynolds of the 
University of Manchester in 1883. Reynolds number is dimensionless quantity 
associated with the smoothness of flow of a fluid. It is an important quantity used in 
aerodynamics and hydraulics. At low velocities fluid flow is smooth, or laminar, and 
the fluid can be pictured as a series of parallel layers, or lamina, moving at different 
velocities. The fluid friction between these layers gives rise to viscosity. As the fluid 
flows more rapidly, it reaches a velocity, known as the critical velocity, at which the 
motion changes from laminar to turbulent, with the formation of eddy currents and 
vortices that disturb the flow.  
 
Walter had claimed that his paper [15] was the first published article on dimensional 
analysis in biology making use of dimensionless number and functional dimensional 
equations. But this paper had not published any of his mathematical and experimental 
works. It had consolidated many important works based on dimensional analysis such 
as: 
(a) Dimensional considerations were used by Gunther & Guerra in 1955 [6] 
for analysis of heart and respiratory rate as a function of animal weight. 
(b) Felix Klein in 1939 [7] used dimensional equations and dimensionless 
numbers to get solutions for the general affine space motion group. 
(c) Works had been done by Rashevsky [25] and Reiner [26] on dimensional 
analysis for cellular physiochemical problems and proliferation of biomass.   
(d) The technique was applied by Brillouin [28], Yockey [29], Luce [30] and 
Cherry [31] for dimensions in information based on basic mathematical 
function suggested by Boltzmann. 
 
Walter [15] had also mentioned that the use of characteristic ratios such as C/C* and 
T/T*, in which the starred value is some convenient reference point in biological 
system was published by Thun [27] in 1960. In which Thun had emphasized that any 
dimensional identity could be converted into a dimensionless form by making a 
quotient of left and right sides. He used this technique for classifying biomathematical 
identities and equations. 
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In Walter’s second paper [16], he had further illustrated the application of 
dimensional analysis in biology by using functional equations of dimensionless 
numbers dealing with renal physiology, lung physiology and leaf shape. In his paper, 
he had presented twelve dimensional tables for general fundamental biological 
applications.  
 
Even though Langhaar in 1951 [8] reveals that modeling is rarely possible for more 
than two dimensionless numbers at a time, and these must be chosen on the basis of 
experimental capability and basic goals of the particular model. Our work has shown 
that this is possible by careful compartmental modeling. 
 
The ability to get dimensional and dimensionless relationships from differential 
equations is of great importance when the later too complex for analytic solution. 
 
Derivation of suitable dimensionless terms yields terms yields major insights into 
physical nature of particular problem [12-15]. 
 
Dimensional analysis has contribution to make to almost any problem and especially 
those where analytic methods fail [12-15]. 
 
Dimensional analysis has contribution to make to almost any problem and especially 
those where analytic methods fail [12-15]. 
 
 
0.3. Dimensional Analysis 
 
Dimensional analysis is a mathematical tool often applied in physics, chemistry, and 
engineering to simplify a problem by reducing the number of variables to the smallest 
number of "essential" parameters and how they should be presented for analysis. This 
process is based on the Buckingham π-Theorem [1-5]. Systems which share these 
essential parameters are called similar and do not have to be studied separately [1-5, 
10].  
 
The dimension of a physical quantity is the type of unit needed to express it. For 
instance, the dimension of a speed is distance/time and the dimension of a force is 
mass×distance/time. In mechanics, every dimension can be expressed in terms of 
distance (which physicists often call "length"), time, and mass, or alternatively in 
terms of force, length and mass. Depending on the problem, it may be advantageous 
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to choose one or the other set of fundamental units. Every unit is a product of 
(possibly fractional) powers of the fundamental units, and the units form a group 
under multiplication. 
 
In the most primitive form, dimensional analysis is used to check the correctness of 
algebraic derivations as described in the previous section. In every physically 
meaningful expression, only quantities of the same dimension can be added or 
subtracted. The two sides of any equation must have the same dimensions (Dimension 
Homogeneity). Furthermore, the arguments to exponential, trigonometric and 
logarithmic functions must be dimensionless numbers, which is often achieved by 
multiplying a certain physical quantity by a suitable constant of the inverse dimension. 
 
Table 0.1 Dimensions of some common physical quantities. The following table lists 
dimensions and SI units of some commonly physical quantities. 
 
 
 
Physical Quantities SI Units Dimension 
Symbol 
Length m L 
Mass kg M 
Time s T 
Force N MLT-2 
Electric Charge C Q 
Velocity ms-1 LT-1 
Acceleration ms-2 LT-2 
Energy J ML2 T-2 
Power W ML2 T-3 
Pressure Nm-2 ML-1 T-2 
Density kgm-3 ML-3  
Viscosity Nsm-2 ML-1 T-1 
Surface Tension Nm-1 MT-2 
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0.3.1. Dimensional Homogeneity 
 
Any equation describing a physical system will only be valid if both sides have 
identical dimensions. This is known as dimensional homogeneity. 
 
Before further discussing about Non-Dimensional Analysis, let’s understand the 
importance of Dimensional Analysis. 
 
• Dimensional analysis is used in numerical calculations, and in converting 
units 
• Dimensional analysis can help identify whether an equation is set up correctly 
(i.e. the resulting units should be expected) 
• Units are treated similarly to the associated numerical values, i.e. if a variable 
in an equation is supposed to be square, then the associated dimensions are 
squared, etc  
 
Units are a critical part of describing every measurement. Before we can work with 
units mathematically, we frequently must convert from one unit to another. 
 
An equation in which each term has the same dimensions is said to be dimensionally 
correct. All equations used in any science should be dimensionally correct. The only 
time we will encounter one which is not is if there is an error in the equation. So 
dimensional analysis is a valuable tool in helping you to detect an equation in which 
you made an error in algebra, for example. 
 
Consider Einstein’s well-known equation 2E mc= . Dimension Analysis requires both 
sides of the equations to have the same dimensions.  
 
E is energy, which has units of 2 2  /  mass length time×  ( )2 2/ML T . (This is because 
energy = force x length, and force = mass x acceleration, and acceleration = 
length/time2.) 
 
m is mass, which is M. 
c is speed, which has units L/T. 
 
The left-hand side, E, therefore has units of 2 2/ML T . 
The right-hand side, 2mc , has units 2 2/ML T . 
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The two sides therefore have the same dimensions. 
 
0.3.2 Buckingham π-Theorems 
 
Buckingham π-Theorems [1-5] states that if a system has k physical quantities of 
relevance that depend on depend on r independent dimensions, then there are a total 
of k-r independent dimensionless products π1, π2, …, πk-r. The behavior of the system 
is describable by a dimensionless equation: 
 
1 2( ,  ,  ..., ) 0k rθ π π π − =   (2) 
 
There are two theorems accredited to Buckingham π-Theorem, and known as his π-
Theorems. 
 
0.3.2.1 First π-Theorem 
 
This theorem describes how every physically meaningful equation involving k 
variables can be equivalently rewritten as an equation of k-r dimensionless 
parameters, where r is the number of fundamental units used. Furthermore, and most 
importantly, it provides a method for computing these dimensionless parameters from 
the given variables, even if the form of the equation is still unknown. 
 
0.3.2.2 Second π-Theorem 
 
Each π group is a function of r governing or repeating variables plus one of the 
remaining variables. The repeating variables are those which we think will appear in 
all or most of the π groups. As the π groups are all dimensionless, we can use the 
principle of Dimensional Homogeneity (in previous section) to equate the dimensions 
for each π group. 
 
It is very important that the initial choice of variables is carried out with great care. If 
extra unimportant variables are introduced, then extra π groups will be formed. They 
will play very little role influencing the physical behaviour of the problem concerned. 
If an important variable was missed, then a π group would be missing. 
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0.3.3 Application of Dimensional Analysis 
 
Based on the Buckingham π-Theorems, we have derived the following dimensional 
analysis method: 
 
(a) List all variables and their dimensions. 
(b) Count the number of variables k and the number of independent 
dimensional constraints r. 
(c) Based on Buckingham π-Theorem, find k-r independent dimensionless 
groups 1 2 3,  ,  ,  ...,π π π  by multiplying variables. 
 
The following is an example of Dimensional Analysis. 
 
A stationary sphere in water moving at a velocity of 1.6m/s experiences a drag of 4N.   
Another sphere of twice the diameter is placed in a wind tunnel. Find the velocity of 
the air and the drag which will give dynamically similar conditions. The ratio of 
kinematics viscosities of air and water is 13, and the density of air 1.28kg/m3.  
 
(a) List all variables and their dimensions. 
 
Variable Water Air Dimension 
u 1.6m/s uair LT-1 
Drag 4N Dair MLT-2 
ν  ν  13 ν  LT-1 
ρ 1000 kgm-3 1.28 kgm-3 ML-3 
d d 2d L 
 
(b) Count the number of variables k and the number of independent dimensional 
constraints r. 
 
Kinematic viscosity is dynamic viscosity over density =  ν  = µ/ρ.  
  
The Reynolds number: Re ud udρµ ν= =  
 
From Bukingham π-Theorem we have k- r = 5 – 3 = 2, non-dimensional groups. 
 
 xxvii
(c) Based on Buckingham π-Theorem, find k-r independent dimensionless groups 
1 2 3,  ,  ,  ...,π π π  by multiplying variables. 
 
( )
( )
1 1 1
2 2 2
1 2
1
2
, , , , 0
          , 0
                     
                     
a b c
a b c
d D
d D
d
θ µ ρ ν
θ π π
π µ ρ
π µ ρ ν
=
=
=
=
 
 
Each π  group is dimensionless. 
 
Considering 1π : 
   ( ) ( ) ( )1 110 0 0 1 3 2a cbM L T LT L ML MLT− − −=  
] 0 = 1
     1
1
1
M c
 c
+
= −  
 
1 1
1
] 0 =  -3  + 1
   -4 = 
1
1
L a b c
a b
+
+  
 
] 0 = - 2
      = -2
1
1
T a
a
−
 
 
      = -21b  
 
2 2 1
1
2 2    = 
d D
D
d
π µ ρ
µ ρ
− − −=
 
 
Considering 2π : 
( ) ( ) ( )2 220 0 0 1 3 2 1a cbM L T LT L ML L T− − −=  
 
] 0 = 
     0
2
2
M c
 c =  
 
 
2 2
2
] 0 =  -3  + 2
   -2 = 
2
2
L a b c
a b
+
+  
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] 0 = - 1
      = -1
2
1
T a
a
−
 
 
      = -11b  
 
1 1 0
2 
      =
d
d
π µ ρ ν
ν
µ
− −=
 
 
So the physical situation is described by this function of non-dimensional numbers, 
 
( )1 2 2 2, , 0Dd d
νθ π π θ µ ρ µ
⎛ ⎞= =⎜ ⎟⎝ ⎠  
 
For dynamic similarity these of non-dimensional numbers are the same for both the 
sphere in water and in the wind tunnel i.e. 
 
1 1
2 2
air water
air water
π π
π π
=
=  
 
For 2π : 
 
 
 
2 1.6
          
air water
air
d d
d d
ν ν
µ µ
ν ν
µ
⎛ ⎞ ⎛ ⎞=⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠
=× ×
-1
airµ = 10.4ms
 
 
For 1π  : 
 
( )
2 2 2 2
2 2 22
         
4
1.6 100010.4 2 1.28
                      
air water
air
D D
d d
D
dd
µ ρ µ ρ
⎛ ⎞ ⎛ ⎞=⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠
= × ××
airD = 0.865N
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0.4 Non-Dimensional Analysis 
 
In the physical sciences, dimensionless number is a quantity which describes a certain 
physical system and which is a pure number without any physical units. Such a 
number is typically defined as a product or ratio of quantities which do have units, in 
such a way that all units cancel. 
 
For example: "one out of every 10 apples I gather is rotten." The rotten-to-gathered 
ratio is [1 apple] / [10 apples] = 0.1, which is a dimensionless quantity. 
 
Dimensionless numbers are widely applied in the field of mechanical and chemical 
engineering. According to the Buckingham π-theorem [1-5] of dimensional analysis, 
the functional dependence between a certain number of variables; k can be reduced by 
the number of independent; r dimensions occurring in those variables to give a set of  
p = k − r independent, dimensionless numbers. For the purposes of the experimenter, 
different systems which share the same description by dimensionless numbers are 
equivalent. When plotting graphs, the quantities plotted are also dimensionless - the 
notation x (/s), for example, serves to divide the data (time in seconds) by the unit 
vector t, and produces a dimensionless value for plotting. 
 
A dimensionless group θ  formed from variables a, b, c ,d is a product of the variables 
raised to powers α, β, γ, δ, such that: 
  
• a b c dα β γ δθ =  
• (α, β, γ, δ) ≠ (0, 0, 0, 0) 
 
The constraint that θ  be dimensionless implies linear relationships among α, β, γ, δ. 
For the relativistic mass example, the constraint that m m v cα β γ δθ ≡  has no mass (M) 
dimension gives: 
 
0α β+ =   (3) 
 
The constraint that θ  has no length (L) dimension gives: 
 
0γ δ+ =   (4) 
 
The third dimensional constraint on θ  (no time T) reproduces constraint (2), so the 
number of independent constraints is just 2. 
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A set of dimensionless groups 1 2 3,  ,  ,θ θ θ  are independent if there is no relationship 
of the form: 
l m n
µ νθ θ θ=   (5) 
 
between them. Equivalently, if we think of the numbers (α, β, γ, δ) associated with 
each group as defining vectors, the groups are independent if the vectors  (α, β, γ, δ)1, 
(α, β, γ, δ)2, (α, β, γ, δ)3 are linearly independent. 
 
If there’s more than one dimensionless group, then there are indeed many choices for 
the set of independent groups. For example, the triangle problem 
 
Physical parameters Symbol Dimension
Area A L2 
Base a L 
Height b L 
No. of constraints 3 1 
 
can yield the dimensionless groups 
 ( ) ( )
( ) ( )
( ) ( )
2
2
3 4
and a b ;
or
 and b ;
or
Aband ;a
A a
A aab
Aa
b
 
 
But the answer from dimensional analysis, 
 
(one group)= F(all the groups), 
 
is always correct, and this answer is equivalent for any choice of the independent 
groups. All the changes is the meaning and form of the dimensionless function F. For 
example, for the first two choices of groups listed above, ( )1 12F x x=  and 
( )2 12F x =  respectively. If we wish to express the answer from dimensional analysis 
in the form (one variable) = f(the others), for example A = f(a, b) then we should 
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ensure that the chosen variable appears in only one of the groups. So the choice of 
groups 
 ( )Aab  and ( )2A a ; 
  
are valid, but not useful when we are trying to write ( , )A f a b= . 
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0.5 Information Calculus 
 
Claude E. Shannon (1960-2001) has been called "the father of information theory". 
His theory for the first time considered communication as a rigorously stated 
mathematical problem in statistics and gave communications engineers a way to 
determine the capacity of a communication channel in terms of the common currency 
of bits. The transmission part of the theory is not concerned with the meaning 
(semantics) of the message conveyed, though complementary wing of information 
theory concerns itself with content through lossy compression of messages subject to 
a fidelity criterion. 
 
On the early 1940’s, Shannon developed a mathematical theory [32], called 
information theory, for dealing with the most fundamental aspect of communication 
systems. Since then, researchers, engineers and scientists have been applying the 
theory in many areas of their own expertise for analyzing collected results such as [11, 
17, 20-22, 29].  
 
0.5.1 Fundamentals of Information Calculus (Information 
Theory) [20-22] 
 
Information comes in the form of data collected by researchers, engineers and 
scientists from which they derive conclusions and make conjectures. The modern 
computerized technologies in data acquisitions have enabled many parameters in an 
experiment to be colleted at simultaneously ease. This naturally makes researchers, 
engineers and scientists to collect data any time they think; it might be potentially 
important.  
 
As a result, they have included more data that might be irrelevant than to exclude 
them. As a result, it is easy to collect data and often difficult to analyze them. It was 
obviously, not all of the collected information is relevant to their research works. 
Hence, it will be necessary for them to be able systematically to single out variables 
that are important and discard those that are not. 
 
0.5.2 Information Calculus to select Relevant Variables if the 
variables are    Independent 
 
Intuitively, we assume that a variable is important if it is highly related to our problem 
and not important if it has nothing to do with our problem. For example, if the 
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percentage of diabetic patients is the same for every race (Chinese, Indians, Malays 
and minority races) is not important for diabetic-insulin kinetics research. On the 
other hand, if diabetic is much more prevalent among over-weight than normal-
weight subjects, then we say that over-weight is important for diabetic-insulin kinetics 
research. 
 
But how do we measure the degree of importance? Assume that we have two 
variables Y and X where Y is a dependent variable and X is an independent variable. 
Then the relevance of X with respect to Y is reflected by the statistical dependence 
between X and Y. X is absolutely irrelevant to Y if X is statistically independent of Y. 
 
 Besides, a variable might not be important for its sake. If everyone on this world is 
diabetic, then diabetic cannot be very interesting for diabetic-insulin kinetics research.  
(In fact diabetic cannot be interesting for any research, in this case). For either 
everyone gets diabetic or only some get it. In the case where only some become 
diabetic, over-weight obviously cannot be used to predict diabetics. In those cases 
where everyone get diabetic, although over-weight might cause diabetic, we cannot 
conclude anything because we do not have any data on non-diabetic. 
 
0.5.3 Measure of Self-Importance 
 
As pointed in the previous section, a variable cannot be important if it does not vary 
much; for example, it assumes only one value in all situations. Therefore, a 
reasonable way to measure self-importance of a variable is to measure its 
“randomness”. 
 
Let us denote a measure of the importance of an independent variable X with respect  
to a dependent variable Y by M(Y,X) and it should meet the following requirements: 
 
(a) M(Y,X) takes into account both the self-importance of X and its relevance with 
respect to Y. 
(b) M(Y,X) assumes the minimum value iff Y and X are statistically independent. 
(c) M(Y,X1) > M(Y,X2) iff X1 is more relevant to Y than X2 is.  
 
In our work of glucose-insulin kinetics modeling, we work intensely with mutual 
information. The concept of mutual information actually consists of two concepts: 
self-importance and conditional self-importance. The former corresponds to self-
importance and the latter corresponds to our concept of relevance.  
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0.5.4 Self-Information, Conditional Information and Mutual 
Information 
 
Definition 1: The self-information of an event E is defined as  
 
1( ) log
( )
I E
P E
=   (6) 
Definition 2: If random variable X assumes the values 1 2 ,, ,..., nx x x then the average 
self-information of X, H(x) is defined by 
 
1
( ) ( ) ( )
n
i i
i
H X P x I x
=
= ∑   (7) 
or 
 
1
1( ) ( ) log
( )
n
i
i i
H X P x
P x=
=∑   (8) 
 
and ( )H X is called the entropy of X. 
 
Similarly, the conditional entropy, 
 
Definition 3: For events E and F, the conditional self-informations are  
 
1( | ) log
( | )
I E F
P E F
=   (9) 
and 
 
1( | ) log
( | )
I F E
P F E
=   (10) 
 
Definition 4: For random variables Y and X assuming values 1 2, ,..., my y y  and 
1 2, ,..., mx x x  respectively, the conditional entropies are 
 
1 1
1 1
( | ) ( | ) ( | )
1               = ( | ) log
( | )
m n
i j i j
i j
m n
i j
i j i j
H Y X P y x I y x
P y x
P y x
= =
= =
=∑∑
∑∑
  (11) 
and 
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1 1
1 1
( | ) ( | ) ( | )
1               = ( | ) log
( | )
m n
j i j i
i j
m n
j i
i j j i
H X Y P x y I x y
P x y
P x y
= =
= =
=∑∑
∑∑
  (12) 
 
In the above, we have defined self-information and conditional self-information, we 
are going to define the final important concept, the mutual information I(Y,X). 
 
Definition 5: Let E and F be two events. The amount of information provided by the 
occurrence of event F about the occurrence of event E is defined as 
 
( | )( , ) log
( )
P E FI E F
P E
=   (13) 
 
The following function is defined because the information provided by F about E is 
indicated, in some way, by the change of the probability P(E) to P(E|F). The equation 
(8) can be expressed as: 
 
( | ) ( )( , ) log ;
( ) ( )
P E F P FI E F
P E P F
=   (14) 
( , )             = log ;
( ) ( )
P E F
P E P F
  (15) 
( | )             = log ;
( )
P F E
P F
  (16) 
 
If E and F are statistically independent, then P(E,F)=P(E)P(F). In this case, as can be 
seen from (10), I(A,B) reduces to zero (log 1 = 0). 
 
Definition 6: 
 
Let X and Y be two random variables where Y assumes values 1 2 ,, ,..., ny y y  and X 
assumes values 1 2 ,, ,..., nx x x . Then the expected value of information between Y and X 
is: 
1 1
1 1
( , ) ( , ) ( , )
( , )
               = ( , ) log
( ) ( )
m n
i j i j
i j
m n
i j
i j
i j i j
I Y X P y x I y x
P y x
P y x
P y P x
= =
= =
=∑∑
∑∑
  (17) 
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I(Y,X) is called the mutual information between Y and X. An important property of 
I(Y,X) can be expressed by the following two equations. 
 
( , ) ( ) ( | )I Y X H X H X Y= −   (18) 
and 
 
( , ) ( ) ( | )I Y X H Y H Y X= −   (19) 
 
In information theory, I(Y,X) is interpreted as the average information received by Y 
transmitted from X; H(X) is interpreted as the average information transmitted by X; 
and H(X|Y) is the loss. 
 
In data analysis, we interpret (Y,X) as the relative importance of X with respect to Y, 
H(Y) as the self-importance of X, and H(X|Y) as the irrevelance of X with respect to Y. 
 
We can conclude that I(Y,X) does meet the requirements  of the measurement 
M(Y,X): 
 
(a) I(Y,X) takes into account the self-importance of X and the relevance of X with 
respect to Y (13). 
(b) I(Y,X) is always nonnegative and I(Y,X) is zero iff Y and X are statistically 
independent of each other. 
(c) From (14), we obtain the relation 1 2( , ) ( , )I Y X I Y X>  iff 
1 2 ( | ) ( | )H Y X H Y X< . Since H(Y|X) is a measure of independence between 
Y and X, 1 2 ( | ) ( | )H Y X H Y X<  means that Y depends on X1 more than it 
depends X2. This justifies our claim that variable X1 is better than variable X2. 
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0.6 Information Calculus to select Relevant Variables 
if the variables are not Independent 
 
In section 0.5.2, we have presented Information Calculus to select variables if they are 
independent. In this section, we will discuss how to use Information Calculus to 
analyze medical data where the variables are not exclusive. The reduction of number 
of symptoms needed for characterization of patient’s state, diagnosis and prognosis. 
 
In the paper [18], Lee proposed that arranging the variables 1X , 2X ,…, mX  in 
decreasing order of mutual information shared with a variable Y. Once this has been 
done, one may set a maximum loss of information about Y which must not be 
exceeded. Then we may progressively discard those variables which tell us the least 
about Y from the bottom of this list until our threshold is reached. 
 
In his analysis, Lee decided to retain only the assumption of statistical independence 
of the iX . We now restate briefly his selection method. He derives the ranking 1sX , 
2sX , …, smX  by requiring that: 
 
I(Y, 1sX ) ≥  I(Y, Xs2,)≥ •••  ≥ I(Y, Xsm,)                                (20) 
 
because, when the Xi are statistically independent, 
 
I(y; 1sX , 2sX , …, snX ) = I(Y, 1sX ) + I(Y, 2sX ) + ••• + I(y, snX ), n ≤m,  
where 
I(Y, siX ) = H(Y) + H( siX ) - H(Y, siX )                              (21) 
 
By substituting (2) into (1), we derive (3), which is found in the paper [11] 
 
1 2
1 1
( ;  ,  ,....,  ) . ( ) ( ) ( , ),              
n n
s s sn si si
i i
I Y X X X n H Y H X H Y X n m
= =
= + − ≤∑ ∑       (22) 
 
Lee comments that the problem becomes much more complicated without this 
assumption of independence. Such a supposition is, however, seldom justified in the 
analysis of medical data for the variables are often highly correlated. Thus, the 
following more general solution is proposed. It will be shown that the extra work 
involved in dropping Lee's assumption need not be prohibitive [17]. 
 
The desired ranking may be achieved by using the formula 
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1 2 1 2
1 2
( ;  ,  ,....,  ) ( ) ( , ,....,  )
                                       ( ; , ,....,  ),              
s s sn s s sn
s s sn
I Y X X X H Y H X X X
H Y X X X n m
= +
− ≤                 (23) 
 
The complications to which Lee refers arise because instead of performing only m 
calculations using (2) of the mutual information 1( Y, Xt) of two variables and then 
substituting these to get (3), we now have to use (4), which requires 2m - 1 evaluations 
of the mutual information of up to m variables jointly. These complications can, 
however, be greatly reduced by retaining the X„ found from maximizing 1( Y; X, = 
Xi), j = 1, 2, . . ., m and then using it in the selection test for X,,,: maximization with 
respect to j of I(Y; X,,, X,,. = Xi), j = 1, 2, ..., m and s2≠s1, . Similarly, succeeding 
variables are found from 
 
1 2 1 2 1max ( ;  ,  ,....,  ), 1,2,..., ; , ,...,s s si j i iI Y X X X X j m s s s s −= = ≠   (24) 
 
 
This retention of each previously generated Xsi necessitates only in + (m - 1) + (m - 2) 
+ ... + 2 + 1 = m(m - 1)/2 calculations with (4) of mutual information as opposed to 
the previously mentioned 
 
2 1
1 2 1
mm m m m
m m
⎛ ⎞ ⎛ ⎞ ⎛ ⎞ ⎛ ⎞+ + ⋅⋅ ⋅ + + = −⎜ ⎟ ⎜ ⎟ ⎜ ⎟ ⎜ ⎟−⎝ ⎠ ⎝ ⎠ ⎝ ⎠ ⎝ ⎠  
 
needed for reevaluation of all the X„ whenever (4) is used to determine the next one 
in the ranking. 
 
The large reduction in computer time obtained by this slight sacrifice in rigor is 
obvious and the results we obtained by this technique [18, 19]. 
 
Now, the maximum knowledge we possess about Y is contained in all our m variables 
and is I(Y; Xs1 Xs2, . . ., Xm). So if we desire to reduce the size of our data base while 
maintaining most of this information content, we may use the maximization procedure 
(5) to tell us which of the Xi may be neglected without falling below a desired 
threshold 
 
1 2(1 ) ( ; , ,..., )mI Y X X Xε− ⋅ , 
 
where ε ? 1. Iteration proceeds n times until we first achieve 
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( )1 2 1 2( ;  ,  ,....,  ) 1 ( ;  ,  ,....,  )s s sn mI Y X X X I Y X X Xε≥ − ⋅   (25) 
 
If, say, ε = 0.05, then the "minimal subset"  1 2,  ,....,  s s snX X X  gives us 95% of the 
information about Y which is contained in all m members 1 2,  ,....,  mX X X  of the 
complete data base. 
 
It is useful to normalize the information I which is shared with Y by dividing into it 
the total information which Y possesses, H(Y), in order to get an explicit index of the 
amount of information known about Y relative to the total amount H(Y) which can 
ideally be known. This quotient has been defined by Nikl and Perez as the 
"information influence coefficient Z" [21] and can be readily seen to act as an index 
of the efficiency of our iteration procedure and thus of our ability to predict Y from 
the Xs. So, restating (6), iteration will proceed n times until we first achieve 
( )1 2 1 2( ;  ,  ,....,  ) 1 ( ;  ,  ,....,  )s s sn mZ Y X X X I Y X X Xε≥ − ⋅   (26) 
From the theory and discussion so far, it can be observed that Information Calculus 
relies on probability and statistics to determine the health conditions, treatment 
improvement and diseases classification. Even with high probability, there still a 
chance of false classification. Our modeling techniques that we are proposing will 
ensure the classification to be as accurate as the acquired data for our models. 
 
 xl
0.7 Summary of Author’s work on Non Dimensional 
Physiological Indices 
 
In the following chapters (1 to 5), we have realized that dimensional analysis has 
contribution to make to almost any problem and especially those where analytic 
methods fail. The ability to get dimensional and dimensionless relationships from 
differential equations is of great importance when the later too complex for analytic 
solution. Derivation of suitable dimensionless terms yields terms yields major insights 
into physical nature of particular problem .We have developed NDPIs for: 
 
(i) Oral Glucose Tolerance Test, to classify the patients into non-diabetic, 
diabetic or at-risk. The NDPIs can also distinguish the patients who are at-
risk from non-diabetic and diabetic. Then they can undergo pre-emptive 
medications [41-42]. 
 
6max 2 max
2 5
2
_ 10d
y y T T
G NDI
AG T
×= × × ×  
_I NDI βγδα=  
6max 2 max
2
2
_ _
        = 10d
NDI G NDI I NDI
y y T T
A TG
βγδ
α
= ×
× × × × ×  
α  : increases means insulin removed 
β  : increases means insulin responsive to glucose concentration 
γ  : decreases means blood glucose increases and not enough glucose 
absorbed by     tissues. 
δ : decreases means blood glucose increases and inadequate tissue glucose 
utilization. 
 
(ii) Lung Ventilatory function, to enable us to diagnose lung diseases in terms 
of just one non-dimensional lung-ventilatory index (VTI) number, 
incorporating the lung parameters resistance (R) and compliance (C) as 
well as the lung breathing rate [9, 45, 48].  
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(iii) Lung Gases Metabolism, to enable us to determine the lung efficiency in 
oxygen consumption and carbon dioxide rates, by one NDPI incorporating 
oxygen diffusion coefficient
2OD and carbon dioxide diffusion coefficient 
2COD [44,46-47, 49-51]. 
VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τa2 (BR)2 602 
where BR is the breathing rate. 
[ ] [ ]2
2
1
22 3 1 2 3
2
( ) ( )
P P P C
BR TV BR R TV
VTI
PC P C P C
τ= =  
 
(iv) Kidney Renal Dysfunctions, to enable us to quantify the severity of renal 
obstructions of both the patient’s kidneys by a NDPI [52-53]. 
 
NDI = 
Area under the curve between 60 sec and 120 sec for left kidney
Area under the curve between 60 sec and 120 sec for right kidney
 
 
In the paper by Naoki et. al [40], the team has developed a set of physiological indices 
based on electroencephalogram (EEG), electrocardiogram (ECG) and skin potential 
response (SPR) to reflect human condition related to comfortable aspect. These set of 
indices will be used as control parameters by the system to bring the user to the state 
of relaxation through audio-visual means. The system works based on the binary 
values of “low” or “high”. The scales of differentiation are determined through a 
series of experiments. But the team has not able to combine these qualitative ranges 
into quantitative values or a single non-dimensional physiological index. The 
significance of the above PNDIs will be discussed in the respective proceeding 
chapters. 
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Chapter 1 Glucose & Insulin Kinetics 
 
 
1.1 Motivation behind the Project 
 
Currently, there is no existing automated quantitative system to diagnose the 
endocrinological conditions of diabetic or diabetic prone patients. The diagnostic 
results are mainly based on qualitative analysis [14, 43, 57-58] by qualified clinicians. 
 
The desirability of maintaining an equivocal category of test results is supported in 
the interest of avoiding overdiagnosis of diabetes. ? pre-emptative, prevention  
 
1.2 Background 
 
Diabetes is a group of disorders resulting from insulin deficiency, impaired 
effectiveness of insulin action or both [27]. Insulin impairment leads to high levels of 
glucose in the blood as the body cannot break down this basic sugar. Diabetes 
mellitus is a serious condition in itself, but is also a risk factor for other conditions 
including blindness, renal failure, macro-vascular diseases, such as stroke, and 
ischaemic heart disease. There are four different types of diabetes based on aetiology 
and clinical presentation. These are type 1 diabetes, type 2 diabetes, gestational 
diabetes and other specific types of diabetes. Our work focuses on type 2 diabetes, 
which is characterized by insulin resistance and relative insulin deficiency [27].  
 
The prevalence of diabetes mellitus in Singapore has increased from 1.9% in 1975 to 
8.6% in 1992. The prevalence among Singaporeans aged 30 to 69 is 12%. Diabetes 
mellitus in Singapore is mainly of the non-insulin dependent type. Diabetes mellitus 
has been identified as a priority health program in the Singapore Government's 
National Health Agenda for the 1990s [12-15]. The Ministry of Health appointed the 
National Diabetes Commission (NDC) as an expert panel to review and provide 
advice on measures to prevent and control diabetes in Singapore. The NDC, in 
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consultation with a large number of physicians and health care professionals in 
Singapore and in reference to established guidelines from developed centres around 
the world, has drawn up the Singapore Practice Guidelines. These are mainly aimed at 
primary health physicians and members of the Diabetes Health Care Team who 
manage diabetics in Singapore.  
 
Type 2 diabetes mellitus is a complex metabolic disorder which leads to a variety of 
complications that include nephropathy, retinopathy and cerebrovascular and 
cardiovascular disease. The rapid economic development and the associated to 
lifestyles changes in Singapore have resulted in significant increases in the prevalence 
of coronary heart disease (CHD), which is now among top three leading causes of 
death among Singaporean [12]. Singapore is similar to other industrialized nations in 
that diabetes is an important risk factor for the development of CHD. In the Singapore 
Cardiovascular Cohort Study [16], one-third of patients who developed CHD had type 
2 diabetes at baseline. Individuals with type 2 diabetes are also at increased risk of 
mortality compared with non-diabetics, with heart disease contributing to about three 
out of every four deaths among persons diabetes [17]. 
 
According to the 1988 National Healthy Survey (NHS) [18], among Singaporeans 
aged 18-64 years of age, the prevalence of diabetes and impaired glucose was 
approximately 9% and 15%, respectively. In this survey, 62% of patients diagnosed 
with diabetes were previously undiagnosed. Globally, this places Singapore among 
countries with a  high rate of diabetes [19]. There are marked ethnic differences in the 
prevalence of diabetes in Singapore. The highest rate is seen among Indians (15.8%), 
followed by Malays (11.3%), and is lowest in Chinese (8.0%) [18]. The rate of 
increase in the prevalence of diabetes is occurring in both sexes and is particularly 
marked among the Chinese, with prevalence doubling from 4.7% in 1984 to 8% in 
1998 [12, 20, 21]. Singaporean Indians (15.8%) and Chinese (8.0%) are also at higher 
risk of developing diabetes than their counterparts from rural India (2.7%) and China 
(1.6%) [20]. 
 
Several factors may account for the higher prevalence of diabetes in Singapore. 
Although the molecular basis for type 2 diabetes is still poorly understood, both 
insulin resistance and beta-cell dysfunction are well documented [22, 23] and is likely 
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a result of both environmental influences and genetic factors [24, 25]. The ageing 
population in Singapore, increasing prevalence of obesity and a sedentary lifestyle 
parallel the rise in diabetes, and are likely contributors to this metabolic abnormality 
[12].  
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Figure 1.1 The organs of the digestive system. The pancreas is the organ responsible 
for regulating the blood glucose concentration by release of insulin. [Prof Gunther H, 
Bodyworlds] 
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Diabetes mellitus, named by Aretaeus of Cappadocia (AD 81-138), has been 
diagnosed since roughly 1500 BC. Nevertheless it is only recently that its treatment 
has been made possible, due to the discovery of insulin by Banting and Best in 1921. 
Diabetes has by the increased thirst and frequent urination experienced by the person 
with diabetes. Often, this person also feels a generalised weakness. Later in 1679 the 
discovery that the urine of a diabetic person had a sweet taste, gave the condition its 
name. The term "diabetes mellitus" was derived from 2 terms: 
 
(a) The Greek word Diabetes = to Siphon /pass through 
(b) The Latin word mellitus = sweet as honey 
 
Diabetes mellitus is a condition in which patients have high blood sugar. It is a 
common condition and affects 8.6% of the population in Singapore [12]. This is an 
increase from 4.7% in 1984. It is an important condition because there are many 
complications that can occur as a result of diabetes mellitus. These can be divided 
broadly into those that occur in the short term (the acute complications) and those that 
occur over a long time (the chronic complications). 
 
1.2.1 Types of Diabetes Mellitus 
 
There are 2 major types of diabetes mellitus [12, 18, 22, 23]: 
 
(i) Type 1 diabetes mellitus has also been known as juvenile-onset diabetes mellitus 
or insulin dependant diabetes mellitus. This is the less common type and usually 
occurs in young persons below the age of 35. In this condition, the body is unable 
to produce insulin. Insulin is a hormone produced by the pancreas, a gland that is 
in the abdomen. Insulin is a hormone that controls the use of different fuels for 
energy. It is especially important because it allows the body to use glucose (simple 
sugar) instead of fats. When there is no insulin, the body cannot use or store the 
glucose that comes from food and this causes the blood sugars to become very 
high. Instead, the body uses fat as a source of fuel giving rise to some of the acute 
complications of diabetes mellitus. 
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(ii) Type 2 (adult-onset or non-insulin requiring) diabetes mellitus is much more 
common and is the type of diabetes that affects most Singaporeans. In this type of 
diabetes, there is no shortage of insulin (at least at the start of the disease). Instead, 
the cells and tissues of the body are unable to respond to the insulin produced by 
the pancreas. This type of diabetes commonly occurs in persons who are 
overweight and have high blood pressure. There are often other family members 
who also have the disease. 
 
1.2.2 Acute complications of Diabetes  
 
Acute complications of diabetes include those in which the blood sugar is high 
(hyperglycaemia) and those in which the blood sugar is low (hypoglycaemia). These 
include diabetic ketoacidosis and hyperosmolar non-ketotic coma. 
 
1.2.2.1 Diabetic ketoacidosis  
 
Diabetic ketoacidosis occurs when there is insufficient insulin to deal with the amount 
of sugar in the blood stream. When this occurs, the body uses fat as an energy source 
and this resulted in the production of ketones that accumulate in the body. These 
ketones also appear in the urine and can be detected with a simple urine labstix test. 
 
Diabetic ketoacidosis often occurs in type 1 diabetes mellitus when the patient does 
not give him/herself insulin injections. In type 2 diabetes mellitus, it usually occurs 
when a patient has some other illness at the same time. This would include all types of 
infections or fever such as urine infection or chest infections. Other types of stressful 
events can also lead to diabetic ketoacidosis such as a heart attack. 
 
The symptoms of diabetic ketoacidosis include thirst, passing large volumes of urine, 
feeling very tired, nausea, vomiting and abdominal pain. Others may notice very deep, 
rapid breathing and a fruity smell on the breath. In severe cases, patients can become 
drowsy and become unconscious. This is an emergency and you must be seen 
immediately in a hospital. 
Diabetic ketoacidosis could be prevented by taking insulin and medication regularly, 
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especially when one is sick. When one is unwell, one should monitor one’s blood 
sugar frequently and give additional insulin when the blood sugar is high. 
 1.2.2.2 Hyperosmolar Non Ketotic Coma 
Compared to diabetic ketoacidosis, which can occur very quickly, hyperosmolar non 
ketotic coma occurs more gradually. One may feel thirst and pass large volumes of 
urine. This will result in one becoming more and more dehydrated. One will feel tired 
and may lose weight. Usually the urine ketones are negative or present only in small 
quantities. Patients may become more and more drowsy and become unconcious. This 
condition is more common in type 2 diabetes mellitus and may occur because of 
insufficient medication. More commonly, it occurs due to some other illness or injury 
such as infection. Once again, if the blood sugar is very high and you feel very 
unwell, it is important to consult one’s doctor quickly as this is also a diabetic 
emergency. 
 1.2.2.3 Chronic complications of diabetes mellitus 
 
Apart from the acute diabetic emergencies, high blood sugar does not cause death or 
disabilty in itself. Most of the disability from diabetes mellitus results from the 
chronic complications of diabetes mellitus and we stress again, these are preventable. 
The complications of diabetes mellitus affect many organs in the body and these 
include the eyes, heart, feet, kidneys, and the nervous system. 
 
1.2.2.4 Eye disease in Diabetes mellitus  
 
Diabetes mellitus can affect the eye in many ways. Cataracts and glaucoma are more 
common in patients with diabetes mellitus. In addition, it can affect the part of the eye 
at the back which is responsible for sensing light and colour, the retina. In the retina, 
small vessels become "leaky" resulting in the formation of exudates, which are the 
yellow areas seen in the picture below. If these exudates are too close to the most 
sensitive area of the retina, the macula, this can impair one’s vision. 
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Figure 1.2 Pictures illustrating haemorrhages and exudates. The basic anatomy of 
human eye ball is shown above [SGH, Endocrine Lab]. 
. 
 
Diabetes mellitus also causes weakness in the blood vessel walls causing them to 
bulge and form microaneurysms. Generally, all persons with diabetes mellitus 
develop some of these microaneurysms or exudates if they have diabetes for a 
sufficient length of time. Unless the exudates are very close to the macula, they and 
the microaneuryms are harmless and will not impair one’s vision. We call this 
"background retinopathy." In fact, almost all persons who have diabetes mellitus for 
20 years have changes that are due to background retinopathy. 
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Figure 1.3 Normal retina versus abnormal retina [SGH, Endocrine Lab]. 
Patients who have diabetes mellitus can also develop "proliferative retinopathy". In 
these cases, new blood vessels grow on the retina. These new blood vessels are fragile 
and can bleed giving rise to haemorrhage in the eye and this can lead to blindness.  
 It is important to pick up the changes due to maculopathy and proliferative 
retinopathy early as laser therapy can reduce the likelihood of loss of vision. In order 
to make sure that this is carried out at the right time, you need to go for regular eye 
screening. It is recommended that one have one’s eyes screened when one first find 
out one have type 2 diabetes mellitus. If they are normal, one should continue to have 
screening once a year. If there are any abnormalities that require attention, one’s 
doctor will refer one to an ophthalmologist (eye specialist) for treatment. Patients with 
type 1 diabetes mellitus do not require eye screening until 3 years after the diagnosis 
has been made and then once a year thereafter. 
 
 
 
  
 
Figure 1.4 Retina after treatment[SGH, Endocrine Lab]. 
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Screening can take 2 forms. Many centres can carry out fundal photography where a 
photograph is taken of the back of you eye allowing a doctor to look for any changes 
on the retina. The photograph will serve as a permanent record. In Singapore, the 
polyclinics have this service available. Contact your nearest polyclinic to find out 
when they have this service available as there are 2 cameras that move to various 
polyclinics at various times of the year. When a fundal camera is not available, your 
doctor can look at the retina directly using an instrument called an ophthalmoscope. 
Most doctors who manage diabetes will have an ophthalmoscope that can be used to 
examine the eyes carefully. Remember that your doctor has many patients to look 
after and make it a point to remind him or her of the time to examine your eyes. 
Diabetic eye disease is one of the reasons we must try to keep the blood sugar under 
strict control, the Diabetes Control and Complications Trial (DCCT) has shown us 
that good control of blood sugar results in less eye disease and even if you already 
have eye disease, it can prevent it from getting worse. 
The Diabetes Control and Complications Trial or DCCT was a large multi centre 
study conducted in the US which showed convincingly that tight glucose control 
prevented complications in type 1 diabetes mellitus. 
 
This was a large study that followed up 1441 patients with type 1 diabetes mellitus. 
The results showed that tight control of blood sugar reduced the development of 
diabetic eye disease by 76%. If patients already had eye disease, it prevented the 
worsening of the eye disease by 54%. There was also a reduction in kidney disease by 
50% and nerve disease by 60%. It is for this reason that we say that the chronic 
complications of diabetes mellitus are preventable. However, this requires effort on 
your part and also that of your health care team to maintain this kind of control. In 
addition, the treatment given results in an increase in the rate of hypoglycaemia (low 
blood sugar) and this must be carefully monitored. 
 
1.2.2.5 Diabetes mellitus and the heart [12, 19, 20] 
 
Coronary artery disease or blockage of the arteries supplying the heart is the major 
cause of death in patients with diabetes mellitus. It can result in heart attacks, heart 
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failure or angina. The risk of developing coronary artery disease in diabetic patients is 
known to be several times higher at every level of cholesterol. The multiple risk factor 
intervention trial (MRFIT) found that coronary artery disease risk in diabetic subjects 
at any given plasma cholesterol level was approximately four times greater than in 
non-diabetic patients. This is especially true in women who lose their "natural" 
protection against heart disease. 
 
With respect to heart disease, diabetes mellitus is more than just a problem of high 
blood sugar. In contrast to eye and kidney disease, good blood sugar control alone is 
not enough to prevent the development of heart disease. Diabetes mellitus is 
associated with widespread abnormalities in the blood. Of particular importance to 
heart disease are the blood lipids, which includes cholesterol and triglyceride. High 
triglyceride and low HDL cholesterol (the good cholesterol) is often seen in diabetic 
patients. In addition, the LDL cholesterol (the bad cholesterol) in diabetics may be 10-
15% higher than in non-diabetics. 
 
1.2.2.6 Kidney disease in diabetes mellitus [12, 19, 20] 
 
30-50% of patients with diabetes mellitus may develop kidney disease. Diabetes 
mellitus is now the more common cause of kidney failure requiring dialysis in 
Singapore.  
 
Kidney disease in diabetes mellitus usually follows a set pattern. It begins with the 
appearance of small amounts of a protein called albumin in the urine. This is called 
microalbuminuria and can be detected using specialised tests. It is important to screen 
for this stage of diabetic kidney disease because aggressive treatment can normalise 
the kidney function at this time. Speak to your doctor about a test for urine 
microalbumin. As with eye disease, this stage of kidney disease produces no 
symptoms and you will not know you have it unless you test for it. This should be 
done at the time of diagnosis for type 2 diabetes mellitus and yearly thereafter. Those 
with type 1 diabetes mellitus can wait 3 years before doing their first test. 
  
Later on, the amount of protein increases and patients reach a stage called nephrotic 
syndrome. This stage may be associated with swelling of the ankles or abdomen. As 
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the disease progresses, the patient can eventually develop kidney failure. These later 
stages of kidney disease are not reversible, i.e. Your kidneys cannot return to normal. 
However, treatment at this time can still slow down the progression of kidney disease. 
This is important as it will delay your requirement for dialysis, sometimes as much as 
5-10 years. 
 
The regulation of carbohydrate metabolism is a complicated process in which the 
anterior pituitary, the pancreas, the thyroid, the adrenal cortex and medulla, and the 
central nervous system are all involved. The mode of action of the hormones of the 
anterior pituitary on the blood sugar has not been fully elucidated, whereas the 
pancreas is known to produce glucagons as well as insulin. [18] on chromium (III) 
and the so-called “glucose tolerance factor” suggests that yet another biochemical 
mechanism may be involved in the regulation of glucose tolerance. There is 
consequently a large number of possible pathways through which carbohydrate 
metabolism can be influenced by the environment.  The possibility of disturbances in 
the regulation of carbohydrate metabolism on the day following a glucose tolerance 
test does not seem to have been taken account by [19], although such disturbances 
may be less marked if the subject’s diets are standardized before the test. In such 
circumstances, comparison of the results of glucose and galactose tolerance tests, 
performed on subsequent days, might not distinguish quantitatively between changes 
in glucose absorption and changes in glucose tolerance.    
 
1.3 Literature Review 
 
1.3.1 Conventional Screening 
 
From the paper [32], the differentiation between normality and very mild diabetes 
requires a somewhat arbitrary definition of criteria. Determination of the 
concentration of blood glucose 2 hours after a high-carbohydrate meal will often 
yield diagnostic information. 
 
Determination of the concentration of fasting blood glucose as an initial screening 
procedure in patients who are suspected of having diabetes because of such reasons 
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as obesity, family history of diabetes, previous glycosuria, or a history of large 
babies. 
 
The purpose of the study in [14] was to determine what correlation exists between 
the level of the blood glucose before the administration of a test dose of glucose and 
the frequency of significant abnormality, arbitrarily defined, of the subsequent 
glucose tolerance curve [2, 10, 12, 31, 26]. 
 
1.3.1.1 Methods 
 
For at least a day before the test [32], the patients were instructed to eat a diet high in 
carbohydrates. The tests were done in the morning after an overnight fast. The dose 
of glucose was 1gm per 1 kg of the actual body weight. Samples of venous blood for 
determination of glucose were obtained before and at hourly intervals for 3 hours 
after administration of the test dose. 
 
1.3.1.2 Analysis 
 
For a variety of reasons, overdiagnosis of diabetes should be avoided [32, 63], and an 
equivocal category such as we have employed seems justifiable. In this category the 
results of the tests are neither normal nor sufficiently abnormal to warrant a firm 
diagnosis of diabetes. In our experience, an appreciable number of patients with such 
tests eventually prove to have diabetes. 
  
In the definition of normality or abnormality [32] of the glucose tolerance curve, one 
must avoid, insofar as possible, the pitfall of “circular reasoning”, in which the 
persons subjected to the test are classified as nondiabetic or diabetic on the basis of 
the test under study. 
 
Even so, some circulatory of reasoning will be inescapable, for any large group of 
supposedly normal subjects is certain to include some mild diabetes. 
 
The above issues will be addressed and solutions will be proposed by our [2, 41, 31]. 
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Table 1.1 Tentative Arbitrary Criteria Employed at the Mayo Clinic in the Diagnosis 
of Diabetes Mellitus [32]. 
 
True blood glucose, mg per 100ml Test 
Normal Equivocal Abnormal 
Fasting 65 to 90 91 to 110 > 110 
Glucose tolerance*    
1 hour 140 or less 141 to 150 >150 
2 hour 90 or less 91 to 110 >110 
 
In the interpretation of the glucose tolerance curve, both the 1 and 2-hour values for 
blood glucose must fulfill the designated criteria: the fasting value is not considered. 
 
Table 1.2 Diagnostic values for the OGTT for diabetes mellitus: WHO definitions for 
1980, 1985 and 1999 compared. [26].  
 
Glucose concentration mmol/litre (mg/dl) 
Diagnostic 
criteria for 
diabetes 
mellitus 
compared 
Whole Blood Plasma 
 Venous Capillary Venous Capillary 
Fasting Value     
1980 ≥7.0 ≥7.0 ≥8.0 - 
1985 ≥6.7 (≥120) ≥6.7 (≥120) ≥6.7 (≥140) ≥6.7 (≥140) 
1999 ≥6.1 (≥110) ≥6.1 (≥110) ≥7.0 (≥126) ≥7.0 (≥126) 
OGTT: 2 hours 
post glucose 
load of 75g 
    
1980 ≥10.0 ≥11.0 ≥11.0 - 
1985 ≥10.0 (≥180) ≥11.1 (≥200) ≥11.1 (≥200) ≥12.2 (≥200) 
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1999 ≥10.0 (≥180) ≥11.1 (≥200) ≥11.1 (≥200) ≥12.2 (≥200) 
The SuRF report [26] includes data on the prevalence of diabetes which is presented 
with well-defined detection methods and diagnostic criteria. Detection methods of 
choice are a fasting blood glucose measure and/or an oral glucose tolerance test (using 
a 75 gram glucose load). The preferred diagnostic criteria are those of WHO from one 
of the following three time periods, 1980, 1985 and 1999 as shown in Table 1.2.  
 
The cut-off point for fasting blood glucose concentration has been lowered, meaning 
that the number of people considered to be diabetic now is different than in the past, 
based on this screening test. For the oral glucose tolerance test (OGTT), the 
diagnostic blood glucose concentration has remained the same. The OGTT is the 
preferred measure of diabetes in the population because it also detects impaired 
glucose tolerance and it provides a consistent measure of the prevalence of diabetes in 
populations over time.  
 
1.3.2 Physiological Modeling Techniques 
 
The paper [46] only works on one equation: 0 sin
tG G Ae tα ω−= +  for glucose 
response. Only critical damping and underdamp cases were studied. No overdamp 
cases were ever studied. 
 
In the paper [47], both the diabetic and non-diabetic clinical data sets are evaluated 
by the same equation. The data sets used are from a published paper [2]. Only 1 set 
per class for each example. Besides, 2 points were removed in figure 2 and 2 points 
added in figure 3, in order to get a fit. No experiments were done on reproducibility. 
No normalization has been performed.  
 
The paper [46] does not derive the any overdamp system equation. The diabetic data 
set used in figure 3 has never been verified by the overdamp case. The single 
parameter 2oω  gives the results of the subject under study. No insulin response to the 
bolus of glucose has been studied. 
 
In the paper [33], it is an extension of the earlier paper based on a segmented set of 
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characteristic equations.  Only non-diabetic cases are studied even though 31 subjects 
are involved in this research. Only glucose response was studied. 
 
1.3.3 Why OGTT ? 
Elrick et al. [45] had compared the insulin response to oral and intravenous glucose 
administration with the results of ten metabolically normal adult humans. They had 
discovered that plasma insulin responses shown a sifnificant difference: oral glucose 
resulted in a significant and sustained rise, whereas intravenous glucose was 
associated with a smaller and transient increase.  The plasma insulin increase with 
intravenous glucose is due to the effect of hyperglycemia on insulin secretion. The 
greater and more sustained increase in plasma insulin with oral glucose due to an 
additional stimulus to insulin secretion, possibly a gastrointestinal or liver factor 
triggered by alimentary glucose. Similar observations were also observed by 
Franckson et. Al [50], Hales et al. [51] and Vallance-Owen [52]. 
 
The Figure 1.5 from Elrick at al [45] shows the mean blood glucose throughout the 
2-hour study period fro two routes of glucose administration plotted as values above 
the fasting level. During the first hour, the glucose levels with the intravenous 
glucose averaged 14.8mg/dl higher than with oral glucose. During the second hour, 
the glucose concentrations averaged 7.6mg/dl higher with the oral glucose. In the 
combined 2-hour study period, the mean blood glucose difference between the two 
routes of glucose administration was 4.1 mg/dl (intravenous higher then oral). 
  
Figure 1.5 Blood glucose response to oral and intravenous glucose [45]. Each point 
is the mean value (for 10 patients) above the fasting level during and following a 60-
min constant infusion of glucose. 
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The Figure 1.6 is a plot of the mean plasma insulin levels at each time interval for the 
two routes of glucose administration plotted as values above the fasting level. During 
the first hour, there was a significant rise in plasma insulin with both oral and 
intravenous glucose. The mean increase with oral glucose was about 2/3 greater than 
that with intravenous. 
 
Figure 1.6 Plasma insulin responses to oral and intravenous glucose [45]. Each 
point is the mean value (for 10 patients) above the fasting level during and following 
a 60-min constant infusion of glucose. 
 
Solomon and Rosalyn [53] have investigated into the glucose and insulin responses 
of about 200 nondiabetic subjects and untreated nonketotic diabetic patients in 
various categories according to weight and degree of impairment of glucose 
tolerance. Both obesity and impairment of glucose tolerance are associated with 
higher than normal plasma insulin curves following glucose administration as shown 
in the Figure 1.7. The classifications are very similar what we had discussed earlier 
by Tables 1.1 and 1.2. 
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Figure 1.7 Blood glucose and plasma insulin concentrations in the fasting state and 
following oral administration of glucose in adult subjects [53]. Criteria employed: 
Non-diabetic peak <160 mg/dl and 2-hour glucose < 120 mg/dl; frank diabetes peak 
glucose  > 180 mg/dl and 2-hour glucose > 120 mg/dl; impaired glucose tolerance – 
glucose curves not satisfying either of above criteria.  
 
Because OGTT exhibits more responsive insulin responses after a bolus of glucose 
administered orally, we have selected OGTT modeling in our work [2, 10, 30, 31]. 
We will elaborate the details in the later part of this thesis. 
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 1.3.4 OGTT Kinetic Modeling 
 
1.3.4.1 Bolie Model 
 
Bolie [1] has formulated a glucose-insulin feedback theory for the purpose of the  to 
determine which physiological sensitivity coefficients dominate the mathematical 
characteristics of normal insulin and glucose tolerance curves. The mathematical 
model consists of coefficients for the insulin and glucose responses of liver, pancreas 
and peripheral tissues. 
 
The applicability of Bolie’s model has been justified by numerous medical 
publications [54-59]. The model has focused on the functions of major organs such 
as liver, pancreas and peripheral tissues acting through a single compartmental 
system. The model has been simplified to omit the actions of the kidneys and does 
not account for intravascular-extravascular differences in concentrations of insulin 
and glucose. As a result, the model has been the following limitations [1]: 
 
(a) glucose fluctuations outside the range of about 150 mg/dl; 
(b) rapid phenomena requiring gradations of time finer than 5-minute intervals; 
and 
(c) slow phenomena requiring time spans  of more then 5-hour. 
 
( ) -x p t x yα β= +?         (1) 
( )y q t x yγ δ= − −?                                                           (2) 
 
where x: blood insulin concentration (from its fasting level) in U/l, y : blood glucose 
concentration (from its fasting level) in g/l, p : insulin input-rate in U/hr/l, q : glucose 
input-rate in g/h/l, for unit blood-glucose compartment volume(V) in l, where x
?
, y
?
 
denote the first-derivatives of  x and y with respect to time. In these equations, the 
Glucose-Insulin model system parameters (regulatory coefficients) are α, β, γ, δ.  
 
α :  represents pancreatic insulin sensitivity to insulin in (hr)-1 
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β : pancreatic insulin sensitivity to elevated glucose blood concentrations in (Units) 
(hr)-1(gms)-1 
γ : liver glycogen storage to elevated blood-glucose concentrations in (gms)(hr)-1 
(Units)-1  
δ : tissue glucose utilisation to elevated blood-glucose concentrations in (hr)-1 
The experimental  data by Bolie [1] shows that these physiological coefficients 
approximate the critical-damping criteria of servomechanism theory. 
 
During his time, Bolie has no access to powerful digital computer which has perform 
iterative numerical calculations for convergence when calculating the regulatory 
coefficients (α, β, γ, δ). As a result, his work is mainly focused on critical damping 
response. In this thesis, our work [2, 10, 30, 31] explores the underdamp and 
overdamp responses as well as critical damping. We have adapted Bolie’s model into 
our multi-compartmental model which includes gastrointestinal and blood pool 
responses which we will elaborate in details later. 
 
1.3.4.2 Ackerman Model 
 
Ackerman et al [46] have derived a simplified block diagram the response of the body 
to added glucose as depicted in figure 1. Emphasis has been given to two variables; 
the blood-glucose concentration, G, and the blood-insulin concentration, H, both of 
which will vary as functions of time. 
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Figure 1.8 Block-diagram representation of feedback loop involved in glucose 
tolerance test. Question marks indicate uncertain reactions. Diagram is vastly 
oversimplified in that there is a different rate of metabolic utilization of glucose for 
each tissue [46]. 
 
From Figure 1.8, we can observe that organs and tissues are interlocked in a feedback 
loop. As a result, the system can oscillate. Ackerman et al.’s contains 16 
physiological  parameters, a few of which are uncertain. However, this number 16 is 
a minimum since one should indicate, for example, a different rate of glucose 
utilization in each tissue and also the roles of other hormones and of the nervous 
system. The model is also oversimplified in that it fails to take explicit account the 
role of the adrenal cortical and medullary function in glucose economy and of the 
portable heterogeneity of pancreatic insulin. 
Ackerman et al [46] have shown that the natural period measured can be used to 
distinguish diabetics, non-diabetic and normal-diabetic. But they only used one 
equation for all cases: 
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0 sin
tG G Ae tα ω−= +  
 
where 0G  : Fasting blood glucose concentration 
  α   :independent removal rates of glucose and insulin 
 A   :Underdamped amplitude 
 ω   : 2 2 20ω ω α= − ; 0ω  system natural frequency; and 
  ω   :system damped frequency 
 
The following Figures 1.9 to 1.11 show three types of curves that they have 
encountered. The curves are the best least-squares fit to the glucose concentrations in 
the blood. The Figure 1.9 is a physiologically normal one, and has constants that are 
slightly altered by deleting points at 30 and 90 minutes.  
 
Figure 1.9 A normal glucose-tolerance curve (example A of Table 2). Points show 
measured values, whereas solid curve shows computed best fit [46]. 
 
The curve in Figure 1.10 is a typical abnormal one which also be only slightly altered 
by adding points 30 and 90 minutes.  
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Figure 1.10 An abnormal glucose-tolerance curve (example C of Table 2). Note 
high, slow response [46]. 
 
The Figure 1.11 is a typical clinically normal subject response. It has normal 20ω , but 
it differs from the earlier normal curve in that the damping factor is and the free 
frequency is very small. This type of curve as shown would be drastically 
misinterpreted by the author’s curve-fitting rountine if the 30-minute point were 
omitted. 
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Figure 1.11 A normal glucose-tolerance curve (example B of Table 2). Note 
difference between this critically damped curve and the more usual normal curve of 
Figure 1.9 [46]. 
 
Table 1.3 Glucose-tolerance test. Curves fitted by formula 0 sin
tG G Ae tα ω−= + [78]. 
 
 
Ackerman et al. emphasize the importance of the choice of 0ω  rather than ω  or α  as 
the single most significant parameter in distinguishing health from disease. In order 
for a curve to be diagnosed as ‘abnormal’ on the criterion of low 0ω , it is necessary 
that both ω  and α  have low values. Our work [10, 30] have also the similar 
observations which we will describe in details later. 
 
 25
The response as shown in the Figure 1.11, is referred as ‘critically damping’ by Bolie 
[1]. In their works [78, 79], they have concluded that more than half of the normal 
curves and all of their abnormal subjects are ‘underdamp’. Ackerman et al. have 
reinforced their results for critcally damped subjects in [79]. In our work [41, 61], we 
have discovered that some subjects who classified as normal were in fact at-risk 
(critically damped) and some classified as diabetic clinically damped were at-risk; 
while some classified as normal were diabetic. 
 
1.3.4.3 Glucose Clamp Model 
 
During the 70’s, there were several new techniques had been introduced to quantify 
the influence of decreased peripheral insulin sensitivity on the impairment of the 
patient’s ability to tolerate a standard glucose load. These techniques allow for 
observation of the relationship between insulin and glucose utilization under 
conditions, in which the usual effect of glucose on the β-cells is prevented. This 
interaction is prevented either by suppression of insulin release by a combined 
infusion of glucose, epinephrine, and propranolol (“pancreatic Suppression Test” 
(PST)) [60-62] or by manual stabilization of the blood glucose concentration by 
variable “glucose-clamp” [3, 62]. 
 
The maintenance of blood sugar in man is a complex process involving 
feedback control of insulin on glucose and of glucose on insulin. For example, insulin 
administration to a person in a postabsorptive state produces hypoglycemia 
which is followed by counterregulatory mechanisms aimed at raising the 
decreased blood glucose but which may also affect the secretion of insulin 
itself. By use of the glucose clamp technique [74-75], the blood glucose 
concentration is maintained by a feedback-controlled glucose infusion after 
administration of physiologic amounts of insulin, thus preventing the appearance of 
such counterregulatory variables. The glucose infused to maintain a constant blood 
glucose is a measure of glucose utilization under such conditions. 
 
Insulin is also known to inhibit endogenous glucose productions in experimental 
animals and in man [63-73]. This effect supplements increased peripheral glucose 
utilization in causing blood glucose concentration to fall. 
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Analysis of isotope kinetic data involving a combination of tracer and tracee (cold) 
glucose experiments allows the development of a formal mathematical model in 
which the various metabolic factors can be imbedded and studied. A number of 
glucose models have been described so far; include feedback control of insulin on 
glucose [76-81]. These models did not isolate the individual controls but rather 
combined the entire system into a simplified glucose-insulin feedback system. By 
maintaining a constant blood glucose concentration, Insel et al. [34] have disrupted 
the feedback loop and were able to study isolated subsystem.  
 
 
 
Figure 1.12 The three-compartment basal glucose model with the mean population 
values for masses and exchange constants (n=6). Rate constants are in units/min; 
mean±SD. [3] 
 
Analyses of the control of glucose metabolism by insulin have been hampered by 
changes in blood glucose concentration induced by insulin administration with 
resultant activation of hypoglycemic counter regulatory mechanisms. To eliminate 
such mechanism, Insel et al.  [3] have employed the glucose clamp technique which 
allows maintenance of fasting blood glucose concentration during and after the 
administration of insulin. 
 
Glucose clamp involves 14C⎡ ⎤⎣ ⎦  glucose administered during a glucose clamp 
experiment. The analysis permitted Insel et al.  [3] to define a three-compartment 
glucose model to describe the control of insulin on glucose utilization, to quantify 
changes in endogenous glucose production induced by changes in insulin. 
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Pancreatic Suppression Test (PST) [60-62] and glucose-clamp techniques [3] have 
complicated technical problems for the estimation of insulin resistance. Thus we will 
not pursue further for our work. 
 
1.3.4.4 Minimal Model by Bergman 
 
Bergman et al. [4] has derived a set of seven mathematical models of glucose 
disappearance to estimate insulin sensitivity. Glucose was injected into subjects and 
the measured time course of insulin was regarded as “input”, and the falling glucose 
concentration as “output” of the physiological system storing and using glucose. The 
seven mathematical models of glucose uptake were compared to identify the 
representation most capable of simulating glucose disappearance in Table 3.  
  
The model structure, G is the measured plasma glucose concentration; 2G  is  
concentration in a compartment different from plasma; i is the deviation from basal 
value of actual plasma insulin concentration I ; 'i  is the deviation of insulin 
concentration 'I  in a compartment remote from plasma; LP  is glucose liver 
production; the k’s represent either fractional turnover rates or control actions; V is 
the glucose space; mV , mK  are Michaelis-Menten parameters. 
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Figure 1.13 Three proposed insulin-independent models of glucose metabolism. Left 
panel: proposed structure; middle panel: mathematical representation when 
parameters are defined as shown on the right panel. Values of k represent fractional 
turnover rates (min-1); P, hepatic glucose production; V, glucose space, and maxV and 
mK , Michaelis-Menten parameters. (0)G is glucose concentration that would obtain 
immediately after injection assuming no dynamics of mixing in glucose space [4]. 
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Figure 1.14 Four proposed insulin-dependent models of glucose metabolism. ( )I t , 
time course of plasma insulin supplied to model; 'I , concentration of insulin in a 
compartment remote from plasma. 0B , extrapolated hepatic glucose production at 0 
glucose concentration [4]. 
 
1.3.4.4.1 Model I 
 
It is assumed in this model that glucose production is constant, that glucose 
distributes in a single compartment, and that the rate of glucose utilization is a linear 
function of plasma glucose concentration. The parameter 1k  in this model (Figure 
1.13) represents the classical diagnostic glucose disappearance term KG, which is 
obtained from a semilogarithmic plot of glucose disappearance kinetics. The success 
of this model is therefore related to the acceptability of KG as a measure of the 
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glucose disappearance rate. The equation of this model is thus 
 
( )1 2 , 0 ssdG p G p  G Gdt = + =  
 
where ( )0 ssG G=  , 1 1p k=  and 2 Lp p=   
 
1.3.4.4.2 Model II 
 
This model is identical to model I except that glucose utilization is a saturable 
process that obeys Michaelis-Menten kinetics and depends on the plasma glucose 
concentration: 
 
1
3
2
,p GdG p
dt p G
= ++  
 
where 1 m 2 m
Vp , p K ,
V
−= =  and 3 Lp =p  . 
 
1.3.4.4.3 Model III 
 
The third model assumes that glucose distribution is represented by two 
compartments. Disappearance from either compartment is linearly dependent on 
glucose concentration in that compartment. Glucose production is constant. 
Multicompartmental glucose distribution has been widely suggested. 
 
( )1 2 3 , 0 ssdG p G p X p  G Gdt = + + =  
 
( )4 , 0 0dX G p X  Xdt = + =  
 
where ( )2 1 1 3 2 1 2
1
, 3 L
GX , p k k , p k k  p p  
k
= = − + = =  , and ( )4 2 4p k k= − + . 
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1.3.4.4.4 Model IV 
 
Glucose disappearance in this model is linearly dependent on both the plasma 
glucose and insulin concentrations. Glucose distributes in a single compartment, and 
the production is assumed constant. The relationships among insulin, glucose, and 
glucose disappearance used in this model were first proposed by Bolie [1] and have 
been assumed in a substantial fraction of those studies that have used system (model) 
identification to analyze to analyze glucose kinetics for clinical purposes e.g. 
Ackerman [38] and Segre et al. [76]. The extent of the success of model IV to 
account for disappearance relates to the potential applicability of the Bolie model [1] 
(and its descendants) for purposes of diagnosis. 
 
( )1 2 3, 0 ssdG p G p I p  G Gdt = + + =  
 
where 1 1 2 2p k , p k , = − = − and 3 Lp p= . 
 
1.3.4.4.5 Model V 
 
This model assumes that glucose uptake is directly dependent on the concentration of 
insulin, not in plasma but in a second compartment of insulin distribution remote 
from plasma. This proposition is based on the studies of Sherwin et al. [75] and is 
consistent with the existence of a remote receptor compartment that is intimately 
involved in the action of insulin, Zeleznik and Roth [82]. In this model insulin enters 
the remote compartment, concentration 'I , and it is this which increases glucose 
disappearance independent of insulin, and glucose production is constant. 
 
( )1 2 3, 0 ssdG p G p I p  G Gdt = + + =  
 
( )4 0dX p X i, X 0dt = + =  
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where 
'
2
iX
k
= ,  1 1 2 2 4p k , p k k , = − = − 3 Lp p= , 4 3p k= − , ssi I I= − , and ' ' ssi I I= − . 
 
In models I-V, glucose production is assumed to be constant at all times. Because it 
has long known that insulin inhibits glucose production, model VI and VII are 
introduced in which this interaction is included. Two approached are used. In model 
VI, glucose production and hepatic glucose uptake are lumped together as net hepatic 
glucose balance. In model VII an alternative approach is used; that is hepatic and 
peripheral glucose utilization are lumped together, and absolute glucose production is 
represented explicitly. 
 
1.3.4.4.6 Model VI 
 
In this model the rate of change of glucose is the difference between the net hepatic 
glucose balance B (which may take on positive (production) or negative (uptake) 
values), and the disappearance of glucose into peripheral tissues only ( pU ). It has 
previously been shown that hepatic glucose balance varies according to a relation of 
the form [4]. 
 
( )'0 5 6B B k k i G= − −  
 
where B is the net hepatic glucose balance; and 0B is the value expected when plasma 
glucose concentration is extrapolated to zero. It is assumed that the insulin acts from 
a remote compartment, as in model V. 
 
For glucose utilization we may write a similar expression 
 
( )'1 4pU k k i G= +  
 
where ( ) '4 6X k k i= + , ( )1 1 5p k k= − + , 2 3p k= − , ( )3 2 4 6p k k k= + , and 4 0p B= . 
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1.3.4.4.7 Model VII 
 
In this model “absolute” hepatic glucose production and its inhibition by remote 
insulin are explicitly represented. Utilization (which, in this case, includes hepatic 
and peripheral) is described by a similar nonlinear function as in model VI. 
 
 
( ) ( )31 2
4
, 0
1 ss
pdG p p X G  G G
dt p X
= + + =+  
 
( )5 0dX p X i, X 0dt = + =  
 
where  
'
2
iX
k
= , 1 1p k= − , 2 2 4p k k= − , 3
5
Lpp
k
= , 24
5
kp
k
=  and 5 3p k= − . 
Initial conditions in all models are related to basal values of glucose and insulin 
concentrations. The rapid glucose intravenous injection is treated as an impulsive 
input function [in all models a parameter ( )0G +  can also be defined, that is, the 
glucose concentration that would obtain immediately after the injection assuming no 
dynamics of mixing in the glucose space]. In models IV-VII the measured time 
course of insulin was supplied as a model input. 
 
 
34
Ta
bl
e 
1.
4 
Su
m
m
ar
y 
of
 M
in
im
al
 M
od
el
 se
le
ct
io
ns
 a
nd
 b
eh
av
io
ur
s. 
 M
od
el
 
Th
eo
re
tic
al
 
Id
en
tif
ia
bl
y 
Pr
ac
tic
al
 
Id
en
tif
ia
bl
y 
St
at
ist
ic
s O
f 
R
es
id
ua
l 
Er
ro
rs
 
G
oo
dn
es
s o
f F
it 
an
d 
N
um
be
r 
of
 
Pa
ra
m
et
er
s 
A
cc
ep
ta
nc
e 
on
 t
he
 B
as
ic
s 
of
 Id
en
tif
ic
at
io
n 
R
es
ul
ts
 
O
ve
ra
ll 
Ph
ys
io
lo
gi
ca
l 
Pl
au
sib
ili
ty
 
I 
U
ni
qu
el
y 
Id
en
tif
ia
bl
e 
U
na
cc
ep
ta
bl
e 
A
cc
ep
ta
bl
e 
U
na
cc
ep
ta
bl
e 
N
o 
N
ot
 c
on
si
de
re
d 
II
 
U
ni
qu
el
y 
Id
en
tif
ia
bl
e 
U
na
cc
ep
ta
bl
e 
U
na
cc
ep
ta
bl
e 
N
ot
 c
on
si
de
re
d 
N
o 
N
ot
 c
on
si
de
re
d 
II
I 
U
ni
qu
el
y 
Id
en
tif
ia
bl
e 
U
na
cc
ep
ta
bl
e 
U
na
cc
ep
ta
bl
e 
N
ot
 c
on
si
de
re
d 
N
o 
N
ot
 c
on
si
de
re
d 
IV
 
U
ni
qu
el
y 
Id
en
tif
ia
bl
e 
U
na
cc
ep
ta
bl
e 
U
na
cc
ep
ta
bl
e 
N
ot
 c
on
si
de
re
d 
N
o 
N
ot
 c
on
si
de
re
d 
V
 
U
ni
qu
el
y 
Id
en
tif
ia
bl
e 
A
cc
ep
ta
bl
e 
A
cc
ep
ta
bl
e 
A
cc
ep
ta
bl
e 
Y
es
 
M
ar
gi
na
lly
 a
cc
ep
ta
bl
e 
V
I 
U
ni
qu
el
y 
Id
en
tif
ia
bl
e 
A
cc
ep
ta
bl
e 
A
cc
ep
ta
bl
e 
A
cc
ep
ta
bl
e 
Y
es
 
A
cc
ep
ta
bl
e 
V
II
 
Id
en
tif
ia
bl
e 
U
na
cc
ep
ta
bl
e 
U
na
cc
ep
ta
bl
e 
N
ot
 c
on
si
de
re
d 
N
o 
N
ot
 c
on
si
de
re
d 
  
 35
The works and results of Bergman et al. [4] are summarized the results are shown in 
Table 1.4. From the table, only models V and VI appear to be acceptable in being 
able to describe the experimental data set with the smallest set of identifiable and 
feasible parameters. They have been compared from a physiological point of view: 
model VI includes insulin inhibition of liver glucose production (represented as net 
hepatic glucose balance), whereas model V assumes constant production. Model VI 
was therefore selected as it is more consistent with known physiology on glucose 
metabolism. Implicit assumption in the chosen model are that: 
 
(a) glucose distributes into a single well-mixed compartment, and 
(b) the disappearance of glucose and the net rate of hepatic glucose 
appearance are nonlinear functions of plasma glucose and insulin in a 
compartment remote from plasma. 
 
Bergman et al. [4] have discussed the failure of model IV, which represents the 
glucose portion of the model first introduced by Bolie [1] to analyze glucose tolerance 
tests for clinical purposes. The failure is as a result of the poor parameters 
identification and fitting. Prof Dhanjoo Ghista has adopted and improved the works of 
Bolie [1] and model VI by Bergman et al. [4] to form a new model for our continual 
research work [2, 10, 30]. Numerous simulations have been done to verify the new 
model and non-dimensional indices were derived based on the identified system 
parameters for glucose and insulin responses from clinical data collected by OGTT. 
We will discuss the details later in the chapter. 
 
1.3.5 Reproducibility 
 
[35] has reported that changes in glucose tolerance may occur if a glucose tolerance 
test is repeated more than once in 5 days. [47] suggests, however, that the occurrence 
of such changes is restricted to the day following a glucose tolerance test. 
 
Loh KM et al. [2, 10, 30, 31]  have tested the reproducibility of the system models by 
performing simulations with clinical data. The derived non-dimensional indices NDIs 
have shown convergence and reproductivity discussed by Loh KM and Prof Dhanjoo 
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Ghista [30] . 
 
Our work’s parameters were chosen for quality reflect the key medical attributes of 
the patient response (fitting process with very high R-Square (>95%) and low SSE 
(<<5%)). 
 
1.3.6 Fitting Results  
 
Displays detailed results for the current fit including the fit type (model, spline, or 
interpolant), the fitted coefficients and 95% confidence bounds for parametric fits, 
and these goodness of fit statistics:  
 
SSE -- The sum of squares due to error. This statistic measures the deviation of the 
responses from the fitted values of the responses. A value closer to 0 indicates a better 
fit.  
 
R-square -- The coefficient of multiple determinations. This statistic measures how 
successful the fit is in explaining the variation of the data. A value closer to 1 
indicates a better fit.  
 
1.3.7 The Oral Glucose Tolerance Testing Protocol Adopted 
 
The test subjects need to fast for 12 hours before the test and during the 2-hour test. A 
blood sample of the subject is taken before the beginning of the test. After the subject 
drinks a 75 g of glucose solution dissolved in 250 mL to 300 mL of water, the 
subject’s blood glucose and insulin concentrations are measured at specified intervals 
of 30 minutes, 60 minutes, 90 minutes and 120 minutes. 
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1.3.7.1 Qualitative interpretation of the results, for preliminary categorisation of 
the patients: 
 
(a) Blood glucose normal values [11, 12, 26, 42]:  
fasting: 70 to 115 mg/dL, 
30 min : less than 200 mg/dL, 
1 hour : less than 200 mg/dL, 
2 hours : less than 140 mg/dL. 
 
Normal insulin level (reference range): 1 to 30 mU/L [11, 12, 26, 42]: 
 
 (b) Impaired Glucose Regulation: 
When a person has a fasting glucose equal to or greater than 110 mg/dL and 
less than 126 mg/dL, it is considered as impaired fasting glucose. This is 
considered as a risk factor for diabetes and will likely trigger another test in 
the future, but by itself does not provide sufficient evidence for the diagnosis 
of diabetes. 
 
A person is said to have impaired glucose tolerance when the 2-hour glucose results 
from the oral glucose tolerance test are greater than or equal to 140 mg/dL but less 
than 200 mg/dL.  This is also considered a risk factor for future diabetes. A person is 
deemed to be diabetic when the oral glucose tolerance tests show that the blood 
glucose level at 2 hours is equal to or more than 200 mg/dL.  This must be confirmed 
by a second test on another day. 
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1.4 Author’s Work of Systems Engineering View of 
OGTT Blood Glucose & Insulin Responses 
 
When a glucose bolus is administered to a normal person, typical blood glucose and 
insulin concentration-time profiles are illustrated in Figure 1.15, and can be regarded 
to be under-damped responses [10, 30]. However, when a glucose bolus is 
administered to a typical diabetic patient, the blood glucose and insulin concentration-
time profiles (illustrated in Figure 1.16) appear to be over-damped. 
 
 
Figure 1.15 When glucose bolus is administered to a normal person, a typical 
response of blood glucose and insulin correlation (normalised). 
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Figure 1.16 When glucose bolus is administered to a diabetic patient, a typical 
response of blood glucose and insulin correlation (normalized). 
 
Comparing figures 1.15 and 1.16 [1-3, 10, 30], we note that a normal person’s glucose 
response is such that the blood-glucose concentration (normalised with respect to the 
fasting or initial value) peaks at levels of up to 1.06 g/L, and is back to 0 g/L by the 
end of 2 hours. Likewise, the response curve for blood-insulin (normalised with 
respect to fasting blood-insulin concentration) can peak up to 0.2 U/l and should 
return to 0 U/L at the end of 2-hour. On the other hand for this typically diabetic 
patient, the blood-glucose concentration is peaking at 2.28 g/L, and falls to only 2.20 
g/L by the end of 2 hours. The blood insulin curve peaks at 0.04 U/L at the end of 2 
hours, and remains at this level. 
 
The advantage in plotting the responses in the form of curves is that it enables us to 
quantify the clinical criteria in the form of the nature (and parameters) of the response 
curve (i.e., under-damped or over-damped). There are patients who do not fall into 
either clinical category. Their response curves can place them into a critically damped 
domain, whereby they are neither normal nor diabetic but at risk of becoming 
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diabetic. Even more relevantly, we can combine the parameters into a nondimensional 
index. 
 
There are many works on modeling of glucose-insulin dynamic and regulation [1-3, 
5-10, 30]. However, this paper is specifically oriented to modeling the glucose and 
insulin responses to ingested glucose bolus for OGTT. Herein, the glucose 
concentration-time data is simulated by an appropriate type of solution (under- or 
over- or critically damped) of the governing differential equations for glucose and 
insulin responses to glucose bolus ingestion. The diagnosis of the patient (as normal, 
at risk of being diabetic, as borderline diabetic, as diabetic) depends on the solution 
category into the clinical data fall.  
 
This chapter uses 3 equations from the author’s work [10, 30]. Each set of equations 
for each system response and y(t) for glucose and x(t) for insulin responses (the 
derivations are shown in section 1.4.1.2): 
 
y(t) = (G/ ω) e-At sinωt    (underdamp : non-diabetic) 
 
( ) ( ) ( ) ( )(sin( ) sin( ) cos( ) )
( ) 2 2 22
GAt At t Atwt Ae wt e e w wt e w
wx t
A A w
αα β
α α
− − − −− − − +
=
− + +
 
 
G -Aty(t)= e sinhwt
ω       (overdamp : diabetic) 
1 (cosh( ) sinh( ) cosh( )
2
sinh( ) sinh( ) cosh( )
sinh( ) sinh( ) cosh( )
cosh( ) cosh( ) 2 sinh(
( )
wt At t A wt At t A wt At t A
wt At t A wt At t w wt At t w
wt At t wt At t wt At t
wt At t w wt At t w wt
x t
α α α
α α α
α α α α α α
α α α
+ − + − + − − − + − −
+ − + − − − − + − −
− − − + + − − + − −
− − + − + − + + −
= ( )
( )
2 2 2
) )
 
2
t GAt t w e
w
w A A
αα β
α α
−
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟+ −⎜ ⎟⎝ ⎠
− + − +
 
 
-Aty(t)= Gte   (crtically damp : at the rim of becoming diabetic) 
 
( ) ( ) ( ) ( )
2
( )( )
( )
At At At tG tAe t e e ex t
A
αβ α
α
− − − −− − + −= −  
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In the author’s published paper [10, 30], each set of clinical data is analyzed by the 
above 3 equations to determine the class of system response based on the best fit 
result. All the clinical data sets are collected and analyzed by a qualified clinician 
concurrently. The models are tested for reproducibility using about 37 sets of clinical 
data. The results are verified against the clinician’s diagnosis. None of the points 
were removed. All the data points were crucial. 
 
All the clinical data is normalized by the respective fasting values. Normalization 
helps improve the accuracy of subsequent numeric computations. All the glucose & 
insulin parameters (α, β, γ & δ) to determine the actual physiological performance of 
the system. The best fit results of individual determines the class of response. 
 
Both the blood glucose and insulin responses are analyzed simultaneously. From our 
work it is very crucial to know both the glucose and insulin responses simultaneously 
to be certain if the patient has been diagnosed correctly. The worst scenario will be a 
at-risk case be wrong classified as non-diabetic ? no pre-emptive treatment can be 
done. The models applied in this paper can help to reduce the risk. 
 
We do not used segmented equation as published in [33, 46-47] as a result, we do 
need predetermined ranges and hence we do not have discontinuities. The system is 
modeled continuously. We have studies 37 subjects aged range from 19 to 67 years 
old, all 3 classes of responses were studied in detail. Both glucose and insulin were 
studies simultaneously. How the physiological system responses to the orally 
ingested bolus of glucose were monitored closely for 2 hours at 30 minutes intervals. 
In all cases, we have accurately diagnosed the heath conditions of the patients. The 
accuracy of diagnosis is contributed by both the glucose and insulin responses being 
analyzed simultaneously. 
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 1.4.1 Differential equation model of the Glucose-Insulin System  
 
The compartmental block diagram of the Blood Glucose & Insulin Regulatory System 
(BGIRS) [1-3] is illustrated in figure 1.17. The glucose input-rate into the blood-pool 
is represented by ‘q’ in the figure. From the blood-pool, glucose is metabolised into 
the tissues in two ways, as represented by the two terms δy (removal-rate of glucose 
from the blood-pool independent of insulin) and γx (removal-rate of glucose under the 
influence of insulin). In return, the glucose influences the release-rate of insulin into 
the blood-pool by the pancreas, as represented by the term βy. The insulin is also 
removed independently of glucose, as per the term αx. 
 
 
1.4.1.1 Modeling of Glucose-Insulin Regulation of Oral Glucose Tolerance Test 
(OGTT) 
 
We will adopt the linearised  bio-mathematical model of Bolie [1], as the basis of our 
modelling, because it is simple but still compatible with the known physiological 
mechanisms. This model characterizes the Glucose - Insulin system by means of the 
differential equations (given below as equations 1& 2) with four parameters: α, β, γ 
and δ, representing pancreatic insulin sensitivity to insulin and glucose blood 
concentrations, tissue glycogen storage and tissue glucose utilization to elevated 
blood-glucose concentrations.  
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Figure 1.17 Blood Glucose-Insulin Control System (BGIRS). Block diagram of (i) 
insulin level & rate-of-change of insulin ( )x t
?
 governs blood-glucose 
concentration ( )y t , and (ii) rate-of-change of glucose ( )y t
?
 is influenced by insulin 
concentration ( )x t  & ingested glucose input rate ( )q t . 
 
The above block diagram [1, 3] of how (i) Insulin level and rate of change of insulin 
governs blood-glucose concentration  y(t), and (ii) rate-of-change of glucose is 
influenced by insulin concentration x(t) and injected glucose input rate q(t). 
α :  represents pancreatic insulin sensitivity to insulin in (hr)-1 
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β : pancreatic insulin sensitivity to elevated glucose blood concentrations in (Units) 
(hr)-1(gms)-1 
γ : liver glycogen storage to elevated blood-glucose concentrations in (gms)(hr)-1 
(Units)-1  
 
δ : tissue glucose utilisation to elevated blood-glucose concentrations in (hr)-1 
 
1.4.1.2 The Governing Differential equations for Glucose and Insulin Systems 
By considering the conservation-rates of glucose and insulin in their respective 
compartments, we obtain the basic equations, governing BGIRS. With reference to 
the Blood Glucose-Insulin Control System (depicted in figure 1.17), the 
corresponding first-order differential - equations of the insulin and glucose regulatory 
sub-systems are given by [32, 34, 35]: 
  
( ) -x p t x yα β= +?         (1) 
( )y q t x yγ δ= − −?                                                           (2) 
 
where x: blood insulin concentration (from its fasting level), y : blood glucose 
concentration (from its fasting level), p : insulin input-rate, q : glucose input-rate, for 
unit blood-glucose compartment volume(V), where x׀, y׀ denote the first-derivatives of  
x and y with respect to time. In these equations, the Glucose-Insulin model system 
parameters (regulatory coefficients) are α, β, γ, δ.  
 
From equations (1) & (2), we obtain the differential-equation model (for glucose- 
concentration (y) and insulin-concentration (x), for insulin infusion rate (p=0) and 
glucose inflow rate (q). For glucose response, we obtain:  
 
Differentiating equation (2) on either side with respect to ‘t’, we get: 
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( )
( )
( )
( ) ( )
     ,  upon substituting for  from equation (1)
     
     , upon substituting for ( x)from equation (2)
     
y q x y
q x y y x
q x y y
q q y y y y
q q y y
γ δ
γ α β δ
α γ βγ δ
α δ βγ δ γ
α α δ αδ βγ
= − −
= − − + −
= + − −
′= + − − − −
= + − + − +
?? ? ? ?
? ? ?
? ?
? ?
? ?
 
 
Rearranging we get the Differential equation: 
 
( ) ( )y y y q qα δ αδ βγ α+ + + + = +?? ? ?                                         (3)  
 
wherein  y
?
 &  y
??
 denote first & second time derivatives of y.  
 
Differentiating equation (1) on both sides with respect to ‘t’, we get 
 
( )
( )
,  assuming p  0
    ,  upon substituting for  from equation (2)
    
    ,  upon substituting for y from equation (1)
x x y
x q x y y
x q x y
x q x x x
α β
α β γ δ
α β βγ δ β
α β βγ δ α β
= − + =
= − + − −
= − + − −
⎛ ⎞= − + − − +⎜ ⎟⎝ ⎠
?? ? ?
? ?
?
? ?
 
 
( ) ( )x x x qα δ αδ βγ β+ + + + =?? ?                                                                            (4)  
 
wherein x
?
 &  x
??
 denote first & second time derivatives of x.  
 
1.4.1.3 Laplace Transform Representation of the Governing Equations (3 & 4)  
 
The Transfer-function (TF) corresponding to equation (3) is obtained by taking 
Laplace transforms on both sides (assuming the initial conditions to be zero): 
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s2Y(s) + sY(s) (α+δ) + Y(s) (αδ + βγ) = Q(s) (s + α)  
  
Thereby, we obtain (for glucose response):  
 
( ) ( )( ) ( ) )()(/)( 2 sGss
ssQsYsG =++++
+== βγαδδα
α                      (5)     
 
This transfer function, G(s) can be expressed in the form  
 
( )( )( )21)(/)()( psps
ssQsYsG ++
+== α      (6) 
 
and if 1 2p p α δ+ = + , and 1 2p p αδ βγ= + , and 1p  & 2p  are the roots of the 
quadratic equation: 
 
( ) ( )2 0p pα δ αδ βγ− + + + =      (7-a) 
 
and are given by 
 
( ) ( ) ( ){ }
( ) ( ){ }
1/ 22
1 2
1/ 22
4
&
2
4
             
2
p p
α δ α δ αδ βγ
α δ α δ βγ
+ ± + − +=
+ ± − −=
     (7-b)                                        
                                                                                                                                 
Let us put 
 
22 ,  &  nAα δ αδ βγ ω+ = + =  
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Then 
( )
1 2
1
2 2 2
,  
,   
,   
n
n
n
p p
A A
A if A
A i if A
ω
ω ω
ω ω
⎫= ± − ⎪⎪= ± > ⎬⎪= ± < ⎪⎭
       (7-c) 
 
and for nWA > : 
 
2 2
1 2 np p A ω ω= − = , 
 
1 2 2p p A+ =  , 1 2 2p p ω− = , 1 2
1 2
p pA
p pω
+= − , 
   
While ( ) ( )AA −=−+=− αααδα 22      (7-d) 
 
Then the response of the system, y(t) i.e., the solution of the differential equation (3), 
is obtained by taking the inverse transform of  
 
( ) ( )( )( ) ( )
( )( )
( )( )2 1 2
Q s s Q s s
Y s
s s s p s p
α α
α δ αδ βγ
+ += =+ + + + + +     (7-e) 
 
A. Similarly from eq (4), we get for insulin response 
 
( ) ( )βγαδδα
β
++++= sssQsX 2)(/)(      (8) 
 
 
In OGTT test, the glucose is administered in a single dose orally (instead of being 
injected into blood). In this test, a fasting person is given an oral glucose dose of 1 
gm/kg, for diabetes diagnostic purpose. If the subject is normal and free from 
diabetes, the blood glucose level rises from the fasting value of, say, 80mg/dl to 120-
140mg/dl, and then falls back to below normal in about 2 hours. 
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 The physiology of the GI tract suggests that the intestinal glucose absorption rate is 
constant for a limited time duration. Hence, the glucose rectangular-pulse input q(t) 
into the blood pool is representative of this phenomena. This in fact is made 
physiologically possible by means of the combined effect of two mechanisms: (i) due 
to the pyloric sphincter valve-resistance which controls the transfer of glucose from 
the stomach to the intestines in inverse proportion to the stomach distension, and (ii) 
due to the active transport of glucose from the intestines into the blood (across the 
intestinal wall) at its maximum rate, according to Mechaelis - Menten equation, 
graphically depicted in Figure 1.18.  
 
 
Figure 1.18 Effect of substrate and enzyme concentrations on the rate of enzyme-
catalyzed reaction. The general form of Michaelis-Menten equation for active 
transport is:  
 
Rate of Reaction = k1 (Enzyme conc.) (substrate conc.)/(k2 + substrate conc.) 
 
When there is no glucose in blood, during hypoglycaemia (i.e., when ‘y’ is much 
below the fasting level), the active transport is carried out at its maximum rate. Thus 
the passive and active transports work together to maximize the intestinal glucose 
transport, so as to tide over the crisis of hypoglycaemia in diabetics. 
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The Transfer-function (TF) corresponding to equation (3) is obtained, by taking 
Laplace transforms on both sides (assuming the initial conditions to be zero), as: 
 
2 ( ) ( )( ) ( )( ) ( )( )s Y s sY s Y s Q s sα δ αδ βγ α+ + + + = +  
  
Thereby, we obtain (for glucose response):  
 
( ) ( )( ) ( )( ) / ( ) 2
sG s Y s Q s
s s
α
α δ αδ βγ
+= = + + + +                          
( )
( ) ( )
( )
or, ( )= 2
Q ssY s
s s
α
α δ αδ βγ
+
+ + + +       (5) 
 
Similarly from equation (4), we get for insulin response 
 
( ) ( )
( ) ( )                                                                              
( ) / ( ) 2
( ),   ( ) (6)2
X s Q s
s s
Q sor X s
s s
β
α δ αδ βγ
β
α δ αδ βγ
= + + + +
= + + + +
       
Now for OGTT simulation, we note that (i) the GI has the transfer function1 ( )s α+ , 
[2, 7] which is tantamount to a decay in glucose concentration (at the rate of α) during 
its transmission through the GI tract, while Q(s) = G (amount of glucose per litre of 
blood-pool volume per hour) constitutes the glucose input into the blood-pool, as 
shown in Figure 1.19. 
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Figure 1.19 LaPlace Transform format of the GI tract and Blood Pool system of 
governing equation (5), to simulate the monitored OGTT glucose response curve 
(adapted from 33 & 38). 
  
Hence, from equation (5), we have: 
( ) 1( ) 2 ( )( ) ( )
       =                                                 (7) 2 2( ) ( )
where ( ) and ( )                                             d
sY s G
ss s
G G
s s s T sd
T
α
αα δ αδ γβ
α δ αδ γβ λ λ
λ αδ γβ λ α δ
+= × ×++ + + +
=
+ + + + + +
= + = +                         
 
This equation (7) can be adopted to represent the response of the blood-glucose 
(proportional + derivative) feedback control-system model for simulating glucose 
metabolism during OGTT, as illustrated by Figure 3. 
 
Equation (7) can also be written as: 
 
-1 -1
2
(in gms litre hr )( )                                                                                        (8)2 2 n
GY s
s As ω= + +  
 
 where nω λ=  is the natural frequency of the system; A (the attenuation or damping 
constant of the system) 22 d nA T ωλ == , and 2 2( )n Aω ω= −  is the angular frequency of 
dampened oscillation of the system. 
 
1.4.1.4 Solutions to the Governing Differential Equation, for Glucose Response 
(y) to Glucose Bolus Ingestion [2, 10] 
 
Based on equation (8), the governing differential equation is 
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22 ( )                                                                                               (9)y A y y G tnω δ+ + =?? ?  
wherein y0 = 0, y G=
?
, and the damped oscillation-frequency ω = (ωn2 – A2)1/2 
 
Solution For Under-damped Case: 
 
For A2 < ωn2 or A2 - ωn2 < 0, i.e., for ωn2 – A2 (=ω2) > 0, we have the solution to 
equation (9) as: 
 
 y(t) = (G/ ω) e-At sinωt                                                                                           (10) 
 
Solution For Over-damped Case: 
 
For A2 > ωn2, or A2 - ωn2 > 0, we have: 
 
G -Aty(t) = e sinhwt
ω
                            (11) 
 
Solution for Critically Damped Case: 
 
For ω=0, we have: 
 
-Aty(t) = Gte                                                                                                             (12)              
 
From the above equations, we can determine G,w,A  for each clinical case, by making 
the corresponding solution (for under-damped or over-damped or critically damped) 
response match the clinical data, by MatLab-based parameter identification 
procedure. 
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1.4.2 Solutions to the Governing Differential Equations and for 
Insulin Response to Glucose Bolus Ingestion 
 
Having developed the analysis for evaluating the model parameters (G,w,A), we  will 
now proceed to solve for the remaining parameters β, γ and δ. Then from the 
knowledge of (w,A) and (β, γ, δ), we can also evaluate the α parameter. 
 
For underdamped response of normal subjects, we obtain from equations (1) and (10): 
 
sin                                                                    (13)AtGx x y x e tα β α β ωω
−= − + = − +?  
 
Solving equation (13), we get the corresponding insulin response as: 
 
( ) ( ) ( ) ( )(sin( ) sin( ) cos( ) )
( )  2 2 22
GAt At t Att Ae t e e t e
x t
A A
αω ω α ω ω ω β ω
α α ω
− − − −− − − +
=
− + +
           (14) 
 
For over-damped response of a diabetic subject, we obtain from equations (32) and 
(41):  
  
' sinh                                                                  (15)AtGx x y x e t
w
α β α β ω−= − + = − +  
 
Solving equation (15), we get the insulin response as follows: 
 
 
1 (cosh( ) sinh( ) cosh( )
2
sinh( ) sinh( ) cosh( )
sinh( ) sinh( ) cosh( )
cosh( ) cosh( ) 2 sinh(
( )
t At t A t At t A t At t A
t At t A t At t t At t
t At t t At t t At t
t At t t At t t
x t
ω α ω α ω α
ω α ω α ω ω α ω
ω α α ω α α ω α α
ω α ω ω α α ω ω
+ − + − + − − − + − −
+ − + − − − − + − −
− − − + + − − + − −
− − + − + − + + −
= ( )
( )
2 2 2
) )
            (16)
2
t GAt t e
A A
αα ω β ω
ω α α
−
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟+ −⎜ ⎟⎝ ⎠
− + − +
 
 
For a critically-damped response (of a borderline subject), we obtain the insulin 
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response from equations (1) and (12): 
 
' '                                                                           (17)Atx x yx x Gteα β α β −= − + = − +  
 
The solution of equation (17) is given by: 
( ) ( ) ( ) ( )
2
( )( )                                                       (18)
( )
At At At tG tAe t e e ex t
A
αβ α
α
− − − −− − + −= −  
 
1.4.2.1 Obtaining Solutions for All the Model Parameters 
 
By simulating the glucose response with our y(t) solutions (of equations 10 or 11 or 
12), we can evaluate the parameters G, A and ω. We will now proceed to solve for the 
parameters: β, γ and δ. 
 
From equations (7) & (8), we have the following relationships: 
 
2 ( )                                                                                               (19)
2 ( )                                                                           
n
dT A
ω λ γβ αδ
λ γ α
= = +
= = +                     (20)  
 
Then, after evaluating the parameter A (by matching the y(t) solution to the glucose 
response data), we can obtain the value of ( )  α γ+ from equation (20), as: 
 = 2                                                                                                            (21)Aα γ+  
 
Now, by matching the x(t) solution to the insulin response data, we can evaluate the 
parameters α & β. Hence, from equation (21), by substituting this evaluated value of 
α, we can obtain the value of γ. Now, we have solved for α, β & γ. But we still need to 
determine the parameter δ.  
 
For instance, in the case of under-damped response (of normal subjects) 
2 2 2                                                                                                         (22)n Aω ω= −  
Upon substituting equation (22) into equation (19), we obtain:  
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2
2 2
( )
and hence,                                                                         (23)
n
A
ω λ γβ αδ
ω λ γβ αδ
= = +
− = = +  
Now, in this equation, since only δ is unkown, we can evaluate it. Hence, we can 
determine all the four model parameters  α,  β, γ and δ for normal subjects. 
 
In the case of over-damped response (of diabetic subjects), 
2 2 2                                                                                                        (24)nAω ω= −  
Upon substituting (24) into (19) : 
2
2 2
( ),
( )                                                                                      (25)
n or
A
ω λ γβ αδ
ω λ γβ αδ
= = +
− = = +  
Hence, again in this above equation, since only δ is as yet unknown, we can determine 
δ. Hence all the model parameters (α, β, γ & δ) can be determined. 
 
 59
1.5 Clinical Application of Model 
 
We will now study typically normal patients (so classified as per clinical criteria 
delineated in section 1). We have decided that for a patient to be classified in any one 
of the three (under-damped, over-damped and critically damped) categories, the 
model solution equation should fit the data with a very high degree of correlation 
coefficients: R-square ≥0.90 and SSE ≤ 0.1. In case a patient data fits all the 3 (under-
damped, over-damped and critically damped) response categories, we will designate 
the patient to the category for which the R-Square value is the highest. 
 
1.5.1 Under-damped Category for Patients Clinically Designated 
to be Normal 
 
Based on the high degree of fit, patients as shown in Table 1.7 fit best the under-
damped category, and hence are also designated as normal by our systems-
engineering basis. Their Glucose and Insulin responses are shown in Appendix A 
respectively. 
 
Table 1.7 Subjects that were well fitted by underdamped characteristic model 
equation. 
Best Fitted (R-Square > 95%) 
N02 
N05 
N11 
N14 
N16 
N19 
 
D03 
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Parameters Values Fitting Remarks 
A 2.863 SSE 0.001478 
G 9.9   
ω 3.558 
Glucose 
Fit 
R-Square 0.9961 
α 1.1219 SSE 0.001394 
β 0.04619   
γ 4.6041 R-Sqauare 0.8254 
δ 18.4 
Insulin 
Fit 
  
S02 is normal. 
Just as the 
clinician has 
diagnosed. 
 
Figure 1.20  The Glucose-Insulin response of N02 is a good example of  a normal 
response e.g. no-diabetic. This result correlates very well with clinically diagnosis. 
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Parameters Values Fitting Remarks 
A 0.2845 SSE 1.982e-012 
G 2.336   
ω 1.589 
Glucose 
Fit 
R-Square 1 
α -10.3358 SSE 0.001944 
β 0.01677   
γ 10.9048 R-Sqauare 0.8198 
δ -0.2344 
Insulin 
Fit 
  
D03 should be 
normal. But D03 
was wrongly 
classified as 
diabetic 
clinically.  
 
Figure 1.21 The Glucose-Insulin response of D02 is a good example of a wrong 
clinical diagnosis. The subject may be subjected to unnecessary medication and 
procedures which are physiologically and morally depressing. 
. 
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1.5.2 Over-damped Category of Patients Clinically Designated as 
Diabetic 
 
Now, we display patients who were well fitted by overdamp characteristic model 
equation. Because they fit best our over-damped model category, we also designate 
them to be diabetic by our systems-engineering methodology. Their Glucose and 
Insulin responses are shown in Appendix B. 
 
Table 1.8 Subjects that were well fitted by overdamped characteristic model 
equation. 
 
Best Fitted (R-Square > 95%) 
N01 
N07 
 
D01 
D02 
D04 
D08 
D09 
D10 
D11 
D13 
D14 
D15 
D16 
D18 
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Parameters Values Fitting Remarks 
A 17.06 SSE 0.00439 
G 23.81   
ω 16.6 
Glucose 
Fit 
R-Square 0.9739 
α 0.4580 SSE 0.000236 
β 0.0530   
γ 1.2539 R-Sqauare 0.97 
δ 33.6620 
Insulin 
Fit 
  
N01 actually is 
diabetic even the 
clinician 
diagnosed him as 
normal. 
 
Figure 1.22 The Glucose-Insulin response of N01 is another good example of a 
wrong clinical diagnosis. The subject may not be given the required medical attention 
and the consequences can be very depressing.  
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Parameters Values Fitting Remarks 
A 0.6417 SSE 0.005257 
G 3.969   
ω 0.0002767 
Glucose 
Fit 
R-Square 0.9986 
α 0.3084 SSE 0.0002635 
β 0.004821   
γ 23.0383 R-Sqauare 0.8995 
δ 0.9750 
Insulin 
Fit 
  
Glucose comes 
down very 
slowly. D01 is 
diabetic. 
 
Figure 1.23  The Glucose-Insulin response of D01 is a good example of  a overdamp 
response e.g. diabetic. This result correlates very well with clinically diagnosis. D01 
will undergo immediate medical attention. 
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1.5.2.1 Critically-damped Category of Patients 
 
There are some patients (as shown in Table 1.9)  who were clinically diagnosed to be 
normal, for whom the critically damped solution gives a better fit of their glucose and 
insulin response data (and a higher value of R-Square) than the under-damped 
solution. One such patient is N04, whose response curves for under-damped and 
critically (refer to Appendix A for figures). This patient is clinically diagnosed to be 
normal, but are at risk of becoming diabetic. This is because their data is best 
represented by the critically-damped solution. Likewise, patient D05 who has been 
identified as diabetic, but he is only at-risk of getting diabetic. Their response curves 
are illustrated in Appendix C. 
 
Table 1.9 Subjects that were well fitted by critically damped characteristic model 
equation. 
Best Fitted (R-Square > 95%) 
N03 
N04 
N06 
N08 
N10 
N12 
N13 
N18 
 
D05 
D06 
D07 
D12 
D17 
D19 
D20 
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Parameters Values Fitting Remarks 
A 1.9650 SSE 4.06e-005 
G 3.6740   
ω 0 
Glucose 
Fit 
R-Square 0.9999 
α 3.0000 SSE 9.172e-006 
β 0.1194   
γ 8.9717 R-Square 0.9719 
δ 0.9300 
Insulin 
Fit 
  
S03 is in a 
dangerous rim. 
The insulin 
response is too 
little. 
 
Figure 1.24 The Glucose-Insulin response of N03 is a good example of a missed 
clinical diagnosis or a good example of pre-emptive treatment beneficial. Even 
though the subject is diagnosed as normal clinically e.g. non-diabetic, the subject in 
fact is at-risk e.g. preventive medical attention is required to prevent the current 
health conditions to deteriorate. N03 requires prevent medical measures immediately. 
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Parameters Values Fitting Remarks 
A 1.3530 SSE 0.01169 
G 5.0750   
ω 0 
Glucose 
Fit 
R-Square 0.9912 
α 2.24 SSE 0.0006006 
β 0.1862   
γ 4.2254 R-Sqauare 0.9122 
δ 0.4660 
Insulin 
Fit 
  
D05 fits both the 
D05 has been 
diagnosed as 
diabetic. 
 
Figure 1.25 The Glucose-Insulin response of D05 is a good example of a wrong 
clinical diagnosis. The subject may be subjected to unnecessary medication and 
procedures which are physiologically and morally depressing. D05 only requires only 
preventive medical attention to prevent the current health conditions to deteriorate 
and not diabetic medical procedures which can be health hazardous.  
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1.6 Non-Dimensional Physiological Index (NDPI) 
 
Classification based on NDPI. Comparing the NDIs from 3 classes, we can determine 
which class the patients belong to: 
 
System Parameters Identification 
 
The resulting OGTT glucose and insulin data of individual will be used for system 
parameter identification process [30-31]. The non-dimensionless for blood glucose 
response (G_NDI) is given by :  
 
6max 2 max
2 5
2
_ 10d
y y T TG NDI
AG T
×= × × ×       (26) 
where: maxy : maximum blood glucose value in gram/liter;  2y : blood glucose value at 
2h; G : glucose administered to the system in gram/liter hour; dT : derivative-time in 
hour derivative time; A : attenuation constant in hour-1 ; maxT : time at which ymax 
occurs ;  2T : 2h. 
 
The non-dimensionless for insulin response is given by: 
_I NDI βγδα=           (27) 
where: :α  represents pancreatic insulin sensitivity to insulin in (hr)-1; :β  pancreatic 
insulin sensitivity to elevated glucose blood concentrations in (Units) (hr)-1(gms)-1; :γ  
liver glycogen storage to elevated blood-glucose concentrations in (gms)(hr)-1 (Units)-
1 ; :δ  tissue glucose utilisation to elevated blood-glucose concentrations in (hr)-1. 
The final non-dimensionless index is given by: 
 
6max 2 max
2
2
_ _
        = 10d
NDI G NDI I NDI
y y T T
A TG
βγδ
α
= ×
× × × × ×             (28) 
 
α  : increases means insulin removed 
β  : increases means insulin responsive to glucose concentration 
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γ  : decreases means blood glucose increases and not enough glucose absorbed by     
tissues. 
δ : decreases means blood glucose increases and inadequate tissue glucose utilization. 
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The above figure shows the final plot of the non-dimensional indexes. The above 
figure confirms that the chosen index provides the best discrimination e.g. separating 
non-diabetic from diabetic at the extreme ends of the plot while those at-risk diabetic 
patients are at the centre of the plot. 
 
The other plots which are used to determine goodness of discrimination were shown 
in the Appendix D. 
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1.7 CONCLUSIONS 
 
We have shown that we can obtain more accurate assessment of diabetic patients by 
means of our under-damped, over-damped and critically-damped simulation model 
solutions. Some patients were diagnosed clinically as normal but were in-fact 
diabetic. The consequences can be very depressing to the patients. They may be given 
the immediate essential medical attention which could lead them to acute 
complications such as diabetic ketoacidosis, hyperosmolar non ketotic coma, kidney 
failures, etc [12, 19-20]. While some of those are diagnosed as normal but were in fact 
at-risk. They require immediate preventive medial attention to prevent their current 
health conditions from deteriorating any further. While some of patient who are at-
risk but were diagnosed as diabetic clinically. The unnecessary medial attention and 
procedures can be a health hazardous.   
 
As we continue this work, we will develop a clinically-implementable software for 
model parameters identification and designation of the subjects as normal or at-risk of 
becoming diabetic or border-line diabetic or distinctly diabetic.  
 
In conclusion, the NDPI can assist clinicians in determining the patients’ diabetic 
state and concentrate precious scarce medical resources for appropriate treatment 
accordingly, especially for those in the borderline case where early preventative 
measures can be exercised immediately before the endocrine system failed. 
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Chapter 2 Automated Insulin Infusion 
Regulation System for Lowering Blood 
Glucose After a Meal 
 
 
In the previous chapter, we have discussed the classification of normal, at-risk and 
diabetic patients, and how we have derived the required relevant models for the 
respective group of patients for glucose-insulin kinematics. In this chapter, we will 
discuss the development of an artificial pancreas for type II diabetic patients. The 
system we are proposing are non-invasive in nature and based on our findings from 
the previous chapter. 
 
2.1 Motivation behind the Project 
 
Long-term clinical studies show that the onset of complications can be significantly 
reduced through proper control of blood glucose levels [6]. A vital element of 
diabetes management is the self-monitoring of blood glucose levels by diabetics in the 
home environment. A significant disadvantage of current monitoring techniques is 
that they discourage regular use due to the inconvenient and painful nature of drawing 
blood through the skin prior to analysis. Therefore, new methods for self-monitoring 
of blood glucose levels are required to improve the prospects for more rigorous 
control of blood glucose in diabetic patients. 
 
The artificial pancreas are developed from 1980’s, this device senses continuous 
blood glucose concentration level and controls injection quantity of insulin. The 
control methodologies for the artificial pancreas are to provide quantitative bounds on 
the required performance of sensors/actuators to be used in an artificial pancreas 
system. The four most important areas of concern in the design of the artificial 
pancreas are [1]: 
 
(a) The subject dynamic systems (a patient’s glucose/insulin kinematics) are 
inherently nonlinear and poorly modeled relative to required performance 
levels. 
(b) The subject dynamic systems are subject to external disturbances that are not 
under the authority of the control system (physical activity or food 
consumption by diabetic patient). 
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(c) The subject dynamic systems have limited actuator authority (insulin delivery 
rates are bounded and non-negative) and may suffer from unreliable actuation 
(patient compliance). 
(d) Safe operation of the subject dynamic systems requires that system state 
variables be kept within a prescribed operating range. 
(e) The glucose & insulin regulations must consider the controllable inputs such 
as meals, insulin injection and exercise. In other words, the artificial pancreas 
must mimic the actual healthy pancreas functions and only limited by our 
current technologies. 
 
 
2.2 Functions of the Pancreas 
 
The key hormones involved in glucose counter regulation are insulin, glucagon, and 
in cases of glucagon deficiency, adrenaline [3]. Insulin, secreted from the β cells in 
the pancreas, is the only hormone involved in lowering glucose levels. 
 
Glucagon is secreted from the α cells of the pancreas during periods of low glucose 
concentrations and is suppressed by high insulin levels [2]. Somastatin, secreted from 
the δ cells of the pancreas, inhibits glucagon and insulin secretion [3]. The normal 
fasting concentration of glucagon in circulating blood is s 100-150 pg/ml and has a 
half-life of ~ 5-10 minutes. Insulin secretion is stimulated by glucagon [2], a rise in 
glucose levels, a rise in blood ketones and by glucagon from the α cell. In contrast, 
insulin is inhibited by the secretion of somastatin, adrenaline and by decreasing 
blood glucose levels [3]. The normal basal rate of insulin release from the β cell is 
1 iu/hour (1µU=0.04ng [2]). Insulin degrades in the liver by 50 % each time it passes 
through, but this fraction varies among individuals and in an individual under 
different instances [2]. The typical fasting concentrations of insulin in circulating 
blood is 10-50 µ iu/ml, and have a half-life of 5-10 minutes [3]. 
 
Glucagon is secreted from the α cells of the pancreas during periods of low glucose 
concentrations and is suppressed by high insulin levels [2]. Somastatin is of insulin in 
circulating blood are 10-50 ,u iu/ml, and have a half-life of 5-10 minutes [3]. 
 
2.2.1 Glucose production  
 
In the basal state glucose production is approximately 2 mg/kg body weight per 
minute. In this state, gluconeogenesis, the formation of glucose or glycogen from 
 85
non-carbohydrate sources, contributes 30% of glucose production in the liver, and 
this percentage increases as fasting continues [2]. The remaining hepatic 
production relies on glycogenolysis, the conversion of glycogen to glucose. 
During fasting the liver depletes glycogen stores at a rate of 11% per hour. As 
fasting continues, glycogen stores are depleted thus increasing the role of 
gluconeogenesis. Glycogen stores consist of 60 grams in a 1.5kg liver, and 250 
grams in 28 kg muscle tissue [2]. 
 
Increases in glucose production are controlled by several hormones including 
glucagon, adrenaline, cortisol, and growth hormone [3]. Glucagon and adrenalin 
have an immediate effect on raising blood glucose levels via glycogenolysis, and 
in prolonged hypoglycemia, via gluconeogenesis. Cortisol and glucagon, in the 
presence of prolonged hypoglycemia, promote gluconeogenesis. During acute 
insulin induced hypoglycemia, glucagon levels increase by a factor of four [3], in 
attempts to return glucose levels within the normal range. Growth hormone and 
cortisol act to increase glucose concentrations by suppressing glucose uptake as well 
as increasing hepatic glucose production [2]. Cortisol, growth hormone and thyroxin 
have slower onsets and more prolonged effects to increasing the glucose level [3]. 
 
Glucose production is inhibited by an increase in insulin concentration. In the 
liver, a 5-7 µU/ml increase of plasma insulin concentration will result in a half-
maximum suppression of hepatic glucose production [2], and an increment of 100 
µU/ml will decrease hepatic glucose production to less than 10-15% of basal 
production [4]. The inhibition of hepatic glucose production is three times as 
sensitive to insulin than peripheral glucose uptake [2]. Glycogenolysis and 
gluconeogenesis are decreased by insulin [2], which in part is due to the reduction 
of circulating glucagon. 
 
2.2.2 Glucose Uptake 
 
Insulin acts to lower blood glucose levels by increasing cellular glucose uptake 
[3]. Insulin increases cell membrane permeability to glucose, amino acids and 
potassium and it meanwhile decreases intracellular cyclic adenosine mono-
phosphate (cAMP), the basic regulator of cell metabolism. Classic insulin 
sensitive tissues are adipocyte and brown fat, skeletal, heart and smooth muscle [2], 
this constitutes only a fraction of the tissues involving glucose uptake. The brain, 
liver, kidneys, and intestines undergo insulin independent glucose uptake. The 
brain requires ≈1mg/kg of glucose per minute, and glucose oxidation provides 
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almost 90% of the energy required for the brain and nervous system to operate 
properly. Basal glucose uptake is ≈2 mg/kg per minute of which 50% is required by 
the brain, 25 % by the splanchnic (liver and gut) tissues, and the other 25% by 
insulin dependent tissues. Under normal circumstances the rate limiting step for 
glucose uptake is the phosphorylation within the cell by hexokinase [2]. Glucose 
uptake is inhibited other hormones. Half-maximal glucose utilization is produced 
when insulin concentration increase by a factor of 3. 
 
 
2.3 Literature Review 
 
2.3.1 Glucose Measurement 
 
Currently there are numerous approaches for measuring blood glucose levels, ranging 
from invasive methods such as microdialysis [7] to noninvasive technologies that rely 
on spectroscopy [8], ion sensitive field effect transistor (ISFET) [9] and millimeter 
waves [10]. Each method has associated advantages and disadvantages, but only a few 
have received approval from certifying agencies. To date, no noninvasive techniques 
for the self-monitoring of blood glucose have been certified. 
 
One method, near-infrared spectroscopy involves the illumination of a spot on the 
body with near-infrared electromagnetic radiation (light in the wavelength range 750-
2500 nm). The light is partially absorbed and scattered, according to its interaction 
with the constituents of the tissue prior to being reflected back to a detector. The 
detected light contains quantitative information that is based on the known interaction 
of the incident light with components of the body tissue including water, fat, protein 
and glucose. 
 
2.3.1.1 Noninvasive Glucose Measurement 
 
Previously reported methods for the noninvasive measurement of glucose through 
near-infrared spectroscopy rely on the detection of the magnitude of light attenuation 
caused by the absorption signature of blood glucose as represented in the targeted 
tissue volume. The tissue volume is the portion of irradiated tissue from which light is 
reflected or transmitted to the spectrometer detection system. The signal due to the 
absorption of glucose is extracted from the spectral measurement through various 
methods of signal processing and one or more mathematical models. The models are 
developed through the process of calibration on the basis of an exemplary set of 
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spectral measurements and associated reference blood glucose values (the calibration 
set) based on an analysis of capillary (fingertip) or venous blood. 
 
Near-infrared spectroscopy has been demonstrated in specific studies to represent a 
feasible and promising approach to the noninvasive prediction of blood glucose levels. 
M. Robinson and et. al. [8] have reported three different instrument configurations for 
measuring diffuse transmittance through the finger in the 600-1300 nm range. Meal 
tolerance tests were used to perturb the glucose levels of three subjects and calibration 
models were constructed specific to each subject on single days and tested through 
cross-validation. Absolute average prediction errors ranged from 19.8 to 37.8 mg/dl. 
The papers [11-14] present results through a diffuse reflectance measurement of the 
oral mucosa in the 1111-1835 nm range with an optimized diffuse reflectance 
accessory. In vivo experiments were conducted on single diabetics using glucose 
tolerance tests and on a population of 133 different subjects. The best standard error 
of prediction reported was 43 mg/dl and was obtained from a two-day single person 
oral glucose tolerance test that was evaluated through cross-validation. 
 
The papers [15-18] recorded spectra in diffuse reflectance over the 800-1350 nm 
range on the middle finger of the right hand with a fiber-optic probe. Each experiment 
involved a diabetic subject and was conducted over a single day with perturbation of 
blood glucose levels through carbohydrate loading. Results, using both partial least 
squares regression and radial basis function neural networks were evaluated on single 
subjects over single days through cross-validation. Danzer et al. [17] reports an 
average root mean square prediction error of 36 mg/dl through cross-validation over 
31 glucose profiles. 
 
J. Burmeister et al. [19] collected absorbance spectra through a transmission 
measurement of the tongue in the 1429-2000 nm range. A study of five diabetic 
subjects was conducted over a 39-day period with five samples taken per day. Every 
fifth sample was used for an independent test set and the standard error of prediction 
for all subjects was greater than 54 mg/dl. 
 
In T. Blank et al. [20], reported studies demonstrate noninvasive measurement of 
blood glucose during modified oral glucose tolerance tests over a short time period. 
The calibration was customized for the individual and tested over a relatively short 
time period. 
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In all of these studies, limitations were cited that would affect the acceptance of such 
a method as a commercial product. These limitations included sensitivity, sampling 
problems, time lag, calibration bias, long-term reproducibility and instrument noise. 
Fundamentally, however, accurate noninvasive estimation of blood glucose is 
presently limited by the available near-infrared technology, the trace concentration of 
glucose relative to other constituents and the dynamic nature of the skin and living 
tissue of the patient [21]. As reported by S. Malin, T et al. [22], the entirety of which 
is hereby incorporated by reference, chemical, structural and physiological variations 
occur that produce dramatic and nonlinear changes in the optical properties of the 
tissue sample [23-30]. 
 
The measurement is further complicated by the heterogeneity of the sample, the 
multi-layered structure of the skin and the rapid variation related to hydration levels, 
changes in the volume fraction of blood in the tissue, hormonal stimulation, 
temperature fluctuations and blood analyte levels. This can be further considered 
through a discussion of the scattering properties of skin. 
 
2.3.1.2 Skin Structure 
 
The structure and composition of skin varies widely among individuals as well as 
between different sites and over time on the same individual. Skin consists of a 
superficial layer known as the stratum corneum, a stratified cellular epidermis, and an 
underlying dermis of connective tissue. Below the dermis is the subcutaneous fatty 
layer or adipose tissue. The epidermis, with a thickness of 10-150 um, together with 
the stratum corneum provides a barrier to infection and loss of moisture, while the 
dermis is the thick inner layer that provides mechanical strength and elasticity [31]. In 
humans, the thickness of the dermis ranges from 0.5 mm over the eyelid to 4 mm on 
the back and averages approximately 1.2 mm over most of the body [32]. 
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Figure 2.1 Components of the integumentary system. The skin consists of a thin, 
superficial epidermis and a deep, thicker dermis. Deep to the skin is the subcutaneous 
layer, which attaches the dermis to underlying organs and tissues [10].  
 
In the dermis, water accounts for approximately 70% percent of the volume. The next 
most abundant constituent is collagen, a fibrous protein comprising 70-75% of the dry 
weight of the dermis. Elastin fibers, also a protein, are plentiful though they constitute 
only a small proportion of the bulk. In addition, the dermis contains a wide variety of 
structures (e.g., sweat glands, hair follicles and blood vessels) and other cellular 
constituents [31]. Conversely, the subcutaneous layer (adipose tissue) is by volume 
approximately 10% water and consists primarily of cells rich in triglycerides (fat). 
The concentration of glucose varies in each layer according to the water content, the 
relative sizes of the fluid compartments, the distribution of capillaries and the 
perfusion of blood. Due to the high concentration of fat, the average concentration of 
glucose in subcutaneous tissue is significantly lower than that of the dermis. 
 
 90
2.3.1.3 Optical Properties of Skin 
 
When near-infrared (NIR) light is delivered to the skin, a percentage of it is reflected, 
while the remainder penetrates into the skin. The proportion of reflected light, or 
specular reflectance is typically between 4-7% of the delivered light over the entire 
spectrum from 250-3000 nm (for a perpendicular angle of incidence) [33]. The 93-
96% of the incident light that enters the skin is attenuated due to absorption and 
scattering within the many layers of the skin. These two processes, combined with 
orientation of the sensors of the spectrometer instrument, determine the tissue volume 
irradiated by the source and "sampled" through the collection of diffusely reflected 
light. 
 
Diffuse reflectance or remittance is defined as that fraction of incident optical 
radiation that is returned from a turbid sample. Alternately, diffuse transmittance is 
the fraction of incident optical radiation that is transmitted through a turbid sample. 
Absorption by the various skin constituents mentioned above accounts for the spectral 
extinction of the light within each layer. Scattering is the only process by which the 
beam may be returned to contribute to the diffuse reflectance of the skin. Scattering 
also has a strong influence on the light that is diffusely transmitted through a portion 
of the skin. 
 
The scattering in tissues is due to discontinuities in the refractive index on the 
microscopic level, such as the aqueous-lipid membrane interfaces between each tissue 
compartment or the collagen fibrils within the extracellular matrix [34]. The spatial 
distribution and intensity of scattered light depends upon the size and shape of the 
particles relative to the wavelength, and upon the difference in refractive index 
between the medium and the constituent particles. The scattering of the dermis is 
dominated by the scattering from collagen fiber bundles in the 2.8 µm diameter range 
occupying 21% of the dermal volume, and the refractive index mismatch is 1.38/1.35 
[33]. The spectral characteristics of diffuse remittance from tissue result from a 
complex interplay of the intrinsic absorption and scattering properties of the tissue, 
the distribution of the heterogeneous scattering components and the geometry of the 
point(s) of irradiation relative to the point(s) of light detection. 
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Figure 2.2 Shows a typical absorbance spectrum measurement from the forearm of a 
human subject [33]. 
 
The absorption of light in tissue is primarily due to three fundamental constituents: 
water, protein and fat. As the main constituent, water dominates the near-infrared 
absorbance above 1100 nm and is observed through pronounced absorbance bands 
(for example, see Figure 2.2). Protein in its various forms, and in particular collagen, 
is a strong absorber of light that irradiates the dermis. Near-infrared light that 
penetrates to subcutaneous tissue is absorbed primarily by fat. In the absence of 
scattering, the absorbance of near-infrared light due to a particular analyte, A, can be 
approximated by Beers Law at each wavelength by 
 
A cl=∈      (1) 
 
[where ∈ is the analyte specific absorption coefficient, c is the concentration and l is 
the pathlength. The overall absorbance at a particular wavelength is the sum of the 
individual absorbances of each particular analyte given by Beer's Law. The 
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concentration of a particular analyte, such as glucose, can be determined through a 
multivariate analysis of the absorbance over a multiplicity of wavelengths because E 
is unique for each analyte. However, in tissue compartments expected to contain 
glucose, the concentration of glucose is at least three orders of magnitude less than 
that of water. Consequently, the signal targeted for detection by reported approaches 
to near-infrared measurement of glucose (the absorbance due to glucose in the tissue) 
is expected to be at most three orders of magnitude less than other interfering tissue 
constituents. Therefore, the nearinfrared measurement of glucose requires a high level 
ofsensitivity over a broad wavelength range, and the application of methods of 
multivariate analysis. 
 
However, the diverse scattering characteristics of the skin (e.g., multiple layers and 
heterogeneity) cause the light returning from an irradiated sample to vary in a highly 
nonlinear manner with respect to tissue analytes, in particular, glucose. Simple linear 
models, such as the Beer's Law have been reported to be invalid for the dermis [R. 
Anderson, J. Parrish, The optics of human skin, Journal of Investigative Dermatology, 
77:1, pp. 13-19 (1981).]. Such nonlinear variation is a recognized problem and several 
reports have disclosed unique methods for compensating for the nonlinearity of the 
measurement while providing the necessary sensitivity [22, 36]. 
 
2.3.1.4 Dynamic Properties of the Skin 
 
While knowledge of and utilization of the optical properties of the skin, high 
instrument sensitivity and compensation for inherent nonlinearities are all vital for the 
application of near-infrared spectroscopy to noninvasive blood analyte measurement, 
an understanding of biological and chemical mechanisms that lead to time dependent 
changes in the optical properties of skin tissue is equally important and, yet, largely 
ignored. At a given measurement site, skin tissue is often assumed to be static except 
for changes in the target analyte and other absorbing species. However, variations in 
the physiological state of tissue profoundly affect the optical properties of tissue 
layers and compartments over a relatively short period of time. Such variations are 
often dominated by fluid compartment equalization through water shifts and are 
related to hydration levels and changes in blood analyze levels. 
 
Total body water accounts for over 60% of the weight of the average person and is 
distributed between two major compartments: the extracellular fluid (one-third of total 
body water) and the intracellular fluid (two-thirds of total body water) [37]. The 
extracellular fluid in turn is divided into the interstitial fluid (extravascular) and the 
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blood plasma (intravascular). Water permeable lipid membranes separate the 
compartments and water is transferred rapidly between them through the process of 
diffusion, in order to equalize the concentrations of water and other analytes across 
the membrane. The net water flux from one compartment to another constitutes the 
process of osmosis and the amount of pressure required to prevent osmosis is termed 
the osmotic pressure. Under static physiological conditions the fluid compartments 
are at equilibrium. However, during a net fluid gain or loss as a result of water intake 
or loss, all compartments gain or lose water proportionally and maintain a constant 
relative volume. 
 
The primary mechanism for distributing substances contained in blood serum that are 
needed by the tissues, such as water and glucose, is through the process of diffusion. 
The invention recognizes that Fick's law of diffusion drives the short-term intra-/extra 
vascular fluid compartment balance. The movement of water and other analytes from 
intravascular to extravascular compartments occurs rapidly as tremendous numbers of 
molecules of water and other constituents, in constant thermal motion, diffuse back 
and forth through the capillary wall. On average, the rate at which water molecules 
diffuse through the capillary membrane is about eighty times greater than the rate at 
which the plasma itself flows linearly along the capillary. In the Fick's Law 
expression, the actual diffusion flux, IOA, is proportional to the concentration gradient, 
dc/dx between the two compartments and the diffusivity of the molecule, DA 
according to the equation: 
 
OA A
dcI D
dx
−= −       (2) 
 
Short-term increases (or decreases) in blood glucose concentrations lead to an 
increase (or decrease) in blood osmolality (number of molecules per unit mass of 
water). Fluid is rapidly re-distributed accordingly and results in a change in the water 
concentration of each body compartment. For example, the osmotic effect of 
hyperglycemia is a movement of extravascular water to the intravascular space. 
Conversely, a decrease in blood glucose concentration leads to a movement of water 
to extravascular space from the intravascular compartment. 
 
Because the cell membrane is relatively impermeable to most solutes but highly 
permeable to water, whenever there is a higher concentration of a solute on one side 
of the cell membrane, water diffuses across the membrane toward the region of higher 
solute concentration. Large osmotic pressures can develop across the cell membrane 
with relatively small changes in the concentration of solutes in the extracellular fluid. 
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As a result, relatively small changes in concentration of impermeable solutes in the 
extracellular fluid, such as glucose, can cause tremendous changes in cell volume. 
 
Long-term fluid compartment balances are influenced by fluid intake, exercise, diet, 
drug therapy and other physiological factors. The ancillary calibration of glucose to 
fluid compartment shifts is possible over short-term periods. The calibration of 
glucose to fluid shifts over longer periods of time requires a bias correction of the 
analytical signal and the associated blood glucose to compensate for the sources of 
long-term fluid compartment shifts. It is noted that Fick's Law equation (2) relates the 
flux in water concentration to the change in glucose concentration. Thus, this 
measurement based on first principles only permits the determination of the relative 
movement of glucose. Bias correction of both the spectroscopic water signal and the 
associated glucose concentration are required because the initial water concentration 
is not strictly a function of the associated glucose concentration. Accordingly, without 
more, it is only feasible to predict relative movement of glucose. Generating an 
absolute glucose value would require using a paired glucose/ water measurement to 
adjust the time dependent bias in the ancillary fluid shift signal. 
 
2.3.1.5 Issues Regarding NIR Spectrometry 
 
Re-distribution of water between various tissue compartments alters the optical 
properties of the tissue through changes in the water concentration, the concentration 
of other analytes, the refractive indices of various layers, the thickness of tissue layers 
and the size and distribution of scattering centers. Therefore, the optical properties of 
the tissue sample are modified in a highly nonlinear and profound manner. In addition, 
the actual tissue volume sampled (and the effective or average pathlength of light) is 
varied. Consequently, the spectral measurement varies in a complex manner that is 
incompatible with current modes of near-infrared detection of glucose. For example, 
changes in blood glucose concentration will result in water compartment shifts to 
compensate for the increase or decrease in intravascular osmolality. A change in the 
distribution of water will lead to a rapid change in the optical properties of the tissue 
that is correlated to a change in the absorption of glucose. 
 
Several methods are reported to compensate in some part for the dynamic variation of 
the tissue. For example, several reported methods of noninvasive glucose 
measurement develop calibration models that are specific to an individual over a short 
period of time [8, 19-20]. This approach avoids modeling the differences between 
patients and therefore cannot be generalized to more individuals. However, the 
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calibration models have not been tested over long time periods and no means of 
compensating for variation related to the dynamic water shifts of fluid compartments 
is reported. 
 
Malin et al. [22] and Ruchti et al [20] report a method for compensating for variation 
related to the structure and state of the tissue through an intelligent pattern recognition 
system capable of determining calibration models that are most appropriate for the 
patient at the time of measurement. The calibration models are developed from the 
spectral absorbance of a representative population of patients that have been 
segregated into groups. The groups or classes are defined on the basis of structural 
and state similarity such that the variation within a class is small compared to the 
variation between classes. Classification occurs through extracted features of the 
tissue absorbance spectrum related to the current patient state and structure. However, 
the described invention does not use features for directly compensating for 
physiological changes in the tissue. Further, the direct use of features representing the 
physiological state of the subject (or subject's measurement site) for noninvasive 
measurement of glucose was not described. 
 
E. Thomas et al. [38] identifies a method for reducing intra-subject variation through 
the process of mean-centering both the direct and indirect measurements. However, 
this does not address the key problem related to short-term physiological and 
chemical changes related to the dynamic nature of the tissue. 
 
No reported method provides a method and apparatus for detecting features that 
reflect changes in the optical properties of tissue related to physiological properties of 
the tissue such as the shifting of water between fluid compartments. Second, no 
reported method utilizes features that reflect the dynamic nature of the tissue to detect 
conditions unsuitable for near-infrared measurement of blood glucose. Third, no 
method exists to use these features to compensate glucose measurements for bias 
caused by physiological changes. Finally, no reported method utilizes fluid compart-
ment shifts as reflected in spectral features related to the optical properties of tissue to 
indirectly measure glucose. As a result, noninvasive measurement of glucose is 
limited by the dynamic nature of tissue related to the tissue's physiological response to 
various conditions and the re-distribution of water among tissue fluid compartments. 
 
In view of the problems left unsolved by the prior art, there exists a need for a method 
and apparatus to first detect changes in the optical properties of the tissue due to the 
changing physiology of the subject, specifically changes related to water shifts 
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between tissue compartments. Second, use of these features to determine conditions 
unsuitable for glucose measurement through near-infrared spectroscopy would be a 
useful advancement. Finally, it would be a significant advancement to determine a 
means for either using the features to compensate for the changing optical properties 
of the tissue or alternately, utilizing the features to measure glucose. 
 
Throughout their studies, Salzsieder, Fischer, and their coauthors have examined 
closed-loop control of diabetic patient glucose in dogs and humans [26-29] For 
humans, the control algorithms were employed as decision support systems or in 
simulation studies using individualized patient models. Linear algorithms were 
employed for insulin delivery based on a glucose measurement using proportional-
derivative control [26], pole-placement techniques [28], adaptive methods [27], and 
modifications of the Biostator algorithm [29]. Fischer and coauthors [27] demonstrated 
that blood glucose controllers showed markedly improved performance when the 
controller either adapted on-line or was customized to the specific patient. Of 
potential concern for these control algorithms is the sampling rate (typically one 
minute intervals), which is faster than the speed of response of implantable in vivo 
biosensors [11]. 
Sorensen [30], using the internal model control framework, developed a detailed 
compartmental model and a linear model-based controller. To simplify controller 
synthesis, the 19th-order nonlinear model was approximated by a first-order-
plus-time-delay (FOTD) transfer function. The controller resulting from this 
simplified structure was then implemented in the time domain. Performance was 
adequate, although improvement through use of a more detailed model in 
controller design is virtually guaranteed. Also, the controller demonstrated 
significant performance loss (in terms of ability to reject meal disturbances) when 
patient parameters differed from those of the model. 
 
An analysis paper by Doyle, et al. [31], examined modeling and experimental 
techniques for controlling blood glucose. A key observation in their work was that 
low-order models may not adequately describe the real process and therefore could 
contain both unacceptable levels of modeling error and significant process-model 
mismatch. A nonlinear feedforward-feedback controller synthesized using feedback 
linearization, a nonlinear differential-geometric technique, was the control scheme 
proposed for glucose regulation. Also proposed was a polymer (gel) device able to act 
as sensor, controller, and actuator all-in-one. This device would sense glucose as pH 
changes, and release insulin into the bloodstream according to the pH variation. The 
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control characteristics, such as dynamic behavior and magnitude of release, are designed 
into the gel through material selection and preparation. 
 
State-dependent Riccati equations were used by Parrish and Ridgely [32] to control 
blood glucose concentration in diabetic patients. Their controller was designed from a 
partial linearization of the model developed by Naylor, et al. [33]. This nonlinear 
full-state feedback control method is limited by an inability to measure several states in 
the diabetic patient model, such as total stores of glucose and insulin. Cancellation of the 
nonglucose feedback gains resulted in successful rejection of low-magnitude 
disturbances, although overaggressive control and increased insulin usage were 
both observed. The authors used manipulated variable weighting to reduce insulin 
delivery rates, while maintaining adequate glucose control. Due to the formulation 
of their controller, the tracking problem demonstrated steady-state offset. 
 
Robust control using the H_ control methodology was the topic of a paper by Kienitz 
and Yoneyama [34]. Glucose and insulin dynamics were governed by a low-order 
model containing patient-dependent parameters. The controller was designed based on 
a nominal patient model, and a set of frequency-dependent weighting functions was 
tuned to capture the entire expected patient population (based on parameter 
variations). Patients who are within the design set will, by definition, satisfy the 
performance criterion because H_ controllers bound worst-case performance. Meal 
disturbance simulations were promising for the nominal patient. The controller was 
robust to small amounts of patient uncertainty, but inferences to larger patient 
variability sets would require retuning of certain controller parameters. 
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2.4 Overview of Current Treatment and Monitoring 
Methods 
 
The current treatment methods for insulin-dependent diabetes include subcutaneous 
insulin injection or continuous infusion of insulin. Subcutaneous insulin treatment 
may require four to five daily injections, which usually correspond with mealtimes. 
The amount of insulin injected is typically based on consideration of a glucose 
measurement (finger prick), an approximation of the glucose content of the upcoming 
meal, and the estimated insulin release kinetics from the subcutaneous depot. Lente or 
ultra-lente (slower release) insulin preparations allow for an overnight release of 
insulin to prevent highly elevated glucose concentrations in the early morning hours. 
The continuous infusion insulin pump allows for more predictable delivery due to its 
constant infusion rate into an intraperitoneal or subcutaneous delivery site. An 
additional feature of some pumps is their ability to be “primed” so that a bolus of insulin 
can be released to compensate for anticipated glucose intake. 
 
Either of the above two diabetes treatment methods can result in significant, and 
sometimes frequent, glucose concentration variations because of the predominantly 
open-loop nature of the insulin delivery. Intravenous delivery of insulin has 
significant advantages: (i) rapid delivery with negligible dead-time; (ii) a higher 
percentage of drug reaches the bloodstream, as compared with subcutaneous or 
intraperitoneal delivery sites; ( i ii)  faster  response to insulin over-delivery; 
and (iv) potential for improved closed-loop controller performance. However, 
there are shortcomings to this approach as well: (i) indwelling venous catheters may 
irritate the blood vessel; (ii) the catheter may dislodge from the vein; and (iii) the 
catheter may occlude (although this problem is present in all catheter delivery 
devices). Given the significant benefits of utilizing intravenous insulin delivery versus 
subcutaneous or intraperitoneal approaches, this review will concentrate on 
intravenous delivery methods for glucose control. 
 
The development of a closed-loop device capable of maintaining normoglycemia 
over extended periods of time could dramatically improve the quality of life for insulin-
dependent diabetic patients (Fig. 1). A device of this type would contain three primary 
components: (i) a mechanical pump; (ii) an in vivo glucose sensor; and (iii) a 
mathematical algorithm to regulate the pump given a sensor measurement. 
Extracorporeal and implantable insulin pumps have been in service for over 15 years 
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[39-41], and recent advances have made available programmable and variable-rate 
infusion pumps [42]. 
 
 
Figure 2.3 A closed-loop glucose control system. 
Current blood glucose monitoring is accomplished through invasive methods, such as 
a finger prick, but the use of a noninvasive monitor would increase patient comfort and 
therefore compliance to the insulin therapy. An implantable glucose concentration sensor 
would measure diabetic patient blood glucose levels on-line and thus eliminate the 
patient from the feedback loop. A number of research groups are working on 
implantable glucose sensors (see, for example, [43-45]), and the duration of in vivo 
sensor reliability continues to increase. This review will focus on the various control 
algorithms proposed by researchers working on this problem, as well as some new 
results by the authors on uncertainty characterization and modelbased controller synthesis 
in the presence of uncertainty.  
 
2.4.1 Intravenous Insulin Delivery Algorithms BiostatorTM and 
Nonlinear PID 
Early diabetes regulation work dates to the glucose controlled insulin infusion system 
(GCIIS) [46] and later to the “Biostator” algorithm and device of Clemens 
[47]. This feedback controller utilized a low-volume continuous-flow blood glucose 
sampling mechanism with a dual infusion system (insulin and dextrose) to maintain 
blood glucose concentration at a user-defined value. The control algorithm was a 
nonlinear proportional-plus-derivative type structure, using a five-point moving 
average of glucose measurements to minimize noise effects. While adequate for 
bedside implementation, implantation would be more difficult due to the additional 
size associated with the dual-reservoir system necessary for a device of this type. Patient 
specificity was also an issue, as the algorithm would require individualization prior to 
its use. 
Albisser, et al. [48], studied blood glucose control, also using a two-channel system. 
Dextrose infusion was regulated by a nonlinear function of glucose concentration, 
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while the infusion of insulin was governed by a projected glucose concentration. This 
prediction used the current measured value of blood glucose plus an exponential 
difference factor computed from the four-minute average rate of change of 
glucose concentration. This factor was designed to emphasize increasing glucose 
trends over decreasing concentrations. Several patient-dependent or operator-
selected parameters were required in this control algorithm. 
 
A comparison of similar methods for artificial (3-cell control, based on a glucose 
measurement and its rate of change, was presented by Broekhuyse, et al. [49]. These 
algorithms included a modified version of the algorithm in Albisser, et al. [48] by Botz 
[50] and by Marliss, et al. [51]; a modification of this controller introduced by Kraegen, 
et al. [52]; two variants of the Biostator algorithm [47, 53, 54]; and a linear glucose 
control algorithm developed by Fischer, et al. [55]. No single controller was found to be 
uniformly superior, and it was concluded that significant further work in controller 
development was required to normalize diabetic patient blood glucose concentration. 
 
Bellomo, et al. [56], examined the use of the Biostator control algorithm on diabetic 
patients but extended its application through the use of a patient model update 
mechanism. This update occurred over a period defined by the particular parameters 
being estimated. Rising and falling gains (related to the derivative term in the pro-
portional-plus-derivative type algorithm), as well as the endogenous insulin release and 
glucose effectiveness, are calculated to minimize the sum-squared error (SSE) between the 
predicted and actual glucose concentrations over the duration of the current trend in blood 
glucose (rising or falling). This discrimination, based on the direction of glucose 
change, is used because of the different controller dynamics desired for the two 
cases. Other patient-specific coefficients in the controller minimize a quadratic 
objective function, with terms representing insulin expense and glucose deviation from the 
basal state. This controller represents a clear advantage over the static Biostator 
algorithms but still displays significant hyperglycemic peaks during controller operation. 
 
An extended version of the Bergman “minimal model” [70], including insulin 
antibody binding, was studied by Furler, et al. [57]. The control algorithm was governed 
by a saturation function that calculated insulin delivery rate as a function of the current 
glucose measurement. Linear interpolation between the two limits was used to set the 
rate of insulin infusion. Measurements were taken at intervals of one to four hours, and 
performance was shown to be superior to a similar control algorithm used in clinical 
studies [58]. The controller based on the modified saturation function [57] performed 
well in returning initially hyperglycemic patients to steady state, although no analysis 
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of meal disturbances was performed. It should be noted, however, that this algorithm was 
not intended for meal disturbance rejection but for basal-level glucose control in a con-
trolled environment such as a hospital. 
 
2.4.2 Advanced Control Algorithms 
 
Throughout their studies, Salzsieder, Fischer, and their coauthors have examined 
closed-loop control of diabetic patient glucose in dogs and humans [59-62] For 
humans, the control algorithms were employed as decision support systems or in 
simulation studies using individualized patient models. Linear algorithms were 
employed for insulin delivery based on a glucose measurement using proportional-
derivative control [59], pole-placement techniques [61], adaptive methods [60], and 
modifications of the Biostator algorithm [62]. Fischer and coauthors [60] demonstrated 
that blood glucose controllers showed markedly improved performance when the 
controller either adapted on-line or was customized to the specific patient. Of 
potential concern for these control algorithms is the sampling rate (typically one 
minute intervals), which is faster than the speed of response of implantable in vivo 
biosensors [45]. 
 
Sorensen [72], using the internal model control framework, developed a detailed 
compartmental model and a linear model-based controller. To simplify controller 
synthesis, the 19th-order nonlinear model was approximated by a first-order-
plus-time-delay (FOTD) transfer function. The controller resulting from this 
simplified structure was then implemented in the time domain. Performance was 
adequate, although improvement through use of a more detailed model in 
controller design is virtually guaranteed. Also, the controller demonstrated 
significant performance loss (in terms of ability to reject meal disturbances) when 
patient parameters differed from those of the model. 
 
An analysis paper by Doyle, et al. [63], examined modeling and experimental 
techniques for controlling blood glucose. A key observation in their work was that 
low-order models may not adequately describe the real process and therefore could 
contain both unacceptable levels of modeling error and significant process-model 
mismatch. A nonlinear feedforward-feedback controller synthesized using feedback 
linearization, a nonlinear differential-geometric technique, was the control scheme 
proposed for glucose regulation. Also proposed was a polymer (gel) device able to act 
as sensor, controller, and actuator all-in-one. This device would sense glucose as pH 
changes, and release insulin into the bloodstream according to the pH variation. The 
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control characteristics, such as dynamic behavior and magnitude of release, are designed 
into the gel through material selection and preparation. 
 
State-dependent Riccati equations were used by Parrish and Ridgely [64] to control 
blood glucose concentration in diabetic patients. Their controller was designed from a 
partial linearization of the model developed by Naylor, et al. [65]. This nonlinear 
full-state feedback control method is limited by an inability to measure several states in 
the diabetic patient model, such as total stores of glucose and insulin. Cancellation of the 
nonglucose feedback gains resulted in successful rejection of low-magnitude 
disturbances, although overaggressive control and increased insulin usage were 
both observed. The authors used manipulated variable weighting to reduce insulin 
delivery rates, while maintaining adequate glucose control. Due to the formulation 
of their controller, the tracking problem demonstrated steady-state offset. 
 
Robust control using the H∞ control methodology was the topic of a paper by Kienitz 
and Yoneyama [66]. Glucose and insulin dynamics were governed by a low-order 
model containing patient-dependent parameters. The controller was designed based on 
a nominal patient model, and a set of frequency-dependent weighting functions was 
tuned to capture the entire expected patient population (based on parameter 
variations). Patients who are within the design set will, by definition, satisfy the 
performance criterion because H∞ controllers bound worst-case performance. Meal 
disturbance simulations were promising for the nominal patient. The controller was 
robust to small amounts of patient uncertainty, but inferences to larger patient 
variability sets would require retuning of certain controller parameters. 
 
2.4.3 Optimal Control Theory 
Using a linear diabetic patient model and a quadratic performance criterion, Swan [63] 
solved the glucose control problem for the optimal insulin infusion rate. This approach 
uses optimal control theory and solution of a nonlinear algebraic Riccati equation, 
and it refines the results of Kikuchi [64, 65], who solved the problem using an 
approximate solution to the Riccati equation. The insulin delivery rate is a function of 
both the current insulin and glucose concentrations, although under certain assumptions 
(no glucose-dependent endogenous insulin release) the insulin state can be removed to 
yield a solution only in terms of the glucose concentration. The article focused on the 
initially hyperglycemic diabetic patient, so meal disturbance attenuation was not 
treated. 
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Normalization of patient blood glucose in response to both meal consumption and 
initial hyperglycemia was studied by Fisher and Teo [38]. Various infusion protocols 
were tested, with Fisher and Teo [38]. Various infusion protocols were tested, with the 
objective being the minimization of sum-squared glucose tracking error. Impulse 
control (a single injection at time = 0 min) was found to provide superior control in 
both cases, with perfect reference tracking achievable if a good estimate of the meal 
was available (under certain assumptions regarding the shape of the meal disturbance and 
insulin effects). Lim and Teo [66] studied impulse control for the same situations, but 
in the presence of fuzzy model parameters (patient uncertainty). For the chosen 
uncertainty set, and again under assumptions about the dynamic behavior of meals and 
insulin injection, the impulse control method was found to be robust and numerically 
stable. 
 
Application of optimal control theory to the “minimal model” of Bergman, et al. 
[70], was undertaken in two studies. One, by Ollerton [67], utilized an integral-
squared error (ISE) cost function based on deviation from the desired glucose value. 
Sampling times of 10 min and 180 min were studied. The longer sampling time was 
less sensitive to noise about the basal state, but it had a longer rise time and could 
also miss significant disturbances that occurred within the inter-sample window. 
Due to the calculation times experienced, Ollerton discretized the “minimal 
model” for use in the 10 min sampling time studies. This controller was sensitive to 
oscillation of the glucose profile about the basal state, and it resulted in physiologically 
unrealistic insulin profiles characterized by highamplitude sustained oscillations (ring-
ing). An insensitive model was introduced, most likely based on a type of dead-
band control, but no method for its development was discussed. 
 
Fisher [68] performed another study of the “minimal model,” also using an ISE-
based objective function. His cost criterion minimized deviations in glucose 
concentration from a reference value. As a secondary objective, the amount of insulin to 
perform the corrective action was minimized. The study examined three insulin 
infusion profiles, determining that an initial injection plus optimal hourly infusion 
minimized the cost function for an initially hyperglycemic patient. Similar to the 
control design of Ollerton [40], this algorithm was not robust to patient uncertainty, and 
it also suffered from the long sampling time (180 min) problem of missing fast or inter-
sample disturbances. 
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Parker, et al. [69], and Parker [71] examined the use of a model predictive controller 
(MPC), both with and without state estimation, for regulating blood glucose. Controller 
synthesis was accomplished by linearizing a modified version of the nonlinear patient 
model from Sorensen [72]. This controller solved an optimization problem with a 
quadratic objective function at each time step. Terms were included for setpoint tracking 
over a future prediction time horizon as well as a penalty for insulin delivery. Constraints 
on insulin delivery rate and rate of change were included in the control algorithm, 
and the linear controller was evaluated in simulation studies treating the full nonlinear 
model as the patient. Disturbance rejection and hyperglycemic initial condition 
simulations showed the efficacy of the controller, which maintained glucose above 
the hypoglycemic bound of 60 mg/dL as well as regulated blood glucose within 20 
mg/dL of the 80 mg/dL setpoint when challenged with unmeasured 50 g meal disturbances. 
It was also demonstrated that a nonlinear control algorithm (nonlinear quadratic 
dynamic matrix control with state estimation [67]) did not radically improve blood 
glucose control. 
 
2.4.4 Model-Based Predictive Control Under Patient Uncertainty 
Model predictive control has characteristics that make it an attractive choice for blood 
glucose concentration regulation. These include (i) the ability to regulate nonlinear 
systems using a linear algorithm; (ii) inherent input constraint handling; (iii) the explicit 
prediction of future behavior based on past manipulated variable moves; and (iv) 
straightforward incorporation of parameter updating. The unconstrained controller 
guarantees optimal drug delivery through solution of an optimization problem at each 
time step [73]. Although significant computational power can be required, an analytic 
solution is available in the unconstrained case [73]. A key benefit of using predictive 
control in place of a classical control algorithm is the estimation of future glucose 
behavior based on the past insulin inputs using an explicit model of patient dynamics. 
As a result, the MPC controller can adjust insulin delivery in response to a predicted 
hypo- or hyperglycemic excursion well before the event occurs. A feedback-only 
controller would respond only after the effect of the disturbance manifests itself in the 
measured output. The patient glucose concentration measurement is used as a feedback 
signal to correct the predictions for deviations between the internal model and the actual 
patient dynamics. The human glucose-insulin control problem has inherent input rate 
and magnitude constraints, as well as an output magnitude constraint, which are all 
incorporated into the MPC algorithm [73, 74] in a straightforward manner. In the 
controller development, an implantable glucose sensor is considered with 
measurements representative of the well-mixed blood being delivered to the organs 
(an “arterial” glucose measurement). Insulin delivery is assumed to be directly into 
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the venous bloodstream, such that the controller could be utilized in both an 
implantable device as well as a bedside or portable unit for hospitalized patients. 
Although research has demonstrated that portal vein insulin delivery is necessary 
to return the diabetic glucose distribution to that of a healthy patient [75], the 
choice of delivery location does not have a dramatic impact on the ability to 
regulate glucose concentration. 
 
Although many of the above control methodologies demonstrated adequate 
performance, the inherent uncertainty in the model (or patient) typically has not been 
explicitly addressed. This omission can lead to significant performance degradation 
should the model parameters not represent the actual dynamics of patient glucose and 
insulin dynamics. Significant variability among patients, and within a given patient over 
the course of a day or week, has been documented in the literature [76-79]. To avoid 
complete retuning of the controller for each patient, while recognizing that some minor 
patient- to-patient adjustments will be required, the control algorithms utilized in an 
insulin delivery device must be able to compensate for the uncertainty that exists between 
the internal model and the actual patient. An adaptation mechanism that updates the 
controller internal model based on the variability between the predicted glucose con-
centration and the measured patient glucose concentration is incorporated into the 
MPC with state estimation (MPCSE) algorithm developed in [69]. The resulting MPC 
with state and parameter estimation (MPCSPE) algorithm updates selected model 
parameters through a Kalman filter at each time step [80]. 
 
2.4.5 Uncertainty Characterization 
 
Uncertainty due to differences between an actual patient and the diabetic patient 
model may be related to variations in model parameters. A sensitivity analysis, using 
the modified Sorensen model [71, 72], identified the metabolic terms as most 
responsible for changes in blood glucose and insulin dynamics, and glucose 
metabolism is described by the following threshold function: 
 
( ){ }tanhe iE A B C x DΓ Γ Γ ΓΓ = + +⎡ ⎤⎣ ⎦   (1) 
 
Here the subscript i is the state vector element involved in the metabolic effect and 
the e subscript denotes specific effects within the model, such as the effect of glucose 
on hepatic glucose production (EGHGP), the effect of glucose on hepatic 
glucose uptake (EGHGU), or the effect of insulin on peripheral glucose uptake 
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(EIPGU). Inter- or intra-patient uncertainty could be classified physiologically as 
either a receptor (parameter) or post-receptor ( EΓ parameter) defect. This 
uncertainty formulation implies a structured effect of variability on the model, 
such that the tissues most important to parametric uncertainty are the liver and the 
peripheral (muscle/fat) tissues. 
 
Parametric sensitivity was determined individually and pair-wise for the glucose 
metabolic parameters in the diabetic patient model. Mathematically, it was assumed 
that 50% parametric variability represented a broad range of potential patients. 
Parameter sets were contrasted using sensitivity in the large [81], where the time-
domain SSE between the nominal and parametrically perturbed patient models was 
the sensitivity criterion. The up-to-four possible parameter pairings were combined 
with a series of five insulin step changes from the nominal delivery rate in the 
analysis. A “total sensitivity” was used for comparison, where the total represented 
the summation of squared errors for: (i) a specified parameter or parameter pair 
perturbation set, and (ii) the series of insulin step changes. 
 
The most sensitive parameter pairing that resulted from this procedure was EGHGP-
EΓ  with EIPGU- DΓ , which had 17% more total error than the next highest pairing. A 
concise graphical analysis is shown in Fig. 2. Variations in the EGHGP- EΓ  
parameter had dramatic effects on the process dynamic response, with the ±50% 
changes shown by the dashed lines. The range of possible process behaviors 
displayed by the perturbed models was further increased by adding the EIPGU- DΓ  
parameter variations to those of EGHGP- EΓ . Note that increases in EGHGP- EΓ  and 
decreases in EIPGU- DΓ  produced the worst-case variations shown in Fig. 2. Also, 
observe that greater variability in process dynamics and steady-state behavior was 
demonstrated by insulin-sensitive patients (lower dashed and dash-dot lines in the 
figure), while insulin-resistant patients were dynamically similar, with only 
moderate steady-state variation.  
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Figure 2.4 Graphical sensitivity analysis. Glucose profiles in response to the insulin step 
change -22.33 mU/min. Solid: nominal model response; dashed: response bounds for the ± 
50% variations in EGHGP-Er; dash-dot: response bounds for the simultaneous ±50% 
perturbations in EGHGP-E r and EIPGU-Dr [81]. 
 
2.4.6 Derivative Control 
 
J. Geoffrey Chase, et al. [80-83] have applied a modified PD control algorithm in 
their insulin infusion system. In their work, they have used a PD controller with heavy 
emphasis on the derivative term. They found that the derivative term outperforms the 
typically used proportional-weighted controllers in glucose tolerance and multi-meal 
tests. The form of the PD controller is: 
 
0( ) 1 p du t u k G k G
⎛ ⎞= + +⎜ ⎟⎝ ⎠
?
 
 
This controller incorporates proportional and derivative control with independent 
weightings and the basal infusion 0u . Heavy emphasis implies that the derivative 
gain, dk , is significantly larger than the proportional gain, pk . As a result, this 
controller focuses almost exclusively on controlling the slope of the blood glucose 
curve rather than its absolute magnitude. This approach is a far different one than 
normally taken and made possible by the emerging capability to measure blood sugar 
far more regularly via semi- or non-invasive means. 
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The optimal control discussed in the earlier section has also been explored by J. 
Geoffrey Chase, et al. [80, 81]. The equation applied is: 
 
( )2 2 0
3
( ) ( ) (0) ( ) (0) ( )
B
Vu t P t P n p P t P np P t u
p G
⎡ ⎤⎛ ⎞= + + + + + +⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
?? ? ?
 
 
The optimal solution includes first and second derivatives of the exogenous glucose 
P(t). However, it is unreaslistic to implement since P(t) is not known a priori, and 
because it is not practical to remove insulin (or add glucose) as is suggested if some 
terms become negative. This equation is also an explicit function of the time constants 
and other model parameters subjecting it to potential modeling error. This solution 
does act as a benchmark for the performance of the other controllers. 
 
J. Geoffrey Chase, et al. [80, 81] have also explored the Relative Proportional Control 
(RPC) [84].  
 
0 0( ) 1 ,  b
b
Gu t u u nVI
G
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This controller is based on a relative proportional control ( )bG G with a constant term. 
Note that bG G=  the blood sugar is at the desired level and the insulin infusion rate 
0u , the basal infusion rate necessary to maintain blood glucose at a constant level. 
 
J. Geoffrey Chase, et al. [80, 81] have modeled the OGTT by equation: 
 
( )( )( )2( ) exp lnmP t P a bt c= − −  
 
where mP  is the peak value and a, b and c are constants, which determine the slopes 
and curvatures. 
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Figure 2.5 Glucose input model of OGTT curve used in the simulations by Geoffrey 
Chase, et al. [80-81]. 
 
 
The Figure 2.6 shows the glucose response for a OGTT using the PD controller with 
sensor measures every 1 and 20 min, and for the RPC system measuring every 20 min. 
The nearly flat optimal control result in shown as well. There is also a graph of no 
controller, labeled ‘Accumulation of glucose input’, which shows glucose input 
profile. 
 
Figure 2.6 Glucose response for an OGTT [81]. 
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The Figure 2.7 shows the insulin infusion rate for the RPC and PD controllers, where 
the step shape is due to the 20 min between sensor measurements and changes to the 
insulin infusion (control) input. Note that the insulin infusion rate is smoother and 
more like an injection for the PD controller in both cases and particularly when sensor 
measurements are made every minute. 
 
  
Figure 2.7 Insulin infusion rate for an OGTT [80-81]. 
 
In judging controller performance the critical factors are the magnitude of the 
excursion for a given input and the time required to return to basal blood sugar levels. 
The PD controller limits the excursion and returns to the basal level much faster, in 
each case, due to the higher infusion rates generated by large initial slopes of the 
glucose curve. 
 
As seen in Figure 4, the optimal controller has an almost flat response. The insulin 
infusion rate for the optimal solution is not shown, however, it is effectively an 
injection of approximately 3U of insulin followed by a small glucose infusion over 25 
min. Although the optimal solution cannot be practically implemented, it does show 
that the optimal solution approaches current injection practice in a way that achieves 
neat perfect glucose response given the controllers knowledge of the input P(t). 
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2.4.7 Multi-Meal Tests 
 
J. Geoffrey Chase, et al. [81] have designed multi-meals tests to give the system a 
more strenuous physiological test such as two meals within 6 h. The inputs vary in 
magnitude from 50 to 400 kcal and are given in two groups, at t = 0, 10, 30 min and 
for the second meal at t = 210 and 300 min. At the end of 6 h, the total intake of 
glucose into the body is over 1000 kcal with 1000 kcal input over the first 4 h. Fig. 6 
shows the glucose input profile for these meals and the results are shown in Figures 
2.9 – 2.11. 
 
 
 
Figure 2.8 Multi-meal glucose input profile [81]. 
 
The Figure 2.9 shows that the PD controller works slightly better than a normal 
person, in terms of peak reduction as well as settling time with a sensor bandwidth of 
1 min. This result illustrates the potential of this controller to replace physiological 
dysfunction. Figure 2.9 also includes a plot of the response for a normal subject under 
the same conditions. 
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Figure 2.9 Glucose level of a normal human and controlled diabetic individual with 
1-min sampling period for each controller type. 
 
 
Figure 2.10 compares results at different sensor bandwidths and Figure 2.11 shows 
the insulin infusion profiles. These figures show similar trends to the OGTT results, 
where the more the insulin infusion profile tends towards injections, the better the 
control of blood sugar. For the optimal controller, inset in Figure 2.10 with a scaled 
glucose input profile, the insulin input is essentially two injections closely following 
the onset of each meal. The optimal controller glucose curve in Figure 2.10 is nearly 
flat and as the sensor sampling period approaches zero this solution should not vary at 
all to glucose inputs. 
 113
 
 
Figure 2.10 Multi-meal glucose level for controllers at different sampling periods. 
 
It is worth noting that the RPC performance is relatively resistant to changes in 
sampling period from 1 to 20 min. The PD controller result almost doubles in 
magnitude and requires slightly more time to return to basal level. The PD controller 
with a sample period of 20 min also has a slightly hypoglycemic response where the 
graph dips just below the basal value. 
 
 
Figure 2.11 Infusion rate for controllers at different sampling periods for the multi-
meal test. 
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The primary results from this testing are that the algorithm is robust to significant 
multiple inputs with the same gains as designed for OGTT inputs and that as sampling 
period decreases the insulin input profile for the PD controller approaches that of 
injections at the beginning of a meal input. This latter result tends to match current 
accepted clinical practice for the management of Type I diabetes in New Zealand and 
elsewhere. In particular, the PD controller with derivative weighting provides a basal 
input, u0, in the absence of elevated blood sugar and leads to injection-like insulin 
infusion profiles when glucose inputs are applied. In clinical practice low, basal 
insulin infusion is required to prevent diabetic ketoacidosis (DKA) in the absence of 
insulin in the system, while injections of rapid-acting insulin are used to handle meals 
and other post-prandial glucose spikes. Basal levels are typically maintained, 
clinically, via long-acting insulin injections. As a result, the behaviour of the 
derivative-weighted PD controller mimics current clinical practice that has evolved 
over several years with a basal infusion level augmented in injection-like insulin 
infusion profiles for hyperglycemic events due to exogenous glucose input. Hence, 
there exists a great similarity between the insulin infusion profile for the PD and 
optimal controllers, and typical clinical recommendations using current practice. The 
primary difference is that these controllers are able to effectively take advantage of a 
greater amount of blood glucose data using a model-based controller. 
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2.5 Non-Invasive Insulin Deliver System 
 
Since the introduction of the first through the skin (TTS) therapeutic in 1980, a total 
of 34 TTS products have been marketed and numerous drugs have been tested by 
more than 50 commercial organisations for their suitability for TTS delivery [122]. 
Most of the agents which have been tested have had low molecular weights, due to the 
impermeability of the skin barrier. This barrier resides in the outermost skin layer, the 
stratum corneum. It is mechanical, anatomical, as well as chemical in nature; laterally 
overlapping cell multi-layers are sealed by tightly packed, intercellular, lipid multi-
lamellae. Chemical skin permeation enhancers increase the transport across the barrier 
by partly solubilising or extracting the skin lipids and by creating hydrophobic pores. 
This is often irritating and not always well-tolerated. The TTS approach allows drugs 
(< 400 kDa in size) to permeate through the resulting pores in the skin, with a short 
lag-time and subsequent steady-state period. Drug bioavailability for TTS delivery is 
typically below 50%, avoiding the first pass effect. Wider, hydrophilic channels can 
be generated by skin poration, with the aid of a small electrical current (> 0.4 
mA/cm2) across the skin (iontophoresis) or therapeutic ultrasound (few W/cm2; 
sonoporation). High-voltage (> 150 V, electroporation) widens the pores even more 
and often irreversibly. These standard poration methods require experience and 
equipment and are therefore, not practical; at best, charged/small molecules (< or = 
4000 kDa in size) can be delivered efficiently across the skin. In spite of the potential 
harm of gadget-driven skin poration, this method is used to deliver molecules which 
conventional TTS patches are unable to deliver, especially polypeptides. Lipid-based 
drug carriers (liposomes, niosomes, nanoparticle microemulsions, etc.) were proposed 
as alternative, low-risk delivery vehicles. Such suspensions provide an improved drug 
reservoir on the skin, but the aggregates remain confined to the surface. Conventional 
carrier suspensions increase skin hydration and/or behave as skin permeation 
enhancers. The recently developed carriers; Transferomes [112], comprise 
pharmaceutically-acceptable, established compounds and are thought to penetrate the 
skin barrier along the naturally occurring transcutaneous moisture gradient. 
Transfersomes are believed to penetrate the hydrophilic (virtual) channels in the skin 
and widen the former after non-occlusive administration. Both small and large 
hydrophobic and hydrophilic molecules are deliverable across the stratum after 
conjugation with Transfersomes. Drug distribution after transdermal delivery 
probably proceeds via the lymph. This results in quasi-zero order kinetics with 
significant systemic drug levels reached after a lag-time of up to a few hours. The 
relative efficiency of TTS drug delivery with Transfersomes is typically above 50 %; 
with the added possibility of regional drug targeting. 
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Using Transfersomes [113], ensures reproducible and efficient transcutaneous carrier 
and drug transport. Insulin-loaded Transfersomes, for example, can deliver the drug 
through the non-compromised skin barrier with a reproducible drug effect that 
resembles closely that of an ultralente insulin injected under the skin; the 
pharmacokinetic and pharmacodynamic properties of the injected and transdermal 
insulin are also comparable. The efficacy of transcutaneously delivered insulin in 
Transfersomes is not affected by the previous therapy, similar results having been 
measured in patients normally receiving intensified insulin therapy or a continuous 
subcutaneous infusion of insulin solution. 
 
2.5.1 Insulin Delivery by Ultrasound 
 
Seungjun Lee, et al. [5, 115] have demonstrated the feasibility of using short 
ultrasound exposure times to nonivasively deliver insulin with a lightweight (<22 g), 
low-profile (37 x 37x 7 mm3) cymbal array (f = 20kHz). 
 
 
Figure 2.12 The cymbal transducer made of piezoelectric material PZT-4 operated at  
a frequency of 20kHz. The cymbal disk was placed between two titanium caps with air 
cavities beneath the caps that give rise to radial oscillations of the disk [5, 115]. 
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Figure 2.13 The lightweight, low-profile array was constructed using 4 cymbal 
transducers connected in parallel and encased in URALITE polymer. The dimensions 
of the array were 37x37x7 mm3 and it weighed less than 22g [5]. 
 
The device has been demonstrated successfully on diabetic rates to delivery insulin 
transdermally in a short period of time. But the intensity of the ultrasound energy 
must be kept low (100-125mW/cm2) without damaging the skin. 
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Figure 2.14 Over a period of 90 minutes, the blood glucose level of the rats 
decreased from the insulin with ultrasound (US) exposure ( 2100 /sptpI mW cm= ) using 
the cymbal array. Both control experiments (insulin-no US or saline-US) varied no 
greater than 40 mg/dl over the 90 minutes from the baseline. With 10 minutes of 
ultrasound exposure, the glucose level decreased -224.7 mg/dl, and the 5 minutes of 
ultrasound exposure decreased the glucose level -233.3 mg/dl [5]. 
 
 
2.5.2 Insulin Delivery by Pulsation 
 
Zakzeswski C, el at. [85] have applied electrically-enhanced iontophoretic 
transdermal delivery of insulin. The iontophoretic drug electrode was filled with 
insulin. 
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Figure 2.15 Profile of the pulsed current simulation used to enhance transdermal 
penetration of insulin [85]. 
 
They found that when iontophoretic drug electrode  was applied on the shaved skin 
surface, regular insulin (100 IU/ml) did move across the skin and reduce blood 
glucose levels in  the chronic diabetic rate model. 
 
Sershen SR, et al. [116] have applied composites of thermally-sensitive hydrogels and 
optically-active nanopartilces for transdermal photothermally modulated drug 
delivery. Copolymers of N-isopropylacrylamide (NIPAAm) and acrylamide (AAm) 
exhibit a lower critical solution temperature (LCST) that is slightly above body 
temperature. Gold-gold sulfide nanoshells have been incorporated into poly 
(NIPAAm-co-AAm) hydrogels to initial a temperature change with light. The 
nanoshells heat upon irradiation at their peak absorption wavelight, causing the 
collapse of the polymer and the subsequent release of any drug contained within the 
polymer matrix. For this to occur, the light must pass through the skin and retain 
enough power to cause sufficient heating in the nanoshells. Light between 800 and 
1200 nm has been shown to have relatively low levels of attenuation in tissue. 
Composite polymers of the nanoshells and NIPAAm-co-AAm can deliver controlled 
pulsatile doses of insulin in response to near-IR (NIR) irradiation. The activity of the 
released insulin was determined by measuring glucose uptake by adipocytes that had 
been exposed to photothermally released insulin.  
 
 
The Figure 2.16 shows the multiple “bursts” of release of insulin from nanoshell-
composite hydrogels via periodic irradiation. The release rate of insulin peaks during 
the periods in which the laser was active, and returns to a baseline level once the laser 
is turned off. 
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Figure 2.16 Release rate of insulin from nanoshell-composite hydrogels in response 
to cyclic irradiation of 821 nm (1.7 W/cm2). The data are mean ± SEM. The lower 
graph shows the irradiation response [116]. 
 
2.5.3 Glucose Responsive Insulin Release System and 
Techniques 
 
Since 1980s, a new type microcapsules, environmental stimuli-sensitive 
microcapsules have been investigated widely. These microcapsules can control 
permeation of their contents responding to environmental stimuli. They are 
considered to have potential usefulness as a controlled release system especially a 
drug delivery system, because the target of a controlled drug delivery system is for an 
improved drug treatment (outcome) through rate- and time-programmed and site-
specific drug delivery [88]. By encapsulated inside these microcapsules, chemicals or 
drugs can be released at a desired rate only when and/or where the release is needed. 
Up to date, environmental stimuli-sensitive microcapsules have been reported to act in 
response to changes in environmental temperature [89–95], pH [96–102], light [103], 
external electric field [104], redox [105], ions [106], and other stimuli, and these 
“smart” microcapsules are gathering increasing attention. In order to promote the 
applications of environmental stimuli-responsive microcapsules, development of new 
signal-sensitive microcapsules remains essential. 
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Chu LY, et al. [87] have developed a glucose-sensitive microcapsule with a porous 
membrane and glucose-responsive functional gates is prepared by using plasma-graft 
pore-filling polymerization method. The concept of the proposed microcapsule is 
schematically illustrated in Figure 2.17. The proposed microcapsule is composed of a 
porous membrane and linear grafted polyacrylic acid (PAAC) chains in the membrane 
pores and covalently bound glucose oxidase (GOD) enzymes. The linear grafted 
PAAC chains in the membrane pores act as the pH-responsive gates, and the 
immobilized GOD enzymes act as glucose sensors and catalyzer. At neutral pH in the 
absence of glucose, the pores in the microcapsule membrane are closed because the 
repulsion between negative charges make the PAAC chains extended; On the other 
hand, when environmental glucose concentration increases, GOD catalyzes the 
oxidation of glucose into gluconic acid, as a result the grafted PAAC chains shrink 
because of the reduced electrostatic repulsion and then the pores open. This is the first 
time that glucose-sensitive hollow microcapsule particulate drug carriers with a 
porous membrane and functional gates have been fabricated. 
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Figure 2.17 Schematic [87] representation of the glucose-sensitive release principle 
of microcapsules with a porous membrane and functional gates. The microcapsule is 
composed of a core-shell porous membrane and grafted PAAC chains and covalently 
bound glucose GOD enzymes in the pores. The substance to be released is dissolved 
in a solution inside the microcapsule interior. At neutral pH in the absence of glucose, 
the membrane pores are closed because the repulsion between negative charges make 
the PAAC chains extended; when environmental glucose concentration increases, the 
grafted PAAC chains shrink because of the reduced electrostatic repulsion and then 
the pores open. 
 
 
The developed glucose-sensitive microcapsule with a porous membrane and with 
linear-grafted polyacrylic acid (PAAC) chains and covalently bound glucose oxidase 
(GOD) enzymes in the membrane pores acting as functional gates was successfully 
prepared. Polyamide microcapsules with a porous membrane were prepared by 
interfacial polymerization, PAAC chains were grafted into the pores of the 
microcapsule membrane by plasma-graft pore-filling polymerization, and GOD 
enzymes were immobilized onto the PAAC-grafted microcapsules by a carbodiimide 
method. The release rates of model drug solutes from the fabricated microcapsules 
were significantly sensitive to the existence of glucose in the environmental solution. 
In solution, the release rate of either sodium chloride or VB12 molecules from the 
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microcapsules was low but increased dramatically in the presence of 0.2 mol/L 
glucose. The prepared PAAC-grafted and GOD-immobilized microcapsules showed a 
reversible glucose-sensitive release characteristic. The proposed microcapsules 
provide a new mode for injection-type self-regulated drug delivery systems having the 
capability of adapting the release rate of drugs such as insulin in response to changes 
in glucose concentration, which is highly attractive for diabetes therapy.  
 
Liang YC, et al. [86] have developed a  glucose-responsive gating membranes with 
grafted poly(acrylic acid) (PAAC) gates and covalently bound glucose oxidase (GOD) 
were prepared by grafting PAAC onto porous polyvinylidene fluoride (PVDF) 
membrane substrates with a plasmagraft pore-filling polymerization method [107–
110], and immobilizing GOD onto the grafted membranes with a carbodiimide 
method [111]. The preparation process route and the principle of glucose-responsive 
control of the permeation through the gating embrane are schematically illustrated in 
Figure 4. Investigations were carried out on the morphological examination of the 
grafting, on the control of pH-responsive pore size of the membrane and pH- and 
glucose-responsive permeability through the membrane by the PAAC grafting yield, 
and on the glucose-responsive insulin diffusion coefficient. 
 
 
Liang YC, et al. [86] have developed membrane with a pore size and permeability 
control of a glucose-responsive gating membrane with plasma-grafted poly(acrylic 
acid) (PAAC) gates and covalently bound glucose oxidase (GOD) enzymes were 
investigated systematically. The PAAC-grafted porous polyvinylidene fluoride 
(PVDF) membranes with a wide range of grafting yields were prepared using a 
plasma-graft pore-filling polymerization method, and the immobilization of GOD was 
carried out by a carbodiimide method. The linear grafted PAAC chains in the 
membrane pores acted as the pH-responsive gates or actuators. The immobilized 
GOD acted as the glucose sensor and catalyzer; it was sensitive to glucose and 
catalyzed the glucose conversion to gluconic acid. The experimental results showed 
that the glucose responsivity of the solute diffusional permeability through the 
proposed membranes was heavily dependent on the PAAC grafting yield, because the 
pH-responsive change of pore size governed the glucose-responsive diffusional 
permeability. It is very important to design a proper grafting yield for obtaining an 
ideal gating response. For the proposed gating membrane with a PAAC grafting yield 
of 1.55%, the insulin permeation coefficient after the glucose addition (0.2 mol/l) was 
about 9.37 times that in the absence of glucose, presenting an exciting result on 
glucose-sensitive self-regulated insulin permeation.  
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Figure 2.18 Schematic [86] illustration of the preparation process route and the 
principle of glucose-responsive control of the permeation through the gating 
membrane: (a) porous membrane substrate; (b) pH-responsive gating membrane with 
poly(acrylic acid) (PAAC) gates prepared using a plasma-graft pore-filling 
polymerization to graft linear PAAC chains into the pores of the membrane substrate; 
(c) glucose-responsive gating membrane prepared by immobilizing glucose oxidase 
(GOD) onto the PAAC-grafted membrane. At neutral pH in the absence of glucose, 
the carboxyl groups of the grafted PAAC chains are dissociated and negatively 
charged, therefore the membrane gates ‘‘closed’’ because the repulsion between 
negative charges make the PAAC chains extended; and (d) when glucose 
concentration increased, GOD catalyzes the oxidation of glucose into gluconic acid, 
thereby lowering the local pH in the microenvironment, protonating the carboxylate 
groups of the grafted PAAC chains, therefore the gates ‘‘open’’ because of the 
reduced electrostatic repulsion between the grafted PAAC chains in the pores. 
 
 
The membrane developed by Liang YC, et al. [86] shows that the glucose-responsive 
diffusional permeability of insulin through the proposed gating membrane with PAAC 
grafting yield of 1.55% caused by glucose addition. In the absence of glucose, the 
diffusional permeation coefficient of insulin molecules across the membrane was as 
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low as 0.79x10-7 cm2/s, and the amount of insulin permeated increased linearly with 
time. When the environmental glucose concentration was changed from 0 to 0.2 mol/l 
by adding glucose, the insulin permeation coefficient increased to 7.40x10-7 cm2/s 
dramatically. The permeation coefficient after the glucose addition was about 9.37 
times that before the addition of glucose. The results presented an exciting glucose-
sensitive self-regulated permeation of insulin molecules. 
  
 
Figure 2.19 Glucose-responsive diffusional permeation of insulin through the 
proposed gating membrane with PAAC grafting yield of 1.55% [86]. 
 
2.5.4 Inhale Insulin 
 
Subcutaneous injection has been the only route of insulin administration for patients 
with type 1 or type 2 diabetes for the past 80 years. Although research and 
development in this time has improved the insulin treatments themselves, it is only 
now that alternative routes of insulin administration are becoming viable. Many 
avenues of insulin administration have been explored, including oral, buccal, and 
pulmonary routes. However, these methods of noninvasive insulin delivery are not 
free from difficulties and only preliminary data are available for oral insulin pills and 
buccal insulin sprays. The most promising alternative route of delivery appears to be 
inhaled insulin and two devices are already in phase III testing [114].  
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2.6 System Block Diagram 
 
The figure below shows the control block of the artificial pancreas without Insulin 
Sensor. The glucose sensor monitors the blood glucose concentration continuously. 
Each sample will refine the controller response. 
 
 
 
Figure 2.20 Block diagram of a insulin infusion system without insulin sensor. 
 
 
Figure 2.21 Responses of  controllers based on patient D18 data. 
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The figure below shows the control block of the artificial pancreas with Insulin 
Sensor. 
 
 
 
Figure 2.22 Overview of the Insulin Release System. In this system, there are two 
sensors; namely non-invasive glucose and insulin sensors. The sensors provide the 
instant glucose and insulin concentrations to the respective computation sub-systems. 
In turn, the Glucose-Insulin Kinetics System Response Parameters Computer will 
derive the required amount of insulin the human biological system required after a 
meal.  
 
2.6.1 Non-Invasive Blood Glucose Sensor 
 
Numerous methods and techniques have been explored for measuring blood glucose 
levels, ranging from invasive methods such as microdialysis to noninvasive 
technologies such as spectroscopy and millimeter waves. 
 
2.6.2 Non-Invasive Insulin Sensor 
 
2.6.2.1 Blood Glucose Response Computer 
 
This controller is constructed based on the formulation as described in the previous 
chapter. It will calculate the values of A, G and ω for underdamp, critical and 
overdamp scenarios based on the glucose concentration response, y(t). 
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2.6.2.2 Insulin Response Computer 
 
This controller is constructed based on the formulation as described in the previous 
chapter. It will calculate the values of β, x’ for underdamp, critical and overdamp 
scenarios based on the insulin concentration x(t) response caused by the glucose input 
impulse, y(t) and the preceding controller’s A, G and ω outputs. 
 
2.6.2.3 Glucose-Insulin Kinetics System Response Parameters Computer (α, γ, δ) 
 
This controller is constructed based on the formulation as described in the previous 
chapter. It will calculate the values of α, γ, δ for underdamp, critical and overdamp 
scenarios based on the insulin concentration x(t)  response caused by the glucose 
input impulse, y(t) and the preceding controller’s A, G,  β and x’ outputs.  
 
It will calculate the physiological indexes and determine if the patient is normal, at-
risk and diabetic. It will determine the insulin amount requires at that moment and 
send a signal which represents the amount of insulin requires in the blood-pool. This 
amount is modulated by the current amount of insulin present in the blood pool. The 
resulting amount will be sent to the next module for insulin release. 
 
 
2.7 Control System 
 
We will discuss the design of the insulin infusion controller in this chapter. The basics 
in control theory can be found in the standard reference book by Ogata [79]. The key 
function of the controller in our system is to bring the blood glucose concentration 
down as soon as possible but prevent hypoglycemia within a sample period of two 
hours. 
 
We will discuss the three common control techniques and recommend the most 
suitable controller type for the insulin infusion system. 
 
2.7.1 Time-Domain Interpretation of Proportional-Derivative 
(PD) Control 
 
The effect of the PD control on the transient response of a control system can be 
investigated by referring to the time responses shown in the following figure. 
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Assuming that a unit-step response of a stable system with only proportional control 
is as shown in (a), which has a relatively high maximum overshoot and is rather 
oscillatory. The corresponding error signal, which is the difference between the unit-
step input and the output y(t), and its time derivative de(t)/dt are shown in (b) and (c) 
respectively. The overshoot and oscillation characteristics are also reflected in e(t)and 
de(t)/dt.  
 
 
 
 
Figure 2.23 Waveforms of y(t), e(t), and de(t)/dt, showing the effect of derivative 
control. (a) Unit-step response, (b) Error signal and (c) Time rate of change of the 
error signal [78]. 
 
For the sake of illustration we assume that the system contains a motor of some kind 
with its torque proportional to e(t). The performance of the system with proportional 
control is analyzed as follows: 
 
(a) During the time interval, 0 < t < t1. The error signal e(t) is positive. The 
motor torque is positive. The large overshoot and subsequent oscillations 
in the  output y(t) are due to the excessive amount of torque developed by 
the motor and the lack of damping during this time interval. 
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(b) During the time interval,  t1  < t < t3. The error signal e(t) is negative, and 
the corresponding motor torque is negative. This negative torques tends to 
slow down the output acceleration and eventually causes the direction of 
the output y(t) to reverse and undershoot. 
(c) During the time interval,  t3 <  t < t5. The motor torque is again positive, 
thus tending to reduce the undershoot in the response caused by the 
negative torque in the previous time interval. Since the system is assumed 
to be stable, the error amplitude is reduced with each oscillation, and the 
output eventually settles to its final value. 
 
Considering the analysis above of the system time response, we can say that the 
contributing factors to the high overshoot are: 
 
(a) The positive correcting torque in the interval  0 < t < t1 is too large. 
(b) The retarding torque in the time interval t1  < t < t2 is inadequate. 
 
Therefore, to reduce the overshoot in the step response, without significantly 
increasing rise time, a logical approach would be to: 
 
(a) Decrease the positive correcting torque in the interval  0 < t < t1. 
(b) Increase the retarding torque during t1  < t < t2 . 
 
Similarly, during the time interval, t2  < t < t4, the negative corrective torque in t2  < t < 
t3, should be reduced, and the retarding torque during t3  < t < t4 , which is now in the 
positive direction, should be increased to improve the undershoot of y(t). 
 
The PD series controller can be described with the transfer function: 
 
( )c P DG s k k s= +  
 
where Pk  and Dk  are the proportional  and derivative constants, respectively.  
 
The PD control described by the above equation gives precisely the compensation 
effect required.  
 
(a) For 0 < t  < t1, de(t)/dt  is negative; this will reduce the original torque 
developed due to e(t) alone. 
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(b) For t1  < t < t2, both e(t) and de(t)/dt  are negative, which means that the 
negative retarding torque developed will be greater than that with only 
proportional control. 
(c) For  t2 <  t < t3 , e(t) and de(t)/dt  have opposite signs. Thus the negative 
torque that originally contributes to the undershoot is reduced. 
 
Therefore, all these effects will result in smaller overshoots and undershoots in y(t). 
 
Since de(t)/dt  represents the slope of e(t), the PD control is essentially an anticipatory 
control. That is , by knowing the slope, the controller can anticipate direction of the 
error and use it to better control the process. Normally, in linear systems, if the slope 
of e(t) or y(t) due to a step input is large, a high overshoot will subsequently occur. 
The derivative control measures the instantaneous slope of e(t), predicts the large 
overshoot ahead of time and makes a proper corrective effort before the excessive 
overshoot actually occurs [78, 79]. 
 
   
Derivative control affects the steady-state error of a system only if the steady-state 
error varies with time. If the steady-state error of a system is constant with respect to 
time, the time of this error is zero , and the derivative portion if the controller provides 
no input to the process. But the steady-state error increases with time, a torque is 
developed in portion to de(t)/dt  , which reduces the magnitude of the error.  
 
2.7.1.1 Frequency-Domain Interpretation of Proportional-Derivative (PD) 
Control 
 
For frequency-domain design, the transfer function of the PD controller is given by: 
 
( ) 1 Dc P D P
P
kG s k k s k s
k
⎛ ⎞= + = +⎜ ⎟⎝ ⎠
 
 
So that it is more easily interpreted on the Bode plot. The Bode plot of the above 
equation is shown in the following figure with Pk =1. In general, the proportional-
control gain Pk  can be combined with a series gain of the system, so that the zero-
frequency gain of the PD controller can be regarded as unity. The high-pass filter 
characteristics of the PD controller are clearly shown by the Bode plot as follows. The 
phase-lead property may be utilized to improve the phase margin of a control system. 
Unfortunately, the magnitude of the PD controller pushes the gain-crossover 
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frequency to a higher value. Thus the design principle of the PD controller involves 
the placing of the corner frequency of the controller, P Dk kω = , such that an 
effective improvement of the phase margin is realized at the new gain-crossover 
frequency. For a given system, there is a range of values of P Dk k  that is optimal for 
improving the damping of the system. Another practical consideration in selecting the 
values of Pk  and Dk is in the physical implementation of the PD controller. Other 
apparent effects of the PD control in the frequency domain is that due to its high-pass 
characteristics, in most cases it will increase the BW of the system and reduces the 
rise time of the step response. The practical disadvantage of the PD controller is that 
the differentiator portion is a high-pass filter, which usually accentuates any high-
frequency noise that enters at the input. 
 
 
 
 
Figure 2.24 Bode diagram of 1 + D Pk k . Pk =1 [78]. 
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2.7.1.2 Effects of PD Control 
 
A properly designed PD controller will, affect the performance of a control system in 
the following ways: 
 
(a) Improves damping and reduces maximum overshoot. 
(b) Reduces rise time and settling time. 
(c) Increases bandwidth (BW). 
(d) Improves gain margin (GM), phase margin (PM) and maximum resonant 
amplitude (Mr). 
(e) May accentuates noise at higher frequencies. 
(f) Not effective for lightly damped or initially unstable systems. 
 
 
 
 
Figure 2.25 Unit-step responses of the attitude control system with and without PD 
control [78]. 
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Figure 2.26 The plot of Pk  versus Dk  parameter plane for a PD control system with 
0.2 451.46 D
P
k
k
ξ +=   [78]. 
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2.7.2 Proportional-Integral (PI) Control 
 
In the previous section, we can observe that PD controller can improve the damping 
and rise time of a control system at the expense of higher bandwidth and resonant 
frequency, and the steady-state error is not affected unless it varies with time, which is 
typically not the case for step-function inputs.  
 
The integral part of the PID controller produces a signal that is proportional to the 
time integral of the input of the controller. The transfer function of the PI controller is : 
 
I
c P
kG k
s
= +  
 
The immediate effect of the PI controller are : 
 
(a) Add a zero at s = I
P
k
k
−  to the forward-path transfer function. 
(b) Adds a pole at s = 0 to the forward-path transfer function. This means that 
the system is increased by one to a type-2 system. Thus the steady-state 
error of the original system is improved by one order; that is, if the steady-
state error to a given input is constant, the PI control reduces it to a zero 
(provided that the compensated system remains stable). 
 
 
2.7.2.1 Time-Domain Interpretation of Proportional-Integral (PI) Control 
 
The pole-zero configuration of the PI controller as shown by the equation above is 
shown in the following figure. At the first glance it may seem that the PI control will 
improve the steady-state error at the expense of stability. However, if the location of 
the zero of ( )cG s is properly selected, both the damping and steady-state error can be 
improved. 
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Figure 2.27 Pole-zero configuration of a PI controller [78]. 
 
Since the PI controller is essentially a low-pass filter, the compensated system usually 
will have a slower rise time and longer settling time. A feasible method of designing 
the PI control is to select the zero at I
P
ks
k
= −  so that it is relatively close to the origin 
and away from the most significant poles of the process, and the values of Pk and 
Ik should both be relatively small. 
 
2.7.2.2 Frequency-Domain Interpretation of Proportional-Integral (PI) Control 
 
For the frequency-domain design the transfer function of the PI controller is written: 
 
( )1I P II
c P
k k k skG k
s s
+= + =  
 
The Bode plot of ( )cG jω  is shown in the figure below. Notice that the magnitude of 
( )cG jω  at ω = ∞ is 20lg Pk  dB, which represents an attenuation if the value of Pk is 
less than 1. This attenuation may be utilized to improve the stability of the system. 
The phase of  ( )cG jω  is always negative, which is detrimental to stability. Thus we 
should place the corner frequency of the controller, I Pk kω = , as far to the left as the 
bandwidth requirement allows, so that the phase-lag properties of ( )cG jω  do not 
degrade the achieve phase margin of the system. 
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Figure 2.28 Bode plot of the PI controller Ic P
kG k
s
= +  [78]. 
 
2.7.2.3 Effects of PI Control 
 
A properly designed PI controller will, affect the performance of a control system in 
the following ways: 
 
(a) Improved the damping and reduces maximum overshoot. 
(b) Increases rise time. 
(c) Decreases BW. 
(d) Improves gain margin (GM), phase margin (PM) and maximum resonant 
amplitude (Mr). 
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(e) Filters out high frequencies noise. 
(f) Not effective for lightly damped or initially unstable systems. 
 
 
Figure 2.29 Unit responses of systems with PI and PD controllers [78]. 
 
 
 
2.7.3 Proportional-Integral-Derivative (PID) Control 
 
From the preceding discussions we observe that the PD controller could add damping 
to a system, but the steady-state response is not affected. The PI controller could 
improve the relative stability and improve the steady-state error at the same time, but 
the rise time is increased. This leads to the motivation of using a PID controller so 
that the best features of each of the PI and PD controllers are utilized.  
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Figure 2.30 Unit-step responses of system with PI and PD controllers [78]. 
 
From the above figure, we can observe that as low as Ik  >  Pk , the rise time is slower 
and settling time than when Ik  < Pk . 
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Figure 2.31 Step responses of a system with PD, PI and PID controllers [78]. 
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Figure 2.32 Bode plots of a system with  PD and PID controllers [78]. 
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2.8 Author’s work Type Controller selection 
 
We have investigated, PD, PI and PID controllers.  
 
2.8.1 Comparison of PD, PI and PID controllers 
 
In the following figures (2.33-2.37), we can observe that the PD controller e 
outperforms the PI and PID controllers. The amount of undershoots (under the 
reference blood glucose level) by PD controller is not frequent as the other two 
controllers.
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2.8.2 The Choice Controller: PD 
 
As our insulin infusion system is targeted diabetic patients (overdamp system 
response, as describe in the previous chapter) and based on the information discussed 
in this chapter, we proposed that PD controller be used in our insulin infusion system: 
 
(a) The patient’s glucose-insulin kinetic physiological system is already very 
stable (overdamp). 
(b) We need to infuse insulin as soon as possible. 
(c) The system must settle with the 2-hour period cycle. 
 
The PD control technique must be adapted for our use: 
(a) A unit is appended into the basic PD control system to improve the system 
responsiveness. 
(b) Taking the initial and subsequent effects of the insulin impulse released 
into the blood stream. 
 
As a result of the above reasons, the transfer function of the insulin infusion system is: 
 
c P DG k k s= +  
 
The following sections will investigate the results of this controller. 
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2.9 Derivation of Insulin Response In Blood Pool 
 
In our work [117], we have to determine to concentration of blood glucose after the 
initial release of insulin pulse. As a result, we will adapt our earlier works in Chapter 
1 and remodel the glucose-insulin dynamic system for our here. 
 
2.9.1 Insulin Impulse 
 
' ( )x p t x yα β= − +         (1) 
 
' ( )y q t x yγ δ= − −         (2) 
 
Where: 
x: blood insulin concentration (from its fasting level),  
y: blood glucose concentration (from its fasting level),  
p : insulin input-rate,  
q : glucose input-rate, for unit blood-glucose compartment volume(V), where x׀, y׀ 
denote the first-derivatives of  x and y with respect to time. In these equations, the 
Glucose-Insulin model system parameters (regulatory coefficients) are α, β, γ, δ.  
From equations (1) & (2), we obtain the differential-equation model (for glucose- 
concentration (y) and insulin-concentration (x), for insulin infusion rate (p) and 
glucose inflow rate (q=0).  
 
For insulin response, we obtain:  
( ) ( ) ( ) ( )sX s P s X s Y sα β= − +        
( )( ) ( ) ( )X s s P s Y sα β+ = +        (3) 
( ) ( ) ( )sY s X s Y sγ δ= − −  
( )( ) ( )Y s s X sδ γ+ = −  
( )
( )( ) X sY s
s
γ
δ
−= +         (4) 
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Substitute (4) into (3): 
 
( ) ( )
( ) ( ) ( )
( ) ( ) ( )
( ) ( ) ( )2
( )( ) ( )
( ) ( ) ( )
( ) ( ) ( )
( ) ( )
X sX s s P s
s
X s s s P s s X s
X s s s X s P s s
X s s s P s s
βγα δ
α δ δ βγ
α δ βγ δ
α δ αδ βγ δ
−+ = + +
+ + = + −
+ + + = +
⎡ ⎤+ + + + = +⎣ ⎦
 
( )
( ) ( )2
( )
( )
P s s
X s
s s
δ
α δ αδ βγ
+= + + + +       (5) 
 
Substitute (5) into (4): 
 
( )
( )
( ) ( )2
( )
( )
P s s
Y s
s s s
δγ
δ α δ αδ βγ
+−= ×+ + + + +  
        ( ) ( )2
( )= P s
s s
γ
α δ αδ βγ
−
+ + + +       (6) 
 
We will apply the impulse of insulin ( ) ( )p t I tδ=  where I is the amplitude of insulin 
impulse and ( )tδ  is the finite delta function. The Laplace transform of p(t): 
( )P s I=          (7) 
Substituting equation (7) into (5) and (6): 
( )
( ) ( )2( )
I s
X s
s s
δ
α δ αδ βγ
+= + + + +       (8) 
( ) ( )2( )=
IY s
s s
γ
α δ αδ βγ
−
+ + + +       (9) 
 
Using the results from the previous chapter, we can deduce the solutions for equations 
(8) and (9). 
Soltion for equation (9): 
( ) sinAtIy t e tγ ωω
−−=         (10) 
 
From (8): 
( ) ( ) ( ) ( )2 2( )
sX s I
s s s s
δ
α δ αδ βγ α δ αδ βγ
⎡ ⎤= +⎢ ⎥+ + + + + + + +⎣ ⎦
 
 
Using the standard inverse Laplace table and solution from the previous chapter: 
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( ) sin sin
        sin
bt at
At At
bt at
At
be aex t I e t e t
I be aee t
δω ωω ω
ω δω ω
− −
− −
− −
−
⎡ ⎤+= +⎢ ⎥⎣ ⎦
⎡ ⎤+= +⎢ ⎥⎣ ⎦
 
( ) ( ) ( )
( ) ( ) ( )
2
2
1where 4
2
1          4
2
b
a
α δ α δ αδ βγ
α δ α δ αδ βγ
⎡ ⎤= + − + − +⎢ ⎥⎣ ⎦
⎡ ⎤= + + + − +⎢ ⎥⎣ ⎦
 
 
2.9.2 Blood glucose Responses after Release of Insulin Pulse 
 
We are expecting the system to response as: 
 
Figure 2.38 Response of blood glucose concentration after the insulin impulse infused 
into the GI.  
 
Please note that the above figure is a very ideal response as it only requires a single 
insulin. In our simulation, we will requires a few pulses to bring the blood glucose 
concentration down to a acceptable reference level safely without causing 
hypoglycemia. 
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Figure 2.39 Flow chart of the workings of the insulin infusion system.
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2.10 Simulated Results 
 
In this section, we have make use of the clinical data from diabetic volunteers in 
Chapter 1 as our source. Then we perform simulations under the MatLab and 
Simulink environments to perform system simulations to verify the accuracies of our 
models.  
 
The clinical OGTT data is only 2 hours. We have extended the simulation cycle to 4 
hours to verify the system stability per data set and no insulin should be infused once 
the blood glucose concentration level is at reference level or under. If the 
concentration of the blood glucose is at the reference level or under, the controller 
should not take any action. 
 
Please refer to Appendix F for details. 
 
2.11 Conclusion 
 
We have demonstrated that we can bring down the blood glucose concentration within 
2 hours for those volunteers who were determined as diabetic in Chapter 1 based on 
system simulation under MatLab Simulink environment. The 4-hour simulations were 
also performed to show the system stability. 
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Chapter 3 Lung Ventilation Modeling 
and Assessment [3] 
 
 
3.1 Motivation behind the Project 
 
Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disease of 
the lungs that gradually reduces airflow. It is characterized by phlegmy coughing, 
wheezing and shortness of breath. As the disease progresses, quality of life may be 
severely compromised.  
 
 
COPD is one of the five most lethal diseases in the world. Both its mortality and its 
frequency are increasing. The disease is closely associated with cigarette smoking. 
Studies have shown that smoking is associated with up to a 20-fold increase in the 
risk of death from COPD. Smoking can lead to the two most common forms of this 
disease, emphysema and chronic bronchitis. COPD is largely a disease of the elderly. 
Although symptoms may begin to occur in the 40s, the disease is generally not 
diagnosed until the patient has reached his or her 60s. 
 
There is no known cure for COPD, so it is very important to learn how to effectively 
manage the disease. Strategies for managing COPD include making lifestyle changes 
(e.g., quitting smoking) and taking medications (e.g., bronchodilators). In more severe 
cases, physicians commonly recommend oxygen-replacement therapy, in which 
patients breathe oxygen from either oxygen cylinders/tanks or electric concentrators 
that take the oxygen directly from the air. In extreme cases, surgery might be 
necessary to reduce the volume of the lungs or even lung transplantation. 
 
In terms of prevalence, hospitalization, disability and death, COPD is a major health 
problem in Singapore. Prevalence of moderate to severe COPD is estimated at 2.3%, 
or a population of 3 million or absolute number of 69 000 patients in the community 
[40]. 
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Table 3.1 Model projections of the prevalence of moderate to severe COPD in those 
30 years and older for 12 countries in the Asia-Pacific region [Respiratory,8, 192-
198]. 
 
Country Moderate/Serve COPD cases Prevalence (%) 
1. Australia 558 000 4.7 
2. China 38 160 000 6.5 
3. Hong Kong 139 000 3.5 
4. Indonesia 4 806 000 5.6 
5. Japan 5 014 000 6.1 
6. South Korea 1 467 000 5.9 
7. Malaysia 448 000 4.7 
8. Philippines 1 691 000 6.3 
9. Singapore 64 000 3.5 
10. Taiwan 636 000 5.4 
11. Thailand 1 502 000 5.0 
12. Vietnam 2 068 000 6.7 
          Total 56 553 000 6.3 
 
According to routine official statistics in Singapore, it is the 8th leading cause of death 
(0.9% of all deaths) and 9th leading cause of hospitalization (1.7% of total 
hospitalization). Note, these figures from routine official statistics are likely to be 
under-estimates as they “reported” cases only. 
 
World-wide, it ranks as the 4th leading cause of death alongside HIV. The World 
Health Organization (WHO) estimates that the trend in the social burden of COPD (a 
composite measure which factors in death, and disability) would rise from 12th highest 
in 1990 to 5th highest in year 2020. 
 
We do not have published figures in Singapore, but it can be inferred that the relative 
importance is similar to that in other developed countries by Prof Tan [40]. Please 
refer to Tables 2 and 3. Health care cost (due largely to hospitalization) for COPD is 
twice that of asthma in the USA. 
 
The burden is expected to increase with increasing trends of smoking in the young 
and with the increase in the population of the aged in the population. The present 
population of persons aged 65 plus (7% of the population) is expected to increase to 
20% by 2030. 
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Table 3.2 Direct and indirect costs of lung diseases, 1993 (US $ Billions). Compares 
the estimated costs of various lung disorders in the US 1993. In 1993, the annual 
economic burden of COPD in the US was estimated at 23.9 billion, including $14.7 
billion in direct expenditures for medical care services [GOLD workshop report 2003 
update]. 
 
 Condition Total 
Cost 
Direct 
Medical 
Cost 
Mortality-
Related 
Indirect 
Cost 
Morbidity-
Related 
Indirect 
Cost 
Total 
Indirect 
Cost 
COPD 23.9 14.7 4.5 4.7 9.2 
Asthma 12.6 9.8 0.9 0.9 2.8 
Influenza 14.6 1.4 0.1 13.1 13.2 
Pneumonia 7.8 1.7 4.6 1.5 6.1 
Tuberculosis 1.1 0.7 - - 0.4 
Lung 
Cancer 
25.1 5.1 17.1 2.9 20.0 
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Table 3.3 WHO projection of total social burden world-wide. Leading causes of 
Disability-Adjusted Life Years (DALYs) lost world-wide, 1990 & 2020 (projected) 
[GOLD workshop report 2003 update]. 
 
Disease or injury Rank Percent of 
Total DALYs 
Rank 
2020 
Percent of 
Total DALYs 
Lower respiratory Infections 1 8.2 6 3.1 
Diarrheal diseases 2 7.2 9 2.7 
Perinatal period conditions 3 6.7 11 2.5 
Unipolar Major depression 4 3.7 2 5.7 
Ischemic heart disease 5 3.4 1 5.9 
Cerebrovascular disease 6 2.8 4 4.4 
Tuberculosis 7 2.8 7 3.1 
Measles 8 2.6 25 1.1 
Road traffic accidents 9 2.5 3 5.1 
Congenital anomalies  10 2.4 13 2.2 
Malaria 11 2.3 19 1.5 
COPD 12 2.1 5 4.1 
Trachea, bronchus, lung cancer 33 0.6 15 1.8 
 
 
COPD encompasses two groups of lung disease, chronic bronchitis and emphysema. 
Chronic bronchitis refers to a productive cough for at least 3 months of each of 2 
successive years for which other causes have been ruled out. Emphysema describes 
destruction of the lung architecture with enlargement of the airspaces and loss of 
alveolar surface area. 
 
COPD prevalence increases with age, but there is a dramatic synergy with smoking 
such that smokers have higher COPD prevalence and mortality and lung function 
losses as a function of amount smoked are dose-dependent. Unlike heart disease, 
quitting smoking does not produce substantial reversal of tobacco - harmful effects 
once COPD is established. As a result, in much of the developed world, COPD is 
increasing as a cause of death as cardiovascular death rates fall. 
 
As with other tobacco-associated adverse health effects, smoking either cigarettes or 
cigars increases risks of COPD. Thus, cigar smokers are reported to have a 45% 
higher risk of COPD when compared to nonsmokers. 
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3.2 Pulmonary System 
 
The lung, as seen in Figure 3.1 consists of the collection of alveoli and three 
branching tubular networks; first the bronchial tree which carries air to and from the 
alveoli, next the pulmonary arterial tree which carries blood to the pulmonary 
capillaries, then the pulmonary venous tree which returns the oxygenated blood to the 
heart. The main bronchus, arteries and veins all enter the lung and are divided into 
parallel networks to reach the alveoli. 
 
The primary function of the lung is gas exchange between the air and the blood via 
the alveoli. Air diffuses through the thin air-blood barrier in the alveolar walls (next 
chapter will describe the process and modeling in details), which is lined with blood 
capillaries. The lungs, chest wall and diaphragm are described as a balloon 
mounted inside a mechanical bellows. During spontaneous breathing, the respiratory 
muscles are responsible for the contraction and the pressure difference in the lungs, 
while the bellows will assist in rapid breathing. The muscles and functional group 
involved: 
 
(a) Inspiratory Muscles - Diaphragm is the major muscle here. Contraction results 
in flattening of the muscles and elevation of the lower ribs, which enlarge the 
thorax. 
(b) Expiratory muscle - The exhaling process is usually passive and is caused by 
the elastic recoil of the lungs and chest wall; at high rates of ventilation or 
with airway obstruction. 
(c) The abdominal and intercostals muscles play their part too in generating a 
pressure gradient. 
 
The lung is a difficult area to study deemed by the difficult access to it in its 
natural state. Because the working fluid of this system is a gas rather than a liquid, 
opening the chest destroys the partial vacuum in the space between the chest wall 
and the lung, as well as an incision will cause lung collapse. 
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Figure 3.1 The Respiratory System [American Medical Association]. 
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Figure 3.2 Lungs with main bronchi, windpipe and larynx [Prof Gunther H, 
Bodyworlds]. 
Component of the respiratory system consists of: 
 
(a) The lungs: pulmonary parenchyma, airways and blood vessels; 
(b) The chest wall: the rib cage, intercostals muscles and diaphragm; 
(c) The abdomen: the diaphragm, abdominal musculature and abdominal 
contents; 
(d) The nervous system inputs. 
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3.2.1 Lung Volume and Pressures 
 
The gas volume of the in-vivo lung is classified into eight components as seen in 
Figure 3.3. These varies with body size, age, however, large differences from 
these normal gas volumes are indicators of pulmonary functional problems [41]: 
 
(a) Tidal Volume (TV), 600 ml - Volume of gas inspired and expired during 
normal breathing of a resting person. 
(b) Inspiratory Reserve (IR), 3 L - Volume which can b e inspired starting 
after a normal inspiration 
(c) Inspiratory Capacity (IC), 3.6 L - Sum of TV and IR 
(d) Expiratory Capacity (EC), 1.2 L - Volume which can be expired starting 
after a normal expiration 
(e) Residual Volume (RV), 1.2 L - Volume of gas remaining in lung after 
maximal expiration. 
(f) Functional Residual Capacity (FRC), 2.4 L - Sun of RV + ER, gas 
volume at end of normal expiration. 
(g) Vital Capacity (VC), 4.8 L - Sum of ER, TV and IR. Total possible 
conscious volume change. 
(h) Total Lung Capacity (TLC), 6 L - Sum of RV, ER, TV and IR, total 
gas volume in maximally inflated lung. 
 
 
Figure 3.3 The eight gas volume components  
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Figure 3.4 Dynamics of a normal Tidal Volume breadth [Steven M. Koenig, MD]. 
 
The above figure shows the dynamics of a normal tidal volume breath. The 
tidal volume 1oop is spread out over 5 seconds, 12 breaths/min. The inspiratory 
time, 2 seconds, is shorter than the expiratory time, 3 seconds as airflow 
resistance is higher during expiration, as indicated by the fact that the maximal 
alveolar pressure deflection is only 0.8 cmH2O during inspiration but is 1.2 cm 
H2O during expiration, even though peak airflow is 0.5 litre/sec in each phase. 
The dashed line in the pleural pressure graph represents the pressure necessary to 
overcome lung elastance, the mirror image of the tidal volume curve above. The 
alveolar pressure curve is in phase with the airflow curve. When the alveolar 
pressure swing due to airflow is added to the elastic recoil pressure, one 
obtained the complex curve shown by the heavy solid line in the bottom graph. 
The line segments a, b, c and d show four examples in which the resistive pressure 
has been added to the elastic pressure. The shaded are during inspiration is less 
than the area during expiration because the work to overcome airflow resistance is 
less [42]. 
 
3.2.2 Alveolar Pressure 
 
This is the pressure within the alveoli, the smallest gas exchange units of the lung. 
Alveolar pressure is given with respect to atmospheric pressure, which is always set to 
zero. Thus, when alveolar pressure exceeds atmospheric pressure during exhalation, it 
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is positive; when alveolar pressure is below atmospheric pressure during inspiration, it 
is negative. Hence, alveolar pressure determines whether air will flow into or out of 
the lungs. When alveolar pressure is negative, as is the case during inspiration, air 
flows from the higher pressure at the mouth down the lungs into the lower pressure in 
the alveoli. When alveolar pressure is positive, which is the case during expiration, air 
flows out. At end-inspiration or end-expiration, when flow temporarily stops, the 
alveolar pressure is zero (i.e., the same as the atmospheric pressure). 
 
During breathing, the actions of the respiratory muscles on the chest compress and 
expand the gas within the alveoli. The resultant alveolar pressure is the net force that 
moves air through the airway. Its measurement is necessary to estimate airway 
resistance and can be accomplished using the following form [43]: 
 ( )2H O
alv
L
B P V
P
V
− ∆∆ =        (3-1) 
 
where 
 
V∆ : is measured with a body plethysmograph, L; 
2H O
P  : vapour pressure of water, mmHg 
LV  : thoracic lung, L; 
B : barometric pressure, mmHg 
 
 
 
 
        Inspiration  Pressure                                                    Expiration Pressure 
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Events during inspiration Events during expiration 
Diaphragm & intercostals muscle contract        Diaphragm & external intercostals 
muscle relax 
  
 
Volume of thoracic cavity increases Volume of thoracic cavity decreases 
 
  
 
Pleural pressure becomes more negative Pleural pressure becomes less 
 negative                                                 
 
  
 
Lungs expand Lungs recoil 
 
  
Alveolar pressure becomes negative            Alveolar Pressure rises above 
atmospheric pressure 
 
                              
                   Air flows into lungs                                   Air flows out of lungs  
 
Figure 3.5 Airflow pattern of the lungs 
 
 
3.2.3 Pleural Pressure 
 
Pleural pressure is the pressure surrounding the lung, within the pleural space. During 
quiet breathing, the pleural pressure is negative; that is, it is below atmospheric 
pressure.  
 
The pleura are a thin membrane, which invests the lungs and lines the walls of the 
thoracic cavity. During development the lungs grow into the pleural sacs until they are 
completely surrounded by them. The side of the pleura that covers the lung is referred 
to as the visceral pleura and the side of the pleura that covers the chest wall is called 
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the parietal pleura. These two sides are continuous and meet at the hilum of the lung. 
The two faces of the pleural membranes are directly opposed to one another, and the 
entire potential space within the pleura contains only a few milliliters of serous 
pleural fluid. 
 
During active expiration, the abdominal muscles are contracted to force up the 
diaphragm and the resulting pleural pressure can become positive. Positive pleural 
pressure may temporarily collapse the bronchi and cause limitation of airflow. 
 
3.3 Pulmonary Mechanics 
 
The function of the conducting airways, chest wall and the respiratory muscles is to 
supply fresh oxygen to and remove carbon dioxide from the alveolar capillaries, they 
function like the respiratory "pump" while gas exchange is accomplished within the 
alveoli. Pulmonary mechanics is the study of the elastic and flow-resistive properties 
of the respiratory system components, and their interactions. Several common human 
disease states can be best understood physiologically as an alteration in the static or 
dynamic properties of the pulmonary system. We will briefly discuss the mechanical 
alterations, which result from emphysema, asthma, pulmonary fibrosis, and the 
respiratory distress syndromes. Finally, it is important to understand that the 
pulmonary system functions as an integrated whole to accomplish efficient gas 
exchange at minimal energy cost to the organism. 
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3.3.1 Components of Total Airflow Resistance 
 
During tidal breathing the elastic and resistive properties of the total respiratory 
system determine the pressure required to inflate the lungs. This pressure ( P∆ ) can be 
divided into its elastic component (pressure required to change volume, V) and 
resistive component (Pres, pressure required to generate flow,V
?
) by the simplified 
equation of motion of the lungs: 
 
. .P E V R V∆ = + ?  
 
where E is elastance (the reciprocal of compliance) and R is resistance. The relevant 
elastic properties can be divided into two components, those of the lungs and those of 
the chest wall, which are arranged in series. Similarly the resistive pressure can be 
defined as the total pressure drop in phase with flow through the separate segments of 
the tracheobronchial tree and across the lung tissue and chest wall, which are arranged 
in series. While the pressure drop through the airways is a classic ohmic resistance 
and proportional to flow, pressure drops across the lung tissue and chest wall are not 
proportional to flow, but rather depend on lung volume, tidal volume, and frequency. 
Although usually regarded as small in normal subjects, they are included in 
measurements of total lung resistance (RL) or total respiratory resistance (Rrs) (refer to 
the figure below). Resistance of some of the individual airway segments can be 
measured by catheters or needles but this is rarely done (except for the nose). 
 
Table 3.4 Abbreviations [21] 
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3.3.2 Methods for Measuring Airflow Resistance 
 
There are four methods in clinical use. They have different strengths and weaknesses 
and measure slightly differently parts of the total resistive pressure drop. 
 
3.3.2.1 Body plethysmography to measure airway resistance (Raw) [44] 
 
The body plethysmograph is the only available method for directly measuring airway 
resistance in humans and has the added advantage that absolute lung volume can 
readily be measured, allowing the calculation of a volume corrected (specific) 
resistance or its reciprocal, conductance. The technique has been particularly valuable 
for studies of airway pharmacology in normal subjects and subjects with mild asthma, 
and, suitably modified, in infants. Its disadvantages are its bulk and expense and a 
relative difficulty in using it for different maneuvers or breathing different gas 
mixtures. 
 
 
Figure 3.6 Body plethysmography method. The subject, seated in a whole-body 
plethysmograph (`box') breathes through a pneumotachograph back into the box (V
?
).  
 
The above figure shows the setup for the Body plethysmography method. The mass 
movement of gas from the lungs to box itself results in no change in total volume 
(provided there are no changes in temperature), and so the change in box pressure 
(Pbox) during breathing is due to volume change of the lungs caused by compression 
and rarefaction of alveolar gas; if the volume of alveolar gas is known, the observed 
change in box pressure can be calibrated in terms of change of alveolar pressure. 
Dividing change in alveolar pressure by change in flow at the mouth gives airway 
resistance (Raw). 
 
This method assumes a constant volume; so that any change in thoracic volume which 
is not simply due to mass transfer from lungs to box results in reciprocal changes in 
box pressure (i.e. box pressure rises if there is rarefaction of alveolar gas). To 
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calibrate changes in box pressure in terms of change in volume, a pump is used to 
inject and withdraw repetitively a small volume of gas into the box, while the subject 
to be studied holds his breath. (A large subject occupies more of the plethysmographic 
volume, so that a standard primp volume results in a bigger box pressure change than 
when a small subject is studied.) Alternatively a correction based on subject’s body 
weight can be used and the box calibration performed when empty. 
 
Changes in box pressure on expiration can occur; mainly because of cooling of 
expired air transferred from lungs to box (Instability of box pressure can be caused by 
heating of box air after the subject enters. Some plethysmographs are air-conditioned 
to hold the temperature more stable. there are also small effects from the respiratory 
exchange ratio being < 1.0.) This is minimized either by shallow panting through a 
heated pneumotachograph (this also has the advantage of abducting the cords and 
minimizing glottal resistance) or by rebreathing into a bag heated to 37° or with 
computerized simulated correction for the change in temperature and humidity as gas 
is transferred from lungs to box during tidal breathing. 
The subject is connected by caliber mouthpiece to the pneumotachograph shutter 
assembly. In the first part of the procedure changes in box are plotted against flow 
rate on an oscilloscope and the angle ( boxP V∆ ∆
?
) measured usually around zero 
flow or from 0 to 0.5 Ls-1 inspiratory flow. The shutter is then closed to allow 
`calibration' of the Pbox signal in terms of Palv, by measuring Pmo during panting 
against an occlusion (when it will normally equal Palv) and plotting this against Pbox 
on an oscilloscope, and measuring the ( )mo alv boxP P∆ ∆  slope. Then multiplying the 
two slopes: 
 
box alv alv
box
P P P Raw
PV V
∆ ∆ ∆× = =∆∆ ∆? ?
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Figure 3.7 Changes in (a) airways resistance (Raw), and (b) conductance (Gaw) with 
changes in lung volume in a normal individual. Whereas Raw has a curvilinear 
relation to lung volume, Gaw shows a linear increase as lung volume is increased from 
residual volume (RV) to total lung capacity (TLC). Specific airway conductance 
(sGaw) at any lung volume equals Gaw/VL, where VL is the absolute lung volume (L). 
Because of the intercept of Gaw on the volume axis at RV, sGaw is lower at functional 
residual capacity (FRC) than at a larger lung volume (as indicated by the dashed 
lines from the origin). (c) In chronic obstructive pulmonary disease (COPD) Gaw 
increases less than normal as VL is increased, and there is a large RV. 
 
3.3.2.2 Esophageal Balloon Catheter Technique to Measure Total Lung 
Resistance 
 
Pleural surface pressure can be estimated by placing a small balloon catheter in the 
lower esophagus. During tidal inspiration, changes in pleural (in practice, esophageal) 
pressure are required to oppose the elastic properties of the lung (measured as 
dynamic compliance, CLdyn) and the resistive properties of the lungs and lung tissue 
(total lung resistance, RL). By simultaneous measurement of flow at the mouth (V
?
) 
and change in lung volume ( V∆ ), it is possible to subdivide the change in esophageal 
pressure into CLdyn and RL. 
 
Esophageal Balloon Catheter Technique is the only method that directly measures 
intrathoracic pressure, but its invasiveness means that it is not often used solely to 
measure RL (and CLdyn) in humans. Once an esophageal balloon catheter has been 
placed, a full analysis of pulmonary mechanics can be made with additional 
measurements such as the static pressure-volume curve of the lung and the 
mechanical work of breathing on the lungs and chest. 
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During quiet breathing in normal subjects, most of the tidal change in pleural 
(esophageal) pressure is overcoming the elastic properties of the lungs and a much 
smaller proportion the resistive properties; in addition there is often a notable cardiac 
artifact on the esophageal pressure trace. As a consequence, measurement of CLdyn is 
more reliable than RL. One way to improve the signal-noise ratio is to ask the subject 
to breathe rapidly, with tidal volume similar to that used during quiet breathing; this 
increase in flow accentuates the resistive component of the total pressure change. The 
signal-noise ratio for RL is much better when airways obstruction is present. All 
calculations of the resistive pressure drop assume dynamic compliance to be constant 
during the breath and identical on inspiration and expiration. Alinearities in dynamic 
compliance occur when breathing with large tidal volumes or close to TLC and when 
dynamic compliance is severely reduced, as in fibrosing alveolitis; these alinearities 
result in errors in the calculation of RL. 
 
Measurements of esophageal pressure may be distorted in the supine position because 
of the effects of gravity on the heart and mediastinal contents and the position of the 
diaphragm. 
 
An esophageal balloon catheter is positioned in the lower esophagus and connected to 
a differential pressure transducer which measures the difference between esophageal 
and mouth pressure ( P∆ ). The subject wearing a nose clip, breathes through a 
pneumotachograph which measures instantaneous flow (V
?
) which is integrated to 
give tidal volume ( V∆ ). Data are collected over at least 10 breaths during quiet 
breadth (as shown in the figure below).  
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Figure 3.8 Esophageal-mouth pressure ( P∆ ) versus time. 
 
 
 
 
Figure 3.9 Esophageal-mouth pressure versus volume 
 
For normal subjects, it may be useful to breathe with increased frequency of breathing 
but with a similar tidal volume because this increases the resistive component of P∆  
in the above figure. 
 
Although records against time can be used to calculate RL  and CLdyn , the inter-
relations between the two relations and the calculation of work of breathing can be 
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demonstrated better by plotting the relation between pressure and volume during each 
breath as shown in the above figure. On inspiration pressure becomes more negative 
until end inspiration. On expiration esophageal pressure rises(becomes less negative). 
 
The dynamic compliance (CLdyn) is obtained by dividing tidal volume ( V∆ ) by the 
difference in esophageal pressure between points of no flow (end inspiration), 
distance on pressure axis being equivalent to change in dynamic lung elastic pressure 
( LdynP∆ ). 
 
The total lung resistance ( LR ) is obtained by measuring the width of the esophageal 
pressure volume loop at iso-volume; this indicates the resistive pressure drop ( Pr esP∆ ) 
which can be divided into inspiratory (to the left of the diagonal line) and expiratory 
(to the right of the diagonal line) components and related to the corresponding flow at 
that volume. Usually however the total Pr esP∆  is used and related to the sum of 
inspiratory and expiratory flow at this volume, ( )Pr expL es inspR P V V= ∆ + .  
 
Values of RL in normal subjects are usually slightly higher than values of Raw, 
presumably reflecting tissue resistance of the lungs.' When airway narrowing is 
induced in normal subjects the increment in RL may be larger than that in Raw; this 
may be because RL is measured at a lower breathing frequency than Raw or because RL 
also measures an increase in `tissue resistance' (see later). Few studies have compared 
values of RL and Raw in patients with airways obstruction. Although the method is 
potentially suitable for long-term monitoring of RL (and CLdyn), in practice this is only 
used in intensive care units; in the pulmonary function laboratory, forced oscillation is 
a more acceptable non-invasive technique for monitoring airflow resistance during 
tidal breathing over long periods. The esophageal balloon - catheter technique is the 
best method for measuring resistance during the high flows of exercise. 
 
3.3.2.3 Forced Oscillation Techniques to Measure Total Respiratory Resistance 
(Rrs) [45, 46] 
 
The forced oscillation technique for measuring air flow resistance was introduced in 
1950s at the same time as body plethysmography, but did not become as widely 
established in clinical physiology because the technical requirements for obtaining 
accurate pressure and flow signals and the subsequent signal processing were more 
demanding. Advances in pressure transducer and microcomputer technology have 
removed earlier problems with signal collection and analysis. Oscillation methods 
require less cooperation from the subject and less bulky apparatus than body 
 184
plethysmography, and so the oscillation technique is now becoming more widely 
used. 
 
Forced oscillation techniques deduce the mechanical properties of the respiratory 
system from the response to small, externally produced oscillatory forces. From the 
response measured as the instantaneous pressure flow relationship (impedance) - flow 
resistance and the reactance (the combined effect of elastance and inertance) of the 
respiratory system can be computed. These mechanical properties of the lungs are 
non-linear so it is important that only small external forces (1-2 cmH2O) are applied. 
During quiet breathing the elastic properties (compliance) and resistive properties 
account for all the pressure required to expand the respiratory system. A third 
property, inertance, which is related to the pressure required to accelerate flow, is only 
important in very rapid breaths but becomes significant when oscillation is applied at 
high frequencies. 
 
The main current application in clinical physiology of the forced oscillation technique 
is as a simple method for obtaining the flow resistive properties of the respiratory 
system at different frequencies during tidal breathing. Usually results are presented at 
an oscillation frequency of 4 or 6 Hz and as frequency dependence of Rrs at higher 
frequencies within a breath. 
 
In patients with COPD (and asthma) Rrs is increased at the lower applied frequencies 
but falls with increasing applied frequencies (as shown in the following figure). 
Reactance (Xrs) is lower than in healthy subjects and becomes positive only at higher 
frequencies, so that resonant frequency is increased. In the presence of inhomogeneity 
of mechanical properties of the lungs, resistance falls with increasing frequency, but 
this fall is exaggerated by increased dissipation of the applied oscillatory signal in the 
upper airway (chiefly the cheeks and floor of mouth). The contribution of the cheeks 
and mouth (sometimes called upper airway shunt) to total impedance can be reduced, 
but not eliminated, by firm support of the cheeks and floor of the mouth with the 
palms and fingers. 
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Figure 3.10 Typical changes in total respiratory resistance at different applied 
oscillation frequencies. In a patient with airways obstruction resistance is higher at 
all frequencies than in a normal subject and decreases with increasing frequency; 
reactance is lower at all frequencies and resonant frequency is increased. The tidal 
breathing pattern can be monitored during measurement by integrating moV
?
 and 
absolute volume determined by measuring inspiratory capacity at the end of the 
measurement period to calculate specific rsR . 
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Figure 3.11 Forced oscillation method for measuring input impedance during tidal 
breathing. The loudspeaker is driven to generate a sinusoidal oscillation at one 
frequency, a sequential series of sinusoidal oscillations at different single frequencies. 
The flow signal can be integrated to give tidal volume and at the end of the 
measurement period, inspiratory capacity. 
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3.3.2.4 Airflow interruption technique to measure resistance (Rint) [47] 
 
The interruption technique is the simplest technique for measuring airflow resistance. 
Spontaneous breathing is interrupted by occluding the mouthpiece, and the flow 
immediately before occlusion is related to an estimate of alveolar pressure (Palv) 
shortly after occlusion which is derived from the trace of mouth pressure (Pmo) 
(measured on the alveolar side of the closed mouthpiece) versus time. The method 
requires minimal subject cooperation (the ability to use a flanged mouthpiece), can 
now be measured by simple portable devices, and does not require full inflation or 
unusual breathing maneuvers. 
 
 
 
 
Figure 3.12 Airflow Interruption Apparatus. The subject with nosed clipped breaths 
tidally through the interrupter device which comprises a tube with a fast-closing value 
and a flow measuring device, usually a pneumotachograph screen. Valve closure may 
be triggered at a given flow or randomly and typically lasts 100ms. Pmo before 
occlusion (Ppre) is proportional to screen resistance and is used to measure flow. 
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Figure 3.13 Analysis of Pmouth versus time record. During expiratory flow, month 
pressure (Pmo) is beer than alveolar pressure (Palv) because of the resistance of the 
airways. Pmo indicates the pressure drop across the pneumotachograph screen (Ppre) 
and measures flow (V
?
). When the disk valve closes, flow ceases and Pmo rises rapidly 
to equilibrate with Palv. Following flow interruption, three distinct phases in the Pmo 
versus time curve occur. 
 
In most comparisons, values of Rint have been higher than those of Raw and of RL, in 
normal subjects but the precise reasons for this difference were undetermined. If Pmo 
is back-extrapolated to time of half-closure of the valve, then Rint is similar to Raw in 
normal subjects but is lower than Raw when there is airway obstruction. This 
underestimate is probably caused by slow equilibration of Palv with Pmo. Interpretation 
of the later increase in Pmo on the Pmo versus time curve is less clear because it is not 
possible to distinguish the roles of continuing respiratory muscle activity, stress 
recovery of lung and chest wall tissues, and redistribution of gas - either between 
intra-and extrathoracic airways or between parallel intrathoracic airways. Despite 
these limitations in physiological interpretation, measurement of Rint has proved 
useful for the empirical detection of airway narrowing. 
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3.4 Comparison of Different Methods for Assessing 
Airflow Resistance 
 
Forced oscillation and airflow interruption are more convenient and require less 
subject cooperation than esophageal balloon and body plethysmography methods, but 
unfortunately they are less sensitive than the last two methods and tend to 
underestimate resistance. Only the esophageal balloon catheter directly measures 
intrathoracic pressure, and the measurement is subject to noise. The other three 
methods rely on the measurement of Pmo, changes in which tend to be increasingly 
underestimated as airway obstruction becomes more severe. This is because pressure 
is dissipated in the compliant extrathoracic airway, which is important in the forced 
oscillation technique; in addition there is slow equilibration of alveolar and mouth 
pressure which leads to underestimates of resistance with the airflow interruption 
technique and, in the plethysmographic method, overestimates of lung volume and 
consequent underestimates of Raw (measurements of sRaw or sGaw are not affected). 
Standard techniques for measuring Ri, Raw, and Rrs all average resistance over a whole 
breath, but Rint is usually derived from a single inspiratory or expiratory 
measurement.  
 
In normal subjects resistance values are relatively similar with all four methods, 
although forced oscillation usually gives slightly higher values. 
 
3.4.1 Lung Diseases with Resistance Issues 
 
Airway resistance is the opposition to flow caused by the forces of friction. It is 
defined as the ratio of driving pressure to the rate of airflow. Resistance to flow in the 
airways depends on whether the flow is laminar or turbulent, on the dimensions of the 
airway, and on the viscosity of the gas. 
 
A relatively large driving pressure is required to sustain turbulent flow. Driving 
pressure during turbulent flow is in fact proportional to the square of the flow rate 
such that to double the flow rate one must quadruple the driving pressure. 
 
2P kV∆ =
?
         (3-1) 
 
where: 
P∆  : driving force; 
k     : constant; and 
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V
?
   : air flow 
 
Laminar flow is of low velocity and through narrow tubes, it tends to be more orderly 
and streamlined and to flow in a straight line. This type of flow is called laminar flow. 
Unlike turbulent flow, laminar flow is directly proportional to the driving pressure, 
such that to double the flow rate, one needs only double the driving pressure. 
 
Most of the resistance to airflow is in the large airways, which includes the mouth, 
glottis, the trachea and bronchi (>2mm in diameter). While a single small airway 
provides more resistance than a single large airway, resistance to air flow depends on 
the number of parallel pathways present. Smaller airways rapidly branch to produce a 
large total cross sectional area; therefore the flow velocity is very low and the flow is 
laminar, so the resistance to flow is small as seen in the figure below. 
 
I  
 
Figure 3.14 The Resistance to airflow profile along the airways [J. F. Perkins et. al]. 
 
In addition to the anatomy of the respiratory tree, there are also dynamic factors, 
which influence total respiratory system resistance to flow: 
 
(a) Lung volume - Airway resistance decreases as lung volume increases as 
shown in the figure below, because the airways expand as the lungs inflate, 
and wider airways have lower resistance. 
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Figure 3.15 Resistance against Volume profile [J. F. Perkins et. al]. 
 
(b) Internal airway obstruction (in cases of asthma or tumor obstruction); 
(c) Dynamic airway compression; 
(d) Constriction or relaxation of the bronchial smooth muscle. 
 
Under conditions of laminar flow, the airways are rigid. Airway diameter and the 
viscosity of the gas flowing through them would be the only important determinants 
of airway resistance. However, if the airways are compressible, the external pressure 
in the lungs and pleura is transmitted to the airways. In addition, the internal airway 
pressure that drives air into or out of the lung is dissipated by frictional losses along 
the airway. The transmural pressure (the pressure inside - pressure outside) 
determines whether the airway will narrow. The pressure surrounding the 
intrathoracic airways is close to intrapleural pressure. Dynamic airway compression, 
the narrowing of an airway from negative transmural pressure is an important 
determinant of the flow rate in any particular airway passage. During exhalation, the 
transmural pressure across the airway becomes smaller, the airway narrows and the 
airflow is limited by this mechanism. Whereas during inhalation, the airway enlarges 
hence decreases flow resistance. 
 
 192
3.5 Lung Volumes and Elasticity 
 
The respiratory system is an elastic structure changing volume when pressures are 
generated by inspiratory or expiratory muscles. If the muscles are relaxed the 
respiratory system returns to its relaxation volume (Vr) (referred to in the pediatric 
literature as the elastic equilibrium volume [EEV]), which in normal subjects is the 
end-expired volume or functional residual capacity, FRC, where alveolar pressure is 
equal to atmospheric pressure. 
 
When an anesthetist hand-ventilates a paralyzed patient at this volume by 
applying a positive pressure at the proximal end of the airway and measures 
the change in volume per unit change in applied pressure ( V P∆ ∆ ) the 
`stiffness' or compliance of the total respiratory system (Crs) is measured and 
shown by figures as below. Some of the applied pressure inflates the lungs and 
some the chest wall. Thus, the total respiratory compliance is less than the 
compliance of either structure individually. For example, if the compliance of the 
lungs (CL) is 0.2LcmH2O-1 and that of the chest wall (Ccw) is similarly 0.2LcmH2O-1, 
then to increase the volume of both together by 0.2 L requires a total applied pres-
sure of 2cmH2O (Figure 3.10). Hence, in this situation the total respiratory 
compliance (Crs) is 0.1 L.cmH2O-1 or, more generally, 
 
 
1 1 1
rs L cwC C C
= +  
 
Although in health CL and Ccw are similar in the tidal range, the resting volume 
(volume when any distending or collapsing force is removed) of the chest wall is 
much larger than that of the lungs which collapse down to a small volume in the 
absence of distending forces. 
 
Note that the analysis in Figures 3.16 and 3.17 relates only to gas volume of the lungs 
and that tissue and fluid volumes are ignored. In some diseases (cardiac failure, 
adult respiratory distress syndrome) the fluid volume in the lungs increases markedly 
and may complicate analysis of the balance of pressures across the respiratory system. 
Similarly the volume of a pleural effusion or a pneumothorax is ignored if only 
pulmonary gas volume is considered. 
 193
 
 
 
Figure 3.16 Statistic PV curve of respiratory system with maximal pressures 
generated by respiratory muscles. Static PV curve of the total respiratory system (Prs – 
broken line) compliance in the tidal range (Crs) and functional residual capacity 
(FRC), and the pressures recorded during maximal inspiratory Pmus insp (left side) 
and expiratory efforts Pmus exp (right side) at various lung volumes in a healthy young 
adult (dotted line). Solid lines show alveolar pressure (Palv, i.e. mouth pressure when 
efforts are made against a closed airway). Palv represents the sum of Prs and Pmus. 
Total lung capacity (TLC) is set by the balance between Prs and inspiratory muscle 
effort, i.e. at TLC, Prs is equal and opposite to inspiratory Pmus . Residual volume (RV) 
is set by the balance between Prs (negative because at low volumes net recoil of the 
respiratory system is outward) and expiratory Pmus. 
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Figure 3.17 Static PV curves of respiratory system, lungs and chest wall. ‘Rahn 
diagram’ [50] showing how static PV curve of respiratory system (Prs-broken line) 
shown in Figure 3.9 relates to PV curves of its two components, the lungs and chest 
wall. Scale on pressure axis is expanded. PL, Pcw, Prs represent recoil pressures and 
CL, Ccw, Crs static compliance of lungs, chest wall, and respiratory system 
respectively. Compliance is represented by the slope of the respective PV curve over 
the approximate tidal range (heavy lines). Note: (1) at FRC PL= -Pcw; (2) Crs is less 
than either CL or Ccw alone; (3) PL increases disproportionately towards TLC; (4) Pcw 
becomes increasingly negative towards RV; (5) resting volume (Pcw = 0) of chest wall 
greatly exceeds that of lungs (RV). 
 
3.5.1 Method for Measuring Lung Compliance 
 
In most clinical circumstances the compliance of the chest wall is of little importance. 
Measurement of total respiratory compliance is difficult in the adult conscious subject, 
and so it is rarely measured in the pulmonary function laboratory. 
 
On the other hand, the static compliance of the lungs is of considerable interest 
and is frequently abnormal in disease [48-49]. In practice, however, it is measured 
infrequently because it involves the subject swallowing a tube into the esophagus and 
lengthy breathing maneuvers and analysis. 
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3.5.1.1 Static Pressure-Volume (PV) curve of the lungs 
 
To construct the static PV relationship of the lungs requires measurement of the 
difference between alveolar and pleural pressures (transpulmonary pressure) at 
several lung volumes. This is obtained during breath-holding with a balloon-catheter 
system or a small pressure transducer in the lower esophagus to approximate pleural 
pressure. This pressure is compared to the pressure at the airway opening which 
during breath-holding reflects alveolar pressure.  
 
Volume change measured either with a spirometer or with the subject seated in a 
variable volume body plethysmograph [50-51], which allows direct measurement of 
changing thoracic gas volume. An esophageal balloon or appropriate miniature 
pressure transducer is swallowed, usually via the nose, into the lower third of the 
esophagus. When using a balloon-catheter system a small volume of air is 
introduced with the aim of producing a bubble at the upper end of the balloon. The 
volume of air used needs to be neither too large to distend the esophagus, nor too 
small to cause the balloon itself to develop a negative recoil. In practice this is 
usually between 0.2 and 0.5 ml. The position of the balloon or transducer is adjusted 
up and down to give the most negative values of pressure at FRC, usually by trial 
and error. Alternatively the depth of the balloon may be standardized in relation to 
the height of the subject by using the formula of Zapletal et al [52], based on which 
the tip of a 10 cm balloon should be positioned at a depth of (height[cm]/5 + 9) cm 
from the nostril. 
 
Measurements of transpuhmonary pressure (mouth minus esophageal pressure, PL) 
at various volumes are usually made during deflation after a standard sequence 
(volume history) of three full inflations. If expired volume is used, either the subject 
needs to maintain an inspiratorv effort and open airway during breath-holding at each 
volume or, if allowed to relax against a shutter, a correction to the volume is 
necessary due to the resulting small changes in thoracic volume associated with the 
positive pressure which accompanies relaxation (Boyle's law). With a variable 
volume plethysmograph (with the door closed) no correction is needed as the effects 
of gas compression are measured directly. 
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Figure 3.18 Measurement of lung PV curve and compliance. Record against time of 
volume ( V∆ ) expired during interrupted expiration from total lung capacity (TLC), 
and transpw1monary prtssure (mouth - esophageal pressure). Duruis bieolla-holding 
(plateaux of volume and pressure) mouth = alveolar pressure and thus transpulmonary 
pressure = lung recoil pressure (PL). Irregularities on pressure record are due to 
cardiac pulsation. Gain on pressure amplifier doubled art point indicated by 
converging arrows. 
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3.6 Lung Diseases with Compliance Issues 
 
The three important mechanical characteristics of the lung are its compliance, flow 
resistance and uniformity of various airways paths. Diseases are caused by the 
alteration of each of these three, else by the interference with gas exchange at the 
alveolar walls. 
 
Obstructive lung disease is a respiratory abnormality characterized by a slow rate of 
forced expiration. In those with active asthma or emphysema, a high residual volume 
and functional residual capacity and a low vital capacity are usually seen as well. 
Asthma, bronchitis, and emphysema are all considered obstructive conditions, but the 
way each results in an obstructive defect is quite different. Asthma, a disease 
characterized by airway mucosal swelling, hyperirritability of the bronchial smooth 
muscle, and excessive bronchial mucus production is a disease of flow limitation. 
Asthmatics often have normal lung compliances and suffer from an in ability to 
generate normal airflow velocities. Thus this increases the work of breathing. 
 
Chronic Obstructive pulmonary disease is another common obstructive disease. In 
such cases, patients lost the elastic recoil in large parts of their lungs through 
destruction of elastin, which means they are unable to empty their lungs. The radial 
distending forces on smaller airways are destroyed so airflow limitation is even more 
profound if there were only changes in the compliance. 
 
Emphysema is a disease in which there is destruction of the walls of the air sacs of the 
lung, and it is frequently preceded by chronic bronchitis. Emphysema adds to the 
breathlessness suffered by the patient with chronic bronchitis. Compliance of the lung 
is significantly above normal; the lung becomes easy to distend but empties slowly. 
This results in a chronically over inflated lung (high total lung capacity, functional 
residual capacity, and residual volume), which reduces the curvature of the 
diaphragm, making it less efficient in generating even the small swings in pleural 
pressure necessary for breathing. Pulmonary function tests on a patient with 
emphysema will reveal a compromised expiratory flow (due to their low lung recoil). 
 
Restrictive disease is a condition marked most obviously by a reduction in total lung 
capacity. A restrictive ventilatory defect may be caused by a pulmonary deficit, such 
as pulmonary fibrosis (abnormally stiff, non-compliant lungs), or by non-pulmonary 
deficits, including respiratory muscle weakness, paralysis, and deformity or rigidity of 
the chest wall. 
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In pulmonary tests, an individual with a restrictive ventilatory defect demonstrates a 
low total lung capacity, a low functional residual capacity, and a low residual volume. 
Because large drops in pleural pressure are required to inflate the lungs, deep breaths 
are difficult for individuals with restrictive defects, and they tend to breathe shallowly 
and rapidly. 
 
The figure below shows the relationship between pressure and volume for the 
obstructive and restrictive lung diseases as compared to the normal lung. For lungs 
diagnosed with Emphysema it distends but empties slowly. While fibrosis lungs is 
unable to inflate hence results in a low total lung capacity. 
 
Figure 3.19 Volume-Pressure profile for different lung diseases [J.F. Perkins et. al] 
 
 
 
3.6.1 Lung Distensibility 
 
In response to a pressure differential, elasticity causes the lungs to return to its 
original size by resisting inflation and promotes lung emptying. The reciprocal of 
elastance is compliance. Compliance refers to the distensibility of an elastic structure 
and is defined as the change in volume of that structure produced by a change in 
pressure across the structure. It is important to understand that the lung (or any other 
elastic structure) will not increase in size if the pressure within it and around it is 
increased equally at the same time. 
 
In a normal healthy lung at low volume,  relatively little negative pressure outside (or 
positive pressure inside) needs to be applied to blow up the lung quite a bit. However 
lung compliance decreases with increasing volume. Therefore as the lung increases in 
size, more pressure must be applied to get the same increase in volume. This can be 
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seen from the following pressure-volume curve of the lung: Lung compliance and the 
slope are the same and it is non-linear: 
 
 
 
Figure 3.20 Lung Pressure Volume curve [J F. Perkins et. al]. 
 
The compliance of the lungs is critical to breathing: 
 
(a) The lungs are hard to inflate if the compliance is too low. Therefore, the work 
of breathing is increased. An example of this is pulmonary fibrosis (damaged 
lung tissue grows back as scar tissue), where the thoracic wall is pulled in (the 
lungs win the tug-of-war) and inspiration is difficult. 
 
(b) Too great a compliance and there is little recoil once the lungs are inflated. 
Expiration is difficult as it is caused by the passive recoil of the lungs. Also, 
the thoracic wall wins the tug-ofwar and the lung and thoracic volume expands 
so that the diaphragm flattens and becomes inefficient. An example of this is 
pulmonary emphysema (one of the possible terminal stages of death by 
smoking). These people have barrel chests because of the expanded volume. 
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3.7 Literature Review 
 
3.7.1 The Alveolus Model - A prediction of the pressure-volume 
behavior of the lung 
 
The alveolus model is used to describe the mechanical stability of the inflated lung 
from its microstructure. The alveolus is modeled as a distensible spherical bubble on 
the end of a rigid tube representing the alveolar duct as shown in Figure 3.21. 
 
 
Figure 3.21 Model of an alveolus at the end of an airway. The alveolar wall tissue is 
subjected to equal biaxial stretch [6]. 
 
The inflating pressure is balanced by the surface tension, γ, in the liquid lining of the 
bubble and by the tension, T, in the alveolar walls [6]. The bubble size in radius, RS 
relates to the transmural pressure, P, using Laplace's formula: 
 
( )2 2,  or 
2
s s
s
s
T PRP T
R
γ γ+ −= =       (3-1) 
 
The stresses, σ and the wall thickness, t affect the tissue tension. Since there is only 
one tissue wall between adjacent alveoli, the wall stresses are shared by two alveoli. 
Hence the volume of the alveoli determines the magnitude of the stresses. The tissue 
tension in one alveolar wall is related to the stresses and wall thickness, by: 
 
2
2
s s
s
s s
T PR
t t
γσ −= =         (3-2) 
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From the above relationship, the surface tension, γ in the liquid lining of the bubble, 
reduces with the tissue stress, σ. 
 
The alveolar duct, which is the shape of a cylinder, is modeled as a rigid tube that is 
collapsible at a pressure below a critical value, Pcr and gas is trapped in the alveolar 
bubble, otherwise it is open and rigid above Pcr. The collagen and elastin fibers that 
encircle the alveolar mouths give the tube tissue its rigidity [8]. The pressure is equal 
to the tension, Tc in the fiberous rings and the surface tension of the alveolar and tube 
lining as shown in the Laplace's equation below for a cylinder: 
 
c c
c
c c
T PR
t t
σ = =         (3-3) 
 
Similar to equation (3-2), the surface tension, γ in the liquid lining of the bubble 
reduces with the tissue stress, σ in the alveolar duct. 
 
During deflation, Rc remains constant while Tc, γ and P decreases. At Tc = 0, critical 
pressure occurs and the surface tension, γ is at its minimum, as given by: 
 
min2
cr
c
P
R
γ=          (3-4) 
 
The volume of gas trapped in the collapsed bubble can be determined from the critical 
radius of the sphere, crsR . Since the tissue stresses are zero at this small volume, 
pressure and surface tensions are equal in the bubble and the cylinder, we have: 
 
2crs cR R=          (3-5) 
 
In this situation when Rs reaches the critical value of 2Rc, instability occurs and there 
are two possible bubble volumes, one a segment smaller than a hemisphere (for which 
Rs = Rc) and one larger than the hemisphere (for which Rs>Rc). Lung morphology [8] 
indicates that the smaller volume, which corresponds to a minimum value of Rs, 
occurs at the end of expiration, before inflation. Now, inflation occurs when the 
pressure exceeds Pcr (of equation 3.4), and the bubble starts becoming bigger. The 
bubble will grow without bound if the surface tension and tissue stresses do not 
change i.e. the bubble in Figure 3.22 is unstable until the tissue stresses become large. 
Changing the surface tension (due to surfactant lining) helps maintain the alveolus in 
shape, prevents it from collapsing as well as overstretching. Alveoli vary in size 
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throughout the lungs; some have a radius 3 - 4 times that of others. If surface tension 
were the same in all alveoli, regardless of their size, the pressure required to keep air 
spaces inflated against surface tension would also vary 3 - 4 times. 
 
As all alveoli communicate with one another, there cannot be a huge pressure 
difference in the alveoli of the lung; pressure must be the same in all. However, 
Laplace's law shows that if the air pressure were equal in bubbles of different sizes, 
the smaller bubbles would collapse and the larger ones would over-expand. The 
tension, T in the wall of a spherical bubble tends to contract the bubble, and the 
pressure inside the bubble tends to expand it. Referring to equation (3-1), if the 
surface tension in the bubble remains the same regardless of the radius of the bubble, 
the air pressure to inflate the bubble increases as the tension increases. A low surface 
tension requires a low air pressure to maintain a given radius or volume, whereas one 
with a high surface tension requires a large counter-pressure. This explains why small 
bubbles have a high pressure and large bubbles have low pressure and why small 
bubbles can empty into larger ones as depicted in the figure below. 
 
 
Figure 3.22 Dynamics of soap bubbles [9]. 
 
A real lung contains a distribution of alveolar and alveolar duct diameters hence lung 
behavior is represented by bubbles of different dimensions acting in parallel. The 
variations in surface tension and tissue tensions enable different sizes of alveoli to co-
exist. However, if surface tension were equal, the inflating pressures would be 
unequal and air would flow out of the smaller alveoli into the larger ones: 
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If 1 2γ γ=  during inflation, ( ) ( )1 21 2
1 2
2 2
 and s ss s
T T
R R
P P
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As a result we would have an inhomogeneous lung with a mixture of collapsed and 
maximally extended alveoli. This does not occur in healthy lungs, because firstly the 
surface tension of the alveolar lining is significantly less than that of plasma, and 
secondly the surface tension of the alveolar lining decreases as the film is 
compressed; this probably occurs during expiration when the alveoli becomes smaller. 
Avery et. al. [9] has calculated that this factor, acting in conjunction with elastic 
elements of the tissue, is sufficient to ensure the stability and prevent the collapse of 
small alveoli during expiration, and lead to a stable balance between small and large 
alveoli. The combined effect of alveolar size and surface tension on tranpulmonary 
pressure is required to maintain lung inflation is required. 
 
This alveolar bubble model is valid only for static and quasi-static conditions, as it 
does not take into consideration of the airflow resistance, which is an important 
parameter in a respiratory model. Besides that, it assumes that all alveoli are exposed 
to an inflating pressure equal to the transmural pressure, while only a small amount of 
the alveoli are at the lung's surface. Mead [10] has proved that this is the case for a 
uniformly inflated lung. The alveolar wall tissue transmits pressure without changing 
the pressure into the lung as long as the spatial density of the alveolar walls is 
uniform. However, a stress concentration occurs if one section of the lung is over-
inflated or under-inflated. This is caused by the variation in tissue wall elongation, 
which tends to return the abnormal region to the average inflation of the entire lung. 
Thus the lung structure as well as the surface tension acts as a mechanical stabilizing 
mechanism. 
 
3.7.2 Lung Compliance and Flow Resistance 
 
According to [11], the dynamic lung compliance, dynC  and resistance dynR while 
breathing at any frequency if total airflow and transmural pressure are measured 
simultaneously. Compliance is estimated by taking the ratio of the change in lung 
volume V∆  and the change in transmural pressure P∆  at zero airflow condition: 
 
dyn
VC
P
∆= ∆          (3-7) 
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Likewise, the flow resistance in the pulmonary airways during breathing can be 
estimated by taking the ratio of the change in transmural pressure, P∆  and the change 
in airflow, V∆ ?  at a certain level of lung volume: 
 
dyn
PR
V
∆=
∆ ?
         (3-8) 
 
As this is a linear model, it does not reflect the complex flow patterns within the 
branching airways of the lung. Therefore, our work in the next section we will 
formulate models that incorporates V
?
 and V
??
. The reason being the inertia of the lung 
tissue must be overcome during rapid and big volume changes. This explains why the 
acceleration term V
??
 is added into the governing equation. 
 
Some models include Compliance, C, Resistance of the first compartment, R1 and 
Resistance of the second compartment, R2, such as the theory developed by Otis et al 
[13], which states that uneven ventilation of the lungs is manifested by a decrease in 
dynC and dynR with increasing frequency due to the time-constant imbalance between 
parallel lung units. The equation below represents the model [13]: 
 
( ) ( )( ) ( )
2 22
2 1 1 2 1 2
2 2 2
1 2 2 1 1 2
dyn
C C C C
C
C C C C
ω τ τ
ω τ τ
+ + += + + +       (3-9) 
 
 
where frequency 2 fω π= ; 1 1 1R Cτ =  and 2 2 2R Cτ = . 
 
If 1τ = 2τ : 
 
dynC = 1C + 2C         (3-10) 
 
( ) ( )
( ) ( )
2
1 2 2 1 1 2 1 1 2 2
2 22
2 1 1 2 1 2
dyn
C C C C
R
C C C C
ω τ τ τ τ τ τ
ω τ τ
+ + += + + +     (3-11) 
 
Similarly if 1τ = 2τ : 
 
1 2
1 2( )
dyn
R RR
R R
= +        (3-12) 
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As can be seen above, dynC  and dynR  are independent of frequency unless 1τ  and 2τ  
are unequal. Since dynC  can be measured under static condition (f = 0), it is a better 
assessment of frequency dependence for airway obstruction compared to dynR  which 
is limited to breathing frequencies. In emphysema, the site of obstruction to airflow 
appears to be in the peripheral airways. 
 
3.7.3 The Bronchial Tree Model 
 
The actual analysis of the airflow in the bronchial tree is very complex. The air travels 
through a network of continuously branching tubes of various lengths with diameter, 
cross-sectional area and direction changes at each branch. 
 
Each of these tubes has flexible and collapsible walls and diameters, which vary with 
the regional variations in the transmural pressure difference. Most studies of bronchial 
airflow are based on the regularized dichotomy geometric model developed by 
Weibel [8]. This model states that each airway divides into two airways of smaller 
diameter as seen in Figure 3.23, with trachea divides into the two main bronchi which 
divides into four bronchi which divide into eight. 
 
There are 23 generations or branching between the trachea (generation zero) and the 
alveolar sacs (generation 23). Total cross-sectional area increases by factor of 5000 
from trachea to alveolar sacs. Weibel [8] has developed empirical exponential 
relationship between generation number and average airway dimensions in terms of 
diameter and length. The main characteristic of this model is that all the airways of a 
generation act in parallel for airflow. Thus the total volume flow rate divided by the 
total cross-sectional area of one generation gives the average velocity in that 
generation. For example, in the n-th generation, the flow rate and average velocity in 
one airway are: 
 
2
4 N
N
N
QV
Dπ=
?
         (3-12) 
 
 
where NV
?
 is the volume flow rate of the lung and DN is the diameter of the n-th 
generation. The maximum flow velocities and resistance occur in generations 2 - 4, 
where the area is the smallest. These being some of the longest airways also increase 
the pressure loss and flow resistance. Airways are generally classified as large or 
small airways [14], with a diameter of 2 - 3 nun (generation 6 - 7) being the division 
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point. In large airways, most of the flow resistance and pressure drop occur due to 
having less parallel airways [15]. Clinical tests measure the flow resistance of only the 
large airways, yet several small diseases affect the small airways [15]. 
 
 
Figure 3.23 Regular airway branching model [9]. 
 
 
As mentioned above, resistance due to Poiseuille flow (also known as 1aminar flow) 
changes very slowly, and yields the smallest possible pressure drops in the bronchial 
trees. For one airway, 
 
2
2
32 N N
N
N
LP
D
µ=          (3-14) 
 
where µ = gas viscosity; L= tube length; D = tube diameter. For the entire bronchial 
tree, the Poiseuille pressure loss (using equation (3.14)) between the trachea and 
alveoli is: 
 
23
4
1
128
2
N
N N
N N
LP V
D
µ
π =
⎛ ⎞= ⎜ ⎟⎝ ⎠∑
?
       (3-15) 
 
However the above model is only for small airways where laminar flow is present and 
Reynolds number is below 900 [16].  If turbulent flow (Re ≥  900) is present (in the 
1argest bronchi), it contributes to the high resistance of these airways. The 
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Womersley number (α) is a frequency parameter used to distinguished quasi-steady 
flows from oscillatory pulsatile flow. For oscillatory airflow in the bronchial tube, the 
Womersley number [17] can be used: 
 
1
2
2
ND ωρα µ
⎛ ⎞⎛ ⎞= ⎜ ⎟⎜ ⎟⎝ ⎠⎝ ⎠         (3-16) 
 
If the frequency, α is ≤1, the flow is quasi-steady; if α ≥1, the flow pulsates, for in-
between the flow is transitional. Oscillatory flows have different boundary layer 
thickness and velocity profiles than steady flows. Womersley numbers have been 
calculated for bronchial trees at several breathing rates. The maximum value is α = 5 
in the trachea during exercise (40 breaths/min) [18]. The frequency has the same 
pattern as the Re number, it decreases down the bronchial tress and is always less than 
one beyond the 4th or 5th generation. The large airways' flow is transitions between 
steady and pulsatile, while the small airways have quasi-steady flow. 
 
On large-scaled models of the bronchial tree, it is indicated that the direction changes 
produce eddy currents and distortion of the velocity profiles from the Poiseuille flow 
patterns. This increases the viscous energy losses and flow resistance. Pedley , et al. 
[30] have experimentally develop an index; ZN for the Poiseuille equation to account 
for the direction and area changes for inflation only. 
 
2
0.33 N NN
N
D V PZ
Lµ
⎛ ⎞= ⎜ ⎟⎝ ⎠
        (3-7) 
 
or 1.0NZ = , whichever is larger.      (3-18) 
 
The branching effects, when 1NZ ≥ , are significant in the first ten generations [13]. 
They extend further down the bronchial tree, but are negligent in small airways of 
diameter less than 1 mm. Along with the occurrence of Poiseuille flow near 
generation 10, there is a change of the means of oxygen transport from convection to 
diffusion. 
 
The flexibility of the walls of the bronchi and bronchioles also plays an important role 
in flow resistance. All bronchi have alveolar wall tissue connected to the outside of 
their walls. The forces of these tissue act to distend the bronchi, especially during 
exhalation. Based on studies done on the pressure-volume behavior of bronchial 
segments [6, 19], the small airways have the same compliance as the alveolar tissue, 
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whereas the large airways are stiffer in comparison. This is because of the cylindrical 
shape of the bronchi, the forces of the alveolar wall tissue may not produce the same 
uniform tri-axial expansion that they do on the alveoli [20]. 
 
During lung inflation, the pleural and alveolar pressures are below tracheal and 
bronchial airway pressures. The airways are subjected to a positive transmural 
pressure difference, and are distended, which lowers airway resistance. With positive 
transmural pressure, the airways remain open and cylindrical. These trends are 
reversed for the case of lung deflation. The negative pressure difference decreases the 
tube diameter, increases resistance and tends to make the tube structure unstable, and 
thus collapsible. During deflation, air is trapped in the alveoli by collapsed airways, 
which produces huge compressive pressures. 
 
3.7.4 Multi-Component Model of Lung 
 
It is difficult to develop a general theoretical description, as there are some 
limitations: 
 
(a) The flow in some regimes cannot be accurately described except 
empirically; 
(b)  The bronchial tree model describes only the average geometry; 
(c)  The variety of flow patterns cause mathematical complexity and that the 
tissues' mechanical stiffness, elasticity and the airflows are interrelated. 
 
In multi-component model, (including our own model in this chapter), an important 
characteristic of the lung is that the parallel airways leading to all the alveoli are fluid 
mechanically nearly identical. Whichever path the air molecule takes to an alveolus, it 
will encounter the same resistance. 
 
The model in Fig. 3-4 illustrates a set of balloons (alveoli) with separate tubes 
(airways), connected to one common tube (trachea) enclosed in a bellows (thorax). 
Each balloon has its own stiffness and each tube has its own resistance. Thus the 
governing equation: 
 
1
i
i
P V R V
C
⎛ ⎞∆ = +⎜ ⎟⎝ ⎠
?
        (3-19) 
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Figure 3.24 Single component (a) and multi-component (b) models of the lung [W.R. 
Powell]. 
 
Normal breathing can be represented as a small sinusoidal pressure ( sin( )P tω∆ ) or 
volume ( cos( )V tω∆ ) oscillation [21], so that: 
 
0 sin( )P P P tω∆ = + ∆         (3-20) 
 
0 sin( )V V V tω= + ∆         (3-21) 
 
where ω=2πf, f = breathing frequency. The above representation will not work 
practically, as having the sine term alone is insufficient to accurately represent the 
clinical data parametrically. For that reason, we have added a cosine term in our 
model, so as to yield a more accurate and clinically representative lung volume 
response (as discussed later in the chapter). 
 
The normal lung is represented by the special case of having all of the C and R values 
identical and all the balloons of equal size. Hence equation (3-19) reduces to, upon 
division of each term by M, lung mass: 
 
i
i
RVVP
MC M
⎛ ⎞⎜ ⎟∆ = +⎜ ⎟⎝ ⎠
?
        (3-22) 
 
and the lung can be modeled as equivalent one balloon with one airway. During 
sinusoidal or periodic oscillations, there is a phase lag between the pressure extrema 
(maxima or minima) and the volume extrema (as depicted in the figure below). The 
magnitude of the phase lag for each alveolus depends on the values of R and C. At the 
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volume extrema, the tracheal airflow rate is zero; with equal values of C and R, the 
flow rates in all airways are zero. When all values are the same, the phase lag for 
every alveolus is the same as in the case for a normal lung inflated in-vitro. In vivo, 
there is a small vertical variation in alveolar size, which causes small but detectable 
variations in phase lags [22]. The effect of differing phase lags can cause crossflow of 
air, to increase the flow resistive work and decrease the efficiency of breathing 
However, the problem is insignificant in the in-vivo lungs, due to weight bearing 
stresses. The lung is designed to smoothen the process of gas exchange in millions of 
alveoli effortlessly, by ensuring minimum work is required for breathing through 
adjusting the compliance of the lung, as well as to provide equal transit time by 
appropriate tuning of the airways resistance during exercise. When the oxygen 
demand increases, the lung has an enormous reserve capacity available to cope with 
the increase oxygen demands of exertion. These factors work together to ensure that 
the lung obtains sufficient oxygen at minimal exertion and at vastly different rates 
required by different physical activity levels. 
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Figure 3.25 The flow rates in the total lung model, the upper compartment, and the 
lower compartment as a function of time. 
 
3.8 Work of Breathing 
 
For air to flow from the mouth into the alveoli, the tissues of the lungs and the thorax 
must be stretched by both muscular and ventilator forces. The greater the force 
applied, the greater the volume change in inspiration. These forces in the respiratory 
system can be measured in terms of pressure differences. The following relationship 
shows the work done during a breathing cycle, where it is represented as an area on 
the pressure-volume diagram: 
 
W PdV= ∫          (3-23) 
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0 0
T TV VW RV dV RV V dV
C C
⎛ ⎞ ⎛ ⎞= + = +⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠∫ ∫
? ? ?
     (3-24) 
2
0 0
1 T TW V Vdt R V dt
C
= +∫ ∫? ?        (3-25) 
( )2 2
0 0
1
2
                                    
                                
T T
elas res
d V
W dt R V dt
C dt
W W
= +
↓ ↓
∫ ∫ ?
      (3-26) 
 
Otis el al. [12] were the first to calculate the mechanical work done by a ventilator of 
a volumecontrolled breath and a pressure-controlled breath, where there is no patient's 
effort. A volume control breath maintains a distinct flow wave shape: sinusoidal, 
constant or triangular decreasing waveform during the inspiratory phase of a cycle. 
On the other hand, a pressure control breath maintains a preset airway pressure level 
during the inspiratory phase of a cycle; the waveform has no regular shape and varies 
in-between breaths. They concluded that the area bounded by the relaxation pressure 
curve (see curve ADC in below) and the volume axis represents work done to 
overcome the elastic forces of the lung; elasW  .The area bounded by the relaxation 
pressure and the mouth pressure curve represents the work done to overcome the 
resistive forces of the respiratory system; resW  with elasW and resW  being both 
expressed in equation (3-26). 
 
 
 
Figure 3.26 Pressure-Volume curve of a volume control breath (without patient 
effort) [24]. 
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In the above figure, the area bounded by the ventilator driving pressure and the 
volume axis represents the total work of breathing (by the ventilator): 
 
( )
0
( )
T
vent m atmW P t P dV= −∫        (3-27) 
 
According to Otis et al. who has reviewed the work of normal breathing, the elastic 
work and the work done to overcome lung elasticity decrease with decreasing tidal 
volumes and result in increased breathing rates. At large tidal volume, it exerts a non-
linear elastic behavior (which we will discuss later), whereas the flow resistive work 
is independent of the volume rate as long as the minute volume is constant. 
 
To calculate the work performed in a volume-controlled breath, Martini et al. [23] 
came up with a method, which involves comparing a volume-controlled breath with 
no patient effort with another volume-controlled breath for the same flow settings. 
Based on the identical flow waveforms generated, the difference in ventilator work in 
the two breaths provides the work performed by the patient as shown in Figure 3.26. 
For example, the ventilator performs the total work of breathing in the case of one 
breath while both the ventilator and the patient perform the work in the other breath. 
Then the difference in the ventilator work of the two breaths provides the patient's 
work in the second breath. However, there are drawbacks to this method: 
 
(a) Measuring patient's work in pressure-controlled breaths and spontaneous 
breaths cannot be done, and the inspiratory flow waveform of both types of 
breaths has no regular shape and may vary between any two similar breaths. 
 
(b) The patient's work can only be calculated for volume-controlled breaths. Every 
time the inspiratory volume changes or flow waveform changes, it has to be 
compared with different breaths with no patient's effort and identical flow 
waveform. 
 
 
To overcome the drawbacks, a mathematical measurement is developed. Let Pm*(t) be 
the mouth pressure of a breath which has no patient's involvement, and P m(t) be the 
mouth pressure o f another breath of identical flow waveform. The patient's work can 
be written as the difference in ventilator work of the two breaths [24]: 
 
*
0 0
( ) ( ) ( ) ( )
T T
m mW P t V t dt P t V t dt= −∫ ∫? ?       (3-28) 
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Since V
?
is identical in both breaths: 
 
* ( )m m musP P t P= +         (3-29) 
 
where  musP  is the reduction in pressure created by the muscle respiration. 
 
0
( )
T
musW P t dt= ∫         (3-30) 
Using the same equation as equation (3-27), which provides the ventilator's work 
component, the above equation represents the volume integral of the respiratory 
driving pressure signal, and provides the patient's component of work. ( )musP t  can 
then calculated as: 
 
0
1( ) ( ) ( )
T
mus av m atmP t R V V t dt P t PC
= + − +∫? ?      (3-31) 
 
Where 
0
1( ) ( ) ( )
T
m atm mus avP t P P t R V V t dtC
− + = + ∫? ?     (3-32) 
 
and Raw is airway resistance. 
 
 
Similarly for the work done in our work, we have validated the concept of Otis [12], 
that the work done during a respiratory cycle, is given by the area of the loop 
generated by plotting lung volume (V) against net driving pressure (P). The larger the 
phase shift between the volume-pressure curve, the larger the area, and hence higher 
the WOB. The area can be obtained graphically. At the same time, we can determine 
the WOB by integration of the derived V(P) expression. All of this will be discussed 
later. 
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3.9 Model of Diseased Lung 
 
3.9.1 Large Airway Problems 
 
The diameters of the large bronchi produce significant changes in the pulmonary 
airflow resistance. This problem characterizes bronchitis and asthma. Bronchitis is an 
inflammation of the bronchial tubes, while asthma is a spasmodic contraction of the 
tube diameters. During an asthma attack, the muscle contraction can reduce bronchial 
diameters and increase resistance by a factor of seven. The diameter reductions cause 
increases in velocity, flow-resistance and pressure-drop between the trachea and 
alveoli. Should the body need to maintain the air volume flow rate as the airway 
diameter decreases, the air velocity must increase. Therefore, this is to be 
accompanied by increased pressure drops and an enlargement of the turbulent flow 
regions. To increase the pressure drop, it needs large mechanical work (large chest 
wall motions) as the pleural and alveolar pressures need to be further below 
atmospheric. An alternative to maintaining the flow-rates is maintaining the pressure-
drops as the bronchi constrict. This will reduce the air velocities, flow rates and tidal 
volumes and increase the breathing frequencies. To describe this mathematically, two 
breathing patterns having different frequencies (ω2 > ω1) and tidal volumes (TV2 < 
TV1) with equally large airway losses are compared. Modeling breathing by sinusoidal 
volume changes [25], 
 
1 sin
2
V TV tω∆ =         (3-33) 
 
The pressure drop depends on volume flow rate: 
 
1 cos
2
V TV tω ω∆ =?         (3-34) 
 
Thus, for equal pressure drops: 
 
1 1 2 2TV TVω ω=          (3-35) 
 
The resting minute volume (RMV) depends on frequency and tidal volume minus the 
unchanging dead volume (DV), 
 
( )RMV TV DVω= −         (3-36) 
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Therefore: 
 
( ) ( ) ( )1 2 1 1 2 2 2 1RMV RMV TV DV TV DV DVω ω ω ω− = − − − = −   (3-37) 
 
Since 2 1 2 1 2 1;  ;  TV TV RMV RMVω ω> < < , this illustrates rapid shallow breathing. 
 
Actual responses involve changes in both tidal volume and breathing rate. The sound 
of wheezing in asthma and bronchitis is an indication of the increase in flow rate and 
therefore breathing work. 
 
 
3.9.2 Alveolar Wall Problems 
 
In this problem, the alveolar wall and hence the lung compliance is affected; an 
emphysema diseased lung is one example. It has large holes caused by destroyed 
alveolar walls. This reduces gas exchange by reducing the surface area available for 
exchange. It also increases the tissue stresses in the remaining walls. The expanding 
pressure (P) is balanced by the restraining wall tension (T); as the number of walls 
decreases (t), the tension in each remaining wall must increase in order to maintain 
the force equilibrium [10]. The increased tensions mean increased tissue strains and 
lung volumes, resulting in lower compliance and increased mechanical work of 
breathing [24, 25]: 
 
( )
alv
T
P
t
γ +=          (3-38) 
 
0
1( ) ( )
t
alv atmP t V t dt PC
= +∫ ?        (3-39) 
 
0
1 TW V Vdt
C
= ∫ ?         (3-40) 
 
 
where γ = surface tension in the liquid lining of the bubble. 
 
T
t
σ =           (3-41) 
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The bronchial tree can also be affected, as the tissue stresses on the outside of the tube 
walls deviate from the uniform distribution found in normal lungs. Unsupported 
regions are prone to instability and airway collapse. The enlarged alveoli, lung 
inhomogeneity and airway instability cause increased lung volumes and decreased 
compliance found in emphysema, thereby destroying respiratory function by 
destroying lung structure. 
 
Pulmonary fibrosis diseases produce similar dysfunction of stiffening the alveolar 
wall tissue. If the lung compliance is reduced, the pressure changes needed to 
maintain tidal volume increase, and hence the work of breathing increases. Even 
though fibrosis and emphysema produce similar functional problems, they can be 
distinguished by chest x-rays; this is because fibrosis increases tissue density, while 
emphysema decreases it. 
 
3.9.3 Small Airway Obstruction 
 
The mechanical manifestations of changes in the small airways although are not as 
significant as those due to changes in large airway resistance or compliance. 
However, its links to air pollution and emphysema make small airway obstruction a 
major health concern. One identified cause of small airway obstruction is exposure to 
low levels of nitrogen oxides, which is a major component of automobile exhausts. 
Long-term exposures to low concentrations irritate the cells lining and small airways. 
Small airways obstruction is characterized by localized and large reductions in the 
diameters of the small airways, hence causing non-uniformity of airflow. Its clinical 
name, chronic-obstructive-respiratory-disease (CORD) creates inhomogeneity in the 
lung's airflow patterns and inspired gas distribution, along with detrimental changes in 
the phase lags between pressure and flow and in the mechanical work of breathing. 
 
The effects of the obstruction are larger during expiration. The alveolar volume 
increases as the gas is trapped inside; however, its compliance decreases and its 
contribution to gas exchange is reduced: 
 
i
VP
C
∆ =          (3-42) 
 
The remaining alveoli with normal airways must undergo larger tidal volumes to 
maintain the minute volume. The over-extended alveolar walls sometimes begin to 
disintegrate, and emphysema results. There are two major effects of obstruction and 
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increased flow resistance: First, the lung compliance ceases to be independent of the 
breathing frequency, where viscous pressure losses occur in the lung. Thus, the 
compliance of a lung with obstructed small airways will decrease with the frequency. 
The second effect is a change in the phase lags [26] between pressure and flow, where 
the phase lags are larger for lungs with small airway obstruction. This means the time 
delay between the pressure-maxima and the volume-maxima is larger for these lungs. 
Figure 3.27 shows why the compliance and phase-lags change when one set of airway 
is obstructed. 
 
Figure 3.27 Multi component model of lung reduced to two components: one with 
normal airways and one with obstructed airways. The difference in airway diameters 
causes the component's volume changes to be non-synchronous [W. R. Powell]. 
 
 
The analysis of Otis et al. [12] uses pressure as a sinusoidal driving function with the 
volume lagging behind: 
 
( )0 sinP P P tω∆ = + ∆  (3-43) 
 
0 sin( )i i iV V V tω φ= + ∆ +  (3-44) 
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Combining the above two equations with equations (3-19), (3-43) and (3-44), we 
obtain: 
 
( ) ( )0 01sin sin( ) cos( )i i i i ii
i
P P t V V t R V t
C
ω ω φ ω ω φ⎛ ⎞+ ∆ = + ∆ + + ∆ +⎜ ⎟⎝ ⎠  (3-45) 
 
Then using 1 2V V V= + , the values of  ,   and C R φ  are determined: 
 
( )( )
( ) ( ) ( )
22 2 2
1 2 1 2 1 2 1 1 2 2
2 2 2
1 2 1 2 1 2
R R R R C C R C R C
R
R R C C C C
ω
ω
+ + += + + +  (3-46) 
 
( ) ( ) ( )
( )( ) ( )
2 2 22 2 2
1 2 1 2 1 1 2 2 1 2
22 2 2
1 2 1 1 2 2 1 2
R R C C R C R C C C
C
C C R C R C C C
ω
ω
+ + + + +=
+ + +
 (3-47) 
 
 
1 1tan
RC
φ ω
− ⎛ ⎞= ⎜ ⎟⎝ ⎠  (3-48) 
 
All the above three parameters above depend on ω , the breathing frequency. This is 
the case for obstructed lung. If the compliances and resistances of the two 
compartments are made equal, then the equations for R and C simplify to 
 
1 22 2C C C= = ; 1 22 2
R RR = =              (3-49) 
 
Figure 3.28 Shows the behavior of this model, using compliance and resistance values 
against frequency. For the obstructed lung, R2 is twice as large as R1. The effective 
compliance and resistance both decrease with increasing frequency. But at all 
frequencies, the obstructed model has more resistance and less compliance than the 
normal one with the phase-lag changing approximately 8° from the normal to the 
obstructed model [26]. 
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Figure 3.28 Lung compliance and resistance as functions of breathing frequency for 
models of a normal lung and of a lung with obstructed airways [W. R. Powell]. 
 
 
One major weakness of this two-compartment model for small airway [26] 
obstruction is its simplified treatment of airflow, whereas a more detailed model uses 
a more realistic description of flow-resistance and concentrates all the obstruction in 
the respiratory bronchioles. Another weakness is that it assumes independence of the 
two compartmental model. However, in a real lung, a single tissue wall may separate 
alveoli with obstructed and normal airways. For our proposed two-compartmental 
model, we have assumed an independent relationship between the two compartments, 
otherwise it will greatly complicates our model analysis. When we talk about a non-
independent relationship, the model behavior depends on the amount of diameter 
reduction, the percent of the airways involved, as well as the size of the obstructed 
alveoli. These are minute details that may not produce significant insight into the 
behavior of the lungs. 
 
3.10 Ventilation Distribution Model with Non-linear 
Components 
 
Shykoff et al. [27] presented a model, shown in Figure 3-9 that differed from many 
other respiratory models by incorporating non-linearities into its respiratory 
components. The intention of the model is to determine what difference in gas 
distribution within the lung could be expected from variation of pleural pressure in 
different parts of the lung. The unequal time constants in different portions of the lung 
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are attributed to unequal lung filling. However, some experimental data suggests that 
the variation in lung filling could be caused by the uneven distribution of pleural 
pressure between the upper and lower chest. To test the possibility of a connection 
between pleural pressure differences and lung filling, Shykoff et al proposed a two-
compartment lung model. The upper and lower compartments were treated in a 
parallel arrangement, and each was considered to be represented by a resistance and 
compliance in series. Each was exposed to a different variable pleural pressure. The 
model equations for the common pathway are: 
 
m b cP P R V− =
?
         (3-50) 
 
Where 
mP = pressure at the entrance to the common airway, N/m
2 
bP = pressure at exit from common airway, N/m
2 
cR = common airway resistance, N.sec/m
5 
V
?
= volumetric flow rate, m3/s 
 
and flow rate to compartment: 
 
1 2iV V V= +
? ? ?
         (3-51) 
 
For each compartment: 
 
b i i iP P R V− =
?
         (3-52) 
( )i i i plidV C d P P= −         (3-53) 
 
Where 
 
iV = volume of compartment i, m
3 
pliP = pleural pressure on compartmrnt i, N/m
2 
iC  = compliance of compartment i, m
5/N 
The equation for compliance is: 
 
( ) ( )
( ) ( )
2 2
max min
2 2
1 min 2 max
100i
V V V V VCC
V V V Vλ λ
− −= ×− + −      (3-54) 
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where 
 
maxV , minV  = constants, dimensionless 
1λ , 2λ =constant, N/m2 
VC = vital capacity, m3 
RV = residual volume, m3 
 
The resistance is given by: 
 
1 2
3 4
k k VR
k k V
+= +
?
         (3-55) 
 
where 
R = resistance, N.sec/m5 
1k = constant, N.sec/m
5 
2k = constant, N.sec/m
8 
3k = constant, dimensionless 
4k = constant, m
-3 
 
Airflow into these compartments was driven by sinusoidal, square, or triangular 
waveforms, superimposed on a static pressure difference. The amplitudes of the 
pressures were independently varied on the two compartments: a range of static 
pressures and frequencies was used, and a phase-lag between compartments was 
introduced for sinusoidal and square wave pleural pressure variations. In our two-
compartmental model, the amplitudes of the pressures vary independently as well. 
 
It was found from this model that at low pleural pressure amplitudes and frequencies, 
there was no difference between results using constant compliance and resistance 
values and those using non-linear values. On the other h and, at higher frequencies t 
he difference becomes greater at lower amplitudes and vice versa. Compliance non-
linearities are more important at low flow rates, but resistance non-linearities are 
increasingly more important at higher flow rates. 
 
The ratio of volumes in compartments 1 and 2 does not change significantly for 
sinusoidal, square, or triangular pleural pressure waveform. Thus Shykoff et al. 
conclude that the waveform of the pleural pressure swing has no effect on the 
distribution of tidal volumes. 
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Although this model is simple in structure with a limited scope, it succeeds in 
highlighting the effects of non-linearities. Figure 3.30 shows the instantaneous flow 
rates as a function of time in the total lung volume, the upper compartment, and the 
lower compartment. It can be observed that the lower compartment fills first, followed 
by emptying into the upper compartment. 
 
 
 
 
Figure 3.29 Two-compartmental model of the lung. Resistance and compliances are 
considered to be non-linear [Skykoff et. al]. 
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Figure 3.30 The flow rates in the total lung model, the up ep r compartment, and the 
lower compartment as a function of time [Skykoff et. al]. 
 
3.11 Characterization of the Branching Structure of 
the Lung 
 
This model describes an asymmetric tree model with a predicted pressure-volume 
relationship connected to the distribution Π  (n) of the generation number (n) of the 
trees terminal segments [28]. The purpose of this model is to analyze the problem of 
fluid flow (liquid or gas) in a bifurcating structure containing random blockages, from 
the information of the asymmetric structure of the lung obtained through macroscopic 
(noninvasive) pressure-volume measurements. This relation explores the branching 
structure of the lung, by analyzing experimental pressure-volume data from dog 
lungs. The Π (n) extracted from the data using the model agrees well with 
experimental data on the branching structure. 
 
The problem of fluid flow through bifurcating structures is of considerable interest 
[28]. So far, the case when the structure contains random blockages that can be 
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removed by the fluid pressure has been studied only for the simple case of symmetric 
branching, whereas the real lung is asymmetrical [29]. Such cases are often 
encountered during fluid flow in an organ system, such as for circulation of blood or 
flow of air in the lung where the pathways can be blocked, leading to potentially 
lethal situations [30]. Here, the pressure-volume curve of the lung is modeled to 
obtain a correlation between lung inflation and its branching structure. Next, fitting 
the model to experimental pressure-volume (P-V) data provides information about a 
key microscopic property of the airway tree, namely, the distribution of the generation 
numbers of the tree's terminal segments. Since experiments measuring the P-V curves 
of an inflating lung are noninvasive, this method provides a way to study 
"microscopic" branching structures from "macroscopic" P-V data without the use of 
invasive techniques. 
 
During expiration, peripheral airways in a diseased lung tend to collapse, thereby 
blocking the flow of air, if the surface tension of the lining fluid is abnormally high 
[31]. The lung is assumed to be empty of air with all the airways blocked at the 
beginning of the inspiratory cycle. These blockages can be removed during inflation if 
the pressure (P) reaches the critical opening threshold of the segment [32]; it then 
increases, until all closed segments open. Since the airways are arranged in a treelike 
branching structure, the opening of one segment is not possible until all segments 
connecting it to the root of the tree are opened. If the threshold pressure of a daughter 
segment is smaller than that of its parent, the daughter opens simultaneously with the 
parent. This mechanism also applies to subsequent generations, leading to avalanches 
of opening of airways [33]. 
 
The volume of inhaled air during inspiration in a symmetrical branching follows a 
simple power law, and the numerical value of the exponent was shown to be equal to 
the generation number (no) of the terminal segments [34]: 
 
 α onV P          (3-56) 
 
The P-V curves of the two isolated dog lung lobes (A&B) are determined 
experimentally [28]. The lobes are thoroughly inflated through the main bronchus. 
Over 90% of the air volume recruited into a lung is contained in the terminal alveoli 
(air sacs) [35-39]. Assuming that all alveoli are identical and inelastic, the volume of 
air at any pressure is proportional to the number of ventilated alveoli. 
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Next we discuss the model to account for the asymmetric branching of the airway 
tree. Herein, each air sac is labeled with an index (k) going from 1 to N (the total 
number of air sacs in the lung). The state of being open or closed for each air sac (k) 
at pressure P is then described by a variable, kσ , (which is normalized to enable the 
sum of it to be unity when all air sacs are open) that represents l/N (if the air sac is 
open) or 0 (if it is closed). The depth for air sac, nk, is the number of generations 
between the air sac and the root of the tree as well as the blockages. The variable kσ  
is dependent upon the threshold pressures of all the segments along this path. Each 
segment along the path is denoted by a pair of indices (j, k),where (i) the index k 
identifies the air sac k it connects, whereas (ii) j describes the number of generations 
separating the segment from the air sac (j = 1,..., nk). A segment (j, k) is open only if 
its threshold pressure, Tjk, is less than the pressure P. The threshold pressure of all 
segments, independent of generation, is drawn from a uniform distribution between 0 
and 1 [29], with a threshold pressure of 1 being the pressure at the inflection point. 
This amounts to saying that all air sacs are open when P reaches the inflection point. 
Since the air sac k is open only if all segments j are open, kσ  is given by: 
 
 
( )
1
1 kn
k jkj
P T
N
σ == ΠΘ −         (3-57) 
 
where ( )xΘ  is the unit step function. 
 
The volume, V(P), contained in the lung at pressure, P is thus given by the averaged 
count of all the open air sacs, 
 
1
( )
N
k
k
V P σ
=
=∑          (3-58) 
 
 
Combining equations (3-57) and (3-58), we obtained: 
 
( )1
01
1( )
k
k
n
n
jk jkj
P
V P P T dT
N N=
= Π Θ − =∫       (3-59) 
 
Equation (3-59) expresses kσ  in terms of the number of segments along the path from 
air sac k to the root of the tree. Next using equations (3-58) and (3-59), we obtain an 
average volume as a function of inspiratory pressure: 
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1
( ) ( )k
N
n n
k n
P
V P n P
N=
= = Π∑ ∑        (3-60) 
 
where ( )nΠ  is the distribution of generation number of the terminal segments. 
 
The expression equation (3-60) for the volume is a polynomial containing different 
powers of P, unlike the result for a symmetric tree in equation (3-56) where a unique 
exponent corresponds to the single depth no. The degree of asymmetry is thus 
manifested in the width of the distribution ( )nΠ . Equation (3-60) incorporates the 
effects of the tree structure, as characterized by the depth distribution ( )nΠ  and the 
dynamics characterized by Pn. The experimental data is then fitted with polynomials 
of order 48, which is the known maximum depth in a dog lung [35]. It is found that 
the distributions obtained have two distinct regions: (i) a narrow peak for n < 5, which 
corresponds to the P-V curve at small P when very few air sacs are ventilated, and (ii) 
a broad distribution for 15 < n < 40, which has two main peaks in 22 < n <30. 
 
To conclude, when applied to the P-V curve of the lung, this model is able to estimate 
the terminal structure of the airway tree from noninvasive measurement made at the 
top of the tree. 
 
Conventionally, the P-V curve represents a measurement of the elastic (compliance) 
properties of the lung tissue. This model take advantage of the fact that fluid 
blockages have a profound influence on the characteristics of the P-V curve, which 
allows us a direct representation of the lung structure from data. This approach can be 
useful to other development work done in asymmetrically branched biological and 
physical systems. 
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3.12 Author’s work Lung Ventilation Model [3] 
 
We have developed a lung ventilation model by modeling the lung volume response 
to mouth minus pleural driving pressure (by means of first and second order 
differential equations) in terms of resistance-to-airflow (R) and the lung compliance 
(C). The lung volume solution of the differential equation is matched with the clinical 
volume data, to evaluate the parameters, R and C. These parameters values can help 
us to distinguish obstructive lung and lung with stiffened parenchyma from the 
normal lung, and hence diagnose lung diseases such as asthma and emphysema. We 
have also formulated a nonlinear compliance lung model, and demonstrated deceased 
lung compliance with filling volume. We then formulated a non-dimensional lung-
ventilatory index (VTI), incorporating the parameters R and C as well as the lung 
breathing rate. When the VTI is evaluated for various lung diseases, it will 
conveniently enable us to diagnose lung diseases in terms of just one VTI number. 
Finally, we have shown how to model a two-lobe lung, and differentiate between 
normal and diseased lobes. 
 
3.12.1 Role of Lung Ventilation 
 
Lung ventilation constitutes inhalation of appropriate air volume under driving 
pressure (=mouth pressure-pleural pressure), so as to: (i) provide adequate alveolar O2 
amount at appropriate partial pressure, (ii) oxygenate the pulmonary blood, and (iii) 
thereby provide adequate metabolic oxygen to the cells. Hence, ventilatory function 
and performance assessment entails determining how much air volume is provided to 
the alveoli, to make available adequate alveolar oxygen for blood oxygenation and 
cellular respiration. 
 
 
 
 
 
 
 
 
 
Based on the below figure 1, we get:   (i) (Pa - Pp) - Pel = 0 
                                                             (ii) Pel = (2 a h) / R r = 2 T / r = V/C + Pel0 
                                                             (iii) (Pm -Pa) = R(dV/dt) 
                                                             (iv) PL = Pm -Pp 
                                                             (v) R(dV/dt) + VIC = PL - Pel0   
            (lung elastic recoil pressure at end-expiration) 
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Figure 3.31 Alveolar model. 
 
3.12.2 Lung Ventilation Performance using a Linear First-order 
Model 
 
We first analyze Lung Ventilation function by means of a very simple model 
represented by a first-order differential equation (Deq) in lung-volume (V) dynamics 
in response to the driving pressure (Pl = atmospheric pressure − pleural pressure), as 
displayed in Figure 3.31. The clinical pressure-volume data is in Figure 3.32. 
 
 
Figure 3.32 Lung ventilatory model and lung-volume & pleural-pressure data. Curve 
1 on the curve represents Pel, the pressure required to overcome lung 
elastance (=V/C). Curve 2 represents Pp, the summation of Pel  and Pa. The 
pressure PN(t) in equation 1a equals Pp minus Pel at end-expirartion. 
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The model governing equation (shown derived in Figure 3.31) [1,2] is as follows: 
 
                                              0( ) ( )L Nel
V
RV P t P P t
C
+ = − =
?
                      (1-a) 
wherein:  
 
(i) the values of pressure are obtained from the given PL (= Pm – Pp ) data  
 
(ii) the parameters of this Governing Deq are lung compliance (C) and airflow- 
resistance (R); in the equation both R & C are instantaneous values 
 
(iii) V = V(t) − Vo (the lung volume at the end-expiration 
 
(iv) Pel0 is the lung elastic-recoil pressure at the end of expiration, and  
0el el
V
P P
C
= −           (1-b) 
At end-expiration when ω t = ω T,   PL = Pel0=PN(t), which is represented by  
3
1
( ) sin( )N i i ii
P t P t cω
=
= +∑  
and the governing equation (1) becomes: 
3
1
( ) sin( )N i i ii
V
RV P t P t c
C
ω
=
+ = = +∑
?
                (2-a) 
where the right-hand side represents the net driving pressure minus pleural pressure. 
PN =(Pm -Pp)– Pel0 . This PN is in fact the driving pressure (Pm – Pp) normalized with 
respect to its value at end-expiration. Equation (2-a) can be rewritten as follows: 
 
3
1
1
sin( )i i ii
V
V P t c
RC R
ω
=
+ = +∑
?
;                                (2-b) 
 
wherein the P (t) clinical data (displayed in Figure 3.32) is assumed to be represented 
by:  
3
1
( ) sin( )i i ii
P t P t cω
=
= +∑              (3) 
 
P1= 1.581 cm H2 O, P2  = -5.534  cm H2 O P3  = 0.5523 cm H2 
O 
1ω =1.214 rad/s 2ω = 0.001414 rad/s 3ω = 2.401 rad/s 
1c = -0.3132 rad 2c = 3.297 rad 3c = -2.381 rad 
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The pressure curve (in Figure 3.33) represented by the above equation (3) closely 
matches the pressure data of Figure 3.32. If, in equation (1), we designate Ra and Ca 
as the average values (R & C) for the ventilatory cycle, then the solution of equation 
(1) is given by: 
 
[ ]3
2 21
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( )
(1 ( ) )
a a
t
R Ci a i i i a a i i
i i a a
PC t c b R C t c
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ω ω
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 wherein the term (RaCa )is denoted by  τa . We need to have V = 0 at t = 0  Hence, 
putting V (at t = 0) = 0, gives us: 
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Then from equations (4) and (5),  the overall expressions for V (t) becomes 
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We also want that / 0dV dt =  at t =0, implying no air-flow at the start of inspiration. 
So then by differentiating (6), we get: 
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From (7), we get V ≠? 0 at t = 0, thereby also satisfying this initial condition. 
 
Now, by matching the above V(t) expression (6) with the given V(t) data in Figure 
3.27, and carrying out parameter-identification, we can determine the invivo values of 
Ra and Ca, to be 
  1)− -1a a2 2C = 0.2132 (cmH O R = 2.275cmH Osl    
The computed V(t) curve, represented by equation (6) for the above values of Ca  and 
Ra, is shown in Figure 3.37. We can however analytically evaluate Ra and Ca by 
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satisfying some conditions. For this purpose, we first note that V is maximum (=Tidal 
Volume, TV) at about t=tV =2.02s. At Vt t= , the exponential term a
t
e τ
−
  in (6) 
becomes of the order of 10e− , and hence negligible. Then by  putting ( 2.02)V t =? = 0 
in (7), without the exponential term we obtain: 
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(1 )
i a i i i i a i i
t i i a
PC c c
V
ω ω ω τ ω
ω τ= =
× + + × += =∑ +
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in which the values of , , andi i iP cω  are given by equation (3). Then by solving 
equation (8), we get aτ = 0.522s . We can also put V
??
=0 at t≅ 1.81/2.87s and obtain a 
similar value for τ   
 
Then, we also note that at  tv = 2.02s ( at which /dV dt  = 0) and V = 0.55l . Hence 
upon substituting into equation (6), and neglecting the exponential term, we get the 
following algebraic equation:  
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2.02 2 21
sin( ) cos( )
( ) | 2.55
(1 )
i a i i i a i i
at i i a
PC t c t c
V t C
ω ω τ ω
ω τ= =
+ − += =∑ +
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By employing the values of , andi i iP cω  from equation (3). Now since 
( 2.02 ) 0.55V t s l= = , we get 
 
 
a
-1
a 2
2.55C = 0.55
C = 0.22l(cmH O)
                    (10) 
 
We can substitute, therein, the values of P1 & P2 from (3), and obtain the value of Ca 
as: Ca= 0.22l (cm H2O)-1. Since we have computed τa = 0.485s, therefore   Ra=2.275 
(cmH2O)sl-1. These are the average values of resistance-to-airflow and lung 
compliance during the ventilatory cycle shown in Figure 3.27. 
 
Since Lung disease will influence the values of R and C, these parameters can be 
employed to diagnose lung diseases. For instance in the case of emphysema, the 
destruction of lung tissue between the alveoli produces a more compliant lung, and 
hence results in a larger value of C. In asthma, there is increased airway resistance (R) 
due to contraction of the smooth muscle around the airways. In fibrosis of the lung, 
the membranes between the alveoli thicken and hence lung compliance (C) decreases. 
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Thus by determining the normal and diseased ranges of the parameters R and C, we 
can employ this simple Lung-ventilation model for differential diagnosis.  
 
3.13 Ventilatory Index 
 
Let us, however formulate just one non-dimensional number to serve as a ventilatory 
performance index VTI1 (to characterize ventilatory function), as: 
 
VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τa2 (BR)2 602     (11) 
 
where BR is the breathing rate.  
 
Now, let us obtain its order-of-magnitude by adopting representative values of Ra and 
Ca in normal and disease states. Let us take the above computed values of Ra = 2.275 
(cm H2O)sl-1 and Ca =0.2132 l(cm H2O)-1 and BR = 12m-1 or 0.2s-1, computed for the 
data of figure 2 and equation (3). Then, in a supposed normal situation, the value of 
VTI1 is of the order of 33.88. In the case of obstructive lung disease, (with increased 
Ra ), let us take Ra = 5cm H2Os l-1, Ca = 0.12l (cm H2 O)-1 and BR = 0.3s-1 ; then we 
get VTI1 = 116.6. For the case of emphysema (with enhanced Ca), let us take Ra = 
2.0cm H2O s l-1 , Ca =0.5 l( cm H2O) -1 and BR = 0.2s-1 ; then we obtain VTI1 = 144. 
In the case of lung fibrosis (with decreased Ca ) , we take Ra = 2.0cm H2Osl-1 , Ca 
=0.08 L( cm H2O) -1 and BR = 0.2s-1 ; then we obtain VTI1 = 3.7. We can, hence 
summarize that VTI1 would be in the range of 2-5 in the case of fibrotic lung disease, 
5-50 in normal persons, 50-150 in the case of obstructive lung disease and 150-200 
for the case of emphysema,. This would of course be needed to be verified by 
analyzing a big patient population. 
 
Now, all of this analysis requites pleural pressure data, for which the patient has to be 
intubated. If now we evaluate the patient in an outpatient clinic, in which we can only 
monitor lung volume and not the pleural pressure, then can we develop a non-
invasively obtainable Ventilatory index? 
 
3.13.1 Noninvasively determinable Ventilatory index: 
 
In order to formulate a non-invasively determinable Ventilatory index from (1), we 
need to recognize that in this case ( )NP t  (and hence ,iP ω  and ic ) will be unkowns 
need to redesignate the model parameters to be and indicate their identification 
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procedure. So we make use of the following features from the volume-time data to 
facilitate evaluation of the following three parameters: ( ) ,, , andi a iiP C cω  and τa . 
At t = tv = 2.02s, V is max and /dV dt = 0; hence we rewrite (9) as: 
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Also. at t= tm=1.82/2.87s, V
??
 = 0. Hence by differentiating equation (7), without the 
exponential term ,we obtain: 
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Then, at t=1s, 1 2.02V l= . From equation (6), without the exponential term, this 
condition yields: 
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In addition, we can utilize data information concerning jV  at jt  (j= 1 to 8), and put 
down: 
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From these equations (12-14), we can obtain the values of i aPC  ( but not of P1, P2 and 
P3 by themselves), , andi i acω τ . On the other hand, by also fitting  equation (6), 
(without the exponential term) to the V(t) data, we obtain:  
 
 
1 0.3223PC =  2 0.3143P C =  3 0.02269P C = −  (15)
1 1.178ω = −  2 0.5067ω =  3 1.855ω =  (16)
1 90223c =  2 0.2242c =  3 3.961c = −  
 0.5535aτ =                 (17)
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We can now also formulate another noninvasively-determinable non-dimensional 
ventilatory index (VTI2) in terms of these parameters  as follows:    
   [ ] [ ]22
1
22 3 1 2 3
2
( ) ( )
P P P C
BR TV BR R TV
VTI
PC P C P C
τ= =                              (18) 
 
It is seen that VTI2  can in fact be expressed in terms of P1, P2,  P3 and R, C. This VTI2  
index can be evaluated by computing the values of (BR) and τ, along with (PiC), as 
given by (17). Then, after evaluating VTI2  for a number of patients, its distribution 
can enable us to categorize and differentially diagnose patients with various lung 
disorders and diseases.  
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3.14 Variations in R and C during a Respiratory cycle 
(towards nonlinear C)  
 
Thus far, we have adopted the average cyclic values Ca and Ra for our DEq model 
parameters. However, we expect that C will vary with lung volume (V) ,and that R 
will perhaps vary with the airflow-rate or ( V
?
) or even ω. Hence, for a true 
representation of the lung properties C and R, let us determine their values for 
different times during the ventilatory cycle, and compare them with their average 
values Ca and Ra ,so as to make a case for a nonlinear ventilatory-function model.  
 Let us hence compute the instantaneous value of compliance (C) at time (t = tm), 
when V
??
=0. Let us have differentiate equation (2-a), giving : 
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               (19) 
Now at about mid-inspiration, when t=tm=1.18 and V
?
= 0.48 l/s, V
??
=0 l/s and V = 
0.29l (based on Figure 3.27). By substituting for V
??
, V
?
 and V in (19), we obtain, 
C=0.486l/cm H2O (compared to its Ca value of 0.21). Now, in order to compute R, we 
utilize the data information that at tV =2.02s we substitute V
?
=0 l/s, V
??
=-0.89 l/s and V 
=0.54 l (from the Figure 3.27 data) into equation (2-a), to obtain: 
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Substitute C (at tm=1.18s)=0.486 l/cmH2O in either equation (6) or 2(b), and obtain 
R=1.122 (cmH2O)sl−1. This gives us some idea of the order of magnitude of R and C, 
in comparison to their average values Ca and Ra.. We could naturally expect C at 
mt t=  (which is about mid-inspiration) to be higher than its value at end-inspiration, 
when the lung is fully inflated. Also, we could expect the flow-resistance to be 
minimum at peak-inspiration, when V
?
=0. 
 
Because C and R are not constant, but a function of V and V
?
, we can hence represent 
lung compliance (C) and resistance (R) as follows: 
 
 0 0
1
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C
−= = =
         (21-a) 
0
Rk VR R e=
?
                                            (21-b)
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wherein V
?
 can also be varied by having the subjects breathe at different ventilation 
frequencies (ω). 
 
 
A 
 
B 
Figure 3.33 A The pressure curve represented by equation (3) matched against the 
pressure data (represented by dots). B The volume curve represented by equation (6), 
for from Ca =0.2132(cmH2O)-1 and Ra=2.275 cmH2Osl-1 pp. 3 matched against the 
volume data represented by dots. 
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3.14.1 Nonlinear Compliance: 
 
We note as per the conventional formulation of compliance, given by (2) in Figure 
3.33 as: 
 
0 0el el el
V
P P VE P
C
= + = +                (22) 
 
In the above formulation, we assume that C and E(=1/C) remains constant throughout 
the ventilation cycle. However at the start of inspiration, C=Co at t= 0, and it 
decreases as the lung volume increases, based on the lung (static) volume vs pressure 
curve. So let us improve upon this (22) model, by making Pel to be a nonlinear 
function of volume, as follows: 
 
00
kV
el elP P VE e= +                             (23-a) 
We can alternatively write equation (23) as: 
 
2
00 1 3 )(el elP P V E E t E t= + + +          (23-b) 
 
Employing the above format of compliance, the governing DEq (1) becomes 
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Again at end-expiration, Pel0 = intra-pulmonary pressure=(P0+P1). Hence equation 
(24) becomes: 
3
sin( )0 1
kVRV VE e P t ci i ii
ω+ = +∑=
?
                                  (25-a) 
 
whose RHS is similar to that of (2-a), and the values of P1,  P2, and  P3 are given by (3) 
for the Table 3.5 data. 
 
Solving equation (25-a): 
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3
0 1
30
1
32
0 1 2 1
or,
sin( ),
sin( ),
or, based on equation (23 - b), 
sin( )
kV
i i ii
kV i
i ii
i
i ii
RV VE e P t c
VE P
V e t c
R R
PV
V E E t E t t c
R R
ω
ω
ω
=
=
=
+ = +∑
+ = +∑
+ + + = +∑⎡ ⎤⎣ ⎦
?
?
?
 
This yields: 
 
( )
2 2
0 1 2 0 1 2(6 3 2 ) (6 3 2 ) 3 
6 6
10
( ) sin
tt E E t E t u E E u E u
iR R
i i
i
PV t e e u c du
R
ω
+ + + +
=
= +∑∫                     (25-b)
  
 
We could employ this expression for V(t) to fit the clinical V(t) to fit the clinical V(t) 
data. However, let us try a simpler approach to evaluate these parameters k & E0. For 
this purpose, we again bring to bear the situation that at end-inspiration, for t = tv 
=2.02s, we haveV
?
=0 and V=Vmax=TV=0.55l. Hence, from Table 3.5 data, and (3) and 
(25-a), we obtain: 
0.550.55 2.550
kE e =                                                                  (26) 
Let us now employ the volume data point at which V
??
=0. For this purpose, we 
differentiate (25-a), to obtain: 
 
         
( )
( )
30 1 cos( )
1
31 2 cos( )0 1 2 1
E PCakV i iV e kV t ci iR Ri
PCkV ai iV E E t E t t ci iR Ri
ω ω
ω ω
+ + = +∑=
+ ⎡ ⎤+ + + = +∑⎢ ⎥⎣ ⎦ =
??
??
             (27) 
 
From the Table 3.5 data at about mid-inspiration, for which at t=tm=1.18s, 0V =
??
,  
0.29V =  and 2.53P = ,  from Table 3.5 data. Substituting these values into (27), we get 
: 
 
( )( )1 0.29 1.18 1.39 2.530 1 2k E E E+ + + =                         (28) 
 
Now in equations (26) and (28), we have four unknowns to be identified: 
, , , and0 1 2k E E E . Hence we need two more equations, corresponding to two 
additional time instants. From the values in the following table,  
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Table 3.5 Data. 
                                                           
t  V  V
?
 V
??
 P  Using Equation 
1.18 0.29 0.48 0 2.53 26 
2.02 0.55 0 -0.89 2.55 26 
2.87 0.29 -0.47 0 0.29 28 
4.19 -0.03 0 0.16 -0.15 26 
4.76 -0.02 0.02 0 -0.06 28 
 
we can determine the unknowns: 
 
 k = -0.13,  E0 =4.98, E1=-2.24 and E2 =0.21                  (29) 
 
Hence, by employing the nonlinear formulation, 
 
0
kVP P E eoel el
−= +          (30) 
we obtain the following expression for nonlinear lung compliance (or elastance): 
 
dP 1 kV 0.13Vel = E = = E ke = 0.65eodV C
                                       (31) 
 
Based on this expression, we obtain , for t= tm  and  V = 0.29 l :  
 
 E= 1
C
=0.67cmH2O/ l  and C = 1.48 l /cm H2 O.                                             (32) 
 
Equation (31) can now provide us a more realistic characterization of lung compliance 
as follows: 
 At t= 0 and V = 0, we compute E= 1
C
=0.65 and C = 1.53 cm H2O/ l  
 At t = tm = 1.18s and V = 0.0.29l, E=
1
C
=0.67  and C = 1.48 cm H2O/ l  
At  t = tv = 2.02s and V = 0.55l and  E =
1
C
 = 0.70 and C =1.43 cm H2O/ l  
 
which corresponds to the value of Ca .  
 
Our nonlinear formulation of lung compliance, as depicted by (31) and (33) , indicates 
that compliance decreases from 1.53 cmH2O/ l  at start-inspiration to 1.48 cmH2O/ l  at 
(33) 
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about mid-inspiration, and then to 1.43 cm H2 O /l at the end of inspiration. What this 
also tells us is that the ventilatory model (1) gives the correct reading of the 
compliance at Vmax, i.e. at end-inspiration. At other times of inspiration and 
expiration, the Ca parameter underestimates the instantaneous value of lung 
compliance. Now, we could also obtain an analytical solution of (25) for V(t), and fit 
the expression for V(t) to the lung volume data, to evaluate the parameters  
 
(i) R, Eo & k for an intubated patient 
(ii) R, Eo k & P1, P2  and P3 for a non-intubated patient in the out patient clinic. 
However, this is outside the scope of this chapter. 
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3.15 Work of Breathing (WOB) [23-24] 
 
This is an important diagnostic index, especially if it can be obtained without 
intubating the patient and even without using the ventilator. The premise for 
determining WOB is that the respiratory muscles expand the chest wall during 
inspiration, thereby lowering the pleural pressure (i.e., making it more negative) 
below the atmospheric pressure to create a pressure differential from the mouth to the 
alveoli during inspiration. Then, during expiration, the lung recoils passively. 
 
Hence, the work done during a respiratory life cycle, is given by the area of the loop 
generated by plotting lung volume (V) versus net driving pressure (Pp). This plot is 
shown in Figure 3.34 .Its area can by obtained graphically, as well as analytically as 
shown below: 
 
WOB=
( )
( )
0 0
dP tt T T pVdP t V dtp dt
= =∫ ∫                                             (36) 
  
2sin( ) cos( )3 3
( ) cos( )2 21 10 (1 )
P C t c t ct T a ai i i i i i P t c dti i i ii iai
ω ω τ ω
ω ωω τ
⎡ ⎤+ − += ⎢ ⎥⎣ ⎦= +∑ ∑∫ = =+  
  
cos( ) sin( ) cos sin3
2 21 (1 )
P C T c T c c ca a ai i i i i i i i i
i ai i
ω ω τ ω ω τ
ω ω τ
⎡ ⎤− + + + − −⎣ ⎦= ∑= +             (37)    
 
The above expression for WOB can be evaluated, once the values of Ci and τ (or ωτ) 
and P1, P2 and P3 and have been computed (as shown in the previous section). So let 
us substitute into this equation, the following values associated with equation (3).  
 
P1= 1.581 cm H2 O, P2  = -5.534  cm H2 O P3  = 0.5523 cm H2 O 
1ω = 1.214 rad/s 2ω = 0.001414 rad/s 3ω = 2.401 rad/s 
1c = -0.3132 rad 2c = 3.297 rad 3c = -2.381 rad 
 
We compute the value of WOB to be 0.9446 (cm H2O l ) in 5s, or 0.19 cm H2O l s-1 or 
0.14 mmHg l s-1 or 0.02 W, which is equivalent to an oxygen consumption of about 
0.51 m l /min or about 0.18% of the resting 
2O
V
?
 of 28.87 m l /min. This value can be 
verified by calculating the value of the area of the pressure-volume loop in Figure 
3.29 which is equal to 0.8 cm H2O l . 
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Figure 3.34 Plot of Pressure versus Volume. The area under the curve provides the  
work done. 
 
3.16 Second-Order model for Single-compartment 
Lung Model 
 
Let us now consider the dynamic (instead of static) equilibrium of a spherical segment 
of the lung model in Figure 3.31, obtained as ( by dividing throughout by the 
elemental lung area): 
( ) 0m u P P Ps p a elas+ − + =
??
                                 (38-a) 
 
wherein: Pa and Pp are the alveolar and pleural pressures, u is the alveolar-wall 
displacement, ms =lung mass(M) per unit surface area= M/4πR2 ,               (38-b) 
 
and   2 0
h VP Pelas elR C
σ= = +                                                 (38-c) 
where:  
(i) C is in l  (cm H2O)-1 
(ii) ms (wall mass per unit surface area or surface density)= ρh, ρ is the 
density (mass per unit volume) 
(iii) σ is the wall stress 
(iv) h & R are the wall thickness and radius of the equivalent-lung model. 
Now, the displaced alveolar volume, 34 ( )
3
V R uπ= + , 
from which we get                   24V R uπ≈
?? ??
                                                    (39) 
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Now, from equation (1), by putting  
(i) ( ) ( ) andP P P P P P P P Pp a o a p o o pL− = − + − = −  
so_that_ P P P P P RV Pp a o a L L− = − − = −
?
                               (40) 
(ii) 2 2 2 4 2 4( )( ) ;4 4 16 16s
M V M V M
m u M V M
R R R Rπ π π π
∗ ∗= = = =
?? ??
?? ??
    24
sm
Rπ=        
            (41) 
 
we obtain, from (1), (2) and (3): 
 
* ( ) ;, 2 416
V MM V P P P P Mo a L el oC Rπ
∗+ − + = − =??    ( 24
ms
Rπ= )           (42) 
Now putting o aP P RV− =
?
, we obtain: 
 
3
sin( )0 01
VM V R V P P P t c Pi i iL el elC i
ω∗ + + = − = + −∑=
?? ?
   
        PN=                                            (43) 
Since at end-expiration when for 1 to 3i it T iω ω= =  and PL= Pel0 so that Pel0 = 0. 
In the above (6), we have : 
wherein:  
(i)  M*=ms /4πR2  = sρ h     ; sρ  is the lung volume-density per unit 
surface area (in Kgm-5 ) and M*  is in kgm-4; 
 
 (ii) the clinical data in Figure 3.27 is assumed to be represented by  
 
 
3
( ) sin( )
1
P t P t ci i iN i
ω= +∑= with                                   (44) 
 
P1= 1.581 cm H2 O, P2  = -5.534  cm H2 O P3  = 0.5523 cm H2 O 
1ω = 1.214 rad/s 2ω = 0.001414 rad/s 3ω = 2.401 rad/s 
1c = -0.3132 rad 2c = 3.297 rad 3c = -2.381 rad 
 
Then we can rewrite (6) as : 
 
 
3
( ) sin( )* * *1
PR V iV V t ci iiM CM M
ω+ + = +∑=
?? ?
                     (45-a) 
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or  as: 
     
322 sin( )
1
V nV p V Q t ci i ii
ω+ + = +∑=
?? ?
                     (45-b) 
In the above equation:  
(i) the damping coefficient, 2n = R/M*  
(ii) the natural frequency of the lung ventilatory cycle, p2= 1/CM*  
(iii) Qi = Pi/M*                      (45-c) 
 
So the governing (8) of the lung ventilatory response to the inhalation pressure has 
three parameters: M*, R & C (if the lung pressure is also monitored by intubating the 
patient). The solution of this equation is given by: 
 
2 23
1
1 1
2 2 2 2 2 2 2 22 2
1
2 2 3 2 22
2 2
( 2 cos( ) sin( ) sin( ) )
( ) 2 4 24 2
1 2 ( ) sin ( ) sin 2 cos sin
2 ( ) cos cos sin cos
i i i i i i i i
i
i i i i i i i
i i i i i i i i
i i
Q t c n t c p t ciV t
n p p
Q n p c p n p c n c p n c
n n p c c n c p c e
ω ω ω ω ω
ω ω
ω ω
ω ω ω ω
=
−
− + + + − += ∑
+ −
− − − + − − +
− − − + +
⎧⎡⎪⎢⎨⎢⎪⎣⎩
⎡⎢⎣
⎤⎥⎦
1
2( ( ( )( ) )
1
2 2 2 2 4 2 2 42
13 2 2 2 2 221 2
1
1
2 2 2 2 2
( ( ( )(1
2 2 2 32
( ) (4 2 )
( ) sin sin cos
sin 2 cos 2 ( ) cos
( ) sin cos
n p n p n t
i i
i i i ii
i i i i i i
n p n p
i i i i
n p n p p i
p n p c np c c p
n c n c n n p c
n p c c e
ω ω ω
ω
ω ω ω
ω ω
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟⎝ ⎠
− − − +
=
− − − −
− + − +
+ − − + +∑
+ − + −
+ − −
⎫⎤⎬⎥⎦⎭
⎧⎡⎨⎢⎣⎩
⎤⎥⎦
1
2) )n t
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟⎝ ⎠
+
 
1
2 2 2 2 4 2 2 42( ) (4 2 )in p n p p i iω ω ω− + − +
⎫⎡ ⎤⎪⎬⎢ ⎥⎪⎣ ⎦⎭
        (46) 
 
We will ignore the exponential terms and perform parameters identification by 
matching the above expression for V(t) to the clinical data, shown in Figure 3.33. The 
matching is illustrated in Figure 3.35, wherein the first and second order differentiate 
equation solutions for V(t) are depicted. The computed values of the model parameters 
are also shown in the table below the figure. Further, the first and second order model 
values of R and C are compared in the table. 
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Let us compare these values with those obtained by simulating the First-Order Model 
to the clinical data, as shown below. 
 
 
 First Order Model Second Order Model 
R [ 12cmH Ol s
− ] 2.28 3.44 
C [ 2/l cmH O ] 0.21 0.85 
M*[ 1 22cmH Ol s
− ]  3.02 
n *
R
M
=⎛ ⎞⎜ ⎟⎝ ⎠ [
1s− ]  1.14 
2 2
*
1
[ ]p s
CM
−=⎛ ⎞⎜ ⎟⎝ ⎠  
 0.39 
 
Figure 3.35 Results of Single Compartmental Model based on differentiate equation 
formulation, compared with the First Order differential equation model.  
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3.17 Two-compartmental Linear Model 
 
Now, it is possible that only one of the two lungs (or lung lobes) may be diseased. So, 
let us develop a procedure to distinguish between the normal lung and the 
pathological lung? We hence employ the 2-compartment model (based on our first-
order differential-equation of lung ventilatory function) to solve the problem of a two-
lung model (schematized in Figure 3.36).  
 
For this purpose we make the subject breath at different values of frequency (ω), and 
monitor the total lung pressure PiT(t) (i.e., P1i  and P2i ) and total lung volume Vi(t). 
Correspondingly , we have PiL(t), & ViL(t) and PiR(t) & ViR(t) for the left and right 
lungs, respectively. The governing equations will be as follows (refer Figure 3.36): 
 
1 1 1 2 2 2, . . &
T l R T l R T l RP P P i e P P P P P P= = = = = =                   (47) 
     T l rV V V= +                                       (48) 
 
corresponding to ωi; 
wherein   (i) ( ) ( , , , ( )l l l TV t f R C P tω= )                            (49) 
   (ii) ( ) ( , , , ( )R r r TV t f R C P tω= )                     (50) 
 
In these equations (20). 
(i) the variables ω  , ( ), ( )T TP t V t are deemed to be known, i.e. monitored. 
(ii) the parameters , , and ,l l r rR C R C are to be evaluated. 
Using the first-order differential equation model, (presented in section 2, as given by 
equation 6 or 14): 
 
2 3 2
3
2 21
( ) sin( ) cos( )
( )
(1 )
a ai i i i i i i
i i
P C t c t c
V t
ω ω ω τ ω
ω τ=
⎡ ⎤− + + +⎣ ⎦= ∑ +               (51) 
 
We put down the expression for ( ) ( , ) ( ),,L L R R
T L Rt V C V CV τ τ= +  match it with the 
volume data (using parameter-identification technique (software), to obtain the values 
of ( , )L LC τ  and ( ),R RC τ  by means of which we can differentially diagnose left and 
right lung lobes’ ventilatory capacities and assosciated disorders (or diseases). 
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Figure 3.36 Schematic of two-compartment first-order Lung-Ventilation Model. 
 
3.17.1 Two Compartmental Model Using First Order 
Ventilatory Model 
 
Using equation (6) without the exponential term, we put down the expression for the 
total lung volume equal to the sum of left and right lung volumes, as follows: 
 
          
2sin( ) cos( )3
( ) 2 21 (1 )
2sin( ) cos( )3
2 21 (1 )
PC t c t ci i i i i iL LV t
i i L
PC t c t ci i i i i iR R
i i R
ω ω τ ω
ω τ
ω ω τ ω
ω τ
⎡ ⎤+ − +⎢ ⎥⎣ ⎦= +∑= +
⎡ ⎤+ − +⎢ ⎥⎣ ⎦∑= +
                     (52) 
 
wherein, for the clinical data, we have: 
 
P1= 1.581 cm H2 O, P2  = -5.534  cm H2 O P3  = 0.5523 cm H2 O 
1ω =1.214 rad/s 2ω = 0.001414 rad/s 3ω = 2.401 rad/s 
1c = -0.3132 rad 2c = 3.297 rad 3c = -2.381 rad 
 
We further assume that the ratio of TV of left lung to that of right lung is 0.92. 
 
Now, in order to develop a measure of confidence in our analysis, we first generate 
the total lung volume data by assuming different values of C and R for left and right 
lung lobes. We then use equation (52) along with the above data on pressure and 
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frequency, to generate the total lung volume data. We adopt this generated ling 
volume data as the clinical-volume data. 
 
We now make our volume solution expression (equation (52)) match this generated 
clinical volume data, by means of the parameter-identification procedures, to evaluate 
C and R for the left and right lung-lobes and hence VTL1 and VTL2 (equations (11) 
and (18)) for these lobes. Based on the values of VTL1 and VTL2, we can 
differentially diagnose the left and right lung lobes. 
 
3.17.1.1 Stiff Right Lung (with compliance problems) 
 
We now simulate a normal left lung and stiff right lung, represented by: 
 
          RL=RR=1.14 12cmH Ol s
−  and CL=0.11, CR=0.05 2/l cmH O         (53) 
 
Substituting these parametric values into equation (52), we generate the total lung 
volume data, as illustrated in Figure 3.32.  
 
Now our clinical data for this Two-Compartment Model comprises of the pressure 
data of Figure 3.38 and the generated volume data of Figure 3.31. For this clinical 
data, we match the volume solution given by equation (52) with the generated volume 
data, illustrated in Figure 3.32, and carry our parameter identification. The computed 
values of R and C, listed in the table of Figure 3.32, are in close agreement with the 
initially assumed parametric values of equation (53). This lends credibility to our 
model and to our use of parameter-identification method.   
 
Now for differential diagnosis, we compute the lung ventilatory indices, as shown in 
the Table. 
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Two Compartmental Model 
First Order Model  
Left Lung Right Lung 
R [ 12cmH Ol s
− ] 1.137 1.137 
C [ 2/l cmH O ] 0.1066 0.0533 
VTL1 2.115 0.5289 
VTL2 0.2198 1.0320 
 
Figure 3.37 Results of the Two-Compartment Model, based on First-Order 
differential equation model. Based on our assumption of / 0.92L RTV TV = we have 
0.48 0.48 0.2304LTV l= × =  and 0.52 0.48 0.2496RTV l= × = . 
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3.17.1.2 Right Lung with R problems 
 
Now, we simulate a lung with an obstructive right lung, as represented by:   
 
    RL=1.14 and RR=2.28 12cmH Ol s
−  and CL=CR=0.11 2/l cmH O     (54) 
 
 
 
Two Compartmental Model 
First Order Model  
Left Lung Right Lung 
R [ 12cmH Ol s
− ] 1.138 2.276 
C [ 2/l cmH O ] 0.1066 0.1066 
VTL1 2.1192 8.4766 
VTL2 0.3553 0.8341 
 
Figure 3.38 Results of the Two-Compartment Model, based on First-Order 
differential equation model. Based on our assumption of  / 0.92L RTV TV = we have 
0.48 0.61 0.2928LTV l= × =  and 0.52 0.61 0.3172RTV l= × = . 
 
As in the case of the stiff right lung, we first generate the lung volume data for the 
above values of compliance and resistances. We then match the total lung volume 
solution given by equation (52) with the generated lung volume data, and compute the 
compliance and flow resistance values of the right and left lung. These are tabulated 
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in Figure 3.38, and found to have good correspondence with the assumed values of 
equation (54). 
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3.18 Two Compartmental Model Using Second Order 
Ventilatory Model 
 
In the previous section, we have discussed the 2-compartmental model using first 
order ventilatory model, now let’s derive the second order ventilatory model for the 
model. We employ the 2-compartment model (based on our second-order differential-
equation of lung ventilatory function) to solve the problem of a two-lung model 
(schematized in Figure 3.36).  
 
For this purpose we make the subject breath at different values of frequency (ω), and 
monitor the total lung pressure PiT(t) (i.e., P1i  and P2i ) and total lung volume Vi(t). 
Correspondingly , we have PiL(t), & ViL(t) and PiR(t) & ViR(t) for the left and right 
lungs, respectively. The governing equations will be as follows (refer Figure 3.36) 
 
1 1 1 2 2 2, . . &
T l R T l R T l RP P P i e P P P P P P= = = = = =    from (47) 
      and T l rV V V= +    from  (48) 
 
corresponding to ωi; 
wherein   (i)  ( ) ( , , , ( )li il l TV t f Q C P tω= )                            (55) 
   (ii) ( ) ( , , , ( )ri iR r TV t f Q C P tω= )                     (56) 
 
 
 
Using equations (46) and (52), we put down the expression for the total lung volume 
equal to the sum of left and right lung volumes, as follows: 
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But due to insufficient data points in our clinical model, we are not able to determine the 
numerical solutions. 
 
3.19 Conclusions 
 
We have demonstrated that we can determine the lung resistance and compliance from a 
pressure-volume curve obtained by a ventilator. The second-order one-compartmental gives a 
very accurate result as compared against the first-order one-compartmental model. Due to the 
complexities involved in the second-order two-compartmental model, the current 32-bit and 64-
bit digital computer cannot perform any convergent results. In time, we can try the model on a 
more powerful computer.  
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Chapter 4 Lung Air-Transfer 
Performance Analysis [1-4] 
 
 
4.1 Motivation behind the Project 
 
An outbreak of severe acute respiratory syndrome (SARS) began in Guangdong, China, 
on November 16, 2002. The first three SARS cases in Singapore were confirmed on 
March 6, 2003. By May 5, a total of 204 cases, including 27 deaths, had been 
confirmed. The last case was isolated on May 11, and by July 30, the end of the 
outbreak, 205 patients had recovered and 33 had died [5]. 
 
4.2 Objectives 
 
The primary function of the lung is to (i) oxygenate the blood and thereby provide 
oxygen to the cells for metabolization purposes, and (ii) to remove the collected CO2 
from the pulmonary blood. Herein, we will analyze the compositions of the inspired 
and expired air per breath, and from there compute the O2 consumption and CO2 
production rates. Next, we derive expressions for diffusion coefficients 
2OD and 2COD  
in terms of the evaluated cardiac-output, O2 and CO2 concentrations in arterial and 
venous blood, alveolar and blood O2 and CO2 partial-pressures. We then take up a 
typical case study, and demonstrate the computation of 
2OD and 2COD , to represent the 
lung performance capability to oxygenate the blood. 
 
4.3 Respiratory System 
 
The respiratory system is the system of the body that deals with breathing. When we 
breathe, the body takes in the oxygen that it needs and removes the carbon dioxide that 
it doesn't need. 
 
First the body breathes in the air which is sucked through the nose or mouth and down 
through the trachea (windpipe). The trachea is a pipe shaped by rings of cartilage. It 
divides into two tubes called bronchi. These carry air into each lung.  
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Figure 4.1 Respiratory Passages. [Guyton Hall, Text Book of Medical Physiology, 10th 
ed, Pg 440] 
Inside the lung, the tubes divide into smaller and smaller tubes called bronchioles. At 
the end of each of these tubes are small air sacs called alveoli. 
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Figure 4.2 Trachea, bronchi and Alveoli.[SGH, Respiratory Lab]. 
 
Capillaries, which are small blood vessels with thin walls, are wrapped around these 
alveoli. The walls are so thin and close to each other that the air easily seeps through. 
In this way, oxygen seeps through into the bloodstream and carbon dioxide, in the 
bloodstream, seeps through into the alveoli, and is then removed from the body when 
we breathe out. 
 
4.3.1 Exchange of Carbon Dioxide and Oxygen  
 
The lung is for gas exchange. Its prime function is to allow oxygen to move from the 
air into the venous blood and carbon dioxide move out. It also metabolises some 
compounds, filters toxic materials from the circulation, and acts as a reservoir for 
blood. But its key function is to exchange gas. 
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Figure 4.3 Exchange of Carbon Dioxide and Oxygen. [SGH, Respiratory Lab] 
 
4.3.2 Blood-Gas Interface  
 
Oxygen and carbon dioxide move between air and blood by simple diffusion. Fick’s 
law of diffusion states that the amount of gas which moves across a sheet of tissue is 
proportional to the area of sheet but inverse proportional to its thickness. The blood-
gas barrier is about 0.5µm and has an area of between 50 and 100 m2.  
 
The prodigious surface area for diffusion inside the limited cavity is obtained by 
wrapping the capillaries around an enormous number of alveoli as shown in figure 4-5. 
There are about 300 million alveoli in the human lung, each about 1 3 mm in diameter. 
If they were spherical, their total surface area would be 85 m2, but their volume only 4 
litres. 
 
Gas is brought to one side of the blood-gas interface by airways and blood to the other 
side by blood vessels. 
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Figure 4.4 Electron micrograph showing a pulmonary capillary (C) in the alveolar 
wall. The blood-gas barrier is less than 0.5 µm. The large arrow indicates the diffusion 
path from alveolar gas to the interior of the erythrocyte (EC) and includes the layer of 
surfactant (not shown), alveolar epithelium (EP), interstitium (IN), capillary 
endothelium (EN) and plasma. Parts of structural cells called fibroblasts (FB), 
basement membrane (BM), and a nucleus of an endothelial cell are also seen. [ER 
Weibel: Respiration Physiology 11:54, 1970.] 
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Figure 4.5 Section of the lung showing many alveoli and a small bronchiole. The 
pulmonary capillaries run in the walls of the alveoli (previous figure). The holes in the 
alveolar walls are the pores of Kohn. [Scanning electron micrograph by JA Nowell 
and WS Tyler]. 
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Figure 4.6 Cast of the airways of a human lung. The alveolo have been pruned away, 
but the conducting airways from the trachea to the terminal bronchioles can been seen. 
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4.3.3 Airways and Air Flow 
 
The airways consists of a series of branching tubes which become narrower, shorter 
and more numerous as they penetrate deeper into the lung (Figures 4.3 and 4.6). The 
trachea divides into right and left main bronchi, which in turn divide into lobar, then 
segmental bronchi. This process continues down to the terminal bronchioles, which are 
the smallest airways without alveoli. All these bronchi make up the conducting airways. 
Their function is to lead inspired air to the gas exchanging regions of the lung (Figure 
4.7). Since the conducting airways contain no alveoli and therefore they take no part in 
gas exchange, they constitute the anatomic dead space. Its volume is about 150 ml.  
 
 
 
Figure 4.7 Idealization of the human airways according to Weibel. Note that the first 
16 generations (Z) make up the conducting airways and the last 7 the respiratory zone 
(or the transitional and respiratory zone). BR, bronchus; BL, bronchioles; TBL, 
terminal bronchiole; RBL, respiratory bronchiole; AD, alveolar duct; AS, alveolar sac. 
[ER Weibel, Morphometry of the Human Lung. Berlin, Spring-Verlag, 1963, p 111]. 
 
The terminal bronchioles divide into respiratory bronchioles which have occasional 
alveoli budding from their walls. Finally, we come to the alveolar ducts completely 
lined with alveoli. This alveolated region of the lung where the gas exchange occurs is 
known as the respiratory zone. The portion of the lung distal to a terminal bronchiole 
forms an anatomical unit called the primary lobule or, better, the acinus. The distance 
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from the terminal bronchiole to the most distal alveolus is only about 5 mm, but the 
respiratory zone makes up most of the lung, its volume being about 3000 ml. 
 
During inspiration, the volume of the thoracic cavity increases and air drawn into the 
lung. The increase in volume is brought about partly by contraction of the diaphragm, 
which causes it to descend, and partly by the action of the intercostals muscles, which 
raise the ribs, thus increasing the cross-sectional area of the thorax. Inspired air flows 
down to about the terminal bronchioles by the bulk flow, like water through a hose. 
Beyond that that point, the combined cross-sectional area of the airways is so 
enormous because of the large number of branches (Figure 4-8) that the forward 
velocity of the gas becomes very small. Diffusion of gas within the airways then takes 
over as the dominant mechanism of ventilation in the respiratory zone. The rate of 
diffusion of gas molecules within the airways is so rapid, and the distances to be 
covered are so short, that differences in concentration within the acinus are virtually 
abolished within a second. However, because the velocity of gas falls rapidly in the 
region of the terminal bronchioles, inhaled dust frequently settles out there. 
 
The lung is elastic and returns passively to its pre-inspiratory volume during resting 
breathing.  
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Figure 4.8 Diagram to show the extremely rapid increase in total cross-sectional area 
of the airways in the respiratory zone (compare with the previous figure). As a result, 
the forward velocity of the gas during inspiration becomes very small in the region of 
the respiratory bronchioles, and gaseous diffusion becomes the chief mechanism of 
ventilation. 
  
The pressure required to move gas through the airways is very small. During normal 
inspiration, an air flow rate of 1 litre/sec requires a pressure drop along the airways of 
less than 2 cm water. Compare a smoker’s pipe which needs a pressure of about 500 
cm water for the same flow rate. 
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Figure 4.9 View of an alveolar wall (in a frog) showing the dense network of 
capillaries. A small artery (left) and vein (right) can be seen. The individual capillary 
segments are so short that the blood forms an almost continuous sheet. [JE Maloney 
and BL Castle, Respiratory Physiology 7:150, 1969]. 
  271
 
 
Figure 4.10 Microscopic section of dog lung showing capillaries in the alveolar walls. 
The blood-gas barrier is so thin that  it cannot be identified here (compare with Figure 
4-4). This section was prepared from lung which was rapidly frozen while being 
perfused.[JB Glazier, JMB Hughes, JE Maloney JB West, Journal of Applied 
Physiology 26:65, 1969]. 
 
4.3.4 Blood Vessels and Flow 
 
The pulmonary blood vessels also form a series of branching 
tubes from the pulmonary artery to the capillaries and back to 
the pulmonary veins. Initially the arteries, veins, and bronchi run 
close together, but toward the periphery of the lung, the veins 
move away to pass between the lobules, whereas the arteries and 
bronchi travel together down the centers of the lobules. The 
capillaries form a dense network in the walls of the alveoli 
(Figure 4.9). The diameter of a capillary segment is about 10 mµ , 
just large enough for a red blood cell. The lengths of the segments 
are so short that the dense wall, a vernetwork forms an almost 
continuous sheet of blood in the alveolar wall, a very efficient 
arrangement for gas exchange. Alveolar walls are not often seen 
face on, as in Figure 4.9. The usual microscopic cross-section 
(Figure 4.10) shows the red blood cells in the capillaries and 
emphasizes the enormous exposure of blood to alveolar gas, with 
only the thin blood-gas barrier intervening (compare Figure 4.4). 
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The pulmonary artery receives the whole output of the right 
heart, but the resistance of the pulmonary circuit is astonishingly 
small. A mean pulmonary arterial pressure of only 20 cm water is 
required for a flow of 6 litres/min. (The same flow through a soda 
straw need 120 cm water.) 
 
Each red blood cell spends about 3 4  sec in the capillary network 
and during this time probably transverses two or three alveoli. So 
efficient is the anatomy for gas exchange that this brief time is 
sufficient for virtually complete equilibration of oxygen and 
carbon dioxide between alveolar gas and capillary blood. 
 
The lung has an additional blood system, the bronchial circulation, which supplies the 
conducting airways down to about the terminal bronchioles. Most of this blood is 
carried away from the lung via the pulmonary veins. The flow through the bronchial 
circulation is a mere fraction of that through the pulmonary circulation, and the lung 
can function fairly. 
 
4.3.5 Ventilation 
 
 
 
 
 
Figure 4.11 Diagram of a lung showing typical volume and flows. There is a 
considerable variation around these values. [John B West, Respiratory Physiology, 3rd 
ed., 1984]. 
 
The above figure is a highly simplified diagram of a lung. The various bronchi which 
make up the conducting airways as shown in Figure 4.6 are now represented by a 
single tube labeled anatomic dead space. This leads into the gas exchanging region of 
the lung which is bounded by the blood-gas interface and the pulmonary capillary 
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blood. With each inspiration, about 500 ml of air enter the lung (tidal volume). Note 
how small a proportion of the total lung volume is represented by the anatomical dead 
space. Also note the very small volume of capillary blood, compared with that of 
alveolar gas (compare Figure 4.10). 
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4.3.6 Anatomic Dead Space 
 
This is the volume of the conducting airways (Figures 4-6 and 4-7). The normal value 
is about 150 ml, it increases with large inspirations because of the traction exerted on 
the bronchi by the surrounding lung parenchyma. The dead space also depends on the 
size and posture of the subject; a rule of thumb is that the volume in milliliters of the 
seated subject is approximately equal to the body weight in pounds. 
 
4.3.7 Diffusion 
 
Fick’s Law states that the rate of transfer of a gas through a sheet of tissue is 
proportional to the tissue area and the difference in gas partial pressure between the 
two sides, and inversely proportional to the tissue thickness. 
 
 
 
Figure 4.12 Diffusion through a tissue sheet. The amount of gas transferred is 
proportional to the area, a diffusion constant, and the difference in partial pressure, 
and is inversely proportional to the thickness. The constant is proportional to the gas 
solubility but inversely proportional to the square root of its molecular weight. 
 
From the above figure, the area of the blood-gas barrier in the lung is enormous (50-
100 m2), and the thickness is less than 1 2  mµ  (refer to Figure 4.4), so the dimensions 
of the barrier are ideal for diffusion. In addition, the rate of transfer is proportional to a 
diffusion constant which depends on the properties of the tissue and the particular gas. 
The constant is proportional to the solubility of the gas and inversely proportional to 
the square root of the molecular weight. This means that CO2 diffuses about 20 times 
more rapidly than O2 through tissue sheets since it has a much higher solubility but not 
a very different molecular weight. 
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4.3.8 Diffusion and Perfusion Limitations 
 
The figure below shows the time courses as a red blood cell (RBC) moves through the 
capillary, a process which takes about ¾ sec.  
 
First, let’s take a look what happens when the gas is carbon monoxide. When the RBC 
enters the capillary, carbon monoxide (CO) moves rapidly across the extremely thin 
blood-gas barrier from the alveolar gas into the cell. As a result, the content of CO in 
the cell rises. However, because of the tight bond which forms between CO and 
hemoglobin within the cell, a large amount of CO can be taken up by the cell with 
almost no increase in partial pressure. Thus, as the cell moves through the capillary, the 
CO partial pressure in the blood hardly changes so that no appreciable back pressure 
developed, and the gas continues the move rapidly across the alveolar wall. Therefore, 
the amount of CO which gets into the blood is limited by the diffusion properties of the 
blood-gas barrier and not by the amount of blood available. The transfer of CO is 
diffusion limited. 
 
 
 
 
Figure 4.13 Uptake of carbon monoxide, nitrous oxide, and O2 along the pulmonary 
capillary. Note that the blood partial pressure of nitrous oxide virtually reaches that of 
alveolar gas very early in the capillary so that the transfer of this gas is perfusion 
limited. By contrast, the partial pressure of carbon monoxide in the blood is almost 
unchanged so that its transfer is diffusion limited. O2 transfer can be perfusion or 
partly diffusion limited depending on the conditions. 
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Next let’s take a look at nitrous oxide (N2O). When this gas moves across the alveolar 
wall into the blood, no combination with hemoglobin takes place. As a result the blood 
has nothing like the avidity for N2O that it has for CO and the partial pressure rises 
rapidly. From the above figure, the partial pressure of N2O in the blood has virtually 
reached that of the alveolar gas by the time the RBC is only 1/10 of the way along the 
capillary. Thus the amount of this gas taken up by the blood depends entirely on the 
amount of blood flow and not at all on the diffusion properties of the blood-gas barrier. 
The transfer of N2O is therefore perfusion limited. 
 
Lastly, let’s take a look at what happens when the gas is O2. Its time course lies 
between that of CO and N2O. O2 combines with hemoglobin (unlike N2O) but with 
nothing like the avidity of CO. In other words, the rise in partial pressure when O2 
enters a RBC is much greater than is the case for the same number of molecules of CO. 
Under typical resting conditions, the capillary 2OP virtually reaches that of alveolar gas 
when the RBC is about 1/3 of the way along the capillary. Under these conditions, O2 
transfer is perfusion limited like N2O.  
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Figure 4.14 Oxygen time courses in the pulmonary capillary when diffusion is normal 
and abnormal (for example, because of thickening of the alveolar membrane). A shows 
time courses when the alveolar 2OP  is normal. B shows slower oxygenation when the 
alveolar 2OP  is abnormally low. Note that in both cases, severe exercise reduces the 
time available for oxygenation. 
 
However, in some abnormal circumstances (as shown in the above figure) when the 
diffusion properties of the lung are impaired, for example, because of thickening of the 
alveolar wall, 
2O
P does not reach the alveolar value by the end of the capillary, and now 
there is some diffusion limitation as well. 
 
4.3.9 Carbon Dioxide (CO2) Transfer Along the Pulmonary 
Capillary 
 
In the section 4.3.9, we have seen that the rate of diffusion of CO2 through tissue is 
about 20 times faster than that of O2 because of the much higher solubility of CO2. It is 
possible that a difference between end-capillary blood and alveolar gas can develop if 
the blood-gas barrier is diseased. 
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Figure 4.15 Calculated changes in 2COP  along the capillary when the diffusion 
properties are normal and abnormal (compare the time course of 2OP in Figure 4.14). 
[PD Wagner and JB West, J Appl Physiol 33:62, 1972]. 
 
The above figure shows that the normal time course for CO2 and how it might be 
affected by thickening of the blood-gas barrier. Note that the 2COP of the blood as it 
enters the capillary is about 45mmHg and that the normal 2COP  of alveolar gas is about 
40mmHg. It can be seen that the time taken for the blood to reach virtually the same 
partial pressure as alveolar gas is similar to that for O2 under normal conditions (Figure 
4.14), so that there are good reserves of diffusion. However when the diffusing 
capacity of the membrane is reduced to about ¼ of its normal value, a small difference 
between end-capillary blood and alveolar gas may be seen. 
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4.4 Author’s work Lung Air Composition Analysis 
(and 2O  consumption and 2CO  production rates) [3-4] 
 
The lung functional performance is characterized by (i) its ventilatory capacity, to 
bring air (and hence O2) into the alveoli, and (ii) its capacity to transfer O2 and CO2  
into and from the pulmonary capillary bed. Hence, the O2 and CO2  diffusion 
coefficients as well as the O2 consumption-rate and the CO2 production rate represent 
the lung performance indices.  
 
We carry out a mass balance analysis, involving: 
(i) compositions of air breathed in and out 
(ii) consumption or losses of O2, CO2 and H2O. 
 
The Table 4.1 below provides clinical data on partial pressures and volumes of  2N , 2O , 
2CO and 2H O  of  atmospheric air breathed in and expired air, of one breadth cycle. The 
monitored breathing rate (BR) = 12 breaths/min, at each breadth 500ml of air is 
inspired and we assume PH2O at 37οC = 47mmHg. 
 
Table 4.1 Inspired air composition and partial pressures. (i) We first compute the 
volume of expired air compositions, (ii) their pressures based on percent volume.  
 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/% 
N2 597 393.1 
78.55%
566 393.1 
74.5%
O2 159 104.2 
20.84%
120 80.6  
15.7%
CO2 0.3 0.2 
0.04% 
27 19.1  
3.6% 
H2O 3.7 2.5 
0.49% 
47 32.6  
6.2% 
Total 760 500 
100% 
760 525.3 
100% 
  
It can be noted that the expired air volume exceeds the inspired air volume for this 
particular breath cycle. The H2O loss of 30.1ml (=32.6ml -2.5ml) contributes to the 
major portion of this difference. 
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Note: Water vapor in atmospheric air or inspired air is 0.49% expired air is 6.2%. 
 
In expired air, 393.1 + 80.6 + 19.1 = 492.8ml 
Water vapour in expired air = ( )47 713 492.8 32.4mmHg mmHg × =  
 
4.4.1 Calculation of 2O  Consumption-Rate and CO2  Production-
Rate 
 
We now determine the 2O consumption rate and 2CO  production rates from the 
inspired and expired gases 
 
Assuming the patient breathes at 12 times per minute (and 500ml of air at each 
breadth), we have 
 
2O  Consumption Rate  = (Inspired 2O - Expired 2O ) x 12  
 = (104.2-80.6) x 12 
= 283.2 ml/min  
 
2CO  Production Rate  = (Expired 2CO - Inspired 2CO ) x 12 
= (19.1-0.2) x 12 
=  226.8ml/min  
 
 
The amount of water vapor in the humidified expired air amounts to 6.2% of the 
expired air (compared to 0.49% of the dry inspired air)  corresponding to partial 
pressure ratio of water vapor in the expired air (= 47/760). The volume of the dry 
expired air =(525.3-32.6)ml=492.7ml. 
 
Now, assume that out of 500ml of inspired air, the dead space air volume (not taking 
part in gas transfer process) is 150 ml and the alveolar air volume is 350 ml. We next 
compute the dead space air volume composition. 
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Figure 4.16 Dead Space Volumes. 
 
4.4.2 Dead Space Air Composition 
 
The clinical data of expired air composition is: 
 
    = 393.1
 = 83.36
= 16.87
= 34.15
N ml2
O    ml2
CO ml2
H O ml2
  
Total 527.49 ml                           
 
Now, the dead-space air will be made up of (i) dry air portion from the inspired air 
(assumed to be of amount=141ml), plus (ii) the water vapor taken up by the dry air 
(estimated to be =9ml) since the expired air portion of 141ml will not have under gone 
2O and 2CO  transfer, it’s composition is the same as that of inspired air:  
 
 = 111N ml2 (78.55%), = 29.40O ml2 (20.84%), = 0.06CO ml2 (0.04%), 
= 0.69H O ml2 (0.49%). 
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When this inspired air (in the dead space) of 141 ml  is fully humidified, it will take up 
a further X ml  of 2H O  vapour, in the ratio of the partial-pressures, as: 
 
  47 0.0659
141 713
X = =  
0.0659 141 9.29X ml∴ = × =  of 2H O  vapour (which is close to our estimate).
        
So, by adding 9.29ml of 2H O vapour to 0.69 ml of water vapour in the inspired portion 
of dead-space air volume of 141ml, the total water vapour in the dead-space air is 
9.98ml. The humified dead-space air composition will be: 
 
 
2
2
2
2
N       = 111.00  (=73.78%)
O       = 29.40 (=19.55%)
CO     = 0.06   (=0.04%)
H O    = 9.98 (=6.63%)
Total   = 150.44
ml   
ml      
ml     
ml       
ml
 
 
4.4.3 Alveolar Air Composition and Partial Pressures 
 
We can now compute the alveolar air composition, by subtracting the dead-space air 
from expired air. These values are tabulated in column 4 of the below Table. 
 
Table 4.2 The alveolar air composition. 
 Expired 
Air ( ml ) 
Dead Space 
Air ( ml ) 
Alveolar Air 
( ml ) 
Alveolar Air 
Partial 
Pressure 
(mmHg) 
N2 393.1 ml  111.00 ml  282.1 ml  569.41 mmHg 
O2 80.53 ml  29.40 ml  51.13 ml  103.21 mmHg 
CO2 19.12 ml  0.06 ml  19.06 ml  38.47 mmHg 
H2O 34.21 ml  9.98 ml  24.23 ml  48.91 mmHg 
Total 526.96 ml  150.44 ml  376.52 ml  760 mmHg 
 
Finally, we compute the partial pressure of O2 and CO2 (as well as of N2 and H2O ), so 
that we can determine next the diffusion coefficients of O2 and CO2 based on the 
monitoring of arterial and venous blood concentrations. These values are tabulated in 
column 5 of the above Table. 
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4.5 Lung Gas-Exchange Model & Parametric Analysis  
 
4.5.1 Expressions for 
2O
D and 
2CO
D  
The gas exchange between the alveolar air and pulmonary capillary blood is 
represented by the following 2O  and 2CO  conservation equations (figure 2): 
 
22 2
VE VE AE AE
OO OQ C Q C V
°
= +  (from the alveolar air to capillary blood) 
2
2 2 2 2
( ) ;Oav
capAE AE AE
O O O OQ C P D P P= + ∆ =                   (1) 
in which 
2
cap
OP = 2
PRB
OP      ( 2O  concentration of the pre-oxygenated blood) 
22 2
VE VE AE AE
COCO COQ C Q C V
°
= −  (from capillary blood to alveoli) 
  2
2 2 2 2
( ) ;COav
capAE AE AE
CO CO CO COQ C P D P P= − ∆ =                   (2) 
 
in  which 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre-oxygenated blood) 
wherein 
 
(i) ABQ and VBQ  are arterial and venous blood flow-rates   
(at venous end)  (at arterial end) ,AB VE VB AEQ Q Q Q= = ; 
(ii) 
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial pressures; 
(iii) 
2 2
 2and are the alveolar and capillary partial pressures  
al cap
CO COP P CO ; 
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion coefficients, defined in the caption of 
figure 2; 
(v) 2
2 2
- average of ( ) over the capillary lengthOav
capal
O OP P P=?  
2
2 2
average over the capillary length; of  CO al capav CO OP P P= −?  
(vi) 
2O
V
?
 is the 2O  transfer rate from alveolar air to capillary blood (= 2O consumption 
rate), 
2CO
V
?
is the 2CO  transfer-rate from capillary blood at arterial end to alveolar air. 
 
Now we can equate the arterial and venous blood flow rates, as  
 
ABQ = VBQ =Q=(SV)/(EP) ? / 60CO  
 
SV, EP and CO being the stroke-volume (in cc), ejection-period (in secs) and cardiac-
output (in cc or ml per sec) respectively. Hence the above equations can be rewritten 
as: 
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Figure 4.17 Schematic of blood gas concentration in the Pulmonary Capillary. Note 
that 
2
cap
OP  = 2
AE
OP ; VB: venous blood, AB: arterial blood, AE: arterial end, VE: venous 
end. 
 
We define diffusing capacity of gas across the alveolar-capillary membrane as  
D = Volume-rate of transfer of gas  of gas ( / min)
Average partial pressure difference  of the gas ( )av
V ml
P mmHg
= ∆
?
 
For instance for O2, 2
2 2
from alveolar air to blood ( / min)
 ( )
O
O O
av
V ml
D
P mmHg
= ∆
?
 
We will refer to 
2O
D  as diffusion coefficient of O2 ( 21 / )ml min.mmHg?  
For example, 
2
252 / min 21 / .
12O
mlD ml min mmHg
mmHg
= =   
2O
V  is the 2O  consumption rate, which can either be obtained from inspired and 
expired compositions or from  ( ) ( )2 2 2 2AB VB VE AEO O O OQ C C Q C C− = − . 
 
From equation (1): 
 
2
2
2 2 2 2 2 2
2 2 2
( ) ;
( )
O AE
av
O
av
capVE VE AB AB
O O O O O O
VB AB
O O O
PQ C Q C P D P P
QC QC P D
== + =
= +
?
?
  
2 2
2 2 2 2
2
( ) ( )
( ) ( )
AB VB
O O
av av
VE AE
O O O O O
OPav
Q C C Q C C
P P
V= =
− −=
?
?? ?2O
D       (3) 
 
wherein  2OV
?
 is the oxygen consumption rate. 
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From equation (2): 
 
 
        
2
2 2
2
( )
( )
VE
CO
av
AB
CO CO CO
COPav
Q C C
P
V=
−=
?
??2CO
D      (4) 
 
wherein  2COV
?
is the carbon dioxide production rate. 
 
In equations (3) & (4): 
 
(i) Q, 
2
VE
OC  and 2
AE
OC , 2
VE
COC  and 2
AE
COC  can be monitored because 
2 2 2 2 2 2 2 2
  =  and   = & & & & AB AB VB VBVE VE AE AEO CO O CO O CO O COC C C C C C C C  
(ii) 
2OD  and 2COD represent the lung gas-exchange parameters.  
(iii) 2OPav?  and 
2COPav?  need to be determined in terms of  ( 2
al
OP  & 2
VB
OP ) and ( 2
al
COP  & 
2
VB
COP ) respectively, in order to be able to evaluate 2OD and 2COD . 
(iv) 
2
al
OP  itself depends on 2OV
?
 and ventilation-rate V
?
; 
2
al
COP  itself depends on 2COV
?
 and ventilation-rate V
?
. 
(v) 
2
VB
OP  depends on 2
VB
OC  
2
VB
COP  depends on 2
VB
COC  
 
Now from equations (3) & (4), if we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 2
al
COP , 2
cap
COP  in terms of 
monitorable quantities. In this regard, 
 
(i) Alveolar 
2
al
OP can be expressed in terms of V
°
(the ventilation rate) and 2OV
°
(the 2O  
consumption rate) as Figure 4.18 : 
   
                          
2
(in ) 1
O
V V Vm
mmHg e
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
° ° °−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
2
k2al
O 1P k                             (5) 
 
2
2
2 2 2 2 2 2
2 2 2
( ) ;
( )
CO AE
av
CO
av
capVE VE AE AE VB
CO CO CO CO CO CO
VE AE
O CO CO
Q C Q C P D P P P
QC QC P D
= − = =
= −
?
?
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where mV
?
 is the maximum ventilation rate and 
2OV
?
(the 2O consumption rate or 
absorption rate from the alveoli)= 
2 2
)( AB VBO OQ C C− . Equation (5) implies that as V Vm⎛ ⎞⎜ ⎟⎝ ⎠
? ?
 
increases,  (the exponential term decreases, and)  
2
al
OP  increases (as in Figure 4.18), and 
as 
2OV
?
 increases 
2
al
OP  decreases (as in Figure 4.18). 
 
 
 
 
Figure 4.18 Effect on alveolar 
2O
P  of (i) Alveolar ventilation (
2OV
?
), and (ii) rate of 
Oxygen absorption from alveolar 
2O
P  or 2O  consumption rate, 2OV
?
 [From Guyton 
(1971), p. 476]. This relationship is expressed by equation by equation (5). 
 
(ii) Alveolar 
2
al
COP  can be expressed in terms of V
°
 and 2OV
°
 as in Figure 4.19. 
 
                           
2
(in )
CO
V
V m
V
mmHg e
°
°
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
°−
=
4
al
CO 32
k
P k                                  (6) 
where 
2
°
CO
V (the 2CO  production rate or excretion rate from the blood) = 2 2 )(
VB AB
CO COQ C C− .  
2OV
?
2OV
?
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Figure 4.19 Effect on alveolar 
2CO
P of Alveolar ventilation and rate of Carbon dioxide  
excretion from the blood or  2CO  production rate, 2COV
?
 [From Guyton (1971), p. 476].  
This relationship is expressed by equation by equation (6). 
 
This equation implies that as  mV V
? ?
 increases, 
2
al
COP  decreases; also, as  2COV
?
 increases 
(the exponential term decreases, and hence) 
2
al
COP  increases, as per figure 4. 
 
(iii) Blood
2O
P can be obtained in terms of blood 
2O
C , from the 2O  disassociation curve 
(providing concentrations in arterial or venous blood, as represented in Figure 
4.20.) as: 
 
2
2
2 2
( / 100 ) (1 )
O
m
O
P
P
O O
ml ml mC C e
−
= −
k5
, or  
*
2
2
* 1 O
P
OC e
−= − 5k        (7) 
 
where  
 
• 
2
m
O
C  and 
2
m
O
P  are the maximum values of blood 2O concentration and partial, 
respectively pressure 
• *
2 2 2
m
O O OC C C=  
• 
2 2
*
2O O
m
O
P P P=  
 
 
2CO
V
?
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Figure 4.20 O2 dissociation curves, showing the total oxygen in each 100 ml  of normal 
blood, the portion dissolved in the water of the blood [From Guyton (1971), p. 485]. 
We will adopt oxygen concentration units to be (ml of O2/100 ml of blood), and hence 
we will divide the numbers on the y-axis by 100. 
 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
C , from  the 2CO  disassociation curve 
(providing 2CO  concentration in arterial or venous blood, as represented in Figure 
4.21 ) as: 
 
 
( )2 2
2 2
( / 100 ) (1 )
mPCO COPm
CO CO
ml mlC C e
−= − 6k   
( )2 2
2
*
2*or, 1 1
m
CO CO CO
PP P
COC e e
−− == − −
kk 66   (8) 
2O
C  
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Figure 4.21 The carbon dioxide dissociation curve [From Guyton (1971), p. 491]. We 
will  adopt carbon dioxide concentration units to be (ml of CO2/100 ml of blood), and 
hence we will divide the numbers on the y-axis by 100. 
 
 
4.5.2 Alveolar 2 2O and CO  Partial Pressure Expressions 
 
We will now quantify the earlier mentioned empirical expressions of  
2
al
OP  and 2
al
COP in 
equations (5) and (6). 
 
(a) Now, let us refer equation (5) for the 
2
al
OP  partial pressure curve (Figure 4.18), 
represented by the equation: 
 
2
1
O
m
V V
V
e
°
°
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
°−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
2
2
k
al
O 1P k  
*
21
O
V V
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
2k
1k  , where 
*
V
°
= 
m
V
V
°
°    (9) 
 
2CO
C
 
   
2CO
P (                                                   ) 
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wherein V
?
is the alveolar ventilation rate (in liters/min), mV
°
 is the maximum 
ventilation rate (= 50 liters/min) and 
2O
V
?
is  the 2O consumption rate (in liters/min). 
Herein, the coefficients 1k and 2k  can be determined by having this equation match 
the Figure 4.18 data. Note, in this equation, when 0V
°
= , 
2
0alOP =  from the 
equation ,which satisfies the data. 
 
In figue 3 for 2OV
?
=0.25 liters/min, when 
*
V
°
= 
m
V
V
°
° =0.5, 2
al
OP =140mmHg . Hence , 
0.5
20.25140 1 (1 )e e
⎡ ⎤⎢ ⎥⎣ ⎦− −= − = −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
2
2
k k
1 1k k            (10) 
 
Also, when 2OV
?
=1 / minl , 
*
V
°
=0.3 / minl , 
2
100alOP = mmHg. Hence 
0.3
0.31100 1 (1 )e e
⎡ ⎤⎢ ⎥⎣ ⎦− −= − = −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
2
2
k k
1 1k k    (11) 
 
From equations (10) and (11), we get: 
 
2 2
0.3 0.3
(1 )140 1
100 (1 ) 1
e e
e e
− −
− −
− −= =− −
2 2
2 2
k k
1
k k
1
k
k  
0.3 2
2 0.3, 40 , so that
140 140 100 100
or 100 140 4.18
e e
e e min/l
− −
− −
∴ − = −
= + =
2 2
2 2
k k
k k
2k
        (12) 
 
Upon substituting 4.18min/l=2k  into equation (10) we obtain: 
 
(2 4.18) that140 (1 ), so 140e mmHg− ×= − ≈1 1k k         (13) 
 
Hence, the 
2
al
OP  curve can be represented by: 
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( )
*
24.18
,140 1
OV V
mmHg e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
2
al
OP          (14) 
wherein 2OV
?
=Q 2 2 )(
AB VB
O OC C−  and 
*
50 / minV V l
°
=
?
    
  
 
(b) Now, let us look at the 
2
al
COP  expression: 
 
2 2
*
CO CO
V V V V
V me e
⎡ ⎤⎛ ⎞ ⎡ ⎤⎢ ⎥⎜ ⎟ ⎢ ⎥⎢ ⎥⎜ ⎟ ⎢ ⎥⎢ ⎥⎜ ⎟⎝ ⎠⎣ ⎦ ⎣ ⎦
° ° °− −°
= =
?
2
k k4 4
al
CO 3 3P k k  
We note from Figure 4.19 that for  2 0.2 / minCO lV
°
=  and 
*
0.2mV
°
= , 
2
al
COP =12. Hence, 
from the above equation, we get: 
 
-12 e= 4k3k        (15) 
 
Also, for  2 0.8 /CO l minV =
?
and 
*
0.2mV
°
= , 
2
al
COP =62mmHg. Hence 
0.20
0.80
3
462 e k e
⎡ ⎤⎢ ⎥⎣ ⎦ −−= =4
k
3
k4k      (16) 
 
From equations (15) and (16), we get: 
3
4
4
, so that
12
62
12
ln 2.19
62
3
4
e
e
e
−−= =−
= − =⎛ ⎞⎜ ⎟⎝ ⎠
4 4
4
k k
k
4k k4
   (17) 
 
Substituting 2.19=4k  into equation (16), we obtain : 
2.19
4 ,62 107.18e
−
∴= =3 3k k     (18) 
 
Hence, the 
2
al
COP  curve can be represented as 
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22.19
( ) 107.18
CO
V V
V m
mmHg e
° °
°
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
−
=alCO2P                (19) 
wherein  
*
50 /V V l min
°
=
?
 and 2COV
?
=Q
2 2
)( VB ABCO COC C−  
 
4.5.3 Arterial and Venous and2 2O CO  Partial Pressure 
Expressions 
 
We will now quantify the previous expressions of 
2
AB
OP  and 2
VB
COP  in terms of  2
AB
OC  and 
2
VB
COC , as given by equations (7) and (8). 
 
(a) From the 2O  disassociation curve in Figure 4.20, we had put down: 
 
Blood 
2 2
2
1
m
O O
P P
m
OC e
⎡ ⎤⎢ ⎥⎣ ⎦= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
5
2
-k
OC    
*
2*
2
or, 1 O
P
OC e
−= − 5k        (20) 
where  2
* 2
2
O
O
O
m
C
C
C
=  and 2*2
2
O
O m
O
P
P
P
=  
From Figure 4.20, at 
2
*
OP =
40
0.29
140
mmHg
mmHg
=  (for normal venous blood), and 
2
*
OC
15
0.75
20
= = . 
 
Hence from equation (20): 
0.290.75 1
4.78
e−= −
∴ =
5k
5k
      (21) 
Also, for 2
* 95 0.68
140O
mmHg
P
mmHg
= =  (for normal arterial blood), and 
*
2
0.19
0.95
0.20O
C = =  
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Hence from (20): 
0.68 , or0.95 1 4.4e−= − =5k k5      (22) 
 
So we take the average value of 5k :     
(4.78+4.4)
= 4.59
2
∴ =5k                 (23) 
 
Then the 2O disassociation curve is given by: 
2
2
4.59
140
0.2 1
PO
B
OC e
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= = −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
2O
C ,       (24) 
Hence from the above equation, the partial pressure of 2O in blood (
B
O2
P ) is given by: 
 
2 2
140 0.2 0.2
ln 30.5 ln
4.59 0.2 0.2B BO O
B
C C
= =− −
⎡ ⎤ ⎡ ⎤⎢ ⎥ ⎢ ⎥⎢ ⎥ ⎢ ⎥⎣ ⎦ ⎣ ⎦O2
P    (25) 
 
 
(b) Finally, we look at 2CO disassociation curve (in Figure 4.21), expressed as: 
2
|max2
2
2
*
|max2 2
2
/ max
*
(1 )
or, 1 1
CO
CO
CO
CO CO
P
P
CO
P
P P
CO
C e
C e e
−
− −
= −
= − = −
6
2
6
6
k
CO
k
k
C
   (26) 
 
Based on Figure 4.21, when 2
* 20 0.14
140CO
mmHg
P
mmHg
= = , 
2
* 0.38 0.475
0.80CO
C = = so that 
 
 ,
0.140.475 1 4.60e−= − =6 6k k      (27) 
 
Also, when 2
* 70 0.5
140CO
mmHg
P
mmHg
= = , 2
* 0.60 0.75
0.80CO
C = = , so that 
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0.5 ,0.75 1 2.77e−= − =6 6k k      (29) 
 
  
So we take the average value of 6k : 
 
(4.60+2.77)
= 3.69
2
=6k                   (30) 
 
Then, in CO2 disassociation curve,  the CO2 concentration is given (from equations 26-
30) by: 
 
2
2
3.69
140
0.8 1
COP
B
COC e
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= = −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
2CO
C ,    (31) 
 
so that partial pressure of CO2 in blood is ( BPCO2
) is given by 
2
( )
0.8
37.94 ln
0.8 BCO
B mmHg
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦CO2
P     (32) 
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4.5.4 Determining 2OavP?  and 2COavP?  
 
In order to determine 
2OD  and 2COD , we also need to determine 2OavP?  and 2COavP?  in 
equations (3) and (4) respectively. Figure 4.21 illustrates the variation of 2OP? (= 
2 2 2 2
capal al AB
O O O OP P P P− = − ) along the length (l) of the capillary bed.  
2
2
                                                                                max
*Let, 
*Now we can express  as a function of , as follow:
*( )    (36)
2
2
O
O O
O
l l lm
P l
P P f l
=
=
?
? ?
 
where 
2
*( )   Of l is illustrated in Figure 4.22. 
 
Then 
( )2 2 22 21max max
0
* *( ) F
O OO
O Of l dlP P Pav
⎛ ⎞⎜ ⎟ =∫⎜ ⎟⎝ ⎠
=? ? ?    (37) 
 
Based on data [3], since 2 12Oav mmHgP =?  for 2max 65O mmHgP =? , we have 2F 0.185O = . We 
can hence put down: 
 
2 2
2 2max
( ) 0.185  0.185 OO O O
al VBmmHg P PP Pav
⎛ ⎞= −⎜ ⎟⎝ ⎠=? ?  (38) 
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Figure 4.22 Uptake of oxygen by the pulmonary capillary blood. At arterial end, 
arrows unequal as concentration of O2 goes into capillaries. At venous end, arrows 
equalized. (The curve in this figure was constructed from data in Mihorn and 
Pulley:Biophys. J., 8:337,1968). [From Guyton (1971), p. 434]. 
 
We can similarly determine the average value of 2COavP?  from Figure 4.23 as: 
*Let
Then, we can represent figure 8 as:
*2 2 ( )                                                             (39)max 2
l l lm
CO CO
P P f lCO
=
=? ?
 
Then,
1 * *2 2 2( ) F              (40)max max2 20
CO O CO
P P f l dl Pav CO CO
⎛ ⎞ ⎛ ⎞⎜ ⎟= = ⎜ ⎟∫ ⎜ ⎟⎜ ⎟ ⎝ ⎠⎝ ⎠
? ? ?  
 
Based on data [3], since 2 0.5COav mmHgP =?  for 2max 5CO mmHgP =? , we have 2F 0.1CO = . 
 
We can now put down: 
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2
2 2
2 ( ) 0.1 0.1              (41)max
O
CO CO
CO VB alP mmHg P P Pav
⎛ ⎞= = −⎜ ⎟⎜ ⎟⎝ ⎠
? ?  
 
 
 
 
 
Figure 4.23 Diffusion of carbon dioxide from the pulmonary blood into the alveolus. 
(The curve in this figure was constructed from data in Mihorn and Pulley:Biophys. J., 
8:337,1968). [Modified from Guyton (1971), p. 435] 
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4.5.5 Sequential procedure to compute 
2O
D  and 
2CO
D  
 
2 22
22 2 0.185
2 2
Total  consumed2
AB VB
O OO
OO O
avav
Q C C
al VBP P PO O
O V
D
P
−⎛ ⎞⎜ ⎟⎝ ⎠= = = ⎛ ⎞−⎜ ⎟⎝ ⎠
?
??    (44) 
     
2 22
22 2 0.1
2 2
Total C  produced2
VB AB
CO COCO
COCO CO
avav
Q C C
VB alP P PCO CO
O V
D
P
−⎛ ⎞⎜ ⎟⎝ ⎠= = = ⎛ ⎞−⎜ ⎟⎝ ⎠
?
??   (45) 
 
Note that in the denominators, we need to know 
2
( )OV t
?
 and 
2
( )COV t
?
 for  
2
al
OP  and 2
al
COP  
respectively. 
 
(1) We first monitor: ( ), ( )V t V t
?
, SV(stroke volume), EP(Cardiac ejection period),  
2
VB
OC , 2
AB
OC , 2
VB
COC  & 2C
AB
OC  ( 2O  and 2CO  concentrations in pre-oxygenated and 
post-oxygenated blood). 
 
(2) We substitute the values of 
2
AB
OC  (= 2
VE
OC ) and 2
VB
OC  (= 2
AE
OC ) into equation (3), and 
the values of 
2
AB
COC  (= 2
VE
COC ) and 2
VB
COC  (= 2
AE
COC ) into equation (4). 
 
(3) We next determine: 
Q= SV/ejection period,      
2
( )OV t
?
=Q
2 2
( )VBABO OC C− ,  the O2 consumption rate   
2
( )COV t
?
=Q
2 2
)( ABVBCO COC C− , the CO2 production rate   
 
Using the monitored values of 
2
VB
OC , 2
AB
OC , 2
VB
COC  & 2C
AB
OC  in the above equations. 
(4) We then substitute the expressions for 
2
( )OV t
?
 and 
2
( )COV t
?
as well as of 
*
/ 50V V⎛ ⎞=⎜ ⎟⎝ ⎠
? ?
 into the equations for 
2
al
OP  (equation (14)) and 2
al
COP  (equation 
(19)), to obtain 
2
al
OP  and 2
al
COP .  
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(5) We substitute the monitored values of 
2
VB
OC  (= 2
AE
OC ) and 2
VB
COC  (= 2
AE
COC ) as well 
as of 
*
/ 50V V⎛ ⎞=⎜ ⎟⎝ ⎠
? ?
 into equations (25) & (32), to obtain the values of 
2
 or 
2
VB
O
AEPOP
⎛ ⎞⎜ ⎟⎝ ⎠  and 2  or 2
VB
CO
AEPCOP
⎛ ⎞⎜ ⎟⎝ ⎠ . 
 
(6) We now evaluate 2av
OP∆ in equation (38), by utilizing values of 
2
al
OP  in step (4) 
and 
2
VB
OP  in step (5). 
 
We likewise evaluate 2av
COP∆ in equation (38), by utilizing values of 
2
al
COP  in step 
(4) and 
2
VB
COP  in step (5). 
 
 
(7)  Now, in order to determine the values of the lung gas-exchange parameters (or 
indices) 
2OD  and 2COD  , we substitute into equations (42) and (43) for (i) 2 ( )OV t
?
 
and 
2
( )COV t
?
 from step (3) and for (ii) 2av
OP∆  and 2avCOP∆  from step (6). 
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4.6. Case Studies 
 
(A) We monitor the partial pressures blood concentrations of O2 and CO2 as: 
 
2 2
0.13AE VBO OC C= = , 2 2 0.18
VE AB
O OC C= = , 2 2 0.525
AE VB
CO COC C= = , 
2 2
0.485VE ABCO COC C= = ; Alveolar ventilation rate (V
?
) = 5litres/min, Blood flow rate in the 
pulmonary vascular bed (Q) = 5 litres/min 
 
 
From equation (26), we obtain: 
0.2 0.230.5ln 30.5ln
0.2 0.130.22
2
32.02                                                                                  (44)
VBPO VBCO
mmHg
⎡ ⎤⎢ ⎥ ⎡ ⎤= =⎢ ⎥ ⎢ ⎥−⎣ ⎦⎢ ⎥−⎢ ⎥⎣ ⎦
=
 
 
From equation (32), we obtain: 
 
: 
 
 
 
 
 
 
We now also monitor Q=5 Litres/min and 5 /V l min=
?
, so that 
*
5 / 50 0.1V = =
?
 (46) 
 
 
Then from equation  (34): 
2
( )OV t
?
=Q ( )2 2AB VBO OC C− , so that from the above data,     
  
2
( )OV t
?
=5000 x 0.05=250 ml of O2/min consumption rate         (47) 
 
From equation (35): 
2
( )COV t
?
=Q ( )2 2VB ABCO COC C− =5000(0.04)  
0.8 0.837.94 ln 37.94ln
0.8 0.5250.82
2
40.51                                                                              (45)
VBPCO VBCCO
mmHg
⎡ ⎤⎢ ⎥ ⎡ ⎤= =⎢ ⎥ ⎢ ⎥−⎣ ⎦⎢ ⎥−⎢ ⎥⎣ ⎦
=
  301
= 200 ml of CO2 /min production rate        (48) 
 
Now, from equation (14): 
For 
*°
= 0.1V  (equation 46) and 2 2 :0.25  ,(equation 47) we obtain
al
O OV l  P
°
=  
2
2
*
4.18
                                                                         140 1
V VO
al
OP e
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
° °−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
(49) 
4.18 0.1 0.25140 1 113.7e mmHg⎡ ⎤⎣ ⎦−= − =⎡ ⎤⎣ ⎦      
From equation (19), for 
*°
= 0.1V  (equation (46)) and 
0.20  (equation 48) , we obtain :
2
V lCO
°
=  
 
[ ]
*
2.19
2
2.19 0.1 0.2107.18 107.18                                                                      
2
V V CO
alP e eCO
⎡ ⎤° °⎢ ⎥− ⎢ ⎥ −⎢ ⎥⎣ ⎦= =
 35.86mmHg=       (50) 
 
Now, we can evaluate the diffusion coefficients: 
 
From equations (42, 44, 47, 49): 
 
( )2 2 2 22 2
2 2
(in / )2
2max
        
( ) ( )
5000(0.18 0.13)
16.84 / min/                            (51)2(113.7 31.2) 0.18
AB VB AB VB
O O O O
O O
O O
V ml minO
al VB0.185 P P mmHgFOav
Q C C Q C C
P P
mlO mmHg
= = ⎛ ⎞−⎜ ⎟⎝ ⎠
− −=
−= =− ×
?
? ?2O
 D
 
 
From equations (43, 48, 45, 50): 
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2 2
(in / )2
( )
2 2
2
5000(0.04)           430.11 / min/          (52)2(40.51 35.86) 0.1
O O
V ml minCO
VB al0.1 P P mmHg
VB ABQ C CCO CO
CO
Pav
mlCO mmHg
= ⎛ ⎞−⎜ ⎟⎝ ⎠
−
=
= =− ×
?
?
DCO2
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(B) Alternately, we derive data from: 
 
(i) the inspired and expired air data analysis (such as that carried out in 
section 2.1-2.3); to compute: 
 
O2 consumption rate  = 283.2ml/min,  
CO2 production rate   = 226.8ml/min, 
2
103.03alOP mmHg=  and 2 38.41
al
COP mmHg=   (53) 
 
and  (ii) venous blood gas analysis: 
 
2
0.13VBOC = , 2 0.548
VB
COC =  
 
Then, as per equation (26), 
2
31.2VBOP mmHg=      (54), 
corresponding to 
2
0.13VBOC = . 
 
For  
2
0.617VBOC = , as per equation (32): 
 
0.8 0.837.94ln 37.94ln
0.8 0.5480.82
2
43.84                                                                                (55)
VBPCO VBCCO
mmHg
⎡ ⎤⎢ ⎥ ⎡ ⎤= =⎢ ⎥ ⎢ ⎥−⎣ ⎦⎢ ⎥−⎢ ⎥⎣ ⎦
=
 
 
We obtain, from air composition analysis, that O2 consumption rate 
( ) 283.3 /
2
V t ml minO =
?
                                             (56) 
and CO2 production rate ( ) 226.8 /
2
V t ml minCO =
?
    (57) 
 
Hence, from equations (55, 42 & 55) with the calculated value of 
2
al
OP  (equation 53) 
and of 
2
VB
OP  (equation (54)), we obtain: 
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2
2
283.2 21.90 / min/                         (58)2(103.03 31.2) 0.18
VO
O
Pav
mlO mmHg
=
= =− ×
?
?
DO2  
 
 
 
Likewise, from equations (43) & (56) along with the calculated values of 
2
al
COP (equation (53)) and 2
VB
COP  (equation (57)), we obtain 
2
2
226.8 417.68 / min/                    (59)2(43.84 38.41) 0.1
VCO
CO
Pav
mlCO mmHg
=
= =− ×
?
?
DCO2  
 
The advantage of this method (B) over (A) is that it does not require monitoring the 
cardiac output, and is hence simpler to implement clinically. 
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4.7 Non-Dimensional Physiological Index 
 
 
O2 consumption rate
CO2 production rate
/ min/O2 consumption rate mlO2/min2
CO2 production rate / min/ mlCO2/min2
417.68 / min2
Checking dimensions:
Example:
mlCO mmHg
mlO mmHg
mlCONDPI
×
× = ×
=
DCO2
DO2
DCO2
DO2
NDPI = 
NDPI = 
/   283.2ml/min
=23.8
21.90 / min/ 226.8ml/min2
  mmHg
mlO mmHg
×
 
 
4.8 Conclusion 
 
We derive expressions for diffusion coefficients 
2O
D and
2COD , in terms of the 
evaluated cardiac-output CO, O2 and CO2 concentrations in arterial and venous blood 
as well as alveolar and blood O2 and CO2 partial-pressures. The coefficients 
2OD and 2COD represent the lung capability to oxygenate the blood. We can then also 
determine the cardiac output, from knowing the concentrations of oxygen and carbon 
dioxide in the arterial and venous bloods. The derived information of 
2O
D and
2COD as 
well as of O2 and CO2 metabolic rates can be of considerable use (including for SARS 
assessment). Finally, the derived NDI can be used to assist clinicians in classifying the 
type of pulmonary diseases and concentrate the precious medical resources on the 
diseased patients.  
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Chapter 5 Modeling of Renal 
Obstructions 
 
 
5.1 Purpose of Renal Scan 
 
A renal scan is a simple way to evaluate the split renal function. Split renal function is 
the relative function of each of the kidneys. The scan can show that one of the kidneys 
is contributing 60% and the other is contributing 40% to the overall renal function. 
 
5.2 Evaluation of Renal Function by Radionuclide 
Methods 
 
Radiopharmaceuticals are used in nephrology and urology to evaluate renal function 
and morphology. The three main categories are: 
(a) those excreted by tubular secretion 
(b) those excreted by glomerular filtration 
(c) those bound in the renal tubules for a sufficiently long time to permit 
cortical anatomical imaging 
 
5.2.1 Radionuclide methods used in nephrourology  
  
Renal scintigraphy offers a rapid, noninvasive means of evaluating suspected urinary 
tract disorders. It provides sensitive indices of relative renal blood flow, glomerular 
filtration, tubular function, and urinary excretion. We can use different 
radiopharmaceuticals a also different method to collect data. From this point of view 
it is very important to clearly know the clinician diagnostic question. This knowledge 
makes possible to choose proper radiopharmaceutical and imaging method to answer 
this question. On the other hand we must take in mind that not all renal scans are 
diagnostic. 
  
  
5.2.1.1 Radiopharmaceuticals 
  
(a) 99mTc DTPA: It has a clearance comparable to insulin and may be used to 
measure glomerular filtration rate.  
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(b) 123I or 131I hippurate: Orthoiodohippurate is cleared similarly to 
paraaminohippuric acid and provides a measure of effective renal plasma flow 
and tubular function. Approximately 60 to 80% of OIH entering the kidneys is 
extracted with each pass. A small percentage is cleared by glomerular 
filtration while the remainder is removed by the tubules. In normal conditions, 
the rate of OIH clearance by the kidneys is dependent of renal blood flow. In 
certain disease states, the extraction fraction may fall and OIH clearance is no 
longer a measure of renal plasma flow. 
  
(c) 99mTc DMSA: It binds to the cortical tubules and is considered to represent 
functioning tubular mass. 99mTc DMSA reaches the tubules via the 
glomerular filtrate as well as tubular extraction from the peritubular 
capillaries. About 50% of the injected dose accumulates in the cortex within 1 
hour of injection and remains in the kidneys for 24 hours.  
  
(d) 99mTc MAG3: It has similar properties as OIH does. The clearance of 
99mTc MAG3 can be used as an independent measure of renal function. The 
clearance of 99mTc MAG3 can be calculated based on the dose injected and a 
single sample of plasma obtained 43 minutes postinjection. The image quality 
of 99mTc MAG3 is superior to that obtained with 99mTc DTPA. 
  
  
(e) 51Cr- EDTA: It is excreted by means of glomerular filtration and so it is used 
for in vitro measurement of glomerular filtration rate. This method is supposed 
to be the most accurate. 
  
5.3 Diagnostic methods: In vivo – non-imaging 
methods 
             
5.3.1 GFR and ERPF measurement 
They are not widely used. They require several plasma samples and their 
measurements. They use several mathematical models to calculate particular 
physiologic parameters. They can assess only global parameters. 
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5.3.2 Radionuclide nephrography 
 
They are still used by some departments. They use scintillation probe to measure 
radioactivity over both kidneys and sometimes also blood clearance. They are very 
simple and are used namely in patient follow-up. They make possible evaluation of 
both kidneys separately. 
  
5.3.3 Imaging methods 
 
They are most often used methods for kidney and urinary tract evaluation. They can 
be divided into two types - static and dynamic imaging. 
  
5.3.4 Static imaging 
 
Renal images are usually obtained 2 to 3 hours following intravenous injection of 
99mTc DMSA. Since rapid loss of tracer does not occur, several views of the kidneys 
ca be obtained, including SPECT imaging. The static renal images obtained provide 
good definition of the cortical outline and, in addition, show the relative distribution 
of functional tissue. The ratio of tracer uptake between kidneys provides a measure of 
divided renal function. 
  
5.3.5 Dynamic imaging 
 
Dynamic imaging is performed most often with 99mTc DTPA or 99mTc MAG3.In 
contrast to DMSA the tracers are rapidly excreted, and thus rapid sequential renal 
imaging must be performed. The images that are obtained provide information 
relating to renal vascularity, renal function and excretion. Following an intravenous 
bolus of these tracers an image obtained for the first 30 seconds provides a so called 
vascular image, with the major blood vessels and perfusion to both kidneys, liver and 
spleen being visualized. The amount of activity at each site reflects the relative 
vascularity. Renal function is assessed at 2 minutes after injection, when there is good 
renal visualization and an image show the relative distribution of function between the 
kidneys. Thereafter, cortical activity rapidly diminishes as the tracer is excreted by 
glomerular filtration or tubular secretion. By 5 minutes activity is normally seen in the 
collecting systems and serial images are obtained up to 20 to 30 minutes which show 
progressive excretion of tracer. If there is any suggestion of obstruction, it is 
important to mobilize the patient and obtain a subsequent image to ensure that there is 
no functional hold-up caused by patient positioning. If the question of obstruction has 
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not been resolved, the study will need to be extended and further images obtained 
following diuretic administration.  
  
  
5.4 Patient positioning 
 
Some clinicians image the patient in a seated or prone position, but most image the 
patient supine with the camera positioned beneath the kidneys. In the supine position 
the kidneys are most likely to be equidistant from the camera, and differences in 
uptake will represent differences in relative function rather than differences in 
attenuation. Imaging the patient in an upright or seated position may interfere with 
measurements of relative function. Occasionally, patients will be imaged in the 
upright or seated position to facilitate drainage of the urine from the renal pelvis when 
the clinical question is obstruction. 
  
  
5.5 The renogram curve 
 
The renogram curve is a time-activity curve describing the transit of any tracer 
through the kidney. The curve is obtained by placing a computer-asserted region of 
interest over the whole kidney or the cortex, obtaining the counts in the renal region 
of interest (ROI) for each period of data acquisition, and plotting these counts as a 
function of time. The renogram curve is often divided into the period of tracer 
appearance, tracer extraction and tracer elimination denoted as phase 1, 2 and 3 
respectively. Tracer appearance describes the period of blood flow beneath the 
detector, tracer extraction is proportional to renal plasma flow or glomerular filtration 
rate according to used tracer. The curve peaks when tracer exits from the kidney at the 
same rate it is entering the kidney.  
 
The kidney is limited in the number of ways it can handle a tracer in response to 
disease; it may accumulate less of the tracer, accumulate it at a slower rate, or 
eliminate it at a slower rate. Tracer kinetics can be altered by disease as well as by the 
level of hydration or dehydration. Proper interpretation of the renogram curve requires 
the clinician to understand what the curve implies in terms of renal function and then 
to relate that functional information to potential disease processes. Nowadays 
mathematical function called deconvolution is also used for renogram curve 
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evaluation. It can better detect renal artery stenosis and distinguish between 
obstruction and nonobstructed pelvic dilation and detect transplant rejection. 
  
  
5.6 Clinical applications 
            
5.6.1 Renal function:  
             
Radionuclide renal imaging with quantitation provides the only non-invasive accurate 
method of measuring the contribution of an individual kideny to overall renal 
function. In addition, the technique can be used to assess the regional distribution of 
function within an individual kidney.  
                        
Main clinical situation for renal function evaluation: 
                        (a) Renal function in urinary tract infection 
                        (b) Renal tubular dysfunction 
                        (c) Renal function with calculi 
                        (d) Renal function after renal stone removal 
             
It is important to specify the parameter being measure (GFR, ERPF, DMSA uptake) 
rather than using the more general term  function. 
  
5.6.1.1 Obstruction 
 
Hydronephrosis, the dilatation of the renal pelvis and collection system, is often due 
to obstruction. Intravenous urography, CT and ultrasound can imply the presence of 
obstruction based on pelvic or ureteral dilatation. If obstruction is present, 
intervention is usually indicated. It is well recognized, however, that the ureters and 
renal pelvices may be dilated in patients who have no obstruction to urine flow; 
dilatation can occur in those with reflux, congenital anomalies, previous obstruction, 
and prior urinary tract surgery.  
 
The diuretic-augmented renogram is used to distinguish between them. It can also be 
used to determine if surgery has been successful in relieving a known obstruction. 
 
Main clinical situation for renal obstruction evaluation: 
                        (a) Measurement of renal function in known obstruction 
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                        (b) Assessment of equivocal obstruction after IVU or ultrasound 
                        (c) Baseline during a period of observation 
                        (d) Preoperative evaluation 
                        (e) Postoperative comparison 
  
5.6.1.2 Reflux nephropathy 
 
Radionuclide studies are routinely used in the management of vesicoureteral reflux 
and can be used to help predict which patients will have spontaneous resolution of 
their reflux. There are two radionuclide techniques for reflux detection. Indirect 
method means intravenous administration of tracer. When the tracer reaches the 
bladder, patient is asked to void. The kidneys, ureters, and bladder are monitored by 
use of a gamma camera and the diagnosis of reflux is based on a singificant increase 
in activity in the upper urinary tract during or after voiding. This indirect method is 
simple, but has several limitations. The second technique is direct cystography. It 
serves as an important role in the management of patients with reflux or suspected 
reflux. Bladder catheterization is needed. The bladder volume at which reflux occurs 
should be noted and may be a useful prognostic factor. 
 
Main clinical situation for reflux evaluation: 
                        (a) Determination of presence or absence of renal scars 
                        (b) Measurement of individual kidney function 
                        (c) Identification of presence or absence of reflux 
   
5.6.1.3 Bacterial infection 
             
Clinical singns of  the bacterial of infection like fever, leukocytosis, bacteriuria are 
not able to distinguish between upper and lower urinary tract infection, but this 
disicion is very important. For this purpose, especially in neonates and infants, static 
renal scintigraphy using 99mTc DMSA is routinely used. It can detect focal 
abnormalities of tubular function before distortion of the normal anatomy occurs. 
  
  
5.6.1.4 Trauma 
 
Scintigraphy is both sensitive and specific for detecting traumatic renal injuries. It can 
rapidly assess perfusion to both kidneys; it has also possibility of detecting active 
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intraperitoneal or retroperitoneal hemorhage. Also excretory function can be 
evaluated in a few minutes. 
  
  
 5.6.1.5 Renal failure 
             
We can classify renal failure from the point of view of scintigraphic findings to 
several categories - obstruction, pre-renal (haemorrhage, hypotension, diarrhoea), 
acute tubular necrosis, parenchymal disease (glomerulonephritis), vascular cause and 
chronic renal failure. 
 
Main scintigraphic features are: 
 
            (a)  In obstruction, dilated calyces can be seen. 
(b) In pre-renal failure, we can see normal blood flow and good uptake, but 
delayed intrarenal transit and minimal excretion. 
(c) In acute tubular necrosis, we can see almost normal blood flow, but absent 
or minimal uptake and no excretion. 
(d) In parenchymal disease, minimal blood flow, poor uptake and poor or 
absent excretion can be seen. 
(e) In vascular disorders the findings are almost the same. 
(f) In chronic renal failure, small kidneys, poor blood flow and little or no 
uptake and excretion can be seen. 
  
5.6.1.6 Space-occupying lesions 
  
Radionuclide scanning has a limited use in investigating renal masses because other 
investigations provide the information necessary for the diagnosis and management of 
these patients. Common lesions: 
 
            (a) Tumour 
            (b) Renal cysts 
            (c) Renal calculus 
            (d) Congenital and ectopic abnormalities 
            (e) Cystic disease 
            (f) Horseshoe kidney 
            (g) Crossed renal ectopia 
            (h) Pelvic kidney 
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5.6.1.7 Vascular disorders and hypertension 
             
A functional agent is often used to evaluate patients with suspected renovascular 
hypertension. For this reason mostly the Captopril-Augmented renography is used. It 
often consists of a baseline scan followed at a later time by oral administration of 25 
to 50 mg of captopril and a repeat renogram 1 to 2 hours after the captopril dose. The 
study is positive if there is a major change in relative uptake or in the washout phase 
of the renogram curve.  
                         
Main clinical situation for this evaluation: 
 
                        (a) Hypertension due to renal artery stenosis 
                        (b) Renal infarction 
                        (c) Before surgery - angioplasty 
  
5.6.1.8 Renal transplant 
  
Technical problems that require prompt intervention include obstruction of the ureter, 
leakage at the ureteral anastomosis and renal artery of renal vein stenosis or occlusion. 
Later problems include renal artery stenosis, cyclosporin toxicity and ureteral 
stricture. When the graft fails to function normally, the clinician must distinguish 
between these various possibilities. 
             
Acute renal vessel occlusion, poor parenchymal function, renal infarction, ureteral 
obstruction and extravasation can be usually detected by renal scintigraphy. Serial 
scan obtained during the first 1 to 2 weeks post-transplantation are useful in 
monitoring recovery from transplantation.  
             
Acute rejection is characterized by decreased blood flow, decreased uptake, prolonged 
intrarenal transit time, decreased excretion and increased renal size. 
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5.6.2 Scrotal imaging 
 
It make possible to distinguish between torsion and epididymitis. It enables surgeon to 
avoid unnecessary surgery. The patient is placed uder the gamma camery supine, 
bolus of 99mTc pertechnetate is injected intravenously and a radionuclide angiogram 
is obtained. The statid images are acquired several minutes thereafter. An area of 
decreased perfusion corresponding to the involved testis indicated a high probability 
of torsion. Normally perfused or hypervascular testis can exclude surgery. 
 
 
5.7 RENOGRAPHY 
 
A renogram is simply a tune-activity curve that provides a graphic representation of 
the uptake and excretion of a radiopharmaceutical by the kidneys. Information is 
displayed from the time of injection to about 20 to 30 minutes after injection. The 
classic renogram curve is obtained using agents that are eliminated by tubular 
secretion, 99mTC-MAG3 and, less commonly, 131I-hippurate. Fortunately, the shapes of 
the renogram curves and the associated data using either agent are essentially identical. 
Technetium 99m-MAG3 is the radiopharmaceutical of choice because it allows the 
simultaneous acquisition of high-quality renal images. Renogram curves are generated 
by placing a region of interest around each kidney, usually the entire kidney, but occa-
sionally just around the renal cortex if a considerable amount of collecting system 
activity is present. Background subtraction regions of interest are selected just inferior 
to each kidney (Figure 5.1). An aortic region of interest may be used to assess the 
discreteness of the injected bolus as well as relative renal perfusion. 
 
The normal computer-generated renogram curve employing a tubular 
radiopharmaceutical consists of three phases (Figure 5.2). Initial renal perfusion, or 
the vascular transit phase, lasts about 30 to 60 seconds and represents the initial 
arrival of the radiopharmaceutical in each kidney. Reconstruction of the first 30 to 60 
seconds of the curve using different axes may be performed to assess more carefully 
the renal perfusion phase. Generally, renal peak activity during the perfusion phase 
equals or exceeds that of the aorta and should be reasonably symmetric between the 
two kidneys. The second phase is the cortical or tubular concentration phase of initial 
parenchyma transit. This phase occurs during minutes 1 through 5 and contains the 
peak of the curve. The initial uptake slope closely correlates with ERPF values. The 
third phase is the clearance or excretion phase, which represents the downslope of the 
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curve and is produced by excretion of the radiopharmaceutical from the kidney and 
clearance from the collecting system. 
 
 
 
Figure 5.1 Typical regions of interest for computer analysis. Outlined regions of 
interest are drawn over the aorta, the kidneys, and the bladder. Areas of background 
activity (Bkd) are also drawn. Time-activity curves are then generated for each of 
these after appropriate background subtraction has been made [64]. 
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Figure 5.2 Typical renogram curves. (A) A schematic drawing demonstrates the 
conceptual portions of the time-activity curve within the kidney. (B) An actual 
renogram shows symmetric activity between right and left kidney, rapid dropoff after 
the peak, and a long tail extending to the right. The curve also shows increasing 
activity within the bladder after about 4 minutes [64]. 
 
Overall, the renogram curves for each kidney should be reasonably symmetric, al-
though slight asymmetries are not unusual. The shapes of curves should also be 
inspected individually for alterations in the normal configuration. Semiquantitative 
indices derived from the curves may be helpful in this respect. Data commonly 
derived from the 99mTc-MAG3 and radioiodinated iodohippurate sodium renograms 
include the following: 
 
(a) Time to peak activity. Normal is about 3 to 5 minutes. 
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(b) Relative renal uptake ratios at 2 to 3minutes. This is an index of relative renal 
unction. Activity in each kidney should be equal, ideally 50%. A value of 40% 
or less in one kidney should be considered abnormal. 
(c) Half-time excretion is the time for half of the peak activity to be cleared from 
the kidney. Normal is about 7 to 10 minutes. 
 
(d) Differential cortical retention at 15 minutes. The percentage of retained 
activity about 15 minutes after injection in each kidney should be relatively 
equal. Differences of 20% or more should be considered abnormal. 
 
(e) The 20-minute maximal count ratio. This is the activity measured in each 
kidney at 20 minutes expressed as a percentage of peak curve activity. As 
renal function deteriorates, delayed transit of the radiopharmaceutical in the 
kidney results in an abnormal renogram curve, which can be quantitated using 
this index. In the absence of pelvic calyceal retention, a normal 20-minute 
maximal cortical ratio for 99mTc-MAG3 or 131I-hippurate is less than 0.3. 
 
Patients should be well hydrated when renography is performed because in the pres-
ence of dehydration, an abnormal renogram curve demonstrating delayed peak 
activity, delayed radiopharmaceutical clearance, or an elevation of the excretion slope 
may result. 
 
5.7.1 QUANTITATION OF RENAL FUNCTION 
 
Quantitative assessment of renal function using radionuclide techniques is an 
important part of nuclear nephrology. Because up to half of renal function, including 
Glomerular Filtration Rate (GFR), may be lost before serum creatinine levels become 
abnormal, direct measurement of GFR and ERPF (Effective Renal Plasma Flow) 
using radiopharmaceuticals plays an important role in the assessment of renal function. 
 
The classic measures of renal function involve the ability of the kidneys to clear cer-
tain substances from the plasma. These so-called clearances are expressed as volume 
of plasma cleared of a particular substance per minute (mL/min) as the plasma passes 
through the kidneys. The significance of the clearance depends on the substance em-
ployed. The clearance of inulin, which is entirely filtered, defines the GFR; and the 
clearance of para-aminohippurate (PAH), which is both filtered and secreted by the 
tubules, defines renal plasma flow. The radiopharmaceutical analogs for calculation of 
these clearances are the totally filtered 99mTc-DTPA for inulin clearance and GFR 
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estimation, and 1311 0TH and ~mTc MAG3, which are primarily secreted by the 
tubules, with some filtration, for PAH clearance and ERPF. The latter index is termed 
effective because the radiopharmaceuticals used closely estimate but do not equal the 
PAH clearance. 
 
Two dominant radionuclide methods of determining GFR and ERPF are employed:  
 
(a) Plasma sample-based clearances, which are more tedious but more accurate; 
and 
(b) Camera-based clearances, which do not require sampling of plasma or urine. 
 
5.7.1.1 Plasma Sample-Based Clearances 
 
These measurements are generally obtained by determining the plasma levels of the 
injected radiopharmaceutical at a specified time, although some techniques require 
urine collection as well. For tubular agents such as 131I-OTH and 99mTc-MAG3, 
effective renal plasma flow can be estimated by a single, timed blood sample obtained 
about 45 minutes after injection. Because the glomerular agent 9 Tc DTPA is cleared 
more slowly than tubular agents, plasma samples are obtained 60 and 180 minutes 
after injection. The amount of activity remaining in the blood at these times is a 
measurement of activity not yet cleared by the renal mechanism and therefore is indi-
rectly a measure of activity already cleared. These techniques require meticulous 
attention to detail and must employ personnel expertly trained in in vitro techniques. 
When performed correctly, GFR and ERPF measurements are theoretically more 
accurate than those based on camera measurements. 
 
5.7.1.2 Camera-Based Clearances. 
 
State-of-the-art gamma cameras and computers have allowed the development of 
methods for estimating GFR and ERPF without collecting blood or urine samples. 
Commonly, calculations are made using counts acquired from the syringe containing 
the radiopharmaceutical before injection and subsequent counts over the kidneys after 
injection. Commercially available software for camera-based clearances simplifies 
corrections for patient and acquisition variables and provides reasonably accurate 
computer-derived clearance values. Although camera-based clearances are not as 
accurate as those based on plasma samples, they are highly reproducible and 
sufficiently reliable to be employed in clinical practice. 
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5.8 SCINTIGRAPHIC PROCEDURE  
 
5.8.1 Patient positioning 
 
Renography is performed on patients in either supine or sitting position. When supine, 
the patient is less likely to move and the difference in kidney depth is minimized. 
Moreover, the risk of fainting is negligible [1, 3, 5, 9]. However, patients with a 
severely dilated upper urinary tract will show disability of ureteric peristalsis to 
transport urine from the renal pelvis to the bladder, resulting in impaired emptying of 
the renal pelvis in supine position. Therefore, in many centers diuresis renography is 
performed in sitting position, so that gravity facilitates optimal drainage of the 
collecting system [5, 10].Alternatively, if diuresis renography is performed in supine 
position, postvoid images should be obtained at the conclusion of the study at all 
times." Another advantage of the sitting position is the induction of position-
dependent urinary tract obstruction, which can be observed in severe nephroptosis 
(Figure 5.3). This condition, however, is very rare. 
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Figure 5.3 Position-dependent urinary tract obstruction.  A 33 – year old female with 
low back pain. (A) On the diuresis renogram (F-15 protocol) performed in a supine 
position, the time to peak of the right kidney is slightly longer than that of the left, 
while the excretion phase of both curves follows a symmetrical course. (B) The study 
performed in sitting position (F-15 protocol), however, demonstrated a right sided 
obstruction. Several  minutes after turning into supine position, prompt excretion tool 
place. (C) The images obtained during study (B). In the second minute both kidneys 
are visualized with the same intensity. The right kidney is somewhat larger than the 
left and shows less radioactivity in the medial part because of the enlarged renal 
pelvis. Obvious retention in the right kidney, mainly in the renal cortex, was observed 
at the 20th minute during the study in the sitting position. Three minutes after turing 
into supine position, the renal pelvis is filled with radioactivity and there is excretion 
in the ureters [65]. 
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5.8.2 Data acquisition in standard renography 
 
In patients with native kidneys, imaging should be performed posteriorly. If the 
Patlak-Rutland method of deconvolution analysis is applied, the heart should be 
included within the field of view of the camera. In renal transplant patients the 
detector should be placed anteriorly. With 99mTc-labeled compounds, a LEAP 
collimator is suitable. The LEAP collimator is also suitable for 123I-OIH, but a special 
collimator for the 159 keV energy will reduce scattering, resulting in better images. In 
the literature the duration of the study varies between 20 and 40 min [?, ?, 8, 10], a 
study length of 20 min is usually sufficient, as it is for diuresis renography if 
frusemide is administered before renography [11, 13-15]. 
 
RPI should only be performed when indicated. When not performing RPI, digital data 
acquisition of the whole study can be accomplished in a frame mode with constant 
frame time. In literature, the frame time used for this purpose varies between 10 and 
30s. Using a large field-of-view camera, matrices of 128 x128 are recommended [?, 2, 
102, 5, 10, 12].  In infants, Conway59 recommends zoom mode for easy ROI 
assignment. 
 
5.8.3 Sequential and delayed images 
 
Most centers perform 3-5 min sequential images during renography. In our experience 
it is essential to make 1 min images in the first 10 min of the study. The appearance in 
the renal pelvis or ureter can be determined on these images, which is essential for a 
correct interpretation of the study [11, 13, 15]. For an easier identification of the start 
of tracer excretion into the renal pelvis, contrast enhancement is obtained by 
truncating the file of 1 min images with a number corresponding to 1.25 times the 
maximum count within the third minute frame (Figure 5.7). 
 
In children it is fairly easy to include kidneys, ureters and bladder simultaneously in 
the field of view of a large-field gamma camera. However, in adults this is often 
impossible. To achieve this, we routinely perform a scintigram including the bladder 
at the end of the study. If there is significant retention of activity in the upper tract, a 
post-micturition image should be obtained [4, 16]. As advocated by Rossleigh et a1 
[17], babies and sedated children are kept in an upright position for 10-15 min before 
acquiring an image. A dilated non-obstructive system can thereby be differentiated 
from an obstructive system. In cases of severe obstruction in which excretion is 
 323
seriously impeded, a delayed image may help to localize the abnormality [8, 13-14]. 
Urine leakage, in which tracer excretion starts on time, can also be diagnosed on the 
late image. 
5.9 PROCESSING AND ANALYSIS OF THE 
STUDY 
 
5.9.1 Relative renal function 
 
The relative renal function or left-to-right ratio is important for the management of 
patients with renal disease, in particular those with unilateral renal pathology. Care 
should be exercised in interpreting changes of relative function in patients with 
bilateral disease. Any of the already mentioned radiopharmaceuticals can provide this 
information. Reproducibility of the results is the most important aspect from the 
clinical point of view, since it allows a longitudinal study in patients to see whether 
there is a significant change in renal function [?, 5, 6, 8, 9, 10, 83, 19]. 
 
The measurement is frequently assessed in the follow-up on children with unilateral 
pathology of the upper urinary tract. It is also important for the interpretation of 
renography after ACE inhibition, in particular if DTPA is used. In unilateral renal 
artery stenosis the relative uptake of the affected kidney is almost always decreased 
and will show a further deterioration after ACE inhibition [102, 20-22]. 
 
Initially the consensus report only recommended the application of the integral 
method owing to its simplicity, reproducibility and accuracy; however, in the latest 
report the Rutland-Patlak method is also recommended. As recommended by the 
consensus report, relative uptake should be measured between 1 and 2 or 2.5 min after 
injection. Both time points have been chosen after the consideration that the first point 
should not be chosen too early for it would be reflecting arterial flow and the last 
point should be selected before significant escape of tracer out of the renal ROIs [3, 
23-24]. 
 
In a recent study reproducibility and accuracy of the abovementioned two methods 
and the normalized slope method were compared with DMSA uptake. Reproducibility 
was excellent for the integral and the Rutland-Patlak methods. For the normalized 
slope method, however, differences between successive tests were as great as 10%. 
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Also, the accuracy of the integral and Rutland-Patlak methods was comparable, 
whereas the normalized slope method was less accurate. 
 
The Rutland-Patlak method, in which double background correction is applied, has 
mainly been developed to estimate single kidney GFR from DTPA studies. For DTPA 
renal extraction is about 20%, resulting in high background counts which represent 
50-80% of non-corrected kidney counts. Although this method is robust and accurate, 
its implementation in commercial software is still limited [3]. 
 
5.9.2 ROI assignment 
 
Reproducibility and accuracy of measurement depend on the size of kidney ROI and 
the placing of background ROI (BG ROI). To overcome interobserver variability in 
drawing the ROIs, effort was made to standardize the ROI assignment and to develop 
a computer program for automated ROI selection for both kidneys and BG. Indeed, 
employing such a program, Der Kinderen et al [25] obtained a high degree of 
reproducibility of the left-to-right ratio using 131I-OIH (which already has low BG 
activity). A high degree of accuracy was also obtained by Granerus & Moonen [26] in 
their DTPA study in which the kidney ROIs were drawn manually and the BG ROI of 
each kidney was automatically determined by the computer. A similar software 
program was applied by Taylor et a131 for processing their MAG3 data. Recently 
several methods for automated ROI assignment have been published [18, 27-30]. 
 
Although the choice of ROI method is important for camera based clearance 
measurements, especially in terms of reproducibility and accuracy, for relative renal 
function these different ROI methods probably perform equally well, at least as long 
as renal function is not severely decreased [3]. 
 
5.9.3 Background correction 
 
Renal BG consists of extrarenal and intrarenal components. The extrarenal 
components are often called interstitial, but actually include an intra- and an 
extravascular part. Within the first minutes after injection, activity in the intravascular 
part is rapidly falling, while extravascular Cinterstitial) activity is slowly increasing. 
Depending on the placement of the extrarenal BG ROI, several vascular structures 
(liver, spleen, abdominal vessels) are included. The extrarenal BG curve is an integral 
of the two components within the ROI and will show a plateau or decrease with time 
[28, 27-30]. 
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If only one BG ROI is used, a suprarenal BG ROI including large areas of liver and 
spleen will overestimate the intravascular intrarenal component and underestimate the 
extrarenal/interstitial part, resulting in underestimation of kidney uptake. Conversely, 
a BG ROI below the kidney is presumed to correctly present the extrarenal/interstitial 
part but underestimates the intravascularl intrarenal component. This will result in 
overestimation of renal uptake [23, 31]. 
 
In conclusion, to measure the true renal uptake, data obtained during renography must 
be corrected for radioactivity in extrarenal tissue and intravascular activity within the 
kidney. However, the complicated double background correction method is only 
necessary in estimation of camera-based renal clearance. To measure left-to-right 
ratio the consensus reports recommended a simple ring, elliptical or perirenal BG ROI, 
because such a BG ROI which incorporates a bit of liver or spleen is representative of 
intravascular radioactivity [1, 3, 86, 31]. The accuracy of perirenal BG was 
demonstrated by obtaining the zero function at a nephrectomized site in studies using 
DTPA80'8' and MAG3 [23].To avoid side-scattering, the BG ROI should be slightly 
separated from the kidney ROI. Before subtracting, the BG ROI counts should be 
area-normalized to the kidney ROI [3]. 
 
In azotemic patients, due to elevated background activity and low renal concentration 
of radiotracer, measurement of relative renal function on the renographic data 
between 1-2 min can be misleading. In such patients with delayed excretion, more 
accurate assessment of relative function can be achieved using delayed images before 
excretion of tracer occurs [32]. 
 
5.9.4 Renal depth correction 
 
Determination of renal depth for correction of attenuation by tissue between the 
kidney and the camera is only mandatory if camera based renal clearance is to be 
measured. For estimation of the left to-right ratio, this correction is not necessary as 
in the majority the difference in renal depth between the left and right kidney is less 
than 2 cm. 
 
Among 150 adults studied by Gruenewald et al [33] in the seated position using 
ultrasound, 66% showed a depth difference of less than 1 cm, in 21% the difference 
was between 1 and 2 cm and in the remaining 13% the difference was greater than 2 
cm. Taylor et al [34], who investigated the patients in supine position using CT scan, 
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observed in only three of the 201 adults a difference of more than 2 cm. These 
studies were in accordance with previous studies using renal scintigraphy obtained in 
lateral view [35-37]. Large differences of up to 7 cm were only found in patients with 
lumbar kyphoscoliosis or with an ectopic kidney. In these patients correction of renal 
depth is necessary. This can be achieved by performing a lateral projection scan, 
ultrasound or by calculating the geometric mean from DMSA study or during 
scintirenography with a dual-headed camera [5, 36-39]. 
 
Effective attenuation of 99mTc measured using a renal phantom in a waterbath was 
approximately 0.14 cm-1. Thus, if a 99mTc-labeled compound is used, a difference in 
depth of 1 cm will change a true left-to-right ratio of 50:50 to approximately 53:47; a 
difference of 2 cm will change the ratio to 57:43. Therefore, if depth correction is not 
applied, a range between 43% and 57% should be regarded as normal [32, 38]. 
 
5.9.5 Excretory function 
 
To characterize the pattern of the renographic curve and for objective comparison 
between studies performed successively, numerical parameters were introduced early 
in the 1960s; before this, examination was performed with a gamma camera. Figure 
5.2 shows the most popular parameters derived from a renogram to evaluate the 
excretory function: the time to peak (Tp), the t1/2, and the residual cortical activity [40-
42]. The residual cortical activity is the ratio of counts at 20 min and peak counts, and 
is a recommended parameter for evaluation studies after ACE inhibition [102, 21]. 
Table 108.2 shows normal values obtained with MAG3 in normal volunteers aged 
between 23 and 72 years [41]. Gault et al [44] have demonstrated that the t½, obtained 
from an OTH study correlates with serum creatinine. This correlation was also 
observed in MAG3 renograms [95]. Thus, the t1/2, is not a pure reflection of excretory 
function, but depends on renal clearance as well. 
As mentioned earlier in this chapter, the Tp and the decrease in the third phase depend 
on the transit time of the initial bolus and the further transport of urine leaving the 
collecting system. The background-corrected renogram obtained with the gamma 
camera, in which kidney ROIs include the renal pelvis (the so-called "whole kidney 
curve"), reflects the radioactivity within the renal parenchyma and pelvicalyceal 
system. If there is no pooling of tracer in the renal pelvis, Tp equals the transit time. 
To exclude tracer in the renal pelvis, parameters can be determined on cortical 
renograms using parenchyma) ROIs that exclude any activity in the calyces or pelvis. 
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Cortical renograms are especially important in patients with dilated pelvicaliceal 
systems (see Figure 5.5). The parenchyma ROIs can be drawn either manually or 
automatically using factor analysis [30, 45]. Generating both whole-kidney curves and 
cortical curves is recommended [102, 9]. 
 
Figure 5.4 A typical renogram curve. Parameters frequently used for evaluation of 
the excretory function are time to peak (a), time to half peak (b) and the residual 
cortical activity (d/c) [65]. 
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Figure 5.5 Scintirenography in dilated non-obstructive left renal and ureter. (A) 
Sequential images (0-8 minutes) obtained during diuresis renography (F-15 protocol) 
from a 7-year girl with severely dilated left renal pelvis and ureter due to reflex. 
Reimplantation of the left ureter performed 6 years before. In the 2nd min the dilated 
left renal pelvis is visualized as photon-deficient area. Excretion in both renal pelvis 
and ureters is clearly visualized in the 4th min. The dilated renal pelvis is immediately 
fully filled with tracer. (B) Retention in left renal pelvis and ureter diminished clearly 
after micturition. (C) Whole kidney-curve of the left-kidney (L) shows an obstructive 
pattern. (D) The cortical curve nevertheless demonstrates a normal time to peak 
followed by a sharp decline. For easier recognition of whether the decline is 
symmetrical or not, the curves of the left and right kidney are plotted with the same 
peak curve [65]. 
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 Table 5.1 MAG3 renogram parameters (mean ±  SD) obtained in healthy Volunteer 
(Adapted from [76]). 
 
 N Left Right 
Percent of total clearance 36 49.4 ± 3.9 50.6 ± 3.9 
Peak Time    
    Renal ROI (min)* 36 3.3 ± 2.0 3.8 ± 2.3 
    Cortical ROI (min) 23 2.5 ± 0.2 2.5 ± 0.4 
Half-time    
     Renal ROI (min) 36 5.5 ± 1.6 6.4 ± 3.5 
     Cortical ROI (min) 23 5.0 ± 1.5 5.5 ± 2.0 
*Difference between these two results is statistically significant (P < 0.05). 
 
Tubular transit parameters have been considered useful but have not been addressed 
in the consensus report for two main reasons. First, tubular flow rate is not a specific 
function but rather a composite parameter depending on multiple factors (input 
function, extracellular volume, salt intake, hydration status, downstream pressure in 
the pelvicalyceal system). Second, the real value of mean parenchyma) transit time 
has not been properly evaluated due to the absence of a standardized protocol for 
deconvolution analysis [3, 46-49]. 
 
Although to date in most publications interpretation is still based mainly on the 
pattern of the curves or the changes of numerical parameters, in our opinion 
evaluation of the sequential and delayed images obtained during renography is an 
important part of interpreting the study. In a normal study (Figure 5.7) there is a 
practically symmetrical appearance of the kidneys. In the second minute there is a 
good delineation of the renal cortex. Appearance of activity in the collecting system 
and renal pelves begins in the third or fourth minute. Shortly thereafter the activity 
will reach the ureter and the bladder. If diuresis is voluminous, e.g. after frusemide 
administration, radioactivity in the renal pelves and ureter may be only vaguely 
visible. 
 
The abnormal third phase of the whole-kidney curve in patients with dilated non-
obstructive pelvicaliceal systems is a well-known phenomenon and has led to the 
introduction of diuresis renography. However, despite stimulation of diuresis by 
frusemide the wholekidney curve can be misleading (see Figure 5.5). Differentiation 
between obstructive and non-obstructive cases can then be done by reviewing the 1-
 330
min images. In case of obstruction the dilated pelvicaliceal system is filled with tracer 
slowly, whereas a nonobstructive system is filled on time (Figure 5.6). As shown in 
this figure, the left kidney, with only moderate partial obstruction, also shows a 
delayed filling of the renal pelvis. The interobserver reproducibility of the 
interpretation by the images is acceptable [50]. 
 
For the interpretation of studies obtained in renal transplant patients several excretion 
parameters are applied. In practice, two parameters are applied: the tubular transit 
index and bladder appearance time [14, 51]. Normally the bladder appearance time 
ranges between 120 and 180 s. These values are nearly identical to those of the renal 
transit time calculated from other techniques. In patients with stable renal function 
both parameters are not correlated with serum creatinine levels. The bladder 
appearance time, which is determined during frusemide-stimulated diuresis, is 
obviously prolonged in various parenchyma) diseases and also in partial urinary tract 
obstruction [67]. In partial obstruction, a prolonged bladder appearance time is 
observed before the onset of renal function deterioration; in these cases GFR may 
remain normal for a long period due to the balancing influence of intrarenal 
vasoactive substances [52-54]. 
 
To date, there is little agreement as to what differentiates mild from moderate or 
severe partial obstruction. It has not been proven that the more complex parameters in 
the analysis of transit time impairment improve on the information already provided 
by simple parameters. Techniques which assess drainage relative to kidney uptake 
function, such as renal output efficiency [55], pelvic excretion efficiency [56], and 
normalized residual activity [57], require further investigation [4]. 
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Figure 5.6  Scintirenography in moderate and severe PUJ-stenosis; a 20-month-old 
girl with bilateral stenosis. On ultrasonography the renal length is 7.2 cm on the left 
and 8.6 cm on the right. The volume of the left renal pelvis is 7ml, on the right it is 16 
ml.  Cortical thickness is 6 mm on the left, 3-4 mm on the right (data not shown). After 
pyeloplasty on the right side the kidney has become smaller, although the renal pelvis 
is still dilated and has a volume of 6.5ml. Serum creatinine was normal (29mmol/L) 
and remained unchanged after surgery. (A) Sequential images (0-8 min) obtained 
during diuresis renography (F-15). Zoom 1.6. (B) Images at the end of the study and 
postmicturition image of study (A) [65]. 
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Figure 5.6 (C) Whole-kidney renograms of study (A). (D) Images obtained after right-
sided pyeloplasty. (E) Images at the end of  the study and postmicturition image of 
study (D). The whole-kidney curves in (C) and (F) are plotted with the same peak 
height [65]. 
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Fgure 5.6 (F) Whole kidney renograms of study (D). In the 2nd and 3rd min the dilated 
renal pelvis on both sides are visualized as photo-deficient area. L/R ratio: 55:45. 
The left renal pelvis, with moderate partial obstruction, is fully filled in the 9th min 
(see A), the curve of the left kidney (L) shows a decrease around that time (see C). 
The right kidney, with severe obstruction, shows slower filling of the renal pelvis. The 
right renal pelvis is fully filled only after keeping the child on an upright position (see 
B). The right renal curve (R) shows an accumulation curve (see C). After pyeloplasty 
the right renal pelvis is promptly filled with tracer (see D), whereas the left renal 
pelvis will show slow filling as in the previous study. The whole right kidney 
renogram (R) reaches a maximum around the 5th min followed by a photo-deficient 
area seen in the 2nd min is disappearing. It is fully filled with tracer by the 6th min, at 
which time the right renal curve (R) reaches a plateau. Although the whole-kidney 
curve is still abnormal, the images clearly demonstrate a normalization of excretory 
function. The left kidney (L) with moderate partial obstruction shows a pattern 
identical to the previous study. The L/R ratio is unchanged [65]. 
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Figure 5.7 A normal standard scintirenography. (A) Sequential images obtained in 
the first 8 min in an adult without renal pathology. Study performed with Prism 2000 
XP (Picker) equipped with high-resolution collimator, matrix 128 x 128. Injected 
dose was 74 MBq 99mTc-MAG3. Maximum count in the 3rd min was 123; thus the file 
of 1-min images was truncated with 153. There is a symmetrical appearance of both 
kidneys. The start of excretion in both renal pelvis (4th min) is visualized clearly. 
Thereafter the upper part of the ureters can be identified easily. (B) An image at the 
end of the study and postmicturition image including the bladder. (C) Whole-kidney 
renal curves; R=Right kidney. (D) Cortical curves show shorter times to peak and 
steeper decline than the whole-kidney curves. For easier recognition of whether the 
decline is symmetrical or not, the curves of the left and right kidneys are plotted with 
the same peak height [65]. 
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5.10 RENAL CORTICAL SCINTIGRAPHY 
CLINICAL INDICATIONS 
To date the most important indication for performing renal cortical scintigraphy (RCS) 
is the detection of scarring related to upper urinary tract infection. This modality is 
also sensitive to detect lesions due to acute pyelonephritis. Similar lesions can be 
found in renal abscess, cyst, duplex kidney; hydronephrosis and the combination of 
ultrasound and RCS allows better differentiation between these. Occasioanlly this 
method is applied in searching ectopic kidneys and imaging functional renal 
parenchyma in horseshoe, multicystic, duplex and dyplastic kidneys [101, 17, 10, 91- 
102]. 
 
Figure 5.8 (A) Six consecutive reoriented sagittal sections and (B) three-
dimensional display showing a linear area of absent tracer uptake from the left renal 
hilum into the parenchyma, with an interruption of the rim of cortical uptake. This 
interruption of the rim of renal cortical uptake was best seen on the reoriented 
sagittal display and on the threedimensional surface shade display. (Reproduced 
with permission from de Sadeleer et al [59]) 
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Figure 5.9 (A) Non-reoriented corona) slices and (B) reoriented corona) 
tomographic section. Cortical rim at the right upper pole with decreased uptake 
compared to the lower pole. Quantitative evaluation of the maximal upper and lower 
pole activity revealed differences between the two poles as high as 35%. These 
hypoactive upper poles were also clearly seen on the three-dimensional surface shade 
images (data not shown). (Reproduced with permission from de Sadeleer et al [166]). 
 
(a) An interruption of the normal cortical contour between two prominent 
columns of Bertin (Figure 5.10);  
 
(b) A cortical defect due to the interrenuncular septum described by Rossleigh, 
which less frequently seen in children under the age of [17, 167, 170] (Figure 
5.8); 
 
(c) Hypoactive upper poles (Figure 5.9), probably caused by attenuation from the 
liver or the spleen [171, 172]. 
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Figure 5.10 (A) Normal planar views (posterior, posterior with magnification, right 
posterior oblique, left posterior oblique). (B) Two consecutive non-reoriented 
coronal slices; the left kidney is on the right side of the image. (C) Reoriented 
coronal topographic section; (D) three-dimensional display. A definite focal defect is 
demonstrated on the posterosuperior side of the left kidney on the different displays of 
the SPECT study. It can best be identified on the coronal slices without reorientation, 
but also on the three reoriented images and even on the three-dimensional surface 
shade display [59]. 
 338
5.11 Literature Review on Measurement of 
Glomerular Filtration Rates (GFRs) 
 
The introduction of radionuclides and their use in monitoring renal function has made 
serial measurements of Glomerular Filtration Rates (GFRs) and Effective Renal 
Plasma Flow (ERPF) less time consuming and less demanding to both the patient and 
the technologist. GFR is the clearance rate of a substance that is excreted from the 
body by glomerular filtration and is not secreted or reabsorbed by the tubules. Ideally, 
this substance is not protein bound, does not enter RBCs, and is not changed in the 
process (44). Assuming the substance is cleared solely by glomerular filtration, this 
rate can be inferred by observing the rate of disappearance of the substance from the 
blood, the rate of appearance of the substance in the urine, or the amount of uptake of 
the substance in the kidneys. The methods in the nuclear medicine department 
capitalize on either measuring the activity in the urine, in the blood, or, by using the 
gamma camera, in the kidneys. Although gamma-camera or external probe techniques 
provide differential function and avoid urine and blood sampling, correction for 
attenuation by overlying liver and spleen must be addressed [68]. 
 
Classically, GFR is the urinary clearance of inulin after a steady state is achieved by a 
continuous intravenous infusion. GFR is then calculated according to the following 
formula. 
 
Clearance = UV/P 
 
where   U :  urine inulin concentration in mg/ml; 
 V : urinary flow rate in ml/min; and 
 P : plasma inulin concentration in mg/ml. 
 
 This method requires both continuous infusion and urine sampling [67]. 
 
To measure GFR an agent must be excreted entirely by glomerular filtration and not 
be protein bound. The prototype is inulin. The clearance of 5'CN 
ethylenediaminetetraacetic acid (EDTA) is equivalent to inulin and has been reported 
to be the most accurate radio-labeled measure of GFR [69]. 131I-labeled iothalamate 
has been used instead of 51 Cr-EDTA in the but has the disadvantage of high radiation 
doses. More recently, 99mTc-DTPA has been employed to measure GFR. Because the 
clearance of 99mTc-DTPA is 5% less than that of inulin, 99mTc-DTPA underestimates 
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the true GFR [70]. This is acceptable clinically because creatinine clearance has an 
error of 10% to 15%. The low radiation dose, low expense, and opportunity for renal 
imaging make 99mTc-DTPA the agent of choice for the measurement of GFR [48]. 
 
The inconvenience of urine collection can be circumvented when the renal clearance 
can be extrapolated to infinite time. This can be accomplished only when the agent is 
excreted solely by glomerular filtration, the renal function is not too low, and the 
patient is not too edematous. When these criteria are met, the plasma clearance can be 
estimated from one or two plasma samples and the complete clearance curve need not 
be obtained. This avoids the obvious pitfall of urine collection errors and the need for 
multiple blood samples. In some instances, blood samples are avoided by using the 
gamma-camera detectors. The gamma-camera techniques do not require urine or 
blood samples and are faster than creatinine clearance. An additional advantage to the 
gamma-camera technique over the standard plasma methods is that differential 
function can be calculated [69]. 
 
The two methods of radionuclide administration for GFR measurements are 
continuous infusion and single bolus injection. Clinically, the single injection 
technique has been routinely used. The principle of the continuous infusion method is 
that once equilibrium is established, the rate of disappearance of the tracer via 
glomerular filtration is equivalent to the rate of infusion. The rate of infusion can then 
be substituted for UV in the clearance equation. One potential source of error in the 
continuous infusion method is the buildup of 99mTc-DTPA metabolites that are cleared 
at a slower rate than 99mTc-DTPA. This may artificially overestimate the plasma 
concentration of tracer and therefore underestimate clearance [67]. 
 
The most convenient, least demanding method of measuring GFR is by measuring the 
plasma clearance after single bolus injection. Clearance can be calculated according to 
injected dose 
injected doseclearance = 
area under plasma concentration curve
                =  
( ) 
D
P t dt∫
 
 
The most accurate model of excretion of a GFR tracer is a dual-compartment model 
that follows a biexponential curve. The initial phase of the curve is rapid and 
represents the redistribution of tracer into the extracellular space. The second portion 
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of the curve is much slower and represents elimination of the tracer by glomerular 
filtration once distribution in the extracellular space is complete (Figure 5.11). 
 
 
 
 
Figure 5.11 The dual-compartment elimination curve of a glomerular filtration rate 
agent. 1 represents the rapid distribution into the extracellular or intravascular space. 
2 represents the elimination of the tracer via glomerular filtration. [66]. 
 
The area under the plasma concentration curve is the sum of these two components. 
 
2( ) aIt a tP t Ae Be− −= +  
 
To accurately represent activity in the two compartments, a complete plasma 
clearance curve must be obtained. This requires blood samples from 5 minutes up to 5 
hours. If plasma samples are obtained before distribution in the extracellular fluid, the 
area under the curve will be underestimated and the clearance subsequently 
overestimated [67]. 
 
A simplified method of measuring GFR by the single injection technique is to obtain 
plasma samples 2, 3, and 4 hours after injection. At this time, equilibration with the 
extracellular fluid (ECF) will be complete. By using this method, often referred to as 
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the slope intercept method, the initial fast component of the plasma concentration 
curve will be disregarded and will, therefore, provide GFR values greater than the true 
GFR. The amount of this error is greatly reduced in patients with poor renal function 
[69]. 
 
Waller et al. [72] used a reference GFR by obtaining half hour blood samples and 
corrected the GFR for the single compartment model and for body surface area. This 
group found the closest correlation to the reference GFR when two blood samples at 2 
hours and 4 hours were obtained. The standard error of GFR estimate was 2.8 
mL/minute. The least accurate measure was the external detector method where the 
standard error was greater than 10 mL/minute. 
 
There has been an alternate method of GFR measurement reported that accounts for 
thee volume of distribution. GFR can be calculated from the product of the rate 
constant of the exponential clearance and the volume of distribution of activity. The 
volume of distribution of activity is calculated from the estimated activity per unit 
volume assuming dilution had occurred instantaneously. A correction factor is applied 
to account for the activity already cleared by the kidneys during the distribution phase. 
Without this factor, the volume of distribution would be overestimated [72]. Fawdry 
and Gruenewald [73] studied 800 GFR studies obtained by the standard two-sample 
slope intercept method and compared these to a 3-hour volume of distribution method. 
They found that the accuracy of the volume of distribution method was greatest when 
the GFR was between 60 to 100 mL/minute. 
 
Mulligan et al. [74] examined several methods of measuring GFR with 99mTc-DTPA. 
As stated previously, GFR can be calculated from the activity in single or multiple 
blood samples, from the accumulation of radioactivity in the urine, or from counts 
obtained solely from the gamma-camera. Mulligan et al. found that the two plasma 
sample technique of Russell and the urinary sample technique developed by Jackson 
were the most accurate methods over a large range of renal function. The Russell 
method involves obtaining blood samples at either 30 and 180 minutes or at 60 and 
180 minutes and applying this data to the linear dual-compartment model of 
Sapirstein that follows: 
 
0 0
0 0
1 20
1 2
Q QGFR C C
Pdt λ λ
∞≅ = +∫
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where 0Q  : the injected dose; 
 
0
Pdt
∞∫ : dual-exponential integration of six-point plasma disappearance curve 
by curve stripping;  
 01C , 02C  : the value of the monoexponential compartment curves of the dual-
exponential disappearance curve at time 0, and  
 1λ , 2λ : rate constants of the two monoexponential compartment curves. 
 
For the 30- and 180-minute Russell [11] sample method, the GFR was calculated thus 
 
( ) 180 30 0.97930ln 180ln0 30 180 150ln /
150
P PQ P P
GFR e
−⎡ ⎤= ×⎢ ⎥⎣ ⎦
 
where 0Q : the injected dose and 
30 180,  P P  are the activities of plasma samples drawn at 30- and 180-minute. 
 
In the Jackson urinary method, the GFR is calculated from the terminal slope of a 
plasma disappearance curve. The initial portion of this curve was obtained by 
externally measuring the blood pool activity in the heart and extrapolating this data to 
the postvoid bladder image. The total urinary activity was corrected for unexcreted 
residual bladder activity and the GFR calculated thus. 
 
( )...
0
T
TUA TUAGFR
P tPdt
≅ =
∫
 
where TUA :  the total urinary activity corrected for residual volume; 
 
0
T
Pdt∫ : portion of 
0
Pdt
∞∫  from 0 to T;  
 T  :  the time of postvoid bladder image; and  
 ( )...P t  : mean plasma activity. 
 
This method was found to be as accurate as the two-sample plasma method discussed 
earlier. However, as stated previously, urinary methods are inconvenient and prone to 
collection errors [74]. 
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More recently, the, optimal sample time following a single injection was evaluated for 
GFR measurements assuming the two-compartment model. Russell found that for the 
most accu 
rate values, sample times must begin by 10 minutes and continue 
 
for at least 240 minutes. Although he felt that the long time interval evaluated was 
more important than the number of samples,'' & blood samples were recommended. 
The duration of sampling needed to be at least 3 hours because the slow component of 
excretion accounted for most of the clearance. The accuracy obtained by these 
methods, although essential in research, is seldom required clinically [75]. 
 
The gamma-camera method of GFR and ERPF measurements is seldom used for 
global measurements and is discussed more extensively in regard to differential 
measurements. However, it is discussed briefly here. Chachati et al. [76] reviewed 
Gates' technique of global and differential GFR measurements following injection of 
99mTc-DTPA. Using a scintillation camera, the fraction of the injected dose in the 
kidneys was determined 1 to 3 minutes after injection and compared with the GFR 
obtained by simultaneous infusion of inulin. The renal function of the study group 
varied from normal to anuric and included nine patients with either one kidney or a 
nephrostomy tube. The GFR was calculated according to Gates' [77] equation. 
 
kidney count-background
%Uptake 100
injected dose
ye µ−= ×  
 
where y : the renal depth and µ is the attenuation coefficient for 99mTc. 
 
This group found a good correlation between Gates' method of GFR measurements 
and inulin clearance in global measurements (r = 0.86, n = 24, p < 0.001) and in the 
unilateral group (r = 0.91, n = 9, p < 0.001). Subsequent investigators, however, have 
demonstrated a poor correlation between the gamma-camera method of Gates and a 
complete plasma dualcompartment reference method [74]. 
 
There have been reports of impurities in the commercial preparations of 99mTc-DTPA 
that have resulted in GFR errors. This has been attributed to protein binding. 
Ultrafiltration before use has diminished the amount of impurities and thus the error 
in GFR [78]. 
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The spectrum of accuracy varies widely based on the method chosen to calculate GFR. 
The complete plasma clearance curve is the most accurate but requires multiple blood 
samples. The two-plasma blood sample is only slightly more accurate than the one-
plasma sample method, whereas the gamma-camera techniques are less accurate than 
all of the plasma methods. However, the gamma-camera technique has been shown to 
be more accurate than creatinine clearance and, furthermore, does not require either 
plasma or urine samples. 
 
5.11.1 Effective Renal Plasma Flow (ERPF) 
 
ERPF is another parameter of renal function. As inulin clearance is the gold standard 
in glomerular filtration, para-aminohippurate (PAH) is the gold standard for ERPF 
measurements. Although the measurements of PAH clearance are very accurate, this 
method requires constant infusion, is inconvenient, and lacks precision. For these 
reasons, PAH clearance is now rarely used to measure renal function [69]. 
 
As with GFR measurements, many methods of ERPF measurements have been 
reported in the literature. Most of the variety is between the number of plasma 
samples and the timing of these blood samples (up to six plasma samples). The model 
of 1311-01H distribution and secretion follows biexponential decay according to the 
same dual-compartmental model that the GFR agent 99mTc-DTPA follows. The first 
portion of the decay curve represents the distribution of 131I-OIH in the extracellular 
fluid (the first compartment) and dominates the initial 10 to 15 minutes after 1311-OIH 
administration. The second portion of the curve represents the intravascular (second 
compartment) clearance of 1311-OIH by the kidney and begins about 15 to 20 minutes 
after 1311-OIH injection. The complete plasma concentration curve can be plotted 
when multiple blood samples are obtained over approximately 60 minutes, although 
the minimal gain in accuracy of the additional samples and the inconvenience to both 
the technologist and patient make this technique unfeasible clinically. The most 
common technique of ERPF measurement is a single bolus administration of 1311-OIH 
followed by either one or two plasma samples [79]. 
 
For an agent to measure renal plasma flow, it must have an extraction efficiency of 
100%. PAH is the nearest to the ideal agent with an extraction efficiency of 90% and 
with tubular excretion. Because PAH is not completely extracted, the term effective 
renal plasma flow is used when this agent quantitates renal plasma flow. The two 
radionuclides that most closely resemble the incomplete extraction and tubular 
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excretion of PAH are 1311-OIH and 99mTc-MAG3 [67]. 1311-OIH clearance is slightly 
less than that of PAH. When using a single injection technique, however, the 
measurements obtained with 1311-OIH correlate well with those obtained from 
constant infusion of PAH. The correlation is felt to be secondary to the competing 
effects of 1311-OIH's lower clearance and the inability of the single injection technique 
to accurately quantitate the first few minutes of the plasma time activity curve. These 
errors tend to cancel [69]. 
 
Since 1982, the single injection, single-sample method for ERPF measurements has 
been an established method according to Dubovsky and Russell. The single sample is 
drawn about 44 minutes after 1311-OIH is administered and, therefore, discounts the 
extracellular distribution phase by assuming equilibrium has been obtained. This 
method is the simplest and least time consuming of the plasma techniques [79]. 
 
The two-plasma sample technique has been reported to be more accurate. Russell et al. 
[80] compared the one- and two-plasma sample techniques to a complete reference 
curve. The reference data was obtained from six to nine plasma samples drawn 
between 10 and 90 minutes. The single-sample ERPF measurement was obtained 
from a 44-minute postinjection sample. The two-sample method ERPF was obtained 
by calculating the ERPF from two samples in the reference curve. Russell et al. found 
that the residual standard deviation of the two-plasma sample method (20 mL/minute) 
was approximately half that obtained from a single sample (48 mL/minute). In 
addition, the optimal time interval for the two samples was 8.7 minutes and 92 
minutes postbolus injection. This group recommended the single injection, two-
plasma sample method of ERPF calculation only when accuracy is critical (research) 
and further advised obtaining the samples at 10 to 15 minutes and at 60 to 90 minutes 
postinjection. 
 
The slope intercept method also uses two plasma samples after a single bolus 
injection of 1311-OIH. However, the two samples are drawn between 30 and 60 
minutes. These samples can be used only to estimate the clearance portion of the 
decay curve and, like the single-sample method, it disregards the extracellular 
equilibration. Consequently, the volume of distribution and the ERPF is overestimated. 
This method offers little advantage over the single-sample method and furthermore 
requires an additional plasma sample. 
 
Lear et al. [79] proposed a new two-compartment, two-sample technique and 
compared this technique to the single 44-minute sample technique and to the slope 
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intercept technique. This group based their new technique on the volume of 
distribution and on the exchange between the intravascular and extravascular space 
observed in healthy and unhealthy patients. The volume of distribution is the sum of 
the intravacular and extravascular volumes. They noted that the intravascular (V1) 
and extravascular (V2) components had a stable rate of exchange (k/V1, k/V2) over a 
wide spectrum of renal function. The fraction of the volume of distribution contained 
in V1 ranged from 0.5 to 0.6 with the V1 = 0.6 X Vd in healthy individuals and Vi = 
0.6 X Vd in patients with severe renal disease. In this model, V1 was assumed to 
equal to V2, and the sum was equal to the volume of distribution (Vd). Following is 
the biexponential decay curve of the two-compartment model. 
 
( )
1 1
1 2
1 1 1
2
1 2
2
dC C k kERPF C C
dt V V V
dC k C C
dt V
⎛ ⎞ ⎛ ⎞ ⎛ ⎞= − − +⎜ ⎟ ⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠ ⎝ ⎠
⎛ ⎞= −⎜ ⎟⎝ ⎠
 
 
where C1 is the 131I-OIH concentration in compartment l; C2 is the 131I-OIH 
concentration in compartment 2; k is the rate constant of intercompartmental 
exchange; and ERPF is the effective renal plasma flow. 
 
 
When assuming that V1 = V2, and V1= 0.5 Vd, and k/ V1 = 0.5, the equation is 
simplified to  
 
( )
( )
1 1
1 2
1
2
1 2
0.05
0.05
dC CERPF C C
dt V
dC C C
dt
⎛ ⎞= − − −⎜ ⎟⎝ ⎠
= −
 
 
A personal computer then set certain conditions and generated a time concentration 
curve that best fit the data obtained at 40 and 60 minutes. The ERPF and volume of 
distribution was then calculated. With this method there were certain assumptions that 
do not always hold true. V1 will not always equal 0.5xVd and k will not be constant in 
all patients. This group reported, however, that resulting errors in ERPF values were 
smaller than errors found in other techniques. In addition, adjustments to V1 and Vd 
were suggested in different clinical settings and the computer program was provided 
to accomplish the corresponding calculations. The advantage of this technique over 
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the slope intercept method is that this method accounts for the extravascular 
distribution time [79]. 
 
ERPF has been measured by a gamma-camera method both globally and differentially. 
Chachati et at. [76] examined a gamma-camera method of ERPF calculations 
following 131I-OTH injection and compared this to the PAH infusion method. The 
basis of the gamma-camera method was to determine the fraction of the injected dose 
of 131I-OIH 1-2 minutes after administration according to Schlegel's equation. 
 
2kidney count - background  Relative uptake =  100
1 minute count of injected dose
Y× ×  
 
where Y is the renal depth calculated thus; left kidney: 13.2 (weight/height) + 0.7; and 
right kidney: 13.3 (weight/height) + 0.7. 
 
The renal depth calculation was developed by Tonnesen and cited by Schlegel and 
Hamway [81]. Chachati and his group [76] found a good correlation between PAH 
clearance and ERPF (r = 0.84, n = 22, p < 0.001). The gamma-camera methods are 
infrequently used to measure global function and are discussed more fully during the 
review of differential renal function. 
 
99mTc-MAG3 has a clearance that is nearly half that of 1311 OIH. However, ERPF 
measurements reported with 99mTcMAG3 have correlated with those of 1311-OIH (58). 
Using a dual-channel technique, ERPF was calculated following simultaneous 
administration of 1311-OIH and 99mTc-MAG3 and after obtaining a 44-minute plasma 
sample. The proportionality constant between 1311-OIH and 99mTc-MAG3 was 0.563. 
By taking the product of the 99mTc-MAG3 activity and 0.563 and substituting this 
value for 1311-OIH activity, the ERPF values in 50 patients agreed with those obtained 
with 131I-OIH (r = 0.96) [83]. 
 
One- and two-plasma sample methods for evaluating ERPF with 99mTc-MAG3 were 
compared by Russell et al [84]. The single plasma sample was drawn at 43 minutes 
and resulted in an error of 19 mL/minute (residual standard deviation). The 43-minute 
sample time was the optimum over a large range of renal function. Longer sample 
times in poor renal function and shorter sample times in patients with good renal 
function can be used when renal function is known in advance. The 43minute sample 
time is preferred by these investigators in cases of unknown renal function. The two-
plasma sample technique resulted in an error of 7 ml iminute (standard residual 
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deviation) when the samples were obtained at 12 and 94 minutes. Note that the 
suggested sample times for 99mTc-MAG3 are almost identical to those recommended 
for 131I-OIH. Finally, these investigators felt that the accuracy needed for clinical 
decision making was provided by the single-sample technique and that the two-
sample method should be reserved for research purposes when accuracy is essential. 
 
Muller-Suur et al. [85] found that a single sampling time of 60 minutes provided a 
smaller error of 15 mL/minute as compared with the 19 mL/minute found by Russell 
et al. at 43 minutes. Furthermore, this group reported a regression equation to convert 
the ERPF values obtained with 99mTc-MAG3 to the more familiar corresponding 131I-
OIH values. Muller-Suur et al. used the equation 
 
( )1.86  3   4.6ERFP C MAG= × +  
The obvious advantage of the superior dosimetry of 99mTcMAG3 over 131I-OIH makes 
99mTc-MAG3 the ideal agent for ERPF measurements. The normal ERPF value 
obtained with 1311-OIH is 600 mLlminute, and the normal clearance of 99mTc-MAG3 
is 370 mL/minute. 
Following bolus injection of a tubular agent (131I-OIH or 99mTcMAG3), serial images 
of the kidney are obtained every 2 to 3 minutes (refer to section 5.7). To minimize 
tissue attenuation, these images are anterior images in the transplant patient and 
posterior images in native kidneys. Renogram represents several different components 
of radionudide distribution, the vascular phase, the concentration phase, and the 
excretory phase. Because the kidneys receive approximately 20% of the cardiac 
output, the initial phase of the curve is rapidly upsloping and represents renal 
perfusion. This begins about 15 to 20 seconds after injection and reaches an inflection 
point at 20 to 40 seconds. Renal tubular function and background activity also affect 
the slope. The second portion of the renogram curve has milder increase in activity 
reaching a peak within 3 to 5 minutes. This portion of the curve represents tubular 
accumulation. By about 3 to 5 minutes, the activity in the kidney begins to accumulate 
in the bladder via the collecting system. This is represented by a rapidly falling curve 
(Figure 5.4). In addition, a curve can be generated that represents the perfusion only. 
Rapidly acquired frames immediately following the bolus of either 99mTc-MAG3 or 
99mTc-DTPA delineate the aorta and the kidneys. Normally, activity is seen in the 
kidneys within 3.5 seconds of being seen in the aorta. 
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The shape of the renogram curve is affected by many factors. Prerenal insults will 
affect the perfusion portion of the curve. Renal diseases such as glomerulonephritis 
will affect the tubular function portion of the curve, whereas postrenal diseases such 
as obstruction will prevent activity from reaching the bladder and affect the excretory 
portion of the curve [86]. 
 
5.11.2 Differential Function 
 
The disadvantage of the foregoing techniques for the measurement of GFR and ERPF 
is that the measurements are global measurements and individual kidney function is 
not addressed. Gamma-camera techniques have been developed to measure both 
global and differential GFR and ERPF. Most do not require urine samples, and, 
although most do not require plasma samples, several do use one plasma sample. The 
obvious advantage to gamma-camera techniques is that they are not invasive. How-
ever, this comes at a price. The accuracy of these techniques is not always comparable 
to the plasma clearance methods but is usually superior to creatinine clearance. 
 
Global and differential GFR measurements use the gamma-camera to produce a 
renogram after 99mTc-DTPA bolus injection and apply this data to the following 
equation to obtain the individual kidney glomerular filtration rate (IKGFR). 
 
( )dR P t
dt
α=  
 
where dR is the rate of renal uptake;  
P is the plasma concentration; and  
α is the constant of proportionality and represents IKGFR. 
 
Once correction has been made for background, the IKGFR should be constant for up 
to 2.5 minutes after injection. This is the minimum time it takes for the radionudide to 
transit the renal ROI [87]. Many variations on this equation were reported separately 
by Rutland [88] and Rehling et al. [89] in 1985. 
 
One of the problems of accurate gamma-camera imaging of 99mTc-DTPA is the low 
extraction efficiency and subsequent low target-to-background ratio. The background 
correction is the main source of error in this method. The liver, spleen, adrenals, renal 
hilar vessels, intestine, and soft tissue all contribute to background. These organs vary 
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in their ratio of intravascular to extravascular activity, and no single area accurately 
represents the intravascular and extravascular components of background. Perirenal, 
subrenal, suprarenal, and heart activity have all been used in an attempt to 
approximate the background correctly. Bell and Peters [90] reported that 
extravascular chest wall activity contributed to an error in background cardiac blood 
pool estimation and resulted in overestimation of IKGFR by a factor of 1.17. 
 
Piepsz et al. [91] addressed the problem of background correction. This group 
reported a double background correction method that combines the area ratio method 
and the linear fit method. The area ratio method is stated as 
 
( ) ( ) ( ) ( )b cR t R t T t aP t= + +  
where T(t) represents the extravascular component and aP(t) is the fraction of blood 
pool activity included in the background ROT. Rb(t) is the noncorrected renal activity 
and Rc(t) is the background corrected renal activity. Thus, the background can be 
corrected by the area ratio as 
' 'Background activity = ( ) ( )T t a P t+  
where T'(t) is the extravascular component in the perirenal space. Assuming that the 
activity in the perirenal space is an approximate of the extravascular component in the 
renal space, T = T'. By subtracting the previous two equations and dividing them by 
P(t) one finds  
( )
'
( )
( ')
( ) ( )
c
C P t dtR t
a a
P t P t
= + −∫  
where 'a a− is the fraction of the intravascular component not corrected for by the 
area ratio method. This is an equation for a straight line. The slope of this line is the 
clearance that has been corrected for both int avascu1ar and extravascular activity. 
This method works well when the background ROI is the perirenal or subrenal space. 
The suprarenal space contains the liver, and the activity in this region is not all 
extravascular, as is assumed in both the perirenal and subrenal regions. This results in 
an overestimation of the GFR because this region is not corrected for the intravascular 
activity. Russell [68] compared a method that used cardiac activity as the background 
correction to one that used a deconvoluted least-square technique. He found that the 
cardiac correction had a standard deviation of 18.9 mL/minute as compared with the 
plasma clearance method, whereas the least-square technique had a standard deviation 
of 14.5 mL/minute. 
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Differential ERPF can also be measured with a gamma-camera technique following 
either 131I-OIH or 99mTc-MAG3 injection. Fine et al. [93] compared several gamma-
camera techniques to two plasma clearance techniques using 131I-OIH. The three 
gamma-camera methods differed only in the ROI chosen to correct for background. 
The regions were either between the lower poles, upper poles, or crescents lateral to 
the kidneys. A two-plasma sample method was used as the reference with samples 
drawn at 20 and 45 minutes. An additional plasma method was included that required 
one blood sample at 45 minutes. The ERPF measured with the reference method and 
the one plasma sample method was 384 mLlminute and 319 mL/minute, respectively. 
None of the gamma-camera techniques were as accurate as the plasma methods. 
 
The reproducibility of manually drawn ROIs was also examined and was found to be 
very high (correlation coefficient regardless of the observer was greater than 0.98). 
Fine et al. suggested using either ultrasound or lateral scintigrams to correct for tissue 
depth because the ERPF was not altered by more than 1 % as a result of depth 
correction in any patient in this study. The algorithm developed by Schlegel [81] was 
used. 
 
Tondeur et al. [94] examined ERPF gamma-camera clearance with 99mTc-MAG3. Tc-
MAG3 is significantly protein bound and therefore has a smaller extravascular 
component [95]. It also has a higher renal clearance than 131I-OIH. This was expected 
to result in a more accurate time activity curve by the gammacamera and a higher 
target-to-background ratio. In this study, the ERPF was calculated by the double 
correction method discussed previously, and lateral scintigrams were used to correct 
for tissue depth. Cardiac activity was used to estimate plasma activity and a 20-minute 
plasma sample was drawn for the renal clearance calculation. Three different areas 
were used to correct for background: suprarenal, perirenal, and subrenal regions. The 
clearance calculated by suprarenal correction was repeatedly higher than clearances 
calculated with the other two regions. This was felt to be secondary to the 
unaccounted intravascular component in the suprarenal region. The cardiac plasma 
activity was also compared with plasma sample activity in 6- and 20-minute samples 
and was found to be lower with a mean difference of 19.2%. Even though the high 
protein binding of 99mTC-MAG3 was expected to diminish the error associated with 
extravascular activity in the precordium, the faster clearance of 99mTc-MAG3 
produced rapidly decreasing plasma activity and may have made the precordial 
activity inaccurate except at very early measurements. 
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5.12 Author’s work RENOGRAPHY MODELLING 
[25-26] 
 
In renography, a tracer is introduced into the blood circulation. The kidney extracts 
this tracer from the blood circulation in the glomeruli and for a transient period of 
time in a normal person, the tracer is found within the renal parenchyma. From the 
renal parenchyma, it is excreted into the collecting system of the kidney (mainly the 
renal pelvis), from whence it travels out of the kidney into the urinary bladder. In 
many conditions, there is abnormalities in this outflow part of the kidney. For 
example, renal stones can be found in the outflow tract and cause obstruction to urine 
flow. The result is that the tracer is trapped within the renal pelvis much longer than 
normal.  
 
In this paper, the aim is to model the behavior of tracer from input to the washout 
from the renal pelvis. This results from the model will be compared to actual data 
from renography. 
 353
 
 
Figure 5.12 Compartmental Model. The control volume is the ROI in our work. 
control 
volume in 
the renal 
pelvis 
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Figure 5.13 Human Kidney [Prof Gunther H., BodyWorlds] 
  
If a tracer is injected into the blood circulation and the amount of tracer is measured 
by radioactive means in the renal outflow, the following curve is seen in a normal 
person: 
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Figure 5.14 Renogram showing the normal versus obstructed at the renal pelvis. 
 
 
5.12.1 Control volume around the renal pelvis 
 
 
 
1G : Tracer mass in the chamber 1, renal parenchyma in Counts. 
2G : Tracer mass in the chamber 2, renal pelvis in Counts. 
1C : Concentration of tracer in the chamber 1, renal parenchyma in Counts/dl. 
2C : Concentration of tracer in the chamber 2, renal pelvis in Counts/dl. 
1V : Volume of chamber 1, renal parenchyma in dl. 
2V : Volume of chamber 2, renal pelvis in dl. 
( )I t : Tracer input function in Counts/sec.  
F(t) : Blood Flow from chamber 1 to chamber 2 in dL/sec. 
( )U t :Urine outflow in dl/sec. 
Figure 5.15 The derived two-compartmental renal model. 
time 
amount of 
radioactive 
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1
1 ( )
dG FC I t
dt
= − + , for chamber 1     (1) 
2
1 2 ( )
dG FC C U t
dt
= − , for chamber 2     (2) 
where  (i) 1 1 1( )G C V=  represents the tracer amount in chamber 1,and   
(ii) 2 2 2( )G C V= represents the tracer amount in chamber 2. 
 
In physiological studies of the kidney urine flow, the input function is a tracer bolus 
administered over a short period of time. Compared to the entire duration of the renal 
dynamics, this bolus injection of tracer is approximated by an impulse function 
(Dirac’s delta function). In the following derivation, whenever I(t) appears it will be 
assumed  be equal to δ(t). 
Assuming that the volumes of distribution V1 and V2 are constants (which they 
generally are), and the urinary flow rate U to be a constant unknown (urine flowing 
out of the kidney into the ureters is physiologically continuous and constant with time, 
unless there are changes in body fluid status. Here we are only performing an intra-
renal analysis for any obstruction to the outflow), we have from eq (1) and (2) : 
 
 1 1 1 ( )
V dC FC I t
dt
= − +  (3) 
 
 2 2 1 2
V dC FC C U
dt
= −  (4) 
 
Differentiate eq (4) to obtain : 
 
 
2
2 2 1 2
2
V d C dC dCF U
dt dt dt
= −  (5) 
 
 
Replace the first term on the right hand side with eq (3) : 
 
 
2
2 2 1 2
2
1
V d C I FC dCF U
dt V dt
⎛ ⎞−= −⎜ ⎟⎝ ⎠
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Replace the term with C1 with eq (4) so as to get a differential equation in the variable 
of interest, C2 : 
 
2
2 2 1 2
2
1 1
2
2 2
2
1 1
2 2
2 2
1 1
2 2
2
1 1 1
V d C FC dCIF U
dt V V dt
dCV UC dCI dtF U
V V dt
dC dCF FI V UC U
V V dt dt
dC FVF FUI U C
V dt V V
⎛ ⎞= − −⎜ ⎟⎝ ⎠
⎛ ⎞+⎜ ⎟= − −⎜ ⎟⎜ ⎟⎝ ⎠
⎛ ⎞ ⎛ ⎞⎛ ⎞= − + −⎜ ⎟ ⎜ ⎟⎜ ⎟⎝ ⎠⎝ ⎠ ⎝ ⎠
⎛ ⎞ ⎛ ⎞ ⎛ ⎞= − + −⎜ ⎟ ⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠ ⎝ ⎠
 (6) 
 
 
Eq (6) is a linear second-order differential equation, which we can rearrange as 
follows, where the subscript 2 for C2 has been suppressed, as all the C terms are 
referring to the same concentration of compartment 2 (the renal pelvicalyceal 
compartment). 
 
 22
1 1 1
FVF FUV C I C U C
V V V
⎛ ⎞ ⎛ ⎞ ⎛ ⎞= − + −⎜ ⎟ ⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠ ⎝ ⎠
?? ?  (7) 
 
Let the following indices be defined: 
 
2
1
1
FV U
V
FU
V
β
γ
⎛ ⎞+ =⎜ ⎟⎝ ⎠
⎛ ⎞ =⎜ ⎟⎝ ⎠
         (8) 
 
 
Using the indices as defined above, eq (7) becomes 
 
2 2 2 2
1
2 2 2 2
1
( )
or,
( ) 
FV C I t C C
V
FV C C C I t
V
β γ
β γ δ
⎛ ⎞= − −⎜ ⎟⎝ ⎠
⎛ ⎞+ + = ⎜ ⎟⎝ ⎠
?? ?
?? ?
   (9) 
 358
 
This is a standard form for a linear second-order ordinary differential equation, with I 
as the impulse function. This is the governing differential equation for the behviour of 
tracer within the renal pelvicalyceal compartment. 
 
Solution by Laplace transform method yields the following analytical result: 
 
 
{ }
( )
( )
2
1
2
2 2
1
2 2
21 1 22
2 2
2
2
2 2
22 2
1 2
2
2 2 2 2
( )
( )
1 1( ) ( )
41       
4 2 4
FL V C C C L I t
V
FV s s C s
V
F FC t C t
V VVV s s s s
V V
V VF
VV
s
V V V V V
β γ δ
β γ
β γ β γ
γ β
γ β β γ β
⎧ ⎫⎛ ⎞⎪ ⎪+ + = ⎨ ⎬⎜ ⎟⎪ ⎪⎝ ⎠⎩ ⎭
⎛ ⎞∴ + + = ⎜ ⎟⎝ ⎠
⎛ ⎞ ⎛ ⎞= = =⎜ ⎟ ⎜ ⎟ ⎛ ⎞+ +⎝ ⎠ ⎝ ⎠ + +⎜ ⎟⎝ ⎠
⎛ ⎞ −⎜ ⎟⎛ ⎞⎜ ⎟= ⎜ ⎟⎜ ⎟ ⎛ ⎞⎝ ⎠⎜ ⎟− + + −⎜ ⎟⎜ ⎟⎝ ⎠ ⎝ ⎠
?? ?
2
2
     ⎛ ⎞⎜ ⎟⎝ ⎠
 (10) 
 
Solving the above Laplace transform and taking care of the characteristics of the roots 
(which is now in standard form, by looking up standard tables), we obtain the results 
for the dynamic behavior of the tracer concentration in the renal pelvis for this 
physiological system. The term underneath the square root is the determinant of the 
behavior of the system with regards to whether there is underdamped, critical-damped 
or overdamped behaviour. 
 
This term can be expressed as 2 24Vβ γ− and it yields a significant functional index 
for assessing the outflow status of the kidney. We will classify the observed 
physiological behaviours of renogram systems into underdamped, overdamped or 
critically damped systems based on the index, as follows: 
 
Case 1: 
 
If 2 24 0Vβ γ− < ,  the condition is underdamping, and (7) yields the solution: 
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2
2
2
22
1 2 2 2
2
2 2
1( ) sin
4
4
t
VFC t e t
VV V V
V V
β γ β
γ β
−
⎛ ⎞⎜ ⎟ ⎛ ⎞⎛ ⎞⎜ ⎟= −⎜ ⎟⎜ ⎟⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠⎜ ⎟−⎜ ⎟⎝ ⎠
     (11)  
 
 
               k             1/A                    A 
 
As can be seen from equation (8), the terms which describe urine outflow and 
determine the shape of the tracer-concentration curve of the renogram during the 
tracer wash-out phase are the 22
t
Ve
β−
and 
2
2
2 2
sin
4
t
V V
γ β⎛ ⎞−⎜ ⎟⎜ ⎟⎝ ⎠
. The impartant dynamic  
information captured in these two terms can be succintly found in the physiological 
index that we have described. We will demonstrate the discriminatory nature of this 
index (which will be extracted as A) in section IV when we analyse correlation with 
actual renogram studies. 
 
Equation (8) is a linear second-order ordinary differential equation, very similar to 
that of the linear oscillator with damping. In a functioning renal system, the 
characteristic oscillating-underdamped conditions do not exist.  
 
Case 2: 
 
Whenever there is outflow obstruction, the key term 
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
β γ ⎛ ⎞ ⎛ ⎞ ⎛ ⎞− = + − = − >⎜ ⎟ ⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠ ⎝ ⎠  
and the condition is overdamping. Then,  
2
2
2
22
1 2 2 2
2
2 2
1( ) sinh
4
4
t
VFC t e t
VV V V
V V
β γ β
γ β
−
⎛ ⎞⎜ ⎟ ⎛ ⎞⎛ ⎞⎜ ⎟= −⎜ ⎟⎜ ⎟⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠⎜ ⎟−⎜ ⎟⎝ ⎠
     (12) 
 
    k                1/A    A 
 
We can express output segment of the tracer curve of compartment 2 looks different 
from that of the tracer input  
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2 2
2 2 2
2 2
1 1 1
4 4FV FVFUV U V U
V V V
β γ ⎛ ⎞ ⎛ ⎞ ⎛ ⎞− = + − = −⎜ ⎟ ⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠ ⎝ ⎠  
 
so the key term actually reflects the rate of tracer input (FC1) minus the rate of tracer 
output (UC2). 
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Case 3: 
 
In the normal case, most physiological systems are well-compensated, and hence 
the output are fairly similar, hence,  
 
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
β γ ⎛ ⎞ ⎛ ⎞ ⎛ ⎞− = + − = − =⎜ ⎟ ⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠ ⎝ ⎠  
 
In other words, the renal system is critically damped.  
 
The governing equations for this will be 
 
( ) 22
1 2
t
VFC t te
VV
β−⎛ ⎞= ⎜ ⎟⎝ ⎠
  (12) 
 
For model analysis, because of complications involved in monitoring U (urine flow 
rate), F (plasma flow rate into the renal pelvis) and V1 control volume, we propose 
that our model parameters will be lumped parameters k and A. Next our parameters 
identification will be carried out for k, A, V2 and β. It is important to point out that 
only for critically damped case, we can separate the V2 and β individually during the 
parameters identification process. 
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1 2
Fk
VV
=      (20) 
 
 
2
2
2 2
2
2
2
2 2
2
2
22
2
2
2
22
2
4
4
4
  
4
A
V V
A
V V
A V
V
A V
V
γ β
γ β
βγ
β
= −
= −
⎛ ⎞= + ×⎜ ⎟⎝ ⎠
⎛ ⎞= +⎜ ⎟⎝ ⎠
    (21) 
From (8): 
 
2
1
FV U
V
β = +      (22) 
 
 
1
FU
V
γ =      (23) 
 
From (23): 
 
1
F
U V
γ =      (24) 
 
From (24) & (20): 
 
1
F
U V
γ = = 2kV       
1VF
U
γ=      (25) 
 
Sub (25) into (22): 
 ( )2 2
2
2
V kV U
U kV
β
β
= +
= −     (26) 
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From the parameters identifications, we obtain k, A, β & V2. 
 
Hence, ( )U t  dl/sec. (urine outflow) can be determined. Note that at this point of our 
work, we can only determine the U for critically damped case because only this case 
we can separate the V2 and β individually. 
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5.13 CLINICAL DATA & EVALUATION 
 
We will demonstrate and verify the application of our models using the renograms 
obtained from the Nuclear Medicine and PET Department. The radionuclide used are 
99mTc-DTPA and 99mTc-MAG3.  The degree of match with the governing equations is 
based on the area under the left and right kidney curves against the clinical curves 
between 60 and 120 seconds. 
 
5.13.1 Model Application: 
 
We will first digitalize and normalized the renograms. Next, we will perform 
parameters identification and obtain the system parameters: k, A, β and V2. We will 
only accept the results of the best fit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 Clinical renograms of volunteer coded Patient 7. Note that the (QR-RR) 
segment of the tracer curve for the right kidney is similar to the (PR-QR) segment 
and demonstrates good outflow-rate compared to the (QL-RL) segment of the 
obstructative curve for the left kidney. 
 
P 
QR 
QL 
RR 
RL 
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Figure 5.17 Simulated results based on the clinical data of Patient 7 in Figure 5.15.  
 
TABLE 5.2 Comparison of clinical and calculated results of Patient 7. We can 
observe that the errors for each kidney is less than 1%. 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks
  SSE R Sq  SSE R Sq 
k 0.0124 0.0221 
A 5.48E-03 8.68E-03 
β/ V2 0.01235 0.0209 
  0.0021 0.9966  0.0118 0.9879 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 39.64  50.72   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/
Clinical 
(%) 
Deviation 
(%) 
 
Relative 
Area* 43.87 44.00 0.29% 56.13 56.00 -0.23% 
 
 Calculated  Calculated   
U      
Relative 
U (%)  
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Figure 5.18 Clinical renograms of volunteer coded Patient 19. Left kidney is 
normal while the right kidney has minor obstruction. 
 
 367
 
Figure 5.19 Simulated results based on the clinical data of Patient 19 in Figure 5.17.  
 
TABLE 5.3 Comparison of clinical and calculated results of Patient 19. We can 
observe that the errors for each kidney is less than 3%. 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks
  SSE R Sq  SSE R Sq 
k 0.0100 0.0091 
A   
β 0.0040 0.007 
V2 0.5389 0.0620 0.9462  0.0872 0.9002 
LT(C) 
RT(O)  
(β/ V2) 
 Calculated   Calculated   
Area* 38.52  35.25   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/
Clinical 
(%) 
Deviation 
(%) 
 
Relative 
Area* 52.22 51.00 -2.39 47.78 49.00 2.49 
 
 Calculated  Calculated   
U 0.0010     
Relative 
U (%) 45.77 
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Figure 5.20 Clinical renograms of volunteer coded Patient 11. Left and right 
kidneys are normal. 
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Figure 5.21 Simulated results based on the clinical data of Patient 11 in Figure 5.19.  
 
TABLE 5.4 Comparison of clinical and calculated results of Patient 11. We can 
observe that the errors for each kidney is less than 5%. 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks
  SSE R Sq  SSE R Sq 
k 0.0097 0.0127 
A   
β 0.0037 0.0048 
V2 0.4956 0.0255 0.9818 0.4908 0.0221 0.9852 
LT(C) 
RT(C) 
 Calculated   Calculated   
Area* 36.89  43.58   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/
Clinical 
(%) 
Deviation 
(%) 
 
Relative 
Area* 45.84 48.00 4.49 54.16 52.00 -4.14 
 
 Calculated  Calculated   
U 0.0013  0.0017   
Relative 
U (%) 43.24 
 
56.76 
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Refer to Appendix G for more simulation and clinical data. 
 
5.14 Non-Dimensional Indices for Kidney 
Obstructions 
 
In our discussions in the previous sections, we can observe that the ( )U t  can only be 
calculated for normal cases. Hence, the NDI that we are proposing will be based on 
the area under the curve between 60 sec and 120 sec. 
 
In clinical practice, the clinician will determine if the patient has obstructed kidneys 
based on the range beyond 45:55 or 55:45 (Area of Left Kidney : Area of Right 
Kidney).  
 
NDI = 
Area under the curve between 60 sec and 120 sec for left kidney
Area under the curve between 60 sec and 120 sec for right kidney
 
 
 
 
Figure 5.22 Ranges for indicating the left or right or both kidneys and normal ranges. 
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5.15 CONCLUSION 
 
We have demonstrated modeling of kidney-renal outflow tract compartments with 
derivation of the governing equations from second-order differential equations and 
assessed the clinical relevance with comparison with clinical renogram studies. From 
which, we can derive the urine outflow noninvasively for normal kidneys. NDI for 
identifying kidneys obstruction has also been discussed. 
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Chapter 6 Non-dimensional 
Physiological Indices for Clinical 
Assessment 
 
 
Purpose of Non-Dimensional Indices 
 
This chapter concerns systematic application of dimensional analysis in human 
physiology, in which use is made of parameters of functional second order linear 
differential equations of physiological systems, to develop non-dimensional 
physiological indexes (NDPIs) to qualify  patient health and diseases status as well as 
patient improvement. We have developed NDPIs for several physiological 
phenomena and systems, and indicated as to how they can be employed 
diagnostically. We have formulated NDPIs for: 
 
(i) In Chapter 1, we have use the results of Oral Glucose Tolerance Test, to 
classify the patients into non-diabetic, diabetic or at-risk. The NDPIs can 
also distinguish the patients who are at-risk from non-diabetic and 
diabetic. Then they can undergo pre-emptive medications. 
(ii) Chapter 3, Lung Ventilatory function, to enable us to diagnose lung 
diseases in terms of just one non-dimensional lung-ventilatory index (VTI) 
number, incorporating the lung parameters resistance (R) and compliance 
(C) as well as the lung breathing rate.  
(iii) Chapter 4, Lung Gases Metabolism, to enable us to determine the lung 
efficiency in oxygen consumption and carbon dioxide rates, by one NDPI 
incorporating oxygen diffusion coefficient
2OD and carbon dioxide 
diffusion coefficient 
2COD . 
(iv) Chapter 5, Kidney Renal Dysfunctions, to enable us to quantify the 
severity of renal obstructions of both the patient’s kidneys by a NDPI. 
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6.1 Summary of Author’s work Non Dimensional 
Physiological Indices 
 
From the previous chapters, we have realized that dimensional analysis has 
contribution to make to almost any problem and especially those where analytic 
methods fail. The ability to get dimensional and dimensionless relationships from 
differential equations is of great importance when the later too complex for analytic 
solution. Derivation of suitable dimensionless terms yields terms yields major insights 
into physical nature of particular problem .We have developed NDPIs for: 
 
(i) Chapter 1, Oral Glucose Tolerance Test, to classify the patients into non-
diabetic, diabetic or at-risk. The NDPIs can also distinguish the patients 
who are at-risk from non-diabetic and diabetic. Then they can undergo pre-
emptive medications [2-3]. 
 
6max 2 max
2 5
2
_ 10d
y y T TG NDI
AG T
×= × × ×  
_I NDI βγδα=  
6max 2 max
2
2
_ _
        = 10d
NDI G NDI I NDI
y y T T
A TG
βγδ
α
= ×
× × × × ×  
α  : increases means insulin removed 
β  : increases means insulin responsive to glucose concentration 
γ  : decreases means blood glucose increases and not enough glucose 
absorbed by     tissues. 
δ : decreases means blood glucose increases and inadequate tissue glucose 
utilization. 
 
(ii) Chapter 3, Lung Ventilatory function, to enable us to diagnose lung 
diseases in terms of just one non-dimensional lung-ventilatory index (VTI) 
number, incorporating the lung parameters resistance (R) and compliance 
(C) as well as the lung breathing rate [1, 5, 8].  
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CO2 production rate
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(iii) Chapter 4, Lung Gases Metabolism, to enable us to determine the lung 
efficiency in oxygen consumption and carbon dioxide rates, by one NDPI 
incorporating oxygen diffusion coefficient
2OD and carbon dioxide 
diffusion coefficient 
2COD [4,6-7, 9-11]. 
VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τa2 (BR)2 602 
where BR is the breathing rate. 
[ ] [ ]2
2
1
22 3 1 2 3
2
( ) ( )
P P P C
BR TV BR R TV
VTI
PC P C P C
τ= =  
 
(iv) Chapter 5, Kidney Renal Dysfunctions, to enable us to quantify the 
severity of renal obstructions of both the patient’s kidneys by a NDPI [12-
13]. 
 
NDI = 
Area under the curve between 60 sec and 120 sec for left kidney
Area under the curve between 60 sec and 120 sec for right kidney
 
 
Each Physiological Non-Dimensional Indexes (PNDIs), serves its own functions in 
discriminating the normal from diseasing or diseased physiological organ system. The 
ranges of each indices which represent each class has been discussed in their 
respective chapters.  
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6.2 Conclusions 
 
The author has demonstrated in Chapter 2, how the insulin infusion system has used 
the results of the NDIs from Chapter 1 to bring down the blood glucose concentration 
within the 2-hour critical period. He has used the blood glucose concentration of truly 
diabetic patients in the system model to bring the concentrations of blood glucose 
concentration by control infusion of insulin into the blood-stream. The resulting of the 
new blood glucose concentration is continuously monitored and sequence of infusion 
is spread across at every 0.5 hour intervals. The author wishes to build the system and 
perform clinical in the near future. He believes that this system can definitely benefit 
more diabetic patients and system has no means of invasive techniques in measuring 
the blood glucose concentration and control insulin-infusion into the blood stream. He 
has realized the serious in over or under dosing of insulin, as a result, the negative 
feed-back from the system is a very important safety mechanism.  
 
The NDIs from Chapter 3 and 4 can help clinicians and equipment manufacturers to 
determine the type of pulmonary diseases, such as SARs, emphysema and chronic 
bronchitis and COPD. Each type of lung diseases attacked the lungs in different ways 
such as emphysema has very high compliance and the metabolism is very poor. 
COPD will be very high resistance and metabolism is very poor. The author hopes to 
realize the system. In fact a preliminary version of the system has been patented [14].  
 
At the moment, the renograms collected does not contain the amount of tracers were 
introduced during the procedures. Many a times, the amount was introduced by 
experienced PET radiographers themselves. The author hope that his partners at the 
local government hospitals can convenience them to keep the record so that the actual 
urine outflow can be calculated instead of the relative urine outflow rate. The current 
system model equations were only good for normal flow, more work has to be carried 
out for diseased urine flow-rates so that we can develop a quick and accurate expert 
system. 
 
We have seen how we can formulate and evaluate Non-Dimensional Physiological 
Indices (NDPNs) to serve as physiological-system disorder indices, and hence 
represent health-status. These non-dimensional health-status indicators of diabetic 
risky patients. 
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NDPIs require multi-disciplinary analyses of physiological and/or systems, and 
provides a convenient basis for medical diagnosis in terms of just one number. Thus 
NDPIs can also constitute the basis of effective classification of prognosis. 
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Appendix A 
 
 
Underdamp Responses for Subjects N01-N20 
 
These 40 subjects (N01 to N20) were diagnosed by physician as normal and (D01 to 
D20) were diagnosed by physician as diabetic. 
 
Characteristic equation for glucose fitting for underdamp (healthy and non-diabetic) 
subjects : 
 
y(t) = (G/ ω) e-At sinωt 
 
Characteristic equation for insulin fitting for underdamp (healthy and non-diabetic) 
subjects : 
 
( ) ( ) ( ) ( )
2
( )( )
( )
At At At tG tAe t e e ex t
A
αβ α
α
− − − −− − + −= −  
 
G:  glucose administered to the system in gram/liter hour 
 
A:  attenuation constant in 1/hour 
 
x: blood insulin concentration (from its fasting level) 
 
y : blood glucose concentration (from its fasting level) 
 
α: represents pancreatic insulin sensitivity to insulin (average insulin removal-rate 
independent of glucose) in (hr)-1 
 
β:  pancreatic insulin sensitivity to elevated glucose blood concentrations (net increase 
in insulin release-rate due to glucose) in (Units) (hr)-1(gms)-1 
 
γ : liver glycogen storage to elevated blood-glucose concentrations (net increase in 
glucose removal due to insulin) in (gms)(hr)-1 (Units)-1  
 
δ: tissue glucose utilisation to elevated blood-glucose concentrations (average     
glucose removal-rate independent of insulin) in (hr)-1 
 2
Summary of the fit 
 
Best Fitted (R-Square > 95%) No Fit 
N02 N09 
N05 N20 
N11  
N14  
N16  
N19  
  
D03  
  
 3
 
 
 
 
Parameters Values Fitting Remarks 
A 1.537 SSE 0.0023 
G 2.458   
ω 5.453e-9 
Glucose 
Fit 
R-Square 0.9862 
α 0.7454 SSE 0.0002218 
β 0.05792   
γ 2.3286 R-Sqauare 0.9718 
δ 2.9882 
Insulin 
Fit 
  
S01 actually is 
diabetic even the 
clinician 
diagnosed               
him as normal. 
 
 4
 
 
Parameters Values Fitting Remarks 
A 2.863 SSE 0.001478 
G 9.9   
ω 3.558 
Glucose 
Fit 
R-Square 0.9961 
α 1.1219 SSE 0.001394 
β 0.04619   
γ 4.6041 R-Sqauare 0.8254 
δ 18.4 
Insulin 
Fit 
  
S02 is normal. 
Just as the 
clinician has 
diagnosed. 
 5
 
 
Parameters Values Fitting Remarks 
A 2.051 SSE 0.01343 
G 4.013   
ω 0.79 
Glucose 
Fit 
R-Square 0.9602 
α 1.5534 SSE 6.735e-007 
β 0.01207   
γ 2.9287 R-Square 0.9976 
δ 4.0871 
Insulin 
Fit 
  
S03 is in a 
dangerous rim. 
The insulin 
response is too 
little. 
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Parameters Values Fitting Remarks 
A 2.461 SSE 0.002389 
G 3.21   
ω 2.776e-14 
Glucose 
Fit 
R-Square 0.9831 
α 1.6693 SSE 0.002765 
β 0.1209   
γ 3.2527 R-Sqauare 0.9069 
δ 3.3926 
Insulin 
Fit 
  
S04 is at the rim 
of being diabetic     
due to  
hyperinsulinemia. 
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Parameters Values Fitting Remarks 
A 0.7233 SSE 0.006169 
G 1.327   
ω 2.373 
Glucose 
Fit 
R-Square 0.9633 
α 0.0308 SSE 0.0006957 
β 0.01786   
γ 1.4158 R-Sqauare 0.7759 
δ 199.0439 
Insulin 
Fit 
  
S05 is normal. 
Just as the 
clinician has 
diagnosed.            
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Parameters Values Fitting Remarks 
A 1.532 SSE 0.02654 
G 2.828   
ω 1.279 
Glucose 
Fit 
R-Square 0.9089 
α 1.8563 SSE 0.0002425 
β 0.03851   
γ 1.2077 R-Sqauare 0.946 
δ 2.1205 
Insulin 
Fit 
  
S06 is normal. 
Just as diagnosed 
by the clinician.  
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Parameters Values Fitting Remarks 
A 0.5198 SSE 3.874e-011 
G 1.018   
ω 0.5987 
Glucose 
Fit 
R-Square 1 
α -0.1124 SSE 0.0007118 
β 0.04592   
γ 1.1520 R-Sqauare 0.9298 
δ -5.1243 
Insulin 
Fit 
  
S07 is diabetic. 
But was the 
clinician 
diagnosed as 
normal. 
 10
 
 
Parameters Values Fitting Remarks 
A 2.247 SSE 0.01533 
G 2.522   
ω 6.16e-11 
Glucose 
Fit 
R-Square 0.8279 
α 1.4553 SSE 0.0003162 
β 0.06229   
γ 3.0387 R-Sqauare 0.9066 
δ 3.3394 
Insulin 
Fit 
  
S08 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A 2.247 SSE 0.004918 
G 2.522   
ω 2.472e-8 
Glucose 
Fit 
R-Square 0.9442 
α 1.4553 SSE 0.000468 
β 0.07756   
γ 3.0387 R-Sqauare 0.9424 
δ 3.3074 
Insulin 
Fit 
  
S09 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A 2.38 SSE 0.005696 
G 2.366   
ω 2.332e-6 
Glucose 
Fit 
R-Square 0.9192 
α 1.5885 SSE 1.851e-005 
β 0.05113   
γ 3.1715 R-Sqauare 0.9951 
δ 3.4638 
Insulin 
Fit 
  
S10 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A 1.008 SSE 0.0008173 
G 1.462   
ω 3.637 
Glucose 
Fit 
R-Square 0.9877 
α 0.0449 SSE 0.0004591 
β 0.0687   
γ 1.9711 R-Sqauare 0.7827 
δ 314.3932 
Insulin 
Fit 
  
S11 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A 3.414 SSE 0.003909 
G 4.237   
ω 0.0005159 
Glucose 
Fit 
R-Square 0.9611 
α 2.6223 SSE 0.0003844 
β 0.09101   
γ 4.2057 R-Sqauare 0.9668 
δ 4.2988 
Insulin 
Fit 
  
S12 is at the rim 
of being diabetic 
due to 
hyperinsulinemia. 
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Parameters Values Fitting Remarks 
A 1.453 SSE 5.37e-013 
G 2.841   
ω 1.431 
Glucose 
Fit 
R-Square 1 
α 2.7194 SSE 0.001571 
β 0.0666   
γ 0.1866 R-Sqauare 0.881 
δ 1.524 
Insulin 
Fit 
  
S13 is classified 
as normal. But 
S13 is 
hyperinsulinemia. 
S13 fits all 3 
classes. 
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Parameters Values Fitting Remarks 
A 2.007 SSE 0.0001099 
G 2.795   
ω 1.882 
Glucose 
Fit 
R-Square 0.9992 
α 2.8245 SSE 0.0003034 
β 0.1059   
γ 1.1895 R-Sqauare 0.9871 
δ 2.6355 
Insulin 
Fit 
  
S14 is classified 
as normal. But 
S14 is 
hyperinsulinemia. 
S14 fits all 3 
classes. 
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Parameters Values Fitting Remarks 
A 1.777 SSE 0.0008778 
G 3.015   
ω 4.716e-5 
Glucose 
Fit 
R-Square 0.9964 
α 0.9854 SSE 0.0006281 
β 0.03185   
γ 2.5686 R-Sqauare 0.7741 
δ 3.1216 
Insulin 
Fit 
  
S15 is at the rim. 
S15 is classified 
as 
normal                    
by clinician. 
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Parameters Values Fitting Remarks 
A 1.655 SSE 0.002344 
G 3.443   
ω 3.608 
Glucose 
Fit 
R-Square 0.9843 
α 0.4181 SSE 0.001434 
β 0.07675   
γ 2.8919 R-Sqauare 0.8308 
δ 37.1543 
Insulin 
Fit 
  
S16 is normal just 
as diagnosed by 
clinician. 
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Parameters Values Fitting Remarks 
A 1.043 SSE 0.003526 
G 1.838   
ω 1.363 
Glucose 
Fit 
R-Square 0.9832 
α 1.7481 SSE 0.0003039 
β 0.03522   
γ 0.3379 R-Sqauare 0.8896 
δ 1.6783 
Insulin 
Fit 
  
S17 is normal just 
as diagnosed by 
clinician. 
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Parameters Values Fitting Remarks 
A 2.721 SSE 0.0002998 
G 5.768   
ω 1.525e-7 
Glucose 
Fit 
R-Square 0.9992 
α 1.9295 SSE 0.0003623 
β 0.07495   
γ 3.5125 R-Sqauare 0.9878 
δ 3.7008 
Insulin 
Fit 
  
S18 fit all classes. 
S18 suffers from 
hyperinsulinemia. 
The pancreas will 
not able to sustain 
the insulin 
requirement as 
age catches up.   
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Parameters Values Fitting Remarks 
A 0.7019 SSE 0.00733 
G 1.905   
ω 2.182 
Glucose 
Fit 
R-Square 0.9812 
α -3.3751 SSE 0.001395 
β 0.06236   
γ 4.6789 R-Sqauare 0.9052 
δ -1.5151 
Insulin 
Fit 
  
S19 is at the rim 
even though S19 
is diagnosed as 
normal.  
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Parameters Values Fitting Remarks 
A 2.738 SSE  
G 0.426   
ω 0.8967 
Glucose 
Fit 
R-Square  
α  SSE 1.632e-006 
β 0.5684   
γ  R-Sqauare 0.9998 
δ  
Insulin 
Fit 
  
S20 is at the rim 
even though S20 
is diagnosed as 
normal.                   
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Underdamp Responses for Subjects D01-D20 
 
These 20 subjects were diagnosed by physician as diabatic. 
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Parameters Values Fitting Remarks 
A 0.5659 SSE 0.008731 
G 3.763   
ω 0.3638 
Glucose 
Fit 
R-Square 0.9976 
α -0.1694 SSE 0.0002618 
β 0.004821   
γ 1.3012 R-Sqauare 0.9002 
δ -2.6353 
Insulin 
Fit 
  
Glucose comes 
down very 
slowly. D01 is 
diabetic. 
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Parameters Values Fitting Remarks 
A 0.2063 SSE 0.02156 
G 2.253   
ω 1.53 
Glucose 
Fit 
R-Square 0.9753 
α 5.1255 SSE 0.0003788 
β 0.02099   
γ -4.7129 R-Sqauare 0.931 
δ 0.4843 
Insulin 
Fit 
  
D02 fits both the 
underdamp and 
critical damp but 
D02 is classified 
as diabetic by 
clinician.  
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Parameters Values Fitting Remarks 
A 0.2845 SSE 1.982e-012 
G 2.336   
ω 1.589 
Glucose 
Fit 
R-Square 1 
α -10.3358 SSE 0.001944 
β 0.01677   
γ 10.9048 R-Sqauare 0.8198 
δ -0.2344 
Insulin 
Fit 
  
D03 fit both the 
criticaldamp & 
overdamp cases 
and D03 is 
classified as 
diabetic.  
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Parameters Values Fitting Remarks 
A 0.1751 SSE 0.0214 
G 1.733   
ω 0.8573 
Glucose 
Fit 
R-Square 0.9877 
α -0.2610 SSE 1.026e-005 
β 0.001133   
γ 0.6112 R-Sqauare 0.8733 
δ -2.9305 
Insulin 
Fit 
  
D04 is diabetic 
just as diagnosed 
as diabetic by the 
clinician. 
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Parameters Values Fitting Remarks 
A 0.3309 SSE 0.003104 
G 3.311   
ω 1.538 
Glucose 
Fit 
R-Square 0.9984 
α 6.3722 SSE 0.0004788 
β 0.01501   
γ -5.7104 R-Sqauare 0.93 
δ 0.4018 
Insulin 
Fit 
  
D05 fits both the 
underdamp and 
overdamp classes 
even though D05 
has been 
diagnosed as 
diabetic. 
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Parameters Values Fitting Remarks 
A 0.7652 SSE 7.783e-011 
G 3.254   
ω 0.4575 
Glucose 
Fit 
R-Square 1 
α 0.0639 SSE 0.0003469 
β 0.02078   
γ 1.4665 R-Sqauare 0.9654 
δ 11.9587 
Insulin 
Fit 
  
D06 is diabetic 
just as diagnosed. 
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Parameters Values Fitting Remarks 
A 0.06934 SSE 0.0358 
G 2.284   
ω 1.138 
Glucose 
Fit 
R-Square 0.9835 
α 0.0241 SSE 0.0004136 
β 0.01869   
γ 0.1146 R-Sqauare 0.9648 
δ 53.8405 
Insulin 
Fit 
  
D07 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 2.527e-7 SSE 0.009778 
G 1.673   
ω 1.044 
Glucose 
Fit 
R-Square 0.9943 
α -0.2083 SSE 9.636e-006 
β 0.00446   
γ 0.2083 R-Sqauare 0.986 
δ -5.2292 
Insulin 
Fit 
  
D08 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 2.22e-14 SSE 0.02287 
G 1.484   
ω 1.393 
Glucose 
Fit 
R-Square 0.9716 
α 0.9077 SSE 0.003467 
β 0.04673   
γ -0.9077 R-Sqauare 0.9302 
δ 2.1840 
Insulin 
Fit 
  
D09 is both 
underdamp and 
overdamp. But 
D09 is 
hyperinsulinemia 
which made him 
diabetic. 
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Parameters Values Fitting Remarks 
A 0.2317 SSE 3.504e-014 
G 1.727   
ω 1.25 
Glucose 
Fit 
R-Square 1 
α 0.2408 SSE 0.001175 
β 0.03264   
γ 0.2226 R-Sqauare 0.9191 
δ 6.6821 
Insulin 
Fit 
  
D10 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 0.6341 SSE 0.01286 
G 2.505   
ω 0.2299 
Glucose 
Fit 
R-Square 0.9909 
α -0.1354 SSE 2.38e-006 
β 0.003215   
γ 1.4036 R-Sqauare 0.99 
δ -3.3272 
Insulin 
Fit 
  
D11 is diabetic as 
diagnosed due to 
hypoinsulinemia. 
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Parameters Values Fitting Remarks 
A 1.079 SSE 9.947e-015 
G 2.088   
ω 0.5839 
Glucose 
Fit 
R-Square 1 
α 0.4384 SSE 0.0002028 
β 0.05879   
γ 1.7196 R-Sqauare 0.9856 
δ 3.2030 
Insulin 
Fit 
  
D12 fits all the 3 
classes. But D12 
is 
hyperinsulinemia 
which make D12 
diabetic. 
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Parameters Values Fitting Remarks 
A 0.6509 SSE 2.082e-006 
G 2.626   
ω 0.9838 
Glucose 
Fit 
R-Square 1 
α 0.3579 SSE 3.371e-007 
β 0.01774   
γ 0.9439 R-Sqauare 0.9999 
δ 3.8409 
Insulin 
Fit 
  
D13 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D13  diabetic.         
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Parameters Values Fitting Remarks 
A 0.2949 SSE 0.0004414 
G 1.221   
ω 1.115 
Glucose 
Fit 
R-Square 0.9988 
α 0.2056 SSE 0.0004341 
β 0.0346   
γ 0.3842 R-Sqauare 0.929 
δ 6.4055 
Insulin 
Fit 
  
D14 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D14 diabetic 
(hypoinsulinemia)
.                               
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Parameters Values Fitting Remarks 
A 0.3872 SSE 0.001152 
G 1.314   
ω 1.033 
Glucose 
Fit 
R-Square 0.9967 
α 0.1625 SSE 8.684e-006 
β 0.01933   
γ 0.6119 R-Sqauare 0.9949 
δ 7.4145 
Insulin 
Fit 
  
D15 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D15 diabetic.          
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Parameters Values Fitting Remarks 
A 0.6194 SSE 2.986e-010 
G 1.749   
ω 0.8981 
Glucose 
Fit 
R-Square 1 
α 0.2250 SSE 0.0002776 
β 0.0422   
γ 1.0138 R-Sqauare 0.9763 
δ 5.0993 
Insulin 
Fit 
  
D16 fits all 3 
classes. But the 
poor insulin 
response make 
D16 diabetic.          
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Parameters Values Fitting Remarks 
A 1.493 SSE  
G 0.2053   
ω 0.008486 
Glucose 
Fit 
R-Square  
α  SSE 0.0006155 
β 0.4654   
γ  R-Sqauare 0.8741 
δ  
Insulin 
Fit 
  
D17 is diabetic 
because the 
glucose did not 
come down after 
2 hours. 
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Parameters Values Fitting Remarks 
A 0.4577 SSE 0.9914 
G 1.261   
ω 1.817e-7 
Glucose 
Fit 
R-Square 0.974 
α -0.3340 SSE 0.0002437 
β 0.03025   
γ 1.2494 R-Sqauare 0.9814 
δ -0.5140 
Insulin 
Fit 
  
D18 fits both the 
underdamp and 
overdamp classes 
and D18 is 
diabetic because 
glucose did not 
go down after 2 
hour and 
hypoinulinemia. 
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Parameters Values Fitting Remarks 
A 1.395e-8 SSE 0.004518 
G 0.8465   
ω 0.6069 
Glucose 
Fit 
R-Square 0.996 
α -0.6275 SSE 2.913e-005 
β 0.01634   
γ 0.6275 R-Sqauare 0.9945 
δ -0.5707 
Insulin 
Fit 
  
D19 is at the rim 
of being diabetic 
due to 
hypoinsulinemia 
and the glucose 
cannot go down 
after 2 hours.  
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Parameters Values Fitting Remarks 
A 0.3099 SSE 0.01668 
G 1.989   
ω 0.4528 
Glucose 
Fit 
R-Square 0.9931 
α -0.3932 SSE 1.557e-006 
β 0.002839   
γ 1.0130 R-Sqauare 0.9955 
δ -0.7584 
Insulin 
Fit 
  
D20 is diabetic 
due to 
hypoinsulinemia 
and the glucose 
cannot go down 
after 2 hours.  
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Appendix B 
 
 
Overdamp Responses for Subjects N01-N20 
 
These 40 subjects (N01 to N20) were diagnosed by physician as normal and (D01 to 
D20) were diagnosed by physician as diabetic. 
 
Characteristic equation for glucose fitting for underdamp (healthy and non-diabetic) 
subjects : 
 
y(t) = (G/ ω) e-At sinωt 
 
Characteristic equation for insulin fitting for underdamp (healthy and non-diabetic) 
subjects : 
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G:  glucose administered to the system in gram/liter hour 
 
A:  attenuation constant in 1/hour 
 
x: blood insulin concentration (from its fasting level) 
 
y : blood glucose concentration (from its fasting level) 
 
α: represents pancreatic insulin sensitivity to insulin (average insulin removal-rate 
independent of glucose) in (hr)-1 
 
β:  pancreatic insulin sensitivity to elevated glucose blood concentrations (net increase 
in insulin release-rate due to glucose) in (Units) (hr)-1(gms)-1 
 
γ : liver glycogen storage to elevated blood-glucose concentrations (net increase in 
glucose removal due to insulin) in (gms)(hr)-1 (Units)-1  
 
δ: tissue glucose utilisation to elevated blood-glucose concentrations (average     
glucose removal-rate independent of insulin) in (hr)-1 
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Summary of the fit 
 
Best Fitted (R-Square > 95%) No Fit 
N01 N02 
N07 N04 
 N12 
D01 N16 
D02 N20 
D04  
D08  
D09  
D10  
D11  
D13  
D14  
D15  
D16  
D18  
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Parameters Values Fitting Remarks 
A 17.06 SSE 0.00439 
G 23.81   
ω 16.6 
Glucose 
Fit 
R-Square 0.9739 
α 0.4580 SSE 0.000236 
β 0.0530   
γ 1.2539 R-Sqauare 0.97 
δ 33.6620 
Insulin 
Fit 
  
S01 actually is 
diabetic even the 
clinician 
diagnosed him as 
normal. 
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 0.0005799 
β    
γ  R-Sqauare 0.9274 
δ  
Insulin 
Fit 
  
S02 is normal. 
Just as the 
clinician has 
diagnosed. 
 
 
No Fit !
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Parameters Values Fitting Remarks 
A 1.965 SSE 0.009331 
G 3.673   
ω 6.994e-14 
Glucose 
Fit 
R-Square 0.9724 
α 1.1733 SSE 1.567e-006 
β 0.0107   
γ 58.5790 R-Sqauare 0.9945 
δ 2.7567 
Insulin 
Fit 
  
S03 is in a 
dangerous rim. 
The insulin 
response is too 
little. 
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 3.677e-005 
β    
γ  R-Sqauare 0.9988 
δ  
Insulin 
Fit 
  
S04 is at the rim 
of being diabetic 
due to  
hyperinsulinemia. 
 
 
No Fit !
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Parameters Values Fitting Remarks 
A 2.999 SSE 0.0306 
G 3.047   
ω 3.43e-8 
Glucose 
Fit 
R-Square 0.8182 
α 2.2072 SSE 0.000525 
β 0.01897   
γ 33.0478 R-Sqauare 0.8309 
δ 3.7908 
Insulin 
Fit 
  
S05 is normal. 
Just as the 
clinician has 
diagnosed.            
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Parameters Values Fitting Remarks 
A 2.14 SSE 0.02686 
G 3.631   
ω 1.416e-6 
Glucose 
Fit 
R-Square 0.9078 
α 1.3484 SSE 0.002328 
β 0.05334   
γ 11.7471 R-Square 0.9057 
δ 2.9316 
Insulin 
Fit 
  
S06 is normal. 
Just as diagnosed 
by the clinician.  
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Parameters Values Fitting Remarks 
A 19.49 SSE 0.00368 
G 26.79   
ω 19.38 
Glucose 
Fit 
R-Square 0.98781 
α 0.1090 SSE 0.001322 
β 0.0485   
γ 0.8000 R-Sqauare 0.9127 
δ 38.8710 
Insulin 
Fit 
  
S07 is diabetic. 
But was the 
clinician 
diagnosed as 
normal. 
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Parameters Values Fitting Remarks 
A 13 SSE 0.009592 
G 17.25   
ω 11.85 
Glucose 
Fit 
R-Square 0.8923 
α 1.4005 SSE 0.009592 
β 0.06246   
γ 3.7960 R-Square 0.8923 
δ 24.8600 
Insulin 
Fit 
  
S08 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A 5.147 SSE 0.0001795 
G 1.294   
ω 5.281 
Glucose 
Fit 
R-Square 0.9887 
α 0.1022 SSE 0.0006221 
β 0.1238   
γ -19.6984 R-Sqauare 0.924 
δ 10.1918 
Insulin 
Fit 
  
S09 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A 10 SSE 0.002985 
G 11.81   
ω 8.726 
Glucose 
Fit 
R-Square 0.9577 
α 1.5231 SSE 3.613e-005 
β 0.05142   
γ -83.3224 R-Sqauare 0.9905 
δ 18.4769 
Insulin 
Fit 
  
S10 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 0.000105 
β    
γ  R-Sqauare 0.9909 
δ  
Insulin 
Fit 
  
S12 is at the rim 
of being diabetic 
due to 
hyperinsulinemia. 
 
No Fit !
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Parameters Values Fitting Remarks 
A 2.014 SSE 0.01051 
G 3.449   
ω 7.791e-7 
Glucose 
Fit 
R-Square 0.9648 
α 1.2223 SSE 0.000783 
β 0.06653   
γ 9.4209 R-Sqauare 0.9407 
δ 2.8057 
Insulin 
Fit 
  
S13 is classified 
as normal. But 
S13 is 
hyperinsulinemia. 
S13 fits all 3 
classes. 
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Parameters Values Fitting Remarks 
A 3.338 SSE 0.0009462 
G 4.669   
ω 2.608e-5 
Glucose 
Fit 
R-Square 0.9935 
α 2.5464 SSE 0.0002345 
β 0.1059   
γ 5.9173 R-Sqauare 0.99 
δ 4.1296 
Insulin 
Fit 
  
S14 is classified 
as normal. But 
S14 is 
hyperinsulinemia. 
S14 fits all 3 
classes. 
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Parameters Values Fitting Remarks 
A 1.95 SSE 0.0006351 
G 3.192   
ω 0.8446 
Glucose 
Fit 
R-Square 0.9974 
α 0.8902 SSE 0.001064 
β 0.03186   
γ 12.8649 R-Sqauare 0.747 
δ 3.0098 
Insulin 
Fit 
  
S15 is at the rim. 
S15 is classified 
as normal by 
clinician. 
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 0.001593 
β    
γ  R-Sqauare 0.812 
δ  
Insulin 
Fit 
  
S16 is normal just 
as diagnosed by 
clinician. 
 
No Fit !
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Parameters Values Fitting Remarks 
A 1.0570 SSE 0.007286 
G 2.6370   
ω 0.0001 
Glucose 
Fit 
R-Square 0.9652 
α 1.1653 SSE 0.0003414 
β 0.04395   
γ 0.2667 R-Sqauare 0.8759 
δ 0.9487 
Insulin 
Fit 
  
S17 is normal just 
as diagnosed by 
clinician. 
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Parameters Values Fitting Remarks 
A 3.428 SSE 9.344e-005 
G 7.435   
ω 1.562 
Glucose 
Fit 
R-Square 0.9997 
α 1.8827 SSE 0.0003789 
β 0.0806   
γ -0.6430 R-Sqauare 0.9873 
δ 4.9733 
Insulin 
Fit 
  
S18 fit all classes. 
S18 suffers from 
hyperinsulinemia. 
The p ancreas 
will not able to 
sustain the insulin 
requirement as 
age catches up.   
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Parameters Values Fitting Remarks 
A 3.071 SSE 0.04835 
G 5.294   
ω 9.085e-6 
Glucose 
Fit 
R-Square 0.8762 
α 2.0313 SSE 0.0005561 
β 0.05965   
γ 1943.9449 R-Sqauare 0.9622 
δ 4.1107 
Insulin 
Fit 
  
S19 is at the rim 
even though S19 
is diagnosed as 
normal.  
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 8.242e-006 
β    
γ  R-Sqauare 0.9992 
δ  
Insulin 
Fit 
  
S20 is at the rim 
even though S20 
is diagnosed as 
normal.                   
 
 
 
No Fit ! 
 
 
 22
Overdamp Responses for Subjects D01-D20 
 
These 20 subjects were diagnosed by physician as diabatic. 
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Parameters Values Fitting Remarks 
A 0.6417 SSE 0.005257 
G 3.969   
ω 0.0002767 
Glucose 
Fit 
R-Square 0.9986 
α 0.3084 SSE 0.0002635 
β 0.004821   
γ 23.0383 R-Sqauare 0.8995 
δ 0.9750 
Insulin 
Fit 
  
Glucose comes 
down very 
slowly. D01 is 
diabetic. 
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Parameters Values Fitting Remarks 
A 1.423 SSE 0.08397 
G 3.861   
ω 1.413e-8 
Glucose 
Fit 
R-Square 0.9037 
α 0.0290 SSE 0.001199 
β 0.027   
γ 71.9693 R-Sqauare 0.9113 
δ 2.8170 
Insulin 
Fit 
  
D02 fit both the 
underdamp & 
criticaldamp  but 
D02 is classified 
as diabetic by 
clinician.  
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Parameters Values Fitting Remarks 
A 1.669 SSE 0.07669 
G 4.193   
ω 1.942e-8 
Glucose 
Fit 
R-Square 0.9045 
α 0.8773 SSE 0.001824 
β 0.02348   
γ 26.6938 R-Sqauare 0.8309 
δ 2.4607 
Insulin 
Fit 
  
D03 fit both the 
criticaldamp & 
overdamp cases 
and D03 is 
classified as 
diabetic.  
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Parameters Values Fitting Remarks 
A 0.625 SSE 0.05984 
G 2.549   
ω 0.002262 
Glucose 
Fit 
R-Square 0.9657 
α 0.2916 SSE 9.657e-006 
β 0.001065   
γ 104.3761 R-Sqauare 0.8807 
δ 0.9584 
Insulin 
Fit 
  
D04 is diabetic 
just as diagnosed 
as diabetic by the 
clinician. 
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Parameters Values Fitting Remarks 
A 1.385 SSE 0.1906 
G 5.32   
ω 0.0001507 
Glucose 
Fit 
R-Square 0.9031 
α 0.4972 SSE 0.0004872 
β 0.01742   
γ 45.2428 R-Sqauare 0.9288 
δ 2.2728 
Insulin 
Fit 
  
D05 fits both the 
underdamp and 
overdamp classes 
even though D05 
has been 
diagnosed as 
diabetic. 
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Parameters Values Fitting Remarks 
A 2.645 SSE 0.02143 
G 6.237   
ω 2.666 
Glucose 
Fit 
R-Square 0.9831 
α 0.1224 SSE 0.0008588 
β 0.02389   
γ -31.1520 R-Sqauare 0.9223 
δ 5.1676 
Insulin 
Fit 
  
D06 is diabetic 
just as diagnosed. 
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Parameters Values Fitting Remarks 
A 0.9804 SSE 0.08127 
G 4.903   
ω 4.739e-9 
Glucose 
Fit 
R-Square 0.9626 
α 0.1888 SSE 0.00108 
β 0.01145   
γ 54.7338 R-Sqauare 0.908 
δ 1.7720 
Insulin 
Fit 
  
D07 is diabetic as  
diagnosed. 
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Parameters Values Fitting Remarks 
A 0.6559 SSE 0.03229 
G 2.544   
ω 1.657e-8 
Glucose 
Fit 
R-Square 0.9812 
α 0.3225 SSE  
β 0.0047   
γ 23.7478 R-Sqauare  
δ 0.9893 
Insulin 
Fit 
  
D08 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 0.8842 SSE 0.1222 
G 2.469   
ω 4.399e-7 
Glucose 
Fit 
R-Square 0.8484 
α 0.0926 SSE 0.003369 
β 0.04805   
γ 13.0412 R-Sqauare 0.9321 
δ 1.6758 
Insulin 
Fit 
  
D09 is both 
underdamp and 
overdamp. But 
D09 is 
hyperinsulinemia 
which made him 
diabetic. 
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Parameters Values Fitting Remarks 
A 1.141 SSE 0.03882 
G 2.549   
ω 0.002444 
Glucose 
Fit 
R-Square 0.932 
α 0.3545 SSE 0.0009398 
β 0.03776   
γ 16.3837 R-Sqauare 0.9353 
δ 1.9275 
Insulin 
Fit 
  
D10 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 0.6071 SSE 0.01983 
G 2.34   
ω 0.01611 
Glucose 
Fit 
R-Square 0.986 
α 0.1847 SSE 1.71e-006 
β 0.003146   
γ 56.6408 R-Sqauare 0.9928 
δ 1.0295 
Insulin 
Fit 
  
D11 is diabetic as 
diagnosed due to 
hypoinsulinemia. 
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Parameters Values Fitting Remarks 
A 1.493 SSE 0.01089 
G 2.55   
ω 0.6789 
Glucose 
Fit 
R-Square 0.9601 
α 0.5222 SSE 0.005144 
β 0.06375   
γ 7.5524 R-Sqauare 0.8506 
δ 2.4638 
Insulin 
Fit 
  
D12 fits all the 3 
classes. But D12 
is 
hyperinsulinemia 
which make D12 
diabetic. 
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Parameters Values Fitting Remarks 
A 1.064 SSE 0.007607 
G 3.289   
ω 0.000116 
Glucose 
Fit 
R-Square 0.9908 
α 0.3193 SSE 0.0003601 
β 0.01837   
γ 30.1855 R-Sqauare 0.9525 
δ 1.8087 
Insulin 
Fit 
  
D13 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D13 diabetic.          
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Parameters Values Fitting Remarks 
A 1.138 SSE 0.01089 
G 2.446   
ω 3.697e-12 
Glucose 
Fit 
R-Square 0.97 
α 0.3465 SSE 0.001175 
β 0.02519   
γ 24.8718 R-Sqauare 0.8875 
δ 1.9295 
Insulin 
Fit 
  
D14 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D14 diabetic.          
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Parameters Values Fitting Remarks 
A 0.8598 SSE 0.00493 
G 1.701   
ω 0.00122 
Glucose 
Fit 
R-Square 0.986 
α 0.0681 SSE 7.087e-005 
β 0.01718   
γ 36.4844 R-Sqauare 0.9588 
δ 1.6515 
Insulin 
Fit 
  
D15 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D15 diabetic 
(hypoinsulinemia)
.                               
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Parameters Values Fitting Remarks 
A 0.9321 SSE 0.139 
G 2.024   
ω 2.434e-6 
Glucose 
Fit 
R-Square 0.7794 
α 0.1404 SSE 0.0009265 
β 0.04119   
γ 15.2168 R-Sqauare 0.9261 
δ 1.7238 
Insulin 
Fit 
  
D16 fits all 3  
classes. But the 
poor insulin 
response make 
D16 diabetic.          
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Parameters Values Fitting Remarks 
A 0.4891 SSE 0.1525 
G 1.272   
ω 0.3127 
Glucose 
Fit 
R-Square 0.8738 
α 0.1700 SSE 0.0002298 
β 0.03031   
γ 0.1334 R-Sqauare 0.9824 
δ 0.8082 
Insulin 
Fit 
  
D18 fits both the 
underdamp and 
overdamp classes 
and D18 is 
diabetic because 
glucose did not 
go down after 2 
hour and 
hypoinulinemia. 
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Parameters Values Fitting Remarks 
A 0.8744 SSE 0.005731 
G 1.606   
ω 1.224 
Glucose 
Fit 
R-Square 0.995 
α 0.0300 SSE 0.0003881 
β 0.01575   
γ -49.8517 R-Sqauare 0.9268 
δ 1.7188 
Insulin 
Fit 
  
D19 is at the rim 
of being diabetic 
due to 
hypoinsulinemia 
and the glucose 
cannot go down 
after 2 hours.  
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Parameters Values Fitting Remarks 
A 0.3113 SSE 0.0292 
G 2.145   
ω 0.5711 
Glucose 
Fit 
R-Square 0.9879 
α -0.6534 SSE 5.844e-006 
β 0.002338   
γ 258.5238 R-Sqauare 0.9829 
δ 1.2760 
Insulin 
Fit 
  
D20 is diabetic 
due to 
hypoinsulinemia 
and the glucose 
cannot go down 
after 2 hours.  
 
 
 1
Appendix C 
 
 
Critical Damp Responses for Subjects N01-N20 
 
These 40 subjects (N01 to N20) were diagnosed by physician as normal and (D01 to 
D20) were diagnosed by physician as diabetic. 
 
Characteristic equation for glucose fitting for underdamp (healthy and non-diabetic) 
subjects : 
 
-Aty(t)= Gte  
 
Characteristic equation for insulin fitting for underdamp (healthy and non-diabetic) 
subjects : 
 
( ) ( ) ( ) ( )
2
( )( )
( )
At At At tG tAe t e e ex t
A
αβ α
α
− − − −− − + −= −  
 
G:  glucose administered to the system in gram/liter hour 
 
A:  attenuation constant in 1/hour 
 
x: blood insulin concentration (from its fasting level) 
 
y : blood glucose concentration (from its fasting level) 
 
α: represents pancreatic insulin sensitivity to insulin (average insulin removal-rate 
independent of glucose) in (hr)-1 
 
β:  pancreatic insulin sensitivity to elevated glucose blood concentrations (net increase 
in insulin release-rate due to glucose) in (Units) (hr)-1(gms)-1 
 
γ : liver glycogen storage to elevated blood-glucose concentrations (net increase in 
glucose removal due to insulin) in (gms)(hr)-1 (Units)-1  
 
δ: tissue glucose utilisation to elevated blood-glucose concentrations (average     
glucose removal-rate independent of insulin) in (hr)-1 
 2
Summary of the fit 
 
Best Fitted (R-Square > 95%) No Fit 
N03 N02 
N04 N08 
N06 N09 
N08 N11 
N10 N16 
N12 N20 
N13  
N18  
  
D05  
D06  
D07  
D12  
D17  
D19  
D20  
 3
 
 
 
Parameters Values Fitting Remarks 
A 1.5580 SSE 0.01147 
G 2.4850   
ω 0 
Glucose 
Fit 
R-Square 0.932 
α 14.880 SSE 0.001363 
β 3.3180   
γ 53.4888 R-Square 0.827 
δ -11.7640 
Insulin 
Fit 
  
S01 actually is 
diabetic even the 
clinician 
diagnosed him as 
normal. 
 4
 
 
Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 0.0001546 
β    
γ  R-Square 0.9806 
δ  
Insulin 
Fit 
  
S02 is normal. 
Just as the 
clinician has 
diagnosed.              
 
No Fit !
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Parameters Values Fitting Remarks 
A 1.9650 SSE 4.06e-005 
G 3.6740   
ω 0 
Glucose 
Fit 
R-Square 0.9999 
α 3.0000 SSE 9.172e-006 
β 0.1194   
γ 8.9717 R-Square 0.9719 
δ 0.9300 
Insulin 
Fit 
  
S03 is in a 
dangerous rim. 
The insulin 
response is too 
little. 
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Parameters Values Fitting Remarks 
A 2.3100 SSE 0.001044 
G 3.0480   
ω 0 
Glucose 
Fit 
R-Square 0.9926 
α 3.903 SSE 0.001106 
β 2.369   
γ 1.0712 R-Square 0.9628 
δ 0.7170 
Insulin 
Fit 
  
S04 is at the rim 
of being diabetic 
due to 
hyperinsulinemia. 
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Parameters Values Fitting Remarks 
A 2.5090 SSE 0.004765 
G 4.1120   
ω 0 
Glucose 
Fit 
R-Square 0.977 
α 2.2200 SSE 0.003012 
β 0.6139   
γ 0.1360 R-Square 0.878 
δ 2.7980 
Insulin 
Fit 
  
S06 is normal. 
Just as diagnosed 
by the clinician.  
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 0.0003069 
β    
γ  R-Sqauare 0.9094 
δ  
Insulin 
Fit 
  
S08 is normal. 
Just as diagnosed 
by the clinician. 
 
 
 
No Fit !
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 0.0004597 
β    
γ  R-Square 0.9439 
δ  
Insulin 
Fit 
  
S09 is normal. 
Just as diagnosed 
by the clinician. 
 
No Fit !
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Parameters Values Fitting Remarks 
A 2.3800 SSE 0.003919 
G 2.3660   
ω 0 
Glucose 
Fit 
R-Square 0.9444 
α 4.7000 SSE 2.857e-005 
β 1.8220   
γ 2.9541 R-Sqauare 0.9925 
δ 0.0600 
Insulin 
Fit 
  
S10 is normal. 
Just as diagnosed 
by the clinician. 
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 7.103e-005 
β    
γ  R-Square 0.9671 
δ  
Insulin 
Fit 
  
S11 is normal. 
Just as diagnosed 
by the clinician. 
 
 
 
No Fit !
 12
 
 
Parameters Values Fitting Remarks 
A 3.918 SSE 0.001604 
G 5.531   
ω 0 
Glucose 
Fit 
R-Square 0.984 
α 1.1110 SSE 0.0002499 
β 2.4710   
γ 3.1887 R-Sqauare 0.9784 
δ 6.7250 
Insulin 
Fit 
  
S12 is at the rim 
of being diabetic. 
Due to 
hyperinsulinemia. 
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Parameters Values Fitting Remarks 
A 2.015 SSE 0.007236 
G 3.451   
ω 0 
Glucose 
Fit 
R-Square 0.9758 
α 4.0000 SSE 0.0008218 
β 1.2960   
γ 3.0403 R-Square 0.9377 
δ 0.0300 
Insulin 
Fit 
  
S13 is classified 
as normal. But 
S13 is 
hyperinsulinemia. 
S13 fits all 3 
classes. 
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Parameters Values Fitting Remarks 
A 3.076 SSE 0.0006338 
G 4.096   
ω 0 
Glucose 
Fit 
R-Square 0.9956 
α 7.852 SSE 9.179e-006 
β 3.265   
γ 6.9863 R-Square 0.9996 
δ -1.7000 
Insulin 
Fit 
  
S14 is classified 
as normal. But 
S14 is 
hyperinsulinemia. 
S14 fits all 3 
classes. 
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Parameters Values Fitting Remarks 
A 1.777 SSE 0.0006045 
G 3.015   
ω 0 
Glucose 
Fit 
R-Square 0.9975 
α 1.007 SSE 3.718e-005 
β 0.2051   
γ 2.8908 R-Square 0.9912 
δ 2.5470 
Insulin 
Fit 
  
S15 is at the rim. 
S15 is classified 
as normal by 
clinician. 
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 0.00122 
β    
γ  R-Square 0.8561 
δ  
Insulin 
Fit 
  
S16 is normal just 
as diagnosed by 
clinician. 
 
No Fit !
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Parameters Values Fitting Remarks 
A 1.946 SSE 0.005027 
G 2.593   
ω 0 
Glucose 
Fit 
R-Square 0.976 
α 1.802 SSE 4.278e-005 
β 0.3369   
γ 0.0615 R-Sqauare 0.9845 
δ 2.0900 
Insulin 
Fit 
  
S17 is normal just 
as diagnosed by 
clinician. 
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Parameters Values Fitting Remarks 
A 2.721 SSE 0.0002072 
G 5.768   
ω 0 
Glucose 
Fit 
R-Square 0.9994 
α 5.4000 SSE 0.0003633 
β 3.1960   
γ 2.2456 R-Square 0.9878 
δ 0.0420 
Insulin 
Fit 
  
S18 fit all classes. 
S18 suffers from 
hyperinsulinemia. 
The pancreas will 
not able to sustain 
the insulin 
requirement as 
age catches up.   
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Parameters Values Fitting Remarks 
A 2.67 SSE 0.003802 
G 4.332   
ω 0 
Glucose 
Fit 
R-Square 0.9828 
α 4.62 SSE 6.6e-005 
β 1.288   
γ 2.9523 R-Square 0.9955 
δ 0.7200 
Insulin 
Fit 
  
S19 is at the rim 
even though S19 
is diagnosed as 
normal.  
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Parameters Values Fitting Remarks 
A  SSE  
G    
ω  
Glucose 
Fit 
R-Square  
α  SSE 1.541e-006 
β    
γ  R-Square 0.9998 
δ  
Insulin 
Fit 
  
S20 is at the rim 
even though S20 
is diagnosed as 
normal.                   
 
 
 
 
 
No Fit !
 21
Critical Damp Responses for Subjects D01-D20 
 
These 20 subjects were diagnosed by physician as diabatic. 
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Parameters Values Fitting Remarks 
A 0.6417 SSE 0.00362 
G 3.969   
ω 0 
Glucose 
Fit 
R-Square 0.999 
α 1.2800 SSE 1.856e-005 
β 0.05883   
γ 6.9255 R-Square 0.9914 
δ 0.0034 
Insulin 
Fit 
  
Glucose comes 
down very 
slowly. D01 is 
diabetic. 
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Parameters Values Fitting Remarks 
A 1.365 SSE 0.0573 
G 3.64   
ω 0 
Glucose 
Fit 
R-Square 0.9343 
α 5.6020 SSE 2.153e-005 
β 0.5870   
γ 30.5829 R-Sqauare 0.9961 
δ -2.8720 
Insulin 
Fit 
  
D02 fits both the 
underdamp & 
critical but D02 is 
classified as 
diabetic by 
clinician.  
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Parameters Values Fitting Remarks 
A 1.669 SSE 0.05294 
G 4.193   
ω 0 
Glucose 
Fit 
R-Square 0.9341 
α 2.3 SSE 0.001453 
β 0.2561   
γ 1.5547 R-Square 0.8653 
δ 1.0380 
Insulin 
Fit 
  
D03 fit both the 
criticaldamp & 
overdamp cases 
and D03 is 
classified as 
diabetic.  
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Parameters Values Fitting Remarks 
A 0.6857 SSE 0.02677 
G 2.779   
ω 0 
Glucose 
Fit 
R-Square 0.9846 
α 1.3700 SSE 5.341e-005 
β 0.4901   
γ 0.9555 R-Sqauare 0.3405 
δ 0.0014 
Insulin 
Fit 
  
D04 is diabetic 
just as diagnosed 
as diabetic by the 
clinician. 
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Parameters Values Fitting Remarks 
A 1.3530 SSE 0.01169 
G 5.0750   
ω 0 
Glucose 
Fit 
R-Square 0.9912 
α 2.24 SSE 0.0006006 
β 0.1862   
γ 4.2254 R-Sqauare 0.9122 
δ 0.4660 
Insulin 
Fit 
  
D05 fits both the 
underdamp and 
overdamp classes 
even though D05 
has been 
diagnosed as 
diabetic. 
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Parameters Values Fitting Remarks 
A 0.8552 SSE 0.02032 
G 3.374   
ω 0 
Glucose 
Fit 
R-Square 0.984 
α 1.7100 SSE 0.0008946 
β 0.1883   
γ 3.8804 R-Square 0.919 
δ 0.0004 
Insulin 
Fit 
  
D06 is diabetic 
just as diagnosed. 
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Parameters Values Fitting Remarks 
A 0.9793 SSE 0.05622 
G 4.895   
ω 0 
Glucose 
Fit 
R-Square 0.9741 
α 1.639 SSE 0.0002503 
β 0.1128   
γ 3.8582 R-Sqauare 0.9787 
δ 0.3196 
Insulin 
Fit 
  
D07 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 0.6559 SSE 0.02241 
G 2.544   
ω 0 
Glucose 
Fit 
R-Square 0.9869 
α 1.3000 SSE 3.166e-005 
β 0.5800   
γ 0.7153 R-Sqauare 0.954 
δ 0.0118 
Insulin 
Fit 
  
D08 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 0.8323 SSE 0.08382 
G 2.345   
ω 0 
Glucose 
Fit 
R-Square 0.896 
α 1.6500 SSE 0.005695 
β 0.6853   
γ 0.9757 R-Sqauare 0.8853 
δ 0.0146 
Insulin 
Fit 
  
D09 is both 
underdamp and 
overdamp. But 
D09 is 
hyperinsulinemia 
which made him 
diabetic. 
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Parameters Values Fitting Remarks 
A 1.141 SSE 0.02676 
G 2.548   
ω 0 
Glucose 
Fit 
R-Square 0.9531 
α 1.224 SSE 0.0006304 
β 0.3106   
γ 0.0222 R-Sqauare 0.9566 
δ 1.0580 
Insulin 
Fit 
  
D10 is diabetic as 
diagnosed. 
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Parameters Values Fitting Remarks 
A 0.6563 SSE 0.008877 
G 2.527   
ω 0 
Glucose 
Fit 
R-Square 0.9937 
α 4.949 SSE 2.88e-007 
β 0.06252   
γ 294.7421 R-Sqauare 0.9988 
δ -3.6364 
Insulin 
Fit 
  
D11 is diabetic as 
diagnosed due to 
hypoinsulinemia. 
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Parameters Values Fitting Remarks 
A 1.3190 SSE 0.004315 
G 2.3550   
ω 0 
Glucose 
Fit 
R-Square 0.9842 
α 0.2678 SSE 0.003725 
β 0.2912   
γ 3.7947 R-Sqauare 0.8918 
δ 2.3702 
Insulin 
Fit 
  
D12 fits all the 3 
classes. But D12 
is 
hyperinsulinemia 
which make D12 
diabetic. 
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Parameters Values Fitting Remarks 
A 1.057 SSE 0.005289 
G 3.256   
ω 0 
Glucose 
Fit 
R-Square 0.9936 
α 4.817 SSE 0.0002791 
β 0.4665   
γ 30.3057 R-Sqauare 0.9632 
δ -2.7030 
Insulin 
Fit 
  
D13 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D13 diabetic.          
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Parameters Values Fitting Remarks 
A 1.001 SSE 0.006614 
G 2.093   
ω 0 
Glucose 
Fit 
R-Square 0.9818 
α 5.837 SSE 0.002389 
β 0.8463   
γ 27.6343 R-Sqauare 0.7713 
δ -3.8350 
Insulin 
Fit 
  
D14 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D14 diabetic.          
 36
 
 
 
Parameters Values Fitting Remarks 
A 0.8364 SSE 0.00341 
G 1.662   
ω 0 
Glucose 
Fit 
R-Square 0.9903 
α 18.2 SSE 0.0001411 
β 1.281   
γ 235.3588 R-Sqauare 0.9181 
δ -16.5272 
Insulin 
Fit 
  
D15 fits both 
underdamp and 
overdamp. But 
the poor insulin 
response make 
D15 diabetic 
(hypoinsulinemia)
.                               
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Parameters Values Fitting Remarks 
A 1.093 SSE 0.0004424 
G 2.445   
ω 0 
Glucose 
Fit 
R-Square 0.9989 
α 2.1000 SSE 0.0003494 
β 1.6130   
γ 0.6287 R-Sqauare 0.9702 
δ 0.0860 
Insulin 
Fit 
  
D16 fits all 3 
classes. But the 
poor in sulin 
response make 
D16 diabetic.          
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Parameters Values Fitting Remarks 
A 0.3169 SSE 0.01966 
G 1.112   
ω 0 
Glucose 
Fit 
R-Square 0.9742 
α 0.6000 SSE 0.004513 
β 0.7800   
γ 0.1028 R-Sqauare 0.0771 
δ 0.0338 
Insulin 
Fit 
  
D17 is diabetic 
because the 
glucose did not 
come down after 
2 hours. 
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Parameters Values Fitting Remarks 
A 0.4489 SSE 1.563e-005 
G 1.252   
ω 0 
Glucose 
Fit 
R-Square 1 
α 0.8900 SSE 2.796e-006 
β 0.3504   
γ 0.5553 R-Square 0.9998 
δ 0.0078 
 
Insulin 
Fit 
  
D18 fits both the 
underdamp and 
overdamp classes 
and D18 is 
diabetic because 
glucose did not 
go down after 2 
hour and 
hypoinulinemia. 
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Parameters Values Fitting Remarks 
A 0.1892 SSE 0.003993 
G 0.9563   
ω 0 
Glucose 
Fit 
R-Square 0.9965 
α 0.3700 SSE 5.421e-005 
β 0.6064   
γ 0.0539 R-Sqauare 0.9898 
δ 0.0084 
Insulin 
Fit 
  
D19 is at the rim 
of being diabetic 
due to 
hypoinsulinemia 
and the glucose 
cannot go down 
after 2 hours.  
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Parameters Values Fitting Remarks 
A 0.3942 SSE 0.0124 
G 2.046   
ω 0 
Glucose 
Fit 
R-Square 0.9948 
α 0.7600 SSE 1.256e-005 
β 0.2282   
γ 0.5864 R-Sqauare 0.9633 
δ 0.0284 
Insulin 
Fit 
  
D20 is diabetic 
due to 
hypoinsulinemia 
and the glucose 
cannot go down 
after 2 hours.  
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Appendix D 
 
 
 
 
 
Figure E.1 Non-dimensional plot of Figure 100 Non-dimensional plot of 
6max 2 max
2_ _ 1032
dy y T TG NDI I NDI
G A
βγδ
α
×⎛ ⎞ ⎛ ⎞× = × × × ×⎜ ⎟⎜ ⎟ ⎝ ⎠⎝ ⎠  for all the 40 patients with 
some data removed due to experimental errors. 
 2
 
 
Figure E.2 Non-dimensional plot of Figure 100 Non-dimensional plot of 
( ) 22 max_
_
mn
m m
y yA G xG NDI
y y GI NDI
ω α
β
−⎛ ⎞ ⎛ ⎞× ×= × ×⎜ ⎟ ⎜ ⎟⎝ ⎠⎝ ⎠
 for all the 40 patients with some data 
removed due to experimental errors. 
 3
 
 
 
 
Figure E.3 Non-dimensional plot of Figure 100 Non-dimensional plot of 
( ) 22 max_ _ mn
m m
y yA G xG NDI I NDI
y y G
ω α
β
−⎛ ⎞ ⎛ ⎞× ×× = × × ×⎜ ⎟ ⎜ ⎟⎝ ⎠⎝ ⎠
 for all the 40 patients with some 
data removed due to experimental errors. 
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Appendix E 
 
 
 
TABLE – 1: Nomenclature 
 
SYMBOL MEANING UNITS 
T Time             Hour (hr) 
V Extra-cellular fluid volume  Liter (l) 
I
?
 Rate of insulin injection Units/hour (U/hr) 
G
?
 
Rate of Glucose Injection   Grams/hour (gm/hr) 
X 
 
Extra-cellular insulin 
concentration 
Units/liter (U/l) 
Y 
 
Extra-cellular glucose 
concentration 
Grams/liter (gm/hr) 
X(ss) Steady-state insulin 
concentration 
Units/liter (U/l) 
Y(ss) Steady-state glucose 
concentration      
Grams/liter (gm/hr) 
F1(x) 
 
Rate of insulin destruction  Units/hour (U/hr) 
F2(y) Rate of insulin production Units/hour (U/hr)        
F3(X,Y) Rate of linear 
accumulation of glucose    
Grams/hour (gm/hr) 
F4(X,Y) Rate of tissue utilization of 
glucose   
Grams/hour (gm/hr) 
 
 2
TABLE 2: Abbreviations 
 
 
IVGTT Intravenous Glucose Tolerance Test 
OGTT Oral Glucose Tolerance Test 
GI Gastrointestinal 
BGCS  Blood Glucose Control System 
GIRS   Glucose-Insulin Regulatory System  
  
SYMBOLS   
Y
?
 First derivative of y with respect to time  
Y
??
 Second derivative of y with respect to time 
y(t) Time dependent function of y 
y(0) Initial value of y at time t=0 
Y(s) Laplace transform of y(t)  
sY(s) Laplace transform of y'if y(0) = 0  
s2Y(s) Laplace transform of y" if y'(0) = y(0) = 0  
q Rate of intestinal glucose flow or exogenously injected) into blood 
h Height of rectangular pulse  
0x  Blood Insulin Concentration at t=0, due to intestinal hormonal effect 
of  anticipatory control  
0t  Duration of the above Glucose flow = pulse width  
e Exponential constant 
L Operational symbol for Laplace transformation 
u(t) Unit step function  
v Blood-Glucose compartment volume  
αV Sensitivity of insulinase activity to elevted insulin concentration. 
βV Sensitivity of pancreatic insulin output to elevated glucose 
concentration.  
γV Combined Sensitivity of liver glycogen storage and tissue glucose 
utilization to elevated insulin concentration.  
δV Combined sensitivity of liver glycogen storage and tissue glucose 
 3
utilization to elevated glucose concentration.  
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TABLE – 3: Symbols & Units 
 
SYMBOL                       MEANING               
UNITS 
X0                 Mean physiological value of X                
Units/liter  
Y0                   Mean physiological value of Y                
Grams/liter 
 x                    x=X – X0               
Units/liter  
y                     y=Y-Y0                
Grams/liter 
x(ss)               x(ss)=X(ss)-X0 (ss=steady state)               Units/liter  
y(ss)               y(ss)=Y(ss)-Y0 (ss=steady state)               Grams/liter  
y(0)                y(0)=Y(0) – Y0                
Grams/liter  
p                     p=(I')N                
Units (lit)-1 (hr)-1  
q                     q=(G׀)N                
Grams (lit)-1 (hr)-1 
α                    ( )( ) 01 ,//1 atXXFV ∂∂                
(hr)-1    
β            ( )( ) 02 ,//1 atYyFV ∂∂                                    
(units) (hr)-1 (gms)-1        
γ                    ( )[ ] 0043 ,,///1 YatXxFxFV ∂∂+∂∂              (gms) 
(hr)-1 (units)-1                                                     
δ                    ( )[ ] 0043 ,,///1 YatXyFyFV ∂∂+∂∂              (hr)-1                   
 
 
 
 1
Appendix F 
 
 
 
This appendix contains the results of the Insulin Infusion System based on PD 
controller. 
 2
G.1 Subject D01 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 1.44 2.03 2.35 2.2 
 
From Curve-Fitting 
 
A G ω γ 
0.6417 3.969 0.0003 23.0383 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.003 0.004 0.003 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
1) kp and kd are fixed while I varies. 
2) kp >> kd 
3) Output response is dependant on previous output response, ie. No level off. 
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 4
 
 
 
 
 
 5
G.2 Subject D02 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.92 0.93 0.81 0.08 
 
From Curve-Fitting 
 
A G ω γ 
1.423 3.861 1.4e-8 71.9693 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.002 0.003 0.002 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
4) kp and kd are fixed while I varies. 
5) kp >> kd 
6) Output response is dependant on previous output response, ie. No level off. 
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G.3 Subject D04 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.77 1.54 1.49 1.41 
 
From Curve-Fitting 
 
A G ω γ 
0.625 2.549 0.0023 104.3761 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.0007 0.0008 0.0007 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
7) kp and kd are fixed while I varies. 
8) kp >> kd 
9) Output response is dependant on previous output response, ie. No level off. 
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G.4 Subject D08 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.82 1.32 1.67 1.37 
 
From Curve-Fitting 
 
A G ω γ 
0.6559 2.544 1.6e-8 23.7478 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.003 0.004 0.003 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
10) kp and kd are fixed while I varies. 
11) kp >> kd 
12) Output response is dependant on previous output response, ie. No level off. 
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G.5 Subject D09 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.62 1.02 1.03 0.31 
 
From Curve-Fitting 
 
A G ω γ 
0.8842 2.469 4e-7 13.0412 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.007 0.008 0.007 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
13) kp and kd are fixed while I varies. 
14) kp >> kd 
15) Output response is dependant on previous output response, ie. No level off. 
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G.6 Subject D10 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.72 1.04 0.55 0.52 
 
From Curve-Fitting 
 
A G ω γ 
1.141 2.548 0.0024 16.3837 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.007 0.008 0.007 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
16) kp and kd are fixed while I varies. 
17) kp >> kd 
18) Output response is dependant on previous output response, ie. No level off. 
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G.7 Subject D11 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.91 1.18 1.5 1.36 
 
From Curve-Fitting 
 
A G ω γ 
0.6071 2.34 0.0161 56.6408 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.001 0.0015 0.001 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
19) kp and kd are fixed while I varies. 
20) kp >> kd 
21) Output response is dependant on previous output response, ie. No level off. 
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G.8 Subject D13 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.91 1.16 1 0.67 
 
From Curve-Fitting 
 
A G ω γ 
1.064 3.289 0.0001 30.1855 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.003 0.004 0.003 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
22) kp and kd are fixed while I varies. 
23) kp >> kd 
24) Output response is dependant on previous output response, ie. No level off. 
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G.9 Subject D14 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.5 0.77 0.7 0.48 
 
From Curve-Fitting 
 
A G ω γ 
1.138 2.446 4e-12 24.8718 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.005 0.006 0.005 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
25) kp and kd are fixed while I varies. 
26) kp >> kd 
27) Output response is dependant on previous output response, ie. No level off. 
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G.10 Subject D15 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.53 0.72 0.73 0.51 
 
From Curve-Fitting 
 
A G ω γ 
0.8598 1.701 0.0012 36.4844 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.002 0.003 0.002 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
28) kp and kd are fixed while I varies. 
29) kp >> kd 
30) Output response is dependant on previous output response, ie. No level off. 
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G.11 Subject D16 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.01 0.82 0.75 0.55 
 
From Curve-Fitting 
 
A G ω γ 
0.9321 2.024 2.4e-6 15.2168 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.006 0.007 0.006 0 
kp 0 10 10 10 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
31) kp and kd are fixed while I varies. 
32) kp >> kd 
33) Output response is dependant on previous output response, ie. No level off. 
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 35
G.12 Subject D18 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.5 1.44 0.95 1.02 
 
From Curve-Fitting 
 
A G ω γ 
0.4891 1.272 0.3127 0.1334 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.04 0.05 0.04 0 
kp 0 100 100 100 0 
kd 0 0.01 0.01 0.01 0 
 
NOTE:  
34) kp and kd are fixed while I varies. 
35) kp >> kd 
36) Output response is dependant on previous output response, ie. No level off. 
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G.13 Subject N01 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.57 0.36 0.36 0.3 
 
From Curve-Fitting 
 
A G ω γ 
17.06 23.81 16.6 1.2539 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.1 0.15 0.15 0 
kp 0 100 100 100 0 
kd 0 0.1 0.1 0.1 0 
 
NOTE:  
37) kp and kd are fixed while I varies. 
38) kp >> kd 
39) Output response is dependant on previous output response, ie. No level off. 
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G.13 Subject N07 
 
Data 
 
Time 0 0.5 1 1.5 2 
Glucose Conc. 0 0.68 0.57 0.61 0.56 
 
From Curve-Fitting 
 
A G ω γ 
19.49 26.79 19.38 0.8 
 
Parameters 
 
 0 hr 0.5 hr 1 hr 1.5 hr 2 hr 
I 0 0.2 0.25 0.2 0 
kp 0 100 100 100 0 
kd 0 0.1 0.1 0.1 0 
 
NOTE:  
40) kp and kd are fixed while I varies. 
41) kp >> kd 
42) Output response is dependant on previous output response, ie. No level off. 
 
 
 
 
 
 
 
 42
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Appendix G 
 
 
 
Renogram Simulations Results 
 
This chapter contains the simulated results of the renograms. The clinical renograms were 
provided by PET Centre at SGH.  
 
Definition/Abbreviation 
 
Area is obtained by obtaining the area under the curve from 60 to 120 seconds. 
Deviation is obtained by: (Clinical – Calculated)/Clinical * 100% 
 
 2
Patient 1 
 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0174 0.0189
A 1.50E-02 7.83E-03
β 0.0232 0.0123
V2 0.7692 0.0023 0.9912 0.6923 0.0151 0.9813 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 31.91  49.10   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 39.39 35.00 -12.54 60.61 65.00 6.75 
 
 Calculated  Calculated   
U 0.0129  0.0032   
Relative 
U (%) 79.94 
 
20.06
  
 
 3
Patient 2 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks
  SSE R Sq  SSE R Sq 
k 0.0098 0.0175
A  8.60E-03
β 0.0047 0.0123
V2 0.5280 0.0613 0.9284 0.7027 0.0073 0.9909 
LT(C) 
RT(O) 
 Calculated   Calculated   
Area* 34.95  46.84   
 Calculated/ 
Clinical (%) 
Deviation 
(%) 
Calculated/
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 42.73 46.00 7.10 57.27 54.00 -6.05 
 
 Calculated  Calculated   
U 0.0020  0.0036   
Relative 
U (%) 35.37 
 
64.63
  
 
 4
Patient 3 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0123 0.0149
A 6.06E-03 5.80E-03
β 0.0180 0.0112
V2 1.2130 0.0046 0.9915 0.8187 0.0061 0.9924 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 35.44  45.00   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 44.06 44.00 -0.13% 55.94 56.00 0.10 
 
 Calculated  Calculated   
U -0.0002  0.0012   
Relative 
U (%) -13.37 
 
86.63
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Patient 4 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0188 0.0163
A 9.95E-03 6.90E-03
β 0.0116 0.0098
V2 0.5482 0.0196 0.9703 0.5936 0.0207 0.9767 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 44.20  44.01   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 50.11 51.00 1.75% 49.89 49.00 -1.82% 
 
 Calculated  Calculated   
U 0.0059  0.0040   
Relative 
U (%) 59.36 
 
40.64
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Patient 5 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0908 0.0131
A 5.08E-02 4.51E-03
β 0.0414 0.0107
V2 0.4005 0.0138 0.9723 0.9893 0.0060 0.9926 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 49.62  43.92   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 53.05 48.00 -10.52 46.95 52.00 9.71 
 
 Calculated  Calculated   
U 0.0268  -0.0020   
Relative 
U (%) 92.95 
 
-7.05
  
 
 7
Patient 6 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0087 0.0269
A 3.67E-03 1.42E-02
β 0.0090 0.0125
V2 1.1350 0.0052 0.9935 0.4126 0.0275 0.9621 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 32.99  47.81   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 40.83 44.00 7.20 59.17 56.00 -5.65 
 
 Calculated  Calculated   
U -0.0021  0.0079   
Relative 
U (%) -21.28 
 
78.72
  
 
 8
Patient 7 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0124 0.0221
A 5.48E-03 8.68E-03
β 0.0107 0.0103
V2 0.8664 0.0021 0.9966 0.4928 0.0118 0.9879 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 39.64  50.72   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 43.87 44.00 0.29% 56.13 56.00 -0.23% 
 
 Calculated  Calculated   
U 0.0013  0.0049   
Relative 
U (%) 21.45 
 
78.55
  
 
 9
Patient 8 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks
  SSE R Sq  SSE R Sq 
k 0.0221 0.0221
A 7.61E-03 8.59E-03
β 0.0098 0.0125
V2 0.4959 0.0133 0.9854 0.6248 0.0090 0.9906 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 52.25  52.89   
 Calculated/ 
Clinical (%) 
Deviation 
(%) 
Calculated/
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 49.69 50.00 0.61 50.31 50.00 -0.61 
 
 Calculated  Calculated   
U 0.0043  0.0038   
Relative 
U (%) 53.16 
 
46.84
  
 
 10
Patient 9 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0104 0.0050
A 3.33E-03 4.75E-03
β 0.0085 0.0095
V2 0.8970 0.0146 0.9820 1.0480 0.0004 0.9989 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 36.62  18.15   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 66.86 64.00 -4.47 33.14 36.00 7.94 
 
 Calculated  Calculated   
U 0.0002  0.0041   
Relative 
U (%) 4.30 
 
95.70
  
 
 11
Patient 10 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0052 0.0190
A 1.72E-03 7.79E-03
β 0.0091 0.0166
V2 1.5510 0.0038 0.9908 0.9219 0.0055 0.9946 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 21.48  48.72   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 30.60 37.00 17.31 69.40 63.00 -10.17 
 
 Calculated  Calculated   
U -0.0034  0.0005   
Relative 
U (%) -88.01 
 
11.99
  
 
 12
Patient 11 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0097 0.0127
A  
β 0.0037 0.0048
V2 0.4956 0.0255 0.9818 0.4908 0.0221 0.9852 
LT(C) 
RT(C) 
 Calculated   Calculated   
Area* 36.89  43.58   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 45.84 48.00 4.49 54.16 52.00 -4.14 
 
 Calculated  Calculated   
U 0.0013  0.0017   
Relative 
U (%) 43.24 
 
56.76
  
 
 13
Patient 12 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0104 0.0120
A  
β 0.0049 0.0050
V2 0.5081 0.1188 0.8523 0.5319 0.2430 0.7676 
LT(C) 
RT(C) 
 Calculated   Calculated   
Area* 35.70  41.73   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 46.10 45.00 -2.45 53.90 55.00 2.01 
 
 Calculated  Calculated   
U 0.0023  0.0016   
Relative 
U (%) 58.22 
 
41.78
  
 
 14
Patient 13 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0173 0.0242
A 7.54E-03 1.02E-02
β 0.0133 0.0150
V2 0.7561 0.0412 0.9617 0.6614 0.0239 0.9810 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 45.16  53.21   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 45.91 45.00 -2.02 54.09 55.00 1.65 
 
 Calculated  Calculated   
U 0.0034  0.0044   
Relative 
U (%) 43.12 
 
56.88
  
 
 15
Patient 14 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0149 0.0234
A 6.03E-03 9.89E-03
β 0.0109 0.0098
V2 0.7985 0.0111 0.9855 0.4347 0.0111 0.9850 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 45.01  51.48   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 46.65 46.00 -1.40 53.35 54.00 1.20 
 
 Calculated  Calculated   
U 0.0014  0.0054   
Relative 
U (%) 21.02 
 
78.98
  
 
 16
Patient 15 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0240 0.0163
A 1.37E-02 1.38E-02
β 0.0163 0.0151
V2 0.5668 0.0411 0.9567 0.5094 0.0301 0.9691 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 44.62  29.35   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 60.32 48.00 -25.66 39.68 52.00 23.69 
 
 Calculated  Calculated   
U 0.0086  0.0109   
Relative 
U (%) 44.27 
 
55.73
  
 
 17
Patient 16 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0184 0.0104
A 1.02E-02 8.16E-03
β 0.0056 0.0102
V2 0.2434 0.0069 0.9890 0.6579 0.0290 0.9735 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 39.68  30.18   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 56.80 55.00 -3.28 43.20 45.00 4.01 
 
 Calculated  Calculated   
U 0.0045  0.0057   
Relative 
U (%) 44.31 
 
55.69
  
 
 18
Patient 17 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0117 0.0113
A  
β 0.0049 0.0040
V2 0.5223 0.0615 0.9397 0.4993 0.0726 0.9355 
LT(C) 
RT(C) 
 Calculated   Calculated   
Area* 40.88  41.95   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 49.35 55.00 10.27 50.65 45.00 -12.55 
 
 Calculated  Calculated   
U 0.0017  0.0012   
Relative 
U (%) 58.76 
 
41.24
  
 
 19
Patient 18 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0188 0.0090
A  1.30E-02
β 0.0068 0.0139
V2 0.4973 0.0530 0.9574 0.4843 0.0022 0.9776 
LT(C) 
RT(O) 
 Calculated   Calculated   
Area* 53.67  13.14   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 80.34 76.00 -5.71 19.66 24.00 18.07 
 
 Calculated  Calculated   
U 0.0022  0.0118   
Relative 
U (%) 15.79 
 
84.21
  
 
 20
Patient 19 
 
 
 
Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0100 0.0091
A  
β 0.0040 0.0036
V2 0.5389 0.0620 0.9462 0.5136 0.0872 0.9002 
LT(C) 
RT(O) 
 Calculated   Calculated   
Area* 38.52  35.25   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 52.22 51.00 -2.39 47.78 49.00 2.49 
 
 Calculated  Calculated   
U 0.0010  0.0012   
Relative 
U (%) 45.77 
 
54.23%
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Parameters Left 
Kidney 
Fitting  Right 
Kidney 
Fitting Remarks 
  SSE R Sq  SSE R Sq 
k 0.0039 0.0091
A 4.04E-03 3.74E-03
β 0.0052 0.0099
V2 0.5011 0.0016 0.9824 1.1740 0.0170 0.9787 
LT(O) 
RT(O) 
 Calculated   Calculated   
Area* 13.17  33.92   
 Calculated/ 
Clinical 
(%) 
Deviation 
(%) 
Calculated/ 
Clinical 
(%) 
Deviation (%)  
Relative 
Area* 27.97 22.00 -27.12 72.03 78.00 7.65 
 
 Calculated  Calculated   
U 0.0042  -0.0026   
Relative 
U (%) 61.70 
 
-38.30
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From: "Vladimir Vladimirovich Kulish (Assoc Prof)" <MVVKulish@ntu.edu.sg> 
To: "Dhanjoo N Ghista (Prof )" <MDNGhista@ntu.edu.sg>, "Lua Aik Chong (Assoc Prof)" 
<MACLUA@ntu.edu.sg>, <rjohn2@mednet.swmed.edu>, "#LOH KAH MENG#" 
<kmloh@technologist.com>, "Merryn Tawhai" <m.tawhai@auckland.ac.nz> 
CC: <vb.novozhilov@ulster.ac.uk>, "Lage, Jose" <jll@engr.smu.edu>, 
<CONNIE.HSIA@email.swmed.edu>, "Lim Chu Sing , Daniel (Assoc Prof)" 
<MCHSLIM@ntu.edu.sg>, "Damodaran Murali (Assoc Prof)" <MDAMODARAN@ntu.edu.sg>, "Ong 
Jor Huat (Assoc Prof)" <MJHONG@ntu.edu.sg>, "Alexei Sourin (Assoc Prof)" <assourin@ntu.edu.sg>, 
"Vladimir Vladimirovich Kulish (Assoc Prof)" <MVVKulish@ntu.edu.sg> 
Subject: BOOK ON HUMAN RESPIRATION --- YOUR CONTRIBUTION IS ACCEPTED 
Date: Fri, 13 Aug 2004 12:48:10 +0800 
Dear Colleagues: 
  
I would like to cordially thank all of you for your contributions. 
  
According to the review received on our book: Human Respiration: Anatomy and Physiology, Mathematical 
Modeling, Numerical Simulation and Applications, all the chapters submitted by us are accepted for 
publication.  Congratulations!!!   
  
However, we need to make some minor additions and amendments. 
  
The reviewer’s comment is attached to this message (see below).  In summary, we need to take the following 
steps: 
  
1. All equations are to be numbered and typed by means of MS Word Equation Editor.  Each equation should 
be a single object but not a mixture of text symbols and equations in one line.  
2. All symbols that are used in equations and appear in text must be typed by means of MS Word Equation 
Editor within the text.  
3. All repetitions among the chapters contributed by the same principal author should be removed.  
4. Each principal author has to provide me with nomenclature (in a separate MS Word file), so that the same 
symbols were used by one principal author in all his/her chapters.  
5. Each principal author has to provide me with key words to be included into Subject Index that will follow 
our book.  
6. Each principal author has to send me the amended version of his/her contribution(s) in MS Word format 
together with the nomenclature and key words file by e-mail:  mvvkulish@ntu.edu.sg .  Please ensure that 
each chapter is formatted according to the template that was sent to you previously [otherwise, the 
production of the book can be delayed].  
  
The deadline set by the publisher (WIT Press) is September 20, 2004.  Hence, I have to receive all your amended 
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contributions at least 48 hours before this date.  The book will appear in January 2005 (ISBN 1-85312-944-5). 
  
I am looking forward to hearing from you. 
  
With kindest regards, 
  
Vladimir V. Kulish, Ph. D. 
Corresponding Member of 
The International Academy of Sciences "Collegium", 
Associate Professor 
School of Mechanical & Production Engineering 
Nanyang Technological University 
50 Nanyang Ave., North Spine (N2), Level 2 
Singapore 639798 
Phone: +(65) 67904950;  Fax: +(65) 67911859 
E-mail: mvvkulish@ntu.edu.sg  or  kulishv@asme.org  
URL: http://www.ntu.edu.sg/home/mvvkulish/index.html  
  
  
'Relevance 
The bio-engineering discipline is now recognised as being of substantial importance. Human respiration 
is a significant, challenging and rewarding field: significant because of the increase in airborne 
pollutants and congenital respiratory diseases; challenging because of the wide range of scales in the 
pulmonary system, which span about three orders of magnitude (or five, if the thickness of the alveolar 
membrane is included); and rewarding  
because of the marvellous ingenuity that characterises the system. A text that covers highlights of the 
application of bio-engineering techniques to the study of human respiration is to be welcomed. 
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This text comprises twelve chapters dealing with various topics in human respiration, from fundamental 
aspects of anatomy and physiology through to numerical modelling of processes such as gas diffusion 
and practical applications in the field of respiratory physiotherapy. As such, there is material here that 
will be of interest to seasoned bio-engineers and clinical practitioners, as well as novices to the study of 
human respiration. There should be a good market for the text – WIT should use the success of their 
publication “Medical Application of Computer Modelling – the Respiratory System” as a guide. 
  
Technical Correctness 
The text encompasses such a wide range of material that I cannot comment on all of it. Nevertheless, I 
am satisfied that in the field that I do have some knowledge (fluid mechanics) the material presented is 
correct. Moreover, each chapter appears to be a distillation of a large body of work which has been 
presented and reviewed for publication in technical journals, and this gives me confidence that the whole 
work is accurate and reliable. There are several papers that deal with modelling of gas transfer across 
that alveolar lumen. The nomenclature employed in each paper (or group of papers, where a group 
is characterised by having the same principal author) is slightly different. It would be very helpful 
if a common nomenclature could be employed. A formal definition of nomenclature after the 
Table of Contents would be useful. 
  
There are instances where relatively complex equations have been poorly constructed. For 
example, dots above symbols to represent differentiation with respect to time (e.g. _) have been replaced 
by small “o”s (e.g. _); in some instances the “o” s have been badly misplaced. This is not correct, and is 
unnecessary – the text appears to have been written using Microsoft Word, and Word includes an 
equation editor that has all the functionality required to produce neat equations employing standard 
notation. The final text should not contain any ambiguities in its formulae. 
  
Quality of Text 
The text is written in generally good English. While I am not sure whether it is the reviewer’s role to 
flag (what he thinks may be) grammatical errors, I have annotated the text where I think it might be 
improved. I offer these corrections not critically (they are few in number), but in the hope that through 
such minor corrections to the text, I might contribute to its acceptance in the academic community. 
  
There are some instances of repetition of material between chapters by the same principal 
authors; there is also duplication of introductory material on respiratory anatomy between different 
authors. It would be beneficial to the ease with which the text can be used if (a) the repetitions were 
removed, (b) the duplication was minimised, and (c) the introductory material was brought forward to 
the first and second chapters (see below for more detail). 
  
Order of Chapters 
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If the original 12 chapters are to be retained as they are, then I would suggest the following re-ordering 
of the text: 
Anatomy and Physiology 
1.  Anatomy and Physiology of the Human Respiratory System 
2.  Fundamentals of Alveolar Gas Diffusion Mathematical Modelling and Numerical Simulation  
3.  Lung Gas Composition and Transfer Analysis: O2 and CO2 Diffusion Coefficients and Metabolic 
Rates 
4.  Lung Ventilation Modelling and Assessment 
5.  Visualisation of Alveolar Diffusion 
6.  Modelling of Two-Phase Flow in the Human Respiratory System  
7.  Impact of Microscopic Solid Particles on Alveolar Diffusion  
8.  Quantification of Human Physiological Response to Toxic Substances  
9.  Anatomically-based Modelling of Pulmonary Structure Applications  
10. Applied Chest-Wall Vibration Therapy for Patients with Obstructive Lung Disease 
11. Indicator for Lung Status in a Mechanically Ventilated COPD Patient using Lung Ventilation 
Modelling and Assessment 
12. Mechanics of Proportional Assist Ventilation 
I have suggested that “Anatomy and Physiology of the Human Respiratory System” should come before 
“Fundamentals of Alveolar Gas Diffusion”, and that “Lung Gas Composition and Transfer Analysis” 
and “Lung Ventilation Modelling and Assessment” should precede “Visualisation of Alveolar 
Diffusion”, “Modelling of Two-Phase Flow in the Human Respiratory System” and “Impact of 
Microscopic Solid Particles on Alveolar Diffusion”. This is because it may be easier for the reader to 
deal with the more general issue of lung respiration before approaching the topic of alveolar respiration. 
However, if some reordering of the material in chapters 2 and 5 can be allowed, then I would 
recommend the following titles for these chapters: 2.  Fundamentals of Alveolar Gas Diffusion – 
Physiological Aspects 5.  Alveolar Gas Diffusion – Numerical Modelling and Visualisation Here, 
chapter 2 would deal with the physiology of alveolar gas diffusion, and the modelling aspects would be 
placed in chapter 5. This would have the advantages that: (a) the first section is a relatively easy 
introduction of the topic of human respiration; and (b) the visualisation of the calculations by Kulish et 
al is presented in the best context. 
  
It should also be possible to combine the chapters “Modelling of Two-Phase Flow in the Human 
Respiratory System” and “Impact of Microscopic Solid Particles on Alveolar Diffusion” into a single 
chapter, e.g. “Modelling the Impact of Microscopic Solid Particles on Alveolar Diffusion”. Certainly, 
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the material in “Impact of Microscopic Solid Particles on Alveolar Diffusion” which is a repetition of 
material in “Visualisation of Alveolar Diffusion” should be deleted. 
  
I cannot decide whether the chapter entitled “Quantification of Human Physiological Response to Toxic 
Substances” should be left in the section on “Mathematical Modelling and Numerical Simulation” or 
placed in the section on “Applications”. Perhaps Kulish as the author is the deciding factor, and it should 
remain where it is in proximity to Kulish’s other papers. Thus, the chapter order becomes:  
1.  Anatomy and Physiology of the Human Respiratory System  
2.  Fundamentals of Alveolar Gas Diffusion – Physiological Aspects MathematicalModelling and 
Numerical Simulation 3.  Lung Gas Composition and Transfer Analysis: O2 and CO2 Diffusion 
Coefficients and Metabolic Rates 
4.  Lung Ventilation Modelling and Assessment 
5.  Alveolar Gas Diffusion – Numerical Modelling and Visualisation  
6.  Impact of Microscopic Solid Particles on Alveolar Diffusion  
7.  Quantification of Human Physiological Response to Toxic Substances  
8.  Anatomically-based Modelling of Pulmonary Structure Applications  
9.  Applied Chest-Wall Vibration Therapy for Patients with Obstructive Lung Disease 
10. Indicator for Lung Status in a Mechanically Ventilated COPD Patient using Lung Ventilation 
Modelling and Assessment 
11. Mechanics of Proportional Assist Ventilation ' 
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Abstract— The primary function of the lung is to (i) 
oxygenate the blood and thereby provide oxygen to the cells 
for metabolization purposes, and (ii) to remove the CO2
produced by the tissues from the pulmonary blood. Herein, 
we provide a noninvasive methodology to asses the capacity 
of the lung to oxygenate the pulmonary capillary blood and 
to reduce its CO2 concentration. For this purpose, we 
analyze the compositions of the inspired and expired air per 
breath, and therefrom compute the metabolic O2
consumption rate ( 2OV
?
) and CO2 production rate ( 2COV
?
).
Next we compute the cardiac out (CO) as 
2 2 2
( )AB VBO O OCO V C C? ?
?
.
We have derived the expressions for diffusion 
coefficients (i) 
2OD in terms of 2OV
?
 and the alveolar and 
venous partial pressures, 
2
al
OP  and 2
VB
OP  and (ii) 2COD in 
terms of 2COV
?
,
2
al
COP  and 2
VB
COP . The coefficients 
2OD and 2COD represent the gas transfer capacity of the 
lung. 
The paper provides a case study for the determination of 
Q,
2OD and 2COD . The derived information of 
2OD and 2COD as well as of O2 and CO2 metabolic rates can 
be of considerable clinical use including for SARS 
assessment. 
Keywords— gas exchange, O2 metabolic-rates, CO2
metabolic-rates, diffusion coefficients 
2OD , diffusion 
coefficients
2COD , blood flow rate
I. INTRODUCTION 
 The lung functional performance is characterized by (i) 
its ventilatory capacity, to bring air (and hence O2) into the 
alveoli, and (ii) its capacity to transfer O2 and CO2 into and 
from the pulmonary capillary bed. Hence, the O2 and CO2
diffusion coefficients 
2O
D and
2CO
D as well as the O2
consumption-rate and the CO2 production rate represent the  
lung performance indices. In this paper, we are 
demonstrating their evaluations. 
II. LUNG GAS-EXCHANGED MODEL 
Fig. 1 schematically illustrates the gas-exchange 
between the lung alveolus and the pulmonary capillary-
vasculature. Based on our earlier work [1, 2] the gas 
exchange between the alveolar air and pulmonary capillary 
blood is represented by the following 2O  and 2CO
conservation equations  and Fig. 2. 
22 2
VE VE AE AE
OO OQ C Q C V
?
? ?  (from the alveolar air to 
capillary blood) 
2
2 2
( )Oav
AE AE
O OQ C P D? ? ?               (1) 
22 2
VE VE AE AE
COCO COQ C Q C V
?
? ?
2
2 2
( )COav
AE AE
CO COQ C P D? ? ?                    (2) 
wherein 
(i) ABQ and VBQ  are arterial and venous blood flow-rates;    
(at venous end) (at arterial end),AB VE VB AEQ Q Q Q? ?
(ii)
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial 
pressures 
(iii)
2
al
COP  and 2
cap
COP  are the alveolar and capillary 2CO
partial pressure. 
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion 
coefficients
(v) 2
2 2
-average of ( ) over the capillary length;Oav
capal
O OP P P??
2
2 2
average of ( ) over the capillary lengthCO al capav CO OP P P? ??
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(vi) 
2
cap
OP = 2
PRB
OP  ( 2O  concentration of the pre-oxygenated 
blood) 
2
AE
OP?
(vii) 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre-
oxygenated blood) 
2
VE
COP?
(viii) 
2O
V
?
 is the 2O  transfer rate from alveolar air to 
capillary blood (= 2O consumption rate), 2COV
?
is the 2CO
transfer-rate from capillary blood to alveolar air (= 2CO
production rate). 
Now we can equate the arterial and venous blood flow 
rates, as AEQ ? ABQ = VBQ VEQ? = Q =(SV)/(EP) 
? / 60CO
SV, EP and CO being the stroke-volume, ejection-period 
and cardiac-output respectively. 
Fig. 1: Process of oxygenating the venous blood. 
The low oxygen (O2) concentration Red Blood Cell 
(RBC) is shown in dark blue. As it travels down the 
artery towards the venous end, the O2 concentration 
increases. After the distance L, its O2 has increased to 
0.18 from the initial concentration of 0.13. 
From equations (1) and (2): 
2 2
2 2 2 2
2
( ) ( )
( ) ( )
AB VB
O O
av av
VE AE
O O O O O
OPav
Q C C Q C C
P P
V
? ?
? ?
?
?
?? ?2O
D   (3) 
2
2 2
2
( )
( )
VE
CO
av
AB
CO CO CO
COPav
Q C C
P
V
?
?
?
?
??2
COD      (4) 
Fig. 2: Schematic of blood gas concentration in the 
Pulmonary Capillary. (Adapted from references [3] & [4]) 
III. CLINICAL DATA 
The monitored data consists of inspired and expired air 
gas compositions (TABLE 1) and 2O and 2CO
concentrations of arterial blood and venous blood (TABLE 
2). 
TABLE 1: Air Composition Analysis. Inspired and 
expired air composition and partial pressures are monitored. 
Assumed 
Breathing Rate (BR) = 12 breaths/min. Assumed 
2H O
P  at 
37?C = 47 mmHg. 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/%
N2 597 393.1 
78.55% 
566 393.1 
74.5% 
O2 159 104.2 
20.84% 
120 80.6  
15.7% 
CO2 0.3 0.2 
0.04% 
27 19.1  
3.6% 
H2O 3.7 2.5 
0.49% 
47 32.6  
6.2% 
Total 760 500 
100% 
760 525.3 
100% 
 TABLE 2:  Blood Gas Analysis. The monitored blood  
O2 and CO2 concentration . 
2O
C   of venous blood  (
2
VB
OC ) = 0.13 
2O
C of arterial blood  (
2
AB
OC ) = 0.18 
2CO
C  of venous blood (
2
VB
COC ) = 0.56 
2CO
C  of arterial blood (
2
AB
COC ) = 0.52 
IV. EXPRESSIONS FOR
2O
D AND
2CO
D
If we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 
2
al
COP , 2
cap
COP  in terms of monitorable quantities [1 & 2]. 
(i) alveolar 
2
al
OP can be expressed in terms of V
?
(the 
ventilation rate) and 2OV
?
(the 2O  consumption rate). 
*
2
 ; 
4.18
140 1
OV V
e
? ?
? ?
? ?
? ?? ?
? ?
?? ?? ?
? ?? ?
? ?
? ?? ?
2
al
OP      (5) 
wherein the normalized ventilation rate 
* 60 V V V Vm? ?
? ? ? ?
litres/min, is the consumption rate (in litres/min). 
(ii) alveolar 
2
al
COP  can be expressed in terms of V
?
 and 2OV
?
.
2
*2.19
107.18
COV V
e
? ?
? ?
? ?
? ?? ?
? ?
?
?alCO2
P                    (6) 
wherein 
2CO
V
?
 is  the 2CO production rate (in liters/min).  
(iii) Blood
2O
P can be obtained in terms of  blood 
2O
C , from 
the 2O  disassociation curve. 
2
0.230.5ln
0.2
B
B
OC
? ?
? ??
? ??? ?
O2
P              (7) 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
BC , from 
the 2CO  disassociation curve. 
2
0.837.94ln
0.8
B
B
COC
? ?
? ??
? ??? ?
CO2
P      (8) 
Now,
2O
P?
2 2 2 2
( )Capal al VBO O O OP P P P? ? ? ? and 2COP?
2
( VBCOP? - 2 )
al
COP  vary along the capillary bed. Based on [3], 
we have: 
2 20.185 max
O OP Pav ?? ?                   (9) 
2 20.1   max
CO COP Pav ?? ?            (10) 
Hence, from equations (3 & 9) and (4 &10), 
2 2
2 2 0.185( )
2 2
al VBP PP O O
O O
O O
av
V V
D ? ?
?
? ?
?
    (11) 
2 2
2 2 0.1( )
2 2
CO VB alP PPav CO CO
CO CO
CO
V V
D ? ?
?
? ?
?
    (12) 
V. EVALUATION OF O2 AND CO2 METABOLIC RATES AND
CARDIAC OUTPUT  
From monitored data of inspired-exhaled gas 
compositions, in TABLE 1: 
2O  consumption rate, 2OV
?
= BR(Inspired 2O - Expired 
2O )ml/min =12(104.2-80.6) = 283.2 ml/min               (13) 
2CO consumption rate, 2COV
?
=BR(Expired 2CO -Inspired 
2CO ) ml/min = 12(19.1-0.2)=226.8 ml/min                 (14) 
From monitored 2O  and 2CO concentrations of arterial and 
venous blood, in TABLE 2: 
? 2OV
?
= Q(
2O
C  of arterial blood - 
2O
C of venous blood)   
where Q=blood flow rate?cardiac output 
2 283.2 5664 /
(0.18 0.13) 0.05
OVQ ml min? ? ? ?
?
?
      
VI. EVALUATING OF THE LUNG DIFFUSION COEFFICIENTS 
2O
D AND
2CO
D
From equation (7) and TABLE 2 (
2
VB
OC =0.13), we get 
for 
(venous blood @ arterial end of the pulmonary capillary or 
2
VB
OP )
        
2
VB
OP =
2
0.230.5ln
0.2 VBOC
? ?
? ?
? ??? ?
               = 0.230.5ln
0.2 0.13
? ?
? ??? ?
               = 32.02 mmHg                       (15) 
From equation (8) and TABLE 2 (
2
VB
COC =0.56), we get 
for
2
VB
COP  (venous blood @ arterial end of the pulmonary 
capillary or 
2
VB
COP  ) 
2VB
COP =
2
0.8
37.94 ln
0.8 VBCOC?
? ?
? ?
? ?? ?
         = 
0.8
37.94 ln
0.8 0.56?
? ?
? ?? ?
       
         = 45.68 mmHg                          (16) 
Also, from equation (5) and TABLE 1 ( *V
?
=0.1), we get: 
? ?
*
2
0.1 0.2832
4.18
4.18
      140 108           (17)
140 1
1
OV V
mmHg
e
e
? ?? ?
? ?
? ?? ?
?
?
? ?
? ?
?
? ?
? ?
? ?
? ?? ?
? ?
? ?
2
al
OP
Hence, from equations (9, 15 & 17), we get: 
2 0.185 (108 32.02) 14.06         (18)Oavp mmHg? ? ? ??
Finally, from equations (11) and (18), we get: 
2
2 2
1
283.2 / min
14.06
       20.14  (19)-1
O
O O
av
ml
mmHgP
V
D
mlmin mmHg ?
? ?
?
?
?
Then from equation (6), TABLE 1 ( 0.1V ?
?
), and equation 
(12) we get: 
? ?
2
0.1 0.2268
2.19
2.19
*
          107.18 40.81               
107.18
(20)
COVV
mmHg
e
e
?
? ?
? ?
? ?
? ?
? ?
? ?
?
?
? ?
?
?
al
CO2
P
Hence, from equations (10, 16 & 20), we get: 
2 0.1 (45.68 40.81) 0.487         (21)COavp mmHg? ? ? ??
Finally, from equations (12 & 21), we get: 
        
2
2 2
226.8 / min
0.487
                           465.71              (22)
CO
CO CO
av
ml
mmHgP
-1 -1mlmin mmHg
V
D ? ?
?
?
?
VII. CONCLUSION
We have demonstrated a noninvasive clinical procedure  
? for obtaining (i) O2 consumption rate and CO2
production rate, (ii) cardiac output, Q, (iii) and 
lung diffusion capacities for  O2 and CO2.
? from inhaled and exhaled air composition 
analysis and blood-gas analysis.
This work could have application to SARS testing and 
evaluation.
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Abstract— The primary functions of the kidney are: (i) 
to get rid of the body waste materials that are either ingested 
or produced by metabolism, and (ii) to control the volume 
and composition of the body fluids. Herein, we provide a 
noninvasive methodology to assess physiological function 
of the kidneys. For this purpose, we analyze the renograms 
with 2-compartmental modelling of the kidney-renal 
outflow system, and therefrom compute the amount of flow 
of  renal radionuclide into and out of the renal pelvis 
compartment.  
The derived information of uptake (k/A) and washout 
( 22
t
Ve
??
sinhAt) rates can be of considerable use. The paper 
provides a number of case studies for the verification of the 
derived system governing equations against clinical 
renograms. 
Keywords— Renal outflow obstruction, renal
function, glomerular filtration rate, GFR
I. INTRODUCTION 
The kidney functional performance is characterized by (i) its 
filtering capacity, getting rid the body waste materials that 
are either ingested or produced by metabolism, and (ii) 
control the volume and composition of the body fluids. 
Renogram studies have been used for the assessment of 
renal function for many years [1, 2]. Mathematical 
modelling has been performed for the kidneys, such as one-
compartment model of clearance of tracer [3,4]. However, 
modeling of the tracer transport between renal parenchyma 
pool compartment and renal pelvis compartment; derivation 
of the governing equations for renogram curves has not been 
reported. Here, we note that the tracer uptake and washout  
rates can represent the performance indices. In this paper, 
we evaluate these rates and demonstrate their clinical 
relevance renogram data. 
II. RENAL PELVIS TWO-COMPARTMENTAL MODEL
Fig. 1: illustrates the region of interest (ROI) and we 
have derived the compartmental model for renal pelvis and 
shown in Fig. 2. 
Fig. 1: Control volume around the renal pelvis area.[5] 
1G : Tracer mass in the chamber 1 (renal parenchyma) in 
Counts.
2G : Tracer mass in the chamber 2 (renal pelvis) in Counts.
1C : Concentration of tracer in the chamber 1 in Counts/dL.
2C : Concentration of tracer in the chamber 2 in Counts/dL.
1V : Volume of chamber 1, renal parenchyma in dL.
2V : Volume of chamber 2, renal pelvis in dL.
( )I t : Tracer input function in Counts/sec.
F(t) : Blood Flow from chamber 1 to chamber 2 in dL/sec.
( )U t :Urine outflow in dL/sec.
Fig. 2: The derived two-compartmental renal model. 
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III. DERIVATION and PHYSIOLOGICAL SIGNIFICANCE of 
MODELING SOLUTIONS 
From Fig.. 2, we derive the following: 
1
1 ( )
dG FC I t
dt
? ? ? , for chamber 1     (1) 
2
1 2 ( )
dG FC C U t
dt
? ? , for chamber 2     (2) 
where (i) 1 1 1( )G C V?  represents the tracer amount in 
chamber 1,and (ii) 2 2 2( )G C V? represents the tracer amount 
in chamber 2. 
In physiological studies of kidney function and urine 
outflow status (renography), the input function is a tracer 
bolus administered over a short period of time. Compared to 
the entire duration of the renal dynamics, this bolus injection 
of tracer can be approximated by an impulse function 
(Dirac’s delta function). In the following derivation, 
whenever I(t) appears it will be assumed  be equal to I?(t).
We assume that the compartmental volumes V1 and V2
are constants (which they generally are), and the urinary 
flow rate U as unknown constant (urine flowing out of the 
kidney into the ureters is physiologically continuous and 
constant with time, unless there are changes in body fluid 
status). Here, we are only performing an intra-renal analysis 
for  obstruction to the outflow, we have from (1) and (2) : 
1 1
1 ( )
V dC FC I t
dt
? ? ?  (3) 
2 2
1 2
V dC FC C U
dt
? ?                                           (4) 
By differentiating and combining (3) and (4), we arrive at: 
2 2 2 2
1
2 2 2 2
1
( )
or,
( )                          (5)
FV C I t C C
V
FV C C C I t
V
? ?
? ? ?
? ?
? ? ?? ?
? ?
? ?
? ? ? ? ?
? ?
?? ?
?? ?
where:  
2
1 1
,                                (6)
FV FUU
V V
? ?
? ? ? ?
? ? ?? ? ? ?
? ? ? ?
The equation (5) is a standard form of a linear second-
order ordinary differential equation, with I(t) as the unit 
impulse function. This is the governing differential equation 
for the behavior of tracer within the renal pelvicalyceal 
compartment. 
Solution by Laplace transform method yields the 
following equations, given the initial conditions of C(0) and 
C’(0) = 0.
? ?
? ?
? ?
2
1
2
2 2
1
2 2
21 1 22
2 2
2
2
2 2
22 2
1 2
2
2 2 2 2
( )
( )
1 1( ) ( )
41       
4 2 4
FL V C C C L I t
V
FV s s C s
V
F FC t C t
V VVV s s s s
V V
V VF
VV
s
V V V V V
? ? ?
? ?
? ? ? ?
? ?
? ? ? ? ?
? ?? ?? ?? ? ? ? ?? ?
? ?? ?
? ?
? ? ? ? ? ?
? ?
? ? ? ?
? ? ?? ? ? ? ? ?? ?? ? ? ? ? ?? ?
? ?
? ?
?? ?
? ?? ?? ? ?? ? ? ?? ?? ?? ? ? ?? ?? ?? ? ? ?
?? ?
2
2
    (7)
? ?
? ?
? ?
Solving the above Laplace transform and taking care of 
the characteristics of the roots (which is now in standard 
form, by looking up standard tables), we obtain the results 
for the dynamic behavior of the tracer concentration in the 
renal pelvis for this physiological system. The term 
underneath the square root is the determinant of the behavior 
of the system with regards to whether there is underdamped, 
critical-damped or overdamped behaviour. 
This term can be expressed as 2 24V? ?? and it yields a 
significant functional index for assessing the outflow status 
of the kidney. We will classify the observed physiological 
behaviours of renogram systems into underdamped, 
overdamped or critically damped systems based on the 
index, as follows: 
Case 1:
If 2 24 0V? ?? ? ,  the condition is underdamping, and 
(7) yields the solution: 
2
2
2
22
1 2 2 2
2
2 2
1( ) sin
4
4
t
VFC t e t
V V V V
V V
? ? ?
? ?
?
? ?
? ? ? ?? ?? ? ? ?? ?? ?? ? ? ?? ? ? ?? ??? ?? ?
    (8)  
                k                1/A                     A
As can be seen from equation (8), the terms which 
describe urine outflow and determine the shape of the tracer-
concentration curve of the renogram during the tracer wash-
out phase are the 22
t
Ve
??
and
2
2
2 2
sin
4
t
V V
? ?? ?? ??? ?? ?
. The 
impartant dynamic  information captured in these two terms 
can be succintly found in the physiological index that we 
have described. We will demonstrate the discriminatory 
nature of this index (which will be extracted as A) in section 
IV when we analyse correlation with actual renogram 
studies. 
Equation (8) is a linear second-order ordinary 
differential equation, very similar to that of the linear 
oscillator with damping. In a functioning renal system, the 
characteristic oscillating-underdamped conditions do not 
exist.  
Case 2:
Whenever there is outflow obstruction, the key term 
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
and the condition is overdamping. Then,  
2
2
2
22
1 2 2 2
2
2 2
1( ) sinh
4
4
t
VFC t e t
V V V V
V V
? ? ?
? ?
?
? ?
? ? ? ?? ?? ? ? ?? ?? ?? ? ? ?? ? ? ?? ??? ?? ?
    (9) 
          k                1/A                     A
We can express output segment of the tracer curve of 
compartment 2 looks different from that of the tracer input  
2 2
2 2 2
2 2
1 1 1
4 4
FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
so the key term actually reflects the rate of tracer input 
(FC1) minus the rate of tracer output (UC2).
Case 3:
In the normal case, most physiological systems are 
well-compensated, and hence the output are fairly similar, 
hence,  
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
In other words, the renal system is critically damped.  
The governing equations for this will be 
? ? 22
1 2
t
VFC t te
V V
??? ?
? ? ?
? ?
 (10) 
For model analysis, because of complications involved 
in monitoring U (urine flow rate), F (plasma flow rate into 
the renal pelvis) and V1 control volume, we propose that our 
model parameters will be lumped parameters k and A. Next 
our parameters identification will be carried out for k, A V2
and ?.
IV. CLINICAL DATA & EVALUATION 
We will demonstrate and verify the application of our 
models using the renograms obtained from the Nuclear 
Medicine and PET Department. The radionuclide used are 
99mTc-DTPA and 99mTc-MAG3.  The degree of match with 
the governing equations is based on the area under the left 
and right kidney curves against the clinical curves between 
60 and 120 seconds. 
Model Application:
We will first digitalize and normalized the renograms. 
Next, we will perform parameters identification and obtain 
the system parameters: k, A, ? and V2. We will only accept 
the results of the best fit. 
Fig. 3: Clinical renograms of volunteer coded 
Patient 7. Note that the (QR-RR) segment of the tracer 
curve for the right kidney is similar to the (PR-QR)
segment and demonstrates good outflow-rate compared 
to the (QL-RL) segment of the obstructative curve for the 
left kidney. 
TABLE 1: Comparison of clinical and calculated results. 
We  can observe that the errors for each kidney is less than 
1%.
Identity % Clincal 
Area Under 
the curves 
between 60 
to 120 sec. 
% Calculated 
Area Under 
the curves 
between 60 to 
120 sec 
% Error 
Left Right Left Right Left Righ
t
Patient 
7
44 56 43.87 56.13 0.29 -0.23 
Patient 
8
50 50 49.69 50.31 0.61 -0.61 
(obstructive)
QR
QL
P
RR
RL
(Minor 
obstructive) 
Fig. 4: Clinical renograms of volunteers Patient 8. 
The two kidneys have minor obstructions. 
V. RESULTS
We have performed parametric identification for 
equations (9) and (10) using MatLab 7. The following are 
the best fitted results for  patients 7 & 8. 
            
                                
Fig. 5: Simulated renograms of volunteer coded Patient 
7. The clinical data for both kidneys is best fitted by 
equation (9). The identified parameters are: 
L L 2L
R R 2R
0.0124; A 5.48E-03; 0.0107 and V 0.8664
0.0221; A 8.68E-03; 0.0103 and V 0.4928
L
R
k
k
?
?
? ? ? ?
? ? ? ?
 Fig. 6: Simulated renograms of volunteer coded Patient 
8. The clinical data for both kidneys is best fitted by 
equation (9).The identified parameters are: 
L L 2L
R R 2R
0.0221; A 7.61E-03; 0.0098 and V 0.4959
0.0221; A 8.59E-03; 0.0125 and V 0.6248
L
R
k
k
?
?
? ? ? ?
? ? ? ?
 TABLE 1 shows that the area under the curves from the 
simulation matches that of the clinical with an error less 
than 1%.  
VI. CONCLUSION 
We have demonstrated modeling of kidney-renal 
outflow tract compartments with derivation of the governing 
equations from second-order differential equations and 
assessed the clinical relevance with comparison with clinical 
renogram studies. 
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Introduction
? Biofeedback entails providing a person 
with information about his own on-going 
physiological processes through 
parameters such as EEG or QEEG, ECG, 
EMG, etc. 
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Types of Biofeedback
? There are two types of biofeedback 
systems: Volitional Feedback 
Systems (VBFS) and Non-Volitional 
Feedback Systems (NVFS). 
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Types of Biofeedback
? The VBFS require conscious effort to 
attain a desired physiological state. They 
hence cannot be used in the case of 
subjects who have mental dysfunction or 
mentally depressed. 
? The NVFS do not require subjects to be 
conscious.
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Objectives
? The NVFS  presented in this paper is 
designed for rehabilitation purpose. We 
will also present to you some results that 
we have gathered in our experiments with 
subjects with eyes opened with aids and 
eyes closed with and without aids.
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International 10-20-2. EEGs are taken at 19 
different channels to give us spatial & 
temporal information.
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The Lexicor system that our 
experiments were conducted with. 
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Screen snap shot of the EEG 
display 
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Screen shot of the QEEG 
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Experimental Results
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Experimental results of subjects. Note that alpha energies 
are greatest when eyes closed with the goggles active. 
The goggles are designed to flash at 10 Hz. It has been 
found that the Red super-bright LEDs are most efficient.
Results of V and W
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Application of the Concept
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Conclusions
? The above results have significant 
influence to the system we are designing 
for rehab purpose. 
? The details will be elaborated later in our 
next coming presentation. 
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Thank You
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Introduction
? The use of Virtual Reality (VR) to enhance 
rehabilitation is a relatively new concept. 
? The novel aspect of using VR as an 
evoked-psychological therapy for 
rehabilitation will cause a revolution in 
rehab technology.
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Objectives
? In this paper we will discuss some of these 
concepts. There may be some ideas that 
could be obscure to some of the audience, 
so we elicit an open mind.
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Concepts/Applications
? Firstly we would like to share with you the 
concept about stressed and relaxed mind. 
Next we would like to share with you how 
this concept can be incorporated into a 
rehabilitation system for spinal-cord 
injured patients.
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Deformed Mind’s Transcendence 
into a high-conscious environment.
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Evoked-Psychological 
Response to Initiate 
Rehabilitation Process
? When a person is under stress her/his 
mind is compressed and deformed as 
compared to a relaxed mind under a high 
consciousness level.
? This is especially so when the patients are 
undergoing long monotonous physical 
therapies without experiencing some 
definitive progress. 
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? Then this self-induced frustration acts as a 
positive feedback, further bringing down 
the consciousness level.
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Application of VR
? Our objective is to use VR to help conjure 
a curative and healthy environment, which 
can also bring her/him into a relaxed and 
higher consciousness level, which can be 
verified by examining the EEG alpha-wave 
energy-content. The amount of 
improvement is proportional to the 
increase in alpha wave density. 
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Spinal-Cord Injury Rehabilitation
? For Spinal Cord Injury (SCI) patients, the 
VR system will be designed to 
psychologically made the patient feel that 
the resected spinal cord reconnected, and 
there by the associated physiologically 
disordered (such as bladder control, 
temperature regulation, etc) are also 
remedied.
? For sitting and lying-down, we can design 
a mattress, of skin-breathing synthetic 
material. 
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Spinal-Cord Injury Rehabilitation
65/31/2006 Virtual Reality in Rehabilitation 11
Spinal-Cord Injury Rehabilitation
? The mattress will be designed as a 
controllable pneumatic bed with turbulence 
generators. 
? The waves will act as physiotherapists’
fingers, giving massage. The warm fluid 
with the massage can facilitate blood flow 
to the patient and reduce sustained-
pressure bed-ridden related skin diseases.
5/31/2006 Virtual Reality in Rehabilitation 12
Spinal-Cord Injury Rehabilitation 
System Block Diagram
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SSREFS
? Additionally, a Sympathetic Signal-
Reinforcing EEG Feedback System 
(SSREFS) will be designed to extract 
alpha signals and filter beta signals from 
the EEG. The extracted alpha signals can 
be fed into patient’s spinal cord, to 
stimulate cerebral-neuronal growth.
5/31/2006 Virtual Reality in Rehabilitation 14
Conclusions
? For paraplegic patients,  the VR would be 
employed to make the patient feel that 
she/he is ambulatory, and that autonomic 
system is reconnected and working, so 
that the patient can void independently 
and feel the outside temperature so the 
VR will help the patient develop a strong 
will power to be cured and adopt 
independent living mood.
85/31/2006 Virtual Reality in Rehabilitation 15
Thank You
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Abstract— The primary function of the lung is to (i) 
oxygenate the blood and thereby provide oxygen to the 
cells for metabolization purposes, and (ii) to remove the 
collected CO2 from the pulmonary blood. Herein, we 
provide a noninvasive methodology to asses physiological 
metabolic rates as well as blood-oxygenation capacity of 
the lung. For this purpose, we analyze the compositions 
of the inspired and expired air per breath, and 
therefrom compute the metabolic O2 consumption and 
CO2 production rates.  
Next, we derive expressions for diffusion coefficients 
2OD and 2COD , in terms of the evaluated cardiac-output 
CO, O2 and CO2 concentrations in arterial and venous 
blood as well as alveolar and blood O2 and CO2 partial-
pressures. The coefficients 
2OD and 2COD represent the 
lung  capability to oxygenate the blood. We can then also 
determine the cardiac output, from knowing the 
concentrations of oxygen and carbon dioxide in the 
arterial and venous bloods.  
The derived information of 
2OD and 2COD as well as 
of O2 and CO2 metabolic rates can be of considerable use 
(including for SARS assessment). The paper provides a 
case study for the determination of  Q, 
2OD and 2COD . 
 
Keywords— gas exchange, O2 metabolic-rates, CO2  
metabolic-rates, diffusion coefficients 
2OD , diffusion 
coefficients 
2COD , blood flow rate 
 
 
I.  SCOPE 
 
 The lung functional performance is characterized by (i) 
its ventilatory capacity, to bring air (and hence O2) into the 
alveoli, and (ii) its capacity to transfer O2 and CO2 into and 
from the pulmonary capillary bed. Hence, the O2 and CO2 
diffusion coefficients 
2O
D and 
2CO
D as well as the O2 
consumption-rate and the CO2 production rate represent the 
lung performance indices. In this paper, we are 
demonstrating their evaluations. 
 
 
 
 
 
II LUNG GAS-EXCHANGED MODEL 
Figure 1 schematically illustrates the gas-exchange 
between the lung alveolus and the pulmonary capillary-
vasculature. Based on our earlier work [2] the gas exchange 
between the alveolar air and pulmonary capillary blood is 
represented by the following 2O  and 2CO  conservation 
equations  and Figure 2. 
 
22 2
VE VE AE AE
OO OQ C Q C V
°
= +  (from the alveolar air to 
capillary blood) 
2
2 2
( )Oav
AE AE
O OQ C P D= + ∆               (1) 
22 2
VE VE AE AE
COCO COQ C Q C V
°
= −  
  2
2 2
( )COav
AE AE
CO COQ C P D= − ∆                    (2) 
wherein 
(i) ABQ and VBQ  are arterial and venous blood flow-rates;    
(at venous end)  (at arterial end) ,AB VE VB AEQ Q Q Q= =
 
(ii) 
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial 
pressures 
(iii) 
2 2
 2and are the alveolar and capillary partial pressure  
al cap
CO COP P CO
 
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion 
coefficients 
(v) 2
2 2
- average of ( ) over the capillary length;Oav
capal
O OP P P=+  
2
2 2
average over the capillary length of ( ) CO al capav CO OP P P= −+
 
(vi) 
2
cap
OP = 2
PRB
OP  ( 2O  concentration of the pre-oxygenated 
blood) 
2
AE
OP=  
(vii) 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre-
oxygenated blood) 
2
VE
COP=  
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(viii) 
2O
V
a
 is the 2O  transfer rate from alveolar air to 
capillary blood (= 2O consumption rate), 2COV
a
is the 2CO  
transfer-rate from capillary blood to alveolar air. 
 
Now we can equate the arterial and venous blood flow rates, 
as  
AEQ = ABQ = VBQ VEQ= = Q =(SV)/(EP)  / 60CO  
SV, EP and CO being the stroke-volume, ejection-period 
and cardiac-output respectively. 
 
 
 
Figure 1: Process of oxygenating the venous blood. The low 
oxygen (O2) concentration Red Blood Cell (RBC) is shown 
in dark blue. As it travels down the artery towards the 
venous end, the O2 concentration increases. After the 
distance L, its O2 has increased to 0.18 from the initial 
concentration of 0.13. 
 
 
 
Figure 2: Schematic of blood gas concentration in the 
Pulmonary Capillary. 
 
III. CLINICAL DATA 
 
The monitored data consists of inspired and expired air gas 
compositions (Table 1) and 2O and 2CO  concentrations of 
arterial blood and venous blood (Table 2). 
 
Table 1: Air Composition Analysis. Inspired and expired air 
composition and partial pressures are monitored. Assumed 
Breathing Rate (BR) = 12 breaths/min. Assumed 
2H O
P  at 
37οC = 47 mmHg. 
 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/% 
N2 597 393.1 
78.55% 
597 393.1 
74.52% 
O2 159 104.2 
20.84% 
84.5 83.37  
15.7% 
CO2 0.3 0.2 
0.04% 
29 16.87  
3.20% 
H2O 3.7 2.5 
0.49% 
49.5 34.15  
6.47% 
Total 760 500 
100% 
760 527.49 
100% 
 
  
Table 2:  Blood Gas Analysis. The monitored blood  O2 and 
CO2 concentration . 
2O
C   of venous blood  (
2
VB
OC ) = 0.13 
2O
C   of arterial blood  (
2
AB
OC ) = 0.18 
2CO
C  of venous blood (
2
VB
COC ) = 0.5 
2CO
C  of arterial blood (
2
AB
COC ) = 0.46 
 
IV. EXPRESSIONS FOR 
2O
D AND 
2CO
D  
If we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 
2
al
COP , 2
cap
COP  in terms of monitorable quantities [1 & 2]. 
 
(i) Alveolar 
2
al
OP can be expressed in terms of V
°
(the 
ventilation rate) and 2OV
°
(the 2O  consumption rate). 
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*
24.18
 ;                                 (3)
*wherein the nomalised ventilation rate,  60 
 is  the  consumption rate (in liters/min).
140 1
OV V
V V V Vm
litres/min, 
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= =
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
a a a a
2
al
OP
 
(ii) Alveolar 
2
al
COP  can be expressed in terms of V
°
 and 
2OV
°
. 
22.46 *
114.68
COV V
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
−
=alCO2P             (4) 
wherein 
2CO
V
a
 is  the 2CO production rate (in liters/min).  
 
(iii) Blood
2O
P can be obtained in terms of  blood 
2O
C , from 
the 2O  disassociation curve. 
 
2
0.2
29.72 ln
0.2 BO
B
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦O2
P        (5) 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
BC ,from 
the 2CO  disassociation curve. 
 
2
0.8
29.72 ln
0.8 BCO
B
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦CO2
P      (6) 
Now, 
2 2 2 2
( )Capal al VBO O O OP P P P= − = −  both 2OP+ and 2COP+  
2 2
)( VB alCO COP P= −  vary along the capillary bed. Based on [3], 
we have: 
2 2
max0.185
OOP Pav =+ +        (7) 
2 2
max0.1   
COCOP Pav =+ +        (8) 
From the above expressions, we obtain: 
2 2
2 2 0.185( )
2 2
O O
O O
av
al VBP PP O O
V V
D = = −
a a
+
     (9) 
2 2
2 2 0.1( )
2 2
CO CO
CO CO VB alP PPav CO CO
V V
D = = −
a a
+
    (10) 
 
 
V.  DETERMINATION OF O2 AND CO2 METABOLIC 
RATES AND CARDIAC OUTPUT 
 
From monitored data of inspired-exhaled gas compositions, 
in Table 1: 
 
2O  consumption rate, 2OV
a
= BR(Inspired 2O - Expired 
2O )ml/min =12(104.2-83.37) = 250 ml/min               (11) 
 
2CO consumption rate, 2COV
a
=BR(Expired 2CO -Inspired 
2CO ) ml/min = 12(16.87-02)=200 ml/min                  (12) 
 
From monitored 2O  and 2CO concentrations of arterial and 
venous blood, in Table 2: 
 
∵ 2OV
a
= Q( 2CO  of arterial blood - 2CO of venous blood)   
 
where Q=blood flow rate≡cardiac output 
 
2 250 5000 /
(0.18 0.13) 0.05
OVQ ml min∴ = = =−
a
      
  
VI. EVALUATING OF THE LUNG DIFFUSION 
COEFFICIENTS 
2O
D  AND 
2CO
D  
From equation (3) and Table 2 (
2
AB
OC =0.18), we get for 
(arterial blood @ venous end of the pulmonary capillary or 
2
VE
OP )  
        
2
AB
OP =
2
0.2
29.72 ln
0.2 ABOC−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
 
       = 
0.2
29.72 ln
0.2 0.18−
⎡ ⎤⎢ ⎥⎣ ⎦   
      = 68.43 mmHg                        (13)                        
 
 
From equation (5) and Table 2 (
2
VB
OC =0.13), we get for 
2
VB
OP  (venous blood @ arterial end of the pulmonary 
capillary or 
2
AE
OP  ) 
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2
VB
OP   =  
2
0.2
29.72 ln
0.2 VBOC−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
 
       = 
0.2
29.72 ln
0.2 0.13−
⎡ ⎤⎢ ⎥⎣ ⎦            
      = 31.20 mmHg                  (14)         
           
 Also, from equation (3) and Table 1 ( *V
a
=0.1), we get: 
 
[ ]
*
2
0.1 0.25
4.18
4.18
      140 113                          (15)
140 1
1
OV V
mmHg
e
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
−= =
= −
−
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎣ ⎦
2
al
OP
 
         
Hence, from equations (14 & 15), we get: 
 
2 0.185 (113 31.2) 14.95Oavp mmHg= × − =+               (16) 
 
Finally, from equations (11) and (16), we get: 
 
2
2 2
1
250 / min
14.95
       16.72     (17)                            -1
O
O O
av
ml
mmHgP
V
D
mlmin mmHg−
= =
=
a
+  
                      
From equation (6) and Table 2 (
2
VB
COC =0.5), we get: 
2
          29.15                     (18)
0.8
29.72 ln
0.8
0.8
29.72 ln
0.8 0.5
VB
CO
VB AE
mmHg
C
=
= =
= −
−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎢ ⎥⎣ ⎦
CO CO2 2
P P
       
Then from equation (4), Table 1 ( 0.1V =
a
), and equation 
(12) we get: 
[ ]
2
0.1 0.2
2.46
2.46
*
33.52                                (19)
114.68
114.68
COVV
mmHg
e
e
°
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
−
−= =
=
a
al
CO2
P  
         
 
Hence, from equations (8, 18 & 19), we get: 
 
2 0.1 (33.52 29.15) 0.44COavp mmHg= × − =+           (20) 
     
Finally, from equations (10 & 20), we get: 
2
2 2
200 / min
0.44
                           454.55                     (21)
CO
CO CO
av
ml
mmHgP
-1 -1mlmin mmHg
V
D = =
=
a
+                             
VII.  CONCLUSION 
 
We have demonstrated a noninvasive clinical procedure:  
• for obtaining (i) O2 consumption rate and CO2 
production rate, (ii) cardiac outflow-rate or 
output, Q, (iii) and lung diffusion capacities for  
O2 and CO2. 
• from inhaled and exhaled air composition 
analysis, and blood-gas analysis. 
This work could have application to SARS testing and 
evaluation. 
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Abstract— This paper provides a systems-engineering 
analysis of the glucose-insulin responses to an ingested 
bolus of glucose for OGTT (Oral Glucose Tolerance 
Test). The clinical data of patients is fitted by either 
under-damped or over-damped or critically-damped 
solutions of the model’s governing equations for glucose 
and insulin responses to glucose bolus ingestion. Based 
on the best fit of the three types of solutions, we 
designate the patients (and their response) to be normal 
(and under-damped), diabetic (and over-damped) and 
either border-line or at-risk of becoming diabetic (and 
critically-damped). In this way, the model simulation of 
the clinical data enables more reliable diagnosis relative 
to the clinical assessment. 
  
 
Keywords—diabetic, systems-engineering model, under-
damp, over-damp, critically-damped, R-square, fitting, clinical 
diagnosis  
 
I.  INTRODUCTION 
 
Oral Glucose Tolerance Testing Protocol 
 The test subjects need to fast for 12 hours before the test 
and during the 2-hour test. A blood sample of the subject is 
taken before the beginning of the test. Then after the subject 
drinks a 75 g of glucose solution dissolved in 250–300 mL 
of water, the subject’s blood glucose and insulin 
concentrations are measured at specified intervals 30 
minutes, 60 minutes, 90 minutes and 120 minutes [1, 2, 4]. 
Qualitative interpretation of the results, for preliminary 
categorization of the patients [1, 2, 4]: 
(a) Blood glucose normal values:  
fasting: 70 to 115 mg/dl  
30 min.: less than 200 mg/dl 
1 hour : less than 200 mg/dl 
2 hour : less than 140 mg/dl  
(b) Normal insulin level (reference range): 1-30 mU/L 
When a person has a fasting glucose equal to or greater 
than 110 mg/dl and less than 126 mg/dl, it is considered as  
impaired fasting glucose. This is considered a risk factor 
for future diabetes and will likely trigger another test in the 
future, but, by itself, does not make the diagnosis of 
diabetes. 
A person is said to have impaired glucose tolerance 
when the 2-hour glucose results from the oral glucose 
tolerance test are greater than or equal to 140 but less than 
200 mg/dl.  This is also considered a risk factor for future 
diabetes. A person has diabetes when oral glucose tolerance 
tests show that the blood glucose level at 2 hours is equal to 
or more than 200 mg/dl.  This must be confirmed by a 
second test (any of the three) on another day.  
 
II. SYSTEM SOLUTIONS FOR DIABETIC, NON-
DIABETIC AND AT-RISK PATIENTS 
 
The governing differential equation for glucose response to 
glucose bolus intake is: 
 
( )y q t x yγ δ′ = − −                                          (1) 
The governing differential equation for insulin response to 
glucose bolus intake is: 
 
( ) -x p t x yα β′ = +          (2) 
 
y(t) : Glucose response of the patient to the oral bolus of    
glucose. 
x(t) : Insulin response of the patient due to y(t). 
 
Solution For Underdamped Case (non-diabetic): 
y(t) = (G/ ω) e-At sinωt                (3) 
 
( )
( )(sin( )
( )sin( )
( ) ( )cos( ) )
( ) 2 2 22
Atwt Ae
Atwt e
t Ate w wt e w
G
wx t
A A w
α
α
β
α α
−⎡ ⎤−⎢ ⎥−⎢ ⎥−⎢ ⎥− −⎢ ⎥− +⎢ ⎥⎢ ⎥×⎢ ⎥⎣ ⎦=
− + +
            (4) 
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Solution For Overdamped Case (diabetic): 
 G -Aty(t)= e sinhwt
ω
                    (5)     
 
  
1 (cosh( ) sinh( )
2
cosh( ) sinh( )
sinh( ) cosh( )
sinh( ) sinh( )
cosh( ) cosh( )
cosh( ) 2
sinh(
( )
wt At t A wt At t A
wt At t A wt At t A
wt At t w wt At t w
wt At t wt At t
wt At t wt At t w
wt At t w
wt
x t
α α
α α
α α
α α α α
α α α
α α
+ − + − + −
− − + − − + −
+ − − − − + −
− − − − + + −
− + − − − −
+ − + − +
+ −
= ( )
( )
2 2 2
) )
2
t GAt t w e
w
w A A
αα β
α α
−
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟+ −⎜ ⎟⎝ ⎠
− + − +
(6) 
 
Solution For Critically Damped Case (at the dangerous 
boundary): 
 
-Aty(t)= Gte                     (7) 
( ) ( ) ( ) ( )( )
( ) 2( )
At At At tG tAe t e e e
x t
A
αβ α
α
− − − −− − + −=
−
 (8) 
 
III.  CLINICAL APPLICATION AND DISCUSSION 
 
Under-damped Category and Normal Designated Patient 
 
These y(t) and x(t) response solutions are fitted to the 
monitored glucose and insulin data, and the fitness 
coefficients are determined. Based on the high degree of fit, 
patient S14 fits best the under-damped category, and hence 
is designated to be normal.  His Glucose and Insulin 
responses, shown in Figure 1, illustrates the fast recovery of 
blood glucose and insulin concentrations.  
 
 
The below table displays the values of the model parameters 
and the R-Square coefficients of fitness and the model slution 
to the clinical data. 
 
 
Figure 1: Patient S14 is designated to be under-damped and 
normal. However, this patient is quite hyper-insulinemic; in 
other words, this patient has elicited considerable insulin 
response in order to maintain an under-damped glucose 
response. 
Over-damped Category of Patients Designated as Diabetic 
 
     For patients D05, our over-damped model solution fits the 
clinical data best of the 3 solution categories. Hence, this 
patient is designated to be diabetic. His Glucose and Insulin 
responses are shown in Figure 2, and the model parameters are 
given in the Table. 
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Figure 2: This patient D05 has the higher R-Square value when 
fitted by the over-damped solution, and is hence classified as 
diabetic. 
 
Critically-damped Category of Patients 
 
There are some patients clinically diagnosed to be 
normal for which the critically-damped solution gives a 
better fit of the data (and a higher value of R-Square) than 
the under-damped solution. One such patient is S04, whose  
under-damped and critically-damped model response-curves 
are shown in Figures 3 and 4. Similarly, patients S06 and 
S19 are not normal as clinically diagnosed, but at the risk of 
becoming diabetic. Their response curves are illustrated in 
Figures 5 and 6. 
 
 
 
 
 
Figure 3: This S04 patient’s data is fitted by the under-damped 
solution. Next, we will compare the results fitted by the 
critically-damped solution as shown in the following figure. 
 
 
 
 
Figure 4: This S04 patient’s data is better fitted (i.e. at higher 
R-Square value) by the critically-damped solution than by the 
under-damped solution. Because of the critically-damped 
model solution giving us a better fit (terations of a higher 
value of R-Square), we differ from the clinical diagnosis and 
alert this patient that he is at risk at becoming diabetic. 
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Figure 5: This S06 patient’s data is better fitted (i.e. at higher 
R-Square value) by the critically-damped solution than by the 
under-damped solution. Hence, we will differ from the clinical 
diagnosis and designate this patient to be at risk of becoming 
diabetic. 
 
 
 
 
Figure 6: This S19 patient’s response curves are best fitted 
(with a higher value of  R-Square) by the critically-damped 
solution than by the under-damped solution. 
 
 
V.  CONCLUSION 
 
We have shown that we can obtain more accurate 
assessment of diabetic patients by means of our under-
damped, over-damped and critically-damped simulation 
model solutions. Some patients (diagnosed to be normal) 
were designated by us to be in the borderline category. 
However, some patients who were clinically declared to be 
diabetic turned out to be only border-line. As we continue 
this work, we will develop a clinically-implementable 
software for model parameter identification and designation 
of the subjects as normal or at-risk of becoming diabetic or 
border-line diabetic or distinctly diabetic.  
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Scientific Programme – DAY 1 
 
Wednesday, September 08 2004 
 
0800 – 0920  Registration 
 
0920 – 0940 Opening Ceremony 
 
0940 – 1010 Nanostructure Processing of Advanced Biomaterials 
Invited Speaker: Dr. Jackie Ying 
 
1010 – 1040 
 
Bioengineering, Technology Commercialization and Entrepreneurship 
Invited Speaker: Dr. Yongmin Kim 
 
1040 - 1100 Tea break 
 
1100 – 1130 
 
Esophageal Tissue Engineering 
Invited Speaker: Dr. Buddy Ratner 
 
1130 – 1200 
 
A Case Study of Integrated Biomedical Engineering: A Novel Method for Creating an 
Automated Sutureless Anastomosis  
Invited Speaker: Dr. Adam Sharkawy 
 
1200 –1230 
 
Advances in Cancer Imaging 
Invited Speaker: Dr. James Khoo 
 
1230 – 1330 Lunch 
 
1330 – 1400 
 
Tissue Engineering Heart Constructs using Bone Marrow Stem Cells 
Invited Speaker: Dr. Philip Wong 
 
1400 – 1430 Computational Technologies to Accelerate Biotech Innovation 
Invited Speaker: Dr. Ulrich Meier 
 
1430 – 1500 A new Approach to Protein Structure Prediction 
Invited Speaker: Dr. Heiko Schroder 
 
1500 – 1515 Tea break
 
Day 1 (continued) 
Session 01 Tissue Engineering 
(Room 1) 
1515 – 1730 
Chairs: S. Chian, P. Wong 
Session 02 Cancer Detection & 
Therapy (Room 2) 
1515 – 1715 
Chair: J. Khoo 
Session 03A Medical Image 
Processing (Room 3) 
1515 – 1745 
Chairs: Z. Kuanyi 
• Automated Segmentation of 
Breast Masses in Mammograms 
Zhang H., Foo S.W., Thng C.H. 
 
• Diagnosis of Lung Cancer Using 
NIR Raman Spectroscopy 
Huang Z., McWilliams A., Lam S., 
McLean D.I., Lui H., Zeng H. 
 
• Extraction of head and neck 
tumors using deformation 
models from MR images 
Zhou J., Chong V. 
 
• Breast Cancer Diagnosis using 
Thermography and 
complementary learning fuzzy 
neural network 
Tan T.Z., Quek C., Ng G.S., Ng E.Y.K. 
 
• Magnetic Particles for 
Hyperthermia Treatment of 
Cancer 
Ramanujan R.V., Lao L.L. 
 
• Gene Selection for Cancer 
Classification from Microarray 
Data using PLS-RLSC 
Shen L., Tan E. C. 
 
• Micelle-like Nanoparticles of 
Linear and Branched PLA/PEG 
Block Copolymer as Anti-Cancer 
Drug Carrier 
Pan J., Feng M., Chan W.A., 
Venkatraman S., Boey F.Y.C. 
 
• Identify human colorectal 
cancerous via Laser Induced 
Autofluorescence spectra 
confocal image 
Sheng F., Chia T.C., Kwek L.C., Diong  
C.H., Tang, C.L. 
 
Session 04 Microfluidics/MEMS 
(Room 2) 
1715-1800 
Chair: D. Trau 
• Enhancement of Meniscus 
Repair using Mesenchymal 
Stem Cells in a Porcine Model 
Dutton A., Hui J.P.P., Lee E.H. 
 
• Cardiac Differentiation of 
Adult Bone Marrow 
Mesenchymal Stem Cells 
 Tan G.M.Y., Wong P., Chua T., 
Tan J., Chua Y.L., Tan Y.S., Sin 
Y.K., Lim C.H., Liu T.C., Teh M., 
Sim E.K.W., Shim W.S.N. 
 
• Polyurethane Membranes for 
Chondroctye Transplantation 
and Cartilage Engineering 
Chia S.L., Gorna K., Gogolewski K., 
Alini M. 
 
• Theoretical and Experimental 
Determination of State of Two 
Dimensional Strain in a 
Bioreactor 
Ong W.F., Wijaya S., Ritchie A.C. 
 
• Culture of Rodent 
Hepatocytes on Microgrooved 
Surfaces: Application for a 
Flat-Plate Bioartificial Liver 
Device 
Ting K.S., Wang N.D., Grant M.H., 
Henderson C. 
 
• Simultaneous Probing of 
Morphology, Cytoskeleton, 
and Adhesion Dynamics of 
HepG2 Cells 
Feng Z. Q., Liao K., Chan V. 
 
• ECM-Dependent Proliferation 
of Adult Bone Marrow 
Mesenchymal Stem Cells 
Tan G.M.Y., Shim W.S.N., Chua T., 
Liu T.C., Teh M., Sim E.K.W., 
Wong P. 
 
• Parameters for Scaffold 
Design of Esophageal Tissue 
from a Structural Constitutive 
Model 
Yang W., Fung T.C., Chian K. S., 
Chong C. K. 
 
• Surface modification of 
biodegradable poly(L-lactide-
co-caprolactone) (PLLC) 
membrane with proteins to 
enhance the growth of 
esophageal smooth muscle 
cells 
Yabin Z., Chan-Park M.B., Chian 
K.S 
• AFM Characterization and 
Selectivity of Immobilization of 
Antibodies in Bio-MEMS 
Joshi M., Rao R., Mukherji S. 
 
• Cross-Talk, a Potential Source of 
Noise in a Fluorescence Multi-
channel Microfluidic System 
Irawan R., Tjin S.C. , Yager P., Zhang 
D.W. 
 
• Microfluidic Protein Patterning 
using Embedded Cavities in 
Microchannels 
Garcia E., Yager P. 
 
• ALA-Induced-PPIX Fluorescence 
Imaging of Normal and 
Neoplastic Tongue Tissue using 
Confocal Endomicroscopy 
Zheng W., Harris M., Kho K.W., Thong 
P.S.P., Hibbs A., Soo K.C., Olivo M. 
 
• A Simulation System for Remote 
Interventional Radiology 
Procedures 
Zhao L., Ma X., Aziz A., Zheng W., 
Nowinski W.L. 
 
• An Improved Active Contour 
Method for Heart Wall Boundary 
Detection in Echocardiographic 
Image Sequence 
Fang W., Chan K.L., Anantharaman V. 
 
• Augmented Reality Assisted 
Sinus Surgery 
Shi D. M., Ng W. S., Ling K. V., Shao 
W., Chen H. J., Kwoh C. K. 
 
• Brain Atlas-assisted 
Segmentation of the 
Hippocampus from MR 
Neuroimages 
Minh P.D., Prakash K.N.B., Nowinski 
W.L. 
 
• Removing Blocking Artifacts in 
Compressed Medical Images 
Singh S., Vinod K., Verma H.K. 
 
• Simulated Annealing based 
Simplified Snakes for Weak 
Edged Medical Image 
Segmentation 
You J., Zhou Z., Heng P.A., Xia D. 
 
• Extraction of the Two Modified 
Talairach Cortical LandMarks (I 
and S) from MR T1-Weighted 
Images 
Hu Q., Qian G., Nowinski W.L. 
 
• Knowledge-based Interpolation 
of the Talairach-Tournoux Brain 
Atlas 
Liu J., Nowinski W.L. 
 
• Mapping Human Skin and Aural 
Temperature with ANNs and IR 
Imager 
Ng E.Y.K., Chong C. 
 
END OF DAY 1 
 
 
 
Scientific Programme – DAY 2 
 
Thursday, September 09 2004 
 
0830 – 0900 
 
Development of Microfluidic-Based Point-of-Care Diagnostic Systems 
Invited Speaker: Dr. Paul Yager 
 
0900 – 0930 
 
Innovation in The Medical Device Industry: Development of Cypher - the first Drug-Eluting 
Stent 
Invited Speaker: Mr. Alok Mishra 
 
0930 – 1000 
 
Heart Tissue Engineering 
Invited Speaker: Dr. Buddy Ratner 
 
1000 – 1015 
 
Tea break 
 
 
Session 05 Biomaterials & Drug 
Delivery (Room 1) 
1015 – 1230 
Chairs: Y. Yiyan, S. Miao 
Session 06 Biomechanics 
(Room 2) 
1015 – 1230 
Chairs: S.L. Chia, F.K. Fuss 
Session 07A Computational 
Bioengineering 1 (Room 3) 
1015 – 1230 
Chairs: V. Zagorodnov, K. C. 
Keong 
• Smart Polymer Nanocarriers for 
Targeted Delivery 
Yang Y.Y 
• Release of Lipoplexes from a 
Biodegradable Polymer Film: 
Preliminary Study 
Chan W.A., Ramgopal Y.  
 
• Cross linking of Bovine Serum 
Albumin with Genipin: 
Investigation of Mechanical 
Properties 
Sathappan K., Chian K.S., Chua L.P. 
 
• Porous Beta-TCP and Its 
Modification with PLGA Coating 
for Bone Regeneration 
Miao X. and Kurniawati T. 
 
• In vitro Study on the Release 
Kinetics of Bovine Serum 
Albumin (BSA) from Injectable 
PLGA/BB Depot 
Wang L.W., Venkatraman S. 
 
• Effects of Plasticization on 
Heparin Release from 
Biodegradable Matrices 
Tan L.P, Venkatraman S., Sung P.F., 
Wang  X.T., Wong P. 
 
o Porous Bioinert Alumina 
Prepared by Vacuum Infiltration 
Liu J., Ng M.Y., Loh K.H., Hu Y., 
Miao X. 
 
• Clinical Applications of 
Magnetic Nanomaterials 
Ramanujan R. V. 
 
• Biomechanics Highlights in 
Sports, Physiology and Medicine 
Ghista D.N. 
 
• Evolution and Biomechanics of 
the Cruciate Ligaments 
Fuss F.K. 
 
• The Double-Bundle ACL Graft 
Reconstruction: A superior 
technique to restore knee 
kinematics 
Lie D.T.T., Amis A. 
 
• Finger Pulley Injuries are Self-
Propagating: A Mathematical 
Analysis of the A2-Pulley 
Tan M.A., Fuss F.K., Niegi G. 
 
• A Comparative Study of 
Different Gripping Methods for 
Tendons 
Ng B.H., Chou S.M., Krishna V. 
 
• Statistical Analysis of Human 
Metacarpal Morphology using 
CT Scan Data 
Zhai L.Y., Chou S.M., Lim B.H., 
Chong A., Tsou I., Ng S.Y. 
 
• Mechanics and Finite Element 
Analysis of the Auditory 
Ossicles 
Ho K.L.I., Fuss F.K. 
 
• Foot Characterization and 
Anatomical Landmarks 
Localization 
Liu X., Kim W.D., Drerup B. 
 
• A Case Study on Pattern-based 
Systems for Computational 
Biology 
Liu W., Schmidt B. 
 
• A Grid Implementation of 
Database Searching 
Chen C., Schmidt B. 
 
• The Use of Computer Modelling 
to elucidate the Efficacy of Slit 
Arteriortomy for End-to-side 
Arterial Anastomosis in 
Microsurgery 
Chua A.W.C, Gu H., Tan B. K., Chew 
W., Li J.Z., Song C.  
 
• A Mixed SVM-Based 
Hierarchical Learning Approach 
for Abnormal ECG Beat 
Recognition 
Li P., Chan K.L., Chan Y.W. 
 
• Capturing Cellular Life In-Silico 
Dhar P.K. 
 
• Finite Element Modeling of the 
Human Brain with Detailed 
Anatomy for Surgery Simulation 
Based on a Brain Atlas 
Gao C., Tay F.E.H., Nowinski W.L. 
 
• Fuzzy c-Means and Neural 
Network Framework for 
Arrhythmia Classification 
Chaudhari N.S., Liew C.S.  
 
• VRML Modeling for Bio-
Molecular Structures 
Indhumathi C., Lu B.F., Cai Y.Y. 
 
• BioSequence Comparison for 
Large Database on 
Reconfigurable Platforms 
Wong M.T., Schmidt B. 
LUNCH 
1230 - 1330 
 
 
 
 
Day 2 (continued) 
Session 08A Cardiovascular 
Engineering 1 (Room 1) 
1330 – 1530 
Chair: A.C. Ritchie 
Session 09A Sport Engineering 1 
(Room 2) 
1330 – 1530 
Chairs: W. Kim, F.K. Fuss 
Session 07B Computational 
Bioengineering 2 (Room 3) 
1330 – 1415 
Chair: B. Schmidt 
• Clustering Based Watershed 
Segmentation for Two-
Dimensional Gel 
Electrophoresis Image 
Diao X. N., Mao K. Z.  
 
• Estimating error-dimensionality 
relationship for gene 
expression based cancer 
classification 
Chu F., Wang L. 
 
• Finite Element Analysis of Brain 
for Neurosurgical Procedure 
Roy A., Nowinski W.L., Tay F.E.H.  
 
Session 10A Ultrasonic Imaging 1 
(Room 3) 
1415 – 1530 
Chair: M. Kezhi 
• A Decoupled Control Method 
for the Magnetic Bearings of a 
Blood Pump 
Lim T.M., Zhang D., Kim M.T.  
 
• An Immersed Membrane 
Method For Simulation of Fluid-
Structure Interaction in Bio-
Fluid Flows 
Xia G.H., Zhao Y., Yeo J.H., Tai C.H.  
 
• Computation of Gap Flow Field 
in a Bio-Centrifugal Blood 
Pump 
Chua L.P., Song G. L., Yu S.C.M.  
 
• Computational Studies of 
Steady Flows In Designed 
Sleeve Models At Distal 
Anastomoses 
Chua L.P., Tong J.H.  
 
• Contractility of the Left 
Ventricle in Terms of its 
Sacromere Power Generation 
Zhong L., Ghista D.N., Ng E.Y.K  
 
• Detection of Cardiac Arrhythmia 
using Phase Space Analysis 
Wong M. T., Srinivasan N., Chan 
Y.W. 
 
• Flow Studies in Aorto-Right 
Coronary Bypass Graft System 
Meena S, Chua  L P, Ghista D N, Tan 
Y S 
 
• LV Twisting Analyzed for 
Pressure-Increase During Iso-
Volumic Contraction 
Liu L, Yeo S.Y., Ghista D.N., Chua 
L.P., Chai G.B., Tan Y.S., Tan R.S. 
• Quantitative analysis of 
Singapore Golfers 
Lim S. L., Xie X., Ong V., Teh K. C.  
 
• Three-Dimensional Kinematics 
Study of Left Hand During Golf 
Swing 
Teu K. K., Kim W., Fuss F. K., Tan J.  
 
• Investigation of Weight Transfer 
during Golf Swing 
Teu K. K., Kim W., Fuss F. K., Tan J.  
 
• Biomechanics of Push-up 
Exercise and Triceps 
Contractility 
Tan M. A., Zhong L., Fuss F. K., 
Ghista D. N.  
 
• Comparison of Pinch- and Open 
Hand Grip during Sport 
Climbing 
Yap Y. H., Fuss F. K., Niegl G., Tan 
M. A.  
 
• Friction at the Climbing 
Handhold under Different 
Conditions and its Implications 
for Sport Climbing 
Tan M. A., Fuss F. K., Niegl G.  
 
• Finger Load Distribution During 
Sport Climbing 
See W. N. W., Fuss F. K., Niegl G., 
Yap Y. H.  
 
• Analysis of Badminton Smash 
Using Dual Euler Angles 
Algorithm 
Liu X., Teu K. K., Kim W., Tan J., 
Fuss F. K.  
 
• Medical Ultrasound Imaging: 
Current Status and Future 
Trends 
Yoo Y.M., Kim Y.M. 
 
• Reconfigurable and 
Programmable Architecture for 
Digital Receive Beamformer 
Schneider F.K., Yoo Y.M., Agarwal 
A., Kim Y.M. 
 
• Adaptive  Speckle Reduction 
Based on Nakagami 
Distribution in Medical 
Ultrasound Imaging 
Zhang L.C., Wong E.M.C. 
 
• Specific Homomorphic 
Nonlinear Diffusion for Speckle 
Reduction in Ultrasound B-
mode Images 
Zhang F., Koh L.M. 
 
• Design and Optimization of 
Broadband Ultrasonic Sparse 
Array Transducers for Medical 
Imaging Applications 
Wang Q. B., Guo N. Q.  
 
Tea Break 
1530 -1545 
 
Day 2 (continued) 
Session 08B Cardiovascular 
Engineering 2 (Room 1) 
1545 – 1645 
Session Chair:  A.C. Ritchie 
Session 09B Sport Engineering 2 
(Room 2) 
1545 – 1630 
Chairs: B. Tan, K.C. Teh 
Session 10B Ultrasonic Imaging 2 
(Room 3) 
1545 – 1645 
Chair: M. Kezhi 
• Multiple-Model Adaptive Control 
by Means of a Fuzzy Controller-
based Control System 
Zheng H., Zhu K. Y., Tan Y. S.  
 
• Numerical Investigation of 
Hemodynamics for the 
Coronary Artery Bypass Graft 
Model 
Chua L.P., Zhang J.M., Zhou T.M., 
Yu S.C.M., Ghista D.N., Tan Y.S. 
 
• Numerical Investigation of 
Stress Field in Distal End-to-
side Anastomoses 
Liu L., Chua L.P., Ghista D.N., Tan 
Y.S. 
 
• PIV Measurements on the 
Pulsatile Flow Characteristics in 
45-degree Backward Proximal 
Anastomosis 
Ji W.F., Chua L.P., Yu S.C.M.,  
Ghista D. N., Zhou T. M., Tan Y. S.  
 
• Determinants of Maximal Hiking 
Performance in Laser Sailors 
Tan B., Aziz A.R., Spurway N.C, Toh 
C., Mackie H., Xie W., Wong J., Fuss 
F.K., Teh K.C. 
 
• Comparative Study on the 
techniques of Singapore and 
Thailand Table Tennis players 
during SEA Games 2001 
Lee K.T., Xie W., Teh K.C.  
 
• Experimental Study on Different 
Types of Service Spins for 
Singapore National Table 
Tennis players 
Lee K.T., Xie W.  
• Field of View-based Imaging for 
Efficient Beamforming in Low-
end Portable Ultrasound 
Systems 
Agarwal A., Schneider F.K., Yoo 
Y.M., Kim Y. 
 
• Low Sampling Frequency 
Digital Beamformer for 
Ultrasonic Imaging without 
Interpolation 
Gao C.Q., Zhang L.C., Wong E.M.C. 
 
• Comparative Evaluation of 
Wavelet Filters for Speckle 
Reduction in Ultrasound 
Medical Images 
Thakur A., Anand R.S. 
 
• Window Function Optimization 
by Genetic Algorithm for 
Ultrasound Imaging System 
Cao J., Koh L.M. 
Session 11 Respiratory 
Biomechanics (Room 1) 
1645 – 1730 
Chair: V. V. Kulish 
Session 12A Orthopaedic 
Engineering 1 (Room 2) 
1630 – 1745 
Chairs: S.M. Chou, D.T.T. Lie 
Session 13A Biosignal Processing 
1 (Room 3) 
1645 – 1745 
Chair: O. Chutatape 
• Determination of O2 and CO2 
Metabolic Rates and Lung O2 
and CO2 Diffusion Coefficients 
Loh K.M., Ghista D.N.  
 
• Oxygen Saturation Profiles in a 
Hollow Fibre Oxygenator 
Ritchie A.C., Thimm G.  
 
• Graphical Technique for 
Assessing Pulmonary Disease 
Loo C. M., Ang K. C., Ong J. H., 
Ghista D. N., Lim G. H.  
 
• Design Optimisation in 
BioMedical Engineering 
Koh E.C.Y., Fuss F. K. 
 
• Design Classification and 
Mechanics of Artificial Discs 
Fuss F.K.  
 
• Extraforaminal Lumbar 
Interbody Fusion: Simulation of 
the Fusion Process Based on 
Different Implant Materials 
Fuss F. K., Sabitzer R. J.  
 
• FE Investigation on Spinal 
Interbody Fusion 
Lee K. K., Teo E. C., Fuss F. K., 
Sabitzer R. J.  
 
• Optimization of Cervical Ring 
Cage by Taguchi Philosophy 
Yang K., Teo E. C., Fuss F. K.  
 
• A Novel Approach to Automatic 
Left Ventricular Contour 
Tracking 
Cheng J.R., Foo S.W. 
 
• A Novel Wavelet Based ECG 
Compression with X-tree 
Coding 
Swain S., Chutatape O., Dandapat S. 
 
• Left Ventricular Surface 
Kinematics During Isovolumic 
Contraction 
Yeo S.Y.,Tan R.S., Liu L., Chai G.B., 
Ghista D.N. 
 
• Evaluation of Slice Sensitivity 
Profiles for TPRF Algorithm 
Yan M., Zhang C.S. 
 
END OF DAY 2 
 
 
 
 
 
 
Scientific Programme – DAY 3 
 
Friday, September 10 2004 
 
0830-0900 
 
Biological Resurfacing of Articular Cartilage – from Bench to Bedside 
Invited Speaker: Dr. Lee Eng Hin 
 
0900-0930 
 
Virtual Reality, Augmented Reality and its Medical Application 
Invited Speaker: Dr. Uli Bockholt 
 
0930-1000 
 
Vital Signs in the Real World 
Invited Speaker: Mr. Stephen Wilson 
 
1000-1030 
 
Clinical Endoscopy System: Present and Future 
Invited Speaker: Dr. Tsuneo Hidaka 
 
1030-1045 Tea break 
 
 
Session 14 Biosensors/Diagnostic 
Tools (Room 1) 
1045-1200 
Chair: K. L. Chan  
Session 13B Biosignal 
Processing 2 (Room2) 
1045-1130 
Chair: C. Zhang 
Session 15 Distributed Diagnosis 
& Home Healthcare (Room 3) 
1045-1130 
Chair: S. C. Tjin  
• Uni-channel PCA for noise 
reduction from ECG signals 
Palaniappan R., Tan E.K.  
  
• Wavelet-Based Denoising and 
Analysis of Phonocardiogram 
Wang P., Anantharaman V.  
 
• Dynamical Analysis of Heart 
Rate Variability Signals 
Rajendra A.U., Kannathal N., Lim 
C.M. 
 
• Distributed Diagnosis and 
Home Healthcare (D2H2) and 
Patient-Centered Electronic 
Medical Record 
Kim E.H., Kim J. J., Matsen F.A., 
Kim Y.M. 
 
• Advanced System Architecture 
for Telecardiology 
Goh K. W., Kugean C., Tan E. K., 
Prabaharan K.  
 
• Disposable Microfluidic Card 
and Fluorescence Detection 
System for Point-of-Care 
Diagnostic Applications 
Irawan R., Tjin S. C., Fu C. Y., Ng 
B.K., Yuan X.C., Zhang D.W. 
 
Session 12B Orthopaedic 
Engineering 2 (Room 2) 
1130-1215 
Chairs: D. Ghista, S. Idapalapati 
Session 03B Medical Image 
Processing (Room 3) 
1130-1215 
Chair: S. C. Tjin  
• Multi-Parameter Clinical 
Diagnosis using Neural 
Networks 
Tan E.K.  
• An Otoacoutic Emissions 
Detecting System using USB 
AD/DA Board 
Qian X., Ye D. 
 
• Oral Glucose Tolerance Test 
Modeling For Diabetes 
Characterization 
Loh K.M., Ghista D.N. 
 
• Feasibility of biosensing based 
on two-dimensional square 
photonic lattice 
Zhang D. W., Irawan R., Tjin S. C., 
Yuan X. C.  
 
• Application of Artificial Neural 
Network Technique in 
Healthcare Expenditure 
Analysis 
Chia E., Khong P.W., Ghista D.N. 
 • Integration of CAD to FEA for 
Prosthetic Socket Design 
Goh J. C. H., Lee P. V. S., Toh S. L., 
Ooi C. K. 
 
• Analyses of Fractured Bone 
(Femur) with Plate and Intra-
Medullary Rod Fixations 
Chen Q., Fan S.C., Ghista D.N.  
 
• Biomechanics of Long Bone 
Geometry and Fracture 
Fixation 
Krishna K.R., Sridhar I., Sivashanker 
S., Khong K.S., Ghista D. N.  
• Automatic 3-D optic Disk Image 
Reconstruction from Low-
Resolution Fundus Image for 
Glaucoma Analysis 
Xu J., Chutatape O.  
 
• Low-Complexity Unified-
Adaptive Compression of 
Biomedical Images Using 
Integer Hartley Transform 
Meher P.K., Srikanthan T., Agarwal 
H.K., Gupta J. 
 
• Modified Deformable region 
model for Lumen Extraction 
from Colonoscopic Image and 
Comparison with FCM 
Tjoa M. P., Zheng M. M., 
Doraiswami R., Tang C.L. 
 
End of Conference 
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SYSTEM AND METHOD FOR DETECTING OF PULMONARY DISEASES  
 
Field of the Invention 
 
[0001] The present invention generally relates to systems and method for detecting 
of pulmonary diseases, and more particularly to non-invasive systems and methods for 
detecting of pulmonary diseases by analyzing inhalation and exhalation. 
 
Background of the Invention 
 
[0002]  Lung is a vital organ allowing exchanges of O2 and CO2 between the 
alveolar sockets and bloods.  When the lung is impaired, e.g., viral or bacterial infections, 
its physical appearance and/or functions will be altered, resulting in pulmonary diseases.  
The current detection of pulmonary diseases is mainly done by X-ray.  However, the X-ray 
is not only invasive, but also only able to detect the physical alterations of lungs.  Thus, the 
X-ray is not applicable for detecting pulmonary diseases at early stages.  In addition, there 
are a broad range of so-called pulmonary function tests.  For example, spirometry measures 
how well the lungs exhale.  Lung volume measurement permits detection of restrictive lung 
diseases.  Testing the diffusion capacity permits as estimate of how efficiently the lungs are 
able to transfer oxygen from the air into the bloodstream.  However, all the available 
function tests are mere measures of systemic metabolism rather than of pulmonary 
functions. 
[0003]  It is well known that the components of exhalation could be utilized for 
diagnosis of certain diseases.  For example, U.S. Pat. 4,823,803 discloses a device for 
testing human exhalation for halitosis by using sensors that are sensitive to malodorant 
gases of predetermined chemical compositions for producing signals variable with the 
detected concentrations of the malodorant gases.  However, this patent is directed to the 
detection of malodorant gases rather than the lung functions. 
[0004] There are situations in which an early detection of viral infection is critical 
for treatment of the victim and more importantly for the control of the epidemic.  For 
example, the recent epidemic of SARS (Severe Acute Respiratory Syndrome) has raised 
concerns about effective detection of such relevant diseases, especially at a much earlier 
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stage of infection in human bodies.  Upon early detection, scarce and precious medical 
resources can be focused on the infected persons.  In the early stages of the infections, the 
X-ray screening may not be useful because the pathogenic damages on the lungs may not 
be evident enough to be detected by the machine.  The current available function tests may 
not be able to detect the early signs of infections because the functions tests measure the 
systemic metabolism only.  While PCR is powerful in detecting the early infection, it is 
prone to mutations.  Massive mutations will handicap this technique severely.   
[0005] Therefore, there is an imperative need to develop non-invasive systems and 
methods for detecting pulmonary diseases, especially ones inflicted by viral or bacterial 
infections.  Furthermore, the detection is independent of the mutations of infectious agents.  
This invention satisfies this need by disclosing systems and methods of detecting 
pulmonary diseases by analyzing of the inhalation and exhalation of a test person.  Other 
advantages of this invention will be apparent with reference to the detailed description. 
 
Summary of the Invention 
 
[0006] The present invention provides a to be completed upon agreement of 
claims. 
[0007] The objectives and advantages of the invention will become apparent from 
the following detailed description of preferred embodiments thereof in connection with the 
accompanying drawings. 
 
Brief Description of the Drawings 
 
[0008] Preferred embodiments according to the present invention will now be 
described with reference to the Figures, in which like reference numerals denote like 
elements. 
[0009] FIG 1 is a block diagram of the pulmonary disease detection system (PDDS) 
in accordance with one embodiment of the present invention. 
[0010] FIG 2 shows a breath analyzer configured in accordance with one 
embodiment of the present invention. 
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[0011] FIG 3 shows a flowchart of detecting pulmonary diseases on the basis of 
altered oxygen consumption and carbon dioxide generation. 
[0012] FIG 4 shows another functional flowchart of detecting pulmonary diseases 
in accordance with another embodiment of the present invention. 
[0013] FIG 5a shows a diagram illustrating the directional relationships among the 
different pressures that may be detected or induced from the air flow rates detected by the 
breath analyzer as shown in FIG 2.   
[0014] FIG 5b shows that different pressures are functions of time. 
 
Detailed Description of the Invention 
 
[0015] The present invention may be understood more readily by reference to the 
following detailed description of certain embodiments of the invention. 
[0016] Throughout this application, where publications are referenced, the 
disclosures of these publications are hereby incorporated by reference, in their entireties, 
into this application in order to more fully describe the state of art to which this invention 
pertains. 
[0017]  The present invention provides systems and methods for detecting 
pulmonary diseases.  While there are provided more details about the systems and methods 
hereinafter, it is to be appreciated that the present systems and methods are based on the 
understanding that anyone developing any pulmonary diseases would demonstrate certain 
detectable breathing deficiencies.  The deficiencies may be manifested by the changes of 
the oxygen consumption and carbon dioxide generation, or the differences of lung 
compliance and airflow-resistance.   
[0018]  There is provided a block diagram of the pulmonary disease detection 
system (PDDS) as shown in FIG 1 in accordance with one embodiment of the present 
invention.  The PDDS 100 comprises a breath analyzer 102, a computer processor 103, and 
a medical database 104.  The breath analyzer 102 will take in the breath from a test person 
101 and output the information of components of the breath from the person to the 
computer processor 103.  The computer processor 103 contains algorithms for 
manipulating the information of the breath and comparing the manipulated results with the 
medical database 104, so that the computer processor provides the results of diagnosis 105.   
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[0019] The breath analyzer 102 may be any apparatus that can obtain breathing 
information from a test person that is sufficient for the application of the algorithms 
embedded in the computer processor 103.  For example, for the application of an algorithm 
based on oxygen consumption and carbon dioxide generation, the breath analyzer 102 
basically comprises of gas sensors such as sensors for oxygen, carbon dioxide and water 
vapor.  The compositions of both inhale and exhale gases are analyzed.  Then the 
respective compositions are further processed by the computer processor 103. 
[0020] FIG 2 shows a breath analyzer 102 configured in accordance with one 
embodiment of the present invention.  The breath analyzer 102 comprises a mask 1, a data 
acquisition unit 7, and an air tank 11.  The mask 1 is configured to cover the nose and 
mouth of a test person so that maximum fresh air is delivered to the test person and 
minimum exhaled air is lost before proper measurement is completed.  As shown in FIG 2, 
the mask 1 includes an air outlet membrane 2 as a seal for preventing air within the mask 
from leaking; an exhaust flip valve 3 that will open to allow all the expired air to flow out 4 
of the mask when the test person breaths out; an air inlet membrane 21 as a seal for 
preventing air within the mask from leaking; an inhale flip valve 22 that will open to allow 
the fresh air from the air tank 11 to flow in 23 when the test person breaths in; an oxygen 
electrode 25 for detecting the oxygen in the air composition; a carbon dioxide gas electrode 
24 for detecting the carbon dioxide in the air composition; a nitrogen gas electrode 17 for 
detecting the nitrogen in the air composition; a water vapor electrode 18 for detecting the 
water vapor in the air composition; an inspired air flow rate electrode 19 for determining 
the flow rate of exhale air; an expired air flow rate electrode 20 for determining the flow 
rate of exhale air; and signal conductors 5 that transmit the information from the electrodes 
to the data acquisition unit 7.  The signal conductors may be ultra-low impedance 
conductor or fiber optic. 
[0021] The air tank 11 contains pressurized air so as to ensure a measurable and 
controllable air supply to the test person.  An air delivery pipe 16 connects the air tank with 
the mask so as to deliver a stream of controlled air from the air tank to the mask.  The air 
tank 11 also includes four electrodes 12, 13, 14, 15 for detecting the oxygen, carbon 
dioxide, nitrogen, and water vapor respectively.  The signal conductors 10 transmit the data 
from the four electrodes to the data acquisition unit 7.  The signal conductors may be ultra-
low impedance conductor or fiber optic.  
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[0022] The data acquisition unit 7 includes connectors 6, 9 for connecting to the 
signal conductors 5, 10 so that it will receive all the information from the air tank and the 
mask.  Then the data acquisition unit 7 transmits the received signals to the computer 
processor 103 which acts as the central processing unit (CPU).  The transmitted 
information may be digitalized packets. 
[0023] After the CPU receives the data of the air compositions from the data 
acquisition unit 7, it will process the air composition data.  In one aspect of the present 
invention, the detection of pulmonary diseases is based on the understanding that anyone 
developing any pulmonary diseases would demonstrate certain detectable breathing 
deficiencies.  The inventors of the present invention further discovered that the breathing 
deficiencies are manifested by altered oxygen consumption and carbon dioxide generation.  
FIG 3 shows a flowchart of detecting pulmonary diseases on the basis of altered oxygen 
consumption and carbon dioxide generation.   
[0024] Referring now to FIG 3, when the PDDS 100 starts 301, it obtains through 
the data acquisition unit 7 the information including oxygen composition, carbon dioxide 
composition, nitrogen composition, water vapor composition, and air flow rate 302.  It is to 
be noted that the air flow rate data will be discussed hereinafter when the air flow rate will 
be used to calculate the volume compliance and air-flow resistance in another algorithm of 
the present invention.  Then the CPU will calculate the overall relatives of all gases 
compositions 303.  Then the processed data is searched against the stored database to 
determine whether the test person has pulmonary diseases 304.  Then diagnostic results 
will be outputted 305 and the operation comes to an end 306.  It is noted from FIG 3 that 
the stored database is continuously updated so that the database will become more useful 
when more data is collected. 
[0025] Now there is provided a more detailed description of detecting pulmonary 
diseases on the basis of altered oxygen consumption and carbon dioxide generation.  The 
basic assumption is that the composition of expired air from a patient such as a person with 
SARS infection is different from that of a normal person.  It is further assumed that with an 
expired air, (a) its O2 content (or % vol.) will be greater (because of less O2 consumed from 
alveoli) and closer to that of inspired air; (b) its CO2 content will be lesser, and more akin 
to that of inspired air; and (c) the transfer coefficients for O2 & CO2 will be lesser as 
compared to a medically normal person.  Therefore, the mass balance analysis involves (i) 
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compositions of air breathed in and out; and (ii) consumption or generation of O2, CO2 and 
H2O.   
[0026] For calculation of inhale and exhale compositions, there are a few general 
assumptions: (1) Breathing Rate (BR) = 12 breaths/min; (2) PH2O at 37oC = 47mmHg; (3) 
O2 metabolic consumption rate at (at BTP) = 284 ml/min; and (4) CO2 production rate (at 
BTP) = 227 ml/min.  Thus, the expected compositions of the expired air can be calculated 
from the atmospheric air or vice versa.  For example, as shown in Table 1, the expected 
expired air compositions can be calculated from the numbers of the atmospheric air 
column: 
[0027] N2 = 393.1 ml 
[0028] O2 = 104.2-(284/12) = 80.53 ml 
[0029] CO2 = 0.2+(227/12) = 19.12 ml 
[0030] Total = 492.75 ml (1) 
[0031] Ratio of water vapor/dry gas in the expired air = 49.5mmHg/(760-47) 
mmHg.= 49.5/713 = 6.94%  (2)  
[0032] Volume of water vapor in the Expired air = (1)x(2)=492.75 0.0694=34.21ml   
(3) 
[0033] Total Expired air = [1]+[3]=492.75+34.21=526.96 ml  (4) 
[0034] Thus the percentage of the gases components in the expired air can be 
calculated as follows: 
[0035] N2 = 393.1/526.96 = 74.6%; 
[0036] O2 = 80.52/526.96 = 15.28%; 
[0037] CO2 = 19.12/526.96 = 3.63%; and 
[0038] H2O = 34.21/526.96 = 6.49%. 
[0039] All the numbers of the atmospheric air and expired air are presented in 
Table 1.   
[0040] Table 1.  An exemplary air compositions  
[0041]  
Atmospheric Air Humidified Air Alveolar Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/ % mmHg ml/% mmHg ml/% 
N2 597 393.1 
78.62% 
563.3 117.8 
78.5% 
569 275.3 
74.9% 
597.5 393.1 
78.62 
O2 159 104.2 
20.84% 
149.3 31.3 
20.9% 
104 49.3 
13.6% 
84 55.3  
11.06 
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CO2 0.3 0.2 
0.04% 
0.3 0.09 
0.06% 
40 19 
5.3% 
29 19.1  
3.82 
H2O 3.7 2.5 
0.5% 
47.0 0.81 
0.54% 
47 22.7 
6.2% 
49.5 32.5  
6.5 
Total 760 500 
100% 
760 150 
100% 
760 366.3 
100% 
760 500 
100% 
 
[0042] So far it has been shown that if the rates of oxygen consumption and carbon 
dioxide generation are known, the ideal composition of an expired air can be calculated 
from the original composition of the atmospheric air.  This is important for initializing the 
stored databases because in the early stages, the PDDS may have to generate part of the 
database by calculating the components of the expired airs from the atmospheric airs based 
on certain assumptions.  With the gradual accumulation of the database, more and more 
actual data will supplement or substitute the calculated ones.  As discussed early, the breath 
analyzer 102 of the present invention can acquire the data of individual gas components of 
the expired air from the test person and the CPU can manipulate the data to give the 
percentages of each gas component as to the expired air.  The processed data of each gas 
components will be compared with the stored medical database.  If the test person suffers 
from any illness that affects pulmonary functions, it is expected that the processed data of 
the expired air from a test person will be deviated from that of the stored database for a 
normal person.  If this is so, the CPU will output the diagnostic results showing that the test 
person is probably having pulmonary diseases.  Then the test person can seek further 
examinations to determine which kind of pulmonary diseases he/she is developing. 
[0043] As shown in Table 1, it is apparent that the rates of oxygen consumption 
and carbon dioxide generation may be derived from the actual measurements of individual 
gas components of the atmospheric air and expired air.  It is noted that all of the data of 
individual gas components can be obtained by the breath analyzer as shown in FIG 2.  The 
calculated rates can be compared with the stored database to determine whether the test 
person is suffering any pulmonary diseases. 
[0044] As mentioned earlier, the choice of a breath analyzer 102 for the present 
PDDS is limited by its function only.  For example, when the lung compliance and airflow-
resistance are used for detecting pulmonary diseases, the breath analyzer 102 may be a 
commercially available spirometer.  Now referring to FIG 4, there is provided another 
functional flowchart of detecting pulmonary diseases in accordance with another 
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embodiment of the present invention.  When the PDDS starts 400, it obtains data from the 
breath analyzer 401 (the same as the one shown in FIG 2) to determine the volume breath 
characteristics of the test person 402, and further extract the parameters of P0, P1, P2, Ra, 
Ca and W 403.  If the extracted parameters are not the best filtered results 404, the program 
will go back to step 403 to try to get the best parameters.  If the extracted parameters are 
the best filtered results 404, then the VTI1, VTI2 and VTI3 will be determined 405.  Then 
the program will conduct diagnosis 407 by utilizing the medical databases 406, 408, and 
output the results 409, resulting the end of the program 410.   
[0045] FIG 5a shows a diagram illustrating the directional relationships among the 
different pressures that may be detected or induced from the air flow rates detected by the 
breath analyzer as shown in FIG 2.  FIG 5b shows that different pressures are functions of 
time.  From there are derived a few fundamental equations that are the foundation for the 
algorithm shown in FIG 4: 
[0046]  
 (i) (Pa - Pp) - Pel = 0 
                                               (ii) Pel = (2 a h) / R r = 2 T / r = V/C + Pel, 0 
                                             (iii) (Po -Pa) = R(dV/dt) 
                                             (iv) PL = Po -Pp 
                                             (v) R(dV/dt) + VIC = PL - Pel, 0 
 
[0047] Now there is provided a more detailed description of determination of the 
volume breath characteristics of the test person 402.  In one embodiment of the present 
invention, the lung ventilation function is analyzed by means of a very simple model 
represented by a first-order differential equation (Deq) in lung-volume (V) dynamics in 
response to the driving pressure (PL = atmospheric pressure - pleural pressure), as shown in 
FIG 5  
[0048] First, the model governing equation derived from the basic equations is as 
follows: 
R
•
V  + V/C = PL(t) -Pel , 0  = Po  + P1 cosω t+ P2 sinω t   -Pel 0                 (1) 
[0049] wherein (i) Po, P1 and P2 are obtained from the given PL (= Po – Pp ) data; 
(ii) the parameters of this Governing Deq are lung compliance (C) and airflow-resistance 
(R), wherein in the equation both R and C are instantaneous valves; (iii) V = V(t) - Vo (the 
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lung volume at the end-expiration); and (iv) Pel,o is the lung elastic recoil pressure at the 
end of expiration and Pel,o= Pel – V/C. 
[0050] At end-expiration when ωt = ωT, PL = Pel,o. Hence, 
[0051] Pel,o = Po + P1 , and the governing equation (1) becomes: 
 R
•
V  + V/C = -P1   +  P1 cosω t     +  P2 sinωt =Pn                        (2-a) 
 
[0052] where the right-hand side represents the net pleural pressure. (Pn =Patm -Pp – 
Pel,o) curve.  This Pn is in fact the driving pressure (Po – Pp) normalized with respect to its 
value at end-expiration.  Equation(2-a) can be rewritten as follows: 
•
V  + V/R C =− P1  / R+  (P1 / R )cosω t     +  (P2 / R) sinωt   ;      RC=τ    (2-b) 
 
[0053] wherein the P(t) clinical data displayed in FIG 5b is assumed to be 
represented by:  
[0054] Po = 9.84 cm H2 O, P1 = -1.84 cm H2 O, and P2 = 3.16 cm H2 O  (3) 
[0055] If, in equation (1), Ra and Ca are designated as the average values (R and C) 
for the ventilatory cycle, then the solution of equation (1) is given by: 
V(t) = − P1 Ca + P1 Ca [ (Cos ωt + ω  Ra  Ca    Sin ωt) / (1+ω2  Ra2   Ca2) ]  + P2 Ca [(sinωt 
– ωRa Ca cosωt) / (1+ω2  Ra2   Ca2)] + H e -t/R a     (4) 
[0056] wherein the term (RaCa) is denoted by τa , and ω = 1.55 rad/s (based on the 
data in FIG 5b.  If V = 0 at t = 0, then, putting V (at t = 0) = 0 gives us: 
H ={ Ca ω τa / (1+ ω 2τa2 )} ( P2 + P1 ω τa )             (5) 
 
[0057]  Then from equations (4) and (5), the overall expression for V (t) becomes: 
 V (t) = − P1 Ca + { P1 Ca  (cos ω t + ω τ a Sin  ω t) / (1+ ω 2τa2 )} 
+{ P2 Ca (Sin ω t - ω τ a Cos  ω t) / (1+ ω 2τa2 )}   
+{ e-t/τa  ω  Ca τa ( P2 + P1 ω τa) / (1+ ω 2τa2 )}               (6) 
[0058]   If dV/dt = 0 at t = 0, implying no air-flow at the start of inspiration, then 
equation (6) can be differentiated into:  
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•
V  = {P1 Ca / (1+ ω 2τa2 )} ( - ω Sin ω t + ω2 τa Cos  ω t) 
   +{P2 Ca / (1+ ω 2τa2 )}(ω cos ω t + ω2 τa Sin  ω t) 
  +{- Ca  e-t/τa / (1+ ω 2τa2 )} ( ω P2  +  P1 ω 2τa)                      (7) 
[0059]  From equation (7), we get: 
•
V  = 0 at t = 0, thereby also satisfying this 
initial condition.  By matching the above V(t) expression (6) with the given V(t) data (in 
FIG 5b), and carrying out parameter-identification, the in vivo values of Ra and Ca can be 
determined.  As a check, it can be verified that the substitution of (6) and (7) satisfies 
equation (2).  
[0060] However, we can also analytically evaluate Ra and Ca by satisfying some 
conditions. For this purpose, we first note that V is maximum (=Tidal Volume, TV) at 
about t (= tv )= 1.6s,   i.e. at ω tv = 2.48 rad.  Now, for ω tv = 2.48 rad, we get : 
sin(ωtv)=0.62, cos (ω tv) = -0.79 and tan (ω tv) = -0.78. Also, for ω tv = 2.48 rad ( and 
based on the knowledge of the range of τa ), the exponential term e- t/τa ( in equation 6) 
becomes of the order of e-3  and  less; hence, we decide to neglect it. So then, by and 
putting 
•
V  = 0 in equation. (7), we obtain: 
 tan (ω tv) = ( P2 + ω τa P1 )  / ( P1 − P2 ω τa )  = -0.78             (8) 
 
[0061] Upon substituting the values of P1  and P2 from equation (3), and putting ω 
= 1.55 rad s-1 , we obtain the value of τa = 0.26s. We can also put ••V =0 at t≅0.58 or ωt=93 
and obtain a similar value for τ. Then, we also note that at  tv = 1.6s ( for which dv /dt = 0), 
V = 0.6l . Hence upon substituting for cos(ω tv) = -0.79 and sin(ω tv) = 0.62 in equation(7), 
and again neglecting the exponential term we get the following algebraic equation: 
− P1 Ca −( 0. 54 P1 Ca / D) +   (0. 94 P2 Ca / D)   =   0.6;              (9) 
[0062] wherein D = 1 + ω2 τa2   ,  ω = 1.55 rad/s, and  τa = 0. 26s; this equation 
can hence be rewritten as: 
Ca  (−1.54 P1  + 0. 94 P2 )= 0.7                              (10) 
[0063] We can substitute, therein, the values of P1 & P2 from equation (3), and 
obtain the value of  Ca = 0.12 L (cm H2 O)-1  . Since we have computed τa =  0.26 s,   
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therefore   Ra = 2.20 (cm H2 O)  s L-1 . These are the average values of resistance- to – 
airflow and lung compliance during the ventilatory cycle shown in FIG 5b.   
[0064] Since Lung disease will influence the values of R and C, these parameters 
can be employed to diagnose lung diseases. For instance in the case of emphysema, the 
destruction of lung tissue between the alveoli produces a more compliant lung, and hence 
results in a larger value of C. In asthma, there is increased airway resistance (R) due to 
contraction of the smooth muscle around the airways. In fibrosis of the lung, the 
membranes between the alveoli thicken and hence lung compliance (C) decreases. Thus by 
determining the normal and diseased ranges of the parameters R and C, we can employ this 
simple Lung-ventilation model for differential diagnosis. Let us, however formulate just 
one non-dimensional number to serve as a ventilatory performance index VTI1 (to 
characterize ventilatory function), as: 
 
VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τ2 (BR)2 602     (11) 
 
where BR is the breathing rate. Now, let us obtain its order-of-magnitude by adopting 
representative values of Ra and Ca in normal and disease states. Let us take the above 
computed values of Ra = 2.2(cm H2O) s L-1 and Ca =0.12 L(cm H2O) -1 and BR = 12m-1 or 
0.2s-1, computed for the data of Fig(1) and equation(3). Then, in a supposed normal 
situation, the value of VTI1  is of the order of 9.75. In the case of obstructive lung disease, 
(with increased Ra ), let us take Ra = 3cm H2 O s L-1, Ca = 0.12 L (cm H2 O)-1 and BR = 
0.3s-1 ; then we get VTI1 = 42. For the case of emphysema (with enhanced Ca),  let us take 
Ra = 2.0cm H2O s L-1 , Ca =0.2 L( cm H2O) -1 and BR = 0.2s-1 ; then we obtain VTI1 = 
23.04. In the case of lung fibrosis (with decreased Ca ) , we take Ra = 2.0cm H2O s L-1 , Ca 
=0.08 L( cm H2O) -1 and BR = 0.2s-1 ; then we obtain VTI1 = 3.7. We can, hence 
summarize that VTI1 would be in the range of 2-5 in the case of fibrotic lung disease, 5-15 
in normal persons, 15-25 for the case of emphysema, 25-50 in the case of obstructive lung 
disease. This would of course be needed to be verified by analyzing a big patient 
population. 
[0065] Now, all of this analysis requires pleural pressure data, for which the patient 
has to be intubated.  If now we evaluate the patient in an outpatient clinic, in which we can 
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only monitor lung volume and not the pleural pressure, then we have to develop a non-
invasively obtainable Ventilatory index. 
[0066] In order to formulate a non-invasively determinable Ventilatory index from 
equation (1), we need to redesignate the model parameters, and indicate their identification 
procedure.  So we make use of the following features from the volume-time data to 
facilitate evaluation of the following three parameters: : (P1 C), (P2 C) and τ : 
[0067] At t = tv = 1.6s & ω tv = 2.48, V is max & dV/dt = 0; hence we rewrite 
equation (9) as: 
[0068]   
tan (ω tv  ) = -0.78 = (P2 + ω t P1) / (P1 – P 2ω t )                         (12) 
 
[0069] At t = tm , 
••
V  = 0 ; hence by differentiating equation. (7), without the 
exponential term ,we obtain: 
 ••
V =0=
 P1C(-ω2 cos ω tm - ω3 τ sin ω tm) +P2 C (-ω2 sinω tm - ω3 τ sinω tm) (1+ ω 2τ2) 
 
i.e.                  tan ω tm   = (-P1 + ωτ  P2) / (P 1ωτ + P2 )                             (13) 
 
[0070] At t = 1s &ω t = π/2, V = V1 (whose value is obtainable from FIG 5b); this 
condition yields (without the exponential term): 
 V1= -(P1C) – {ω τ (P1C)/(1+ ω 2τ2)} +{ (P2 C) /(1+ ω 2τ2)}          (14) 
[0071] At t = 2s & ω t =π/2 , V = V2 (whose value is obtainable from FIG 5b); this 
condition yields (without the exponential term): 
V2= -(P1C) – {(P1C)/(1+ ω 2τ2)} +{ωτ (P2 C) /(1+ ω 2τ2)}            (15) 
[0072] At t = 0.3s & ω t =270 , V = V3  gives: 
 V3 = -(P1C) – { ωτ (P1C)/(1+ ω 2τ2)} -{ (P2 C) /(1+ ω 2τ2)}           (16) 
[0073] From equations (12) & (13) and any one of the equation(s) (14-16), we can 
only obtain the values of ω τ (or of τ  , since ω = 1.55) and of (P1 C) &  (P2 C)  but not of 
P1 & P2 by themselves. On the other hand, by also fitting equation (6), (without the 
exponential term) to the V(t) data, we obtain: 
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[0074] We can nevertheless formulate another non-invasively-determinable non-
dimensional ventilatory index (V T I2) in terms of these parameters. (ωτ , P1 C  and P2 C) 
as follows: 
[0075]  
V T I2= 60 (ωτ) (T V)2 /2π (P1 C )(P2 C)                                       (18) 
=30 ω (R/C) (T V)2 /π P1 P2  
[0076]  It is seen that VTI2  can in fact be expressed in terms of P1, P2 and R, C. 
This VTI2  index can be evaluated by computing the values of τ, alongwith (P1 C ) & (P2 C)  
as given by equation (17).  Then, after evaluating V T I2  for a number of persons, and 
patients its distribution can enable us to categorize and differentially diagnose patients with 
various lung disorders and diseases. Between the two indices VTI1  and VTI2 , we can 
employ the one that enables more distinct separation of subjects with different ventilatory 
disorders. 
[0077] Thus far, we have adopted the average cyclic values Ca and Ra for our DEq 
model parameters. However, we expect that C will vary with lung volume (V) ,and that R 
will perhaps vary with the airflow-rate or (
•
V ) or even ω. Hence, for a true representation 
of the lung properties C & R, let us determine their values for different times during the 
ventilatory cycle, and compare them with their average values Ca & Ra ,so as to make a 
case for a non-linear ventilatory-function model. 
[0078] Let us hence compute the instantaneous value of compliance (C) at mid-
inspiration at (t = tm ), and compare it with that of its average cyclic value of Ca . For this 
purpose let us differentiate equation (2-a) , giving : 
[0079]   
R 
••
V  + 
•
V /C = -  P1 ωSinω t + P2 ω Cosω t                            (19) 
[0080] Now at about mid-inspiration, when t ≅ 0.87 s and ω t = ω tm ≅ 1.32 rad or 
78°, 
••
V = 0 and 
•
V  = 0.5 L/s (based on fig1). By substituting for 
••
V  and 
•
V  in equation (19), 
we obtain, C  ≅ 0.14L/cm H2O (compared to its Ca  value of 0.118). Now, in order to also 
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compute R at ω tm  =1.32 we substitute •V = 0.5 L/s and V = 0.3L (from the fig1 data) into 
equation (2-a), to obtain: 
[0081]   
0.5 R   +   0.3 / C   = -P1 + P1 Cos 78ο   + P2 Sin 78ο   =   3.8            (20) 
[0082] Now, since C(at ω tm = 1.32) ≅ 0. 14L/cm H2 O, we obtain R=4.6(cmH2O) s 
L−1 , compared to Ra = 2.20. This gives us some idea of the order of magnitude of R & C, 
in comparison to their average values Ca & Ra.. We could also expect C at mid-inspiration 
to be higher than its value at end-inspiration, when the lung is fully inflated. Also, we 
could expect the flow-resistance to be maximum at mid-inspiration, when 
•
V  is maximal. 
[0083] We can hence represent lung compliance (C) and resistance (R) as follows: 
[0084]  
                     C = n1 (V)
n2 – C o    or   C = C o  e
n(V))     ,                                          (21-a) 
          
•== VeRRVsR so
s
or
2
21                                                                         (21-b) 
[0085] wherein 
•
V  can also be varied by having the subjects breathe at different 
tidal volumes (TVs) and ventilation frequency (ω) 
[0086] We note as per the conventional formulation of compliance, given by 
equation(ii) in FIG 5b as: 
Pel   = V/C   +   Pel, 0  ;                                                     (22) 
[0087] In the above formulation, we assume that C and E(= 1/C) remains constant 
throughout the ventilation cycle. However at the start of inspiration, C = Co at t= 0, and it 
decreases as the lung volume increases, based on the lung (static) volume vs pressure 
curve. So let us improve upon this equation(22) model, by making Pel  to be a non-linear 
function of volume, as follows: 
[0088]   
kv
oelel eEPP 0, +=                                                                           (23) 
[0089] Employing the above format of compliance, the governing DEq  (1) 
becomes 
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[0090]  R 
•
V  + E0  ekV  = PL ( t) - Pel, 0 = Po+ P1 cos ω t + P2  sin  ω t - Pel, 0      (24) 
[0091] Again at end-expiration,  Pel, 0 = intra-pulmonary pressure =(P0 + P1). 
Hence equation.(24) becomes: 
[0092]   
R 
•
V +   E0 ek V   =   −P1  +   P1 cos ω t + P2  sin ω t                                  (25) 
 
[0093] whose RHS is similar to that of equation(2-a), and the values of P1  & P2 are 
given by equation(3) for the FIG 5b data. 
[0094] In order to evaluate these parameters k & E0  ,we again bring to bear the 
situation that at end-inspiration, for t = tv  =1.6 s (for which ω t =ω tv = 2. 48 rad, sin ω tv 
= 0.62 & cos ω tv= −0. 79), we have 
•
V  = 0  and V = Vmax =TV = 0.6 L. Hence, from fig (1) data, and equations (3 & 25), we 
obtain: 
[0095]   
E0  e0.6 k    =  8.75                                                                (26)  
[0096] Let us now employ the volume data point at which 
••
V =0. For this purpose, 
we differentiate equation (25) , to obtain: 
[0097]  R 
••
V  +    E0 k e kV =   −P1ω sin (ω t)  + P2ω cos (ω t)                  (27) 
[0098] From the Fig (1) data at about mid-inspiration, for which t = tm  =  0. 87s & 
ω tm = 1.32 = 78o     with cos (ω tm)= 0.2  & sin (ω tm)  = 0.98), we have ••V ≅ 0, •V  =0.5 
Ls−1,  V = 0.3 L , from fig(1) data. Substituting these values into equation.(27), we get : 
[0099]  
E0  e 0.3k =  3.8                                                   (28) 
[00100] Now from equation(s) (27) & (28),  we get:  
e –0.3 k    =  1.38                                                (29) 
[00101] for which,   k   =  1.07 and  (from equation 26 or 28)  E0   =  2.75 (30) 
[00102] Hence, by employing the non-linear formulation, 
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kv
ooelel eEPP += ,  
[00103] we obtain the following expression for lung compliance (or elastance): 
[00104]   
VkV
o
el ekeE
C
E
dV
dP 07.1
94.21 ====                                          (31) 
[00105] Based on this expression, we obtain ,for t = tm &  V = 0.3L: 
E =1/C = 4.06cm H2O / L;  and C = 0.25 L/cm H2 O.                                                  (32) 
[00106] Equation(32) can now provide us a more realistic characterization of lung 
compliance as follows: 
 At t= 0 and V = 0, we compute E=1/ C =2.94 and C = 0.34 cm H2 O / L. 
 At t = tm = 0.87s   &    V = 0.3L,   E=  1/C = 4.06,    and C = 0.25. 
 At  t = tv = 1.6s  &  V = 0.6L ,  and E = 1/C = 5.6   and    C = 0.18, 
 which corresponds to the value of Ca .  
[00107] Our non-linear formulation of lung compliance, as depicted by equation. (31 
& 33) , indicates that compliance decreases from 0.34 cm H2 O /L at start-inspiration to  
0.25 cm H2 O /L at about mid-inspiration, and then to 0.18 cm H2 O /L at the end of 
inspiration. What this also tells us is that the ventilatory model equation.(1) gives the 
correct reading of the compliance at Vmax , i.e. at end-inspiration. At other times of 
inspiration and expiration, the Ca parameter underestimates the instantaneous value of lung 
compliance. Now how about obtaining an analytical solution of equation(25) for V(t), and 
fitting the expression for V(t) to the lung volume data, to evaluate the parameters (i) R, Eo 
& k for an intubated patient and (ii) R, Eo k & P1 & P2 for a non-intubated patient in the out 
patient clinic. 
[00108] Finally, while it is important to determine the normal and pathological 
diagnostic ranges of Ca & Ra , or better still of the parameters (E0 & k ) of the C vs V and R 
vs 
•
V relationships, it would be more useful to construct and employ a non-dimensional 
ventilatory index  We have already formulated VT I1 & VT I2 in equations (11) & (18), 
respectively. We will now formulate yet another index : 
[00109]   
(33) 
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VT I3  = [60 ( Ra / Ca  ) (BR) (TV)2]/ P1 P2                                         (34) 
[00110] wherein (i) BR (the breathing rate in # / sec) = 0.5 ω / π  (ii) and ⏐ P1 P2 ⏐ is 
the absolute value of the product P1 P2 (because of P1 being negative). For the fig (1) 
clinical data, of BR= 0.25, with TV=0.6L & /P1 P2/ 1.18
)3(= , and for the computed value of 
Ra/Ca=18.33cm H2O s L-1, we obtain VTI3  = 5.47. Between VTI1  and VTI3  , we can 
decide which index enables us to better differentially diagnose subjects with ventilatory 
disorders. 
[00111] Now, let us go one step further and recognize that, for non-intubated 
patients, we cannot monitor P1 and P2 , and hence cannot evaluate Ra & Ca as demonstrated 
in § A. However for evaluating ventilatory index in out-patient clinics, we can infact adopt 
(P1 C)  and (P2 C ) to be the model-system parameters, and evaluate them as delineated in § 
B. We can hence adopt the non-invasively-obtainable ventilatory-performance index VT I2  
(given by equation 18): 
[00112]   
VTI2  =  30 ωτ (TV)2 / π (P1 C) (P2 C);  ω = 2π(BR )(in #s-1) 
        = 60 (BR)(R / C) (TV)2 / (P1 P2 ) =     VT I3                      (35) 
[00113] which is noted to be the same expression as for index VTI3 , except that it 
can be evaluated without intubating the patient. Hence, it would be even more useful to 
determine the distribution of VTI2 for patients with a wide range of lung pathologies and 
ventilatory disorders. Then, we can delineate the normal and pathological ranges of this 
index, and employ this information to diagnose patients into different disease categories. 
[00114]  Now referring to FIG 6 and FIG 7, there is provided a more detailed 
description of the ways by which the PDDS searches the database.   
[00115] The index will fire up numerous search engine in finding the best match 
diseases.  There is a possibility that there is more than one type of diseases being 
suspected.  Statistical means are used to determine which is the best match diseases and 
thereby  putting all these best fit diseases to the expert database system to further refine the 
possibilities. 
[00116] This expert database will feedback data which is erroneous through a 
database interface to the intelligent DBMS for further confirmation by firing up other 
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possibilities of diseases type. This interface can be realise through a query module 
interface. The query module will consult the expert DB2 for expert information before in 
deciding the redundancy of the data. 
[00117] The DISS (disease identification software system) is used to identify the 
best match disease after consulting the expert DB. The algorithm can be found in annex. 
The query module is responsible for all communication between the DISS, expert DB, GUI 
and also the intelligent DBMS. In particular, it can decide whether an DISS request can be 
displayed with the expert DB helps or whether it is necessary to require input from the 
user. 
[00118]  While the present invention has been described with reference to particular 
embodiments, it will be understood that the embodiments are illustrative and that the 
invention scope is not so limited.  Alternative embodiments of the present invention will 
become apparent to those having ordinary skill in the art to which the present invention 
pertains.  Such alternate embodiments are considered to be encompassed within the spirit 
and scope of the present invention.  Accordingly, the scope of the present invention is 
described by the appended claims and is supported by the foregoing description.
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CLAIMS 
 
What is claimed is: 
 
1. A pulmonary disease detection system for detecting breathing deficiencies of a test 
person, comprising:  
 a breath analyser for analysing the inhale and exhale airs of the test person; 
 a computer processor for receiving from the breath analyser the information and 
processing the received analysis data to give values to different parameters of the inhale 
and exhale airs of the test person; and  
 a medical database for storing different parameters of breaths of the public and 
normal ranges for healthy persons; 
 thereby the computer processor compares the values of different parameters of the 
inhale and exhale airs of the test person with the ones stored in the medical database so as 
to yield a test result of whether the test person is suffering breath deficiencies. 
 
2. The pulmonary disease detection system of claim 1, wherein the breathing 
deficiencies may be caused by bacterial infection, viral infection, physical injuries and 
cancer. 
 
3. The pulmonary disease detection system of claim 1, wherein the breath analyser 
comprises:  
 a mask for covering the nose and mouth of the test person so as to maximizing the 
delivery of fresh air and minimizing the loss of the exhaled air; 
 an air tank for supplying measurable and controllable air to the mask; and 
 an acquisition unit electrically connected with the mask and the air tank so as to 
receive all the information from the air tank and the mask. 
 
4. The pulmonary disease detection system of claim 3, wherein the mask comprises a 
group of electrodes including an oxygen electrode, a carbon dioxide gas electrode, a 
nitrogen electrode, a water vapor electrode, an inspired air flow rate electrode and an 
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expired air flow rate electrode; wherein each electrode detects each designated component 
of the inhale and exhale airs. 
 
5. The pulmonary disease detection system of claim 4, wherein the computer 
processor is embedded with an algorithm for processing the information from the breath 
analyser; wherein the algorithm calculates the breathing rate, oxygen consumption rate and 
carbon dioxide generation rate from the composition information of the inhale and exhale 
airs of the test person; thereby comparing the rates of the test person with the ones stored in 
the medical database so as to conclude whether the test person is suffering any breath 
deficiencies. 
 
6. The pulmonary disease detection system of claim 4, wherein the computer 
processor is embedded with an algorithm for processing the information from the breath 
analyser; wherein the algorithm calculates the composition values of the exhale air from 
the composition values of the inhale air and the assumed normal rates including breathing 
rate, oxygen consumption rate and carbon dioxide generation rate; thereby comparing the 
composition values of the exhale air with the ones stored in the medical database so as to 
conclude whether the test person is suffering any breath deficiencies. 
 
7. The pulmonary disease detection system of claim 4, wherein the computer 
processor is embedded with an algorithm for processing the information from the breath 
analyser; wherein the algorithm calculates the volume compliance and air-flow resistance 
of the test person from the composition values and pressure values derived from the inhale 
air rate and exhale air rate; thereby comparing the volume compliance and air-flow 
resistance values with the ones stored in the medical database so as to conclude whether 
the test person is suffering any breath deficiencies. 
 
8. The pulmonary disease detection system of claim 7, wherein the derived pressure 
values include pleural pressure and alveolar pressure. 
 
9. The pulmonary disease detection system of claim 8, wherein the volume 
compliance and air-flow resistance are calculated by the equation: 
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VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τ2 (BR)2 602      
wherein VTI1 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein Ra and Ca are designated as the 
average values (R and C) for the ventilatory cycle, and BR is the breathing rate. 
 
 10. The pulmonary disease detection system of claim 8, wherein the volume 
compliance and air-flow resistance are calculated by the equation: 
V T I2= 60 (ωτ) (T V)2 /2π (P1 C )(P2 C) =30 ω (R/C) (T V)2 /π P1 P2  
wherein V T I2 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein TV is tidal volume; P1& P2  as 
pleural pressures and  ωτ as determined by equations (14-16). 
 
11. The pulmonary disease detection system of claim 8, wherein the volume 
compliance and air-flow resistance are calculated by the equation: 
 VT I3  = [60 ( Ra / Ca  ) (BR) (TV)2]/ P1 P2 
 wherein VTI3 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein  TV is tidal volume; P1& P2  as 
pleural pressures. 
 
12. A method of detecting a pulmonary disease of a test person by investigating the 
breath deficiencies of the test person: 
 acquiring the information of inhale and exhale airs of the test person; 
 processing the acquired information to give values of designated aspects of the 
inhale and exhale airs of the test person; and  
 comparing the calculated values with the ones stored in a medical database so as to 
conclude whether the test person is suffering any pulmonary diseases. 
 
13. The method of claim 12, wherein the breathing deficiencies may be caused by 
bacterial infection, viral infection, physical injuries and cancer. 
 
14. The method of claim 12, wherein the information of inhale and exhale airs of the 
test person is acquired by a breath analyser; and wherein the breath analyser comprises:  
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 a mask for covering the nose and mouth of the test person so as to maximizing the 
delivery of fresh air and minimizing the loss of the exhaled air; 
 an air tank for supplying measurable and controllable air to the mask; and 
 an acquisition unit electrically connected with the mask and the air tank so as to 
receive all the information from the air tank and the mask. 
 
15. The method of claim 14, wherein the mask comprises a group of electrodes 
including an oxygen electrode, a carbon dioxide gas electrode, a nitrogen electrode, a water 
vapor electrode, an inspired air flow rate electrode and an expired air flow rate electrode; 
wherein each electrode detects each designated component of the inhale and exhale airs. 
 
16. The method of claim 15, wherein the processing is executed within a computer 
processor that is embedded with an algorithm for processing the information from the 
breath analyser; wherein the algorithm calculates the breathing rate, oxygen consumption 
rate and carbon dioxide generation rate from the composition information of the inhale and 
exhale airs of the test person; thereby comparing the rates of the test person with the ones 
stored in the medical database so as to conclude whether the test person is suffering any 
breath deficiencies. 
 
17. The method of claim 15, wherein the processing is executed within a computer 
processor that is embedded with an algorithm for processing the information from the 
breath analyser; wherein the algorithm calculates the composition values of the exhale air 
from the composition values of the inhale air and the assumed normal rates including 
breathing rate, oxygen consumption rate and carbon dioxide generation rate; thereby 
comparing the composition values of the exhale air with the ones stored in the medical 
database so as to conclude whether the test person is suffering any breath deficiencies. 
 
18. The method of claim 15, wherein the processing is executed within a computer 
processor that is embedded with an algorithm for processing the information from the 
breath analyser; wherein the algorithm calculates the volume compliance and air-flow 
resistance of the test person from the composition values and pressure values derived from 
the inhale air rate and exhale air rate; thereby comparing the volume compliance and air-
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flow resistance values with the ones stored in the medical database so as to conclude 
whether the test person is suffering any breath deficiencies. 
 
19. The method of claim 18, wherein the derived pressure values include pleural 
pressure and alveolar pressure. 
 
20. The method of claim 19, wherein the volume compliance and air-flow resistance 
are calculated by the equation: 
VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τ2 (BR)2 602      
wherein VTI1 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein Ra and Ca are designated as the 
average values (R and C) for the ventilatory cycle, and BR is the breathing rate. 
 
 21. The method of claim 19, wherein the volume compliance and air-flow resistance 
are calculated by the equation: 
V T I2= 60 (ωτ) (T V)2 /2π (P1 C )(P2 C) =30 ω (R/C) (T V)2 /π P1 P2  
wherein V T I2 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein TV is tidal volume; P1& P2  as 
pleural pressures and  ωτ as determined by equations (14-16). 
 
22. The method of claim 19, wherein the volume compliance and air-flow resistance 
are calculated by the equation: 
 VT I3  = [60 ( Ra / Ca  ) (BR) (TV)2]/ P1 P2 
 wherein VTI3 is denoted as ventilatory performance index; C as lung-
volume compliance; and R as air-flow resistance; and wherein TV is tidal volume; P1& P2  
as pleural pressures and  ωτ as determined by equations (14-16). 
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SYSTEM AND METHOD FOR DETECTING OF PULMONARY DISEASES 
 
ABSTRACT 
 
The present invention provides a to be completed upon agreement of claims.   
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TABLE – 1: Nomenclature 
 
SYMBOL MEANING UNITS 
C Lung Compilance 1)−2(cmH O  
aC  Average Lung Compilance 
1)−2(cmH O  
R Lung air-flow resistance -12cmH Osl  
aR  Average Lung air-flow resistance 
-1
2cmH Osl  
                                                   
 
TABLE 2: ABBREVIATIONS 
 
 VTI Lung-Ventilatory Index 
WOB Work of Breathing  
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Subject: BOOK ON HUMAN RESPIRATION --- YOUR CONTRIBUTION IS ACCEPTED 
Date: Fri, 13 Aug 2004 12:48:10 +0800 
Dear Colleagues: 
  
I would like to cordially thank all of you for your contributions. 
  
According to the review received on our book: Human Respiration: Anatomy and Physiology, Mathematical 
Modeling, Numerical Simulation and Applications, all the chapters submitted by us are accepted for 
publication.  Congratulations!!!   
  
However, we need to make some minor additions and amendments. 
  
The reviewer’s comment is attached to this message (see below).  In summary, we need to take the following 
steps: 
  
1. All equations are to be numbered and typed by means of MS Word Equation Editor.  Each equation should 
be a single object but not a mixture of text symbols and equations in one line.  
2. All symbols that are used in equations and appear in text must be typed by means of MS Word Equation 
Editor within the text.  
3. All repetitions among the chapters contributed by the same principal author should be removed.  
4. Each principal author has to provide me with nomenclature (in a separate MS Word file), so that the same 
symbols were used by one principal author in all his/her chapters.  
5. Each principal author has to provide me with key words to be included into Subject Index that will follow 
our book.  
6. Each principal author has to send me the amended version of his/her contribution(s) in MS Word format 
together with the nomenclature and key words file by e-mail:  mvvkulish@ntu.edu.sg .  Please ensure that 
each chapter is formatted according to the template that was sent to you previously [otherwise, the 
production of the book can be delayed].  
  
The deadline set by the publisher (WIT Press) is September 20, 2004.  Hence, I have to receive all your amended 
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8/14/2004http://adsfree02.mail.com/scripts/mail/mesg.mail?msg_uid=1092411954&folder=INBOX...
contributions at least 48 hours before this date.  The book will appear in January 2005 (ISBN 1-85312-944-5). 
  
I am looking forward to hearing from you. 
  
With kindest regards, 
  
Vladimir V. Kulish, Ph. D. 
Corresponding Member of 
The International Academy of Sciences "Collegium", 
Associate Professor 
School of Mechanical & Production Engineering 
Nanyang Technological University 
50 Nanyang Ave., North Spine (N2), Level 2 
Singapore 639798 
Phone: +(65) 67904950;  Fax: +(65) 67911859 
E-mail: mvvkulish@ntu.edu.sg  or  kulishv@asme.org  
URL: http://www.ntu.edu.sg/home/mvvkulish/index.html  
  
  
'Relevance 
The bio-engineering discipline is now recognised as being of substantial importance. Human respiration 
is a significant, challenging and rewarding field: significant because of the increase in airborne 
pollutants and congenital respiratory diseases; challenging because of the wide range of scales in the 
pulmonary system, which span about three orders of magnitude (or five, if the thickness of the alveolar 
membrane is included); and rewarding  
because of the marvellous ingenuity that characterises the system. A text that covers highlights of the 
application of bio-engineering techniques to the study of human respiration is to be welcomed. 
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This text comprises twelve chapters dealing with various topics in human respiration, from fundamental 
aspects of anatomy and physiology through to numerical modelling of processes such as gas diffusion 
and practical applications in the field of respiratory physiotherapy. As such, there is material here that 
will be of interest to seasoned bio-engineers and clinical practitioners, as well as novices to the study of 
human respiration. There should be a good market for the text – WIT should use the success of their 
publication “Medical Application of Computer Modelling – the Respiratory System” as a guide. 
  
Technical Correctness 
The text encompasses such a wide range of material that I cannot comment on all of it. Nevertheless, I 
am satisfied that in the field that I do have some knowledge (fluid mechanics) the material presented is 
correct. Moreover, each chapter appears to be a distillation of a large body of work which has been 
presented and reviewed for publication in technical journals, and this gives me confidence that the whole 
work is accurate and reliable. There are several papers that deal with modelling of gas transfer across 
that alveolar lumen. The nomenclature employed in each paper (or group of papers, where a group 
is characterised by having the same principal author) is slightly different. It would be very helpful 
if a common nomenclature could be employed. A formal definition of nomenclature after the 
Table of Contents would be useful. 
  
There are instances where relatively complex equations have been poorly constructed. For 
example, dots above symbols to represent differentiation with respect to time (e.g. _) have been replaced 
by small “o”s (e.g. _); in some instances the “o” s have been badly misplaced. This is not correct, and is 
unnecessary – the text appears to have been written using Microsoft Word, and Word includes an 
equation editor that has all the functionality required to produce neat equations employing standard 
notation. The final text should not contain any ambiguities in its formulae. 
  
Quality of Text 
The text is written in generally good English. While I am not sure whether it is the reviewer’s role to 
flag (what he thinks may be) grammatical errors, I have annotated the text where I think it might be 
improved. I offer these corrections not critically (they are few in number), but in the hope that through 
such minor corrections to the text, I might contribute to its acceptance in the academic community. 
  
There are some instances of repetition of material between chapters by the same principal 
authors; there is also duplication of introductory material on respiratory anatomy between different 
authors. It would be beneficial to the ease with which the text can be used if (a) the repetitions were 
removed, (b) the duplication was minimised, and (c) the introductory material was brought forward to 
the first and second chapters (see below for more detail). 
  
Order of Chapters 
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If the original 12 chapters are to be retained as they are, then I would suggest the following re-ordering 
of the text: 
Anatomy and Physiology 
1.  Anatomy and Physiology of the Human Respiratory System 
2.  Fundamentals of Alveolar Gas Diffusion Mathematical Modelling and Numerical Simulation  
3.  Lung Gas Composition and Transfer Analysis: O2 and CO2 Diffusion Coefficients and Metabolic 
Rates 
4.  Lung Ventilation Modelling and Assessment 
5.  Visualisation of Alveolar Diffusion 
6.  Modelling of Two-Phase Flow in the Human Respiratory System  
7.  Impact of Microscopic Solid Particles on Alveolar Diffusion  
8.  Quantification of Human Physiological Response to Toxic Substances  
9.  Anatomically-based Modelling of Pulmonary Structure Applications  
10. Applied Chest-Wall Vibration Therapy for Patients with Obstructive Lung Disease 
11. Indicator for Lung Status in a Mechanically Ventilated COPD Patient using Lung Ventilation 
Modelling and Assessment 
12. Mechanics of Proportional Assist Ventilation 
I have suggested that “Anatomy and Physiology of the Human Respiratory System” should come before 
“Fundamentals of Alveolar Gas Diffusion”, and that “Lung Gas Composition and Transfer Analysis” 
and “Lung Ventilation Modelling and Assessment” should precede “Visualisation of Alveolar 
Diffusion”, “Modelling of Two-Phase Flow in the Human Respiratory System” and “Impact of 
Microscopic Solid Particles on Alveolar Diffusion”. This is because it may be easier for the reader to 
deal with the more general issue of lung respiration before approaching the topic of alveolar respiration. 
However, if some reordering of the material in chapters 2 and 5 can be allowed, then I would 
recommend the following titles for these chapters: 2.  Fundamentals of Alveolar Gas Diffusion – 
Physiological Aspects 5.  Alveolar Gas Diffusion – Numerical Modelling and Visualisation Here, 
chapter 2 would deal with the physiology of alveolar gas diffusion, and the modelling aspects would be 
placed in chapter 5. This would have the advantages that: (a) the first section is a relatively easy 
introduction of the topic of human respiration; and (b) the visualisation of the calculations by Kulish et 
al is presented in the best context. 
  
It should also be possible to combine the chapters “Modelling of Two-Phase Flow in the Human 
Respiratory System” and “Impact of Microscopic Solid Particles on Alveolar Diffusion” into a single 
chapter, e.g. “Modelling the Impact of Microscopic Solid Particles on Alveolar Diffusion”. Certainly, 
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the material in “Impact of Microscopic Solid Particles on Alveolar Diffusion” which is a repetition of 
material in “Visualisation of Alveolar Diffusion” should be deleted. 
  
I cannot decide whether the chapter entitled “Quantification of Human Physiological Response to Toxic 
Substances” should be left in the section on “Mathematical Modelling and Numerical Simulation” or 
placed in the section on “Applications”. Perhaps Kulish as the author is the deciding factor, and it should 
remain where it is in proximity to Kulish’s other papers. Thus, the chapter order becomes:  
1.  Anatomy and Physiology of the Human Respiratory System  
2.  Fundamentals of Alveolar Gas Diffusion – Physiological Aspects MathematicalModelling and 
Numerical Simulation 3.  Lung Gas Composition and Transfer Analysis: O2 and CO2 Diffusion 
Coefficients and Metabolic Rates 
4.  Lung Ventilation Modelling and Assessment 
5.  Alveolar Gas Diffusion – Numerical Modelling and Visualisation  
6.  Impact of Microscopic Solid Particles on Alveolar Diffusion  
7.  Quantification of Human Physiological Response to Toxic Substances  
8.  Anatomically-based Modelling of Pulmonary Structure Applications  
9.  Applied Chest-Wall Vibration Therapy for Patients with Obstructive Lung Disease 
10. Indicator for Lung Status in a Mechanically Ventilated COPD Patient using Lung Ventilation 
Modelling and Assessment 
11. Mechanics of Proportional Assist Ventilation ' 
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Abstract 
  
The primary function of the lung is to (i) oxygenate the blood and thereby 
provide oxygen to the cells for metabolization purposes, and (ii) to remove the 
collected CO2 from the pulmonary blood. Herein, we will analyze the 
compositions of the inspired and expired air per breath, and from there compute 
the O2 consumption and CO2 production rates. Next, we derive expressions for 
diffusion coefficients 
2O
D and 
2CO
D  in terms of the evaluated cardiac output, 
O2 and CO2 concentrations in arterial and venous blood, alveolar and blood O2 
and CO2 partial pressures. We then take up a typical case study, and demonstrate 
the computation of 
2O
D and
2CO
D , to represent the lung-performance capability 
to oxygenate the blood. 
 
 
 2 
1 Introduction 
 
The lung functional performance is characterized by (i) its ventilatory capacity, 
to bring air (and hence O2) into the alveoli, and (ii) its capacity to transfer O2 and 
CO2 into and from the pulmonary capillary bed. Hence, the O2 and CO2  
diffusion coefficients as well as the O2 consumption rate and the CO2 production 
rate represent the lung-performance indices. 
 
2. Lung air composition analysis (and 2O  consumption and 
2CO  production rates) 
 
We carry out a mass balance analysis, involving: 
(i) compositions of air breathed in and out 
(ii) consumption or losses of O2, CO2 and H2O. 
 
 
The Table 1 below provides clinical data on partial pressures and volumes of  
2N , 2O , 2CO and 2H O  of  atmospheric air breathed in and expired in one 
breath cycle. The monitored breathing rate (BR) = 12 breaths/min, and we 
assume PH2O at 37οC = 47 mmHg. 
 
Table 1: Inspired air composition and partial pressures. 
 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/% 
N2 597 393.1 
78.55% 
566 393.1 
74.5% 
O2 159 104.2 
20.84% 
120 80.6  
15.7% 
CO2 0.3 0.2 
0.04% 
27 19.1  
3.6% 
H2O 3.7 2.5 
0.49% 
47 32.6  
6.2% 
Total 760 500 
100% 
760 525.3 
100% 
 
It can be noted that the expired air volume exceeds the inspired air volume for 
this particular breath cycle. The H2O loss of 30.1ml (=32.6 ml – 2.5 ml) 
contributes  the major portion of this difference. 
 3 
2.1 Calculation of 2O  consumption-rate and CO2  production-rate 
 
We now determine the O2 consumption rate and CO2  production rates from the 
inspired and expired gases 
 
Assuming the patient breathes at 12 times per minute we have 
 
2O  Consumption Rate  = (Inspired 2O – Expired 2O ) ×  12  
 = (104.2–80.6) ×  12 
= 283.2 ml/min  
 
2CO  Production Rate  = (Expired 2CO – Inspired 2CO ) ×  12 
= (19.1–0.2) ×  12 
=  226.8 ml/min  
 
 
The amount of water vapor in the humidified expired air amounts to 6.2% of the 
expired air (compared to 0.49% of the dry inspired air) corresponding to the 
partial-pressure ratio of water vapor in the expired air (= 47/760). The volume of 
the dry expired air =(525.3–32.6) ml=492.7 ml. 
 
Now, assume that out of 500 ml of inspired air, the dead space air volume (not 
taking part in gas transfer process) is 150 ml and the alveolar air volume is 350 
ml. We next compute the dead space air volume composition. 
 
 
 
                       Fig. 1: Dead-space volume 
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2.2 Dead space air composition 
 
The clinical data of expired air composition is: 
 
2
2
2
2
    
    
N = 393.1 ml
O = 83.36 ml
CO = 16.87 ml
H O = 34.15 ml
  
Total 527.49 ml                           
 
Now, the dead-space air will be made up of (i) a dry air portion from the inspired 
air (assumed to be =141 ml), plus (ii) the water vapor taken up by the dry air 
(estimated to be =9 ml) since the expired air portion of 141 ml will not have 
under gone O2 and CO2  transfer, it’s composition is the same as that of 
inspired air:  
2N  = 111  ml (78.55%), 2O = 29.40 ml (20.84%), 2CO = 0.06 ml (0.04%), 
2H O = 0.69 ml (0.49%). 
 
When this inspired air (in the dead space) of 141 ml  is fully humidified, it will 
take up a further X ml  of 2H O  vapor, in the ratio of the partial-pressures, as: 
 
  
47
0.0659
141 713
X = =  
X = 0.0659×141 = 9.29 ml∴  of H O2  vapor (which is close to our 
estimate).        
 
So, by adding 9.29 ml of H O2 vapor to 0.69 ml of water vapor in the inspired air 
volume of 141 ml, the total water vapor in the dead-space air is 9.98 ml. The 
humified dead-space air composition will be: 
 
 
N       = 111.00 ml    (= 73.78%)2
O       = 29.40 ml      (= 19.55%)2
CO     = 0.06 ml       (= 0.04%)2
H O    = 9.98 ml       (= 6.63%)2
Total   = 150.44 ml
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2.3 Alveolar air composition and partial pressures 
 
We can now compute the alveolar air composition, by subtracting the dead-space 
air from the expired air. These values are tabulated in column 4 of the Table 
below. 
 
 Expired Air 
( ml ) 
Dead Space 
Air ( ml ) 
Alveolar Air 
( ml ) 
Alveolar Air 
Partial Pressure 
(mmHg) 
N2 393.1 111.00 282.1 569.41 
O2 80.53 29.40 51.13 103.21 
CO2 19.12 0.06 19.06 38.47  
H2O 34.21 9.98 24.23 48.91  
Total 526.96 150.44 376.52 760  
 
Finally, we compute the partial pressure of O2 and CO2 (as well as of N2 and 
H2O), so that we can determine next the diffusion coefficients of O2 and CO2 
based on the monitoring of arterial and venous blood concentrations. These 
values are tabulated in column 5 of the above table. 
 
 
 
 
 Fig. 2: Schematic of blood-gas concentration in the Pulmonary Capillary. 
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3. Lung gas-exchange model & parametric analysis  
 
3.1 Expressions for 
2O
D and 
2CO
D  
The gas exchange between the alveolar air and pulmonary capillary blood is 
represented by the following 2O  and 2CO  conservation equations. (Fig. 2): 
 
22 2
VE VE AE AE
OO OQ C Q C V
°
= +  (from the alveolar air to capillary blood) 
2
2 2 2 2
( ) ;Oav
capAE AE AE
O O O OQ C P D P P= + ∆ =  ,                 (1) 
in which 
2
cap
OP = 2
PRB
OP      ( 2O  concentration of the pre oxygenated blood) 
22 2
VE VE AE AE
COCO COQ C Q C V
°
= −  
  2
2 2 2 2
( ) ;COav
capAE AE VE
CO CO CO COQ C P D P P= − ∆ = ,                  (2) 
 
in  which 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre oxygenated blood), 
wherein 
 
(i) ABQ and VBQ  are arterial and venous blood flow-rates;    
(at venous end)  (at arterial end) ,AB VE VB AEQ Q Q Q= =  
(ii) 
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial pressures 
(iii) 
2 2
 2and are the alveolar and capillary partial pressure  
al cap
CO COP P CO  
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion coefficients 
(v) 2
2 2
 average of ( ) over the capillary length;Oav
capal
O OP P P= −?  
2
2 2
average over the capillary length of  CO al capav CO OP P P= −?  
 
Now we can equate the arterial and venous blood flow rates, as  
 
ABQ = VBQ =Q=(SV)/(EP) ? / 60CO  
 
SV, EP and CO being the stroke volume, ejection period and cardiac output, 
respectively. Hence the above equations can be rewritten as: 
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(vi) 
2O
V
?
 is the 2O  transfer rate from alveolar air to capillary blood 
(= 2O consumption rate), 2COV
?
is the 2CO  transfer rate from capillary blood to 
alveolar air. 
 
From eqn. (1): 
2
2
2 2 2 2 2 2
2 2 2
( ) ;
( )
O AE
av
O
av
capVE VE AB AB
O O O O O O
VB AB
O O O
PQ C Q C P D P P
QC QC P D
== + =
= +
?
?
  
2 2
2 2 2 2
( ) ( )
( ) ( )
AB VB
O O
av av
VE AE
O O O OQ C C Q C C
P P
=
− −=
? ?2O
D .   (3) 
 
  
From eqn. (2): 
 
        
2
2 2
( )
( )
VE
CO
av
AB
CO COQ C C
P
−=
?2CO
D  ,  (4) 
wherein  
 
(i) Q, 
2
VE
OC  and 2
AE
OC , 2
VE
COC  and 2
AE
COC  can be monitored because 
2 2 2 2 2 2 2 2
 and  =  and  and  and  = and    AB AB VB VBVE VE AE AEO CO O CO O CO O COC C C C C C C C  
(ii) 
2OD  and 2COD  (eqns. (3) & (4)) represent the lung gas-exchange 
parameters.  
 
Now from eqns. (3) and (4), if we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 2
al
COP , 2
cap
COP  in terms of 
monitorable quantities. In this regard, 
 
2
2
2 2 2 2 2 2
2 2 2
( ) ;
( )
CO AE
av
CO
av
capVE VE AE AE VB
CO CO CO CO CO CO
VE AE
O CO CO
Q C Q C P D P P P
QC QC P D
= − = =
= −
?
?
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(i) Alveolar 
2
al
OP can be expressed in terms of V
°
(the ventilation rate) and 
2OV
°
(the 2O  consumption rate) as Fig. 3 : 
   
                          
O2
m
1
V V V
e
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
° ° °−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
2
2al
O 1
k
P k ,              (5) 
 
where mV
?
 is the maximum ventilation rate and 
2OV
?
(the 2O consumption rate or 
absorption rate from the alveoli)= 
2 2O O
)( AB VBQ C C− . Eqn. (5) implies that as 
mV V
⎛ ⎞⎜ ⎟⎝ ⎠
? ?
 increases,  (the exponential term decreases, and)  
2O
alP  increases (as in 
Fig. 3), and as 
2O
V
?
 increases 
2O
alP  decreases (as in Fig. 3). 
(ii) Alveolar 
2
al
COP  can be expressed in terms of V
°
 and 2OV
°
 as in Fig. 4. 
 
         
CO2
V
V m
V
e
°
°
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
°−
=
4
al
CO 32
k
P k  ,          (6) 
where
2CO
°
V (the 2CO  production rate or excretion rate from the blood) 
=
2 2CO CO
)( VB ABQ C C− . This equation implies that as  mV V
? ?
 increases, 
2CO
alP  
decreases; also, as  
2CO
V
?
 increases (the exponential term decreases, and hence) 
2CO
alP  increases. 
 
(iii) Blood
2O
P can be obtained in terms of blood 2CO , from the 2O  
disassociation curve (providing concentrations in arterial and venous blood), 
is represented in Fig. 5, as: 
 
O2
O2
2 2
5
O O
(1 )
m
P
k
PmC C e
−
= − , or  
*
O2
2
*
O 1
P
C e
−= − 5k  , (7) 
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where  
 
• 
2O
mC  and 
2O
mP  are the maximum values of blood 2O  partial pressure 
• *2 2 2CO CO COm=  
• 
2 2
*
O O O2
mP P P=  
 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
C , from  the 2CO  
disassociation curve or 2CO  concentration in arterial and venous blood can 
be represented as per Fig. 6 as: 
 
 
( )CO CO2 2
2 2
CO O
(1 )
mP6k PmC C e
−= −   
( )CO CO2 2
2
*
2*or, 1 1
m
CO
k Pk P P 66
COC e e
−− == − −  (8) 
 
3.2 Alveolar 2 2O and CO  partial pressure expressions 
Now, let us refer eqn. (4) for the 
2
al
OP  partial pressure curve (Fig. 3), represented 
by the eqn.: 
 
2
2O
1
2 O
m
Vk V
Val
1P k e
°
°
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
°−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
 
*
21
2 O
k V V
1k e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
 , where 
*
V
°
= 
m
V
V
°
°   (9) 
 
wherein V
?
is the alveolar ventilation rate (in liters/min), mV
°
 is the maximum 
ventilation rate (= 50 liters/min) and 
2O
V
?
is  the 2O consumption rate (in 
liters/min). Herein, the coefficients 1k and 2k  can be determined by having this 
 10
equation match the Fig. 3 data. Note, in this equation, when 0V
°
= , 
2O
0alP =  
from the equation ,which satisfies the data. 
 
Now for 2OV
?
=0.25 liters/min, when 
*
V
°
= 
m
V
V
°
° =0.5, 2O
alP =140 mmHg . Hence , 
0.5
20.25140 1 (1 )
2
2
k k
1 1k e k e
⎡ ⎤⎢ ⎥⎣ ⎦− −= − = −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
.  (10) 
 
Also, when 2OV
?
=1 / minl , 
*
V
°
=0.3 / minl , 
2
100alOP = mmHg. Hence 
0.3
0.31100 1 (1 )
2
2
k k
1 1k e k e
⎡ ⎤⎢ ⎥⎣ ⎦− −= − = −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
.  (11) 
 
From eqns. (10) and (11), we get: 
 
2 2
0.3 0.3
(1 )140 1
100 (1 ) 1
2 2
2 2
k k
1
k k
1
k e e
k e e
− −
− −
− −= =− −  
0.3 2
2 0.3, 40 , so that
140 140 100 100
or 100 140 4.18
2 2
2 2
k k
k k
2k
e e
e e min/l
− −
− −
∴ − = −
= + =
        (12) 
 
Upon substituting 4.18 min/l2k =  into eqn. (10) we obtain: 
 
(2 4.18) that140 (1 ), so 140 mmHg1 1k e k
− ×= − ≈         (13) 
 
Hence, the 
2
al
OP  curve can be represented by: 
 
*
2
2
4.18
O ,140 1
OV V
alP e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
          (14) 
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wherein 2OV
?
=Q
2 2
)( AB VBO OC C−  and 
*
50 / minV V l
°
=
?
   
   
Now, let us look at the 
2CO
alP  expression: 
 
2 2
2
*
CO
CO CO
Vk V k V V4 4V mal
3 3P k e k e
⎡ ⎤⎛ ⎞ ⎡ ⎤⎢ ⎥⎜ ⎟ ⎢ ⎥⎢ ⎥⎜ ⎟ ⎢ ⎥⎢ ⎥⎜ ⎟⎝ ⎠⎣ ⎦ ⎣ ⎦
° ° °− −°
= =
?
, 
We note from Fig. 4 that for  2 0.2 / minCOV l
°
=  and 0.2mV
°
= , 
2CO
alP =12. 
Hence, from the above eqn., we get: 
 
12 4-k3k e=        (15) 
 
Also, for  2 0.8 /OV l min=
?
and 0.2mV
°
= , 
2CO
alP = 62 mmHg. Hence 
4
0.20
0.80
362
44
kk
3k e k e
⎡ ⎤⎢ ⎥⎣ ⎦
−−
= =      (16) 
 
From eqn.s (15) and (16), we get: 
4
2
3
, so that
12
62
12 2
ln 2.46
62 3
4 4
4
k k
k
4
e
e
e
k k4
−−= =−
= − =⎛ ⎞⎜ ⎟⎝ ⎠
    (17) 
 
Substituting 2.464k =  into eqn. (16), we obtain : 
2.46
4 ,62 114.683 3k e k
−
∴= =      (18) 
 
Hence, the 
2
al
COP  curve can be represented as 
 
22.46
CO2
114.68
CO
V V
V malP e
° °
°
⎡ ⎤⎛ ⎞⎢ ⎥⎜ ⎟⎢ ⎥⎜ ⎟⎜ ⎟⎢ ⎥⎝ ⎠⎣ ⎦
−
=      (19) 
wherein  
*
50 l/minV V
°
=
?
 and 2COV
?
=Q
2 2
)( VB ABCO COC C−  
 12
 
 
 
Fig. 3: Effect on alveolar 
2O
P  of (i) alveolar ventilation, and (ii) rate of Oxygen 
absorption from alveolar 
2O
P  or 2O  consumption rate [from Guyton 
(1971), p. 476]. 
 
 
 
Fig. 4: Effect on alveolar 
2CO
P of  alveolar ventilation and rate of carbon dioxide  
excretion from the blood or  2CO  production rate [from Guyton 
(1971), p. 476]. 
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3.3 Arterial and venous 2 2O and CO  partial pressure expressions 
We now need to express 
2O
ABP  and 
2CO
VBP  in terms of  
2O
ABC  and 
2CO
VBC . 
 
So that let us look at the 2O  disassociation curve, as shown in Fig. 5. 
 
|max2 2
2 2O |max
1 5 O O
k P P
OC C e
⎡ ⎤⎣ ⎦= −⎡ ⎤⎢ ⎥⎣ ⎦
-
,   
*
2*
2
or, 1 5 O
k P
OC e
−= −  ,      (20) 
where  
2
O* 2
O O |max2
C
C C= , 
2*
2
|max2
O
O
O
P
P
P
= . 
From Fig. 5, at 
2
*
OP =
40 mmHg
0.29
140 mmHg
=  (for normal venous blood), and 
2
*
OC
15
0.75
20
= = . 
 
Hence from eqn. (20): 
0.290.75 1
4.78.
5k
5
e
k
−= −
∴ =
      (21) 
Also, 
2
* 95 mmHg 0.68
140 mmHgO
P = =  (for normal arterial blood), and 
*
2
19
0.95
20O
C = = . 
Hence from (20): 
0.68 , or0.95 1 4.45ke k5
−= − = .     (22) 
 
So, we take the average value of 5k :     
(4.78+4.4)
= 4.59
25
k∴ = .                    (23) 
 
Then the 2O disassociation curve is given by: 
 
 14
2
2 2
O4.59
140
O O 0.2 1
P
BC C e
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= = −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
,       (24) 
and 
2
2 2
O
O O
140 0.2 0.2
ln 30.5 ln
4.59 0.2 0.2B B
P
C C
= =− −
⎡ ⎤ ⎡ ⎤⎢ ⎥ ⎢ ⎥⎢ ⎥ ⎢ ⎥⎣ ⎦ ⎣ ⎦
.   (25) 
 
Finally, we look at the 2CO disassociation curve 
2
|max2
2
2
*
|max2 2
2
/ max
*
(1 ),
or, 1 1 .
CO
CO
CO
CO CO
P
P
CO
P
P P
CO
C e
C e e
−
− −
= −
= − = −
6
2
6
6
k
CO
k
k
C
   (26) 
 
Based on Fig. 6, when 
2
* 20 mmHg 0.14
140 mmHgCO
P = = , 
2
* 38 0.475
80CO
C = = , so that 
 
,0.140.475 1 4.606 6
ke k−= − =      (27) 
 
when 
2
*
CO
70 mmHg
0.5
140 mmHg
P = = , 
2
* 60 0.75
80CO
C = = , so that 
 
0.5 ,0.75 1 2.776 6
ke k−= − = .     (28) 
 
So we take the average value of 6k : 
 
(4.60+2.77)
= 3.69
26
k =                     (29) 
 
Then the CO2 concentration is given (from eqns. 26-29) by: 
 
CO2
2 2
3.69
140
CO CO 0.8 1
P
BC C e
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= = −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
    (30) 
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and 
2
2
CO
CO
0.8
37.94 ln
0.8 B
P
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
.     (31) 
 
 
 16
 
 
 
 
 
Figure 5: O2 dissociation curves, showing the total oxygen in each 100 ml  of 
normal blood, the portion dissolved in the water of the blood [from 
Guyton (1971), p. 485]. 
 
 
 
Figure 6: The carbon dioxide dissociation curve [from Guyton (1971), p. 491]. 
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3.4 Sequential procedure to compute 
2O
D  and 
2CO
D  
(1) We first monitor: ( ), ( )V t V t
?
, SV(stroke volume), EP(cardiac ejection 
period),  
2O
VBC , 
2O
ABC , 
2CO
VBC  and 
2CO
ABC  ( 2O  and 2CO  concentrations 
in pre oxygenated and post oxygenated blood). 
 
(2) We substitute the values of 
2O
ABC  (=
2O
VEC ) and 
2O
VBC  (=
2O
AEC ) into eqn. 
(3), and the values of 
2CO
ABC  (=
2CO
VEC ) and 
2CO
VBC  (=
2CO
AEC ) into eqn. (4). 
 
(3) We next determine: 
Q= SV/ejection period,     (33) 
2O
( )V t
?
=Q
2 2O O
( )VBABC C− ,     (34) 
2CO
( )V t
?
=Q
2 2CO CO
)( ABVBC C− .    (35) 
(4) We then substitute the expressions for 
2O
( )V t
?
 and 
2CO
( )V t
?
 into the 
eqns. for 
2O
alP  (eqn. (14)) and 
2CO
alP  (eqn. (19)).  
 
(5) We substitute the monitored values of 
2O
VBC  (=
2O
AEC ) and 
2CO
VBC  
(=
2CO
AEC ) into eqns. (25) and (32), to obtain the values of 
2O
AEP  and 
2CO
AEP . 
 
(6) Now, in order to determine the values of the lung gas-exchange 
parameters 
2O
D  and 
2CO
D  , we substitute into eqns. (3) and (4) for Q 
from eqn. (33), 
2O
alP   from (14), 
2CO
alP  from eqn. (19),  
2O
VBP  from eqn. 
(26), and 
2CO
VBP  from eqn. (32) . 
 
 
3.5 Determining 
2O
D  and 
2CO
D  
 
Fig. 7 illustrates the variation of 2OP? (= 
2 2 2 2O O O O
capal al ABP P P P− = − ) along the 
length (l) of the capillary bed.  
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2 2
2
.
*( )  .                                                                                         max
*Let
Then we can express:
 (36)OO Of l
l l lm
P P
=
=? ?
 
( )2 2 22 21max max
0
* *( ) F .                                   
Then,
              (37)O OO O Of l dlP P Pav
⎛ ⎞⎜ ⎟ =∫⎜ ⎟⎝ ⎠
=? ? ?  
 
Based on data [3], since 2 12 mmHgOavP =?  for 2Omax 65 mmHgP =? , we have 
2
F 0.185.O =  
 
We can similarly determine the average value of 2COavP?  from Fig. 8 as: 
2 2
2
.
*( ).                                                                                          max
*Let
Then, we can represent figure 8 as:
 (38)COCO Of l
l l lm
P P
=
=? ?
 
( )2 2 22 21max max
0
* *( ) F .                                  
Then,
        (39)O COCO CO COf l dlP P Pav
⎛ ⎞⎜ ⎟ =∫⎜ ⎟⎝ ⎠
=? ? ?  
 
Based on data [3], since 2CO 0.5 mmHgavP =?  for 2COmax 5 mmHgP =? , we have 
2
F 0.1.CO =  
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 From the 2OavP? and 2
CO
avP?  expressions, we can  determine the O2 consumption 
and the CO2 production rates,  as follows: 
 
2 22
22 2 2
Total  consumed2
AB VB
O OO
OO O O
av avav
Q C C
P P
O V
D
P
−⎛ ⎞⎜ ⎟⎝ ⎠= = =
?
? ??
   (40) 
     
2 22
22 2 2
Total C  produced2
VB AB
CO COCO
COCO CO CO
av avav
Q C C
P P
O V
D
P
−⎛ ⎞⎜ ⎟⎝ ⎠= = =
?
? ??
.  (41) 
 
4. Case Studies 
 
(A) We monitor the partial pressures blood concentrations of O2 and CO2 as: 
 
2 2
0.13AE VBO OC C= = , 2 2 0.18
VE AB
O OC C= = , 2 2 0.525,
AE VB
CO COC C= =  
2 2
0.485VE ABCO COC C= =  
 
From eqn. (26), we obtain: 
2
2
0.2 0.2
30.5 ln 30.5 ln
0.2 0.2 0.13
32.02 mmHg                                                                                (42)
VB
O VB
O
P
C
= =− −
=
⎡ ⎤ ⎡ ⎤⎢ ⎥ ⎢ ⎥⎣ ⎦⎢ ⎥⎣ ⎦  
 
From eqn. (32), we obtain: 
 
We now also monitor Q=5 l/min, 
*
0.1V
°
=  and 5 /minV l=? : 
 
Then from eqn. (34): 
2
( )OV t
?
=Q ( )2 2AB VBO OC C− , so that from the above data,   
    
2
0.8 0.8
37.94 ln 37.94 ln
0.8 0.8 0.5252
40.51 mmHg                                                                            (43)
VB
CO
VBPCO C
= =− −
=
⎡ ⎤ ⎡ ⎤⎢ ⎥ ⎢ ⎥⎣ ⎦⎢ ⎥⎣ ⎦
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2
( )OV t
?
=5000 ×  0.05=250 mlO2/min consumption rate                   (44) 
 
From eqn. (35): 
2
( )COV t
?
=Q ( )2 2VB ABCO COC C− =5000(0.04)  
= 200 mlCO2 /min production rate.        (45) 
 
Now, from eqn. (14): 
For 
*°
= 0.1V  and 2 2O O :0.25 , we obtain
alV  l  P
°
=  
2
2
*
4.18
4.18 0.1 0.25
                                                                            (46)140 1
140 1 113.7 mmHg
V V O
al
OP e
e
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎣ ⎦
° °−
−
= −
= − =
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎣ ⎦
 
 
From eqn. (19), for 
*°
= 0.1V  and 2 2CO CO :0.20 l, we obtain
alV  P
°
=  
 
[ ]
*
CO2
2
2.19
2.19 0.1 0.2
CO 107.18 107.18
35.86 mmHg                                                                                    (47)
                                        
V V
alP e e
° °⎡ ⎤⎢ ⎥− ⎢ ⎥ −⎣ ⎦= =
=
 
 
Now, we can evaluate the diffusion coefficients: 
 
From eqns. (3, 37, 42 and 46): 
 
2 2
2
( )
5000(0.18 0.13)
16.84 mlO /min/mmHg.                          (48)2(113.7 31.2) 0.18
AB VB
O O
O
av
Q C C
P
−=
−= =− ×
?2O
D
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From eqn. (4): 
 
2 2
2 2
CO CO
CO CO
( )
5000(0.04)
430.11 m CO /min/mmHg.                 (49)2(40.51 35.86) 0.1
VB AB
av
Q C C
P
l
−=
= =− ×
?
D
 
 
(B) Alternately, we derive data from: 
 
(i) the inspired and expired air analysis (such as that carried out in 
section 2.3): 
 
O2 consumption rate  = 283.2 ml/min,  
CO2 production rate   = 226.8 ml/min, 
2O
103.03 mmHgalP =  and
2CO
38.41 mmHgalP =  
 
and  (ii) venous blood gas analysis: 
 
2O
0.13VBC = ,
2CO
0.548VBC =  
 
Then, as per eqn. (42), 
2O
31.2 mmHgVBP =                 (50) 
corresponding to 
2
0.13VBOC = and, as per eqn. (43): 
 
2
0.8 0.8
37.94 ln 37.94 ln
0.8 0.8 0.5482
43.84 mmHg                                                                              (51)
VB
CO
VBPCO C
= =− −
=
⎡ ⎤ ⎡ ⎤⎢ ⎥ ⎢ ⎥⎣ ⎦⎢ ⎥⎣ ⎦  
We obtain, from air composition analysis, that 
2
283.3 ml/min( )OV t =
?
  (52) 
and 
2CO
226.8 ml/min.( )V t =
?
     (53) 
 
 22
Hence, 
 
2
2 2
O
283.2
21.90 mlO /min/mmHg,                      (54)2(103.03 31.2) 0.18
O
O
av
V
P
=
= =− ×
?
?
D
 
 
and 
 
2
2 2
CO
CO CO
226.8
417.68 mlCO /min/mmHg.                  (55)2(43.84 38.41) 0.1
av
V
P
=
= =− ×
?
?
D
 
 
The advantage of this method (B) over (A) is that it does not require monitoring 
of the cardiac output, and is hence simpler to implement clinically. 
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Figure. 7: Uptake of oxygen by the pulmonary capillary blood. (The curve in this    
figure was constructed from data in Mihorn and Pulley:Biophys. J., 
8:337,1968). [from Guyton (1971), p. 434.] 
 
 
 
 
 
Figure. 8: Diffusion of carbon dioxide from the pulmonary blood into the 
alveolus. (The curve in this figure was constructed from data in 
Mihorn and Pulley:Biophys. J., 8:337,1968). [From Guyton (1971), p. 
435.] 
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TABLE – 1: Nomenclature 
 
SYMBOL MEANING UNITS 
2OD  2O diffusion coefficients 2
/ min/mlO mmHg
 
2COD  2CO diffusion coefficients 2
/ min/mlCO mmHg
 
2
al
OP  Alveolar 2O partial pressures 
mmHg  
2
cap
OP   Capillary 2O partial pressures mmHg  
2
al
COP  2  Alveolar partial pressureCO  
mmHg  
2
cap
COP   2Capillary partial pressureCO  mmHg  
2O
avP?  2 2- ( )average of  over the capillary 
length
capal
O OP P  
mmHg  
2CO
avP?  2 2average of  over the capillary 
length
al cap
CO OP P−  mmHg  
ABQ  Arterial blood flow-rate  / minl  
AEQ  Arterial blood flow-rates at arterial end  / minl  
VBQ  Venous blood flow-rates / minl  
VEQ  Venous blood flow-rates at venous end  / minl  
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Abstract— The primary function of the lung is to (i) 
oxygenate the blood and thereby provide oxygen to the cells 
for metabolization purposes, and (ii) to remove the CO2
produced by the tissues from the pulmonary blood. Herein, 
we provide a noninvasive methodology to asses the capacity 
of the lung to oxygenate the pulmonary capillary blood and 
to reduce its CO2 concentration. For this purpose, we 
analyze the compositions of the inspired and expired air per 
breath, and therefrom compute the metabolic O2
consumption rate ( 2OV
?
) and CO2 production rate ( 2COV
?
).
Next we compute the cardiac out (CO) as 
2 2 2
( )AB VBO O OCO V C C? ?
?
.
We have derived the expressions for diffusion 
coefficients (i) 
2OD in terms of 2OV
?
 and the alveolar and 
venous partial pressures, 
2
al
OP  and 2
VB
OP  and (ii) 2COD in 
terms of 2COV
?
,
2
al
COP  and 2
VB
COP . The coefficients 
2OD and 2COD represent the gas transfer capacity of the 
lung. 
The paper provides a case study for the determination of 
Q,
2OD and 2COD . The derived information of 
2OD and 2COD as well as of O2 and CO2 metabolic rates can 
be of considerable clinical use including for SARS 
assessment. 
Keywords— gas exchange, O2 metabolic-rates, CO2
metabolic-rates, diffusion coefficients 
2OD , diffusion 
coefficients
2COD , blood flow rate
I. INTRODUCTION 
 The lung functional performance is characterized by (i) 
its ventilatory capacity, to bring air (and hence O2) into the 
alveoli, and (ii) its capacity to transfer O2 and CO2 into and 
from the pulmonary capillary bed. Hence, the O2 and CO2
diffusion coefficients 
2O
D and
2CO
D as well as the O2
consumption-rate and the CO2 production rate represent the  
lung performance indices. In this paper, we are 
demonstrating their evaluations. 
II. LUNG GAS-EXCHANGED MODEL 
Fig. 1 schematically illustrates the gas-exchange 
between the lung alveolus and the pulmonary capillary-
vasculature. Based on our earlier work [1, 2] the gas 
exchange between the alveolar air and pulmonary capillary 
blood is represented by the following 2O  and 2CO
conservation equations  and Fig. 2. 
22 2
VE VE AE AE
OO OQ C Q C V
?
? ?  (from the alveolar air to 
capillary blood) 
2
2 2
( )Oav
AE AE
O OQ C P D? ? ?               (1) 
22 2
VE VE AE AE
COCO COQ C Q C V
?
? ?
2
2 2
( )COav
AE AE
CO COQ C P D? ? ?                    (2) 
wherein 
(i) ABQ and VBQ  are arterial and venous blood flow-rates;    
(at venous end) (at arterial end),AB VE VB AEQ Q Q Q? ?
(ii)
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial 
pressures 
(iii)
2
al
COP  and 2
cap
COP  are the alveolar and capillary 2CO
partial pressure. 
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion 
coefficients
(v) 2
2 2
-average of ( ) over the capillary length;Oav
capal
O OP P P??
2
2 2
average of ( ) over the capillary lengthCO al capav CO OP P P? ??
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(vi) 
2
cap
OP = 2
PRB
OP  ( 2O  concentration of the pre-oxygenated 
blood) 
2
AE
OP?
(vii) 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre-
oxygenated blood) 
2
VE
COP?
(viii) 
2O
V
?
 is the 2O  transfer rate from alveolar air to 
capillary blood (= 2O consumption rate), 2COV
?
is the 2CO
transfer-rate from capillary blood to alveolar air (= 2CO
production rate). 
Now we can equate the arterial and venous blood flow 
rates, as AEQ ? ABQ = VBQ VEQ? = Q =(SV)/(EP) 
? / 60CO
SV, EP and CO being the stroke-volume, ejection-period 
and cardiac-output respectively. 
Fig. 1: Process of oxygenating the venous blood. 
The low oxygen (O2) concentration Red Blood Cell 
(RBC) is shown in dark blue. As it travels down the 
artery towards the venous end, the O2 concentration 
increases. After the distance L, its O2 has increased to 
0.18 from the initial concentration of 0.13. 
From equations (1) and (2): 
2 2
2 2 2 2
2
( ) ( )
( ) ( )
AB VB
O O
av av
VE AE
O O O O O
OPav
Q C C Q C C
P P
V
? ?
? ?
?
?
?? ?2O
D   (3) 
2
2 2
2
( )
( )
VE
CO
av
AB
CO CO CO
COPav
Q C C
P
V
?
?
?
?
??2
COD      (4) 
Fig. 2: Schematic of blood gas concentration in the 
Pulmonary Capillary. (Adapted from references [3] & [4]) 
III. CLINICAL DATA 
The monitored data consists of inspired and expired air 
gas compositions (TABLE 1) and 2O and 2CO
concentrations of arterial blood and venous blood (TABLE 
2). 
TABLE 1: Air Composition Analysis. Inspired and 
expired air composition and partial pressures are monitored. 
Assumed 
Breathing Rate (BR) = 12 breaths/min. Assumed 
2H O
P  at 
37?C = 47 mmHg. 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/%
N2 597 393.1 
78.55% 
566 393.1 
74.5% 
O2 159 104.2 
20.84% 
120 80.6  
15.7% 
CO2 0.3 0.2 
0.04% 
27 19.1  
3.6% 
H2O 3.7 2.5 
0.49% 
47 32.6  
6.2% 
Total 760 500 
100% 
760 525.3 
100% 
 TABLE 2:  Blood Gas Analysis. The monitored blood  
O2 and CO2 concentration . 
2O
C   of venous blood  (
2
VB
OC ) = 0.13 
2O
C of arterial blood  (
2
AB
OC ) = 0.18 
2CO
C  of venous blood (
2
VB
COC ) = 0.56 
2CO
C  of arterial blood (
2
AB
COC ) = 0.52 
IV. EXPRESSIONS FOR
2O
D AND
2CO
D
If we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 
2
al
COP , 2
cap
COP  in terms of monitorable quantities [1 & 2]. 
(i) alveolar 
2
al
OP can be expressed in terms of V
?
(the 
ventilation rate) and 2OV
?
(the 2O  consumption rate). 
*
2
 ; 
4.18
140 1
OV V
e
? ?
? ?
? ?
? ?? ?
? ?
?? ?? ?
? ?? ?
? ?
? ?? ?
2
al
OP      (5) 
wherein the normalized ventilation rate 
* 60 V V V Vm? ?
? ? ? ?
litres/min, is the consumption rate (in litres/min). 
(ii) alveolar 
2
al
COP  can be expressed in terms of V
?
 and 2OV
?
.
2
*2.19
107.18
COV V
e
? ?
? ?
? ?
? ?? ?
? ?
?
?alCO2
P                    (6) 
wherein 
2CO
V
?
 is  the 2CO production rate (in liters/min).  
(iii) Blood
2O
P can be obtained in terms of  blood 
2O
C , from 
the 2O  disassociation curve. 
2
0.230.5ln
0.2
B
B
OC
? ?
? ??
? ??? ?
O2
P              (7) 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
BC , from 
the 2CO  disassociation curve. 
2
0.837.94ln
0.8
B
B
COC
? ?
? ??
? ??? ?
CO2
P      (8) 
Now,
2O
P?
2 2 2 2
( )Capal al VBO O O OP P P P? ? ? ? and 2COP?
2
( VBCOP? - 2 )
al
COP  vary along the capillary bed. Based on [3], 
we have: 
2 20.185 max
O OP Pav ?? ?                   (9) 
2 20.1   max
CO COP Pav ?? ?            (10) 
Hence, from equations (3 & 9) and (4 &10), 
2 2
2 2 0.185( )
2 2
al VBP PP O O
O O
O O
av
V V
D ? ?
?
? ?
?
    (11) 
2 2
2 2 0.1( )
2 2
CO VB alP PPav CO CO
CO CO
CO
V V
D ? ?
?
? ?
?
    (12) 
V. EVALUATION OF O2 AND CO2 METABOLIC RATES AND
CARDIAC OUTPUT  
From monitored data of inspired-exhaled gas 
compositions, in TABLE 1: 
2O  consumption rate, 2OV
?
= BR(Inspired 2O - Expired 
2O )ml/min =12(104.2-80.6) = 283.2 ml/min               (13) 
2CO consumption rate, 2COV
?
=BR(Expired 2CO -Inspired 
2CO ) ml/min = 12(19.1-0.2)=226.8 ml/min                 (14) 
From monitored 2O  and 2CO concentrations of arterial and 
venous blood, in TABLE 2: 
? 2OV
?
= Q(
2O
C  of arterial blood - 
2O
C of venous blood)   
where Q=blood flow rate?cardiac output 
2 283.2 5664 /
(0.18 0.13) 0.05
OVQ ml min? ? ? ?
?
?
      
VI. EVALUATING OF THE LUNG DIFFUSION COEFFICIENTS 
2O
D AND
2CO
D
From equation (7) and TABLE 2 (
2
VB
OC =0.13), we get 
for 
(venous blood @ arterial end of the pulmonary capillary or 
2
VB
OP )
        
2
VB
OP =
2
0.230.5ln
0.2 VBOC
? ?
? ?
? ??? ?
               = 0.230.5ln
0.2 0.13
? ?
? ??? ?
               = 32.02 mmHg                       (15) 
From equation (8) and TABLE 2 (
2
VB
COC =0.56), we get 
for
2
VB
COP  (venous blood @ arterial end of the pulmonary 
capillary or 
2
VB
COP  ) 
2VB
COP =
2
0.8
37.94 ln
0.8 VBCOC?
? ?
? ?
? ?? ?
         = 
0.8
37.94 ln
0.8 0.56?
? ?
? ?? ?
       
         = 45.68 mmHg                          (16) 
Also, from equation (5) and TABLE 1 ( *V
?
=0.1), we get: 
? ?
*
2
0.1 0.2832
4.18
4.18
      140 108           (17)
140 1
1
OV V
mmHg
e
e
? ?? ?
? ?
? ?? ?
?
?
? ?
? ?
?
? ?
? ?
? ?
? ?? ?
? ?
? ?
2
al
OP
Hence, from equations (9, 15 & 17), we get: 
2 0.185 (108 32.02) 14.06         (18)Oavp mmHg? ? ? ??
Finally, from equations (11) and (18), we get: 
2
2 2
1
283.2 / min
14.06
       20.14  (19)-1
O
O O
av
ml
mmHgP
V
D
mlmin mmHg ?
? ?
?
?
?
Then from equation (6), TABLE 1 ( 0.1V ?
?
), and equation 
(12) we get: 
? ?
2
0.1 0.2268
2.19
2.19
*
          107.18 40.81               
107.18
(20)
COVV
mmHg
e
e
?
? ?
? ?
? ?
? ?
? ?
? ?
?
?
? ?
?
?
al
CO2
P
Hence, from equations (10, 16 & 20), we get: 
2 0.1 (45.68 40.81) 0.487         (21)COavp mmHg? ? ? ??
Finally, from equations (12 & 21), we get: 
        
2
2 2
226.8 / min
0.487
                           465.71              (22)
CO
CO CO
av
ml
mmHgP
-1 -1mlmin mmHg
V
D ? ?
?
?
?
VII. CONCLUSION
We have demonstrated a noninvasive clinical procedure  
? for obtaining (i) O2 consumption rate and CO2
production rate, (ii) cardiac output, Q, (iii) and 
lung diffusion capacities for  O2 and CO2.
? from inhaled and exhaled air composition 
analysis and blood-gas analysis.
This work could have application to SARS testing and 
evaluation.
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Abstract— The primary functions of the kidney are: (i) 
to get rid of the body waste materials that are either ingested 
or produced by metabolism, and (ii) to control the volume 
and composition of the body fluids. Herein, we provide a 
noninvasive methodology to assess physiological function 
of the kidneys. For this purpose, we analyze the renograms 
with 2-compartmental modelling of the kidney-renal 
outflow system, and therefrom compute the amount of flow 
of  renal radionuclide into and out of the renal pelvis 
compartment.  
The derived information of uptake (k/A) and washout 
( 22
t
Ve
??
sinhAt) rates can be of considerable use. The paper 
provides a number of case studies for the verification of the 
derived system governing equations against clinical 
renograms. 
Keywords— Renal outflow obstruction, renal
function, glomerular filtration rate, GFR
I. INTRODUCTION 
The kidney functional performance is characterized by (i) its 
filtering capacity, getting rid the body waste materials that 
are either ingested or produced by metabolism, and (ii) 
control the volume and composition of the body fluids. 
Renogram studies have been used for the assessment of 
renal function for many years [1, 2]. Mathematical 
modelling has been performed for the kidneys, such as one-
compartment model of clearance of tracer [3,4]. However, 
modeling of the tracer transport between renal parenchyma 
pool compartment and renal pelvis compartment; derivation 
of the governing equations for renogram curves has not been 
reported. Here, we note that the tracer uptake and washout  
rates can represent the performance indices. In this paper, 
we evaluate these rates and demonstrate their clinical 
relevance renogram data. 
II. RENAL PELVIS TWO-COMPARTMENTAL MODEL
Fig. 1: illustrates the region of interest (ROI) and we 
have derived the compartmental model for renal pelvis and 
shown in Fig. 2. 
Fig. 1: Control volume around the renal pelvis area.[5] 
1G : Tracer mass in the chamber 1 (renal parenchyma) in 
Counts.
2G : Tracer mass in the chamber 2 (renal pelvis) in Counts.
1C : Concentration of tracer in the chamber 1 in Counts/dL.
2C : Concentration of tracer in the chamber 2 in Counts/dL.
1V : Volume of chamber 1, renal parenchyma in dL.
2V : Volume of chamber 2, renal pelvis in dL.
( )I t : Tracer input function in Counts/sec.
F(t) : Blood Flow from chamber 1 to chamber 2 in dL/sec.
( )U t :Urine outflow in dL/sec.
Fig. 2: The derived two-compartmental renal model. 
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III. DERIVATION and PHYSIOLOGICAL SIGNIFICANCE of 
MODELING SOLUTIONS 
From Fig.. 2, we derive the following: 
1
1 ( )
dG FC I t
dt
? ? ? , for chamber 1     (1) 
2
1 2 ( )
dG FC C U t
dt
? ? , for chamber 2     (2) 
where (i) 1 1 1( )G C V?  represents the tracer amount in 
chamber 1,and (ii) 2 2 2( )G C V? represents the tracer amount 
in chamber 2. 
In physiological studies of kidney function and urine 
outflow status (renography), the input function is a tracer 
bolus administered over a short period of time. Compared to 
the entire duration of the renal dynamics, this bolus injection 
of tracer can be approximated by an impulse function 
(Dirac’s delta function). In the following derivation, 
whenever I(t) appears it will be assumed  be equal to I?(t).
We assume that the compartmental volumes V1 and V2
are constants (which they generally are), and the urinary 
flow rate U as unknown constant (urine flowing out of the 
kidney into the ureters is physiologically continuous and 
constant with time, unless there are changes in body fluid 
status). Here, we are only performing an intra-renal analysis 
for  obstruction to the outflow, we have from (1) and (2) : 
1 1
1 ( )
V dC FC I t
dt
? ? ?  (3) 
2 2
1 2
V dC FC C U
dt
? ?                                           (4) 
By differentiating and combining (3) and (4), we arrive at: 
2 2 2 2
1
2 2 2 2
1
( )
or,
( )                          (5)
FV C I t C C
V
FV C C C I t
V
? ?
? ? ?
? ?
? ? ?? ?
? ?
? ?
? ? ? ? ?
? ?
?? ?
?? ?
where:  
2
1 1
,                                (6)
FV FUU
V V
? ?
? ? ? ?
? ? ?? ? ? ?
? ? ? ?
The equation (5) is a standard form of a linear second-
order ordinary differential equation, with I(t) as the unit 
impulse function. This is the governing differential equation 
for the behavior of tracer within the renal pelvicalyceal 
compartment. 
Solution by Laplace transform method yields the 
following equations, given the initial conditions of C(0) and 
C’(0) = 0.
? ?
? ?
? ?
2
1
2
2 2
1
2 2
21 1 22
2 2
2
2
2 2
22 2
1 2
2
2 2 2 2
( )
( )
1 1( ) ( )
41       
4 2 4
FL V C C C L I t
V
FV s s C s
V
F FC t C t
V VVV s s s s
V V
V VF
VV
s
V V V V V
? ? ?
? ?
? ? ? ?
? ?
? ? ? ? ?
? ?? ?? ?? ? ? ? ?? ?
? ?? ?
? ?
? ? ? ? ? ?
? ?
? ? ? ?
? ? ?? ? ? ? ? ?? ?? ? ? ? ? ?? ?
? ?
? ?
?? ?
? ?? ?? ? ?? ? ? ?? ?? ?? ? ? ?? ?? ?? ? ? ?
?? ?
2
2
    (7)
? ?
? ?
? ?
Solving the above Laplace transform and taking care of 
the characteristics of the roots (which is now in standard 
form, by looking up standard tables), we obtain the results 
for the dynamic behavior of the tracer concentration in the 
renal pelvis for this physiological system. The term 
underneath the square root is the determinant of the behavior 
of the system with regards to whether there is underdamped, 
critical-damped or overdamped behaviour. 
This term can be expressed as 2 24V? ?? and it yields a 
significant functional index for assessing the outflow status 
of the kidney. We will classify the observed physiological 
behaviours of renogram systems into underdamped, 
overdamped or critically damped systems based on the 
index, as follows: 
Case 1:
If 2 24 0V? ?? ? ,  the condition is underdamping, and 
(7) yields the solution: 
2
2
2
22
1 2 2 2
2
2 2
1( ) sin
4
4
t
VFC t e t
V V V V
V V
? ? ?
? ?
?
? ?
? ? ? ?? ?? ? ? ?? ?? ?? ? ? ?? ? ? ?? ??? ?? ?
    (8)  
                k                1/A                     A
As can be seen from equation (8), the terms which 
describe urine outflow and determine the shape of the tracer-
concentration curve of the renogram during the tracer wash-
out phase are the 22
t
Ve
??
and
2
2
2 2
sin
4
t
V V
? ?? ?? ??? ?? ?
. The 
impartant dynamic  information captured in these two terms 
can be succintly found in the physiological index that we 
have described. We will demonstrate the discriminatory 
nature of this index (which will be extracted as A) in section 
IV when we analyse correlation with actual renogram 
studies. 
Equation (8) is a linear second-order ordinary 
differential equation, very similar to that of the linear 
oscillator with damping. In a functioning renal system, the 
characteristic oscillating-underdamped conditions do not 
exist.  
Case 2:
Whenever there is outflow obstruction, the key term 
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
and the condition is overdamping. Then,  
2
2
2
22
1 2 2 2
2
2 2
1( ) sinh
4
4
t
VFC t e t
V V V V
V V
? ? ?
? ?
?
? ?
? ? ? ?? ?? ? ? ?? ?? ?? ? ? ?? ? ? ?? ??? ?? ?
    (9) 
          k                1/A                     A
We can express output segment of the tracer curve of 
compartment 2 looks different from that of the tracer input  
2 2
2 2 2
2 2
1 1 1
4 4
FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
so the key term actually reflects the rate of tracer input 
(FC1) minus the rate of tracer output (UC2).
Case 3:
In the normal case, most physiological systems are 
well-compensated, and hence the output are fairly similar, 
hence,  
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
In other words, the renal system is critically damped.  
The governing equations for this will be 
? ? 22
1 2
t
VFC t te
V V
??? ?
? ? ?
? ?
 (10) 
For model analysis, because of complications involved 
in monitoring U (urine flow rate), F (plasma flow rate into 
the renal pelvis) and V1 control volume, we propose that our 
model parameters will be lumped parameters k and A. Next 
our parameters identification will be carried out for k, A V2
and ?.
IV. CLINICAL DATA & EVALUATION 
We will demonstrate and verify the application of our 
models using the renograms obtained from the Nuclear 
Medicine and PET Department. The radionuclide used are 
99mTc-DTPA and 99mTc-MAG3.  The degree of match with 
the governing equations is based on the area under the left 
and right kidney curves against the clinical curves between 
60 and 120 seconds. 
Model Application:
We will first digitalize and normalized the renograms. 
Next, we will perform parameters identification and obtain 
the system parameters: k, A, ? and V2. We will only accept 
the results of the best fit. 
Fig. 3: Clinical renograms of volunteer coded 
Patient 7. Note that the (QR-RR) segment of the tracer 
curve for the right kidney is similar to the (PR-QR)
segment and demonstrates good outflow-rate compared 
to the (QL-RL) segment of the obstructative curve for the 
left kidney. 
TABLE 1: Comparison of clinical and calculated results. 
We  can observe that the errors for each kidney is less than 
1%.
Identity % Clincal 
Area Under 
the curves 
between 60 
to 120 sec. 
% Calculated 
Area Under 
the curves 
between 60 to 
120 sec 
% Error 
Left Right Left Right Left Righ
t
Patient 
7
44 56 43.87 56.13 0.29 -0.23 
Patient 
8
50 50 49.69 50.31 0.61 -0.61 
(obstructive)
QR
QL
P
RR
RL
(Minor 
obstructive) 
Fig. 4: Clinical renograms of volunteers Patient 8. 
The two kidneys have minor obstructions. 
V. RESULTS
We have performed parametric identification for 
equations (9) and (10) using MatLab 7. The following are 
the best fitted results for  patients 7 & 8. 
            
                                
Fig. 5: Simulated renograms of volunteer coded Patient 
7. The clinical data for both kidneys is best fitted by 
equation (9). The identified parameters are: 
L L 2L
R R 2R
0.0124; A 5.48E-03; 0.0107 and V 0.8664
0.0221; A 8.68E-03; 0.0103 and V 0.4928
L
R
k
k
?
?
? ? ? ?
? ? ? ?
 Fig. 6: Simulated renograms of volunteer coded Patient 
8. The clinical data for both kidneys is best fitted by 
equation (9).The identified parameters are: 
L L 2L
R R 2R
0.0221; A 7.61E-03; 0.0098 and V 0.4959
0.0221; A 8.59E-03; 0.0125 and V 0.6248
L
R
k
k
?
?
? ? ? ?
? ? ? ?
 TABLE 1 shows that the area under the curves from the 
simulation matches that of the clinical with an error less 
than 1%.  
VI. CONCLUSION 
We have demonstrated modeling of kidney-renal 
outflow tract compartments with derivation of the governing 
equations from second-order differential equations and 
assessed the clinical relevance with comparison with clinical 
renogram studies. 
REFERENCES
[1] Maisey M, “Radionuclide Renography: A Review,” 
Curr. Opin Nephrol Hypertens, 12(6): 649 – 52, 2003. 
[2] O’Reilly P H, “Consensus Committee of the Society of 
Radionuclides in Nephrourology. Standardization of the 
Renogram Technique for Investigating the Dilated Upper 
Urinary Tract and Assessing the Results of Surgery,”  
British J Urology Int , 91(3) : 239 – 43, 2003;. 
[3] Rutland D, “A Comprehensive Analysis of DTPA Renal 
Studies,” Nuclear Medicine Communications, 6: 11 –30, 
1985. 
[4] Oriuchi N, Onishi Y, Kitamura H, Inoue T, Tomaru Y, 
Higachi T, Inoue T, Endo K., “Non-Invasive 
Measurement of Renal Function with 99mTc-MAG3 
Gamma Camera Renography Based On One 
Compartment Model,” Clin Nephrol, 50 (5): 289 – 94, 
1998. 
[5] Davies A, et al., “Human Physiology,” Churchill 
Livingston, 2001. 
 
 
 
Technical Programme 
 
 
 
Scientific Programme – DAY 1 
 
Wednesday, September 08 2004 
 
0800 – 0920  Registration 
 
0920 – 0940 Opening Ceremony 
 
0940 – 1010 Nanostructure Processing of Advanced Biomaterials 
Invited Speaker: Dr. Jackie Ying 
 
1010 – 1040 
 
Bioengineering, Technology Commercialization and Entrepreneurship 
Invited Speaker: Dr. Yongmin Kim 
 
1040 - 1100 Tea break 
 
1100 – 1130 
 
Esophageal Tissue Engineering 
Invited Speaker: Dr. Buddy Ratner 
 
1130 – 1200 
 
A Case Study of Integrated Biomedical Engineering: A Novel Method for Creating an 
Automated Sutureless Anastomosis  
Invited Speaker: Dr. Adam Sharkawy 
 
1200 –1230 
 
Advances in Cancer Imaging 
Invited Speaker: Dr. James Khoo 
 
1230 – 1330 Lunch 
 
1330 – 1400 
 
Tissue Engineering Heart Constructs using Bone Marrow Stem Cells 
Invited Speaker: Dr. Philip Wong 
 
1400 – 1430 Computational Technologies to Accelerate Biotech Innovation 
Invited Speaker: Dr. Ulrich Meier 
 
1430 – 1500 A new Approach to Protein Structure Prediction 
Invited Speaker: Dr. Heiko Schroder 
 
1500 – 1515 Tea break
 
Day 1 (continued) 
Session 01 Tissue Engineering 
(Room 1) 
1515 – 1730 
Chairs: S. Chian, P. Wong 
Session 02 Cancer Detection & 
Therapy (Room 2) 
1515 – 1715 
Chair: J. Khoo 
Session 03A Medical Image 
Processing (Room 3) 
1515 – 1745 
Chairs: Z. Kuanyi 
• Automated Segmentation of 
Breast Masses in Mammograms 
Zhang H., Foo S.W., Thng C.H. 
 
• Diagnosis of Lung Cancer Using 
NIR Raman Spectroscopy 
Huang Z., McWilliams A., Lam S., 
McLean D.I., Lui H., Zeng H. 
 
• Extraction of head and neck 
tumors using deformation 
models from MR images 
Zhou J., Chong V. 
 
• Breast Cancer Diagnosis using 
Thermography and 
complementary learning fuzzy 
neural network 
Tan T.Z., Quek C., Ng G.S., Ng E.Y.K. 
 
• Magnetic Particles for 
Hyperthermia Treatment of 
Cancer 
Ramanujan R.V., Lao L.L. 
 
• Gene Selection for Cancer 
Classification from Microarray 
Data using PLS-RLSC 
Shen L., Tan E. C. 
 
• Micelle-like Nanoparticles of 
Linear and Branched PLA/PEG 
Block Copolymer as Anti-Cancer 
Drug Carrier 
Pan J., Feng M., Chan W.A., 
Venkatraman S., Boey F.Y.C. 
 
• Identify human colorectal 
cancerous via Laser Induced 
Autofluorescence spectra 
confocal image 
Sheng F., Chia T.C., Kwek L.C., Diong  
C.H., Tang, C.L. 
 
Session 04 Microfluidics/MEMS 
(Room 2) 
1715-1800 
Chair: D. Trau 
• Enhancement of Meniscus 
Repair using Mesenchymal 
Stem Cells in a Porcine Model 
Dutton A., Hui J.P.P., Lee E.H. 
 
• Cardiac Differentiation of 
Adult Bone Marrow 
Mesenchymal Stem Cells 
 Tan G.M.Y., Wong P., Chua T., 
Tan J., Chua Y.L., Tan Y.S., Sin 
Y.K., Lim C.H., Liu T.C., Teh M., 
Sim E.K.W., Shim W.S.N. 
 
• Polyurethane Membranes for 
Chondroctye Transplantation 
and Cartilage Engineering 
Chia S.L., Gorna K., Gogolewski K., 
Alini M. 
 
• Theoretical and Experimental 
Determination of State of Two 
Dimensional Strain in a 
Bioreactor 
Ong W.F., Wijaya S., Ritchie A.C. 
 
• Culture of Rodent 
Hepatocytes on Microgrooved 
Surfaces: Application for a 
Flat-Plate Bioartificial Liver 
Device 
Ting K.S., Wang N.D., Grant M.H., 
Henderson C. 
 
• Simultaneous Probing of 
Morphology, Cytoskeleton, 
and Adhesion Dynamics of 
HepG2 Cells 
Feng Z. Q., Liao K., Chan V. 
 
• ECM-Dependent Proliferation 
of Adult Bone Marrow 
Mesenchymal Stem Cells 
Tan G.M.Y., Shim W.S.N., Chua T., 
Liu T.C., Teh M., Sim E.K.W., 
Wong P. 
 
• Parameters for Scaffold 
Design of Esophageal Tissue 
from a Structural Constitutive 
Model 
Yang W., Fung T.C., Chian K. S., 
Chong C. K. 
 
• Surface modification of 
biodegradable poly(L-lactide-
co-caprolactone) (PLLC) 
membrane with proteins to 
enhance the growth of 
esophageal smooth muscle 
cells 
Yabin Z., Chan-Park M.B., Chian 
K.S 
• AFM Characterization and 
Selectivity of Immobilization of 
Antibodies in Bio-MEMS 
Joshi M., Rao R., Mukherji S. 
 
• Cross-Talk, a Potential Source of 
Noise in a Fluorescence Multi-
channel Microfluidic System 
Irawan R., Tjin S.C. , Yager P., Zhang 
D.W. 
 
• Microfluidic Protein Patterning 
using Embedded Cavities in 
Microchannels 
Garcia E., Yager P. 
 
• ALA-Induced-PPIX Fluorescence 
Imaging of Normal and 
Neoplastic Tongue Tissue using 
Confocal Endomicroscopy 
Zheng W., Harris M., Kho K.W., Thong 
P.S.P., Hibbs A., Soo K.C., Olivo M. 
 
• A Simulation System for Remote 
Interventional Radiology 
Procedures 
Zhao L., Ma X., Aziz A., Zheng W., 
Nowinski W.L. 
 
• An Improved Active Contour 
Method for Heart Wall Boundary 
Detection in Echocardiographic 
Image Sequence 
Fang W., Chan K.L., Anantharaman V. 
 
• Augmented Reality Assisted 
Sinus Surgery 
Shi D. M., Ng W. S., Ling K. V., Shao 
W., Chen H. J., Kwoh C. K. 
 
• Brain Atlas-assisted 
Segmentation of the 
Hippocampus from MR 
Neuroimages 
Minh P.D., Prakash K.N.B., Nowinski 
W.L. 
 
• Removing Blocking Artifacts in 
Compressed Medical Images 
Singh S., Vinod K., Verma H.K. 
 
• Simulated Annealing based 
Simplified Snakes for Weak 
Edged Medical Image 
Segmentation 
You J., Zhou Z., Heng P.A., Xia D. 
 
• Extraction of the Two Modified 
Talairach Cortical LandMarks (I 
and S) from MR T1-Weighted 
Images 
Hu Q., Qian G., Nowinski W.L. 
 
• Knowledge-based Interpolation 
of the Talairach-Tournoux Brain 
Atlas 
Liu J., Nowinski W.L. 
 
• Mapping Human Skin and Aural 
Temperature with ANNs and IR 
Imager 
Ng E.Y.K., Chong C. 
 
END OF DAY 1 
 
 
 
Scientific Programme – DAY 2 
 
Thursday, September 09 2004 
 
0830 – 0900 
 
Development of Microfluidic-Based Point-of-Care Diagnostic Systems 
Invited Speaker: Dr. Paul Yager 
 
0900 – 0930 
 
Innovation in The Medical Device Industry: Development of Cypher - the first Drug-Eluting 
Stent 
Invited Speaker: Mr. Alok Mishra 
 
0930 – 1000 
 
Heart Tissue Engineering 
Invited Speaker: Dr. Buddy Ratner 
 
1000 – 1015 
 
Tea break 
 
 
Session 05 Biomaterials & Drug 
Delivery (Room 1) 
1015 – 1230 
Chairs: Y. Yiyan, S. Miao 
Session 06 Biomechanics 
(Room 2) 
1015 – 1230 
Chairs: S.L. Chia, F.K. Fuss 
Session 07A Computational 
Bioengineering 1 (Room 3) 
1015 – 1230 
Chairs: V. Zagorodnov, K. C. 
Keong 
• Smart Polymer Nanocarriers for 
Targeted Delivery 
Yang Y.Y 
• Release of Lipoplexes from a 
Biodegradable Polymer Film: 
Preliminary Study 
Chan W.A., Ramgopal Y.  
 
• Cross linking of Bovine Serum 
Albumin with Genipin: 
Investigation of Mechanical 
Properties 
Sathappan K., Chian K.S., Chua L.P. 
 
• Porous Beta-TCP and Its 
Modification with PLGA Coating 
for Bone Regeneration 
Miao X. and Kurniawati T. 
 
• In vitro Study on the Release 
Kinetics of Bovine Serum 
Albumin (BSA) from Injectable 
PLGA/BB Depot 
Wang L.W., Venkatraman S. 
 
• Effects of Plasticization on 
Heparin Release from 
Biodegradable Matrices 
Tan L.P, Venkatraman S., Sung P.F., 
Wang  X.T., Wong P. 
 
o Porous Bioinert Alumina 
Prepared by Vacuum Infiltration 
Liu J., Ng M.Y., Loh K.H., Hu Y., 
Miao X. 
 
• Clinical Applications of 
Magnetic Nanomaterials 
Ramanujan R. V. 
 
• Biomechanics Highlights in 
Sports, Physiology and Medicine 
Ghista D.N. 
 
• Evolution and Biomechanics of 
the Cruciate Ligaments 
Fuss F.K. 
 
• The Double-Bundle ACL Graft 
Reconstruction: A superior 
technique to restore knee 
kinematics 
Lie D.T.T., Amis A. 
 
• Finger Pulley Injuries are Self-
Propagating: A Mathematical 
Analysis of the A2-Pulley 
Tan M.A., Fuss F.K., Niegi G. 
 
• A Comparative Study of 
Different Gripping Methods for 
Tendons 
Ng B.H., Chou S.M., Krishna V. 
 
• Statistical Analysis of Human 
Metacarpal Morphology using 
CT Scan Data 
Zhai L.Y., Chou S.M., Lim B.H., 
Chong A., Tsou I., Ng S.Y. 
 
• Mechanics and Finite Element 
Analysis of the Auditory 
Ossicles 
Ho K.L.I., Fuss F.K. 
 
• Foot Characterization and 
Anatomical Landmarks 
Localization 
Liu X., Kim W.D., Drerup B. 
 
• A Case Study on Pattern-based 
Systems for Computational 
Biology 
Liu W., Schmidt B. 
 
• A Grid Implementation of 
Database Searching 
Chen C., Schmidt B. 
 
• The Use of Computer Modelling 
to elucidate the Efficacy of Slit 
Arteriortomy for End-to-side 
Arterial Anastomosis in 
Microsurgery 
Chua A.W.C, Gu H., Tan B. K., Chew 
W., Li J.Z., Song C.  
 
• A Mixed SVM-Based 
Hierarchical Learning Approach 
for Abnormal ECG Beat 
Recognition 
Li P., Chan K.L., Chan Y.W. 
 
• Capturing Cellular Life In-Silico 
Dhar P.K. 
 
• Finite Element Modeling of the 
Human Brain with Detailed 
Anatomy for Surgery Simulation 
Based on a Brain Atlas 
Gao C., Tay F.E.H., Nowinski W.L. 
 
• Fuzzy c-Means and Neural 
Network Framework for 
Arrhythmia Classification 
Chaudhari N.S., Liew C.S.  
 
• VRML Modeling for Bio-
Molecular Structures 
Indhumathi C., Lu B.F., Cai Y.Y. 
 
• BioSequence Comparison for 
Large Database on 
Reconfigurable Platforms 
Wong M.T., Schmidt B. 
LUNCH 
1230 - 1330 
 
 
 
 
Day 2 (continued) 
Session 08A Cardiovascular 
Engineering 1 (Room 1) 
1330 – 1530 
Chair: A.C. Ritchie 
Session 09A Sport Engineering 1 
(Room 2) 
1330 – 1530 
Chairs: W. Kim, F.K. Fuss 
Session 07B Computational 
Bioengineering 2 (Room 3) 
1330 – 1415 
Chair: B. Schmidt 
• Clustering Based Watershed 
Segmentation for Two-
Dimensional Gel 
Electrophoresis Image 
Diao X. N., Mao K. Z.  
 
• Estimating error-dimensionality 
relationship for gene 
expression based cancer 
classification 
Chu F., Wang L. 
 
• Finite Element Analysis of Brain 
for Neurosurgical Procedure 
Roy A., Nowinski W.L., Tay F.E.H.  
 
Session 10A Ultrasonic Imaging 1 
(Room 3) 
1415 – 1530 
Chair: M. Kezhi 
• A Decoupled Control Method 
for the Magnetic Bearings of a 
Blood Pump 
Lim T.M., Zhang D., Kim M.T.  
 
• An Immersed Membrane 
Method For Simulation of Fluid-
Structure Interaction in Bio-
Fluid Flows 
Xia G.H., Zhao Y., Yeo J.H., Tai C.H.  
 
• Computation of Gap Flow Field 
in a Bio-Centrifugal Blood 
Pump 
Chua L.P., Song G. L., Yu S.C.M.  
 
• Computational Studies of 
Steady Flows In Designed 
Sleeve Models At Distal 
Anastomoses 
Chua L.P., Tong J.H.  
 
• Contractility of the Left 
Ventricle in Terms of its 
Sacromere Power Generation 
Zhong L., Ghista D.N., Ng E.Y.K  
 
• Detection of Cardiac Arrhythmia 
using Phase Space Analysis 
Wong M. T., Srinivasan N., Chan 
Y.W. 
 
• Flow Studies in Aorto-Right 
Coronary Bypass Graft System 
Meena S, Chua  L P, Ghista D N, Tan 
Y S 
 
• LV Twisting Analyzed for 
Pressure-Increase During Iso-
Volumic Contraction 
Liu L, Yeo S.Y., Ghista D.N., Chua 
L.P., Chai G.B., Tan Y.S., Tan R.S. 
• Quantitative analysis of 
Singapore Golfers 
Lim S. L., Xie X., Ong V., Teh K. C.  
 
• Three-Dimensional Kinematics 
Study of Left Hand During Golf 
Swing 
Teu K. K., Kim W., Fuss F. K., Tan J.  
 
• Investigation of Weight Transfer 
during Golf Swing 
Teu K. K., Kim W., Fuss F. K., Tan J.  
 
• Biomechanics of Push-up 
Exercise and Triceps 
Contractility 
Tan M. A., Zhong L., Fuss F. K., 
Ghista D. N.  
 
• Comparison of Pinch- and Open 
Hand Grip during Sport 
Climbing 
Yap Y. H., Fuss F. K., Niegl G., Tan 
M. A.  
 
• Friction at the Climbing 
Handhold under Different 
Conditions and its Implications 
for Sport Climbing 
Tan M. A., Fuss F. K., Niegl G.  
 
• Finger Load Distribution During 
Sport Climbing 
See W. N. W., Fuss F. K., Niegl G., 
Yap Y. H.  
 
• Analysis of Badminton Smash 
Using Dual Euler Angles 
Algorithm 
Liu X., Teu K. K., Kim W., Tan J., 
Fuss F. K.  
 
• Medical Ultrasound Imaging: 
Current Status and Future 
Trends 
Yoo Y.M., Kim Y.M. 
 
• Reconfigurable and 
Programmable Architecture for 
Digital Receive Beamformer 
Schneider F.K., Yoo Y.M., Agarwal 
A., Kim Y.M. 
 
• Adaptive  Speckle Reduction 
Based on Nakagami 
Distribution in Medical 
Ultrasound Imaging 
Zhang L.C., Wong E.M.C. 
 
• Specific Homomorphic 
Nonlinear Diffusion for Speckle 
Reduction in Ultrasound B-
mode Images 
Zhang F., Koh L.M. 
 
• Design and Optimization of 
Broadband Ultrasonic Sparse 
Array Transducers for Medical 
Imaging Applications 
Wang Q. B., Guo N. Q.  
 
Tea Break 
1530 -1545 
 
Day 2 (continued) 
Session 08B Cardiovascular 
Engineering 2 (Room 1) 
1545 – 1645 
Session Chair:  A.C. Ritchie 
Session 09B Sport Engineering 2 
(Room 2) 
1545 – 1630 
Chairs: B. Tan, K.C. Teh 
Session 10B Ultrasonic Imaging 2 
(Room 3) 
1545 – 1645 
Chair: M. Kezhi 
• Multiple-Model Adaptive Control 
by Means of a Fuzzy Controller-
based Control System 
Zheng H., Zhu K. Y., Tan Y. S.  
 
• Numerical Investigation of 
Hemodynamics for the 
Coronary Artery Bypass Graft 
Model 
Chua L.P., Zhang J.M., Zhou T.M., 
Yu S.C.M., Ghista D.N., Tan Y.S. 
 
• Numerical Investigation of 
Stress Field in Distal End-to-
side Anastomoses 
Liu L., Chua L.P., Ghista D.N., Tan 
Y.S. 
 
• PIV Measurements on the 
Pulsatile Flow Characteristics in 
45-degree Backward Proximal 
Anastomosis 
Ji W.F., Chua L.P., Yu S.C.M.,  
Ghista D. N., Zhou T. M., Tan Y. S.  
 
• Determinants of Maximal Hiking 
Performance in Laser Sailors 
Tan B., Aziz A.R., Spurway N.C, Toh 
C., Mackie H., Xie W., Wong J., Fuss 
F.K., Teh K.C. 
 
• Comparative Study on the 
techniques of Singapore and 
Thailand Table Tennis players 
during SEA Games 2001 
Lee K.T., Xie W., Teh K.C.  
 
• Experimental Study on Different 
Types of Service Spins for 
Singapore National Table 
Tennis players 
Lee K.T., Xie W.  
• Field of View-based Imaging for 
Efficient Beamforming in Low-
end Portable Ultrasound 
Systems 
Agarwal A., Schneider F.K., Yoo 
Y.M., Kim Y. 
 
• Low Sampling Frequency 
Digital Beamformer for 
Ultrasonic Imaging without 
Interpolation 
Gao C.Q., Zhang L.C., Wong E.M.C. 
 
• Comparative Evaluation of 
Wavelet Filters for Speckle 
Reduction in Ultrasound 
Medical Images 
Thakur A., Anand R.S. 
 
• Window Function Optimization 
by Genetic Algorithm for 
Ultrasound Imaging System 
Cao J., Koh L.M. 
Session 11 Respiratory 
Biomechanics (Room 1) 
1645 – 1730 
Chair: V. V. Kulish 
Session 12A Orthopaedic 
Engineering 1 (Room 2) 
1630 – 1745 
Chairs: S.M. Chou, D.T.T. Lie 
Session 13A Biosignal Processing 
1 (Room 3) 
1645 – 1745 
Chair: O. Chutatape 
• Determination of O2 and CO2 
Metabolic Rates and Lung O2 
and CO2 Diffusion Coefficients 
Loh K.M., Ghista D.N.  
 
• Oxygen Saturation Profiles in a 
Hollow Fibre Oxygenator 
Ritchie A.C., Thimm G.  
 
• Graphical Technique for 
Assessing Pulmonary Disease 
Loo C. M., Ang K. C., Ong J. H., 
Ghista D. N., Lim G. H.  
 
• Design Optimisation in 
BioMedical Engineering 
Koh E.C.Y., Fuss F. K. 
 
• Design Classification and 
Mechanics of Artificial Discs 
Fuss F.K.  
 
• Extraforaminal Lumbar 
Interbody Fusion: Simulation of 
the Fusion Process Based on 
Different Implant Materials 
Fuss F. K., Sabitzer R. J.  
 
• FE Investigation on Spinal 
Interbody Fusion 
Lee K. K., Teo E. C., Fuss F. K., 
Sabitzer R. J.  
 
• Optimization of Cervical Ring 
Cage by Taguchi Philosophy 
Yang K., Teo E. C., Fuss F. K.  
 
• A Novel Approach to Automatic 
Left Ventricular Contour 
Tracking 
Cheng J.R., Foo S.W. 
 
• A Novel Wavelet Based ECG 
Compression with X-tree 
Coding 
Swain S., Chutatape O., Dandapat S. 
 
• Left Ventricular Surface 
Kinematics During Isovolumic 
Contraction 
Yeo S.Y.,Tan R.S., Liu L., Chai G.B., 
Ghista D.N. 
 
• Evaluation of Slice Sensitivity 
Profiles for TPRF Algorithm 
Yan M., Zhang C.S. 
 
END OF DAY 2 
 
 
 
 
 
 
Scientific Programme – DAY 3 
 
Friday, September 10 2004 
 
0830-0900 
 
Biological Resurfacing of Articular Cartilage – from Bench to Bedside 
Invited Speaker: Dr. Lee Eng Hin 
 
0900-0930 
 
Virtual Reality, Augmented Reality and its Medical Application 
Invited Speaker: Dr. Uli Bockholt 
 
0930-1000 
 
Vital Signs in the Real World 
Invited Speaker: Mr. Stephen Wilson 
 
1000-1030 
 
Clinical Endoscopy System: Present and Future 
Invited Speaker: Dr. Tsuneo Hidaka 
 
1030-1045 Tea break 
 
 
Session 14 Biosensors/Diagnostic 
Tools (Room 1) 
1045-1200 
Chair: K. L. Chan  
Session 13B Biosignal 
Processing 2 (Room2) 
1045-1130 
Chair: C. Zhang 
Session 15 Distributed Diagnosis 
& Home Healthcare (Room 3) 
1045-1130 
Chair: S. C. Tjin  
• Uni-channel PCA for noise 
reduction from ECG signals 
Palaniappan R., Tan E.K.  
  
• Wavelet-Based Denoising and 
Analysis of Phonocardiogram 
Wang P., Anantharaman V.  
 
• Dynamical Analysis of Heart 
Rate Variability Signals 
Rajendra A.U., Kannathal N., Lim 
C.M. 
 
• Distributed Diagnosis and 
Home Healthcare (D2H2) and 
Patient-Centered Electronic 
Medical Record 
Kim E.H., Kim J. J., Matsen F.A., 
Kim Y.M. 
 
• Advanced System Architecture 
for Telecardiology 
Goh K. W., Kugean C., Tan E. K., 
Prabaharan K.  
 
• Disposable Microfluidic Card 
and Fluorescence Detection 
System for Point-of-Care 
Diagnostic Applications 
Irawan R., Tjin S. C., Fu C. Y., Ng 
B.K., Yuan X.C., Zhang D.W. 
 
Session 12B Orthopaedic 
Engineering 2 (Room 2) 
1130-1215 
Chairs: D. Ghista, S. Idapalapati 
Session 03B Medical Image 
Processing (Room 3) 
1130-1215 
Chair: S. C. Tjin  
• Multi-Parameter Clinical 
Diagnosis using Neural 
Networks 
Tan E.K.  
• An Otoacoutic Emissions 
Detecting System using USB 
AD/DA Board 
Qian X., Ye D. 
 
• Oral Glucose Tolerance Test 
Modeling For Diabetes 
Characterization 
Loh K.M., Ghista D.N. 
 
• Feasibility of biosensing based 
on two-dimensional square 
photonic lattice 
Zhang D. W., Irawan R., Tjin S. C., 
Yuan X. C.  
 
• Application of Artificial Neural 
Network Technique in 
Healthcare Expenditure 
Analysis 
Chia E., Khong P.W., Ghista D.N. 
 • Integration of CAD to FEA for 
Prosthetic Socket Design 
Goh J. C. H., Lee P. V. S., Toh S. L., 
Ooi C. K. 
 
• Analyses of Fractured Bone 
(Femur) with Plate and Intra-
Medullary Rod Fixations 
Chen Q., Fan S.C., Ghista D.N.  
 
• Biomechanics of Long Bone 
Geometry and Fracture 
Fixation 
Krishna K.R., Sridhar I., Sivashanker 
S., Khong K.S., Ghista D. N.  
• Automatic 3-D optic Disk Image 
Reconstruction from Low-
Resolution Fundus Image for 
Glaucoma Analysis 
Xu J., Chutatape O.  
 
• Low-Complexity Unified-
Adaptive Compression of 
Biomedical Images Using 
Integer Hartley Transform 
Meher P.K., Srikanthan T., Agarwal 
H.K., Gupta J. 
 
• Modified Deformable region 
model for Lumen Extraction 
from Colonoscopic Image and 
Comparison with FCM 
Tjoa M. P., Zheng M. M., 
Doraiswami R., Tang C.L. 
 
End of Conference 
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Conference Papers 
 
 
Invited Speakers  
1 Nanostructure Processing of Advanced Biomaterials (Ying J.) 18 
2 Bioengineering, Technology Commercialization and Entrepreneurship (Kim Y.) 19 
3 Esophageal Tissue Engineering (Ratner B.) -- 
4 A Case Study of Integrated Biomedical Engineering: A Novel Method for Creating an 
Automated Sutureless Anastomosis (Sharkawy A.) 
20 
5 Advances in Cancer Imaging (Khoo J.) 21 
6 Tissue Engineering Heart Constructs using Bone Marrow Stem Cell (Wong P.) -- 
7 Computational Technologies to Accelerate Biotech Innovation (Meier U.) -- 
8 A new Approach to Protein Structure Prediction (Schroder H.) 22 
9 Development of Microfluidic-Based Point-of-Care Diagnostic Systems (Yager P.) 23 
10 Innovation in The Medical Device Industry: Development of Cypher - the first Drug-Eluting 
Stent (Mishra A.) 
-- 
11 Heart Tissue Engineering (Ratner B.) -- 
12 Biological Resurfacing of Articular Cartilage - from Bench to Bedside (Lee E.H.) 24 
13 Virtual Reality, Augmented Reality and its Medical Application (Bockholt U.) 25 
14 Vital Signs in the Real World (Wilson S.) 26 
15 Clinical Endoscopy System: Present and Future (Hidaka T.) -- 
Session: 01 Tissue Engineering                                                                              Day 1 1515- 1715 hrs 
1 Enhancement of Meniscus Repair using Mesenchymal Stem Cells in a Porcine Model 
(Dutton A.Q., Hui J.P.P., Lee E.H., Goh J.) 
27 
2 Cardiac Differentiation of Adult Bone Marrow Mesenchymal Stem Cells (Tan G.M.Y., 
Wong P., Chua T., Tan J., Chua Y.L., Tan Y.S., Sin Y.K., Lim C.H., Liu T.C., Teh M., Sim 
E.K.W., Shim W.S.N.) 
30 
3 Polyurethane Membranes for Chondroctye Transplantation and Cartilage Engineering 
(Chia S.L., Gorna K., Gogolewski K., Alini M.) 
33 
4 Theoretical and Experimental Determination of State of Two Dimensional Strain in a 
Bioreactor (Ong W.F., Wijaya S., Ritchie A.C.) 
34 
5 Culture of Rodent Hepatocytes on Microgrooved Surfaces: Application for a Flat-Plate 
Bioartificial Liver Device (Ting K.S., Wang N.D., Grant M.H., Henderson C.) 
38 
6 Simultaneous Probing of Morphology, Cytoskeleton, and Adhesion Dynamics of HepG2 
Cells (Feng Z. Q., Liao K., Chan V.) 
42 
7 ECM-Dependent Proliferation of Adult Bone Marrow Mesenchymal Stem Cells (Tan 
G.M.Y., Shim W.S.N., Chua T., Liu T.C., Teh M., Sim E.K.W., Wong P.) 
49 
8 Parameters for Scaffold Design of Esophageal Tissue from a Structural Constitutive 
Model (Yang W., Fung T.C., Chian K.S., Chong C.K.) 
51 
Session 02: Cancer Detection & Therapy                                                                Day 1 1515-1700 hrs 
1 Automated Segmentation of Breast Masses in Mammograms (Zhang H., Foo S.W., Thng 
C.H.) 
54 
2 Diagnosis of Lung Cancer Using NIR Raman Spectroscopy (Huang Z., McWilliams A., 
Lam S., McLean D.I., Lui H., Zeng H.) 
58 
3 Extraction of head and neck tumors using deformation models from MR images (Zhou J., 
Chong V.) 
61 
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4 Breast Cancer Diagnosis using Thermography and complementary learning fuzzy neural 
network (Tan T.Z., Quek C., Ng G.S., Ng E.Y.K.) 
65 
5 Magnetic Particles for Hyperthermia Treatment of Cancer (Ramanujan R.V., Lao L.L.) 69 
6 Gene Selection for Cancer Classification from Microarray Data using PLS-RLSC (Shen 
L., Tan E. C.) 
73 
7 Micelle-like Nanoparticles of Linear and Branched PLA/PEG Block Copolymer as Anti-
Cancer Drug Carrier (Pan J., Feng M., Chan W.A., Venkatraman S., Boey F.Y.C.) 
77 
Session 03A: Medical Image Processing                                                                 Day 1 1515-1745 hrs 
1 ALA-Induced-PPIX Fluorescence Imaging of Normal and Neoplastic Tongue Tissue using 
Confocal Endomicroscopy (Zheng W., Harris M., Kho K.W., Thong P.S.P., Hibbs A., Soo 
K.C., Olivo M.) 
81 
2 A Simulation System for Remote Interventional Radiology Procedures (Zhao L., Ma X., 
Aziz A., Zheng W., Nowinski W.L.) 
85 
3 An Improved Active Contour Method for Heart Wall Boundary Detection in 
Echocardiographic Image Sequence (Fang W., Chan K.L., Anantharaman V.) 
89 
4 Augmented Reality Assisted Sinus Surgery (Shi D. M., Ng W. S., Ling K. V., Shao W., 
Chen H.J., Kwoh C. K.) 
93 
5 Brain Atlas-assisted Segmentation of the Hippocampus from MR Neuroimages (Minh 
P.D., Prakash K.N.B., Nowinski W.L.) 
97 
6 Removing Blocking Artifacts in Compressed Medical Images (Singh S., Vinod K., Verma 
H.K.) 
101 
7 Simulated Annealing based Simplified Snakes for Weak Edged Medical Image 
Segmentation (You J., Zhou Z., Heng P.A., Xia D.) 
105 
8 Extraction of the Two Modified Talairach Cortical LandMarks (I and S) from MR T1-
Weighted Images (Hu Q., Qian G., Nowinski W.L.) 
109 
9 Knowledge-based Interpolation of the Talairach-Tournoux Brain Atlas (Liu J., Nowinski 
W.L.) 
113 
10 Mapping Human Skin and Aural Temperature with ANNs and IR Imager (Ng E.Y.K., 
Chong C.) 
117 
Session 03B:  Medical Image Processing                                                                Day 3 1130-1215 hrs 
1 Automatic 3-D optic Disk Image Reconstruction from Low-Resolution Fundus Image for 
Glaucoma Analysis (Xu J., Chutatape O.) 
121 
2 Low-Complexitiy Unified-Adaptive Compression of Biomedical Images Using Integer 
Hartley Transform (Meher P.K., Srikanthan T., Agarwal H.K., Gupta J.) 
125 
3 Modified Deformable region model for Lumen Extraction from Colonoscopic Image and 
Comparison with FCM (Tjoa M.P., Zheng M. M., Doraiswami R., Tang C.L.) 
129 
Session 04: Microfluidics/MEMS                                                                               Day 1 1700-1800 hrs 
1 AFM Characterization and Selectivity of Immobilization of Antibodies in Bio-MEMS (Joshi 
M., Rao R., Mukherji S.) 
133 
2 Cross-Talk, a Potential Source of Noise in a Fluorescence Multi-channel Microfluidic 
System (Irawan R., Tjin S.C., Yager P., Zhang D.W.) 
137 
3 Disposable Microfluidic Card and Fluorescence Detection System for Point-of-Care 
Diagnostic Applications (Irawan R., Tjin S.C., Fu C.Y., Ng B.K., Yuan X.-C., Zhang D.W.) 
141 
4 Microfluidic Protein Patterning using Embedded Cavities in Microchannels (Garcia E., 
Yager P.) 
145 
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Session 05: Biomaterials & Drug Delivery                                                               Day 2 1015-1230 hrs  
1 Smart Polymer Nanocarriers for Targeted Delivery (Yang Y.Y.) 149 
2 Release of Lipoplexes from a Biodegradable Polymer Film: Preliminary Study (Chan 
W.A., Ramgopal Y.) 
150 
3 Cross linking of Bovine Serum Albumin with Genipin: Investigation of Mechanical 
Properties (Sathappan K., Chian K.S., Chua L.P.) 
154 
4 Porous Beta-TCP and Its Modification with PLGA Coating for Bone Regeneration (Miao 
X., Kurniawati T.) 
158 
5 In vitro Study on the Release Kinetics of Bovine Serum Albumin (BSA) from Injectable 
PLGA/BB Depot (Wang L.W., Venkatraman S.) 
162 
6 Effects of Plasticization on Heparin Release from Biodegradable Matrices (Tan L.P., 
Venkatraman S., Sung P.F., Wang X.T., Wong P.) 
166 
7 Porous Bioinert Alumina Prepared by Vacuum Infiltration (Liu J., Ng M.Y., Loh K.H., Hu 
Y., Miao X.) 
170 
8 Clinical Applications of Magnetic Nanomaterials (Ramanujan R.V.) 174 
Session 06: Biomechanics                                                                                        Day 2 1015-1230 hrs  
1 Biomechanics Highlights in Sports,  Physiology and Medicine (Ghista D.N.) 178 
2 Evolution and Biomechanics of the Cruciate Ligaments (Fuss F.K.) 181 
3 The Double-Bundle ACL Graft Reconstruction: A superior technique to restore knee 
kinematics (Lie D.T.T., Amis A.) 
185 
4 Finger Pulley Injuries are Self-Propagating: A Mathematical Analysis of the A2-Pulley 
(Tan M.A., Fuss F.K., Niegl G.) 
188 
5 A Comparative Study of Different Gripping Methods for Tendons (Ng B.H., Chou S.M., 
Krishna V.) 
192 
6 Statistical Analysis of Human Metacarpal Morphology using CT Scan Data (Zhai L.Y., 
Chou S.M., Lim B.H., Chong A., Tsou I., Ng S.Y.) 
196 
7 Mechanics and Finite Element Analysis of the Auditory Ossicles (Ho K.L.I., Fuss F.K.) 199 
8 Foot Characterization and Anatomical Landmarks Localization (Liu X., Kim W., Drerup B.) 202 
Session 07A: Computational Bioengineering 1                                                       Day 2 1015-1230 hrs 
1 A Case Study on Pattern-based Systems for Computational Biology (Liu W., Schmidt B.) 205 
2 A Grid Implementation of Database Searching (Chen C., Schmidt B.) 209 
3 The Use of Computer Modelling to elucidate the Efficacy of Slit Arteriortomy for End-to-
side Arterial Anastomosis in Microsurgery (Chua A.W.C., Gu H., Tan B.K., Chew W., Li 
J.Z., Song C.) 
213 
4 A Mixed SVM-Based Hierarchical Learning Approach for Abnormal ECG Beat 
Recognition (Li P., Chan K.L., Chan Y.W.) 
217 
5 Capturing Cellular Life In-Silico (Dhar P.K.) 221 
6 Finite Element Modeling of the Human Brain with Detailed Anatomy for Surgery 
Simulation Based on a Brain Atlas (Gao C., Tay F. E. H., Nowinski W.L.) 
224 
7 Fuzzy c-Means and Neural Network Framework for Arrhythmia Classification (Chaudhari 
N.S., Siang L.C.) 
228 
8 VRML Modeling for Bio-Molecular Structures (Indhumathi C., Lu B.F., Cai Y.Y.) 232 
9 BioSequence Comparison for Large Database on Reconfigurable Platforms (Wong M.T., 
Schmidt B.) 
237 
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Session 07B: Computational Bioengineering 2                                                       Day 2 1330-1415 hrs 
1 Clustering Based Watershed Segmentation for Two-Dimensional Gel Electrophoresis 
Image (Diao X.N., Mao K.Z.) 
240 
2 Estimating error-dimensionality relationship for gene expression based cancer 
classification (Chu F., Wang L.) 
244 
3 Finite Element Analysis of Brain for Neurosurgical Procedure (Roy A., Nowinski W.L., Tay 
F.E.H.) 
247 
Session 08A: Cardiovascular Engineering 1                                                           Day 2 1330-1530 hrs  
1 A Decoupled Control Method for the Magnetic Bearings of a Blood Pump (Lim T.M., 
Zhang D., Kim M.T.) 
251 
2 An Immersed Membrane Method For Simulation of Fluid-Structure Interaction in Bio-Fluid 
Flows (Xia G.H., Zhao Y., Yeo J.H., Tai C.H.) 
255 
3 Computation of Gap Flow Field in a Bio-Centrifugal Blood Pump (Chua L.P., Song G.L., 
Yu S.C.M.) 
259 
4 Computational Studies of Steady Flows In Designed Sleeve Models At Distal 
Anastomoses (Chua L.P., Tong J.H.) 
263 
5 Contractility of the Left Ventricle in Terms of its Sacromere Power Generation (Zhong L., 
Ghista D.N., Ng E.Y.K.) 
267 
6 Detection of Cardiac Arrhythmia using Phase Space Analysis (Wong M.T., Srinivasan N., 
Chan Y.W.) 
271 
7 Flow Studies in Aorto-Right Coronary Bypass Graft System (Meena S., Chua L.P., Ghista 
D.N., Tan Y.S.) 
274 
8 LV Twisting Analyzed for Pressure-Increase During Iso-Volumic Contraction (Liu L., Yeo 
S.Y., Ghista D.N., Chua L.P., Chai G.B., Tan Y.S., Tan R.S.) 
278 
Session 08B: Cardiovascular Engineering 2                                                           Day 2 1545-1645 hrs 
1 Multiple-Model Adaptive Control by Means of a Fuzzy Controller-based Control System 
(Zheng H., Zhu K.Y., Tan Y.S.) 
282 
2 Numerical Investigation of Hemodynamics for the Coronary Artery Bypass Graft Model 
(Chua L.P., Zhang J.M., Zhou T.M., Yu S.C.M., Ghista D.N., Tan Y.S.) 
286 
3 Numerical Investigation of Stress Field in Distal End-to-side Anastomoses (Liu L., Chua 
L.P., Ghista D.N., Tan Y.S.) 
289 
4 PIV Measurements on the Pulsatile Flow Characteristics in 45-degree Backward Proximal 
Anastomosis (Ji W.F., Chua L.P., Yu S.C.M., Ghista D.N., Zhou T.M., Tan Y.S.) 
293 
Session 09A: Sports Engineering 1                                                                          Day 2 1330-1530 hrs 
1 Quantitative analysis of Singapore Golfers (Lim S.L., Xie X., Ong V., Teh K.C.) 297 
2 Three-Dimensional Kinematics Study of Left Hand During Golf Swing (Teu K.K., Kim W., 
Fuss F.K., Tan J.) 
301 
3 Investigation of Weight Transfer during Golf Swing (Teu K.K., Kim W., Fuss F.K., Tan J.) 305 
4 Biomechanics of Push-up Exercise and Triceps Contractility (Tan M.A., Zhong L., Fuss 
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Abstract— The primary function of the lung is to (i) 
oxygenate the blood and thereby provide oxygen to the 
cells for metabolization purposes, and (ii) to remove the 
collected CO2 from the pulmonary blood. Herein, we 
provide a noninvasive methodology to asses physiological 
metabolic rates as well as blood-oxygenation capacity of 
the lung. For this purpose, we analyze the compositions 
of the inspired and expired air per breath, and 
therefrom compute the metabolic O2 consumption and 
CO2 production rates.  
Next, we derive expressions for diffusion coefficients 
2OD and 2COD , in terms of the evaluated cardiac-output 
CO, O2 and CO2 concentrations in arterial and venous 
blood as well as alveolar and blood O2 and CO2 partial-
pressures. The coefficients 
2OD and 2COD represent the 
lung  capability to oxygenate the blood. We can then also 
determine the cardiac output, from knowing the 
concentrations of oxygen and carbon dioxide in the 
arterial and venous bloods.  
The derived information of 
2OD and 2COD as well as 
of O2 and CO2 metabolic rates can be of considerable use 
(including for SARS assessment). The paper provides a 
case study for the determination of  Q, 
2OD and 2COD . 
 
Keywords— gas exchange, O2 metabolic-rates, CO2  
metabolic-rates, diffusion coefficients 
2OD , diffusion 
coefficients 
2COD , blood flow rate 
 
 
I.  SCOPE 
 
 The lung functional performance is characterized by (i) 
its ventilatory capacity, to bring air (and hence O2) into the 
alveoli, and (ii) its capacity to transfer O2 and CO2 into and 
from the pulmonary capillary bed. Hence, the O2 and CO2 
diffusion coefficients 
2O
D and 
2CO
D as well as the O2 
consumption-rate and the CO2 production rate represent the 
lung performance indices. In this paper, we are 
demonstrating their evaluations. 
 
 
 
 
 
II LUNG GAS-EXCHANGED MODEL 
Figure 1 schematically illustrates the gas-exchange 
between the lung alveolus and the pulmonary capillary-
vasculature. Based on our earlier work [2] the gas exchange 
between the alveolar air and pulmonary capillary blood is 
represented by the following 2O  and 2CO  conservation 
equations  and Figure 2. 
 
22 2
VE VE AE AE
OO OQ C Q C V
°
= +  (from the alveolar air to 
capillary blood) 
2
2 2
( )Oav
AE AE
O OQ C P D= + ∆               (1) 
22 2
VE VE AE AE
COCO COQ C Q C V
°
= −  
  2
2 2
( )COav
AE AE
CO COQ C P D= − ∆                    (2) 
wherein 
(i) ABQ and VBQ  are arterial and venous blood flow-rates;    
(at venous end)  (at arterial end) ,AB VE VB AEQ Q Q Q= =
 
(ii) 
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial 
pressures 
(iii) 
2 2
 2and are the alveolar and capillary partial pressure  
al cap
CO COP P CO
 
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion 
coefficients 
(v) 2
2 2
- average of ( ) over the capillary length;Oav
capal
O OP P P=+  
2
2 2
average over the capillary length of ( ) CO al capav CO OP P P= −+
 
(vi) 
2
cap
OP = 2
PRB
OP  ( 2O  concentration of the pre-oxygenated 
blood) 
2
AE
OP=  
(vii) 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre-
oxygenated blood) 
2
VE
COP=  
Determination of O2 & CO2 Metabolic-Rates and Lung O2 & CO2 Diffusion 
Coefficients, form on the Data of Inspired and Expired Air Compositions 
 
Loh Kah Meng1, Dhanjoo N. Ghista2 
1School of Engineering (Electronics), Nanyang Polytechnic, Singapore 
2Department of Biomedical Engineering, Nanyang technological University, Singapore 
Proceedings of IBEC 2004 377
  
(viii) 
2O
V
a
 is the 2O  transfer rate from alveolar air to 
capillary blood (= 2O consumption rate), 2COV
a
is the 2CO  
transfer-rate from capillary blood to alveolar air. 
 
Now we can equate the arterial and venous blood flow rates, 
as  
AEQ = ABQ = VBQ VEQ= = Q =(SV)/(EP)  / 60CO  
SV, EP and CO being the stroke-volume, ejection-period 
and cardiac-output respectively. 
 
 
 
Figure 1: Process of oxygenating the venous blood. The low 
oxygen (O2) concentration Red Blood Cell (RBC) is shown 
in dark blue. As it travels down the artery towards the 
venous end, the O2 concentration increases. After the 
distance L, its O2 has increased to 0.18 from the initial 
concentration of 0.13. 
 
 
 
Figure 2: Schematic of blood gas concentration in the 
Pulmonary Capillary. 
 
III. CLINICAL DATA 
 
The monitored data consists of inspired and expired air gas 
compositions (Table 1) and 2O and 2CO  concentrations of 
arterial blood and venous blood (Table 2). 
 
Table 1: Air Composition Analysis. Inspired and expired air 
composition and partial pressures are monitored. Assumed 
Breathing Rate (BR) = 12 breaths/min. Assumed 
2H O
P  at 
37οC = 47 mmHg. 
 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/% 
N2 597 393.1 
78.55% 
597 393.1 
74.52% 
O2 159 104.2 
20.84% 
84.5 83.37  
15.7% 
CO2 0.3 0.2 
0.04% 
29 16.87  
3.20% 
H2O 3.7 2.5 
0.49% 
49.5 34.15  
6.47% 
Total 760 500 
100% 
760 527.49 
100% 
 
  
Table 2:  Blood Gas Analysis. The monitored blood  O2 and 
CO2 concentration . 
2O
C   of venous blood  (
2
VB
OC ) = 0.13 
2O
C   of arterial blood  (
2
AB
OC ) = 0.18 
2CO
C  of venous blood (
2
VB
COC ) = 0.5 
2CO
C  of arterial blood (
2
AB
COC ) = 0.46 
 
IV. EXPRESSIONS FOR 
2O
D AND 
2CO
D  
If we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 
2
al
COP , 2
cap
COP  in terms of monitorable quantities [1 & 2]. 
 
(i) Alveolar 
2
al
OP can be expressed in terms of V
°
(the 
ventilation rate) and 2OV
°
(the 2O  consumption rate). 
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*
24.18
 ;                                 (3)
*wherein the nomalised ventilation rate,  60 
 is  the  consumption rate (in liters/min).
140 1
OV V
V V V Vm
litres/min, 
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= =
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
a a a a
2
al
OP
 
(ii) Alveolar 
2
al
COP  can be expressed in terms of V
°
 and 
2OV
°
. 
22.46 *
114.68
COV V
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
−
=alCO2P             (4) 
wherein 
2CO
V
a
 is  the 2CO production rate (in liters/min).  
 
(iii) Blood
2O
P can be obtained in terms of  blood 
2O
C , from 
the 2O  disassociation curve. 
 
2
0.2
29.72 ln
0.2 BO
B
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦O2
P        (5) 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
BC ,from 
the 2CO  disassociation curve. 
 
2
0.8
29.72 ln
0.8 BCO
B
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦CO2
P      (6) 
Now, 
2 2 2 2
( )Capal al VBO O O OP P P P= − = −  both 2OP+ and 2COP+  
2 2
)( VB alCO COP P= −  vary along the capillary bed. Based on [3], 
we have: 
2 2
max0.185
OOP Pav =+ +        (7) 
2 2
max0.1   
COCOP Pav =+ +        (8) 
From the above expressions, we obtain: 
2 2
2 2 0.185( )
2 2
O O
O O
av
al VBP PP O O
V V
D = = −
a a
+
     (9) 
2 2
2 2 0.1( )
2 2
CO CO
CO CO VB alP PPav CO CO
V V
D = = −
a a
+
    (10) 
 
 
V.  DETERMINATION OF O2 AND CO2 METABOLIC 
RATES AND CARDIAC OUTPUT 
 
From monitored data of inspired-exhaled gas compositions, 
in Table 1: 
 
2O  consumption rate, 2OV
a
= BR(Inspired 2O - Expired 
2O )ml/min =12(104.2-83.37) = 250 ml/min               (11) 
 
2CO consumption rate, 2COV
a
=BR(Expired 2CO -Inspired 
2CO ) ml/min = 12(16.87-02)=200 ml/min                  (12) 
 
From monitored 2O  and 2CO concentrations of arterial and 
venous blood, in Table 2: 
 
∵ 2OV
a
= Q( 2CO  of arterial blood - 2CO of venous blood)   
 
where Q=blood flow rate≡cardiac output 
 
2 250 5000 /
(0.18 0.13) 0.05
OVQ ml min∴ = = =−
a
      
  
VI. EVALUATING OF THE LUNG DIFFUSION 
COEFFICIENTS 
2O
D  AND 
2CO
D  
From equation (3) and Table 2 (
2
AB
OC =0.18), we get for 
(arterial blood @ venous end of the pulmonary capillary or 
2
VE
OP )  
        
2
AB
OP =
2
0.2
29.72 ln
0.2 ABOC−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
 
       = 
0.2
29.72 ln
0.2 0.18−
⎡ ⎤⎢ ⎥⎣ ⎦   
      = 68.43 mmHg                        (13)                        
 
 
From equation (5) and Table 2 (
2
VB
OC =0.13), we get for 
2
VB
OP  (venous blood @ arterial end of the pulmonary 
capillary or 
2
AE
OP  ) 
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2
VB
OP   =  
2
0.2
29.72 ln
0.2 VBOC−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
 
       = 
0.2
29.72 ln
0.2 0.13−
⎡ ⎤⎢ ⎥⎣ ⎦            
      = 31.20 mmHg                  (14)         
           
 Also, from equation (3) and Table 1 ( *V
a
=0.1), we get: 
 
[ ]
*
2
0.1 0.25
4.18
4.18
      140 113                          (15)
140 1
1
OV V
mmHg
e
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
−= =
= −
−
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎣ ⎦
2
al
OP
 
         
Hence, from equations (14 & 15), we get: 
 
2 0.185 (113 31.2) 14.95Oavp mmHg= × − =+               (16) 
 
Finally, from equations (11) and (16), we get: 
 
2
2 2
1
250 / min
14.95
       16.72     (17)                            -1
O
O O
av
ml
mmHgP
V
D
mlmin mmHg−
= =
=
a
+  
                      
From equation (6) and Table 2 (
2
VB
COC =0.5), we get: 
2
          29.15                     (18)
0.8
29.72 ln
0.8
0.8
29.72 ln
0.8 0.5
VB
CO
VB AE
mmHg
C
=
= =
= −
−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎢ ⎥⎣ ⎦
CO CO2 2
P P
       
Then from equation (4), Table 1 ( 0.1V =
a
), and equation 
(12) we get: 
[ ]
2
0.1 0.2
2.46
2.46
*
33.52                                (19)
114.68
114.68
COVV
mmHg
e
e
°
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
−
−= =
=
a
al
CO2
P  
         
 
Hence, from equations (8, 18 & 19), we get: 
 
2 0.1 (33.52 29.15) 0.44COavp mmHg= × − =+           (20) 
     
Finally, from equations (10 & 20), we get: 
2
2 2
200 / min
0.44
                           454.55                     (21)
CO
CO CO
av
ml
mmHgP
-1 -1mlmin mmHg
V
D = =
=
a
+                             
VII.  CONCLUSION 
 
We have demonstrated a noninvasive clinical procedure:  
• for obtaining (i) O2 consumption rate and CO2 
production rate, (ii) cardiac outflow-rate or 
output, Q, (iii) and lung diffusion capacities for  
O2 and CO2. 
• from inhaled and exhaled air composition 
analysis, and blood-gas analysis. 
This work could have application to SARS testing and 
evaluation. 
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Abstract— This paper provides a systems-engineering 
analysis of the glucose-insulin responses to an ingested 
bolus of glucose for OGTT (Oral Glucose Tolerance 
Test). The clinical data of patients is fitted by either 
under-damped or over-damped or critically-damped 
solutions of the model’s governing equations for glucose 
and insulin responses to glucose bolus ingestion. Based 
on the best fit of the three types of solutions, we 
designate the patients (and their response) to be normal 
(and under-damped), diabetic (and over-damped) and 
either border-line or at-risk of becoming diabetic (and 
critically-damped). In this way, the model simulation of 
the clinical data enables more reliable diagnosis relative 
to the clinical assessment. 
  
 
Keywords—diabetic, systems-engineering model, under-
damp, over-damp, critically-damped, R-square, fitting, clinical 
diagnosis  
 
I.  INTRODUCTION 
 
Oral Glucose Tolerance Testing Protocol 
 The test subjects need to fast for 12 hours before the test 
and during the 2-hour test. A blood sample of the subject is 
taken before the beginning of the test. Then after the subject 
drinks a 75 g of glucose solution dissolved in 250–300 mL 
of water, the subject’s blood glucose and insulin 
concentrations are measured at specified intervals 30 
minutes, 60 minutes, 90 minutes and 120 minutes [1, 2, 4]. 
Qualitative interpretation of the results, for preliminary 
categorization of the patients [1, 2, 4]: 
(a) Blood glucose normal values:  
fasting: 70 to 115 mg/dl  
30 min.: less than 200 mg/dl 
1 hour : less than 200 mg/dl 
2 hour : less than 140 mg/dl  
(b) Normal insulin level (reference range): 1-30 mU/L 
When a person has a fasting glucose equal to or greater 
than 110 mg/dl and less than 126 mg/dl, it is considered as  
impaired fasting glucose. This is considered a risk factor 
for future diabetes and will likely trigger another test in the 
future, but, by itself, does not make the diagnosis of 
diabetes. 
A person is said to have impaired glucose tolerance 
when the 2-hour glucose results from the oral glucose 
tolerance test are greater than or equal to 140 but less than 
200 mg/dl.  This is also considered a risk factor for future 
diabetes. A person has diabetes when oral glucose tolerance 
tests show that the blood glucose level at 2 hours is equal to 
or more than 200 mg/dl.  This must be confirmed by a 
second test (any of the three) on another day.  
 
II. SYSTEM SOLUTIONS FOR DIABETIC, NON-
DIABETIC AND AT-RISK PATIENTS 
 
The governing differential equation for glucose response to 
glucose bolus intake is: 
 
( )y q t x yγ δ′ = − −                                          (1) 
The governing differential equation for insulin response to 
glucose bolus intake is: 
 
( ) -x p t x yα β′ = +          (2) 
 
y(t) : Glucose response of the patient to the oral bolus of    
glucose. 
x(t) : Insulin response of the patient due to y(t). 
 
Solution For Underdamped Case (non-diabetic): 
y(t) = (G/ ω) e-At sinωt                (3) 
 
( )
( )(sin( )
( )sin( )
( ) ( )cos( ) )
( ) 2 2 22
Atwt Ae
Atwt e
t Ate w wt e w
G
wx t
A A w
α
α
β
α α
−⎡ ⎤−⎢ ⎥−⎢ ⎥−⎢ ⎥− −⎢ ⎥− +⎢ ⎥⎢ ⎥×⎢ ⎥⎣ ⎦=
− + +
            (4) 
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Solution For Overdamped Case (diabetic): 
 G -Aty(t)= e sinhwt
ω
                    (5)     
 
  
1 (cosh( ) sinh( )
2
cosh( ) sinh( )
sinh( ) cosh( )
sinh( ) sinh( )
cosh( ) cosh( )
cosh( ) 2
sinh(
( )
wt At t A wt At t A
wt At t A wt At t A
wt At t w wt At t w
wt At t wt At t
wt At t wt At t w
wt At t w
wt
x t
α α
α α
α α
α α α α
α α α
α α
+ − + − + −
− − + − − + −
+ − − − − + −
− − − − + + −
− + − − − −
+ − + − +
+ −
= ( )
( )
2 2 2
) )
2
t GAt t w e
w
w A A
αα β
α α
−
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟+ −⎜ ⎟⎝ ⎠
− + − +
(6) 
 
Solution For Critically Damped Case (at the dangerous 
boundary): 
 
-Aty(t)= Gte                     (7) 
( ) ( ) ( ) ( )( )
( ) 2( )
At At At tG tAe t e e e
x t
A
αβ α
α
− − − −− − + −=
−
 (8) 
 
III.  CLINICAL APPLICATION AND DISCUSSION 
 
Under-damped Category and Normal Designated Patient 
 
These y(t) and x(t) response solutions are fitted to the 
monitored glucose and insulin data, and the fitness 
coefficients are determined. Based on the high degree of fit, 
patient S14 fits best the under-damped category, and hence 
is designated to be normal.  His Glucose and Insulin 
responses, shown in Figure 1, illustrates the fast recovery of 
blood glucose and insulin concentrations.  
 
 
The below table displays the values of the model parameters 
and the R-Square coefficients of fitness and the model slution 
to the clinical data. 
 
 
Figure 1: Patient S14 is designated to be under-damped and 
normal. However, this patient is quite hyper-insulinemic; in 
other words, this patient has elicited considerable insulin 
response in order to maintain an under-damped glucose 
response. 
Over-damped Category of Patients Designated as Diabetic 
 
     For patients D05, our over-damped model solution fits the 
clinical data best of the 3 solution categories. Hence, this 
patient is designated to be diabetic. His Glucose and Insulin 
responses are shown in Figure 2, and the model parameters are 
given in the Table. 
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Figure 2: This patient D05 has the higher R-Square value when 
fitted by the over-damped solution, and is hence classified as 
diabetic. 
 
Critically-damped Category of Patients 
 
There are some patients clinically diagnosed to be 
normal for which the critically-damped solution gives a 
better fit of the data (and a higher value of R-Square) than 
the under-damped solution. One such patient is S04, whose  
under-damped and critically-damped model response-curves 
are shown in Figures 3 and 4. Similarly, patients S06 and 
S19 are not normal as clinically diagnosed, but at the risk of 
becoming diabetic. Their response curves are illustrated in 
Figures 5 and 6. 
 
 
 
 
 
Figure 3: This S04 patient’s data is fitted by the under-damped 
solution. Next, we will compare the results fitted by the 
critically-damped solution as shown in the following figure. 
 
 
 
 
Figure 4: This S04 patient’s data is better fitted (i.e. at higher 
R-Square value) by the critically-damped solution than by the 
under-damped solution. Because of the critically-damped 
model solution giving us a better fit (terations of a higher 
value of R-Square), we differ from the clinical diagnosis and 
alert this patient that he is at risk at becoming diabetic. 
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Figure 5: This S06 patient’s data is better fitted (i.e. at higher 
R-Square value) by the critically-damped solution than by the 
under-damped solution. Hence, we will differ from the clinical 
diagnosis and designate this patient to be at risk of becoming 
diabetic. 
 
 
 
 
Figure 6: This S19 patient’s response curves are best fitted 
(with a higher value of  R-Square) by the critically-damped 
solution than by the under-damped solution. 
 
 
V.  CONCLUSION 
 
We have shown that we can obtain more accurate 
assessment of diabetic patients by means of our under-
damped, over-damped and critically-damped simulation 
model solutions. Some patients (diagnosed to be normal) 
were designated by us to be in the borderline category. 
However, some patients who were clinically declared to be 
diabetic turned out to be only border-line. As we continue 
this work, we will develop a clinically-implementable 
software for model parameter identification and designation 
of the subjects as normal or at-risk of becoming diabetic or 
border-line diabetic or distinctly diabetic.  
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17th Annual NTU-SGH Symposium 2005
0800–0900 Registration
0900–0930 OPENING CEREMONY
Welcome Address
Organising Chairman, Dr Denny Lie
Opening Address
Guest-of-honour
Prof Su Guaning, President, NTU
0930–1030 PLENARY LECTURE 1
Systems Integration in Genomics and
Biomedicine
Dr Edison Liu
Chair: Prof Soo Khee Chee
1030–1100 Tea Break and Exhibition
1100–1200 PLENARY LECTURE 2
Research in Bioengineering and
Nanotechnology
Prof Jackie Ying
Chair: Prof Michael Khor
1200–1315 SHOWCASE OF NTU-SGH JOINT
PROJECTS
Piezoelectric Pumps for Biomedical
Applications
Asst/Prof Ma Jan
Adult Bone Marrow Mesenchymal Stem
Cells for Cardiac Tissue Engineering
Dr Philip Wong
Rapid Portable System for Screening
Tuberculosis
A/Prof Lim Chu Sing
A Bilayered Scaffold for the Development
of Composite Skin Construct
Mr Alvin Chua & Mr Leong Meng Fatt
Single Living Cell Detection and Sorting
Using Biophotonic Integrated Chip
A/Prof Liu Ai Qun
Chair: A/Prof Tay Boon Keng
1315–1400 Lunch MODERATED
POSTER SESSION
(1315–1340)
Moderators:
Asst/Prof Ang Wei Tech/
Dr Png Hong Hock
Daily
Programme
11 August 2005
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1400–1500 PLENARY LECTURE 3
Distributed Diagnosis and Home
Healthcare – Bringing Affordable
Healthcare to the Home
A/Prof Tjin Swee Chuan
Chair: A/Prof Chan Yew Weng
1500–1610 FREE PAPERS 1 (BIOMECHANICS)
Intrameniscal Forces Determined by Fibre
Bragg Grafting Sensors
Ms Goh Peck Keng (NTU)
Determination of in vivo Constitutive
Properties of Aortic Valve Leaflets from
Phono-echo-cardiograms
Dr Liu Li (NTU)
Prostate Slicer Box and its Validation
Ms Ma Hong Yun (SGH)
Tibiofemoral Pressure Mapping with Fibre
Grafting Sensor
Ms Lipi Mohanty (NTU)
Dynamics of A2 Finger Pulley Rupture
Mr Tan Ming (NTU)
Instantaneous Axes of Rotation of
Thoracolumbar T12-L1 Intervertebral
Joints
A/Prof Teo Ee Chon (NTU)
EOG Based Control of Assistive Platform
for the Severely Disabled
A/Prof Sardha Wijerupage Wijesoma
(NTU)
Chair: A/Prof Kwoh Chee Keong &
Dr Denny Lie
1610–1630 Tea Break and Exhibition
1630–1740 FREE PAPERS 2 (DIAGNOSTICS)
Activity-based Dynamic Insulin Infusion
System
Mr Chan Ting Kwan (TechSource
Systems Pte Ltd)
Volume Visualisation for Surgical Planning
System
Mr Chan Chee Fatt (National
Neuroscience Institute)
Saliva Analysis in the Early Detection of
Oral Cancer Using Surface Enhanced
Raman Spectroscopy (SERS)
Mr Kho Kiang Wei (National Cancer
Centre)
Bioenergy Based Medical Diagnostic
Application Based on Gas Discharge
Visualization
Mr Lee Hwa Chiang Ricky (NTU)
Determination of Urine Outflow and Renal
Function Quantitatively
Mr Loh Kah Meng (Nanyang
Polytechnic)
Antibody-conjugated Gold Nanoparticles
and its Interaction with Epithelial
Carcinoma Cells for Optical Molecular
Imaging
Dr Olivo Malini (National Cancer Centre)
Development of a Laser Confocal
Endomicroscope as a Novel Technique for
in vivo Fluorescence Imaging of the Oral
Cavity
Dr Thong Soo-Ping Patricia (National
Cancer Centre)
Chair: A/Prof Lim Chu Sing &
Dr Mathew Sebastian
1740 End of Scientific Sessions
37th Annual NTU-SGH Symposium 2005
0800–0900 Registration
0900–1015 SYMPOSIUM – MEDICAL
INFORMATICS 1
Medical Informatics in the New
Millennium
Prof KC Lun
IT in Clinical Healthcare Administration
Dr Wong Merng Koon
Chair: Dr Wong Merng Koon
1015–1045 Tea Break and Exhibition
1045–1145 SYMPOSIUM – MEDICAL
INFORMATICS 2
Nursing IT
Ms Tan Siok Bee
Using Reconfigurable Hardware to
Accelerate Biomedical Computation
Asst/Prof Bertil Schmidt
Chair: Dr Wong Merng Koon
1145–1215 LUNCH SYMPOSIUM
Biotechnological Inventions & Intellectual
Property: A Challenge for Patent Law(s)
Mr Gianfranco Matteucci
Chair: Dr Philip Wong
1215–1315 Lunch
1315–1415 FREE PAPERS 3 (MEDICAL
INFORMATICS/MEDICAL SIGNAL
PROCESSING)
IT Security in Biomedical Imaging
Informatics: The Hidden Vulnerability
Mr Chee Wei Siang Adam (KKWCH)
Advanced Integrative Approach for Breast
Thermogram
A/Prof Ng Yin Kwee Eddie (NTU)
Orthopaedics Surgery Simulation
Asst/Prof Olga Sourina (NTU)
Modeling of Brain Response to External
Stimuli
A/Prof Vladimir Kulish (NTU)
Comparison of Linear Transforms in
Power Spectrum Analysis of DNA
Sequences
Mr Lo Chong Chiah (NTU)
Daily
Programme
12 August 2005
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Development of an Electrocardiographic
Diagnostic Tool using Frontal Plane
Vectorcardiogram
Mr Nagenthiran Thurairaj (NTU)
Chair: Asst/Prof Kwek Leong Chuan &
Dr Philip Wong
1415–1455 FREE PAPERS 4 (ADVANCED
BIOMATERIALS/MODELLING/
TISSUE ENGINEERING)
Fabrication and Near-Physiological Testing
of a Biodegradable Metallic Coronary
Stent
A/Prof Lim Chu Sing (NTU)
A New Concept of Active and Passive
Elastance to Explain Left Ventricular
Pressure Dynamics
Dr Zhong Liang (NTU)
Non-invasive Contractility Indices Based
on the Left Ventricular Shape
Dr Zhong Liang (NTU)
Implantation of an Autologous Pericardial
Valve in a Sheep Model
Dr Tan Teing Ee (National Heart Centre)
Chair: A/Prof Frank Fuss &
Dr Guo Chang Ming
1455–1525 Tea Break and Exhibition
1525–1625 FREE PAPERS 5 (NURSING)
An Analysis of the Skin Prick Test Results
of Rhinitis Patients at ENT Centre, SGH
Ms Aishah bte Abdul Latiff
To Facilitate Early Ambulation for Patients
who Require Walking Aids after Surgery
Ms Norhayati Ahmad
To Reduce Time in Levelling Transducer
to Axis Point
Ms Kamsiah Jaafar
Comparison of Temperature Readings
between Tympanic and Oral Mercury-In-
Glass Thermometer
Ms Josephine Teo
Use of a Modified Trolley By Nurses to
Save Time and Ensure Safekeeping of
Patients Record
Ms Tamilchelvi Sinnappan
Perineal Cold Pads Vs Oral Analgesics in
the Relief of Post Partum Perineal Wound
Pain
Ms Punasundri Thangaraju
Chair: Ms Kaldip Kaur &
Ms Cheam Boon See
1625–1630 Closing Remarks
A/Prof Kwoh Chee Keong, Co-chairman
1630 End of Scientific Sessions
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0800–0900 Registration
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1015–1045 Tea Break and Exhibition
1045–1145 SYMPOSIUM – MEDICAL
INFORMATICS 2
Nursing IT
Ms Tan Siok Bee
Using Reconfigurable Hardware to
Accelerate Biomedical Computation
Asst/Prof Bertil Schmidt
Chair: Dr Wong Merng Koon
1145–1215 LUNCH SYMPOSIUM
Biotechnological Inventions & Intellectual
Property: A Challenge for Patent Law(s)
Mr Gianfranco Matteucci
Chair: Dr Philip Wong
1215–1315 Lunch
1315–1415 FREE PAPERS 3 (MEDICAL
INFORMATICS/MEDICAL SIGNAL
PROCESSING)
IT Security in Biomedical Imaging
Informatics: The Hidden Vulnerability
Mr Chee Wei Siang Adam (KKWCH)
Advanced Integrative Approach for Breast
Thermogram
A/Prof Ng Yin Kwee Eddie (NTU)
Orthopaedics Surgery Simulation
Asst/Prof Olga Sourina (NTU)
Modeling of Brain Response to External
Stimuli
A/Prof Vladimir Kulish (NTU)
Comparison of Linear Transforms in
Power Spectrum Analysis of DNA
Sequences
Mr Lo Chong Chiah (NTU)
Daily
Programme
12 August 2005
4 7th Annual NTU-SGH Symposium 2005
Development of an Electrocardiographic
Diagnostic Tool using Frontal Plane
Vectorcardiogram
Mr Nagenthiran Thurairaj (NTU)
Chair: Asst/Prof Kwek Leong Chuan &
Dr Philip Wong
1415–1455 FREE PAPERS 4 (ADVANCED
BIOMATERIALS/MODELLING/
TISSUE ENGINEERING)
Fabrication and Near-Physiological Testing
of a Biodegradable Metallic Coronary
Stent
A/Prof Lim Chu Sing (NTU)
A New Concept of Active and Passive
Elastance to Explain Left Ventricular
Pressure Dynamics
Dr Zhong Liang (NTU)
Non-invasive Contractility Indices Based
on the Left Ventricular Shape
Dr Zhong Liang (NTU)
Implantation of an Autologous Pericardial
Valve in a Sheep Model
Dr Tan Teing Ee (National Heart Centre)
Chair: A/Prof Frank Fuss &
Dr Guo Chang Ming
1455–1525 Tea Break and Exhibition
1525–1625 FREE PAPERS 5 (NURSING)
An Analysis of the Skin Prick Test Results
of Rhinitis Patients at ENT Centre, SGH
Ms Aishah bte Abdul Latiff
To Facilitate Early Ambulation for Patients
who Require Walking Aids after Surgery
Ms Norhayati Ahmad
To Reduce Time in Levelling Transducer
to Axis Point
Ms Kamsiah Jaafar
Comparison of Temperature Readings
between Tympanic and Oral Mercury-In-
Glass Thermometer
Ms Josephine Teo
Use of a Modified Trolley By Nurses to
Save Time and Ensure Safekeeping of
Patients Record
Ms Tamilchelvi Sinnappan
Perineal Cold Pads Vs Oral Analgesics in
the Relief of Post Partum Perineal Wound
Pain
Ms Punasundri Thangaraju
Chair: Ms Kaldip Kaur &
Ms Cheam Boon See
1625–1630 Closing Remarks
A/Prof Kwoh Chee Keong, Co-chairman
1630 End of Scientific Sessions
 4
 


















From: "Vladimir Vladimirovich Kulish (Assoc Prof)" <MVVKulish@ntu.edu.sg> 
To: "Dhanjoo N Ghista (Prof )" <MDNGhista@ntu.edu.sg>, "Lua Aik Chong (Assoc Prof)" 
<MACLUA@ntu.edu.sg>, <rjohn2@mednet.swmed.edu>, "#LOH KAH MENG#" 
<kmloh@technologist.com>, "Merryn Tawhai" <m.tawhai@auckland.ac.nz> 
CC: <vb.novozhilov@ulster.ac.uk>, "Lage, Jose" <jll@engr.smu.edu>, 
<CONNIE.HSIA@email.swmed.edu>, "Lim Chu Sing , Daniel (Assoc Prof)" 
<MCHSLIM@ntu.edu.sg>, "Damodaran Murali (Assoc Prof)" <MDAMODARAN@ntu.edu.sg>, "Ong 
Jor Huat (Assoc Prof)" <MJHONG@ntu.edu.sg>, "Alexei Sourin (Assoc Prof)" <assourin@ntu.edu.sg>, 
"Vladimir Vladimirovich Kulish (Assoc Prof)" <MVVKulish@ntu.edu.sg> 
Subject: BOOK ON HUMAN RESPIRATION --- YOUR CONTRIBUTION IS ACCEPTED 
Date: Fri, 13 Aug 2004 12:48:10 +0800 
Dear Colleagues: 
  
I would like to cordially thank all of you for your contributions. 
  
According to the review received on our book: Human Respiration: Anatomy and Physiology, Mathematical 
Modeling, Numerical Simulation and Applications, all the chapters submitted by us are accepted for 
publication.  Congratulations!!!   
  
However, we need to make some minor additions and amendments. 
  
The reviewer’s comment is attached to this message (see below).  In summary, we need to take the following 
steps: 
  
1. All equations are to be numbered and typed by means of MS Word Equation Editor.  Each equation should 
be a single object but not a mixture of text symbols and equations in one line.  
2. All symbols that are used in equations and appear in text must be typed by means of MS Word Equation 
Editor within the text.  
3. All repetitions among the chapters contributed by the same principal author should be removed.  
4. Each principal author has to provide me with nomenclature (in a separate MS Word file), so that the same 
symbols were used by one principal author in all his/her chapters.  
5. Each principal author has to provide me with key words to be included into Subject Index that will follow 
our book.  
6. Each principal author has to send me the amended version of his/her contribution(s) in MS Word format 
together with the nomenclature and key words file by e-mail:  mvvkulish@ntu.edu.sg .  Please ensure that 
each chapter is formatted according to the template that was sent to you previously [otherwise, the 
production of the book can be delayed].  
  
The deadline set by the publisher (WIT Press) is September 20, 2004.  Hence, I have to receive all your amended 
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contributions at least 48 hours before this date.  The book will appear in January 2005 (ISBN 1-85312-944-5). 
  
I am looking forward to hearing from you. 
  
With kindest regards, 
  
Vladimir V. Kulish, Ph. D. 
Corresponding Member of 
The International Academy of Sciences "Collegium", 
Associate Professor 
School of Mechanical & Production Engineering 
Nanyang Technological University 
50 Nanyang Ave., North Spine (N2), Level 2 
Singapore 639798 
Phone: +(65) 67904950;  Fax: +(65) 67911859 
E-mail: mvvkulish@ntu.edu.sg  or  kulishv@asme.org  
URL: http://www.ntu.edu.sg/home/mvvkulish/index.html  
  
  
'Relevance 
The bio-engineering discipline is now recognised as being of substantial importance. Human respiration 
is a significant, challenging and rewarding field: significant because of the increase in airborne 
pollutants and congenital respiratory diseases; challenging because of the wide range of scales in the 
pulmonary system, which span about three orders of magnitude (or five, if the thickness of the alveolar 
membrane is included); and rewarding  
because of the marvellous ingenuity that characterises the system. A text that covers highlights of the 
application of bio-engineering techniques to the study of human respiration is to be welcomed. 
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This text comprises twelve chapters dealing with various topics in human respiration, from fundamental 
aspects of anatomy and physiology through to numerical modelling of processes such as gas diffusion 
and practical applications in the field of respiratory physiotherapy. As such, there is material here that 
will be of interest to seasoned bio-engineers and clinical practitioners, as well as novices to the study of 
human respiration. There should be a good market for the text – WIT should use the success of their 
publication “Medical Application of Computer Modelling – the Respiratory System” as a guide. 
  
Technical Correctness 
The text encompasses such a wide range of material that I cannot comment on all of it. Nevertheless, I 
am satisfied that in the field that I do have some knowledge (fluid mechanics) the material presented is 
correct. Moreover, each chapter appears to be a distillation of a large body of work which has been 
presented and reviewed for publication in technical journals, and this gives me confidence that the whole 
work is accurate and reliable. There are several papers that deal with modelling of gas transfer across 
that alveolar lumen. The nomenclature employed in each paper (or group of papers, where a group 
is characterised by having the same principal author) is slightly different. It would be very helpful 
if a common nomenclature could be employed. A formal definition of nomenclature after the 
Table of Contents would be useful. 
  
There are instances where relatively complex equations have been poorly constructed. For 
example, dots above symbols to represent differentiation with respect to time (e.g. _) have been replaced 
by small “o”s (e.g. _); in some instances the “o” s have been badly misplaced. This is not correct, and is 
unnecessary – the text appears to have been written using Microsoft Word, and Word includes an 
equation editor that has all the functionality required to produce neat equations employing standard 
notation. The final text should not contain any ambiguities in its formulae. 
  
Quality of Text 
The text is written in generally good English. While I am not sure whether it is the reviewer’s role to 
flag (what he thinks may be) grammatical errors, I have annotated the text where I think it might be 
improved. I offer these corrections not critically (they are few in number), but in the hope that through 
such minor corrections to the text, I might contribute to its acceptance in the academic community. 
  
There are some instances of repetition of material between chapters by the same principal 
authors; there is also duplication of introductory material on respiratory anatomy between different 
authors. It would be beneficial to the ease with which the text can be used if (a) the repetitions were 
removed, (b) the duplication was minimised, and (c) the introductory material was brought forward to 
the first and second chapters (see below for more detail). 
  
Order of Chapters 
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If the original 12 chapters are to be retained as they are, then I would suggest the following re-ordering 
of the text: 
Anatomy and Physiology 
1.  Anatomy and Physiology of the Human Respiratory System 
2.  Fundamentals of Alveolar Gas Diffusion Mathematical Modelling and Numerical Simulation  
3.  Lung Gas Composition and Transfer Analysis: O2 and CO2 Diffusion Coefficients and Metabolic 
Rates 
4.  Lung Ventilation Modelling and Assessment 
5.  Visualisation of Alveolar Diffusion 
6.  Modelling of Two-Phase Flow in the Human Respiratory System  
7.  Impact of Microscopic Solid Particles on Alveolar Diffusion  
8.  Quantification of Human Physiological Response to Toxic Substances  
9.  Anatomically-based Modelling of Pulmonary Structure Applications  
10. Applied Chest-Wall Vibration Therapy for Patients with Obstructive Lung Disease 
11. Indicator for Lung Status in a Mechanically Ventilated COPD Patient using Lung Ventilation 
Modelling and Assessment 
12. Mechanics of Proportional Assist Ventilation 
I have suggested that “Anatomy and Physiology of the Human Respiratory System” should come before 
“Fundamentals of Alveolar Gas Diffusion”, and that “Lung Gas Composition and Transfer Analysis” 
and “Lung Ventilation Modelling and Assessment” should precede “Visualisation of Alveolar 
Diffusion”, “Modelling of Two-Phase Flow in the Human Respiratory System” and “Impact of 
Microscopic Solid Particles on Alveolar Diffusion”. This is because it may be easier for the reader to 
deal with the more general issue of lung respiration before approaching the topic of alveolar respiration. 
However, if some reordering of the material in chapters 2 and 5 can be allowed, then I would 
recommend the following titles for these chapters: 2.  Fundamentals of Alveolar Gas Diffusion – 
Physiological Aspects 5.  Alveolar Gas Diffusion – Numerical Modelling and Visualisation Here, 
chapter 2 would deal with the physiology of alveolar gas diffusion, and the modelling aspects would be 
placed in chapter 5. This would have the advantages that: (a) the first section is a relatively easy 
introduction of the topic of human respiration; and (b) the visualisation of the calculations by Kulish et 
al is presented in the best context. 
  
It should also be possible to combine the chapters “Modelling of Two-Phase Flow in the Human 
Respiratory System” and “Impact of Microscopic Solid Particles on Alveolar Diffusion” into a single 
chapter, e.g. “Modelling the Impact of Microscopic Solid Particles on Alveolar Diffusion”. Certainly, 
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the material in “Impact of Microscopic Solid Particles on Alveolar Diffusion” which is a repetition of 
material in “Visualisation of Alveolar Diffusion” should be deleted. 
  
I cannot decide whether the chapter entitled “Quantification of Human Physiological Response to Toxic 
Substances” should be left in the section on “Mathematical Modelling and Numerical Simulation” or 
placed in the section on “Applications”. Perhaps Kulish as the author is the deciding factor, and it should 
remain where it is in proximity to Kulish’s other papers. Thus, the chapter order becomes:  
1.  Anatomy and Physiology of the Human Respiratory System  
2.  Fundamentals of Alveolar Gas Diffusion – Physiological Aspects MathematicalModelling and 
Numerical Simulation 3.  Lung Gas Composition and Transfer Analysis: O2 and CO2 Diffusion 
Coefficients and Metabolic Rates 
4.  Lung Ventilation Modelling and Assessment 
5.  Alveolar Gas Diffusion – Numerical Modelling and Visualisation  
6.  Impact of Microscopic Solid Particles on Alveolar Diffusion  
7.  Quantification of Human Physiological Response to Toxic Substances  
8.  Anatomically-based Modelling of Pulmonary Structure Applications  
9.  Applied Chest-Wall Vibration Therapy for Patients with Obstructive Lung Disease 
10. Indicator for Lung Status in a Mechanically Ventilated COPD Patient using Lung Ventilation 
Modelling and Assessment 
11. Mechanics of Proportional Assist Ventilation ' 
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Abstract— The primary function of the lung is to (i) 
oxygenate the blood and thereby provide oxygen to the cells 
for metabolization purposes, and (ii) to remove the CO2
produced by the tissues from the pulmonary blood. Herein, 
we provide a noninvasive methodology to asses the capacity 
of the lung to oxygenate the pulmonary capillary blood and 
to reduce its CO2 concentration. For this purpose, we 
analyze the compositions of the inspired and expired air per 
breath, and therefrom compute the metabolic O2
consumption rate ( 2OV
?
) and CO2 production rate ( 2COV
?
).
Next we compute the cardiac out (CO) as 
2 2 2
( )AB VBO O OCO V C C? ?
?
.
We have derived the expressions for diffusion 
coefficients (i) 
2OD in terms of 2OV
?
 and the alveolar and 
venous partial pressures, 
2
al
OP  and 2
VB
OP  and (ii) 2COD in 
terms of 2COV
?
,
2
al
COP  and 2
VB
COP . The coefficients 
2OD and 2COD represent the gas transfer capacity of the 
lung. 
The paper provides a case study for the determination of 
Q,
2OD and 2COD . The derived information of 
2OD and 2COD as well as of O2 and CO2 metabolic rates can 
be of considerable clinical use including for SARS 
assessment. 
Keywords— gas exchange, O2 metabolic-rates, CO2
metabolic-rates, diffusion coefficients 
2OD , diffusion 
coefficients
2COD , blood flow rate
I. INTRODUCTION 
 The lung functional performance is characterized by (i) 
its ventilatory capacity, to bring air (and hence O2) into the 
alveoli, and (ii) its capacity to transfer O2 and CO2 into and 
from the pulmonary capillary bed. Hence, the O2 and CO2
diffusion coefficients 
2O
D and
2CO
D as well as the O2
consumption-rate and the CO2 production rate represent the  
lung performance indices. In this paper, we are 
demonstrating their evaluations. 
II. LUNG GAS-EXCHANGED MODEL 
Fig. 1 schematically illustrates the gas-exchange 
between the lung alveolus and the pulmonary capillary-
vasculature. Based on our earlier work [1, 2] the gas 
exchange between the alveolar air and pulmonary capillary 
blood is represented by the following 2O  and 2CO
conservation equations  and Fig. 2. 
22 2
VE VE AE AE
OO OQ C Q C V
?
? ?  (from the alveolar air to 
capillary blood) 
2
2 2
( )Oav
AE AE
O OQ C P D? ? ?               (1) 
22 2
VE VE AE AE
COCO COQ C Q C V
?
? ?
2
2 2
( )COav
AE AE
CO COQ C P D? ? ?                    (2) 
wherein 
(i) ABQ and VBQ  are arterial and venous blood flow-rates;    
(at venous end) (at arterial end),AB VE VB AEQ Q Q Q? ?
(ii)
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial 
pressures 
(iii)
2
al
COP  and 2
cap
COP  are the alveolar and capillary 2CO
partial pressure. 
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion 
coefficients
(v) 2
2 2
-average of ( ) over the capillary length;Oav
capal
O OP P P??
2
2 2
average of ( ) over the capillary lengthCO al capav CO OP P P? ??
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(vi) 
2
cap
OP = 2
PRB
OP  ( 2O  concentration of the pre-oxygenated 
blood) 
2
AE
OP?
(vii) 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre-
oxygenated blood) 
2
VE
COP?
(viii) 
2O
V
?
 is the 2O  transfer rate from alveolar air to 
capillary blood (= 2O consumption rate), 2COV
?
is the 2CO
transfer-rate from capillary blood to alveolar air (= 2CO
production rate). 
Now we can equate the arterial and venous blood flow 
rates, as AEQ ? ABQ = VBQ VEQ? = Q =(SV)/(EP) 
? / 60CO
SV, EP and CO being the stroke-volume, ejection-period 
and cardiac-output respectively. 
Fig. 1: Process of oxygenating the venous blood. 
The low oxygen (O2) concentration Red Blood Cell 
(RBC) is shown in dark blue. As it travels down the 
artery towards the venous end, the O2 concentration 
increases. After the distance L, its O2 has increased to 
0.18 from the initial concentration of 0.13. 
From equations (1) and (2): 
2 2
2 2 2 2
2
( ) ( )
( ) ( )
AB VB
O O
av av
VE AE
O O O O O
OPav
Q C C Q C C
P P
V
? ?
? ?
?
?
?? ?2O
D   (3) 
2
2 2
2
( )
( )
VE
CO
av
AB
CO CO CO
COPav
Q C C
P
V
?
?
?
?
??2
COD      (4) 
Fig. 2: Schematic of blood gas concentration in the 
Pulmonary Capillary. (Adapted from references [3] & [4]) 
III. CLINICAL DATA 
The monitored data consists of inspired and expired air 
gas compositions (TABLE 1) and 2O and 2CO
concentrations of arterial blood and venous blood (TABLE 
2). 
TABLE 1: Air Composition Analysis. Inspired and 
expired air composition and partial pressures are monitored. 
Assumed 
Breathing Rate (BR) = 12 breaths/min. Assumed 
2H O
P  at 
37?C = 47 mmHg. 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/%
N2 597 393.1 
78.55% 
566 393.1 
74.5% 
O2 159 104.2 
20.84% 
120 80.6  
15.7% 
CO2 0.3 0.2 
0.04% 
27 19.1  
3.6% 
H2O 3.7 2.5 
0.49% 
47 32.6  
6.2% 
Total 760 500 
100% 
760 525.3 
100% 
 TABLE 2:  Blood Gas Analysis. The monitored blood  
O2 and CO2 concentration . 
2O
C   of venous blood  (
2
VB
OC ) = 0.13 
2O
C of arterial blood  (
2
AB
OC ) = 0.18 
2CO
C  of venous blood (
2
VB
COC ) = 0.56 
2CO
C  of arterial blood (
2
AB
COC ) = 0.52 
IV. EXPRESSIONS FOR
2O
D AND
2CO
D
If we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 
2
al
COP , 2
cap
COP  in terms of monitorable quantities [1 & 2]. 
(i) alveolar 
2
al
OP can be expressed in terms of V
?
(the 
ventilation rate) and 2OV
?
(the 2O  consumption rate). 
*
2
 ; 
4.18
140 1
OV V
e
? ?
? ?
? ?
? ?? ?
? ?
?? ?? ?
? ?? ?
? ?
? ?? ?
2
al
OP      (5) 
wherein the normalized ventilation rate 
* 60 V V V Vm? ?
? ? ? ?
litres/min, is the consumption rate (in litres/min). 
(ii) alveolar 
2
al
COP  can be expressed in terms of V
?
 and 2OV
?
.
2
*2.19
107.18
COV V
e
? ?
? ?
? ?
? ?? ?
? ?
?
?alCO2
P                    (6) 
wherein 
2CO
V
?
 is  the 2CO production rate (in liters/min).  
(iii) Blood
2O
P can be obtained in terms of  blood 
2O
C , from 
the 2O  disassociation curve. 
2
0.230.5ln
0.2
B
B
OC
? ?
? ??
? ??? ?
O2
P              (7) 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
BC , from 
the 2CO  disassociation curve. 
2
0.837.94ln
0.8
B
B
COC
? ?
? ??
? ??? ?
CO2
P      (8) 
Now,
2O
P?
2 2 2 2
( )Capal al VBO O O OP P P P? ? ? ? and 2COP?
2
( VBCOP? - 2 )
al
COP  vary along the capillary bed. Based on [3], 
we have: 
2 20.185 max
O OP Pav ?? ?                   (9) 
2 20.1   max
CO COP Pav ?? ?            (10) 
Hence, from equations (3 & 9) and (4 &10), 
2 2
2 2 0.185( )
2 2
al VBP PP O O
O O
O O
av
V V
D ? ?
?
? ?
?
    (11) 
2 2
2 2 0.1( )
2 2
CO VB alP PPav CO CO
CO CO
CO
V V
D ? ?
?
? ?
?
    (12) 
V. EVALUATION OF O2 AND CO2 METABOLIC RATES AND
CARDIAC OUTPUT  
From monitored data of inspired-exhaled gas 
compositions, in TABLE 1: 
2O  consumption rate, 2OV
?
= BR(Inspired 2O - Expired 
2O )ml/min =12(104.2-80.6) = 283.2 ml/min               (13) 
2CO consumption rate, 2COV
?
=BR(Expired 2CO -Inspired 
2CO ) ml/min = 12(19.1-0.2)=226.8 ml/min                 (14) 
From monitored 2O  and 2CO concentrations of arterial and 
venous blood, in TABLE 2: 
? 2OV
?
= Q(
2O
C  of arterial blood - 
2O
C of venous blood)   
where Q=blood flow rate?cardiac output 
2 283.2 5664 /
(0.18 0.13) 0.05
OVQ ml min? ? ? ?
?
?
      
VI. EVALUATING OF THE LUNG DIFFUSION COEFFICIENTS 
2O
D AND
2CO
D
From equation (7) and TABLE 2 (
2
VB
OC =0.13), we get 
for 
(venous blood @ arterial end of the pulmonary capillary or 
2
VB
OP )
        
2
VB
OP =
2
0.230.5ln
0.2 VBOC
? ?
? ?
? ??? ?
               = 0.230.5ln
0.2 0.13
? ?
? ??? ?
               = 32.02 mmHg                       (15) 
From equation (8) and TABLE 2 (
2
VB
COC =0.56), we get 
for
2
VB
COP  (venous blood @ arterial end of the pulmonary 
capillary or 
2
VB
COP  ) 
2VB
COP =
2
0.8
37.94 ln
0.8 VBCOC?
? ?
? ?
? ?? ?
         = 
0.8
37.94 ln
0.8 0.56?
? ?
? ?? ?
       
         = 45.68 mmHg                          (16) 
Also, from equation (5) and TABLE 1 ( *V
?
=0.1), we get: 
? ?
*
2
0.1 0.2832
4.18
4.18
      140 108           (17)
140 1
1
OV V
mmHg
e
e
? ?? ?
? ?
? ?? ?
?
?
? ?
? ?
?
? ?
? ?
? ?
? ?? ?
? ?
? ?
2
al
OP
Hence, from equations (9, 15 & 17), we get: 
2 0.185 (108 32.02) 14.06         (18)Oavp mmHg? ? ? ??
Finally, from equations (11) and (18), we get: 
2
2 2
1
283.2 / min
14.06
       20.14  (19)-1
O
O O
av
ml
mmHgP
V
D
mlmin mmHg ?
? ?
?
?
?
Then from equation (6), TABLE 1 ( 0.1V ?
?
), and equation 
(12) we get: 
? ?
2
0.1 0.2268
2.19
2.19
*
          107.18 40.81               
107.18
(20)
COVV
mmHg
e
e
?
? ?
? ?
? ?
? ?
? ?
? ?
?
?
? ?
?
?
al
CO2
P
Hence, from equations (10, 16 & 20), we get: 
2 0.1 (45.68 40.81) 0.487         (21)COavp mmHg? ? ? ??
Finally, from equations (12 & 21), we get: 
        
2
2 2
226.8 / min
0.487
                           465.71              (22)
CO
CO CO
av
ml
mmHgP
-1 -1mlmin mmHg
V
D ? ?
?
?
?
VII. CONCLUSION
We have demonstrated a noninvasive clinical procedure  
? for obtaining (i) O2 consumption rate and CO2
production rate, (ii) cardiac output, Q, (iii) and 
lung diffusion capacities for  O2 and CO2.
? from inhaled and exhaled air composition 
analysis and blood-gas analysis.
This work could have application to SARS testing and 
evaluation.
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Abstract— The primary functions of the kidney are: (i) 
to get rid of the body waste materials that are either ingested 
or produced by metabolism, and (ii) to control the volume 
and composition of the body fluids. Herein, we provide a 
noninvasive methodology to assess physiological function 
of the kidneys. For this purpose, we analyze the renograms 
with 2-compartmental modelling of the kidney-renal 
outflow system, and therefrom compute the amount of flow 
of  renal radionuclide into and out of the renal pelvis 
compartment.  
The derived information of uptake (k/A) and washout 
( 22
t
Ve
??
sinhAt) rates can be of considerable use. The paper 
provides a number of case studies for the verification of the 
derived system governing equations against clinical 
renograms. 
Keywords— Renal outflow obstruction, renal
function, glomerular filtration rate, GFR
I. INTRODUCTION 
The kidney functional performance is characterized by (i) its 
filtering capacity, getting rid the body waste materials that 
are either ingested or produced by metabolism, and (ii) 
control the volume and composition of the body fluids. 
Renogram studies have been used for the assessment of 
renal function for many years [1, 2]. Mathematical 
modelling has been performed for the kidneys, such as one-
compartment model of clearance of tracer [3,4]. However, 
modeling of the tracer transport between renal parenchyma 
pool compartment and renal pelvis compartment; derivation 
of the governing equations for renogram curves has not been 
reported. Here, we note that the tracer uptake and washout  
rates can represent the performance indices. In this paper, 
we evaluate these rates and demonstrate their clinical 
relevance renogram data. 
II. RENAL PELVIS TWO-COMPARTMENTAL MODEL
Fig. 1: illustrates the region of interest (ROI) and we 
have derived the compartmental model for renal pelvis and 
shown in Fig. 2. 
Fig. 1: Control volume around the renal pelvis area.[5] 
1G : Tracer mass in the chamber 1 (renal parenchyma) in 
Counts.
2G : Tracer mass in the chamber 2 (renal pelvis) in Counts.
1C : Concentration of tracer in the chamber 1 in Counts/dL.
2C : Concentration of tracer in the chamber 2 in Counts/dL.
1V : Volume of chamber 1, renal parenchyma in dL.
2V : Volume of chamber 2, renal pelvis in dL.
( )I t : Tracer input function in Counts/sec.
F(t) : Blood Flow from chamber 1 to chamber 2 in dL/sec.
( )U t :Urine outflow in dL/sec.
Fig. 2: The derived two-compartmental renal model. 
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III. DERIVATION and PHYSIOLOGICAL SIGNIFICANCE of 
MODELING SOLUTIONS 
From Fig.. 2, we derive the following: 
1
1 ( )
dG FC I t
dt
? ? ? , for chamber 1     (1) 
2
1 2 ( )
dG FC C U t
dt
? ? , for chamber 2     (2) 
where (i) 1 1 1( )G C V?  represents the tracer amount in 
chamber 1,and (ii) 2 2 2( )G C V? represents the tracer amount 
in chamber 2. 
In physiological studies of kidney function and urine 
outflow status (renography), the input function is a tracer 
bolus administered over a short period of time. Compared to 
the entire duration of the renal dynamics, this bolus injection 
of tracer can be approximated by an impulse function 
(Dirac’s delta function). In the following derivation, 
whenever I(t) appears it will be assumed  be equal to I?(t).
We assume that the compartmental volumes V1 and V2
are constants (which they generally are), and the urinary 
flow rate U as unknown constant (urine flowing out of the 
kidney into the ureters is physiologically continuous and 
constant with time, unless there are changes in body fluid 
status). Here, we are only performing an intra-renal analysis 
for  obstruction to the outflow, we have from (1) and (2) : 
1 1
1 ( )
V dC FC I t
dt
? ? ?  (3) 
2 2
1 2
V dC FC C U
dt
? ?                                           (4) 
By differentiating and combining (3) and (4), we arrive at: 
2 2 2 2
1
2 2 2 2
1
( )
or,
( )                          (5)
FV C I t C C
V
FV C C C I t
V
? ?
? ? ?
? ?
? ? ?? ?
? ?
? ?
? ? ? ? ?
? ?
?? ?
?? ?
where:  
2
1 1
,                                (6)
FV FUU
V V
? ?
? ? ? ?
? ? ?? ? ? ?
? ? ? ?
The equation (5) is a standard form of a linear second-
order ordinary differential equation, with I(t) as the unit 
impulse function. This is the governing differential equation 
for the behavior of tracer within the renal pelvicalyceal 
compartment. 
Solution by Laplace transform method yields the 
following equations, given the initial conditions of C(0) and 
C’(0) = 0.
? ?
? ?
? ?
2
1
2
2 2
1
2 2
21 1 22
2 2
2
2
2 2
22 2
1 2
2
2 2 2 2
( )
( )
1 1( ) ( )
41       
4 2 4
FL V C C C L I t
V
FV s s C s
V
F FC t C t
V VVV s s s s
V V
V VF
VV
s
V V V V V
? ? ?
? ?
? ? ? ?
? ?
? ? ? ? ?
? ?? ?? ?? ? ? ? ?? ?
? ?? ?
? ?
? ? ? ? ? ?
? ?
? ? ? ?
? ? ?? ? ? ? ? ?? ?? ? ? ? ? ?? ?
? ?
? ?
?? ?
? ?? ?? ? ?? ? ? ?? ?? ?? ? ? ?? ?? ?? ? ? ?
?? ?
2
2
    (7)
? ?
? ?
? ?
Solving the above Laplace transform and taking care of 
the characteristics of the roots (which is now in standard 
form, by looking up standard tables), we obtain the results 
for the dynamic behavior of the tracer concentration in the 
renal pelvis for this physiological system. The term 
underneath the square root is the determinant of the behavior 
of the system with regards to whether there is underdamped, 
critical-damped or overdamped behaviour. 
This term can be expressed as 2 24V? ?? and it yields a 
significant functional index for assessing the outflow status 
of the kidney. We will classify the observed physiological 
behaviours of renogram systems into underdamped, 
overdamped or critically damped systems based on the 
index, as follows: 
Case 1:
If 2 24 0V? ?? ? ,  the condition is underdamping, and 
(7) yields the solution: 
2
2
2
22
1 2 2 2
2
2 2
1( ) sin
4
4
t
VFC t e t
V V V V
V V
? ? ?
? ?
?
? ?
? ? ? ?? ?? ? ? ?? ?? ?? ? ? ?? ? ? ?? ??? ?? ?
    (8)  
                k                1/A                     A
As can be seen from equation (8), the terms which 
describe urine outflow and determine the shape of the tracer-
concentration curve of the renogram during the tracer wash-
out phase are the 22
t
Ve
??
and
2
2
2 2
sin
4
t
V V
? ?? ?? ??? ?? ?
. The 
impartant dynamic  information captured in these two terms 
can be succintly found in the physiological index that we 
have described. We will demonstrate the discriminatory 
nature of this index (which will be extracted as A) in section 
IV when we analyse correlation with actual renogram 
studies. 
Equation (8) is a linear second-order ordinary 
differential equation, very similar to that of the linear 
oscillator with damping. In a functioning renal system, the 
characteristic oscillating-underdamped conditions do not 
exist.  
Case 2:
Whenever there is outflow obstruction, the key term 
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
and the condition is overdamping. Then,  
2
2
2
22
1 2 2 2
2
2 2
1( ) sinh
4
4
t
VFC t e t
V V V V
V V
? ? ?
? ?
?
? ?
? ? ? ?? ?? ? ? ?? ?? ?? ? ? ?? ? ? ?? ??? ?? ?
    (9) 
          k                1/A                     A
We can express output segment of the tracer curve of 
compartment 2 looks different from that of the tracer input  
2 2
2 2 2
2 2
1 1 1
4 4
FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
so the key term actually reflects the rate of tracer input 
(FC1) minus the rate of tracer output (UC2).
Case 3:
In the normal case, most physiological systems are 
well-compensated, and hence the output are fairly similar, 
hence,  
2 2
2 2 2
2 2
1 1 1
4 4 0FV FVFUV U V U
V V V
? ?
? ? ? ? ? ?
? ? ? ? ? ? ?? ? ? ? ? ?
? ? ? ? ? ?
In other words, the renal system is critically damped.  
The governing equations for this will be 
? ? 22
1 2
t
VFC t te
V V
??? ?
? ? ?
? ?
 (10) 
For model analysis, because of complications involved 
in monitoring U (urine flow rate), F (plasma flow rate into 
the renal pelvis) and V1 control volume, we propose that our 
model parameters will be lumped parameters k and A. Next 
our parameters identification will be carried out for k, A V2
and ?.
IV. CLINICAL DATA & EVALUATION 
We will demonstrate and verify the application of our 
models using the renograms obtained from the Nuclear 
Medicine and PET Department. The radionuclide used are 
99mTc-DTPA and 99mTc-MAG3.  The degree of match with 
the governing equations is based on the area under the left 
and right kidney curves against the clinical curves between 
60 and 120 seconds. 
Model Application:
We will first digitalize and normalized the renograms. 
Next, we will perform parameters identification and obtain 
the system parameters: k, A, ? and V2. We will only accept 
the results of the best fit. 
Fig. 3: Clinical renograms of volunteer coded 
Patient 7. Note that the (QR-RR) segment of the tracer 
curve for the right kidney is similar to the (PR-QR)
segment and demonstrates good outflow-rate compared 
to the (QL-RL) segment of the obstructative curve for the 
left kidney. 
TABLE 1: Comparison of clinical and calculated results. 
We  can observe that the errors for each kidney is less than 
1%.
Identity % Clincal 
Area Under 
the curves 
between 60 
to 120 sec. 
% Calculated 
Area Under 
the curves 
between 60 to 
120 sec 
% Error 
Left Right Left Right Left Righ
t
Patient 
7
44 56 43.87 56.13 0.29 -0.23 
Patient 
8
50 50 49.69 50.31 0.61 -0.61 
(obstructive)
QR
QL
P
RR
RL
(Minor 
obstructive) 
Fig. 4: Clinical renograms of volunteers Patient 8. 
The two kidneys have minor obstructions. 
V. RESULTS
We have performed parametric identification for 
equations (9) and (10) using MatLab 7. The following are 
the best fitted results for  patients 7 & 8. 
            
                                
Fig. 5: Simulated renograms of volunteer coded Patient 
7. The clinical data for both kidneys is best fitted by 
equation (9). The identified parameters are: 
L L 2L
R R 2R
0.0124; A 5.48E-03; 0.0107 and V 0.8664
0.0221; A 8.68E-03; 0.0103 and V 0.4928
L
R
k
k
?
?
? ? ? ?
? ? ? ?
 Fig. 6: Simulated renograms of volunteer coded Patient 
8. The clinical data for both kidneys is best fitted by 
equation (9).The identified parameters are: 
L L 2L
R R 2R
0.0221; A 7.61E-03; 0.0098 and V 0.4959
0.0221; A 8.59E-03; 0.0125 and V 0.6248
L
R
k
k
?
?
? ? ? ?
? ? ? ?
 TABLE 1 shows that the area under the curves from the 
simulation matches that of the clinical with an error less 
than 1%.  
VI. CONCLUSION 
We have demonstrated modeling of kidney-renal 
outflow tract compartments with derivation of the governing 
equations from second-order differential equations and 
assessed the clinical relevance with comparison with clinical 
renogram studies. 
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Introduction
? Biofeedback entails providing a person 
with information about his own on-going 
physiological processes through 
parameters such as EEG or QEEG, ECG, 
EMG, etc. 
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Types of Biofeedback
? There are two types of biofeedback 
systems: Volitional Feedback 
Systems (VBFS) and Non-Volitional 
Feedback Systems (NVFS). 
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Types of Biofeedback
? The VBFS require conscious effort to 
attain a desired physiological state. They 
hence cannot be used in the case of 
subjects who have mental dysfunction or 
mentally depressed. 
? The NVFS do not require subjects to be 
conscious.
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Objectives
? The NVFS  presented in this paper is 
designed for rehabilitation purpose. We 
will also present to you some results that 
we have gathered in our experiments with 
subjects with eyes opened with aids and 
eyes closed with and without aids.
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International 10-20-2. EEGs are taken at 19 
different channels to give us spatial & 
temporal information.
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The Lexicor system that our 
experiments were conducted with. 
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Screen snap shot of the EEG 
display 
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Screen shot of the QEEG 
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Experimental Results
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Experimental results of subjects. Note that alpha energies 
are greatest when eyes closed with the goggles active. 
The goggles are designed to flash at 10 Hz. It has been 
found that the Red super-bright LEDs are most efficient.
Results of V and W
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Application of the Concept
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Conclusions
? The above results have significant 
influence to the system we are designing 
for rehab purpose. 
? The details will be elaborated later in our 
next coming presentation. 
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Thank You
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Introduction
? The use of Virtual Reality (VR) to enhance 
rehabilitation is a relatively new concept. 
? The novel aspect of using VR as an 
evoked-psychological therapy for 
rehabilitation will cause a revolution in 
rehab technology.
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Objectives
? In this paper we will discuss some of these 
concepts. There may be some ideas that 
could be obscure to some of the audience, 
so we elicit an open mind.
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Concepts/Applications
? Firstly we would like to share with you the 
concept about stressed and relaxed mind. 
Next we would like to share with you how 
this concept can be incorporated into a 
rehabilitation system for spinal-cord 
injured patients.
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Deformed Mind’s Transcendence 
into a high-conscious environment.
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Evoked-Psychological 
Response to Initiate 
Rehabilitation Process
? When a person is under stress her/his 
mind is compressed and deformed as 
compared to a relaxed mind under a high 
consciousness level.
? This is especially so when the patients are 
undergoing long monotonous physical 
therapies without experiencing some 
definitive progress. 
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? Then this self-induced frustration acts as a 
positive feedback, further bringing down 
the consciousness level.
5/31/2006 Virtual Reality in Rehabilitation 8
Application of VR
? Our objective is to use VR to help conjure 
a curative and healthy environment, which 
can also bring her/him into a relaxed and 
higher consciousness level, which can be 
verified by examining the EEG alpha-wave 
energy-content. The amount of 
improvement is proportional to the 
increase in alpha wave density. 
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Spinal-Cord Injury Rehabilitation
? For Spinal Cord Injury (SCI) patients, the 
VR system will be designed to 
psychologically made the patient feel that 
the resected spinal cord reconnected, and 
there by the associated physiologically 
disordered (such as bladder control, 
temperature regulation, etc) are also 
remedied.
? For sitting and lying-down, we can design 
a mattress, of skin-breathing synthetic 
material. 
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Spinal-Cord Injury Rehabilitation
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Spinal-Cord Injury Rehabilitation
? The mattress will be designed as a 
controllable pneumatic bed with turbulence 
generators. 
? The waves will act as physiotherapists’
fingers, giving massage. The warm fluid 
with the massage can facilitate blood flow 
to the patient and reduce sustained-
pressure bed-ridden related skin diseases.
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Spinal-Cord Injury Rehabilitation 
System Block Diagram
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SSREFS
? Additionally, a Sympathetic Signal-
Reinforcing EEG Feedback System 
(SSREFS) will be designed to extract 
alpha signals and filter beta signals from 
the EEG. The extracted alpha signals can 
be fed into patient’s spinal cord, to 
stimulate cerebral-neuronal growth.
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Conclusions
? For paraplegic patients,  the VR would be 
employed to make the patient feel that 
she/he is ambulatory, and that autonomic 
system is reconnected and working, so 
that the patient can void independently 
and feel the outside temperature so the 
VR will help the patient develop a strong 
will power to be cured and adopt 
independent living mood.
85/31/2006 Virtual Reality in Rehabilitation 15
Thank You
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Abstract— The primary function of the lung is to (i) 
oxygenate the blood and thereby provide oxygen to the 
cells for metabolization purposes, and (ii) to remove the 
collected CO2 from the pulmonary blood. Herein, we 
provide a noninvasive methodology to asses physiological 
metabolic rates as well as blood-oxygenation capacity of 
the lung. For this purpose, we analyze the compositions 
of the inspired and expired air per breath, and 
therefrom compute the metabolic O2 consumption and 
CO2 production rates.  
Next, we derive expressions for diffusion coefficients 
2OD and 2COD , in terms of the evaluated cardiac-output 
CO, O2 and CO2 concentrations in arterial and venous 
blood as well as alveolar and blood O2 and CO2 partial-
pressures. The coefficients 
2OD and 2COD represent the 
lung  capability to oxygenate the blood. We can then also 
determine the cardiac output, from knowing the 
concentrations of oxygen and carbon dioxide in the 
arterial and venous bloods.  
The derived information of 
2OD and 2COD as well as 
of O2 and CO2 metabolic rates can be of considerable use 
(including for SARS assessment). The paper provides a 
case study for the determination of  Q, 
2OD and 2COD . 
 
Keywords— gas exchange, O2 metabolic-rates, CO2  
metabolic-rates, diffusion coefficients 
2OD , diffusion 
coefficients 
2COD , blood flow rate 
 
 
I.  SCOPE 
 
 The lung functional performance is characterized by (i) 
its ventilatory capacity, to bring air (and hence O2) into the 
alveoli, and (ii) its capacity to transfer O2 and CO2 into and 
from the pulmonary capillary bed. Hence, the O2 and CO2 
diffusion coefficients 
2O
D and 
2CO
D as well as the O2 
consumption-rate and the CO2 production rate represent the 
lung performance indices. In this paper, we are 
demonstrating their evaluations. 
 
 
 
 
 
II LUNG GAS-EXCHANGED MODEL 
Figure 1 schematically illustrates the gas-exchange 
between the lung alveolus and the pulmonary capillary-
vasculature. Based on our earlier work [2] the gas exchange 
between the alveolar air and pulmonary capillary blood is 
represented by the following 2O  and 2CO  conservation 
equations  and Figure 2. 
 
22 2
VE VE AE AE
OO OQ C Q C V
°
= +  (from the alveolar air to 
capillary blood) 
2
2 2
( )Oav
AE AE
O OQ C P D= + ∆               (1) 
22 2
VE VE AE AE
COCO COQ C Q C V
°
= −  
  2
2 2
( )COav
AE AE
CO COQ C P D= − ∆                    (2) 
wherein 
(i) ABQ and VBQ  are arterial and venous blood flow-rates;    
(at venous end)  (at arterial end) ,AB VE VB AEQ Q Q Q= =
 
(ii) 
2
al
OP and 2
cap
OP  are the alveolar and capillary 2O partial 
pressures 
(iii) 
2 2
 2and are the alveolar and capillary partial pressure  
al cap
CO COP P CO
 
(iv) 
2OD and 2COD  are the 2O  and 2CO  diffusion 
coefficients 
(v) 2
2 2
- average of ( ) over the capillary length;Oav
capal
O OP P P=+  
2
2 2
average over the capillary length of ( ) CO al capav CO OP P P= −+
 
(vi) 
2
cap
OP = 2
PRB
OP  ( 2O  concentration of the pre-oxygenated 
blood) 
2
AE
OP=  
(vii) 
2
cap
COP = 2
PRB
COP  ( 2CO  concentration of the pre-
oxygenated blood) 
2
VE
COP=  
Determination of O2 & CO2 Metabolic-Rates and Lung O2 & CO2 Diffusion 
Coefficients, form on the Data of Inspired and Expired Air Compositions 
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(viii) 
2O
V
a
 is the 2O  transfer rate from alveolar air to 
capillary blood (= 2O consumption rate), 2COV
a
is the 2CO  
transfer-rate from capillary blood to alveolar air. 
 
Now we can equate the arterial and venous blood flow rates, 
as  
AEQ = ABQ = VBQ VEQ= = Q =(SV)/(EP)  / 60CO  
SV, EP and CO being the stroke-volume, ejection-period 
and cardiac-output respectively. 
 
 
 
Figure 1: Process of oxygenating the venous blood. The low 
oxygen (O2) concentration Red Blood Cell (RBC) is shown 
in dark blue. As it travels down the artery towards the 
venous end, the O2 concentration increases. After the 
distance L, its O2 has increased to 0.18 from the initial 
concentration of 0.13. 
 
 
 
Figure 2: Schematic of blood gas concentration in the 
Pulmonary Capillary. 
 
III. CLINICAL DATA 
 
The monitored data consists of inspired and expired air gas 
compositions (Table 1) and 2O and 2CO  concentrations of 
arterial blood and venous blood (Table 2). 
 
Table 1: Air Composition Analysis. Inspired and expired air 
composition and partial pressures are monitored. Assumed 
Breathing Rate (BR) = 12 breaths/min. Assumed 
2H O
P  at 
37οC = 47 mmHg. 
 
Atmospheric Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/% 
N2 597 393.1 
78.55% 
597 393.1 
74.52% 
O2 159 104.2 
20.84% 
84.5 83.37  
15.7% 
CO2 0.3 0.2 
0.04% 
29 16.87  
3.20% 
H2O 3.7 2.5 
0.49% 
49.5 34.15  
6.47% 
Total 760 500 
100% 
760 527.49 
100% 
 
  
Table 2:  Blood Gas Analysis. The monitored blood  O2 and 
CO2 concentration . 
2O
C   of venous blood  (
2
VB
OC ) = 0.13 
2O
C   of arterial blood  (
2
AB
OC ) = 0.18 
2CO
C  of venous blood (
2
VB
COC ) = 0.5 
2CO
C  of arterial blood (
2
AB
COC ) = 0.46 
 
IV. EXPRESSIONS FOR 
2O
D AND 
2CO
D  
If we want to evaluate the diffusion coefficients 
2OD and 2COD , we need to also express 2
al
OP , 2
cap
OP  and 
2
al
COP , 2
cap
COP  in terms of monitorable quantities [1 & 2]. 
 
(i) Alveolar 
2
al
OP can be expressed in terms of V
°
(the 
ventilation rate) and 2OV
°
(the 2O  consumption rate). 
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*
24.18
 ;                                 (3)
*wherein the nomalised ventilation rate,  60 
 is  the  consumption rate (in liters/min).
140 1
OV V
V V V Vm
litres/min, 
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
= =
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
a a a a
2
al
OP
 
(ii) Alveolar 
2
al
COP  can be expressed in terms of V
°
 and 
2OV
°
. 
22.46 *
114.68
COV V
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
−
=alCO2P             (4) 
wherein 
2CO
V
a
 is  the 2CO production rate (in liters/min).  
 
(iii) Blood
2O
P can be obtained in terms of  blood 
2O
C , from 
the 2O  disassociation curve. 
 
2
0.2
29.72 ln
0.2 BO
B
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦O2
P        (5) 
(iv) Blood 
2CO
P can be obtained in terms of 
2CO
BC ,from 
the 2CO  disassociation curve. 
 
2
0.8
29.72 ln
0.8 BCO
B
C
= −
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦CO2
P      (6) 
Now, 
2 2 2 2
( )Capal al VBO O O OP P P P= − = −  both 2OP+ and 2COP+  
2 2
)( VB alCO COP P= −  vary along the capillary bed. Based on [3], 
we have: 
2 2
max0.185
OOP Pav =+ +        (7) 
2 2
max0.1   
COCOP Pav =+ +        (8) 
From the above expressions, we obtain: 
2 2
2 2 0.185( )
2 2
O O
O O
av
al VBP PP O O
V V
D = = −
a a
+
     (9) 
2 2
2 2 0.1( )
2 2
CO CO
CO CO VB alP PPav CO CO
V V
D = = −
a a
+
    (10) 
 
 
V.  DETERMINATION OF O2 AND CO2 METABOLIC 
RATES AND CARDIAC OUTPUT 
 
From monitored data of inspired-exhaled gas compositions, 
in Table 1: 
 
2O  consumption rate, 2OV
a
= BR(Inspired 2O - Expired 
2O )ml/min =12(104.2-83.37) = 250 ml/min               (11) 
 
2CO consumption rate, 2COV
a
=BR(Expired 2CO -Inspired 
2CO ) ml/min = 12(16.87-02)=200 ml/min                  (12) 
 
From monitored 2O  and 2CO concentrations of arterial and 
venous blood, in Table 2: 
 
∵ 2OV
a
= Q( 2CO  of arterial blood - 2CO of venous blood)   
 
where Q=blood flow rate≡cardiac output 
 
2 250 5000 /
(0.18 0.13) 0.05
OVQ ml min∴ = = =−
a
      
  
VI. EVALUATING OF THE LUNG DIFFUSION 
COEFFICIENTS 
2O
D  AND 
2CO
D  
From equation (3) and Table 2 (
2
AB
OC =0.18), we get for 
(arterial blood @ venous end of the pulmonary capillary or 
2
VE
OP )  
        
2
AB
OP =
2
0.2
29.72 ln
0.2 ABOC−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
 
       = 
0.2
29.72 ln
0.2 0.18−
⎡ ⎤⎢ ⎥⎣ ⎦   
      = 68.43 mmHg                        (13)                        
 
 
From equation (5) and Table 2 (
2
VB
OC =0.13), we get for 
2
VB
OP  (venous blood @ arterial end of the pulmonary 
capillary or 
2
AE
OP  ) 
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2
VB
OP   =  
2
0.2
29.72 ln
0.2 VBOC−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
 
       = 
0.2
29.72 ln
0.2 0.13−
⎡ ⎤⎢ ⎥⎣ ⎦            
      = 31.20 mmHg                  (14)         
           
 Also, from equation (3) and Table 1 ( *V
a
=0.1), we get: 
 
[ ]
*
2
0.1 0.25
4.18
4.18
      140 113                          (15)
140 1
1
OV V
mmHg
e
e
° °⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
−
−= =
= −
−
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎣ ⎦
2
al
OP
 
         
Hence, from equations (14 & 15), we get: 
 
2 0.185 (113 31.2) 14.95Oavp mmHg= × − =+               (16) 
 
Finally, from equations (11) and (16), we get: 
 
2
2 2
1
250 / min
14.95
       16.72     (17)                            -1
O
O O
av
ml
mmHgP
V
D
mlmin mmHg−
= =
=
a
+  
                      
From equation (6) and Table 2 (
2
VB
COC =0.5), we get: 
2
          29.15                     (18)
0.8
29.72 ln
0.8
0.8
29.72 ln
0.8 0.5
VB
CO
VB AE
mmHg
C
=
= =
= −
−
⎡ ⎤⎢ ⎥⎢ ⎥⎣ ⎦
⎡ ⎤⎢ ⎥⎣ ⎦
CO CO2 2
P P
       
Then from equation (4), Table 1 ( 0.1V =
a
), and equation 
(12) we get: 
[ ]
2
0.1 0.2
2.46
2.46
*
33.52                                (19)
114.68
114.68
COVV
mmHg
e
e
°
⎡ ⎤⎢ ⎥⎢ ⎥⎢ ⎥⎢ ⎥⎣ ⎦
−
−= =
=
a
al
CO2
P  
         
 
Hence, from equations (8, 18 & 19), we get: 
 
2 0.1 (33.52 29.15) 0.44COavp mmHg= × − =+           (20) 
     
Finally, from equations (10 & 20), we get: 
2
2 2
200 / min
0.44
                           454.55                     (21)
CO
CO CO
av
ml
mmHgP
-1 -1mlmin mmHg
V
D = =
=
a
+                             
VII.  CONCLUSION 
 
We have demonstrated a noninvasive clinical procedure:  
• for obtaining (i) O2 consumption rate and CO2 
production rate, (ii) cardiac outflow-rate or 
output, Q, (iii) and lung diffusion capacities for  
O2 and CO2. 
• from inhaled and exhaled air composition 
analysis, and blood-gas analysis. 
This work could have application to SARS testing and 
evaluation. 
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Abstract— This paper provides a systems-engineering 
analysis of the glucose-insulin responses to an ingested 
bolus of glucose for OGTT (Oral Glucose Tolerance 
Test). The clinical data of patients is fitted by either 
under-damped or over-damped or critically-damped 
solutions of the model’s governing equations for glucose 
and insulin responses to glucose bolus ingestion. Based 
on the best fit of the three types of solutions, we 
designate the patients (and their response) to be normal 
(and under-damped), diabetic (and over-damped) and 
either border-line or at-risk of becoming diabetic (and 
critically-damped). In this way, the model simulation of 
the clinical data enables more reliable diagnosis relative 
to the clinical assessment. 
  
 
Keywords—diabetic, systems-engineering model, under-
damp, over-damp, critically-damped, R-square, fitting, clinical 
diagnosis  
 
I.  INTRODUCTION 
 
Oral Glucose Tolerance Testing Protocol 
 The test subjects need to fast for 12 hours before the test 
and during the 2-hour test. A blood sample of the subject is 
taken before the beginning of the test. Then after the subject 
drinks a 75 g of glucose solution dissolved in 250–300 mL 
of water, the subject’s blood glucose and insulin 
concentrations are measured at specified intervals 30 
minutes, 60 minutes, 90 minutes and 120 minutes [1, 2, 4]. 
Qualitative interpretation of the results, for preliminary 
categorization of the patients [1, 2, 4]: 
(a) Blood glucose normal values:  
fasting: 70 to 115 mg/dl  
30 min.: less than 200 mg/dl 
1 hour : less than 200 mg/dl 
2 hour : less than 140 mg/dl  
(b) Normal insulin level (reference range): 1-30 mU/L 
When a person has a fasting glucose equal to or greater 
than 110 mg/dl and less than 126 mg/dl, it is considered as  
impaired fasting glucose. This is considered a risk factor 
for future diabetes and will likely trigger another test in the 
future, but, by itself, does not make the diagnosis of 
diabetes. 
A person is said to have impaired glucose tolerance 
when the 2-hour glucose results from the oral glucose 
tolerance test are greater than or equal to 140 but less than 
200 mg/dl.  This is also considered a risk factor for future 
diabetes. A person has diabetes when oral glucose tolerance 
tests show that the blood glucose level at 2 hours is equal to 
or more than 200 mg/dl.  This must be confirmed by a 
second test (any of the three) on another day.  
 
II. SYSTEM SOLUTIONS FOR DIABETIC, NON-
DIABETIC AND AT-RISK PATIENTS 
 
The governing differential equation for glucose response to 
glucose bolus intake is: 
 
( )y q t x yγ δ′ = − −                                          (1) 
The governing differential equation for insulin response to 
glucose bolus intake is: 
 
( ) -x p t x yα β′ = +          (2) 
 
y(t) : Glucose response of the patient to the oral bolus of    
glucose. 
x(t) : Insulin response of the patient due to y(t). 
 
Solution For Underdamped Case (non-diabetic): 
y(t) = (G/ ω) e-At sinωt                (3) 
 
( )
( )(sin( )
( )sin( )
( ) ( )cos( ) )
( ) 2 2 22
Atwt Ae
Atwt e
t Ate w wt e w
G
wx t
A A w
α
α
β
α α
−⎡ ⎤−⎢ ⎥−⎢ ⎥−⎢ ⎥− −⎢ ⎥− +⎢ ⎥⎢ ⎥×⎢ ⎥⎣ ⎦=
− + +
            (4) 
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Solution For Overdamped Case (diabetic): 
 G -Aty(t)= e sinhwt
ω
                    (5)     
 
  
1 (cosh( ) sinh( )
2
cosh( ) sinh( )
sinh( ) cosh( )
sinh( ) sinh( )
cosh( ) cosh( )
cosh( ) 2
sinh(
( )
wt At t A wt At t A
wt At t A wt At t A
wt At t w wt At t w
wt At t wt At t
wt At t wt At t w
wt At t w
wt
x t
α α
α α
α α
α α α α
α α α
α α
+ − + − + −
− − + − − + −
+ − − − − + −
− − − − + + −
− + − − − −
+ − + − +
+ −
= ( )
( )
2 2 2
) )
2
t GAt t w e
w
w A A
αα β
α α
−
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟⎜ ⎟+ −⎜ ⎟⎝ ⎠
− + − +
(6) 
 
Solution For Critically Damped Case (at the dangerous 
boundary): 
 
-Aty(t)= Gte                     (7) 
( ) ( ) ( ) ( )( )
( ) 2( )
At At At tG tAe t e e e
x t
A
αβ α
α
− − − −− − + −=
−
 (8) 
 
III.  CLINICAL APPLICATION AND DISCUSSION 
 
Under-damped Category and Normal Designated Patient 
 
These y(t) and x(t) response solutions are fitted to the 
monitored glucose and insulin data, and the fitness 
coefficients are determined. Based on the high degree of fit, 
patient S14 fits best the under-damped category, and hence 
is designated to be normal.  His Glucose and Insulin 
responses, shown in Figure 1, illustrates the fast recovery of 
blood glucose and insulin concentrations.  
 
 
The below table displays the values of the model parameters 
and the R-Square coefficients of fitness and the model slution 
to the clinical data. 
 
 
Figure 1: Patient S14 is designated to be under-damped and 
normal. However, this patient is quite hyper-insulinemic; in 
other words, this patient has elicited considerable insulin 
response in order to maintain an under-damped glucose 
response. 
Over-damped Category of Patients Designated as Diabetic 
 
     For patients D05, our over-damped model solution fits the 
clinical data best of the 3 solution categories. Hence, this 
patient is designated to be diabetic. His Glucose and Insulin 
responses are shown in Figure 2, and the model parameters are 
given in the Table. 
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Figure 2: This patient D05 has the higher R-Square value when 
fitted by the over-damped solution, and is hence classified as 
diabetic. 
 
Critically-damped Category of Patients 
 
There are some patients clinically diagnosed to be 
normal for which the critically-damped solution gives a 
better fit of the data (and a higher value of R-Square) than 
the under-damped solution. One such patient is S04, whose  
under-damped and critically-damped model response-curves 
are shown in Figures 3 and 4. Similarly, patients S06 and 
S19 are not normal as clinically diagnosed, but at the risk of 
becoming diabetic. Their response curves are illustrated in 
Figures 5 and 6. 
 
 
 
 
 
Figure 3: This S04 patient’s data is fitted by the under-damped 
solution. Next, we will compare the results fitted by the 
critically-damped solution as shown in the following figure. 
 
 
 
 
Figure 4: This S04 patient’s data is better fitted (i.e. at higher 
R-Square value) by the critically-damped solution than by the 
under-damped solution. Because of the critically-damped 
model solution giving us a better fit (terations of a higher 
value of R-Square), we differ from the clinical diagnosis and 
alert this patient that he is at risk at becoming diabetic. 
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Figure 5: This S06 patient’s data is better fitted (i.e. at higher 
R-Square value) by the critically-damped solution than by the 
under-damped solution. Hence, we will differ from the clinical 
diagnosis and designate this patient to be at risk of becoming 
diabetic. 
 
 
 
 
Figure 6: This S19 patient’s response curves are best fitted 
(with a higher value of  R-Square) by the critically-damped 
solution than by the under-damped solution. 
 
 
V.  CONCLUSION 
 
We have shown that we can obtain more accurate 
assessment of diabetic patients by means of our under-
damped, over-damped and critically-damped simulation 
model solutions. Some patients (diagnosed to be normal) 
were designated by us to be in the borderline category. 
However, some patients who were clinically declared to be 
diabetic turned out to be only border-line. As we continue 
this work, we will develop a clinically-implementable 
software for model parameter identification and designation 
of the subjects as normal or at-risk of becoming diabetic or 
border-line diabetic or distinctly diabetic.  
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Sathappan K., Chian K.S., Chua L.P. 
 
• Porous Beta-TCP and Its 
Modification with PLGA Coating 
for Bone Regeneration 
Miao X. and Kurniawati T. 
 
• In vitro Study on the Release 
Kinetics of Bovine Serum 
Albumin (BSA) from Injectable 
PLGA/BB Depot 
Wang L.W., Venkatraman S. 
 
• Effects of Plasticization on 
Heparin Release from 
Biodegradable Matrices 
Tan L.P, Venkatraman S., Sung P.F., 
Wang  X.T., Wong P. 
 
o Porous Bioinert Alumina 
Prepared by Vacuum Infiltration 
Liu J., Ng M.Y., Loh K.H., Hu Y., 
Miao X. 
 
• Clinical Applications of 
Magnetic Nanomaterials 
Ramanujan R. V. 
 
• Biomechanics Highlights in 
Sports, Physiology and Medicine 
Ghista D.N. 
 
• Evolution and Biomechanics of 
the Cruciate Ligaments 
Fuss F.K. 
 
• The Double-Bundle ACL Graft 
Reconstruction: A superior 
technique to restore knee 
kinematics 
Lie D.T.T., Amis A. 
 
• Finger Pulley Injuries are Self-
Propagating: A Mathematical 
Analysis of the A2-Pulley 
Tan M.A., Fuss F.K., Niegi G. 
 
• A Comparative Study of 
Different Gripping Methods for 
Tendons 
Ng B.H., Chou S.M., Krishna V. 
 
• Statistical Analysis of Human 
Metacarpal Morphology using 
CT Scan Data 
Zhai L.Y., Chou S.M., Lim B.H., 
Chong A., Tsou I., Ng S.Y. 
 
• Mechanics and Finite Element 
Analysis of the Auditory 
Ossicles 
Ho K.L.I., Fuss F.K. 
 
• Foot Characterization and 
Anatomical Landmarks 
Localization 
Liu X., Kim W.D., Drerup B. 
 
• A Case Study on Pattern-based 
Systems for Computational 
Biology 
Liu W., Schmidt B. 
 
• A Grid Implementation of 
Database Searching 
Chen C., Schmidt B. 
 
• The Use of Computer Modelling 
to elucidate the Efficacy of Slit 
Arteriortomy for End-to-side 
Arterial Anastomosis in 
Microsurgery 
Chua A.W.C, Gu H., Tan B. K., Chew 
W., Li J.Z., Song C.  
 
• A Mixed SVM-Based 
Hierarchical Learning Approach 
for Abnormal ECG Beat 
Recognition 
Li P., Chan K.L., Chan Y.W. 
 
• Capturing Cellular Life In-Silico 
Dhar P.K. 
 
• Finite Element Modeling of the 
Human Brain with Detailed 
Anatomy for Surgery Simulation 
Based on a Brain Atlas 
Gao C., Tay F.E.H., Nowinski W.L. 
 
• Fuzzy c-Means and Neural 
Network Framework for 
Arrhythmia Classification 
Chaudhari N.S., Liew C.S.  
 
• VRML Modeling for Bio-
Molecular Structures 
Indhumathi C., Lu B.F., Cai Y.Y. 
 
• BioSequence Comparison for 
Large Database on 
Reconfigurable Platforms 
Wong M.T., Schmidt B. 
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Day 2 (continued) 
Session 08A Cardiovascular 
Engineering 1 (Room 1) 
1330 – 1530 
Chair: A.C. Ritchie 
Session 09A Sport Engineering 1 
(Room 2) 
1330 – 1530 
Chairs: W. Kim, F.K. Fuss 
Session 07B Computational 
Bioengineering 2 (Room 3) 
1330 – 1415 
Chair: B. Schmidt 
• Clustering Based Watershed 
Segmentation for Two-
Dimensional Gel 
Electrophoresis Image 
Diao X. N., Mao K. Z.  
 
• Estimating error-dimensionality 
relationship for gene 
expression based cancer 
classification 
Chu F., Wang L. 
 
• Finite Element Analysis of Brain 
for Neurosurgical Procedure 
Roy A., Nowinski W.L., Tay F.E.H.  
 
Session 10A Ultrasonic Imaging 1 
(Room 3) 
1415 – 1530 
Chair: M. Kezhi 
• A Decoupled Control Method 
for the Magnetic Bearings of a 
Blood Pump 
Lim T.M., Zhang D., Kim M.T.  
 
• An Immersed Membrane 
Method For Simulation of Fluid-
Structure Interaction in Bio-
Fluid Flows 
Xia G.H., Zhao Y., Yeo J.H., Tai C.H.  
 
• Computation of Gap Flow Field 
in a Bio-Centrifugal Blood 
Pump 
Chua L.P., Song G. L., Yu S.C.M.  
 
• Computational Studies of 
Steady Flows In Designed 
Sleeve Models At Distal 
Anastomoses 
Chua L.P., Tong J.H.  
 
• Contractility of the Left 
Ventricle in Terms of its 
Sacromere Power Generation 
Zhong L., Ghista D.N., Ng E.Y.K  
 
• Detection of Cardiac Arrhythmia 
using Phase Space Analysis 
Wong M. T., Srinivasan N., Chan 
Y.W. 
 
• Flow Studies in Aorto-Right 
Coronary Bypass Graft System 
Meena S, Chua  L P, Ghista D N, Tan 
Y S 
 
• LV Twisting Analyzed for 
Pressure-Increase During Iso-
Volumic Contraction 
Liu L, Yeo S.Y., Ghista D.N., Chua 
L.P., Chai G.B., Tan Y.S., Tan R.S. 
• Quantitative analysis of 
Singapore Golfers 
Lim S. L., Xie X., Ong V., Teh K. C.  
 
• Three-Dimensional Kinematics 
Study of Left Hand During Golf 
Swing 
Teu K. K., Kim W., Fuss F. K., Tan J.  
 
• Investigation of Weight Transfer 
during Golf Swing 
Teu K. K., Kim W., Fuss F. K., Tan J.  
 
• Biomechanics of Push-up 
Exercise and Triceps 
Contractility 
Tan M. A., Zhong L., Fuss F. K., 
Ghista D. N.  
 
• Comparison of Pinch- and Open 
Hand Grip during Sport 
Climbing 
Yap Y. H., Fuss F. K., Niegl G., Tan 
M. A.  
 
• Friction at the Climbing 
Handhold under Different 
Conditions and its Implications 
for Sport Climbing 
Tan M. A., Fuss F. K., Niegl G.  
 
• Finger Load Distribution During 
Sport Climbing 
See W. N. W., Fuss F. K., Niegl G., 
Yap Y. H.  
 
• Analysis of Badminton Smash 
Using Dual Euler Angles 
Algorithm 
Liu X., Teu K. K., Kim W., Tan J., 
Fuss F. K.  
 
• Medical Ultrasound Imaging: 
Current Status and Future 
Trends 
Yoo Y.M., Kim Y.M. 
 
• Reconfigurable and 
Programmable Architecture for 
Digital Receive Beamformer 
Schneider F.K., Yoo Y.M., Agarwal 
A., Kim Y.M. 
 
• Adaptive  Speckle Reduction 
Based on Nakagami 
Distribution in Medical 
Ultrasound Imaging 
Zhang L.C., Wong E.M.C. 
 
• Specific Homomorphic 
Nonlinear Diffusion for Speckle 
Reduction in Ultrasound B-
mode Images 
Zhang F., Koh L.M. 
 
• Design and Optimization of 
Broadband Ultrasonic Sparse 
Array Transducers for Medical 
Imaging Applications 
Wang Q. B., Guo N. Q.  
 
Tea Break 
1530 -1545 
 
Day 2 (continued) 
Session 08B Cardiovascular 
Engineering 2 (Room 1) 
1545 – 1645 
Session Chair:  A.C. Ritchie 
Session 09B Sport Engineering 2 
(Room 2) 
1545 – 1630 
Chairs: B. Tan, K.C. Teh 
Session 10B Ultrasonic Imaging 2 
(Room 3) 
1545 – 1645 
Chair: M. Kezhi 
• Multiple-Model Adaptive Control 
by Means of a Fuzzy Controller-
based Control System 
Zheng H., Zhu K. Y., Tan Y. S.  
 
• Numerical Investigation of 
Hemodynamics for the 
Coronary Artery Bypass Graft 
Model 
Chua L.P., Zhang J.M., Zhou T.M., 
Yu S.C.M., Ghista D.N., Tan Y.S. 
 
• Numerical Investigation of 
Stress Field in Distal End-to-
side Anastomoses 
Liu L., Chua L.P., Ghista D.N., Tan 
Y.S. 
 
• PIV Measurements on the 
Pulsatile Flow Characteristics in 
45-degree Backward Proximal 
Anastomosis 
Ji W.F., Chua L.P., Yu S.C.M.,  
Ghista D. N., Zhou T. M., Tan Y. S.  
 
• Determinants of Maximal Hiking 
Performance in Laser Sailors 
Tan B., Aziz A.R., Spurway N.C, Toh 
C., Mackie H., Xie W., Wong J., Fuss 
F.K., Teh K.C. 
 
• Comparative Study on the 
techniques of Singapore and 
Thailand Table Tennis players 
during SEA Games 2001 
Lee K.T., Xie W., Teh K.C.  
 
• Experimental Study on Different 
Types of Service Spins for 
Singapore National Table 
Tennis players 
Lee K.T., Xie W.  
• Field of View-based Imaging for 
Efficient Beamforming in Low-
end Portable Ultrasound 
Systems 
Agarwal A., Schneider F.K., Yoo 
Y.M., Kim Y. 
 
• Low Sampling Frequency 
Digital Beamformer for 
Ultrasonic Imaging without 
Interpolation 
Gao C.Q., Zhang L.C., Wong E.M.C. 
 
• Comparative Evaluation of 
Wavelet Filters for Speckle 
Reduction in Ultrasound 
Medical Images 
Thakur A., Anand R.S. 
 
• Window Function Optimization 
by Genetic Algorithm for 
Ultrasound Imaging System 
Cao J., Koh L.M. 
Session 11 Respiratory 
Biomechanics (Room 1) 
1645 – 1730 
Chair: V. V. Kulish 
Session 12A Orthopaedic 
Engineering 1 (Room 2) 
1630 – 1745 
Chairs: S.M. Chou, D.T.T. Lie 
Session 13A Biosignal Processing 
1 (Room 3) 
1645 – 1745 
Chair: O. Chutatape 
• Determination of O2 and CO2 
Metabolic Rates and Lung O2 
and CO2 Diffusion Coefficients 
Loh K.M., Ghista D.N.  
 
• Oxygen Saturation Profiles in a 
Hollow Fibre Oxygenator 
Ritchie A.C., Thimm G.  
 
• Graphical Technique for 
Assessing Pulmonary Disease 
Loo C. M., Ang K. C., Ong J. H., 
Ghista D. N., Lim G. H.  
 
• Design Optimisation in 
BioMedical Engineering 
Koh E.C.Y., Fuss F. K. 
 
• Design Classification and 
Mechanics of Artificial Discs 
Fuss F.K.  
 
• Extraforaminal Lumbar 
Interbody Fusion: Simulation of 
the Fusion Process Based on 
Different Implant Materials 
Fuss F. K., Sabitzer R. J.  
 
• FE Investigation on Spinal 
Interbody Fusion 
Lee K. K., Teo E. C., Fuss F. K., 
Sabitzer R. J.  
 
• Optimization of Cervical Ring 
Cage by Taguchi Philosophy 
Yang K., Teo E. C., Fuss F. K.  
 
• A Novel Approach to Automatic 
Left Ventricular Contour 
Tracking 
Cheng J.R., Foo S.W. 
 
• A Novel Wavelet Based ECG 
Compression with X-tree 
Coding 
Swain S., Chutatape O., Dandapat S. 
 
• Left Ventricular Surface 
Kinematics During Isovolumic 
Contraction 
Yeo S.Y.,Tan R.S., Liu L., Chai G.B., 
Ghista D.N. 
 
• Evaluation of Slice Sensitivity 
Profiles for TPRF Algorithm 
Yan M., Zhang C.S. 
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Scientific Programme – DAY 3 
 
Friday, September 10 2004 
 
0830-0900 
 
Biological Resurfacing of Articular Cartilage – from Bench to Bedside 
Invited Speaker: Dr. Lee Eng Hin 
 
0900-0930 
 
Virtual Reality, Augmented Reality and its Medical Application 
Invited Speaker: Dr. Uli Bockholt 
 
0930-1000 
 
Vital Signs in the Real World 
Invited Speaker: Mr. Stephen Wilson 
 
1000-1030 
 
Clinical Endoscopy System: Present and Future 
Invited Speaker: Dr. Tsuneo Hidaka 
 
1030-1045 Tea break 
 
 
Session 14 Biosensors/Diagnostic 
Tools (Room 1) 
1045-1200 
Chair: K. L. Chan  
Session 13B Biosignal 
Processing 2 (Room2) 
1045-1130 
Chair: C. Zhang 
Session 15 Distributed Diagnosis 
& Home Healthcare (Room 3) 
1045-1130 
Chair: S. C. Tjin  
• Uni-channel PCA for noise 
reduction from ECG signals 
Palaniappan R., Tan E.K.  
  
• Wavelet-Based Denoising and 
Analysis of Phonocardiogram 
Wang P., Anantharaman V.  
 
• Dynamical Analysis of Heart 
Rate Variability Signals 
Rajendra A.U., Kannathal N., Lim 
C.M. 
 
• Distributed Diagnosis and 
Home Healthcare (D2H2) and 
Patient-Centered Electronic 
Medical Record 
Kim E.H., Kim J. J., Matsen F.A., 
Kim Y.M. 
 
• Advanced System Architecture 
for Telecardiology 
Goh K. W., Kugean C., Tan E. K., 
Prabaharan K.  
 
• Disposable Microfluidic Card 
and Fluorescence Detection 
System for Point-of-Care 
Diagnostic Applications 
Irawan R., Tjin S. C., Fu C. Y., Ng 
B.K., Yuan X.C., Zhang D.W. 
 
Session 12B Orthopaedic 
Engineering 2 (Room 2) 
1130-1215 
Chairs: D. Ghista, S. Idapalapati 
Session 03B Medical Image 
Processing (Room 3) 
1130-1215 
Chair: S. C. Tjin  
• Multi-Parameter Clinical 
Diagnosis using Neural 
Networks 
Tan E.K.  
• An Otoacoutic Emissions 
Detecting System using USB 
AD/DA Board 
Qian X., Ye D. 
 
• Oral Glucose Tolerance Test 
Modeling For Diabetes 
Characterization 
Loh K.M., Ghista D.N. 
 
• Feasibility of biosensing based 
on two-dimensional square 
photonic lattice 
Zhang D. W., Irawan R., Tjin S. C., 
Yuan X. C.  
 
• Application of Artificial Neural 
Network Technique in 
Healthcare Expenditure 
Analysis 
Chia E., Khong P.W., Ghista D.N. 
 • Integration of CAD to FEA for 
Prosthetic Socket Design 
Goh J. C. H., Lee P. V. S., Toh S. L., 
Ooi C. K. 
 
• Analyses of Fractured Bone 
(Femur) with Plate and Intra-
Medullary Rod Fixations 
Chen Q., Fan S.C., Ghista D.N.  
 
• Biomechanics of Long Bone 
Geometry and Fracture 
Fixation 
Krishna K.R., Sridhar I., Sivashanker 
S., Khong K.S., Ghista D. N.  
• Automatic 3-D optic Disk Image 
Reconstruction from Low-
Resolution Fundus Image for 
Glaucoma Analysis 
Xu J., Chutatape O.  
 
• Low-Complexity Unified-
Adaptive Compression of 
Biomedical Images Using 
Integer Hartley Transform 
Meher P.K., Srikanthan T., Agarwal 
H.K., Gupta J. 
 
• Modified Deformable region 
model for Lumen Extraction 
from Colonoscopic Image and 
Comparison with FCM 
Tjoa M. P., Zheng M. M., 
Doraiswami R., Tang C.L. 
 
End of Conference 
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SYSTEM AND METHOD FOR DETECTING OF PULMONARY DISEASES  
 
Field of the Invention 
 
[0001] The present invention generally relates to systems and method for detecting 
of pulmonary diseases, and more particularly to non-invasive systems and methods for 
detecting of pulmonary diseases by analyzing inhalation and exhalation. 
 
Background of the Invention 
 
[0002]  Lung is a vital organ allowing exchanges of O2 and CO2 between the 
alveolar sockets and bloods.  When the lung is impaired, e.g., viral or bacterial infections, 
its physical appearance and/or functions will be altered, resulting in pulmonary diseases.  
The current detection of pulmonary diseases is mainly done by X-ray.  However, the X-ray 
is not only invasive, but also only able to detect the physical alterations of lungs.  Thus, the 
X-ray is not applicable for detecting pulmonary diseases at early stages.  In addition, there 
are a broad range of so-called pulmonary function tests.  For example, spirometry measures 
how well the lungs exhale.  Lung volume measurement permits detection of restrictive lung 
diseases.  Testing the diffusion capacity permits as estimate of how efficiently the lungs are 
able to transfer oxygen from the air into the bloodstream.  However, all the available 
function tests are mere measures of systemic metabolism rather than of pulmonary 
functions. 
[0003]  It is well known that the components of exhalation could be utilized for 
diagnosis of certain diseases.  For example, U.S. Pat. 4,823,803 discloses a device for 
testing human exhalation for halitosis by using sensors that are sensitive to malodorant 
gases of predetermined chemical compositions for producing signals variable with the 
detected concentrations of the malodorant gases.  However, this patent is directed to the 
detection of malodorant gases rather than the lung functions. 
[0004] There are situations in which an early detection of viral infection is critical 
for treatment of the victim and more importantly for the control of the epidemic.  For 
example, the recent epidemic of SARS (Severe Acute Respiratory Syndrome) has raised 
concerns about effective detection of such relevant diseases, especially at a much earlier 
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stage of infection in human bodies.  Upon early detection, scarce and precious medical 
resources can be focused on the infected persons.  In the early stages of the infections, the 
X-ray screening may not be useful because the pathogenic damages on the lungs may not 
be evident enough to be detected by the machine.  The current available function tests may 
not be able to detect the early signs of infections because the functions tests measure the 
systemic metabolism only.  While PCR is powerful in detecting the early infection, it is 
prone to mutations.  Massive mutations will handicap this technique severely.   
[0005] Therefore, there is an imperative need to develop non-invasive systems and 
methods for detecting pulmonary diseases, especially ones inflicted by viral or bacterial 
infections.  Furthermore, the detection is independent of the mutations of infectious agents.  
This invention satisfies this need by disclosing systems and methods of detecting 
pulmonary diseases by analyzing of the inhalation and exhalation of a test person.  Other 
advantages of this invention will be apparent with reference to the detailed description. 
 
Summary of the Invention 
 
[0006] The present invention provides a to be completed upon agreement of 
claims. 
[0007] The objectives and advantages of the invention will become apparent from 
the following detailed description of preferred embodiments thereof in connection with the 
accompanying drawings. 
 
Brief Description of the Drawings 
 
[0008] Preferred embodiments according to the present invention will now be 
described with reference to the Figures, in which like reference numerals denote like 
elements. 
[0009] FIG 1 is a block diagram of the pulmonary disease detection system (PDDS) 
in accordance with one embodiment of the present invention. 
[0010] FIG 2 shows a breath analyzer configured in accordance with one 
embodiment of the present invention. 
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[0011] FIG 3 shows a flowchart of detecting pulmonary diseases on the basis of 
altered oxygen consumption and carbon dioxide generation. 
[0012] FIG 4 shows another functional flowchart of detecting pulmonary diseases 
in accordance with another embodiment of the present invention. 
[0013] FIG 5a shows a diagram illustrating the directional relationships among the 
different pressures that may be detected or induced from the air flow rates detected by the 
breath analyzer as shown in FIG 2.   
[0014] FIG 5b shows that different pressures are functions of time. 
 
Detailed Description of the Invention 
 
[0015] The present invention may be understood more readily by reference to the 
following detailed description of certain embodiments of the invention. 
[0016] Throughout this application, where publications are referenced, the 
disclosures of these publications are hereby incorporated by reference, in their entireties, 
into this application in order to more fully describe the state of art to which this invention 
pertains. 
[0017]  The present invention provides systems and methods for detecting 
pulmonary diseases.  While there are provided more details about the systems and methods 
hereinafter, it is to be appreciated that the present systems and methods are based on the 
understanding that anyone developing any pulmonary diseases would demonstrate certain 
detectable breathing deficiencies.  The deficiencies may be manifested by the changes of 
the oxygen consumption and carbon dioxide generation, or the differences of lung 
compliance and airflow-resistance.   
[0018]  There is provided a block diagram of the pulmonary disease detection 
system (PDDS) as shown in FIG 1 in accordance with one embodiment of the present 
invention.  The PDDS 100 comprises a breath analyzer 102, a computer processor 103, and 
a medical database 104.  The breath analyzer 102 will take in the breath from a test person 
101 and output the information of components of the breath from the person to the 
computer processor 103.  The computer processor 103 contains algorithms for 
manipulating the information of the breath and comparing the manipulated results with the 
medical database 104, so that the computer processor provides the results of diagnosis 105.   
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[0019] The breath analyzer 102 may be any apparatus that can obtain breathing 
information from a test person that is sufficient for the application of the algorithms 
embedded in the computer processor 103.  For example, for the application of an algorithm 
based on oxygen consumption and carbon dioxide generation, the breath analyzer 102 
basically comprises of gas sensors such as sensors for oxygen, carbon dioxide and water 
vapor.  The compositions of both inhale and exhale gases are analyzed.  Then the 
respective compositions are further processed by the computer processor 103. 
[0020] FIG 2 shows a breath analyzer 102 configured in accordance with one 
embodiment of the present invention.  The breath analyzer 102 comprises a mask 1, a data 
acquisition unit 7, and an air tank 11.  The mask 1 is configured to cover the nose and 
mouth of a test person so that maximum fresh air is delivered to the test person and 
minimum exhaled air is lost before proper measurement is completed.  As shown in FIG 2, 
the mask 1 includes an air outlet membrane 2 as a seal for preventing air within the mask 
from leaking; an exhaust flip valve 3 that will open to allow all the expired air to flow out 4 
of the mask when the test person breaths out; an air inlet membrane 21 as a seal for 
preventing air within the mask from leaking; an inhale flip valve 22 that will open to allow 
the fresh air from the air tank 11 to flow in 23 when the test person breaths in; an oxygen 
electrode 25 for detecting the oxygen in the air composition; a carbon dioxide gas electrode 
24 for detecting the carbon dioxide in the air composition; a nitrogen gas electrode 17 for 
detecting the nitrogen in the air composition; a water vapor electrode 18 for detecting the 
water vapor in the air composition; an inspired air flow rate electrode 19 for determining 
the flow rate of exhale air; an expired air flow rate electrode 20 for determining the flow 
rate of exhale air; and signal conductors 5 that transmit the information from the electrodes 
to the data acquisition unit 7.  The signal conductors may be ultra-low impedance 
conductor or fiber optic. 
[0021] The air tank 11 contains pressurized air so as to ensure a measurable and 
controllable air supply to the test person.  An air delivery pipe 16 connects the air tank with 
the mask so as to deliver a stream of controlled air from the air tank to the mask.  The air 
tank 11 also includes four electrodes 12, 13, 14, 15 for detecting the oxygen, carbon 
dioxide, nitrogen, and water vapor respectively.  The signal conductors 10 transmit the data 
from the four electrodes to the data acquisition unit 7.  The signal conductors may be ultra-
low impedance conductor or fiber optic.  
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[0022] The data acquisition unit 7 includes connectors 6, 9 for connecting to the 
signal conductors 5, 10 so that it will receive all the information from the air tank and the 
mask.  Then the data acquisition unit 7 transmits the received signals to the computer 
processor 103 which acts as the central processing unit (CPU).  The transmitted 
information may be digitalized packets. 
[0023] After the CPU receives the data of the air compositions from the data 
acquisition unit 7, it will process the air composition data.  In one aspect of the present 
invention, the detection of pulmonary diseases is based on the understanding that anyone 
developing any pulmonary diseases would demonstrate certain detectable breathing 
deficiencies.  The inventors of the present invention further discovered that the breathing 
deficiencies are manifested by altered oxygen consumption and carbon dioxide generation.  
FIG 3 shows a flowchart of detecting pulmonary diseases on the basis of altered oxygen 
consumption and carbon dioxide generation.   
[0024] Referring now to FIG 3, when the PDDS 100 starts 301, it obtains through 
the data acquisition unit 7 the information including oxygen composition, carbon dioxide 
composition, nitrogen composition, water vapor composition, and air flow rate 302.  It is to 
be noted that the air flow rate data will be discussed hereinafter when the air flow rate will 
be used to calculate the volume compliance and air-flow resistance in another algorithm of 
the present invention.  Then the CPU will calculate the overall relatives of all gases 
compositions 303.  Then the processed data is searched against the stored database to 
determine whether the test person has pulmonary diseases 304.  Then diagnostic results 
will be outputted 305 and the operation comes to an end 306.  It is noted from FIG 3 that 
the stored database is continuously updated so that the database will become more useful 
when more data is collected. 
[0025] Now there is provided a more detailed description of detecting pulmonary 
diseases on the basis of altered oxygen consumption and carbon dioxide generation.  The 
basic assumption is that the composition of expired air from a patient such as a person with 
SARS infection is different from that of a normal person.  It is further assumed that with an 
expired air, (a) its O2 content (or % vol.) will be greater (because of less O2 consumed from 
alveoli) and closer to that of inspired air; (b) its CO2 content will be lesser, and more akin 
to that of inspired air; and (c) the transfer coefficients for O2 & CO2 will be lesser as 
compared to a medically normal person.  Therefore, the mass balance analysis involves (i) 
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compositions of air breathed in and out; and (ii) consumption or generation of O2, CO2 and 
H2O.   
[0026] For calculation of inhale and exhale compositions, there are a few general 
assumptions: (1) Breathing Rate (BR) = 12 breaths/min; (2) PH2O at 37oC = 47mmHg; (3) 
O2 metabolic consumption rate at (at BTP) = 284 ml/min; and (4) CO2 production rate (at 
BTP) = 227 ml/min.  Thus, the expected compositions of the expired air can be calculated 
from the atmospheric air or vice versa.  For example, as shown in Table 1, the expected 
expired air compositions can be calculated from the numbers of the atmospheric air 
column: 
[0027] N2 = 393.1 ml 
[0028] O2 = 104.2-(284/12) = 80.53 ml 
[0029] CO2 = 0.2+(227/12) = 19.12 ml 
[0030] Total = 492.75 ml (1) 
[0031] Ratio of water vapor/dry gas in the expired air = 49.5mmHg/(760-47) 
mmHg.= 49.5/713 = 6.94%  (2)  
[0032] Volume of water vapor in the Expired air = (1)x(2)=492.75 0.0694=34.21ml   
(3) 
[0033] Total Expired air = [1]+[3]=492.75+34.21=526.96 ml  (4) 
[0034] Thus the percentage of the gases components in the expired air can be 
calculated as follows: 
[0035] N2 = 393.1/526.96 = 74.6%; 
[0036] O2 = 80.52/526.96 = 15.28%; 
[0037] CO2 = 19.12/526.96 = 3.63%; and 
[0038] H2O = 34.21/526.96 = 6.49%. 
[0039] All the numbers of the atmospheric air and expired air are presented in 
Table 1.   
[0040] Table 1.  An exemplary air compositions  
[0041]  
Atmospheric Air Humidified Air Alveolar Air Expired Air Respiratory 
gases mmHg ml/% mmHg ml/ % mmHg ml/% mmHg ml/% 
N2 597 393.1 
78.62% 
563.3 117.8 
78.5% 
569 275.3 
74.9% 
597.5 393.1 
78.62 
O2 159 104.2 
20.84% 
149.3 31.3 
20.9% 
104 49.3 
13.6% 
84 55.3  
11.06 
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CO2 0.3 0.2 
0.04% 
0.3 0.09 
0.06% 
40 19 
5.3% 
29 19.1  
3.82 
H2O 3.7 2.5 
0.5% 
47.0 0.81 
0.54% 
47 22.7 
6.2% 
49.5 32.5  
6.5 
Total 760 500 
100% 
760 150 
100% 
760 366.3 
100% 
760 500 
100% 
 
[0042] So far it has been shown that if the rates of oxygen consumption and carbon 
dioxide generation are known, the ideal composition of an expired air can be calculated 
from the original composition of the atmospheric air.  This is important for initializing the 
stored databases because in the early stages, the PDDS may have to generate part of the 
database by calculating the components of the expired airs from the atmospheric airs based 
on certain assumptions.  With the gradual accumulation of the database, more and more 
actual data will supplement or substitute the calculated ones.  As discussed early, the breath 
analyzer 102 of the present invention can acquire the data of individual gas components of 
the expired air from the test person and the CPU can manipulate the data to give the 
percentages of each gas component as to the expired air.  The processed data of each gas 
components will be compared with the stored medical database.  If the test person suffers 
from any illness that affects pulmonary functions, it is expected that the processed data of 
the expired air from a test person will be deviated from that of the stored database for a 
normal person.  If this is so, the CPU will output the diagnostic results showing that the test 
person is probably having pulmonary diseases.  Then the test person can seek further 
examinations to determine which kind of pulmonary diseases he/she is developing. 
[0043] As shown in Table 1, it is apparent that the rates of oxygen consumption 
and carbon dioxide generation may be derived from the actual measurements of individual 
gas components of the atmospheric air and expired air.  It is noted that all of the data of 
individual gas components can be obtained by the breath analyzer as shown in FIG 2.  The 
calculated rates can be compared with the stored database to determine whether the test 
person is suffering any pulmonary diseases. 
[0044] As mentioned earlier, the choice of a breath analyzer 102 for the present 
PDDS is limited by its function only.  For example, when the lung compliance and airflow-
resistance are used for detecting pulmonary diseases, the breath analyzer 102 may be a 
commercially available spirometer.  Now referring to FIG 4, there is provided another 
functional flowchart of detecting pulmonary diseases in accordance with another 
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embodiment of the present invention.  When the PDDS starts 400, it obtains data from the 
breath analyzer 401 (the same as the one shown in FIG 2) to determine the volume breath 
characteristics of the test person 402, and further extract the parameters of P0, P1, P2, Ra, 
Ca and W 403.  If the extracted parameters are not the best filtered results 404, the program 
will go back to step 403 to try to get the best parameters.  If the extracted parameters are 
the best filtered results 404, then the VTI1, VTI2 and VTI3 will be determined 405.  Then 
the program will conduct diagnosis 407 by utilizing the medical databases 406, 408, and 
output the results 409, resulting the end of the program 410.   
[0045] FIG 5a shows a diagram illustrating the directional relationships among the 
different pressures that may be detected or induced from the air flow rates detected by the 
breath analyzer as shown in FIG 2.  FIG 5b shows that different pressures are functions of 
time.  From there are derived a few fundamental equations that are the foundation for the 
algorithm shown in FIG 4: 
[0046]  
 (i) (Pa - Pp) - Pel = 0 
                                               (ii) Pel = (2 a h) / R r = 2 T / r = V/C + Pel, 0 
                                             (iii) (Po -Pa) = R(dV/dt) 
                                             (iv) PL = Po -Pp 
                                             (v) R(dV/dt) + VIC = PL - Pel, 0 
 
[0047] Now there is provided a more detailed description of determination of the 
volume breath characteristics of the test person 402.  In one embodiment of the present 
invention, the lung ventilation function is analyzed by means of a very simple model 
represented by a first-order differential equation (Deq) in lung-volume (V) dynamics in 
response to the driving pressure (PL = atmospheric pressure - pleural pressure), as shown in 
FIG 5  
[0048] First, the model governing equation derived from the basic equations is as 
follows: 
R
•
V  + V/C = PL(t) -Pel , 0  = Po  + P1 cosω t+ P2 sinω t   -Pel 0                 (1) 
[0049] wherein (i) Po, P1 and P2 are obtained from the given PL (= Po – Pp ) data; 
(ii) the parameters of this Governing Deq are lung compliance (C) and airflow-resistance 
(R), wherein in the equation both R and C are instantaneous valves; (iii) V = V(t) - Vo (the 
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lung volume at the end-expiration); and (iv) Pel,o is the lung elastic recoil pressure at the 
end of expiration and Pel,o= Pel – V/C. 
[0050] At end-expiration when ωt = ωT, PL = Pel,o. Hence, 
[0051] Pel,o = Po + P1 , and the governing equation (1) becomes: 
 R
•
V  + V/C = -P1   +  P1 cosω t     +  P2 sinωt =Pn                        (2-a) 
 
[0052] where the right-hand side represents the net pleural pressure. (Pn =Patm -Pp – 
Pel,o) curve.  This Pn is in fact the driving pressure (Po – Pp) normalized with respect to its 
value at end-expiration.  Equation(2-a) can be rewritten as follows: 
•
V  + V/R C =− P1  / R+  (P1 / R )cosω t     +  (P2 / R) sinωt   ;      RC=τ    (2-b) 
 
[0053] wherein the P(t) clinical data displayed in FIG 5b is assumed to be 
represented by:  
[0054] Po = 9.84 cm H2 O, P1 = -1.84 cm H2 O, and P2 = 3.16 cm H2 O  (3) 
[0055] If, in equation (1), Ra and Ca are designated as the average values (R and C) 
for the ventilatory cycle, then the solution of equation (1) is given by: 
V(t) = − P1 Ca + P1 Ca [ (Cos ωt + ω  Ra  Ca    Sin ωt) / (1+ω2  Ra2   Ca2) ]  + P2 Ca [(sinωt 
– ωRa Ca cosωt) / (1+ω2  Ra2   Ca2)] + H e -t/R a     (4) 
[0056] wherein the term (RaCa) is denoted by τa , and ω = 1.55 rad/s (based on the 
data in FIG 5b.  If V = 0 at t = 0, then, putting V (at t = 0) = 0 gives us: 
H ={ Ca ω τa / (1+ ω 2τa2 )} ( P2 + P1 ω τa )             (5) 
 
[0057]  Then from equations (4) and (5), the overall expression for V (t) becomes: 
 V (t) = − P1 Ca + { P1 Ca  (cos ω t + ω τ a Sin  ω t) / (1+ ω 2τa2 )} 
+{ P2 Ca (Sin ω t - ω τ a Cos  ω t) / (1+ ω 2τa2 )}   
+{ e-t/τa  ω  Ca τa ( P2 + P1 ω τa) / (1+ ω 2τa2 )}               (6) 
[0058]   If dV/dt = 0 at t = 0, implying no air-flow at the start of inspiration, then 
equation (6) can be differentiated into:  
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•
V  = {P1 Ca / (1+ ω 2τa2 )} ( - ω Sin ω t + ω2 τa Cos  ω t) 
   +{P2 Ca / (1+ ω 2τa2 )}(ω cos ω t + ω2 τa Sin  ω t) 
  +{- Ca  e-t/τa / (1+ ω 2τa2 )} ( ω P2  +  P1 ω 2τa)                      (7) 
[0059]  From equation (7), we get: 
•
V  = 0 at t = 0, thereby also satisfying this 
initial condition.  By matching the above V(t) expression (6) with the given V(t) data (in 
FIG 5b), and carrying out parameter-identification, the in vivo values of Ra and Ca can be 
determined.  As a check, it can be verified that the substitution of (6) and (7) satisfies 
equation (2).  
[0060] However, we can also analytically evaluate Ra and Ca by satisfying some 
conditions. For this purpose, we first note that V is maximum (=Tidal Volume, TV) at 
about t (= tv )= 1.6s,   i.e. at ω tv = 2.48 rad.  Now, for ω tv = 2.48 rad, we get : 
sin(ωtv)=0.62, cos (ω tv) = -0.79 and tan (ω tv) = -0.78. Also, for ω tv = 2.48 rad ( and 
based on the knowledge of the range of τa ), the exponential term e- t/τa ( in equation 6) 
becomes of the order of e-3  and  less; hence, we decide to neglect it. So then, by and 
putting 
•
V  = 0 in equation. (7), we obtain: 
 tan (ω tv) = ( P2 + ω τa P1 )  / ( P1 − P2 ω τa )  = -0.78             (8) 
 
[0061] Upon substituting the values of P1  and P2 from equation (3), and putting ω 
= 1.55 rad s-1 , we obtain the value of τa = 0.26s. We can also put ••V =0 at t≅0.58 or ωt=93 
and obtain a similar value for τ. Then, we also note that at  tv = 1.6s ( for which dv /dt = 0), 
V = 0.6l . Hence upon substituting for cos(ω tv) = -0.79 and sin(ω tv) = 0.62 in equation(7), 
and again neglecting the exponential term we get the following algebraic equation: 
− P1 Ca −( 0. 54 P1 Ca / D) +   (0. 94 P2 Ca / D)   =   0.6;              (9) 
[0062] wherein D = 1 + ω2 τa2   ,  ω = 1.55 rad/s, and  τa = 0. 26s; this equation 
can hence be rewritten as: 
Ca  (−1.54 P1  + 0. 94 P2 )= 0.7                              (10) 
[0063] We can substitute, therein, the values of P1 & P2 from equation (3), and 
obtain the value of  Ca = 0.12 L (cm H2 O)-1  . Since we have computed τa =  0.26 s,   
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therefore   Ra = 2.20 (cm H2 O)  s L-1 . These are the average values of resistance- to – 
airflow and lung compliance during the ventilatory cycle shown in FIG 5b.   
[0064] Since Lung disease will influence the values of R and C, these parameters 
can be employed to diagnose lung diseases. For instance in the case of emphysema, the 
destruction of lung tissue between the alveoli produces a more compliant lung, and hence 
results in a larger value of C. In asthma, there is increased airway resistance (R) due to 
contraction of the smooth muscle around the airways. In fibrosis of the lung, the 
membranes between the alveoli thicken and hence lung compliance (C) decreases. Thus by 
determining the normal and diseased ranges of the parameters R and C, we can employ this 
simple Lung-ventilation model for differential diagnosis. Let us, however formulate just 
one non-dimensional number to serve as a ventilatory performance index VTI1 (to 
characterize ventilatory function), as: 
 
VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τ2 (BR)2 602     (11) 
 
where BR is the breathing rate. Now, let us obtain its order-of-magnitude by adopting 
representative values of Ra and Ca in normal and disease states. Let us take the above 
computed values of Ra = 2.2(cm H2O) s L-1 and Ca =0.12 L(cm H2O) -1 and BR = 12m-1 or 
0.2s-1, computed for the data of Fig(1) and equation(3). Then, in a supposed normal 
situation, the value of VTI1  is of the order of 9.75. In the case of obstructive lung disease, 
(with increased Ra ), let us take Ra = 3cm H2 O s L-1, Ca = 0.12 L (cm H2 O)-1 and BR = 
0.3s-1 ; then we get VTI1 = 42. For the case of emphysema (with enhanced Ca),  let us take 
Ra = 2.0cm H2O s L-1 , Ca =0.2 L( cm H2O) -1 and BR = 0.2s-1 ; then we obtain VTI1 = 
23.04. In the case of lung fibrosis (with decreased Ca ) , we take Ra = 2.0cm H2O s L-1 , Ca 
=0.08 L( cm H2O) -1 and BR = 0.2s-1 ; then we obtain VTI1 = 3.7. We can, hence 
summarize that VTI1 would be in the range of 2-5 in the case of fibrotic lung disease, 5-15 
in normal persons, 15-25 for the case of emphysema, 25-50 in the case of obstructive lung 
disease. This would of course be needed to be verified by analyzing a big patient 
population. 
[0065] Now, all of this analysis requires pleural pressure data, for which the patient 
has to be intubated.  If now we evaluate the patient in an outpatient clinic, in which we can 
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only monitor lung volume and not the pleural pressure, then we have to develop a non-
invasively obtainable Ventilatory index. 
[0066] In order to formulate a non-invasively determinable Ventilatory index from 
equation (1), we need to redesignate the model parameters, and indicate their identification 
procedure.  So we make use of the following features from the volume-time data to 
facilitate evaluation of the following three parameters: : (P1 C), (P2 C) and τ : 
[0067] At t = tv = 1.6s & ω tv = 2.48, V is max & dV/dt = 0; hence we rewrite 
equation (9) as: 
[0068]   
tan (ω tv  ) = -0.78 = (P2 + ω t P1) / (P1 – P 2ω t )                         (12) 
 
[0069] At t = tm , 
••
V  = 0 ; hence by differentiating equation. (7), without the 
exponential term ,we obtain: 
 ••
V =0=
 P1C(-ω2 cos ω tm - ω3 τ sin ω tm) +P2 C (-ω2 sinω tm - ω3 τ sinω tm) (1+ ω 2τ2) 
 
i.e.                  tan ω tm   = (-P1 + ωτ  P2) / (P 1ωτ + P2 )                             (13) 
 
[0070] At t = 1s &ω t = π/2, V = V1 (whose value is obtainable from FIG 5b); this 
condition yields (without the exponential term): 
 V1= -(P1C) – {ω τ (P1C)/(1+ ω 2τ2)} +{ (P2 C) /(1+ ω 2τ2)}          (14) 
[0071] At t = 2s & ω t =π/2 , V = V2 (whose value is obtainable from FIG 5b); this 
condition yields (without the exponential term): 
V2= -(P1C) – {(P1C)/(1+ ω 2τ2)} +{ωτ (P2 C) /(1+ ω 2τ2)}            (15) 
[0072] At t = 0.3s & ω t =270 , V = V3  gives: 
 V3 = -(P1C) – { ωτ (P1C)/(1+ ω 2τ2)} -{ (P2 C) /(1+ ω 2τ2)}           (16) 
[0073] From equations (12) & (13) and any one of the equation(s) (14-16), we can 
only obtain the values of ω τ (or of τ  , since ω = 1.55) and of (P1 C) &  (P2 C)  but not of 
P1 & P2 by themselves. On the other hand, by also fitting equation (6), (without the 
exponential term) to the V(t) data, we obtain: 
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[0074] We can nevertheless formulate another non-invasively-determinable non-
dimensional ventilatory index (V T I2) in terms of these parameters. (ωτ , P1 C  and P2 C) 
as follows: 
[0075]  
V T I2= 60 (ωτ) (T V)2 /2π (P1 C )(P2 C)                                       (18) 
=30 ω (R/C) (T V)2 /π P1 P2  
[0076]  It is seen that VTI2  can in fact be expressed in terms of P1, P2 and R, C. 
This VTI2  index can be evaluated by computing the values of τ, alongwith (P1 C ) & (P2 C)  
as given by equation (17).  Then, after evaluating V T I2  for a number of persons, and 
patients its distribution can enable us to categorize and differentially diagnose patients with 
various lung disorders and diseases. Between the two indices VTI1  and VTI2 , we can 
employ the one that enables more distinct separation of subjects with different ventilatory 
disorders. 
[0077] Thus far, we have adopted the average cyclic values Ca and Ra for our DEq 
model parameters. However, we expect that C will vary with lung volume (V) ,and that R 
will perhaps vary with the airflow-rate or (
•
V ) or even ω. Hence, for a true representation 
of the lung properties C & R, let us determine their values for different times during the 
ventilatory cycle, and compare them with their average values Ca & Ra ,so as to make a 
case for a non-linear ventilatory-function model. 
[0078] Let us hence compute the instantaneous value of compliance (C) at mid-
inspiration at (t = tm ), and compare it with that of its average cyclic value of Ca . For this 
purpose let us differentiate equation (2-a) , giving : 
[0079]   
R 
••
V  + 
•
V /C = -  P1 ωSinω t + P2 ω Cosω t                            (19) 
[0080] Now at about mid-inspiration, when t ≅ 0.87 s and ω t = ω tm ≅ 1.32 rad or 
78°, 
••
V = 0 and 
•
V  = 0.5 L/s (based on fig1). By substituting for 
••
V  and 
•
V  in equation (19), 
we obtain, C  ≅ 0.14L/cm H2O (compared to its Ca  value of 0.118). Now, in order to also 
14 
 
compute R at ω tm  =1.32 we substitute •V = 0.5 L/s and V = 0.3L (from the fig1 data) into 
equation (2-a), to obtain: 
[0081]   
0.5 R   +   0.3 / C   = -P1 + P1 Cos 78ο   + P2 Sin 78ο   =   3.8            (20) 
[0082] Now, since C(at ω tm = 1.32) ≅ 0. 14L/cm H2 O, we obtain R=4.6(cmH2O) s 
L−1 , compared to Ra = 2.20. This gives us some idea of the order of magnitude of R & C, 
in comparison to their average values Ca & Ra.. We could also expect C at mid-inspiration 
to be higher than its value at end-inspiration, when the lung is fully inflated. Also, we 
could expect the flow-resistance to be maximum at mid-inspiration, when 
•
V  is maximal. 
[0083] We can hence represent lung compliance (C) and resistance (R) as follows: 
[0084]  
                     C = n1 (V)
n2 – C o    or   C = C o  e
n(V))     ,                                          (21-a) 
          
•== VeRRVsR so
s
or
2
21                                                                         (21-b) 
[0085] wherein 
•
V  can also be varied by having the subjects breathe at different 
tidal volumes (TVs) and ventilation frequency (ω) 
[0086] We note as per the conventional formulation of compliance, given by 
equation(ii) in FIG 5b as: 
Pel   = V/C   +   Pel, 0  ;                                                     (22) 
[0087] In the above formulation, we assume that C and E(= 1/C) remains constant 
throughout the ventilation cycle. However at the start of inspiration, C = Co at t= 0, and it 
decreases as the lung volume increases, based on the lung (static) volume vs pressure 
curve. So let us improve upon this equation(22) model, by making Pel  to be a non-linear 
function of volume, as follows: 
[0088]   
kv
oelel eEPP 0, +=                                                                           (23) 
[0089] Employing the above format of compliance, the governing DEq  (1) 
becomes 
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[0090]  R 
•
V  + E0  ekV  = PL ( t) - Pel, 0 = Po+ P1 cos ω t + P2  sin  ω t - Pel, 0      (24) 
[0091] Again at end-expiration,  Pel, 0 = intra-pulmonary pressure =(P0 + P1). 
Hence equation.(24) becomes: 
[0092]   
R 
•
V +   E0 ek V   =   −P1  +   P1 cos ω t + P2  sin ω t                                  (25) 
 
[0093] whose RHS is similar to that of equation(2-a), and the values of P1  & P2 are 
given by equation(3) for the FIG 5b data. 
[0094] In order to evaluate these parameters k & E0  ,we again bring to bear the 
situation that at end-inspiration, for t = tv  =1.6 s (for which ω t =ω tv = 2. 48 rad, sin ω tv 
= 0.62 & cos ω tv= −0. 79), we have 
•
V  = 0  and V = Vmax =TV = 0.6 L. Hence, from fig (1) data, and equations (3 & 25), we 
obtain: 
[0095]   
E0  e0.6 k    =  8.75                                                                (26)  
[0096] Let us now employ the volume data point at which 
••
V =0. For this purpose, 
we differentiate equation (25) , to obtain: 
[0097]  R 
••
V  +    E0 k e kV =   −P1ω sin (ω t)  + P2ω cos (ω t)                  (27) 
[0098] From the Fig (1) data at about mid-inspiration, for which t = tm  =  0. 87s & 
ω tm = 1.32 = 78o     with cos (ω tm)= 0.2  & sin (ω tm)  = 0.98), we have ••V ≅ 0, •V  =0.5 
Ls−1,  V = 0.3 L , from fig(1) data. Substituting these values into equation.(27), we get : 
[0099]  
E0  e 0.3k =  3.8                                                   (28) 
[00100] Now from equation(s) (27) & (28),  we get:  
e –0.3 k    =  1.38                                                (29) 
[00101] for which,   k   =  1.07 and  (from equation 26 or 28)  E0   =  2.75 (30) 
[00102] Hence, by employing the non-linear formulation, 
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kv
ooelel eEPP += ,  
[00103] we obtain the following expression for lung compliance (or elastance): 
[00104]   
VkV
o
el ekeE
C
E
dV
dP 07.1
94.21 ====                                          (31) 
[00105] Based on this expression, we obtain ,for t = tm &  V = 0.3L: 
E =1/C = 4.06cm H2O / L;  and C = 0.25 L/cm H2 O.                                                  (32) 
[00106] Equation(32) can now provide us a more realistic characterization of lung 
compliance as follows: 
 At t= 0 and V = 0, we compute E=1/ C =2.94 and C = 0.34 cm H2 O / L. 
 At t = tm = 0.87s   &    V = 0.3L,   E=  1/C = 4.06,    and C = 0.25. 
 At  t = tv = 1.6s  &  V = 0.6L ,  and E = 1/C = 5.6   and    C = 0.18, 
 which corresponds to the value of Ca .  
[00107] Our non-linear formulation of lung compliance, as depicted by equation. (31 
& 33) , indicates that compliance decreases from 0.34 cm H2 O /L at start-inspiration to  
0.25 cm H2 O /L at about mid-inspiration, and then to 0.18 cm H2 O /L at the end of 
inspiration. What this also tells us is that the ventilatory model equation.(1) gives the 
correct reading of the compliance at Vmax , i.e. at end-inspiration. At other times of 
inspiration and expiration, the Ca parameter underestimates the instantaneous value of lung 
compliance. Now how about obtaining an analytical solution of equation(25) for V(t), and 
fitting the expression for V(t) to the lung volume data, to evaluate the parameters (i) R, Eo 
& k for an intubated patient and (ii) R, Eo k & P1 & P2 for a non-intubated patient in the out 
patient clinic. 
[00108] Finally, while it is important to determine the normal and pathological 
diagnostic ranges of Ca & Ra , or better still of the parameters (E0 & k ) of the C vs V and R 
vs 
•
V relationships, it would be more useful to construct and employ a non-dimensional 
ventilatory index  We have already formulated VT I1 & VT I2 in equations (11) & (18), 
respectively. We will now formulate yet another index : 
[00109]   
(33) 
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VT I3  = [60 ( Ra / Ca  ) (BR) (TV)2]/ P1 P2                                         (34) 
[00110] wherein (i) BR (the breathing rate in # / sec) = 0.5 ω / π  (ii) and ⏐ P1 P2 ⏐ is 
the absolute value of the product P1 P2 (because of P1 being negative). For the fig (1) 
clinical data, of BR= 0.25, with TV=0.6L & /P1 P2/ 1.18
)3(= , and for the computed value of 
Ra/Ca=18.33cm H2O s L-1, we obtain VTI3  = 5.47. Between VTI1  and VTI3  , we can 
decide which index enables us to better differentially diagnose subjects with ventilatory 
disorders. 
[00111] Now, let us go one step further and recognize that, for non-intubated 
patients, we cannot monitor P1 and P2 , and hence cannot evaluate Ra & Ca as demonstrated 
in § A. However for evaluating ventilatory index in out-patient clinics, we can infact adopt 
(P1 C)  and (P2 C ) to be the model-system parameters, and evaluate them as delineated in § 
B. We can hence adopt the non-invasively-obtainable ventilatory-performance index VT I2  
(given by equation 18): 
[00112]   
VTI2  =  30 ωτ (TV)2 / π (P1 C) (P2 C);  ω = 2π(BR )(in #s-1) 
        = 60 (BR)(R / C) (TV)2 / (P1 P2 ) =     VT I3                      (35) 
[00113] which is noted to be the same expression as for index VTI3 , except that it 
can be evaluated without intubating the patient. Hence, it would be even more useful to 
determine the distribution of VTI2 for patients with a wide range of lung pathologies and 
ventilatory disorders. Then, we can delineate the normal and pathological ranges of this 
index, and employ this information to diagnose patients into different disease categories. 
[00114]  Now referring to FIG 6 and FIG 7, there is provided a more detailed 
description of the ways by which the PDDS searches the database.   
[00115] The index will fire up numerous search engine in finding the best match 
diseases.  There is a possibility that there is more than one type of diseases being 
suspected.  Statistical means are used to determine which is the best match diseases and 
thereby  putting all these best fit diseases to the expert database system to further refine the 
possibilities. 
[00116] This expert database will feedback data which is erroneous through a 
database interface to the intelligent DBMS for further confirmation by firing up other 
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possibilities of diseases type. This interface can be realise through a query module 
interface. The query module will consult the expert DB2 for expert information before in 
deciding the redundancy of the data. 
[00117] The DISS (disease identification software system) is used to identify the 
best match disease after consulting the expert DB. The algorithm can be found in annex. 
The query module is responsible for all communication between the DISS, expert DB, GUI 
and also the intelligent DBMS. In particular, it can decide whether an DISS request can be 
displayed with the expert DB helps or whether it is necessary to require input from the 
user. 
[00118]  While the present invention has been described with reference to particular 
embodiments, it will be understood that the embodiments are illustrative and that the 
invention scope is not so limited.  Alternative embodiments of the present invention will 
become apparent to those having ordinary skill in the art to which the present invention 
pertains.  Such alternate embodiments are considered to be encompassed within the spirit 
and scope of the present invention.  Accordingly, the scope of the present invention is 
described by the appended claims and is supported by the foregoing description.
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CLAIMS 
 
What is claimed is: 
 
1. A pulmonary disease detection system for detecting breathing deficiencies of a test 
person, comprising:  
 a breath analyser for analysing the inhale and exhale airs of the test person; 
 a computer processor for receiving from the breath analyser the information and 
processing the received analysis data to give values to different parameters of the inhale 
and exhale airs of the test person; and  
 a medical database for storing different parameters of breaths of the public and 
normal ranges for healthy persons; 
 thereby the computer processor compares the values of different parameters of the 
inhale and exhale airs of the test person with the ones stored in the medical database so as 
to yield a test result of whether the test person is suffering breath deficiencies. 
 
2. The pulmonary disease detection system of claim 1, wherein the breathing 
deficiencies may be caused by bacterial infection, viral infection, physical injuries and 
cancer. 
 
3. The pulmonary disease detection system of claim 1, wherein the breath analyser 
comprises:  
 a mask for covering the nose and mouth of the test person so as to maximizing the 
delivery of fresh air and minimizing the loss of the exhaled air; 
 an air tank for supplying measurable and controllable air to the mask; and 
 an acquisition unit electrically connected with the mask and the air tank so as to 
receive all the information from the air tank and the mask. 
 
4. The pulmonary disease detection system of claim 3, wherein the mask comprises a 
group of electrodes including an oxygen electrode, a carbon dioxide gas electrode, a 
nitrogen electrode, a water vapor electrode, an inspired air flow rate electrode and an 
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expired air flow rate electrode; wherein each electrode detects each designated component 
of the inhale and exhale airs. 
 
5. The pulmonary disease detection system of claim 4, wherein the computer 
processor is embedded with an algorithm for processing the information from the breath 
analyser; wherein the algorithm calculates the breathing rate, oxygen consumption rate and 
carbon dioxide generation rate from the composition information of the inhale and exhale 
airs of the test person; thereby comparing the rates of the test person with the ones stored in 
the medical database so as to conclude whether the test person is suffering any breath 
deficiencies. 
 
6. The pulmonary disease detection system of claim 4, wherein the computer 
processor is embedded with an algorithm for processing the information from the breath 
analyser; wherein the algorithm calculates the composition values of the exhale air from 
the composition values of the inhale air and the assumed normal rates including breathing 
rate, oxygen consumption rate and carbon dioxide generation rate; thereby comparing the 
composition values of the exhale air with the ones stored in the medical database so as to 
conclude whether the test person is suffering any breath deficiencies. 
 
7. The pulmonary disease detection system of claim 4, wherein the computer 
processor is embedded with an algorithm for processing the information from the breath 
analyser; wherein the algorithm calculates the volume compliance and air-flow resistance 
of the test person from the composition values and pressure values derived from the inhale 
air rate and exhale air rate; thereby comparing the volume compliance and air-flow 
resistance values with the ones stored in the medical database so as to conclude whether 
the test person is suffering any breath deficiencies. 
 
8. The pulmonary disease detection system of claim 7, wherein the derived pressure 
values include pleural pressure and alveolar pressure. 
 
9. The pulmonary disease detection system of claim 8, wherein the volume 
compliance and air-flow resistance are calculated by the equation: 
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VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τ2 (BR)2 602      
wherein VTI1 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein Ra and Ca are designated as the 
average values (R and C) for the ventilatory cycle, and BR is the breathing rate. 
 
 10. The pulmonary disease detection system of claim 8, wherein the volume 
compliance and air-flow resistance are calculated by the equation: 
V T I2= 60 (ωτ) (T V)2 /2π (P1 C )(P2 C) =30 ω (R/C) (T V)2 /π P1 P2  
wherein V T I2 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein TV is tidal volume; P1& P2  as 
pleural pressures and  ωτ as determined by equations (14-16). 
 
11. The pulmonary disease detection system of claim 8, wherein the volume 
compliance and air-flow resistance are calculated by the equation: 
 VT I3  = [60 ( Ra / Ca  ) (BR) (TV)2]/ P1 P2 
 wherein VTI3 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein  TV is tidal volume; P1& P2  as 
pleural pressures. 
 
12. A method of detecting a pulmonary disease of a test person by investigating the 
breath deficiencies of the test person: 
 acquiring the information of inhale and exhale airs of the test person; 
 processing the acquired information to give values of designated aspects of the 
inhale and exhale airs of the test person; and  
 comparing the calculated values with the ones stored in a medical database so as to 
conclude whether the test person is suffering any pulmonary diseases. 
 
13. The method of claim 12, wherein the breathing deficiencies may be caused by 
bacterial infection, viral infection, physical injuries and cancer. 
 
14. The method of claim 12, wherein the information of inhale and exhale airs of the 
test person is acquired by a breath analyser; and wherein the breath analyser comprises:  
22 
 
 a mask for covering the nose and mouth of the test person so as to maximizing the 
delivery of fresh air and minimizing the loss of the exhaled air; 
 an air tank for supplying measurable and controllable air to the mask; and 
 an acquisition unit electrically connected with the mask and the air tank so as to 
receive all the information from the air tank and the mask. 
 
15. The method of claim 14, wherein the mask comprises a group of electrodes 
including an oxygen electrode, a carbon dioxide gas electrode, a nitrogen electrode, a water 
vapor electrode, an inspired air flow rate electrode and an expired air flow rate electrode; 
wherein each electrode detects each designated component of the inhale and exhale airs. 
 
16. The method of claim 15, wherein the processing is executed within a computer 
processor that is embedded with an algorithm for processing the information from the 
breath analyser; wherein the algorithm calculates the breathing rate, oxygen consumption 
rate and carbon dioxide generation rate from the composition information of the inhale and 
exhale airs of the test person; thereby comparing the rates of the test person with the ones 
stored in the medical database so as to conclude whether the test person is suffering any 
breath deficiencies. 
 
17. The method of claim 15, wherein the processing is executed within a computer 
processor that is embedded with an algorithm for processing the information from the 
breath analyser; wherein the algorithm calculates the composition values of the exhale air 
from the composition values of the inhale air and the assumed normal rates including 
breathing rate, oxygen consumption rate and carbon dioxide generation rate; thereby 
comparing the composition values of the exhale air with the ones stored in the medical 
database so as to conclude whether the test person is suffering any breath deficiencies. 
 
18. The method of claim 15, wherein the processing is executed within a computer 
processor that is embedded with an algorithm for processing the information from the 
breath analyser; wherein the algorithm calculates the volume compliance and air-flow 
resistance of the test person from the composition values and pressure values derived from 
the inhale air rate and exhale air rate; thereby comparing the volume compliance and air-
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flow resistance values with the ones stored in the medical database so as to conclude 
whether the test person is suffering any breath deficiencies. 
 
19. The method of claim 18, wherein the derived pressure values include pleural 
pressure and alveolar pressure. 
 
20. The method of claim 19, wherein the volume compliance and air-flow resistance 
are calculated by the equation: 
VTI1 = [ (Ra Ca )(Ventilatory rate in s-1) 60 ]2  = τ2 (BR)2 602      
wherein VTI1 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein Ra and Ca are designated as the 
average values (R and C) for the ventilatory cycle, and BR is the breathing rate. 
 
 21. The method of claim 19, wherein the volume compliance and air-flow resistance 
are calculated by the equation: 
V T I2= 60 (ωτ) (T V)2 /2π (P1 C )(P2 C) =30 ω (R/C) (T V)2 /π P1 P2  
wherein V T I2 is denoted as ventilatory performance index; C as lung-volume 
compliance; and R as air-flow resistance; and wherein TV is tidal volume; P1& P2  as 
pleural pressures and  ωτ as determined by equations (14-16). 
 
22. The method of claim 19, wherein the volume compliance and air-flow resistance 
are calculated by the equation: 
 VT I3  = [60 ( Ra / Ca  ) (BR) (TV)2]/ P1 P2 
 wherein VTI3 is denoted as ventilatory performance index; C as lung-
volume compliance; and R as air-flow resistance; and wherein TV is tidal volume; P1& P2  
as pleural pressures and  ωτ as determined by equations (14-16). 
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